{
    "0": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to low back pain.\n\n2. The clinical trial is titled \"Low Back Pain Patient Education Evaluation\" and is specifically looking for patients with low back pain who meet certain criteria.\n\n3. The inclusion criteria for the trial are:\n- Must live in the United States\n- Must understand and write English\n- Must have access to a computer with email and expect to have this access for at least 3 years\n- Must be 18 years old\n- Must have seen a doctor for back pain at least once in the past year\n\n4. Based on the patient note provided, there is no mention of the patient having low back pain or meeting any of the inclusion criteria for this specific clinical trial.\n\nTherefore, Trial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1": {
        "output": "To determine the patient's eligibility for the Beta-Blocker Heart Attack Trial (BHAT), let's go through the inclusion criteria:\n\n1. Men and women: The patient is a 58-year-old woman, so she meets this criterion.\n\n2. Ages 30 to 69: The patient is 58 years old, which falls within the age range specified in the inclusion criteria.\n\n3. Documented myocardial infarction: The patient presents with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea, which are symptoms suggestive of a myocardial infarction (heart attack). However, the note does not explicitly state that the patient has had a documented myocardial infarction.\n\nBased on the information provided, the patient meets two out of the three inclusion criteria. However, without a clear documentation of a myocardial infarction, it is uncertain whether the patient would be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to confirm if she has had a documented myocardial infarction.",
        "label": 1
    },
    "2": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old African-American woman, which fits the age range of 25-49 years old specified in the inclusion criteria.\n\nShe presents with chest pain, nausea, diaphoresis, and mild dyspnea, which could be symptoms of hypertension or other cardiovascular issues. However, the inclusion criteria state that participants should be free of major disease.\n\nThe patient is known to have hypertension and obesity, which aligns with the inclusion criteria of being predisposed to the development of hypertension and including some mild to moderately obese subjects.\n\nThere is no mention of the patient being on a special diet or antihypertensive medication, which also fits the inclusion criteria.\n\nThe only potential issue is that her diastolic blood pressure is not mentioned, and the inclusion criteria specify a diastolic blood pressure range of 78-89 mmHg.\n\nOverall, based on the information provided, I would consider referring this patient to this clinical trial upon further investigation of her diastolic blood pressure reading.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "3": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman, which matches the inclusion criteria for ethnicity and age range (18-70 years) for this clinical trial studying diabetes and heart disease risk in Blacks.\n\n2. The patient has hypertension and obesity, which are relevant risk factors for heart disease being studied in this trial. However, she denies having diabetes, which is an exclusion criteria.\n\n3. She is not pregnant or breastfeeding, and there is no mention of her being on any medications that could alter the parameters being studied.\n\n4. Based on the information provided, this patient appears to meet most of the key inclusion criteria, except for the exclusion of having diabetes.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to confirm she does not have undiagnosed diabetes or any other exclusion criteria.",
        "label": 0
    },
    "4": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman, which matches the inclusion criteria of being African American and between 29-85 years of age.\n\n2. The patient presented with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea. This does not seem to be a stroke or cerebral infarct, which is required for inclusion in this trial.\n\n3. The patient has no history of stroke or cerebral infarct mentioned in the note.\n\n4. There is no mention of the patient having a measurable neurologic deficit correlating with a stroke onset.\n\nBased on the information provided in the patient note, this patient does not appear to meet the key inclusion criteria of having had a recent non-cardioembolic ischemic stroke and having a measurable neurologic deficit from that stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "5": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic chest pain, nausea, diaphoresis, and mild dyspnea, which could be indicative of a cardiac issue.\n\n2. She has risk factors for coronary heart disease, such as hypertension and obesity.\n\n3. The clinical trial is the Muscatine Heart Study, which conducts longitudinal and cross-sectional studies of risk factors for coronary heart disease and hypertension in adults.\n\n4. The inclusion criteria for the trial are very broad, with no specific eligibility criteria mentioned.\n\n5. Given the patient's presenting symptoms, risk factors, and the broad inclusion criteria of the trial, it would be reasonable to consider referring this patient to the Muscatine Heart Study for further evaluation and potential enrollment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "6": {
        "output": "To determine the patient's eligibility for the clinical trial \"The Jackson Heart Study of Cardiovascular Disease Among African Americans\", let's go through the inclusion criteria:\n\n1. African American: The patient note states that the patient is a 58-year-old African-American woman, so she meets this criterion.\n\n2. Residents of Jackson, Mississippi: The patient note does not mention the patient's residence, so we cannot confirm if she meets this criterion.\n\nSince the patient meets one of the two inclusion criteria, and we do not have enough information to determine if she meets the other criterion, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "7": {
        "output": "To determine the patient's eligibility for the clinical trial \"Racial Variation in ACE--Genetic and Physiologic Bases\", let's go through the details:\n\nThe patient note states:\n- 58-year-old African-American woman\n- Presenting with chest pain, nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n\nThe clinical trial summary states:\n\"To determine whether differences in the activity of the renin-angiotensin and bradykinin systems are involved in the pathogenesis of blood pressure variation in African Americans.\"\n\nThe inclusion criteria state:\n\"No eligibility criteria\"\n\nSince the trial does not have any specific inclusion criteria and is studying blood pressure variation in African Americans, and the patient is an African-American woman with hypertension, she would likely be eligible for this trial.\n\nHowever, it's important to note that the patient is presenting with concerning symptoms of chest pain, nausea, diaphoresis, and dyspnea, which could potentially indicate an acute cardiac event. Further evaluation and stabilization of her condition would be necessary before considering enrollment in a clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "8": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Subject is competent to provide informed written consent - Not mentioned in the patient note, but likely met.\n2. Subject is 18 years or older - Met, the patient is 58 years old.\n3. Subject has ischemic or non-ischemic cardiomyopathy with NYHA Class III or IV chronic heart failure - Not explicitly stated, but the chest pain and mild dyspnea suggest possible heart failure. More investigation needed.\n4. Subject has LVEF \u2264 35% measured within 60 days - Not mentioned in the patient note.\n5. Subject has LVEDD > 2.7 cm/m2 measured within 12 months - Not mentioned.\n6. Subject is on optimal conventional heart failure therapy except beta-blocker for \u2265 30 days - Not mentioned, patient currently takes no medications.\n7. Subject failed initiation or up-titration of a beta-blocker due to hemodynamic intolerance within 12 months - Not mentioned.\n\nExclusion Criteria:\n1. CHF due to uncorrected valvular, thyroid, obstructive/hypertrophic cardiomyopathy, etc. - Not mentioned, but unlikely based on the information given.\n2. Cardiac revascularization, valvular surgery, or bi-ventricular resynchronization within 60 days - Not mentioned.\n3. Listed for heart transplant expected within 6 months - Not mentioned.\n4. Myocardial infarction within 90 days - Not mentioned.\n5. Concerning ECG findings - ECG shows non-specific changes only.\n6. Sustained VT, unless precipitated by an event - Not mentioned.\n7. AICD fired for VT within 90 days - Not mentioned.\n8. Documented unstable angina or angina limiting activity - Chest pain described, but not clear if it meets angina criteria.\n9. Ventricular reduction surgery or cardiac myoplasty - Not mentioned.\n10. On mechanical assist device - Not mentioned.\n11. Concomitant disease interfering with heart failure course - Obesity and hypertension mentioned, may need further evaluation.\n12. Life-threatening disease with <1 year life expectancy - Not mentioned.\n13. Uncontrolled insulin-dependent diabetes - Not mentioned.\n14. Certain concomitant medications - Not mentioned, patient currently takes no medications.\n15. Contraindication to positive inotropic agents - Not mentioned.\n16. Contraindication to beta-blockers - Not mentioned.\n17. Active hepatic, renal, hematologic, etc. disease - Not mentioned.\n18. Alcohol or drug abuse - Not mentioned.\n19. Potassium <4 or >5.5 mEq/L - Not mentioned.\n20. Digoxin >1.2 ng/mL - Not mentioned.\n21. Pregnant or risk of pregnancy - Not mentioned, but patient is a 58-year-old woman.\n22. Participated in a clinical trial within 30 days - Not mentioned.\n23. Demonstrated non-compliance with medical regimens - Not mentioned.\n24. Hospitalized and hemodynamically unstable or acute illness - Patient presented to the ER, stability not clear.\n\nIn summary, based on the information provided in the patient note, it is difficult to definitively determine eligibility for this clinical trial. More investigation would be needed regarding the patient's cardiac status, left ventricular function, previous beta-blocker use/intolerance, and overall stability.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "9": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Efficacy of Tailored Cognitive-Behavioral Therapy for Chronic Back Pain\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient's primary complaint is chest pain, not chronic back pain. The patient note does not mention any chronic back pain lasting for at least 6 months, which is one of the inclusion criteria.\n\n2. The patient note does not indicate that the patient is currently receiving any treatment by medication or physical therapy for back pain, which is another inclusion criterion.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "10": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to end-stage renal disease or hemodialysis.\n\n2. The clinical trial is studying the effect of amlodipine on mortality in patients with end-stage renal failure on hemodialysis.\n\n3. The inclusion criteria for the trial are:\n   - End-stage renal disease\n   - Hemodialysis\n   - Hypertension\n   - Written informed consent\n\n4. Based on the patient note, there is no mention of the patient having end-stage renal disease or being on hemodialysis. The only relevant information is that the patient has hypertension.\n\nTherefore, based on the provided information, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "11": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states that the 58-year-old African-American woman presents with chest pain, hypertension, and obesity. However, there is no mention of diabetes or impaired glucose tolerance.\n\nThe inclusion criteria for the clinical trial are:\n1. Clinical diagnosis of hypertension\n2. Clinical diagnosis of type 2 diabetes or impaired glucose tolerance\n\nWhile the patient meets the first inclusion criterion of having hypertension, there is no information provided about whether she has diabetes or impaired glucose tolerance.\n\nTherefore, based on the information given, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether she has diabetes or impaired glucose tolerance.",
        "label": 1
    },
    "12": {
        "output": "Okay, let's go through the inclusion criteria for the OSCAR clinical trial and assess the eligibility of the patient based on the provided note.\n\nThe patient is a 58-year-old African-American woman, which meets the age criteria of 65 years or older and less than 85 years.\n\nThe note does not mention if the patient is currently on antihypertensive treatment with monotherapy, which is an inclusion criterion.\n\nThe note states that the patient has hypertension, but it does not provide the specific blood pressure readings. The inclusion criteria require a sitting blood pressure of \u2265140/90 mmHg on two clinic visits.\n\nThe patient has obesity, which is not listed as a risk factor in the inclusion criteria. However, the note does not mention if the patient has any of the listed risk factors, such as diabetes mellitus type 2, history of cerebrovascular events, myocardial infarction, angina pectoris, heart failure, left ventricular hypertrophy, aortic aneurysm or dissection, peripheral arterial obstruction, or proteinuria.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets all the inclusion criteria for the OSCAR clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "13": {
        "output": "To determine the patient's eligibility for the clinical trial \"The Renin-Angiotensin System in Essential Hypertension\", let's go through the inclusion criteria:\n\n1. Essential Hypertension: The patient is described as having hypertension, which meets this criterion.\n\n2. SBP 140-159 mmHg: The patient's systolic blood pressure (SBP) is not provided in the note.\n\n3. DBP 90-99 mmHg: The patient's diastolic blood pressure (DBP) is not provided in the note.\n\nSince the patient's blood pressure values are not given, it is difficult to determine if they meet the specific blood pressure criteria for inclusion in the trial.\n\nHowever, based on the information provided, the patient appears to have essential hypertension, which is one of the key inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their blood pressure values.",
        "label": 1
    },
    "14": {
        "output": "To determine the patient's eligibility for the \"Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina\" clinical trial, let's go through the inclusion criteria:\n\n1. Outpatients >= 18 years of age: The patient is 58 years old, so this criterion is met.\n\n2. Diagnosed clinically stable angina pectoris: The patient presents with episodic pressing/burning anterior chest pain, which radiates to the back and is accompanied by nausea, diaphoresis, and mild dyspnea. These symptoms are consistent with angina pectoris. The note also mentions that this is the first time the patient has experienced these symptoms, suggesting a recent diagnosis of angina.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "15": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old African-American woman presenting with chest pain, which could potentially be related to hypertension or ischemic heart disease.\n\nThe inclusion criteria for the clinical trial are:\n1. Clinical diagnosis of hypertension - The patient is known to have hypertension, so this criterion is met.\n2. Clinical diagnosis of one or more risk factors:\n   - Diabetes - Not mentioned, so this is unclear.\n   - Smoking habit - The patient denies smoking.\n   - Lipid metabolism abnormality - Not mentioned, so this is unclear.\n   - History of ischemic heart disease or cerebrovascular disease - No history of ischemic heart disease is mentioned, but the chest pain could potentially be related to this. More investigation would be needed.\n   - Obesity (BMI>25) - The patient is noted to have obesity, so this criterion is met.\n   - Chronic heart failure (NYHA II-III) - Not mentioned, so this is unclear.\n   - Electrocardiogram (ECG) abnormality (LVH) - The ECG showed nonspecific changes, so this is unclear if it meets the criterion of LVH.\n\nBased on the information provided, the patient meets at least two of the inclusion criteria (hypertension and obesity). However, there are some uncertainties around potential ischemic heart disease, diabetes, lipid abnormalities, and ECG findings that would require further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "16": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old African-American woman presenting with episodic chest pain, which meets the \"atypical chest pain\" inclusion criteria.\n\nShe has a history of hypertension and obesity, which are two of the listed risk factors for coronary artery disease.\n\nHowever, the patient note does not mention if she has a history of diabetes for at least 5 years, which is one of the key inclusion criteria.\n\nWithout knowing the diabetes history, I cannot definitively determine if she meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her diabetes history and duration.",
        "label": 1
    },
    "17": {
        "output": "To determine the patient's eligibility for the clinical trial \"Understanding Pediatric Chest Pain and Other Symptoms\", let's go through the inclusion criteria:\n\n1. Age: The patient is 58 years old, while the inclusion criteria specify an age range of 8-18 years. This patient does not meet the age requirement.\n\n2. Pediatric patients with referrals for innocent heart murmurs: The patient note does not mention any heart murmurs, so this criterion is not applicable.\n\n3. Pediatric patients experiencing chest pain: The patient is experiencing episodic pressing/burning anterior chest pain, which aligns with this inclusion criterion.\n\n4. English speaking: The patient note does not specify the patient's language, but we can assume they are English-speaking since the note is written in English.\n\nWhile the patient meets the criteria for experiencing chest pain and being English-speaking, the age requirement of 8-18 years is not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "18": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\n1. Patients with HF or IHD: The patient note mentions that the patient presented with chest pain, which could be indicative of ischemic heart disease (IHD). However, the diagnosis is not confirmed.\n\n2. Not currently taking the study medications of interest (ACE inhibitors/angiotensin receptor blockers for HF or statins for IHD): The patient note does not mention the patient's current medications, so it is unclear if they are taking these medications or not.\n\n3. Primary care physicians are part of the study population: The patient note does not provide information about the patient's primary care physician.\n\nBased on the available information, it is difficult to make a definitive assessment of the patient's eligibility for the clinical trial. More information is needed regarding the patient's diagnosis, current medications, and their primary care physician's involvement in the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "19": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\n1. Greater than 18 years of age: The patient is 58 years old, so this criterion is met.\n\n2. Patients with high blood pressure: The patient is known to have hypertension, so this criterion is also met.\n\nSince the patient meets both inclusion criteria, they would be eligible for this clinical trial comparing different combinations of high blood pressure medications.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "20": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to metastatic breast cancer.\n\n2. The clinical trial is for investigating different chemotherapy regimens in patients with metastatic breast cancer (MBC).\n\n3. The inclusion criteria specifically mention:\n   - Hormonal therapy-resistant MBC\n   - ER negative, failure of hormonal therapy for MBC, or relapse within 6 months after adjuvant hormonal therapy\n   - No prior anthracyclines or taxanes for MBC\n   - At least 6 months from completion of adjuvant chemotherapy\n   - Measurable or evaluable lesions\n   - Age 20-75 years\n   - Performance status 0-3\n   - Adequate hematologic, hepatic, and renal function\n   - Normal ECG\n   - Written informed consent\n\n4. Based on the patient note provided, there is no mention of the patient having metastatic breast cancer or any prior treatment for breast cancer.\n\n5. Therefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "21": {
        "output": "To determine the patient's eligibility for the clinical trial \"Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris\", let's go through the inclusion criteria one by one:\n\n1. Chronic stable angina pectoris: The patient is presenting with episodic pressing/burning anterior chest pain, which is a symptom of angina pectoris. The note mentions that this is the first time the patient is experiencing this, so it may not be considered \"chronic\" yet.\n\n2. Documented coronary artery disease: The note does not explicitly mention if the patient has documented coronary artery disease or not.\n\n3. Previous treatment with atenolol or other beta-blocker agent: The note states that the patient is currently not taking any medications, so there is no mention of previous treatment with atenolol or other beta-blockers.\n\n4. Exercise tolerance test positivity and stability: The note does not provide any information about an exercise tolerance test being performed or its results.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for this clinical trial. While the patient is presenting with symptoms of angina pectoris, there is no mention of documented coronary artery disease, previous treatment with beta-blockers, or an exercise tolerance test being performed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "22": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Chronic stable angina: The patient is presenting with episodic pressing/burning anterior chest pain, which could be indicative of chronic stable angina.\n\n2. Previous positive exercise tolerance test: The patient note does not mention any previous exercise tolerance test results.\n\n3. Disease not suitable for coronary intervention: There is no information provided about whether the patient's condition is suitable for coronary intervention or not.\n\n4. Do not have overt diabetes: The patient note states that the patient denies having diabetes.\n\n5. Body mass index (BMI) greater than 25: The patient note mentions that the patient has obesity, which typically means a BMI greater than 30.\n\nBased on the information provided in the patient note, the patient seems to potentially meet criteria 1, 4, and 5. However, there is not enough information to determine if criteria 2 and 3 are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "23": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman, which meets the age criteria of \"Women aged 50 and older\" for the clinical trial.\n\n2. The patient's chief complaint is chest pain, which is not related to the clinical trial's focus on osteoporosis prevention.\n\n3. There is no information provided about the patient's menopausal status or bone mineral density (BMD) scores, which are required for the inclusion criteria.\n\n4. Without knowing the patient's menopausal status and BMD scores, it is difficult to determine if she meets the inclusion criteria of \"At least 3 years postmenopausal\" and \"Lumbar spine BMD (L1 to L4) T score between 0 and -2.0\".\n\nBased on the information provided, there is not enough evidence to determine if the patient meets all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her menopausal status and BMD scores.",
        "label": 0
    },
    "24": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not match the inclusion criteria of this trial which is focused on low back pain.\n\n2. The patient's age of 58 years old falls outside the age range of 21-55 years specified in the inclusion criteria.\n\n3. There is no mention of the patient having idiopathic mechanical low back pain, which is a key inclusion criterion.\n\n4. Based on the information provided, this patient does not meet the inclusion criteria for this clinical trial on spinal manipulation for low back pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "25": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic chest pain, nausea, diaphoresis, and mild dyspnea, which are symptoms suggestive of acute coronary syndrome (ACS).\n\n2. The clinical trial is studying the efficacy and safety of intravenous isosorbide dinitrate compared to sublingual isosorbide dinitrate for relief of acute anginal pain episodes in ACS patients.\n\n3. The inclusion criteria for the trial are:\n   - Age > 18 years\n   - Admission to the ICCU with ACS (non-ST elevation ACS or within 24 hours of ST elevation myocardial infarction)\n   - Presence of ischemic symptoms (\u22655 minutes) during hospitalization\n   - Pain assessment of 3 out of 10 on Visual Analog Scale (VAS) or dynamic ECG findings\n   - Willing and able to provide written informed consent\n\n4. The patient meets the age criterion (58 years old) and is presenting with symptoms suggestive of ACS, although a definitive diagnosis is not provided.\n\n5. There is no information given about the patient's pain assessment score or ECG findings during this episode.\n\n6. Based on the available information, the patient potentially meets some of the inclusion criteria, but further investigation would be needed to confirm the diagnosis of ACS and assess the pain score/ECG changes.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "26": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman is presenting with symptoms of chest pain, nausea, diaphoresis, and mild dyspnea, which could be indicative of a cardiac issue. However, there is no mention of pulmonary hypertension or chronic thromboembolic pulmonary hypertension (CTEPH) in the patient note.\n\nThe clinical trial titled \"Gene Mutations in Secondary Pulmonary Hypertension\" has an inclusion criterion of a diagnosis of CTEPH and patient consent.\n\nGiven the lack of information about a CTEPH diagnosis in the patient note, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "27": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluating the Link Between Neighborhood Environments and Obesity Among African American Women\", I will go through the inclusion criteria one by one:\n\n1. \"Participating in the BWHS study\"\nThe patient note does not mention whether the patient is participating in the BWHS study or not. More information is needed to assess this criterion.\n\n2. \"Residing in New York, Los Angeles, or Chicago\"\nThe patient note does not specify the patient's location or place of residence. More information is needed to assess this criterion.\n\nSince there is not enough information provided in the patient note to definitively determine if the patient meets the inclusion criteria, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "28": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Acute episode of chest pain of less than 7 days duration as primary reason for admission to a chest pain clinic.\"\nThe patient note states that the patient presented to the ER with episodic chest pain that began two days earlier, which meets this criterion.\n\n2. \"Admitted to a chest pain clinic, suspected of acute coronary infarction, but with a negative diagnosis confirmed by normal coronary enzymes and normal ECG.\"\nThe patient was admitted to the ER (which can be considered a chest pain clinic) and was suspected of having a cardiac issue, but the EKG showed only nonspecific changes, suggesting a negative diagnosis for acute coronary infarction.\n\n3. \"Pain arising from the thorax and/or neck.\"\nThe patient's chest pain is described as anterior chest pain radiating to the back, which suggests it arises from the thorax.\n\n4. \"Able to read and understand Danish.\"\nThere is no information provided about the patient's ability to read and understand Danish.\n\nBased on the available information, the patient meets criteria 1-3, but there is not enough information to determine if they meet criterion 4. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "29": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to Prader-Willi syndrome or early-onset morbid obesity.\n\n2. The clinical trial is studying the characteristics of Prader-Willi syndrome and early-onset morbid obesity.\n\n3. The inclusion criteria state that for the Prader-Willi syndrome group, participants must have a confirmed diagnosis of Prader-Willi syndrome. For the early-onset morbid obesity group, participants must have a documented medical history of their weight exceeding 150% of ideal body weight or a BMI greater than 97% before age 4, and be under 30 years old.\n\n4. Based on the patient note provided, there is no mention of the patient having Prader-Willi syndrome or early-onset morbid obesity. The note focuses on her chest pain and risk factors like hypertension and obesity.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "30": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT\", let's go through the inclusion criteria:\n\n1. More than 10 years old: The patient is 58 years old, so this criterion is met.\n\n2. Electrocardiographic diagnosis of SVT: The patient's EKG shows nonspecific changes, but there is no clear mention of a diagnosis of Supraventricular Tachycardia (SVT). This criterion is not clearly met based on the information provided.\n\n3. SVT not converted by the vagal manoeuvres: There is no mention of whether vagal manoeuvres were attempted or not.\n\nBased on the available information, it is unclear if the patient meets the inclusion criteria for this clinical trial. The electrocardiographic diagnosis of SVT is not explicitly stated, and it is unknown if vagal manoeuvres were attempted and failed to convert the suspected SVT.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "31": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the clinical trial about preventing recurrence of primary spontaneous pneumothorax.\n\n2. The inclusion criteria for the trial specify:\n- Age between 15 and 40 years old\n- First episode of spontaneous pneumothorax\n- Symptomatic or rim of air > 2cm on CXR requiring simple aspiration\n- Complete or nearly complete and persistent lung expansion after aspiration\n- Adequate hematological, renal and hepatic function\n- Written informed consent\n\n3. Based on the patient note, this 58-year-old woman does not meet the age criteria for the trial (she is outside the 15-40 year age range).\n\n4. There is also no mention of her having a pneumothorax, which is a key inclusion criteria.\n\n5. Therefore, based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "32": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to pulmonary arterial hypertension (PAH), the target condition of the clinical trial.\n\n2. The inclusion criteria for the clinical trial state that participants must have completed a previous Phase 2 study (NCT00046319) of ambrisentan for PAH.\n\n3. There is no mention in the patient note of the patient having PAH or having participated in the previous Phase 2 study.\n\n4. Based on the information provided, this patient does not meet the key inclusion criteria for this PAH clinical trial extension study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "33": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Outpatients aged 65 years or older, and less than 85 years (at the time of informed consent), regardless of sex\n- The patient is 58 years old, which falls outside the age range specified in the criteria.\n\n2. Systolic blood pressure (SBP) \u2265140 mmHg or diastolic blood pressure (DBP) \u226590 mmHg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications.\n- The patient's blood pressure readings are not provided in the note.\n\n3. Systolic blood pressure (SBP) \u2265160 mmHg or diastolic blood pressure (DBP) \u2265100 mmHg in a sitting position on two consecutive measurements at clinic without antihypertensive medication.\n- The patient's blood pressure readings are not provided in the note, and it is not mentioned if she is taking any antihypertensive medications.\n\n4. Require at least one of the following medical history or risk factors:\n    - Medical history: The patient does not have a history of cerebrovascular accident, myocardial infarction, coronary revascularization, or angina pectoris mentioned in the note.\n    - Risk factors: The patient is female, has hypertension, and is obese, which could potentially qualify as risk factors.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for this clinical trial. While she has some risk factors like hypertension and obesity, her age falls outside the specified range, and her blood pressure readings and medication status are not provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "34": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with acute chest pain that started 2 days ago. The pain is episodic, pressing/burning, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea.\n\n2. The clinical trial is studying the effectiveness of manual treatment (chiropractic therapy) versus advice for self-management in patients with acute, musculoskeletal chest pain.\n\n3. The inclusion criteria for the trial are:\n   - Chest pain as the primary complaint\n   - Acute episode of pain less than 7 days duration\n   - Consent to standardized evaluation program\n   - Pain in the thorax and/or neck\n   - Age between 18-75 years\n   - Resident of Funen County, Denmark\n   - Able to read and understand Danish\n\n4. The patient meets several of the inclusion criteria:\n   - Chest pain is the primary complaint\n   - Acute episode of pain (2 days duration)\n   - Pain in the thorax and radiating to the back\n   - Age 58 (within the 18-75 range)\n\n5. However, there are a few potential issues:\n   - The patient's location is not specified, so it's unclear if they meet the residency requirement\n   - The patient's ability to read and understand Danish is not mentioned\n\n6. Additionally, the exclusion criteria include conditions like ACS, PCI/CABG, inflammatory joint disease, insulin-dependent diabetes, fibromyalgia, malignancy, and others. While some of these are ruled out (e.g., no mention of diabetes or fibromyalgia), others like ACS cannot be definitively excluded based on the information provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets several key inclusion criteria, but there are some unanswered questions regarding residency, language proficiency, and potential exclusionary conditions. Further evaluation would be needed to determine full eligibility.",
        "label": 0
    },
    "35": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male: The patient is a 58-year-old woman, so this criterion is not met.\n\n2. Stable angina with one of:\n   - Classical history of exertional angina pectoris: The patient presents with episodic pressing/burning anterior chest pain that started while she was walking, which could be indicative of exertional angina pectoris.\n   - Previous diagnostic exercise test: No information is provided about a previous diagnostic exercise test.\n   - Angiographic evidence of CAD: No information is provided about angiographic evidence of coronary artery disease (CAD).\n\n3. Aged 30 to 80 years: The patient is 58 years old, which falls within the age range.\n\n4. Weight between 60 and 100 Kg: No information is provided about the patient's weight.\n\nBased on the information provided in the patient note, the patient does not clearly meet all the inclusion criteria for this clinical trial. While she presents with symptoms suggestive of angina, her gender does not match the inclusion criteria, and there is no information about her weight or previous diagnostic tests/angiographic evidence of CAD.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "36": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the gastric cancer clinical trial.\n\n2. The clinical trial is specifically for patients with ErbB2 amplified advanced gastric cancer who have received one prior regimen containing 5-fluoropyrimidine and/or cisplatin.\n\n3. The patient note does not mention anything about the patient having gastric cancer or receiving any prior treatment for it.\n\n4. Based on the information provided in the patient note, there is no indication that the patient meets the inclusion criteria for this specific clinical trial on gastric cancer.\n\nTherefore, Trial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "37": {
        "output": "To determine the patient's eligibility for the \"Chest Pain Observation Unit Risk Reduction Trial\" clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: At least one modifiable cardiovascular risk factor (smoking, hyperlipidemia, hypertension, diabetes mellitus, obesity)\n\nFrom the patient note, we can identify the following modifiable cardiovascular risk factors:\n- Hypertension (the patient is known to have hypertension)\n- Obesity (the patient is described as obese)\n\nSince the patient has at least one modifiable cardiovascular risk factor (hypertension and obesity), they meet the inclusion criteria for this clinical trial.\n\nBased on the information provided, I would assess the patient's eligibility as follows:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "38": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Quality of Life Among Survivors of Hodgkin Lymphoma\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient note does not mention any diagnosis or history of Hodgkin Lymphoma. The patient is presenting with chest pain, which appears to be related to a potential cardiac issue.\n\n2. The inclusion criteria specifically state that participants must have biopsy-proven Hodgkin Lymphoma and have participated in specific IRB-approved protocols for the first-line treatment of Hodgkin Lymphoma between 1975-2000.\n\nSince the patient note does not indicate any history of Hodgkin Lymphoma or treatment for it, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "39": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic chest pain, nausea, diaphoresis, and mild dyspnea.\n2. The clinical trial is for patients who were investigated for chest pain or palpitations 6 months ago and still suffer from these symptoms.\n3. The patient note does not mention if she was investigated for these symptoms 6 months ago or if she is still suffering from them after being investigated.\n4. Based on the information provided, there is not enough evidence to determine if she meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "40": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis\", this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient note does not mention any digital ulcers or gangrene, which is a requirement for inclusion in this trial.\n2. The patient note does not indicate that the patient has systemic sclerosis or severe secondary Raynaud's phenomenon, which are also required for inclusion.\n\nThe patient's presenting complaint is episodic chest pain, which is not relevant to the trial's focus on digital ulcers in systemic sclerosis patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "41": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the clinical trial about treating pain in patients undergoing pleurodesis for malignant pleural effusion.\n\n2. The patient does not have a diagnosis of malignant pleural effusion, which is one of the key inclusion criteria for this trial.\n\n3. There is no mention of the patient undergoing or planning to undergo pleurodesis, which is another key inclusion criterion.\n\n4. The patient's chest pain seems to be related to a potential cardiac issue rather than a malignant pleural effusion or pleurodesis procedure.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial on treating pain in patients undergoing pleurodesis for malignant pleural effusion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "42": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old African-American woman presenting with symptoms suggestive of ischemic heart disease (IHD), which matches the target population of the clinical trial.\n\nThe inclusion criteria state:\n1. Men and women admitted for an IHD event (acute coronary syndrome or revascularization procedure) who are at low or moderate risk - This patient seems to be presenting with a potential acute coronary syndrome, so she would likely meet this criterion.\n\n2. Regular Internet access (home, work or other environment) - This is not mentioned in the patient note, so we cannot assume she meets this criterion without further investigation.\n\n3. Over 18 years of age - At 58 years old, she meets this criterion.\n\n4. Permission of the attending physician - This is also not mentioned, so would need further investigation.\n\n5. Able to read, write and understand English without difficulty - Again, not mentioned, so would need clarification.\n\n6. No physical limitations to regular activity - Her physical examination is noted as normal, so she likely meets this criterion barring any undisclosed limitations.\n\nOverall, based on the information provided, this patient appears to potentially meet several of the key inclusion criteria. However, there are a few criteria that would need further investigation or clarification before definitively determining eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "43": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the clinical trial about type 2 diabetes and lifestyle intervention.\n\n2. The clinical trial has the following key inclusion criteria:\n   - New onset of Type 2 Diabetes\n   - BMI > 25 kg/m^2\n\n3. Based on the patient note, there is no mention of the patient having type 2 diabetes or her BMI.\n\n4. Without information on whether the patient meets the key inclusion criteria of new onset type 2 diabetes and BMI > 25 kg/m^2, it would not be appropriate to refer this patient to the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "44": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED),\" the patient does not appear to have metastatic breast cancer. The patient is described as a 58-year-old African-American woman presenting with chest pain, nausea, diaphoresis, and mild dyspnea, which could be indicative of a cardiac condition.\n\nSince the only inclusion criterion mentioned is \"Patients with metastatic breast cancer,\" and the patient note does not indicate that the patient has metastatic breast cancer, I would assess the trial-level eligibility as follows:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "45": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be related to heart disease.\n2. The clinical trial is studying the use of beta-blockers in patients with COPD (chronic obstructive pulmonary disease).\n3. The inclusion criteria for the trial are:\n   - Clinical diagnosis of COPD\n   - Age > 40 years\n   - Smoking history > 15 pack years\n\n4. Based on the patient note, there is no mention of the patient having COPD or a significant smoking history.\n5. Therefore, this patient would likely not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "46": {
        "output": "Based on the given patient note and the clinical trial information, here is my assessment:\n\nThe patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to low back pain. The clinical trial is focused on investigating the effectiveness of neuromuscular balance in treating low back pain in patients aged 20-55 years.\n\nSince the patient's primary complaint is chest pain and not low back pain, and her age is slightly above the inclusion criteria range, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "47": {
        "output": "To determine the patient's eligibility for the clinical trial \"Case Management Alternatives for African American Women at High Risk for HIV\", let's go through the inclusion criteria one by one:\n\n1. Current substance abuse: The patient note does not mention any substance abuse, so this criterion is not met.\n\n2. Current high-risk sexual behavior: There is no information provided about the patient's sexual behavior, so it is unclear if this criterion is met or not.\n\n3. African American racial identification: The patient note states that the patient is a 58-year-old African-American woman, so this criterion is met.\n\nSince only one out of the three inclusion criteria is clearly met, and there is not enough information to determine if the second criterion is met, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "48": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient must be between the ages of 18 and 80 years.\n   - The patient is 58 years old, so this criterion is met.\n\n2. Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator's opinion is acceptable. Females must agree to remain on their established method of contraception through their participation in the study.\n   - This criterion is not applicable since the patient is a woman over 58 years old.\n\n3. Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to the enrollment) of myocardial infarction or significant coronary artery disease with noninvasive or angiographic confirmation.\n   - The patient has a history of episodic chest pain suggestive of angina, but no clear evidence of a prior myocardial infarction or confirmed coronary artery disease is mentioned.\n\n4. Symptoms that support the diagnosis of chronic angina and/or a history of an abnormal exercise response limited by angina and/or electrocardiograph (ECG) changes.\n   - The patient has episodic chest pain suggestive of angina, so this criterion is likely met.\n\n5. Moderate angina pectoris (Class II or Class III, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System)\n   - The severity of the patient's angina is not clearly specified, so it is unclear if this criterion is met.\n\n6. Naive patient or patient who's Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day -7 and day 0\n   - No information is provided about the patient's exercise tolerance or TED, so it is unclear if this criterion is met.\n\n7. All anti-angina regimen (except short-acting nitroglycerin, and one beta-blocker or calcium channel blocker), warfarin or other oral anticoagulants which were used prior to this initial visit can be discontinued.\n   - The patient is not currently taking any medications, so this criterion is met.\n\n8. Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the verbal rating scales and diary cards.\n   - No information is provided about the patient's ability to comply with study procedures, so it is unclear if this criterion is met.\n\n9. Patient must be able to give voluntary written informed consent.\n   - This criterion is likely met, but not explicitly stated.\n\nIn summary, while some of the key criteria are potentially met (age, symptoms suggestive of angina), there is not enough information provided to definitively determine if the patient meets all of the inclusion criteria. Further investigation would be needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "49": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be related to heart failure.\n2. The clinical trial is studying the effects of different beta-blockers (carvedilol vs metoprolol) in patients with heart failure.\n3. One of the key inclusion criteria is \"Patients eligible for the study had objective evidence of systolic dysfunction (ejection fraction \u226440%)\".\n4. The patient note does not mention the patient's ejection fraction or provide objective evidence of systolic dysfunction.\n\nGiven the lack of information about the patient's ejection fraction and systolic function, which are key criteria for this particular trial, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their ejection fraction and evidence of systolic dysfunction.",
        "label": 1
    },
    "50": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be indicative of ischemic heart disease (IHD).\n\n2. The clinical trial is studying the prevalence and outcome of endothelial function in morbidly obese patients undergoing bariatric surgery.\n\n3. The inclusion criteria for the trial is: \"Morbidly obese patients who fulfill the NIH criteria for surgical intervention.\"\n\n4. From the patient note, we know the patient is obese, but it does not explicitly state if she meets the NIH criteria for surgical intervention for obesity.\n\n5. Without knowing if she meets that specific criteria, we cannot definitively say she is eligible or ineligible for the trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether she meets the NIH criteria for surgical intervention for obesity.",
        "label": 1
    },
    "51": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the clinical trial about GIP (glucose-dependent insulinotropic polypeptide) and its effects on adipose tissue metabolism and diabetes.\n\n2. The inclusion criteria for the clinical trial are:\n- Lean subjects with normal glucose tolerance (BMI 20-25 kg/m2)\n- Obese subjects with normal glucose tolerance (BMI > 30 kg/m2)  \n- Obese subjects with impaired glucose tolerance\n- Obese subjects with diet-controlled diabetes mellitus\n- Morbidly obese subjects with type 2 diabetes who have undergone bariatric surgery\n\n3. Based on the information provided in the patient note, there is no mention of the patient's BMI, glucose tolerance status, or whether she has diabetes or has undergone bariatric surgery.\n\n4. Without this crucial information, it is difficult to determine if the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her BMI, glucose tolerance status, and whether she has diabetes or has undergone bariatric surgery.",
        "label": 2
    },
    "52": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could potentially be related to heart disease.\n\n2. The clinical trial is looking at the efficacy of beta-blockers in treating heart failure.\n\n3. One of the inclusion criteria is \"patients with documented heart failure\".\n\n4. Based on the patient note, there is no clear documentation of heart failure yet. The chest pain symptoms could potentially be due to heart failure, but further testing would be needed to confirm a diagnosis.\n\n5. Another inclusion criteria is that the trials must be \"randomized control trials of beta-blocker versus control\".\n\n6. This patient has not been enrolled in any clinical trial yet, so this criteria does not apply at this stage.\n\nGiven the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient's chest pain symptoms could potentially be due to heart failure, which would make them eligible for the beta-blocker trial after a confirmed diagnosis. However, more testing is needed before definitively referring them to this specific clinical trial.",
        "label": 2
    },
    "53": {
        "output": "Based on the given patient note and the clinical trial information, this patient does not meet the inclusion criteria for the clinical trial titled \"A Prospective, Randomised Long-term Follow-up of Operative Versus Non-operative Treatment of Gr. 3 Acromioclavicular Dislocation\".\n\nThe key points are:\n\n1. The patient note describes a 58-year-old African-American woman presenting with chest pain, nausea, diaphoresis, and mild dyspnea, which are symptoms suggestive of a cardiac condition.\n\n2. The clinical trial is focused on comparing operative and non-operative treatment for Tossy grade 3 acromioclavicular (AC) dislocation, which is a shoulder injury.\n\n3. The inclusion criteria specifically state that patients must have a Tossy grade 3 AC dislocation and have been recruited between 1989 and 1991 at Kuopio University Hospital for a randomized controlled study.\n\nSince the patient's condition does not involve an AC dislocation and does not meet the inclusion criteria of being recruited for the specific study between 1989 and 1991, this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "54": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be related to a cardiac condition.\n\n2. The clinical trial is studying the effects of ACE inhibitors during cardiopulmonary bypass in infants and children with congenital heart disease.\n\n3. One of the inclusion criteria is that the patients must be infants or children (newborn to 17 years of age) undergoing cardiopulmonary bypass for elective surgical correction of a congenital heart defect.\n\n4. Another inclusion criterion is that the patients must be taking an ACE inhibitor prior to their operation.\n\n5. Based on the patient note, this 58-year-old woman does not have a congenital heart defect and is not an infant or child. Additionally, there is no mention of her taking an ACE inhibitor.\n\nTherefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "55": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Osteopathic Treatment of Low Back Pain\", the patient does not seem to be eligible for this trial. The key reasons are:\n\n1. The patient's chief complaint is chest pain, not low back pain, which is the focus of the clinical trial.\n2. The inclusion criteria specifically mention including patients between the ages of 19 and 55 years old, while the patient is 58 years old.\n\nUnless there are additional details suggesting the patient has low back pain that meets the inclusion criteria, I would not recommend referring this patient to the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "56": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity.\n\n2. The clinical trial is titled \"The First Therapeutic Intervention in Malignant Pleural Effusion Trial\" and is studying ways to prevent pain during pleurodesis, a procedure to drain fluid caused by cancer cells in the lining of the lung.\n\n3. The key inclusion criteria for this trial are:\n   - Clinically confident diagnosis of malignant pleural effusion requiring pleurodesis\n   - Expected survival more than 1 month\n   - Written informed consent\n\n4. Based on the patient note, there is no mention of the patient having a malignant pleural effusion or requiring pleurodesis. The chest pain and other symptoms could be due to various causes, but there is no clear indication that it is related to a malignant pleural effusion.\n\n5. Therefore, based on the information provided, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "57": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman presents with chest pain, which could be related to cardiovascular disease. However, the clinical trial is specifically examining the genetic influence on the response to beta-blocker medications in people with type 2 diabetes or pre-diabetes.\n\nThe patient note does not mention whether the patient has type 2 diabetes or pre-diabetes, which are the inclusion criteria for this clinical trial. Therefore, without this crucial information, it is difficult to determine the patient's eligibility for this particular trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of whether she has type 2 diabetes or pre-diabetes.",
        "label": 0
    },
    "58": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be indicative of hypertension or a cardiac issue.\n\n2. The clinical trial is studying the efficacy and safety of a drug called PRITOR in patients with arterial hypertension who do not tolerate ACE inhibitors.\n\n3. The inclusion criteria for the trial are:\n   - Patients over 18 years of age (the patient meets this criterion)\n   - Arterial hypertension with SBP < 160 mmHg and DBP < 100 mmHg (the patient is known to have hypertension, but her blood pressure values are not provided)\n   - Patients who do not tolerate ACE inhibitors (the patient's ACE inhibitor tolerance is not mentioned)\n\n4. Based on the information provided, it is unclear if the patient meets all the inclusion criteria for the trial. While she is over 18 years old and has hypertension, her specific blood pressure values and ACE inhibitor tolerance are not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her blood pressure values and ACE inhibitor tolerance.",
        "label": 0
    },
    "59": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to pregnancy or low back pain.\n\n2. The clinical trial is studying treatments for low back pain that started during pregnancy.\n\n3. The inclusion criteria specifically state:\n   - Healthy\n   - 20-49 years old\n   - Pregnant with a singleton\n   - Low back pain began during pregnancy and has lasted more than one week\n   - Low back pain is reproducible with palpation\n\n4. Based on the patient note, this 58-year-old woman is not pregnant and is presenting with chest pain, not low back pain.\n\nTherefore, this patient does not meet the inclusion criteria for this particular clinical trial on pregnancy-related low back pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "60": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to sickle cell disease.\n\n2. The clinical trial is focused on preventing acute chest syndrome (ACS) in patients with sickle cell disease by using transfusions based on elevated secretory phospholipase A2 (sPLA2) levels.\n\n3. The inclusion criteria specifically mention having a hemoglobin diagnosis of sickle cell disease (SS, SC, or S-\u03b2 thalassemia), along with other criteria related to sPLA2 levels, fever, chest X-ray findings, and hemoglobin levels.\n\n4. Since the patient note does not mention any diagnosis of sickle cell disease, she would not meet the primary inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "61": {
        "output": "To determine the patient's eligibility for the clinical trial \"Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction\", let's go through the inclusion criteria one by one:\n\n1. The subject must be 18 years of age or older.\nThe patient is 58 years old, so this criterion is met.\n\n2. The subject must present to the Emergency Department with symptoms consistent with acute coronary syndromes (e.g., chest discomfort/pain, squeezing/fullness in the chest, pain radiating to left or both arms, jaw pain, pain in the back/neck/stomach, shortness of breath, cold sweat, nausea/vomiting, lightheadedness).\nThe patient presents with episodic pressing/burning anterior chest pain that radiates to the back, accompanied by nausea, diaphoresis (cold sweat), and mild dyspnea (shortness of breath). These symptoms are consistent with acute coronary syndromes, so this criterion is met.\n\n3. The subject must present to the Emergency Department within 6 hours of the onset of the most recent symptoms that prompted the subject to seek medical attention in the Emergency Department.\nThe patient's symptoms started two days earlier, so this criterion is not met.\n\n4. The patient agrees to abide by all aspects of the protocol, including all telephone follow-up.\nThere is no information provided about the patient's willingness to participate in the trial, so we cannot determine if this criterion is met or not.\n\nBased on the information provided, the patient meets two out of the four inclusion criteria, but does not meet the time window criterion of presenting within 6 hours of symptom onset. Additionally, we do not have information about the patient's willingness to participate in the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "62": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to childhood obesity.\n\n2. The clinical trial titled \"Trial of the MEND Childhood Obesity Treatment Program\" is specifically for overweight or obese children aged 7-13 years old.\n\n3. The patient does not meet the inclusion criteria of being a child aged 7-13 years old who is overweight or obese.\n\nTherefore, based on the given information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "63": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease\", let's go through the inclusion criteria:\n\nInclusion Criteria: Patients with intermediate (>20%, <90%) risk of IHD based on age, gender, symptoms and exercise stress test results\n\nGiven information:\n- The patient is a 58-year-old African-American woman presenting with episodic chest pain, nausea, diaphoresis, and mild dyspnea.\n- She has hypertension and obesity, but no diabetes, hypercholesterolemia, or family history of heart disease.\n- Physical examination and EKG show non-specific changes.\n\nBased on the provided information, this patient appears to have symptoms suggestive of possible ischemic heart disease (IHD), and her age, gender, and risk factors (hypertension and obesity) would likely put her in the intermediate risk category for IHD.\n\nHowever, the note does not mention if an exercise stress test was performed or the results of such a test. This information would be crucial in determining if she meets the specific inclusion criteria of having an intermediate risk based on age, gender, symptoms, and exercise stress test results.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her exercise stress test results or other risk stratification methods to confirm her intermediate risk status for IHD.",
        "label": 1
    },
    "64": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the inclusion criteria for a clinical trial on acute low back pain.\n\n2. The inclusion criteria specifically state that patients must have \"a clinical diagnosis of acute low back pain that is felt down to the lower leg below the knee with the onset no longer than 30 days before Visit 1.\"\n\n3. There is no mention of the patient having low back pain or any symptoms related to that in the patient note provided.\n\n4. The other inclusion criteria, such as being able to verbalize pain characteristics, being medically stable, and being an appropriate candidate for opioid pain medication, are not clearly met or unmet based on the information given.\n\nTherefore, based on the provided patient note and inclusion criteria for the clinical trial on acute low back pain, I would assess the eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "65": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Should the Joint Capsule of the Painful Stiff Shoulder be Ruptured During Intra-articular Hydraulic Distension?\", this patient would not be eligible for the trial.\n\nThe patient note describes a 58-year-old woman presenting with chest pain, nausea, diaphoresis, and mild dyspnea, which are symptoms suggestive of a cardiac issue rather than a shoulder problem.\n\nThe inclusion criteria for the clinical trial specifically require:\n1. Shoulder discomfort for at least one month\n2. Limited range of motion of the glenohumeral joint (shoulder joint) in at least two directions\n\nThere is no mention of the patient having any shoulder-related issues or limited range of motion in the provided patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "66": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be cardiac in nature.\n2. She has hypertension and obesity, which are risk factors for obstructive sleep apnea (OSA).\n3. However, there is no mention of her having been diagnosed with OSA or being on CPAP therapy.\n4. The inclusion criteria specifically require patients to have an apnea-hypopnea index (AHI) > 20/hr and be on CPAP therapy.\n5. Since there is no information provided about the patient's AHI or CPAP use, we cannot definitively determine if she meets the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether she has OSA and is on CPAP therapy, as well as assessing if her hypertension is uncontrolled despite CPAP.",
        "label": 0
    },
    "67": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be cardiac in nature.\n2. The clinical trial is looking at resistant hypertension in patients with type-II diabetes mellitus.\n3. From the patient note, there is no mention of the patient having diabetes mellitus.\n4. The inclusion criteria specifically state that patients must have type-II diabetes mellitus and hypertension.\n\nBased on the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial on resistant hypertension in type-II diabetes, as there is no indication that the patient has diabetes.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "68": {
        "output": "To determine the patient's eligibility for the clinical trial \"Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test\", let's go through the inclusion criteria:\n\n1. Over 18 years old: The patient is 58 years old, so this criterion is met.\n\n2. CCT > 60 ml/min: There is no information provided about the patient's creatinine clearance (CCT), so this criterion cannot be evaluated.\n\n3. No IHD (Ischemic Heart Disease): The patient is presenting with chest pain, which could be a symptom of IHD, but there is no definitive diagnosis mentioned. This criterion cannot be fully evaluated.\n\n4. No hyper/hypoparathyroidism: There is no information provided about the patient's parathyroid status, so this criterion cannot be evaluated.\n\n5. No active malignancy: There is no mention of the patient having any active malignancy, so this criterion is likely met.\n\n6. Not taking calcium, phosphate: There is no information provided about the patient's medication intake, so this criterion cannot be evaluated.\n\nBased on the available information, some of the inclusion criteria cannot be fully evaluated due to missing details. However, the patient's age and the absence of any mentioned active malignancy suggest that they could potentially be eligible for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "69": {
        "output": "To determine the patient's eligibility for the \"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial\", let's go through the inclusion criteria one by one:\n\n1. The decision to randomize participants was made by a qualified physician or paramedic who was present at the time.\n   - This criterion is not applicable for determining eligibility based on the given patient note.\n\n2. Participants were included in the study if they presented either via ambulance or to a center where PCI was not performed and met all of the following criteria:\n   - The patient note does not mention how the patient presented (via ambulance or to a center without PCI facilities), so this criterion cannot be fully evaluated.\n\n3. Provided written informed consent before initiation of any study related procedures. Participants randomized in the ambulance may initially have signed an abridged version.\n   - This criterion is not applicable for determining eligibility based on the given patient note.\n\n4. Aged \u226518 years at the time of randomization.\n   - The patient is 58 years old, so this criterion is met.\n\n5. Had a presumed diagnosis of STE-ACS with onset of symptoms of >20 minutes and <12 hours with one or more of the following:\n   - ST segment elevation of \u22651 millimeters (mm) in \u22652 contiguous leads\n   - Presumably new left bundle branch block\n   - An infero-lateral myocardial infarction with ST segment depression of \u22651 mm in \u22652 of leads V1-3 with a positive terminal T wave\n   - The patient note mentions that the patient presented with \"episodic pressing/burning anterior chest pain\" and \"nonspecific changes\" on the EKG, but it does not provide specific details about ST segment elevation or depression, left bundle branch block, or infero-lateral myocardial infarction. Therefore, this criterion cannot be fully evaluated based on the given information.\n\n6. All participants would proceed with emergent angiography and primary PCI if indicated <2 hours after first medical contact\n   - The patient note does not mention whether the patient would proceed with emergent angiography and primary PCI, so this criterion cannot be evaluated.\n\nBased on the available information in the patient note, the patient meets the age criterion (\u226518 years), but there is not enough information to determine if the other inclusion criteria are met, particularly the criteria related to the diagnosis of STE-ACS and the planned treatment approach.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "70": {
        "output": "Based on the given patient note and the clinical trial information, this patient does not seem eligible for the trial titled \"Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC\u2122 Model\".\n\nThe patient note describes a 58-year-old woman presenting with chest pain, nausea, diaphoresis, and mild dyspnea, which are symptoms suggestive of a cardiac issue rather than allergic conjunctivitis.\n\nThe only inclusion criterion mentioned for the clinical trial is a positive bilateral conjunctival allergen challenge reaction, which is not present in the patient's case.\n\nTherefore, based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "71": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Stable angina patients whose coronary lesions is confirmed by angiography or receives PCI\n- The patient is presenting with episodic chest pain suggestive of angina, but there is no mention of confirmed coronary lesions or prior PCI. This criterion is not clearly met.\n\n2. Unstable Angina/NSTEMI patients who completed PCI for main lesions\n- There is no indication that the patient has unstable angina or NSTEMI, or that they have undergone PCI. This criterion is not met.\n\n3. Either systolic > 130mmHg or diastolic > 80mmHg, or patients with anti-hypertensive drugs\n- The patient is known to have hypertension, which suggests they may be taking anti-hypertensive drugs. This criterion is potentially met.\n\nOverall, while the patient has hypertension which meets one of the inclusion criteria, there is no clear confirmation of coronary artery disease or prior interventions. Based on the information provided, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional testing, such as an angiogram or stress test, may be needed to confirm the presence of coronary artery disease and determine if the patient fully meets the inclusion criteria for this trial.",
        "label": 1
    },
    "72": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman, which meets the age criteria for the trial (no specific age range given in the inclusion criteria).\n\n2. The patient has obesity based on the note mentioning she is known to have obesity. This meets the inclusion criteria of having a BMI over 25.0 kg/m2.\n\n3. The patient denies smoking, which meets the inclusion criteria of being a non-smoker.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "73": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Diagnosis of unstable angina and non-Q wave myocardial infarction\n- The patient is presenting with symptoms suggestive of unstable angina (episodic chest pain, nausea, diaphoresis, mild dyspnea), so this criterion is likely met.\n\n2. Age 18-75 yr.\n- The patient is 58 years old, which falls within this range.\n\n3. Diameter stenosis of coronary artery<70% diameter stenosis by visual estimation\n- There is no information provided about the degree of coronary stenosis for this patient.\n\n4. Blood pressure >110/70 mmHg\n- The patient's blood pressure is not provided.\n\n5. Heart rate 60-100 bpm, No cardiac arrhythmias\n- The patient's heart rate and rhythm are not provided.\n\nBased on the information given, some key inclusion criteria are potentially met (diagnosis, age), while others cannot be determined (degree of coronary stenosis, blood pressure, heart rate/rhythm). Further investigation would be needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "74": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subject is >18 years of age or < 60 years old\nThe patient is 58 years old, which falls within this range.\n\n2. Subject is undergoing abdominoplasty, bilateral breast reduction, bilateral breast lift, bilateral brachioplasty, bilateral lateral thigh and buttocks lift, or any combination thereof\nThe patient note does not mention any of these procedures, so this criterion is not met.\n\n3. Subject is able to discontinue anticoagulant therapy (including Aspirin)\nThere is no information provided about whether the patient is taking anticoagulants or not.\n\n4. Subject is willing and able to comply with study follow-up procedures\nThere is no information about the patient's willingness or ability to comply with follow-up procedures.\n\n5. Subject is willing to provide written informed consent for their participation in the study\nThere is no information about whether the patient would provide informed consent.\n\nBased on the information provided in the patient note, the key exclusion is that the patient is not undergoing any of the specified procedures required for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "75": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be indicative of ischemic heart disease.\n\n2. The clinical trial is studying the effect of amlodipine (a calcium channel blocker) on the anti-platelet effect of clopidogrel in patients with coronary artery disease.\n\n3. The inclusion criteria for the trial are:\n   - Patient with ischemic heart disease\n   - Currently taking clopidogrel (loading or maintenance dose)\n   - In need of additional medication for blood pressure control (target <130/90 mmHg) or angina control\n\n4. Based on the patient note, the patient is presenting with chest pain suggestive of ischemic heart disease, which meets the first inclusion criterion.\n\n5. The note does not mention if the patient is currently taking clopidogrel, so we cannot confirm if she meets the second inclusion criterion.\n\n6. The patient has hypertension, which may require additional medication for blood pressure control, potentially meeting the third inclusion criterion.\n\nGiven the information provided, we cannot definitively determine if the patient meets all the inclusion criteria. However, the patient appears to have ischemic heart disease and hypertension, which could make her eligible for the trial upon further investigation of her medication history and need for additional blood pressure control.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "76": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be related to hypertension.\n2. The clinical trial is looking at the tolerability of telmisartan, an angiotensin II receptor blocker, in hypertensive patients who had to stop taking ACE inhibitors due to cough.\n3. The inclusion criteria for the trial are:\n   - Hypertension\n   - Age > 18\n   - Previously had to stop ACE inhibitor treatment due to cough\n4. The exclusion criteria are:\n   - Currently taking telmisartan\n   - Cholestatic disorders and severe hepatic failure\n   - Allergy to telmisartan\n   - Pregnancy and lactation\n\n5. Based on the patient note, the patient meets the following inclusion criteria:\n   - Hypertension\n   - Age > 18 (58 years old)\n6. However, there is no mention of the patient previously taking an ACE inhibitor and having to stop due to cough, which is a key inclusion criterion.\n7. There is also no information provided about the exclusion criteria, such as cholestatic disorders, hepatic failure, allergy to telmisartan, or pregnancy/lactation status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets some of the inclusion criteria, but more information is needed to determine if they had to stop an ACE inhibitor due to cough and if they meet the exclusion criteria. Further investigation would be required to make a definitive assessment of eligibility.",
        "label": 0
    },
    "77": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to head and neck cancer.\n\n2. The clinical trial is for locally advanced head and neck squamous cell carcinoma (HNSCC). \n\n3. The inclusion criteria specifically mention:\n   - Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, larynx supraglottix\n   - Locally advanced disease defined by specific tumor staging criteria\n   - No prior treatments for head and neck cancer except under certain conditions\n   - Able to undergo chemotherapy or radiotherapy\n   - Signed informed consent\n\n4. Based on the patient note provided, there is no mention of the patient having head and neck cancer or meeting any of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "78": {
        "output": "Based on the provided patient note and the clinical trial information, this patient does not appear to have acute renal failure or require renal replacement therapy. The patient note describes a 58-year-old woman presenting with chest pain, which is not related to the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "79": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Treatment of Coronary Heart Disease With Amiloride\" and assess the eligibility of the patient based on the provided note.\n\nInclusion Criteria:\n1. Male or female; age 35-75 years having angina (Canada Cardiovascular Society Class II-IV)\n   - The patient is a 58-year-old woman presenting with episodic chest pain suggestive of angina, so this criterion is likely met.\n\n2. Essential Hypertension defined as taking at least 1 anti-hypertensive medication, or average systolic blood pressure \u2265140 mm Hg, or diastolic blood pressure \u226590 mmHg\n   - The patient is known to have hypertension, so this criterion is met.\n\n3. ST-T changes of LVH (Romhilt-Estes or Framingham Heart Study criteria, with typical LV strain pattern, or isoelectric, inverted or biphasic T waves)\n   - There is no mention of LVH or specific ECG changes in the patient note.\n\n4. ST-T changes of ischemia in resting ECG (ST depression, isoelectric, biphasic, negative or inverted T-waves)\n   - The ECG shows nonspecific changes, but it is not clear if there are specific ischemic changes.\n\n5. Serum potassium < 5.0 mmol/L prior to randomization\n   - There is no information provided about the patient's serum potassium level.\n\n6. Negative pregnancy test in child-bearing potential women\n   - This criterion is likely met as the patient is a 58-year-old woman.\n\n7. Willing to comply with scheduled visits\n   - There is no information provided about the patient's willingness to comply with scheduled visits.\n\n8. Informed consent form signed by the subject\n   - There is no information provided about whether the patient has signed an informed consent form.\n\nBased on the available information, some of the inclusion criteria are likely met (age, angina, hypertension), while others are unclear or not mentioned (specific ECG changes, serum potassium level, willingness to comply, informed consent). Further investigation would be needed to determine if the patient meets all the criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "80": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old African-American woman, so her age meets the inclusion criteria which does not specify an age range.\n\nThe patient does not have chronic low back pain for >6 months. The note states that she is presenting with episodic chest pain that began 2 days earlier, which does not meet the inclusion criteria of chronic low back pain for >6 months.\n\nThere is no information provided about the patient's waist circumference, so we cannot determine if she meets that inclusion criteria.\n\nThere is no information about the patient being willing and able to participate in regular exercise for 14 weeks.\n\nThe patient is not mentioned as using pain medications to control low back pain.\n\nThere is no information about the patient being free of abnormal cardiovascular responses during a screening graded maximal walk test.\n\nBased on the information provided in the patient note, this patient does not meet several of the key inclusion criteria for the clinical trial on resistance exercise effects on fear avoidance and physical function in obese older adults with low back pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "81": {
        "output": "To determine the patient's eligibility for the clinical trial \"Expressive Writing for Heart Healing\", let's go through the inclusion criteria one by one:\n\n1. Obesity: The patient note mentions that the patient is known to have obesity, so this criterion is met.\n\n2. Ischemic Heart Disease (IHD): The patient presented with chest pain, which could be a symptom of IHD. However, the note does not explicitly state that the patient has been diagnosed with IHD. More investigation may be needed to confirm this criterion.\n\n3. Signed informed consent: This criterion cannot be evaluated based on the given information.\n\nSince one of the inclusion criteria (IHD) is not clearly met based on the provided information, and the informed consent criterion cannot be evaluated, I would consider the following assessment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "82": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, it is clear that the patient does not have ovarian cancer or pancreatic cancer, which are the target conditions for this trial.\n\nThe patient is a 58-year-old African-American woman presenting with chest pain, which is likely related to cardiovascular issues rather than cancer.\n\nTherefore, this patient would not be eligible for the clinical trial evaluating the combination therapy of Genexol\u00ae-PM plus Carboplatin\u00ae compared to Genexol\u00ae plus Carboplatin\u00ae as a first-line treatment for ovarian cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "83": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic chest pain, which meets the age criteria (18-80 years old) for the clinical trial.\n\n2. The patient's symptoms of pressing/burning anterior chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea, seem to align with the Rome III criteria for Functional Chest Pain of Presumed Esophageal Origin.\n\n3. The patient has no known history of gastroesophageal reflux disease (GERD), esophageal motility disorders, or histopathology that could explain the chest pain.\n\n4. The patient is not currently taking any medications, so it is unclear if she has tried antidepressant therapy for her chest pain.\n\n5. The patient has undergone cardiac evaluation with a normal EKG, suggesting a negative cardiac evaluation.\n\n6. There is no mention of a gastrointestinal evaluation or endoscopy results in the patient note.\n\nBased on the available information, this patient potentially meets several of the inclusion criteria for the clinical trial, but there are some key details missing, such as whether she has tried antidepressant therapy and the results of a gastrointestinal evaluation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "84": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old African-American woman, which meets the \"Men\" inclusion criteria for gender.\n\nShe has obesity based on the note mentioning she is known to have obesity. This meets the \"Obese BMI>30\" criteria.\n\nThere is no mention of her taking aspirin, so she likely meets the \"No aspirin treatment before inclusion\" criteria.\n\nShe is presenting with episodic pressing/burning anterior chest pain that radiates to the back and is accompanied by nausea, diaphoresis and mild dyspnea. This seems to fit the \"Chest pain like stable angina\" criteria.\n\nHowever, the note does not mention if she has undergone coronary angiography or tomography coronary angiography to evaluate for coronary artery disease, which is required based on the \"Coronary exploration: coronary angiography or tomography coronary angiography\" criteria.\n\nBased on the information provided, I would assess her eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of whether she has undergone the required coronary imaging studies.",
        "label": 0
    },
    "85": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Osteopathic Treatment in Adult Patients With Cystic Fibrosis\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient note does not mention a diagnosis of cystic fibrosis, which is one of the inclusion criteria for the trial.\n2. The patient's presenting complaint is chest pain, which is not specifically mentioned as an inclusion criterion for the trial.\n\nWhile the patient is an adult (age 58) and has chest pain, there is no indication that she has cystic fibrosis or meets the other inclusion criteria listed.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "86": {
        "output": "Based on the given patient note and the clinical trial information, this patient does not seem eligible for the trial titled \"Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model\".\n\nThe patient note describes a 58-year-old woman presenting with chest pain, nausea, diaphoresis, and mild dyspnea, which are symptoms suggestive of a cardiac issue rather than allergic conjunctivitis.\n\nThe only inclusion criterion mentioned for the clinical trial is a positive bilateral conjunctival allergen challenge (CAC) reaction, which is not present in the patient's case.\n\nTherefore, based on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "87": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Written informed consent - This is not mentioned in the patient note, so we cannot determine eligibility based on this criterion.\n\n2. Males and females aged 18 to 79 years - The patient is a 58-year-old woman, so she meets this criterion.\n\n3. Able to perform a Sheffield Modified Bruce Treadmill Exercise Protocol - This is not mentioned in the patient note, so we cannot determine eligibility based on this criterion.\n\n4. At least a 3-months history of chronic stable angina triggered by physical effort and relieved by rest and/or sublingual nitroglycerin - The patient presents with episodic pressing/burning anterior chest pain that began two days earlier, which is not consistent with chronic stable angina. Therefore, she does not meet this criterion.\n\n5. Coronary artery disease documented by one or more of the following:\n   - Angiographic evidence of \u2265 50% stenosis of one or more major coronary arteries\n   - History of myocardial infarction (MI) documented by positive CK-MB enzymes, troponins, or ECG changes\n   - Cardiac nuclear scan studies diagnostic of CAD, e.g., thallium scan or ECHO with stress or pharmacologic interventions (adenosine, dipyridamole, etc.)\n   The patient note does not mention any of these, so we cannot determine eligibility based on this criterion.\n\n6. Stable treatment with one of the following antianginal medications for at least 4 weeks prior to Screening:\n   - beta-blocker (atenolol up to 50 mg daily or metoprolol up to 100 mg daily)\n   - dihydropyridine calcium-channel blocker (amlodipine up to 5 mg daily or nifedipine up to 30 mg daily)\n   - non-dihydropyridine calcium-channel blocker (diltiazem 180 to 360 mg daily or verapamil 180 to 360 mg daily)\n   The patient note mentions that she currently takes no medications, so she does not meet this criterion.\n\n7. Willingness to discontinue other antianginals and be treated with one of the allowed antianginal therapies - Since the patient is not taking any antianginal medications, this criterion is not applicable.\n\n8. Documented history of type 2 diabetes mellitus - The patient note mentions that she has hypertension and obesity but does not mention type 2 diabetes mellitus, so she does not meet this criterion.\n\n9. Females of childbearing potential must agree to utilize highly effective contraception methods from Screening throughout the duration of study treatment and for 14 days following the last dose of study drug - This is not mentioned in the patient note, so we cannot determine eligibility based on this criterion.\n\nBased on the information provided in the patient note, the patient does not meet several key inclusion criteria for this clinical trial, such as having chronic stable angina, documented coronary artery disease, stable treatment with antianginal medications, and a documented history of type 2 diabetes mellitus.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "88": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could potentially be related to cardiovascular issues.\n\n2. The clinical trial is investigating the efficacy and safety of ivabradine, a heart rate-lowering medication, in patients with obstructive airway diseases like asthma and COPD.\n\n3. The inclusion criteria for the trial are:\n   - Documented diagnosis of asthma or COPD\n   - Stable condition without exacerbation for at least 1 month\n   - Mean heart rate \u2265 60 bpm\n\n4. Based on the patient note, there is no mention of the patient having asthma or COPD. The chest pain could be related to cardiovascular issues, but the trial specifically focuses on obstructive airway diseases.\n\n5. Additionally, the patient's heart rate is not mentioned, so it's unclear if they meet the heart rate inclusion criterion.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria for this clinical trial, I would assess the eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "89": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Patients of chronic stable angina with abnormal Exercise Myocardial Perfusion Spect Scan with reversible and partially reversible ischemic changes.\"\n   - The patient note mentions that the patient is experiencing episodic chest pain, which could be indicative of angina. However, there is no mention of an Exercise Myocardial Perfusion Spect Scan or any other diagnostic test results.\n\n2. \"Male and female\"\n   - The patient is a 58-year-old woman, so she meets this criterion.\n\n3. \"Age 25 to 65 years\"\n   - The patient is 58 years old, which falls within the age range specified in the inclusion criteria.\n\n4. \"Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the diary cards.\"\n   - There is no information provided about the patient's willingness or ability to comply with the study procedures.\n\n5. \"Patient must be able to give voluntary written informed consent.\"\n   - There is no information provided about the patient's ability to give informed consent.\n\nBased on the information provided in the patient note, it is unclear whether the patient meets the first inclusion criterion regarding the diagnostic test results. Additionally, there is no information about the patient's willingness or ability to comply with the study procedures and provide informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "90": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with symptoms suggestive of an acute coronary syndrome (ACS) like chest pain, nausea, diaphoresis, and mild dyspnea.\n\n2. The clinical trial is studying care-seeking behavior in patients with acute myocardial infarction, acute coronary syndrome, and unstable angina.\n\n3. The inclusion criteria for the trial are: acute myocardial infarction, acute coronary syndrome, unstable angina, men & women, all races & ethnicities.\n\n4. The exclusion criteria is age < 21 years.\n\n5. This patient meets the inclusion criteria of having a suspected acute coronary syndrome based on her symptoms. She also meets the demographic criteria of being a woman and being of African-American ethnicity.\n\n6. There is no information provided that would exclude her based on the age criteria.\n\nTherefore, based on the information provided in the patient note and the trial criteria:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "91": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subject, male or female, is age 18 to 50 years of age.\n   - The patient is 58 years old, which is outside the age range specified in the criteria.\n\n2. Subject must be able to understand and be willing to sign an informed consent document.\n   - There is no information provided about the patient's ability to understand or sign an informed consent.\n\n3. Subject must be willing and able to participate in all aspects of the study and agree to comply with all study requirements for the duration of the study. This includes availability of reliable transportation and sufficient time to attend all follow-up visits.\n   - No information is provided about the patient's willingness or ability to participate in the study requirements.\n\n4. Subject has a BMI of 40 - 45 or 30 to 39.9 plus one or more co-morbid diseases expected to improve with weight loss, including but not limited to hypertension, dyslipidemia, obstructive sleep apnea, or diabetes mellitus.\n   - The patient is noted to have hypertension and obesity, which could potentially meet this criterion, but the patient's BMI is not provided.\n\n5. Subject must be fully ambulatory, without chronic reliance on walking aids such as crutches, walkers or a wheelchair.\n   - No information is provided about the patient's ambulatory status or use of walking aids.\n\n6. Subject must be of sufficient and stable medical health, as evaluated by the Principal Investigator.\n   - No information is provided about the patient's overall medical health stability.\n\n7. Subject must have a primary care physician that will manage the subject for any co-morbid conditions throughout the study.\n   - No information is provided about whether the patient has a primary care physician.\n\n8. Subject must have failed standard obesity therapy of diet, exercise, behavior modification, and pharmacologic agents either alone or in combination, as assessed by an interview with a member of the study team at baseline.\n   - No information is provided about the patient's previous attempts at obesity therapy.\n\n9. Subject agrees to refrain from any type of reconstructive surgery that may affect body weight such as mammoplasty or abdominal lipoplasty or liposuction, during the trial.\n   - No information is provided about the patient's plans for reconstructive surgery.\n\nBased on the limited information provided in the patient note, it is difficult to determine with certainty whether the patient would be eligible for this clinical trial. The patient's age is outside the specified range, and there is not enough information provided about several other key inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "92": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be indicative of heart disease or other cardiovascular issues.\n\n2. The clinical trial is studying the effects of switching from ACE inhibitors to angiotensin II receptor blockers in hypertensive patients.\n\n3. One of the inclusion criteria for the trial is \"essential hypertension\", which this patient has based on her history of hypertension.\n\n4. Another inclusion criterion is that the patient must currently be taking ACE inhibitors. However, the patient note does not mention if she is currently taking any medications, let alone ACE inhibitors specifically.\n\n5. Without knowing if the patient is currently on ACE inhibitors, it is difficult to definitively determine her eligibility for this particular trial.\n\nGiven the available information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether she is currently taking ACE inhibitors.",
        "label": 0
    },
    "93": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman, which meets the age and race criteria for the trial.\n\n2. However, the patient is presenting with chest pain, nausea, diaphoresis, and mild dyspnea, which are symptoms of a potential cardiac issue, not breast cancer. \n\n3. The inclusion criteria specifically state that patients must be breast cancer survivors who are 1-12 months post completion of treatment for stage 0-3 breast cancer.\n\n4. There is no mention of the patient having been diagnosed with or treated for breast cancer in the patient note.\n\n5. Therefore, based on the information provided, this patient would not be eligible for the \"Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "94": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Age > 20 years: The patient is 58 years old, so this criterion is met.\n2. Effort-induced angina relieved by rest or nitroglycerin, or catheterization-documented coronary artery disease or previous myocardial infarction \u2265 3 months before screening: The patient has episodic chest pain that started while walking, which suggests effort-induced angina. This criterion is likely met.\n3. Positive exercise tolerance test (ETT) with ST-segment depression \u2265 1 mm at screening and on the day of enrollment: The patient's ETT results are not provided, so this criterion cannot be fully evaluated.\n4. Female patients must be post-menopausal, using adequate contraception, non-lactating, and have a negative pregnancy test: This criterion is not applicable since the patient is a woman.\n5. Able to provide written informed consent: This criterion is likely met, but not explicitly stated.\n\nExclusion Criteria:\n1. Pre-excitation, conduction abnormalities, pacemaker rhythm, unstable angina, or myocardial infarction within the preceding 3 months: The patient's EKG shows nonspecific changes, and there is no mention of these conditions, so this criterion is likely met.\n2. Heart failure (NYHA class III or IV), uncorrected valvular or congenital heart disease, or need for certain medications: There is no mention of these conditions, so this criterion is likely met.\n3. EKG abnormalities preventing interpretation of ischemia (complete left bundle branch block): The EKG shows nonspecific changes, so this criterion is likely met.\n4. Chronic Obstructive Pulmonary Disease (COPD) requiring bronchodilators: There is no mention of COPD, so this criterion is likely met.\n5. Hepatic failure or renal failure: There is no mention of these conditions, so this criterion is likely met.\n6. Severe gastrointestinal illness: There is no mention of this condition, so this criterion is likely met.\n7. Conditions that interfere with exercise tolerance test: There is no mention of such conditions, so this criterion is likely met.\n\nBased on the information provided, the patient appears to meet most of the inclusion and exclusion criteria, but the exercise tolerance test results are not provided, which is a crucial criterion for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the exercise tolerance test results.",
        "label": 0
    },
    "95": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic chest pain, nausea, diaphoresis, and mild dyspnea. This could potentially be an acute coronary syndrome (ACS) like acute myocardial infarction.\n\n2. The clinical trial is looking at management of acute myocardial infarction in the presence of left bundle branch block (LBBB) on ECG.\n\n3. The inclusion criteria are:\n   - Age 18-75 years (the patient is 58, so meets this)\n   - Ischemic chest pain/discomfort at rest for \u226520 mins within previous 24 hours (the patient had episodic chest pain starting 2 days ago, so meets this)\n   - LBBB on prehospital or admission ECG (the ECG findings are not clearly stated, so this is uncertain)\n   - Urgent coronary angiography +/- PCI within 90 mins of admission (this is a treatment criteria, not an inclusion criteria per se)\n\n4. Based on the available information, the patient potentially meets at least 2 of the key inclusion criteria (age and ischemic symptoms). However, the ECG findings are unclear regarding presence of LBBB.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the ECG findings to confirm presence of LBBB.",
        "label": 0
    },
    "96": {
        "output": "To determine the patient's eligibility for the \"Genetic Mapping for Cardiac Risk Assessment\" clinical trial, let's go through the inclusion criteria:\n\n1. Patients affected by history of IHD with a non-fatal evolution (angina or AMI as first manifestation):\nThe patient is presenting with chest pain suggestive of angina, which could be the first manifestation of ischemic heart disease (IHD). However, it is not explicitly stated that the patient has a confirmed diagnosis of IHD or angina.\n\n2. Age at the onset of the disease (<50 or >60 years):\nThe patient's age is 58 years old, which falls within the specified age range.\n\n3. Patients with acute coronary syndrome as first manifestation of coronary disease, admitted to the coronary unit within 6 hours from the onset of symptoms:\nThe patient presented to the ER with chest pain, which could potentially be an acute coronary syndrome. However, it is not mentioned if the patient was admitted to the coronary unit or the exact time from symptom onset to presentation.\n\nBased on the information provided, there is not enough evidence to definitively confirm or rule out the patient's eligibility for this clinical trial. More investigation may be needed to determine if the patient meets the inclusion criteria, particularly regarding the diagnosis of IHD or acute coronary syndrome and the timing of symptom onset and hospital admission.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "97": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Effectiveness of the Compression Belt for Patients With Sacroiliac Joint Pain\", this patient does not appear to meet the inclusion criteria for the trial.\n\nThe key reasons are:\n\n1. The patient is presenting with anterior chest pain, which is not indicative of sacroiliac joint pain.\n2. The inclusion criteria specifically mention \"unilateral pain near the sacroiliac joint that does not extend pass the knee\", whereas the patient's symptoms are related to chest pain.\n3. There is no mention of the patient having a positive result on any of the sacroiliac joint provocation tests listed in the inclusion criteria.\n\nTherefore, based on the available information, this patient would not be eligible for the mentioned clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "98": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the clinical trial about glaucoma and eye surgery.\n\n2. The clinical trial is titled \"IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy With Collagen Implant\".\n\n3. The inclusion criteria for the trial are:\n   - Diagnosis of primary open angle glaucoma (POAG)\n   - Documented glaucomatous visual field damage with mean defect > 3 dB\n   - Progressing glaucomatous damage justifying deep sclerectomy with collagen implant surgery\n   - Age \u2265 18 years\n   - Refractive error within certain limits\n\n4. Based on the patient note provided, there is no mention of the patient having glaucoma or any eye-related conditions.\n\nTherefore, based on the information given, this patient would not be eligible for the clinical trial about glaucoma surgery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "99": {
        "output": "To determine the patient's eligibility for the clinical trial \"Hatha Yoga Exercises in Pelvic and Lumbar Back Pain in Pregnant Woman\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\n1. Lower back pain and/or posterior pelvic pain when completing the interview.\n2. Gestational age greater than or equal to 12 weeks.\n\nFrom the patient note, there is no mention of the patient being pregnant or her gestational age. The note only states that the patient is a 58-year-old woman presenting with chest pain, nausea, diaphoresis, and mild dyspnea.\n\nSince the patient does not meet the inclusion criteria of being pregnant and having lower back pain or posterior pelvic pain, I would not refer this patient for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "100": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could potentially be related to inappropriate sinus tachycardia.\n\n2. The inclusion criteria for the clinical trial are:\n   - Inappropriate sinus tachycardia (HR >100 bpm at rest ECG and/or medium Holter ECG HR >90 bpm)\n   - Age > 18 years\n\n3. From the patient note, we don't have information about the patient's heart rate at rest or from a Holter ECG monitor. However, the patient is over 18 years old, satisfying one of the inclusion criteria.\n\n4. Without definitive evidence of inappropriate sinus tachycardia, it would be premature to highly likely refer this patient to the clinical trial.\n\nBased on the available information, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her heart rate and potential diagnosis of inappropriate sinus tachycardia.",
        "label": 0
    },
    "101": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to breast cancer or metastatic disease.\n\n2. The clinical trial is for metastatic breast cancer patients who have already received prior treatments like anthracyclines and taxanes.\n\n3. There is no mention of the patient having breast cancer or any prior cancer treatments in the patient note.\n\n4. Based on the information provided in the patient note, the patient does not meet the inclusion criteria for this clinical trial, which requires patients to have histologically-proven, HER-2 negative, measurable stage IV breast cancer and prior exposure to specific treatments.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "102": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic chest pain, which could be angina (stable chest pain).\n2. The clinical trial is looking at the usefulness of CT calcium scoring in patients with suspected stable angina.\n3. The inclusion criteria for the trial are:\n   - Non-acute chest pain (the patient has episodic chest pain, which is non-acute)\n   - Those who underwent CT calcium scoring (it's not mentioned if the patient had this done, but it could be done as part of the evaluation)\n   - Availability of all relevant risk factor information (the patient's age, gender, race, hypertension, obesity are provided)\n\nBased on the information provided, the patient seems to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "103": {
        "output": "To determine the patient's eligibility for the given clinical trial, let's go through the inclusion criteria one by one:\n\n1. Well functioning kidney (serum creatinine <1.2 mg/dl):\nThe patient note does not mention any kidney-related issues or provide serum creatinine levels. Without this information, it is difficult to determine if the patient meets this criterion.\n\n2. Solitary renal stone:\nThe patient note does not mention the presence of any renal stones.\n\n3. Size: 25 mm or less in the largest diameter:\nSince there is no mention of a renal stone, this criterion is not applicable.\n\nBased on the information provided in the patient note, there is no indication that the patient meets the inclusion criteria for this clinical trial, which is focused on evaluating protective effects against shockwave lithotripsy-induced renal injury in patients with renal stones.\n\nThe patient's presenting complaint appears to be related to chest pain, which is not relevant to the clinical trial's focus on renal stones and kidney injury.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "104": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to severe hypertension.\n\n2. The clinical trial is looking to evaluate a device (ROX Anastomotic Coupler System) in patients with severe hypertension.\n\n3. The inclusion criteria specifically states: \"Diagnosis of severe hypertension must be made on the basis of current findings, medical history, and physical examination\"\n\n4. From the patient note, there is no clear indication that the patient has been diagnosed with severe hypertension. The note only mentions that she has a history of hypertension, but does not specify the severity.\n\nBased on the information provided, it does not seem that this patient meets the key inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "105": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the clinical trial about comparing the effects of carbetocin and oxytocin during cesarean sections.\n\n2. The inclusion criteria for the clinical trial are:\n- Viable, singleton pregnancy \u2265 37 weeks gestation undergoing elective lower segment cesarean section (EL LSCS)\n- Low risk for postpartum hemorrhage\n- Ability to provide informed consent\n\n3. Based on the patient note, there is no indication that the patient is pregnant or undergoing a cesarean section.\n\nTherefore, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "106": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 58-year-old African-American woman presenting with chest pain suggestive of angina/ischemic heart disease. This matches the inclusion criteria of \"Stable Ischemic Heart Disease\".\n\nHer BMI is not provided, but she is noted to have obesity, which suggests her BMI could fall within the 28-40 kg/m2 range required.\n\nShe denies diabetes, which meets the exclusion criteria of no known diabetes mellitus and fasting plasma glucose < 7 mmol/L or HbA1c < 7%.\n\nNo other exclusion criteria are mentioned, such as valve disease, heart failure, COPD, cancer, kidney/liver disease, arrhythmias, etc.\n\nThe only potential exclusion is that her physical activity level prior to inclusion is not mentioned. If she was doing organized training more than 2 times per week, she would be excluded.\n\nOverall, based on the information provided, this patient appears to meet the key inclusion criteria and does not definitively meet any of the exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her BMI and pre-inclusion physical activity level.",
        "label": 2
    },
    "107": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with acute chest pain for the first time, which is one of the inclusion criteria for this trial (\"All patients over the age of 18 years presenting with the leading symptom of first time or recurrent acute chest pain\").\n\n2. She does not meet any of the exclusion criteria listed, such as missing informed consent, being cardiopulmonary unstable, not having self-reported chest pain, recent thoracic surgery, inflammatory joint disease, fibromyalgia, or cardiogenic shock.\n\n3. Based on the information provided in the patient note, she appears to be eligible for this clinical trial investigating the usefulness of chest wall tenderness in excluding acute coronary syndrome in different demographic groups.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "108": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman, which matches the inclusion criteria of being an African American woman aged 18 or older.\n\n2. The patient is presenting with chest pain, which is not directly related to the study's focus on breast cancer risk and breast milk samples.\n\n3. There is no mention of the patient currently nursing a baby, which is one of the key inclusion criteria.\n\n4. There is also no mention of the patient being considered for or having had a breast biopsy, which is another inclusion criterion.\n\nBased on the information provided in the patient note, it does not appear that this patient meets the key inclusion criteria of currently nursing a baby and being considered for or having had a breast biopsy. Therefore, my assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "109": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain that radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea. This does not seem to match the inclusion criteria for the tension-type headache clinical trial.\n\n2. The inclusion criteria for the clinical trial specify:\n- Male and female patients from 18 years onwards (the patient meets this criterion)\n- History of episodic tension-type headache (ETTH) for at least one year (the patient's symptoms do not seem to indicate ETTH)\n- Onset of ETTH below 65 years of age (not applicable since the patient does not have ETTH)\n- At least 10 previous headache attacks with specific characteristics (not applicable since the patient does not have headaches)\n\n3. Based on the information provided, the patient does not seem to meet the inclusion criteria for this clinical trial on tension-type headaches.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "110": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female (post menopausal or surgically sterile) and/or male aged 18 years or older\n- The patient is a 58-year-old woman, so she meets this criterion.\n\n2. Presenting with ACS fulfilling the following:\n    a. Symptoms or new ECG changes (ST segment elevation or depression of at least 1 mm in 2 or more contiguous leads on EKG)\n    b. Elevation of biomarkers (CK-MB \u22652 ULN or troponin \u2265 ULN)\n- The patient is presenting with episodic pressing/burning anterior chest pain, which could be a symptom of ACS. However, the note does not mention any ECG changes or elevation of biomarkers, so it's unclear if she meets this criterion.\n\n3. Self-identified as African-American\n- The patient is described as an African-American woman, so she meets this criterion.\n\n4. Treatment with 75-100mg ASA daily\n- The note does not mention if the patient is taking aspirin, so it's unclear if she meets this criterion.\n\nOverall, the patient meets some of the inclusion criteria, but there is not enough information to determine if she definitively meets all of them, particularly regarding the ACS presentation and aspirin treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "111": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic chest pain, which does not seem to match the inclusion criteria for a trial on chronic low back pain.\n\n2. The inclusion criteria specifically mention chronic low back pain lasting for at least 3 months, requiring strong analgesics, and having a neuropathic pain component assessed by the painDETECT questionnaire.\n\n3. There is no mention of the patient having chronic low back pain or completing the painDETECT questionnaire in the patient note.\n\n4. Based on the information provided, this patient does not seem to meet the key inclusion criteria for this particular clinical trial on chronic low back pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "112": {
        "output": "Based on the provided patient note and the clinical trial information, this patient does not appear to meet the inclusion criteria for the \"Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument\" trial.\n\nThe key points are:\n\n1. The patient note does not mention any diagnosis of pulmonary arterial hypertension (PAH), which is a requirement for this trial.\n2. The patient's symptoms (chest pain, nausea, diaphoresis, mild dyspnea) seem more indicative of a potential cardiac issue rather than PAH.\n3. The inclusion criteria specifically state that participants must have completed the previous AC-055-401 study, which is not mentioned in the patient note.\n\nTherefore, based on the available information, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "113": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) They had to have normal glucose tolerance.\n   - The patient note does not mention the patient's glucose tolerance, so this cannot be definitively assessed. More information is needed.\n\n2) They had to have either angiographically documented coronary artery disease or a previous history of myocardial infarction.\n   - The patient note states the patient presented with chest pain suggestive of angina/ischemic heart disease, but does not confirm angiographic evidence of coronary artery disease or previous myocardial infarction.\n\n3) They were required to have an office BP < 130/80 mm Hg\n   - The patient's blood pressure is not provided in the note.\n\n4) The presence of LVH on echocardiography (American Society of Echocardiography criteria LVM index [LVMI] > 115 g/m2 for men and > 95 g/m2 for women).\n   - There is no information provided about the patient's left ventricular mass index.\n\nIn summary, while the patient presents with symptoms suggestive of ischemic heart disease, which is the target condition, there is insufficient information in the note to definitively assess eligibility for this particular trial based on the stated inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "114": {
        "output": "To determine the patient's eligibility for the clinical trial \"Causal Inference Research of Resistant Hypertension Treatment With Chinese Approach in a Cohort Study\", let's go through the inclusion criteria:\n\n1. Essential hypertension subjects: The patient is known to have hypertension, so this criterion is met.\n2. Aged 18-70 years: The patient is 58 years old, which falls within the age range.\n3. Blood pressure > 140/90 mm Hg: The patient's blood pressure is not mentioned, so we cannot confirm if this criterion is met.\n4. Used to be on 3 or more medications for a month: The patient is currently not taking any medications, so this criterion is not met.\n5. Diagnosed as Phlegm and Stasis Syndrome: There is no information provided about this diagnosis for the patient.\n\nBased on the available information, the patient meets some but not all of the inclusion criteria. Specifically, the criteria regarding being on 3 or more medications for a month and the diagnosis of Phlegm and Stasis Syndrome are not confirmed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "115": {
        "output": "To determine the patient's eligibility for the clinical trial \"REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients\", let's go through the inclusion criteria:\n\n1. Provision of subject informed consent: This is not mentioned in the patient note, so we cannot assess this criterion.\n\n2. Patients hospitalized and diagnosed with STEMI or NSTEMI: The patient note mentions that the patient presented to the ER with episodic chest pain, which could be indicative of an acute coronary syndrome (ACS) like STEMI or NSTEMI. However, a definitive diagnosis is not provided.\n\n3. Hospitalized within 24 hours of onset of symptoms or transferred from another hospital within 24 hours of the onset of symptoms: The patient note states that the chest pain began two days earlier, which is longer than the 24-hour window specified in the inclusion criteria.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for this clinical trial. While the patient's symptoms could be indicative of an ACS, there is no definitive diagnosis, and the onset of symptoms was more than 24 hours ago.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "116": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem directly relevant to the clinical trial focused on obesity prevention in adolescents and young adults.\n\n2. The inclusion criteria specify:\n- Age \u2265 12 years old (the patient is 58, so does not meet this criteria)\n- Body image concerns (not mentioned for this patient)\n- Sub-threshold eating disorder symptomatology (not mentioned)\n- Overweight but not obese BMI (patient's BMI not provided, only mentions obesity)\n- Able to commit to weekly 1-hour sessions for 6 weeks and 3 assessment visits (ability not mentioned)\n\n3. Based on the information provided in the patient note, this 58-year-old woman does not seem to meet the key inclusion criteria for the \"Healthy Body Study\" obesity prevention trial in adolescents/young adults.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "117": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic chest pain, nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity.\n\n2. The clinical trial is evaluating pain during chest tube withdrawal using a Pain Monitor device, comparing it to a visual analog scale for pain assessment.\n\n3. The inclusion criteria are:\n   - Patients undergoing removal of a chest tube after lung surgery\n   - Patients able to indicate the pain score\n\n4. Based on the patient note, there is no mention of the patient undergoing lung surgery or having a chest tube in place. Therefore, she would not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "118": {
        "output": "To determine the patient's eligibility for the clinical trial \"Diet and Prevention of Ischemic Heart Disease: a Translational Approach\", let's go through the inclusion criteria:\n\n1. Healthy men and women aged 30 to 65 years: The patient is a 58-year-old woman, which falls within the age range.\n\n2. One or more self-assessed ischemic heart disease risk factors at screening:\n   - Physical inactivity: Not mentioned in the patient note.\n   - Overweight or obese (BMI \u2265 25/m2): The patient is mentioned to have obesity, which satisfies this criterion.\n   - Waist circumference (\u2265 80 cm for women, \u2265 94 cm for men): Waist circumference is not mentioned in the patient note.\n\n3. Motivation and willingness to be randomized to any of the three groups and follow the given protocol: This is not explicitly mentioned in the patient note, but it can be assumed that the patient would be willing to participate if referred.\n\nBased on the information provided, the patient meets at least one of the inclusion criteria (obesity), and her age falls within the specified range. However, there is no information about her physical activity level or waist circumference.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "119": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Live in Ribeir\u00e3o Preto, S\u00e3o Paulo - Brazil.\nThe patient note does not mention the location, so this criterion cannot be evaluated.\n\n2. Age between 18 and 40 years old. \nThe patient is 58 years old, which does not meet this criterion.\n\n3. Female gender.\nThe patient is a female, so this criterion is met.\n\n4. Regular menses. \nThere is no information about the patient's menstrual cycle in the note.\n\n5. Weight inferior than 120 Kg and body mass index (BMI) between 30 and 40 kg/m2, for the group with obesity.\nThe note mentions that the patient has obesity, but does not provide specifics on weight or BMI.\n\n6. BMI between 18.5 and 24.9 kg/m2, for the group without obesity.\nThis criterion is not applicable since the patient has obesity.\n\nBased on the information provided in the patient note, the patient's age does not meet the inclusion criteria. There is also not enough information to determine if other criteria like location, menstrual cycle regularity, and BMI range are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "120": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with episodic chest pain, nausea, diaphoresis, and mild dyspnea, which are symptoms suggestive of angina.\n\n2. The clinical trial is studying the effects of inorganic nitrate supplementation on markers of heart ischemia and frequency of angina.\n\n3. The inclusion criteria for the trial are:\n   - Patients aged 18 and over with chronic stable angina (\u22652 months duration)\n   - A positive exercise ECG, dobutamine stress echocardiogram, myocardial perfusion scan, or coronary angiogram\n\n4. Based on the patient's presenting symptoms of chest pain, nausea, diaphoresis, and dyspnea, which are suggestive of angina, she meets the first inclusion criterion of having chronic stable angina.\n\n5. However, the patient note does not mention any diagnostic tests being performed, such as an exercise ECG, stress echocardiogram, myocardial perfusion scan, or coronary angiogram. These tests are required to confirm the diagnosis of angina and meet the second inclusion criterion.\n\nTherefore, based on the information provided in the patient note, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of diagnostic tests to confirm the diagnosis of angina.",
        "label": 0
    },
    "121": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the clinical trial about respiratory system mechanics in morbidly obese patients.\n\n2. The inclusion criteria for the trial are:\n   - 18 years or older (the patient meets this criterion)\n   - Requiring intubation and mechanical ventilation (the patient does not meet this criterion based on the information provided)\n   - BMI \u2265 40 kg/m2 or IAP \u2265 12 mmHg (there is no information provided about the patient's BMI or intra-abdominal pressure)\n\nSince the patient does not meet the key inclusion criterion of requiring intubation and mechanical ventilation, and there is no information about her BMI or intra-abdominal pressure, it is unlikely that she would be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "122": {
        "output": "To determine the patient's eligibility for the clinical trial \"Protein Supplementation and Weight Loss\", let's go through the inclusion criteria:\n\n1. Subjects aged between 21-65 years\nThe patient is 58 years old, which falls within the age range specified in the inclusion criteria.\n\n2. Subjects with BMI > 23 Kg/m2\nThe patient is described as having obesity, which implies a BMI greater than 23 Kg/m2.\n\nSince the patient meets both inclusion criteria, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "123": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Dietary Nitrate in COPD\", here is my assessment:\n\nThe patient note describes a 58-year-old African-American woman presenting with chest pain, nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity but no diagnosis of COPD (chronic obstructive pulmonary disease) is mentioned.\n\nThe inclusion criteria for the clinical trial are:\n1. Information consenting out-patients with a previous physician diagnosis of COPD\n2. Clinically stable\n3. Ambulatory\n\nSince the patient note does not indicate a diagnosis of COPD, the first inclusion criterion is not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "124": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman, which matches the inclusion criteria of being a woman of African American/African Caribbean/African heritage/Mixed ethnicity and age 18-44.\n\n2. There is no mention of abuse by an intimate male partner in the patient note, which is a key inclusion criteria for this trial. \n\n3. The patient note describes symptoms related to potential cardiac issues, but does not provide any information about intimate partner relationships or risk of STIs/HIV.\n\nBased on the information provided in the patient note, I would assess the eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.\n\nThe main reasons are:\n1) There is no indication that the patient has experienced intimate partner abuse, which is a key inclusion criteria.\n2) The symptoms described relate to potential cardiac issues rather than risks of STIs/HIV, which is the focus of this trial.\n\nWithout any evidence of intimate partner abuse or elevated STI/HIV risk in the patient note, I cannot recommend referring this patient to the \"Empowered Sisters Project Making Choices Reducing Risks\" clinical trial based on the inclusion criteria provided.",
        "label": 0
    },
    "125": {
        "output": "Okay, let's go through the inclusion criteria for the \"Abdominal Compression Elastic Support (ACES)\" clinical trial and assess the eligibility of the patient based on the provided note.\n\nInclusion Criteria:\n1) Must be able to give informed consent for participation in this study\n- The note does not mention the patient's ability to provide informed consent, so I cannot make a definitive assessment on this criterion.\n\n2) Age \u2265 18 years\n- The patient is 58 years old, so they meet this age criterion.\n\n3) A body weight > 100 lb or a body mass index > 18.5\n- The note mentions that the patient has obesity, which implies a high body weight and likely a BMI > 18.5, but the exact values are not provided.\n\n4) End-stage renal disease with hemodialysis in-center three times per week\n- The note does not mention the patient having end-stage renal disease or receiving hemodialysis, so they do not meet this criterion.\n\n5) Not missing any treatments in the preceding two weeks and in compliance with instructions from the health care provider\n- There is no information provided about the patient's treatment compliance.\n\n6) In the last month had at least two episodes of IDH (defined as having hypotensive symptoms such as dizziness, fainting, headache, nausea, vomiting, cramping, weakness, blurry vision and/or a decrease in systolic blood pressure (SBP) of more than 20 mmHg)\n- The note does not mention the patient experiencing any episodes of intra-dialytic hypotension (IDH) or related symptoms.\n\n7) Hemoglobin greater than or equal to 9.0 g/dL (hematocrit 27%) to hemoglobin of 15.0 g/dL (hematocrit 45%)\n- The note does not provide any information about the patient's hemoglobin or hematocrit levels.\n\nBased on the information provided in the patient note, the patient does not meet the key inclusion criterion of having end-stage renal disease and receiving hemodialysis. Additionally, there is no mention of the patient experiencing episodes of intra-dialytic hypotension, which is another critical inclusion criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "126": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old African-American woman presenting with chest pain suggestive of acute coronary syndrome (ACS). This matches the inclusion criteria of being aged \u226518 years and having an ACS event.\n\nThe note does not explicitly state if she was discharged alive from the hospital after this ACS event, which is an inclusion criteria. However, it seems likely since she presented to the ER with this chest pain episode.\n\nThe note does not provide details on if her ACS was specifically unstable angina (UA), STEMI or NSTEMI, which is an inclusion criteria. \n\nThere is no mention of her being started on ticagrelor, prasugrel or clopidogrel at discharge after this ACS event, which is a key inclusion criteria.\n\nOverall, while some of the basic criteria like age and ACS event are met, there are some key missing details like the specific ACS diagnosis, being discharged alive, and being started on one of the antiplatelet medications listed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the missing eligibility details.",
        "label": 0
    },
    "127": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old African-American woman presenting with chest pain, which could be related to coronary artery disease. This matches the inclusion criteria of \"Documented Ischaemic Heart Disease: either angio-graphically documented coronary artery disease or a previous history of myocardial infarction/angina.\"\n\nShe is known to have hypertension and obesity, which could contribute to insulin resistance, matching the criteria \"Fasting insulin resistance index \u2265 2.7 AND/OR HbA1c >5.6 and less than 6.5 at screening.\"\n\nHer blood pressure is not mentioned, but the criteria states \"Blood pressure < 140/85 mm Hg or 24hr BP <135/85 daytime average in screening\", so she may potentially meet this.\n\nThe other criteria like age \u2265 18 years, ability to give informed consent, and comply with study requirements are not definitively mentioned but can potentially be met.\n\nThe main potential issue is that left ventricular hypertrophy is not explicitly stated in the patient note, which is a key inclusion criteria \"Screening echocardiography based diagnosis of LVH.\"\n\nOverall, this patient seems to potentially meet several of the key inclusion criteria, but the lack of confirmed left ventricular hypertrophy diagnosis makes the eligibility somewhat uncertain.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of left ventricular hypertrophy status.",
        "label": 0
    },
    "128": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nAge 18 to 80 years\n- The patient is 58 years old, which falls within this range. This criterion is met.\n\nHistory of stable, exertional angina pectoris (Canadian Cardiovascular Society functional class II to III) for at least 3 months duration prior to enrolment in the study\n- The patient presents with episodic pressing/burning anterior chest pain that began two days earlier for the first time in her life. This does not seem to meet the criteria of having a history of stable, exertional angina for at least 3 months. This criterion is not met.\n\nPatients not currently receiving treatment with antianginal medication (other than short-acting nitrates)\n- The patient currently takes no medications, so this criterion is met.\n\nBetween visits 2 and 3 two treadmill exercise tests, demonstrating \u2265 0.1 mV of horizontal or down sloping ST-segment depression, must be carried out. The difference in symptom-limited exercise duration between these two tests must not exceed 20%\nTotal treadmill exercise duration > 3 minutes (i.e. stage 2 or above on a standard Bruce protocol)\n- There is no information provided about treadmill exercise tests for this patient, so these criteria cannot be evaluated.\n\nCoronary artery disease, preferably (not mandatory) documented by a history of proven myocardial infarction and/or coronary angiography indicating \u2265 50% reduction in luminal diameter of one or more coronary arteries or their primary branches\n- There is no information provided about the patient having documented coronary artery disease, so this criterion cannot be definitively evaluated. However, the note mentions the patient denies a family history of heart disease, which suggests she may not have coronary artery disease herself.\n\nOverall, based on the information provided, the patient does not seem to meet the key inclusion criterion of having a history of stable, exertional angina for at least 3 months. There is also lack of information to evaluate some other criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "129": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be related to the clinical trial about morbid obesity and metabolic syndrome.\n\n2. The patient's BMI is not mentioned, so we cannot determine if she meets the inclusion criteria of morbid obesity (BMI > 30 with comorbidities or BMI > 35).\n\n3. The patient is noted to have hypertension, which is one of the comorbidities listed in the inclusion criteria. However, her BMI is still unknown.\n\n4. There is no mention of the patient having type 2 diabetes or dyslipidemia, the other comorbidities listed.\n\nBased on the information provided, it is unlikely that this patient would be eligible for the clinical trial on morbid obesity and metabolic syndrome, as her BMI is not specified and she does not clearly meet the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "130": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could potentially be an acute coronary syndrome (ACS).\n2. The clinical trial is looking at the safety and efficacy of combining percutaneous coronary intervention (PCI) with renal denervation (RDN) in hypertensive patients with ACS.\n3. The inclusion criteria state that patients must:\n   - Be 18-80 years old (the patient is 58, so meets this criteria)\n   - Have ACS treated with PCI (the patient has chest pain suggestive of ACS, but it's not clear if she has been treated with PCI yet)\n   - Have a history of treated hypertension or newly diagnosed hypertension with office systolic BP >140 despite 3 antihypertensive drugs (the patient is known to have hypertension, but BP values and medication details are not provided)\n   - Have an ejection fraction >40% (the patient's ejection fraction is not provided)\n\n4. Based on the available information, it is unclear if the patient definitively meets all the inclusion criteria. More information is needed regarding whether she is diagnosed with ACS, treated with PCI, her current BP values, medications, and ejection fraction.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "131": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient's presenting complaint is chest pain, which is not related to the trial's focus on tourniquet-induced hypertension during intravenous regional anesthesia for carpal tunnel surgery.\n\n2. There is no mention of the patient undergoing or planning to undergo carpal tunnel surgery, which is a requirement based on the inclusion criteria.\n\n3. The trial appears to be a retrospective study examining patient files from a specific time period (January 2009 to January 2010), and this patient's visit is more recent.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "132": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n\u2265 18 years of age: The patient is 58 years old, so they meet this criterion.\n\nPatients of African, European, and Hispanic descent: The patient is described as African-American, so they meet this criterion.\n\nHistory of typical or early-onset symptomatic (\u22652 episodes/month) paroxysmal/persistent AF: The patient is presenting with their first episode of chest pain, which could potentially be atrial fibrillation, but there is no mention of a history of multiple episodes per month. This criterion is not clearly met based on the information provided.\n\nECG that was recorded within 1 month of randomization showing AF: The ECG shows non-specific changes, but does not confirm atrial fibrillation. This criterion is not met based on the information provided.\n\nEligible for both Flecainide(Class I) and Sotalol (Class III) AAD: There is no information provided about the patient's eligibility for these specific medications.\n\nAble to give informed consent: There is no information provided about the patient's ability to give informed consent, but we can assume this is likely unless stated otherwise.\n\nOverall, based on the information provided in the patient note, some of the key inclusion criteria are not clearly met, such as a confirmed history of frequent atrial fibrillation episodes and an ECG showing atrial fibrillation within the last month.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "133": {
        "output": "To determine the patient's eligibility for the clinical trial \"Early Invasive Versus Conservative Therapy in Women With an Acute Coronary Syndrome\", let's go through the inclusion criteria one by one:\n\n1. Women age 18 years or older\nThe patient is a 58-year-old woman, so she meets this criterion.\n\n2. Non-ST-elevation acute coronary syndrome (defined as new onset chest discomfort that occurs at rest or with low levels of activity/or emotion within the preceding 48 hours) with either:\n- elevated troponin T (\u2265 0.03 ng per milliliter),\n- elevated creatinine kinase MB-isoenzyme (\u2265 5.0 ng per milliliter)\n- elevated NT-pro-BNP (\u2265 450 pg per milliliter),\n- ST-segment depression (\u2265 0.5 mm)\n- or TIMI risk score (> 2)\n\nThe patient presents with new onset chest pain that started while walking (low level of activity) within the preceding 48 hours. The note does not mention specific lab values, but it does state that the EKG shows nonspecific changes, which could indicate ST-segment depression.\n\n3. Women who have elevated cardiac enzymes after non-cardiac surgery will also be considered.\nThis criterion does not apply to the patient.\n\nBased on the information provided, the patient meets the age criterion and potentially meets the criterion for non-ST-elevation acute coronary syndrome, although more information about lab values or TIMI risk score would be needed to confirm this.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "134": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"ACE Stapler Sub Study\", here is my assessment:\n\nThe patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be directly related to the clinical trial focused on obesity treatment. However, the note mentions that she has obesity, which meets one of the inclusion criteria for the main ACE stapling study (\"Subject has a BMI of 40 - 45 or 30 to 39.9 plus one or more co-morbid diseases expected to improve with weight loss\").\n\nSince the patient note does not provide information about whether she meets the other inclusion criteria for the main study, such as failing standard obesity therapy or having a primary care physician to manage co-morbid conditions, it is difficult to determine her eligibility with certainty.\n\nAdditionally, the inclusion criteria for the sub-study specifically state that the patient must be included in the main study.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "135": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem directly relevant to the clinical trial about monitoring sympathetic blocks during lumbar sympathetic blocks.\n\n2. However, the inclusion criteria for the trial are quite broad - patients aged 18-99 presenting for a lumbar sympathetic block.\n\n3. While the patient note does not explicitly state that the patient is scheduled for a lumbar sympathetic block, it is possible that this procedure could be considered as part of the diagnostic workup or treatment for her chest pain symptoms.\n\n4. Given the broad inclusion criteria and the possibility that a lumbar sympathetic block may be performed, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "136": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem directly relevant to the clinical trial about assessing post-operative pain.\n\n2. The clinical trial is focused on patients undergoing total hip replacement (THR) or total knee replacement (TKR) surgery and using a skin conductance monitor to assess their post-operative pain levels.\n\n3. The inclusion criteria specifically mention patients between 18-85 years old undergoing unilateral THR or TKR, regardless of anesthesia/analgesia type. It also allows participation in other studies.\n\n4. Based on the information provided in the patient note, there is no indication that this patient is scheduled for THR or TKR surgery. The note describes chest pain symptoms.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "137": {
        "output": "Based on the patient note provided, this 58-year-old African-American woman is presenting with symptoms suggestive of a cardiac issue (chest pain, nausea, diaphoresis, and mild dyspnea). However, the clinical trial you described is for assessing the efficacy of a drug (BG00012/dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis (RRMS).\n\nThe patient note does not mention any diagnosis or history of multiple sclerosis. Therefore, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "138": {
        "output": "To determine the patient's eligibility for the clinical trial \"Ivabradine and Post-revascularisation Microcirculatory Dysfunction,\" let's go through the inclusion criteria one by one:\n\n1. Symptoms of Angina Pectoris: The patient presents with episodic pressing/burning anterior chest pain, which is a symptom of angina pectoris. This criterion is met.\n\n2. Angiographic evidence of epicardial coronary artery stenosis referred for PCI: The patient note does not mention any angiographic evidence or referral for percutaneous coronary intervention (PCI). This criterion is not clearly met based on the information provided.\n\n3. Flow limiting lesion (Fractional Flow Reserve \u22640.80) in specific locations: The patient note does not provide any information about fractional flow reserve or the location of any potential lesions. This criterion cannot be evaluated based on the given information.\n\n4. Existing beta blocker prescription: The patient note states that the patient is currently not taking any medications, so this criterion is not met.\n\n5. Echocardiogram performed within preceding 12 months: The patient note does not mention any echocardiogram being performed. This criterion cannot be evaluated based on the given information.\n\n6. Patient consent: The patient note does not mention whether the patient has provided consent or not. This criterion cannot be evaluated based on the given information.\n\nBased on the available information in the patient note, some of the inclusion criteria are met, while others cannot be evaluated or are not met. Therefore, further investigation would be required to determine the patient's eligibility for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "139": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 58-year-old African-American woman presenting with chest pain, which could be a symptom of a cardiac condition. However, the clinical trial is focused on overweight individuals and weight loss interventions.\n\nLooking at the inclusion criteria:\n1. Age between 18-65: The patient is 58, so she meets this criterion.\n2. BMI between 25-45: The patient's BMI is not provided, but she is described as obese, which typically means a BMI over 30, so she likely meets this criterion.\n3. Provide written informed consent: This is not mentioned in the patient note, but it's a standard requirement that can be obtained.\n4. English language skills at the 5th grade reading level: Not mentioned, but can be assumed unless stated otherwise.\n5. Free of major medical conditions: The patient has hypertension and obesity, but no other major conditions are mentioned. Her chest pain could be a concern, but more investigation would be needed.\n6. No eating disorders, cognitive impairment, or unstable psychiatric illness: Not mentioned, so can be assumed to be absent.\n7. Not moving out of the San Diego area: Not mentioned, but can be assumed unless stated otherwise.\n8. Not pregnant or lactating: Not mentioned, but can be assumed unless stated otherwise.\n9. Not taking medications that could interfere with the study: Not mentioned, but she is currently not taking any medications.\n10. No history of bariatric surgery: Not mentioned, so can be assumed to be absent.\n11. Not currently enrolled in an organized weight control program: Not mentioned, so can be assumed to be absent.\n\nBased on the information provided, the patient seems to meet most of the inclusion criteria, but her chest pain would need further investigation to determine if it is a major medical condition that could exclude her from the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "140": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which does not seem to be directly related to the clinical trial about hypertension.\n\n2. The inclusion criteria for the clinical trial state that eligible participants should be \"untreated hypertensive men or women aged between 20 and 80 years old with SBP between 130 and 179 mmHg and/or DBP between 85 and 109 mmHg as measured in a sitting position.\"\n\n3. The patient note mentions that the patient is known to have hypertension, but it does not provide any specific blood pressure readings.\n\n4. Without knowing the patient's current blood pressure values, it is difficult to determine if she meets the inclusion criteria for systolic and diastolic blood pressure ranges.\n\nBased on the information provided, I would consider the following assessment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her current blood pressure readings to see if they fall within the specified ranges in the inclusion criteria.",
        "label": 2
    },
    "141": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old African-American woman presenting with chest pain, which could be related to an acute coronary syndrome. This matches the inclusion criteria of \"Subject with compatible symptoms with an acute coronary syndrome\".\n\n2. The chest pain started 2 days ago and the patient is currently experiencing an episode, which falls within the criteria of \"not older than 3 hours\".\n\n3. There is no mention of the patient receiving heparin or low molecular weight heparin before the initial blood sample, so this inclusion criteria is met.\n\n4. The patient is presenting to the ER, so it can be assumed that she would agree to participate in the study if asked.\n\nBased on the information provided in the patient note, this patient seems to meet all the listed inclusion criteria for the clinical trial titled \"A Prospective Pilot Study to Evaluate a New Marker of Ischemia in Chest Pain Triage\".\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "142": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effect of a Meal Replacement on Weight Loss Obesity Patients With Metabolic Syndrome\", let's go through the inclusion criteria:\n\n1. Body mass index more than or equal to 25 kg/m2\nThe patient note does not provide the patient's height and weight, so we cannot calculate their BMI. However, it does mention that the patient has obesity, which typically means a BMI of 30 or higher. This criterion is likely met.\n\n2. Patients with metabolic syndrome\nThe patient note does not explicitly state whether the patient has metabolic syndrome or not. Metabolic syndrome is a cluster of conditions that include high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels. The patient is known to have hypertension and obesity, which are two components of metabolic syndrome, but we don't have information about the other components.\n\n3. Patients who are on anti-hypertensive drugs, oral hypoglycemic drugs and lipid lowering drugs.\nThe patient note mentions that the patient is not currently taking any medications.\n\nBased on the available information, we cannot definitively determine if the patient meets all the inclusion criteria. While the patient likely meets the BMI criterion, we don't have enough information to confirm the presence of metabolic syndrome or the use of relevant medications.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "143": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now presenting with symptoms of a potential complication from the procedure, including a pulsatile mass in the groin area where the catheter was inserted, loss of distal pulses, and a bruit over the puncture site. These findings are concerning for an arterial pseudoaneurysm or arteriovenous fistula.\n3. The clinical trial is studying the use of the anticoagulant bivalirudin in infants under 6 months of age with thrombosis (blood clots).\n4. The key inclusion criteria are: age less than 6 months, gestational age greater than 35 weeks, objectively confirmed thrombotic event, and no contraindication to anticoagulation.\n\nGiven that this patient is 67 years old and the trial is specifically studying infants under 6 months, she would not meet the age criteria for enrollment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "144": {
        "output": "Based on the patient note provided, the 67-year-old woman has developed a femoral artery pseudoaneurysm as a complication of the cardiac catheterization procedure. This is not related to spinal fusion surgery, which is the focus of the clinical trial titled \"Use of Activated Recombinant FVII in Spinal Surgery.\"\n\nThe inclusion criteria for this trial specifically states \"Elective spinal fusion surgery.\" Since the patient note does not mention any spinal fusion surgery, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "145": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes a 67-year-old woman who underwent a cardiac catheterization procedure and is now experiencing complications related to the femoral artery access site, such as a pulsatile mass in the groin, loss of distal pulses, and a bruit over the access site. This suggests a potential vascular complication like a pseudoaneurysm or arteriovenous fistula.\n\nThe clinical trial titled \"Safety and Feasibility of Endovascular Cooling Device in Patients With Hypothermic Cardiopulmonary Resuscitation\" is focused on evaluating an internal cooling catheter and temperature regulatory device for temperature control in cardiac arrest patients who have regained spontaneous circulation but have a low level of consciousness (GCS < 5).\n\nThe inclusion criteria specifically state: \"Non-traumatic collapsed patients, whose pulsation continues and persists more than 5 minutes after return of spontaneous circulation from cardiopulmonary resuscitation and consciousness level is less than GCS 5 points.\"\n\nBased on the information provided in the patient note, there is no indication that this patient experienced a cardiac arrest or required cardiopulmonary resuscitation. The note describes a complication related to a cardiac catheterization procedure, which does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "146": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman, which fits the \"Postmenopausal women\" inclusion criteria for this trial.\n\n2. The patient note does not mention hypertension or blood pressure levels, so it's unclear if she meets the \"Mild to moderate hypertension\" inclusion criteria.\n\n3. There is no information provided about the patient's statin therapy or LDL cholesterol levels, so it's unclear if she meets the \"Statin therapy or LDL\u2264 4.1 mmol/L\" inclusion criteria.\n\nSince there is not enough information to definitively determine if the patient meets all the inclusion criteria, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "147": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now presenting with symptoms suggestive of a femoral artery pseudoaneurysm at the catheterization site - a pulsatile mass in the groin, cool foot, and bruit over the puncture site.\n3. The clinical trial is studying the use of a catheter thrombectomy device (Aspirex 11F) in patients with massive pulmonary embolism and cardiogenic shock.\n4. The key inclusion criteria are:\n   - Age >= 18 years\n   - Massive pulmonary embolism with cardiogenic shock\n   - Failed thrombolysis or contraindication to thrombolysis\n5. The key exclusion criteria are:\n   - Systemic embolism with septal defect\n   - Free-floating heart thrombi\n   - Life expectancy < 1 month\n\nBased on the information provided, this patient does not appear to have a massive pulmonary embolism or cardiogenic shock. Her presentation is more consistent with a vascular complication from the cardiac catheterization procedure.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "148": {
        "output": "Based on the given patient note and the clinical trial information, this patient would not be eligible for the trial titled \"Evaluation of Residual Urine After Intermittent Catheterisation\".\n\nThe key reasons are:\n\n1. The patient is a 67-year-old woman, while the inclusion criteria specify that participants must be male.\n2. The patient note does not mention any information about urinary issues or the need for intermittent catheterization, which is the focus of the clinical trial.\n3. The patient's condition appears to be related to a complication from a cardiac catheterization procedure, which is not relevant to the trial's objectives.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "149": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman, which meets the age inclusion criteria of 18-79 years old.\n\n2. The patient underwent a cardiac catheterization procedure, which suggests she may have had a cardiac event or cardiac arrest, meeting the inclusion criteria of out-of-hospital cardiac arrest due to a presumed cardiac etiology.\n\n3. There is no information provided about the delay between the cardiac arrest and return of spontaneous circulation (ROSC), or the delay between ROSC and starting cooling.\n\n4. There is also no information about whether the patient was obeying verbal commands after ROSC and prior to starting cooling.\n\n5. The availability of the CoolGard device is not mentioned.\n\nBased on the limited information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore details would be needed regarding the timing of the cardiac arrest, ROSC, and neurological status after ROSC to fully determine eligibility. Additionally, the availability of the required cooling device would need to be confirmed.",
        "label": 0
    },
    "150": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day via the right femoral artery.\n2. She is now experiencing a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These symptoms suggest a possible complication from the catheterization procedure, such as a pseudoaneurysm or arteriovenous fistula involving the right femoral artery.\n\n4. The clinical trial is investigating the use of drug-eluting stents versus percutaneous transluminal angioplasty (PTA) for the treatment of infrapopliteal lesions (below the knee) in patients with critical limb ischemia.\n\n5. The inclusion criteria require:\n   - Age > 18 years (the patient is 67, so meets this criteria)\n   - Critical limb ischemia (Fontaine stage III or IV, or Rutherford category 4-6)\n   - Stenotic or occluded infrapopliteal artery lesion \u2264 60 mm in length\n   - Artery diameter between 2-4 mm\n   - Patent iliac, femoral, and popliteal arteries on the ipsilateral side\n   - At least one patent crural artery with expected runoff to the ankle after treatment\n\n6. Based on the provided patient note, there is no mention of critical limb ischemia or infrapopliteal arterial disease. The patient's symptoms appear to be related to a complication from the cardiac catheterization procedure involving the femoral artery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "151": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day via the right femoral artery.\n\n2. She is now presenting with symptoms of a potential complication from the procedure, including a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n\n3. These findings are suggestive of a femoral artery pseudoaneurysm, which is a known complication of arterial catheterization procedures.\n\n4. The clinical trial is studying carotid artery stenting versus medical management for asymptomatic high-grade carotid artery stenosis.\n\n5. The key inclusion criteria are: asymptomatic >80% carotid stenosis, documented progression of stenosis, very tight \u226590% stenosis, silent ischemia on imaging, contralateral >80% stenosis/occlusion, or planned major surgery.\n\n6. This patient's presentation is unrelated to carotid artery disease and does not meet any of the listed inclusion criteria for the trial.\n\nTherefore, based on the provided information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "152": {
        "output": "To determine the patient's eligibility for the clinical trial \"Plug Arterial Closure System (PACS, 7F)\", let's go through the inclusion criteria one by one:\n\n1. \"Scheduled for a coronary diagnostic or interventional procedure\"\nThe patient note mentions that the patient underwent cardiac catheterization earlier in the morning, which is a diagnostic or interventional coronary procedure. This criterion is met.\n\n2. \"Able to undergo emergent vascular surgery if a complication requires it\"\nThere is no information provided about the patient's ability to undergo emergent vascular surgery. We would need further investigation to determine if this criterion is met.\n\n3. \"7F arterial puncture located in the common femoral artery\"\nThe patient note states that the cardiac catheterization was performed via the right femoral artery, which implies a 7F arterial puncture in the common femoral artery. This criterion is met.\n\n4. \"Femoral artery has a lumen diameter of at least 5 mm\"\nThere is no information provided about the lumen diameter of the patient's femoral artery. We would need further investigation to determine if this criterion is met.\n\nBased on the information provided, some of the inclusion criteria are met, while others require further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "153": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day via the right femoral artery.\n2. She is now experiencing symptoms of a potential complication from the procedure, including a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These symptoms suggest a possible femoral artery pseudoaneurysm or arteriovenous fistula as a complication of the catheterization procedure.\n\n4. The clinical trial is focused on monitoring tissue transfer flaps using a novel imaging technique called Modulated Imaging (MI) spectroscopy.\n5. The inclusion criteria specify that the study is enrolling adult patients planned to undergo reconstructive surgery using tissue transfer flaps.\n6. Based on the patient note, this 67-year-old woman did not undergo reconstructive surgery with a tissue transfer flap. She had a cardiac catheterization procedure complicated by a potential vascular injury.\n\nTherefore, this patient would not meet the inclusion criteria for the clinical trial on monitoring tissue transfer flaps.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "154": {
        "output": "To determine the patient's eligibility for the \"Femoral Arterial Access With Ultrasound Trial\", let's go through the inclusion criteria:\n\n1. Adults age 18 and over\n   - The patient is 67 years old, so this criterion is met.\n\n2. Patients undergoing left heart catheterization or peripheral arterial angiography from the retrograde femoral approach\n   - The patient underwent cardiac catheterization via the right femoral artery, so this criterion is met.\n\n3. Willingness and ability to sign consent form\n   - There is no information provided about the patient's willingness or ability to sign a consent form.\n\n4. Scheduled to have procedure performed by operator trained in the ultrasound technique\n   - There is no information provided about whether the operator was trained in the ultrasound technique.\n\nBased on the information given, the patient meets at least two of the inclusion criteria. However, there is not enough information to determine if the patient meets the remaining two criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "155": {
        "output": "Okay, let's analyze the patient note and clinical trial details step-by-step:\n\nThe patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier in the day. She is now experiencing symptoms suggestive of a femoral artery pseudoaneurysm, which is a known complication of femoral artery access for cardiac catheterization.\n\nThe clinical trial titled \"Prospective Registry on Vascular Access in Interventions in Lazio Region\" aims to assess the outcomes related to different vascular access sites (radial vs femoral) for percutaneous cardiovascular procedures.\n\nThe inclusion criteria for this trial are broad, including \"All patients undergoing any percutaneous cardiovascular procedure\".\n\nGiven that the patient has just undergone a percutaneous cardiovascular procedure (cardiac catheterization) and developed a complication related to the vascular access site (femoral artery pseudoaneurysm), she would be eligible for inclusion in this registry study.\n\nMonitoring and documenting the outcomes of patients like her, who develop vascular access site complications, is precisely the goal of this prospective registry.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "156": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier in the day.\n2. She is now complaining of a cool right foot, has a pulsatile mass in the right groin with loss of distal pulses, and a bruit is heard over the femoral artery puncture site.\n3. These findings suggest a complication of the procedure, likely a pseudoaneurysm or arteriovenous fistula at the access site.\n\n4. Looking at the inclusion criteria for the RISE clinical trial:\n- She meets the age criteria of 18-85 years old.\n- She underwent a percutaneous diagnostic procedure via the common femoral artery with a 5F or 6F sheath, which she meets.\n\n5. However, looking at the exclusion criteria:\n- She likely has a pseudoaneurysm or AV fistula at the access site, which is an exclusion criterion.\n- She has a complication of bleeding/hematoma at the access site, which is another exclusion.\n\n6. Given the complications she has developed related to the femoral artery access, she would be excluded from participating in this trial evaluating a vascular closure device.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "157": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman, which does not meet the age inclusion criteria of 4-18 years for this clinical trial.\n\n2. The patient underwent a cardiac catheterization, which is one of the inclusion criteria for this trial. However, the reason for the catheterization is not stated as being for pulmonary arterial hypertension evaluation.\n\n3. There is no mention of the patient having pulmonary arterial hypertension or an elevated mean pulmonary artery pressure, which is a key inclusion criteria.\n\n4. The patient's current issue seems to be related to a complication from the cardiac catheterization procedure (femoral artery pseudoaneurysm), rather than being evaluated for pulmonary hypertension treatment.\n\nBased on the information provided in the patient note, this 67-year-old woman would not meet the key inclusion criteria for this clinical trial on assessing right ventricular contractility in response to sildenafil in children with pulmonary arterial hypertension.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "158": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now experiencing complications from the procedure, including a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These symptoms suggest a potential femoral artery pseudoaneurysm or arteriovenous fistula as a complication of the catheterization.\n4. The clinical trial is studying therapeutic hypothermia for post-cardiac arrest patients.\n5. The key inclusion criteria are: sustained return of spontaneous circulation after cardiac arrest for >30 min, age 18-80 years, hemodynamically stable, and comatose/unresponsive post-resuscitation.\n6. Based on the patient note, there is no indication that this patient suffered a cardiac arrest or required resuscitation.\n7. Therefore, this patient would not meet the key inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "159": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n2. She is now experiencing complications from the procedure, including a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the femoral artery access site.\n3. The clinical trial is studying the use of suture-mediated closure devices for achieving hemostasis and reducing complications following femoral venous access procedures.\n4. One of the key inclusion criteria is that the patient must have received suture-mediated femoral vein closure following catheterization.\n\nGiven the details provided in the patient note, it appears this patient experienced a complication (likely a pseudoaneurysm or arteriovenous fistula) following femoral artery access, not venous access. Therefore, she would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "160": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"COOL-Trial: Outcome With Invasive and Non-invasive Cooling After Cardiac Arrest\", this patient would not be eligible for the trial.\n\nThe patient note describes a 67-year-old woman who underwent cardiac catheterization and is now experiencing complications related to the femoral artery access site. There is no mention of the patient experiencing a sudden cardiac arrest or having a Glasgow Coma Scale (GCS) score of 3, which are the inclusion criteria for the COOL-Trial.\n\nThe COOL-Trial is specifically studying the effects of therapeutic hypothermia in patients who have experienced a sudden cardiac arrest and have a GCS score of 3, indicating a comatose state. The patient in the given note does not meet these criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "161": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now presenting with symptoms of a potential complication from the procedure - a pulsatile mass in the groin with loss of distal pulses and a bruit, suggesting a femoral artery pseudoaneurysm.\n3. The clinical trial is called PROTECT Continued Access Post Marketing Surveillance Trial. It is studying the safety of the Endeavor drug-eluting stent system in patients undergoing coronary stent implantation.\n4. The key inclusion criteria are: age > 18 years, patient consent, lesions amenable to Endeavor stent implantation per instructions for use, and willingness to follow study procedures.\n5. This patient does not seem to be a candidate for this particular stent trial, as her current issue is a vascular complication from a catheterization procedure rather than a coronary artery lesion requiring stenting.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "162": {
        "output": "Let's analyze the patient note and inclusion criteria for the clinical trial step-by-step:\n\nThe patient note describes a 67-year-old woman who underwent a cardiac catheterization procedure and is now experiencing complications, including a pulsatile mass in the groin and loss of distal pulses, suggesting a possible femoral artery pseudoaneurysm.\n\nThe clinical trial is focused on studying the response to cardiac resynchronization therapy (CRT) in heart failure patients based on their arterial stiffness.\n\nThe inclusion criteria for the trial are:\n1. Patients receiving CRT\n2. Medically refractory, symptomatic heart failure (NYHA class III or IV)\n3. QRS duration \u2265 130 ms\n4. Left ventricular ejection fraction \u2264 30%\n\nBased on the information provided in the patient note, there is no mention of the patient's heart failure status, NYHA class, QRS duration, or left ventricular ejection fraction. The note primarily focuses on the complication from the cardiac catheterization procedure.\n\nTherefore, without additional information about the patient's cardiac condition and eligibility for CRT, it is difficult to determine their suitability for this particular clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their cardiac status and eligibility for CRT.",
        "label": 0
    },
    "163": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman, which meets the age criteria of being at least 18 years old.\n\n2. She underwent cardiac catheterization via the right femoral artery, which means she had femoral access for a coronary angiography procedure.\n\n3. The trial specifically mentions including patients undergoing femoral access coronary angiography.\n\n4. While the sheath size is not explicitly mentioned, it is reasonable to assume a standard 6F sheath was used for a routine coronary angiography procedure.\n\n5. The patient is now experiencing complications from the femoral artery access, with a pulsatile mass in the groin and loss of distal pulses. This trial is comparing different closure methods after femoral access.\n\n6. There is no mention of the patient's competency to provide informed consent, but this is generally assumed unless stated otherwise.\n\nBased on the information provided, this patient meets all the key inclusion criteria and would be an excellent candidate for this clinical trial comparing different arterial closure methods after femoral access coronary angiography.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "164": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who recently underwent a cardiac catheterization procedure via the right femoral artery.\n2. She is now presenting with symptoms of a potential complication from the procedure, including a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These findings are suggestive of a femoral artery pseudoaneurysm, which is a known complication of femoral artery catheterization procedures.\n\n4. The clinical trial is studying the use of continuous intra-femoral artery infusion of urokinase for the treatment of diabetic foot ulcers.\n5. The key inclusion criteria are: diabetic foot ulcer, age <= 80 years old, and diabetic foot ulcer Wagner stage 2-4.\n\n6. Based on the patient note, there is no mention of the patient having diabetes or a diabetic foot ulcer.\n7. The patient's presenting symptoms appear to be related to a procedural complication rather than a diabetic foot condition.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "165": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n2. She is now experiencing symptoms of a potential complication from the procedure, including a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery access site.\n3. The clinical trial is evaluating the safety and efficacy of the QuickClose Design 9 closure device for sealing the femoral artery access site after angiogram procedures.\n4. The inclusion criteria include: providing informed consent, undergoing a coronary or peripheral angiogram procedure, target vessel lumen diameter \u22656mm, willingness to comply with follow-up, and having a 5-7F arterial puncture in the common femoral artery.\n5. Based on the information provided, this patient meets the key inclusion criteria of having undergone an angiogram procedure with a femoral artery access site that likely needs closure.\n\nTherefore, given the patient's current condition and symptoms potentially related to the femoral access site, as well as meeting the listed inclusion criteria:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "166": {
        "output": "Based on the given patient note and the clinical trial information, here is my assessment:\n\nThe patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the femoral artery. She is now experiencing complications such as a pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery puncture site, suggesting a possible femoral artery pseudoaneurysm or arteriovenous fistula.\n\nThe clinical trial titled \"Use of Local Anesthetic (0.25% Bupivacaine) for Pain Control in Pediatric Cardiac Catheterization\" is focused on investigating the use of local anesthetic for pain control in children aged 7-18 years undergoing cardiac catheterization procedures.\n\nGiven that the patient is an adult (67 years old) and not within the age range specified in the inclusion criteria (7-18 years), she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "167": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day via the right femoral artery.\n2. She is now presenting with symptoms of a potential complication from the procedure, including a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These findings are suggestive of a femoral artery pseudoaneurysm, which is a known complication of femoral artery catheterization procedures.\n4. The clinical trial is studying the feasibility of endovascular revascularization procedures in diabetic patients with chronic critical limb ischemia due to peripheral artery disease.\n5. The inclusion criteria specify adult diabetic patients with chronic critical limb ischemia as defined by certain clinical and hemodynamic criteria.\n6. While the patient note does not explicitly state whether the patient has diabetes, the presenting symptoms and potential vascular complication from the catheterization procedure suggest the patient may have underlying peripheral artery disease.\n\nBased on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe reason for this assessment is that while the patient meets the age criteria and appears to have a vascular complication potentially related to peripheral artery disease, it is unclear from the note whether the patient definitively meets the inclusion criteria of having chronic critical limb ischemia due to diabetes. Further investigation into the patient's medical history and vascular status would be needed to determine full eligibility for this trial.",
        "label": 0
    },
    "168": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now presenting with symptoms of a potential complication from the procedure - a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These findings are suggestive of a femoral artery pseudoaneurysm, which is a known complication of cardiac catheterization procedures.\n\n4. Looking at the inclusion criteria for the clinical trial:\n- Age > 19 years (the patient is 67, so meets this)\n- Evidence of coronary artery disease requiring intervention (the patient underwent cardiac catheterization, implying coronary disease)\n- No exclusion criteria clearly apply based on the limited information provided\n\n5. While the development of a pseudoaneurysm is a complication, it does not necessarily exclude the patient from participating in this trial evaluating different drug-eluting stents in real-world practice.\n\n6. However, further investigation would be needed regarding:\n- The severity of the pseudoaneurysm and whether it requires intervention that could impact trial participation\n- Whether the patient meets other inclusion/exclusion criteria not mentioned in the note\n- The patient's clinical status and whether they are a suitable candidate overall\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "169": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now presenting with symptoms of a potential complication from the procedure - a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These findings are suggestive of a femoral artery pseudoaneurysm, which is a known complication of cardiac catheterization procedures involving femoral artery access.\n4. The clinical trial is studying the safety and efficacy of two different drug-eluting stent types in patients undergoing percutaneous coronary intervention (PCI) for coronary artery disease.\n5. The key inclusion criteria are: age \u226518 years, symptomatic coronary artery disease, and presence of coronary artery stenosis amenable to stenting.\n6. There is no specific exclusion criteria listed that would definitively rule out this patient.\n\nGiven the information provided, this 67-year-old woman appears to meet the key inclusion criteria for age and presence of coronary artery disease requiring PCI (evidenced by her recent cardiac catheterization). However, the pseudoaneurysm complication may need to be addressed/resolved prior to proceeding with PCI and stent placement.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her coronary artery disease status and management of the pseudoaneurysm complication.",
        "label": 0
    },
    "170": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n\n2. She is now experiencing symptoms of a potential complication from that procedure, including a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n\n3. These symptoms are suggestive of a femoral artery pseudoaneurysm, which is a known complication of femoral artery catheterization procedures.\n\n4. The clinical trial is studying the complication rates of central venous catheterization at different sites (subclavian, internal jugular, femoral).\n\n5. The inclusion criteria are simply that the patient is admitted to the intensive care unit and requires central venous catheterization.\n\n6. This patient meets the inclusion criteria, as she is likely in the intensive care unit setting following her cardiac catheterization complication, and may require central venous access.\n\n7. However, her current complication (suspected femoral pseudoaneurysm) may make the femoral site relatively contraindicated for central line placement.\n\n8. Therefore, while she meets the broad inclusion criteria, her specific clinical situation may make her less than an ideal candidate for this particular trial comparing central line sites.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "171": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who recently underwent a cardiac catheterization procedure via the right femoral artery.\n2. She is now experiencing symptoms of a potential complication from the procedure, including a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These symptoms suggest the possibility of a pseudoaneurysm or arteriovenous fistula formation at the catheterization site.\n4. The clinical trial is studying the effects of acute systemic inflammation (such as sepsis) on arterial stiffness and microcirculation.\n5. The inclusion criteria for the control group require participants to be generally healthy with no significant medical conditions or abnormal test results.\n6. The inclusion criteria for the patient group require participants to have severe sepsis, defined by the presence of systemic inflammatory response syndrome, evidence of infection, and organ failure or signs of tissue hypoperfusion.\n\nBased on the information provided, this patient does not meet the inclusion criteria for either the control group or the patient group in this clinical trial. Her medical condition is related to a procedural complication rather than sepsis or acute systemic inflammation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "172": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day via the right femoral artery.\n2. She is now complaining of a cool right foot, and upon examination, she has a pulsatile mass in her right groin with loss of distal pulses.\n3. Auscultation reveals a bruit (abnormal sound) over the point at which the right femoral artery was entered.\n\n4. The clinical trial is testing a new amplified stethoscope (AudioDoc) that can detect the presence of bruit (abnormal sound) in the carotid and femoral arteries.\n5. The inclusion criteria for the trial are:\n   - Age 19-90 years\n   - Having a clinical ultrasound evaluation of the carotid or femoral artery\n\n6. Based on the patient's presentation and the inclusion criteria, this patient meets the age requirement and has a suspected femoral artery issue, which would likely require an ultrasound evaluation.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "173": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n2. She is now complaining of a cool right foot, and upon examination, she has a pulsatile mass in her right groin with loss of distal pulses and a bruit over the femoral artery access site.\n3. This suggests a complication of the procedure, likely a pseudoaneurysm or arteriovenous fistula at the access site.\n4. The clinical trial is investigating the safety and efficacy of a vascular closure device (CELT ACD) for achieving hemostasis at the common femoral artery access site in patients undergoing percutaneous interventions while on anticoagulation.\n5. The inclusion criteria state that patients must be over 18 years of age, willing to provide informed consent, and undergoing an intra-arterial procedure involving access through the common femoral artery with a 6F or 7F sheath.\n6. This patient meets the age criterion and has undergone a procedure involving access through the common femoral artery, likely with a 6F or 7F sheath (as is common for cardiac catheterization).\n7. However, her current complication (likely a pseudoaneurysm or arteriovenous fistula) may exclude her from the trial or require further investigation to determine if she is still eligible.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "174": {
        "output": "Based on the given patient note and the clinical trial information, the patient does not appear to meet the inclusion criteria for the clinical trial titled \"Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplantation\".\n\nThe key points are:\n\n1. The patient note describes a 67-year-old woman who underwent cardiac catheterization and is now experiencing complications related to the femoral artery access site.\n\n2. The clinical trial is focused on patients undergoing kidney transplantation and assessing the use of a fibrin-based adhesive to prevent surgical complications in that specific procedure.\n\n3. The inclusion criteria for the trial explicitly state \"Patients candidates to renal transplantation\".\n\nSince the patient in the given note is not a candidate for kidney transplantation, but rather experienced complications from a cardiac catheterization procedure, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "175": {
        "output": "Okay, let's analyze the patient note and clinical trial details step-by-step:\n\nThe patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day. She is now presenting with symptoms suggestive of a femoral artery pseudoaneurysm, which is a potential complication of the catheterization procedure.\n\nThe clinical trial is a retrospective study looking at the effect of perioperative medications on outcomes in patients undergoing cardiac surgery. The inclusion criteria is simply \"All cardiac surgical patients\".\n\nSince this patient has undergone a cardiac catheterization procedure, which is a type of cardiac intervention, and is now experiencing a complication related to that procedure, she would likely be eligible for inclusion in this retrospective study analyzing outcomes in cardiac surgical patients.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "176": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day via the right femoral artery.\n2. She is now presenting with symptoms of a potential vascular complication - a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. The clinical trial is studying the use of remote ischemic preconditioning (RIPC) to reduce complications in patients undergoing major vascular surgery.\n4. The inclusion criteria are: age >18 years, willing to provide informed consent, and undergoing one of the specified vascular surgeries (carotid endarterectomy, open/endovascular abdominal aortic aneurysm repair, or lower limb revascularization).\n5. While this patient did not undergo a major vascular surgery procedure, she is experiencing a vascular complication from the cardiac catheterization that may require surgical intervention.\n\nBased on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the age criteria, and depending on the required treatment for her vascular complication, she may potentially undergo a procedure that falls under the inclusion criteria for this trial. However, more information would be needed to definitively determine eligibility.",
        "label": 2
    },
    "177": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day via the right femoral artery.\n\n2. She is now presenting with symptoms suggestive of a femoral artery pseudoaneurysm - a pulsatile mass in the right groin, cool right foot, loss of distal pulses, and a bruit over the catheter entry site.\n\n3. The clinical trial is titled \"Pragmatic Ischaemic Stroke Thrombectomy Evaluation\" and is evaluating mechanical thrombectomy devices for treating acute ischemic strokes caused by large artery occlusions.\n\n4. The key inclusion criteria are:\n   - Clinical diagnosis of acute ischemic stroke\n   - Age \u2265 18 years\n   - Significant neurological deficit (NIHSS \u2265 6)\n   - Eligible for IV thrombolysis within 4.5 hours of symptom onset\n   - Able to start procedure within 90 minutes of IV thrombolysis and within 6 hours of symptom onset\n   - Occlusion of major intracranial artery demonstrated on imaging\n   - Independent prior to stroke (mRS 0-2)\n\n5. This patient does not appear to be having an acute ischemic stroke. Her symptoms are related to a complication from the cardiac catheterization procedure.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "178": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now presenting with symptoms of a potential complication from the procedure, including a pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These findings are suggestive of a femoral artery pseudoaneurysm, which is a known complication of arterial catheterization procedures.\n\n4. The clinical trial titled \"Arterial Elasticity: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)\" is studying the effects of early versus deferred antiretroviral therapy on arterial stiffness in HIV patients.\n\n5. The key inclusion criteria are: 1) Co-enrollment in the START study, and 2) Signed informed consent.\n\n6. Based on the patient note provided, there is no mention of the patient's HIV status or enrollment in the START study.\n\n7. The clinical presentation appears to be unrelated to the aims of studying arterial elasticity and timing of antiretroviral therapy in HIV patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "179": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now presenting with symptoms suggestive of an arterial thrombosis complication from the procedure - a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. The clinical trial is studying antithrombotic prophylaxis and treatment approaches in patients with hematologic malignancies and thrombocytopenia (platelet count < 50 x 10^9/L).\n4. The inclusion criteria specifically mention including patients with a diagnosis of arterial thrombosis like acute coronary syndrome, ischemic stroke, peripheral arterial thrombosis, etc.\n5. While the patient note does not mention if she has an underlying hematologic malignancy, she does appear to have developed an arterial thrombosis complication (likely femoral artery pseudoaneurysm) following her catheterization procedure.\n\nBased on the information provided, I would assess this case as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the criteria of having an objectively diagnosed arterial thrombosis. However, further information is needed about whether she has an underlying hematologic malignancy and current platelet count to fully determine eligibility for this particular trial studying antithrombotic approaches in thrombocytopenic cancer patients.",
        "label": 0
    },
    "180": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman, which meets the \"Women\" inclusion criteria for the trial.\n\n2. The patient note does not explicitly state that she has diabetes, which is one of the inclusion criteria. However, peripheral arterial disease is often associated with diabetes, so it's possible she may have diabetes.\n\n3. The patient is described as having a pulsatile mass in her right groin with loss of distal pulses and a bruit over the femoral artery entry point, which suggests peripheral arterial disease.\n\nGiven this information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient appears to meet two of the three inclusion criteria (being a woman and having peripheral arterial disease), but her diabetes status is unclear from the note. Further investigation into whether she has diabetes would be needed to fully determine her eligibility for this particular trial studying peripheral arterial disease in diabetic women.",
        "label": 0
    },
    "181": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now presenting with symptoms of a potential complication from the procedure, including a pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. The clinical trial is studying the effects of renal denervation in patients with chronic heart failure and severe left ventricular dysfunction.\n4. The inclusion criteria require patients to be over 18 years old, have chronic heart failure (NYHA class II-IV), have a left ventricular ejection fraction \u2264 35%, be on maximum tolerated heart failure medications, and be stable without acute decompensation for at least 4 weeks prior.\n\nBased on the limited information provided in the patient note, there is no mention of the patient having chronic heart failure, their NYHA class, left ventricular ejection fraction, or current heart failure medications. The note is focused on a potential vascular complication from the cardiac catheterization procedure.\n\nTherefore, without additional clinical details about the patient's heart failure status and severity, it would not be appropriate to refer this patient to the renal denervation clinical trial based solely on the information given.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "182": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n2. She is now complaining of a cool right foot, and upon examination, she has a pulsatile mass in her right groin with loss of distal pulses and a bruit over the femoral artery puncture site.\n3. This suggests a complication of the procedure, likely a pseudoaneurysm or arteriovenous fistula at the femoral artery access site.\n4. The clinical trial is studying the safety and performance of a vascular closure device for closing large femoral arterial puncture sites (18-24F) after endovascular procedures.\n5. The inclusion criteria state that patients must be over 18 years of age, willing to provide informed consent, undergoing an endovascular procedure involving femoral artery access with a puncture size of 18-24F, and females must not be pregnant or lactating.\n6. This patient meets the age criteria and has undergone a relevant endovascular procedure with femoral artery access, which has resulted in a complication that may require a vascular closure device.\n7. Assuming she is willing to provide informed consent and is not pregnant or lactating, she would likely be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "183": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now experiencing symptoms of a potential complication from the procedure, including a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These symptoms suggest the possibility of a femoral artery pseudoaneurysm, which is a known complication of cardiac catheterization procedures.\n\n4. The clinical trial is studying neurological recovery in survivors of different types of cardiac arrest who receive therapeutic hypothermia (total body cooling).\n\n5. The key inclusion criteria are:\n   - Adult patient (age \u226518 years)\n   - Admitted to ICU after cardiac arrest (both in-hospital and out-of-hospital arrests are included)\n   - ICU admission between Jan 2008 and Dec 2012\n\n6. Based on the information provided in the patient note, there is no indication that this patient experienced a cardiac arrest. The note describes a complication from a cardiac catheterization procedure, but not a cardiac arrest event.\n\n7. Therefore, this patient would not meet the inclusion criteria for the clinical trial, which specifically requires patients who have survived a cardiac arrest.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "184": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent cardiac catheterization via the right femoral artery earlier that day.\n2. She is now complaining of a cool right foot, and upon examination has a pulsatile mass in her right groin with loss of distal pulses and a bruit over the femoral artery puncture site.\n3. This clinical presentation is consistent with a femoral artery pseudoaneurysm, which is a potential complication of femoral artery catheterization.\n4. The clinical trial is studying immediate mobilization after cardiac catheterization via the femoral artery, compared to the standard 2-hour period of immobilization.\n5. One of the inclusion criteria is \"No hematoma in the groin (> 5 cm in diameter)\".\n6. While the patient does not have a hematoma per se, she does have a pulsatile pseudoaneurysm mass in the groin related to the catheterization.\n7. This pseudoaneurysm could potentially increase her risk of bleeding complications with immediate mobilization after the procedure.\n\nBased on the provided information, I would assess this patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the pseudoaneurysm does not definitively exclude her, I would want more details about the size, stability of the pseudoaneurysm, and the trial investigators' guidance on whether pseudoaneurysms are an exclusion before definitively enrolling the patient. Close monitoring would likely be required if enrolled.",
        "label": 0
    },
    "185": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now experiencing symptoms of a potential complication from the procedure, including a pulsatile mass in the groin area where the catheter was inserted, loss of distal pulses, and a bruit over the insertion site. These findings suggest a possible femoral artery pseudoaneurysm or arteriovenous fistula.\n3. The clinical trial is studying postoperative respiratory depression after coronary artery bypass graft (CABG) surgery.\n4. The inclusion criteria specify patients undergoing CABG with cardiopulmonary bypass, confirmed coronary artery disease, use of certain bypass grafts, remaining on spontaneous ventilation postoperatively, absence of chronic or acute lung disease, and providing informed consent.\n\nBased on the information provided, this patient does not meet the inclusion criteria for this particular clinical trial, as she did not undergo CABG surgery but rather a cardiac catheterization procedure. Additionally, her current complication is not related to postoperative respiratory depression, which is the focus of the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "186": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day via the right femoral artery.\n2. She is now presenting with symptoms of a potential vascular complication - a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site. \n3. The clinical trial is studying the use of remote ischemic preconditioning (RIPC) to reduce complications in patients undergoing major vascular surgery.\n4. The inclusion criteria are:\n   - Age > 18 years\n   - Undergoing elective carotid endarterectomy, open/endovascular abdominal aortic aneurysm repair, or surgical lower limb revascularization\n\n5. This patient meets the age criteria and appears to have suffered a vascular complication from her recent cardiac catheterization procedure, which could potentially qualify her for the trial if further vascular surgery is required to address the complication.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "187": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n2. She is now experiencing symptoms suggestive of a complication from the procedure, such as a pseudoaneurysm or arteriovenous fistula at the access site (pulsatile mass in the groin, loss of distal pulses, bruit over the access site).\n3. The clinical trial is comparing the left radial artery approach versus the right radial artery approach for routine cardiac catheterization in heart transplant patients.\n4. The inclusion criteria specify that eligible patients must be heart transplant recipients aged over 18 years old scheduled for a routine coronary angiography.\n\nBased on the information provided, this patient does not meet the inclusion criteria for this clinical trial for the following reasons:\n- She is not a heart transplant recipient\n- She was undergoing a cardiac catheterization procedure, not a routine coronary angiography\n- The procedure was performed via the femoral artery, not the radial artery\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "188": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n2. She is now experiencing symptoms of a potential complication from the procedure, including a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery access site.\n3. These symptoms are suggestive of a femoral artery pseudoaneurysm, which is a known complication of femoral artery catheterization procedures.\n\n4. The clinical trial is comparing radiation exposure to the operator during radial artery vs. femoral artery access for cardiac catheterization procedures in patients with acute coronary syndromes.\n\n5. The inclusion criteria specifically mention patients with unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI) who are suitable for coronary angiography and/or percutaneous coronary intervention via either radial or femoral access.\n\n6. Based on the patient's presentation with a potential femoral artery complication after undergoing a femoral artery catheterization procedure, she would likely meet the inclusion criteria for this trial.\n\n7. Her acute condition and complication from the femoral access procedure would make her a relevant candidate to potentially enroll in this trial comparing radiation exposure between radial and femoral access techniques.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "189": {
        "output": "Based on the given patient note and the clinical trial information, this patient does not appear to be eligible for the clinical trial titled \"HAL-RAR Versus Hemorrhoidectomy in the Treatment of Grade III-IV Hemorrhoids. Prospective, Randomized Trial\".\n\nThe patient note describes a 67-year-old woman who underwent cardiac catheterization and is now experiencing complications related to the femoral artery access site, such as a pulsatile mass in the groin, loss of distal pulses, and a bruit over the entry point. This condition is not related to hemorrhoids or the inclusion criteria specified for the clinical trial.\n\nThe inclusion criteria for the clinical trial state that eligible participants should have \"symptomatic grade III or IV hemorrhoids (bleeding, pain, itching, soiling or prolapse) that are eligible for surgical treatment with both methods.\" The patient note does not mention any symptoms or conditions related to hemorrhoids.\n\nTherefore, based on the information provided, this patient would not be eligible for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "190": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n2. She is now complaining of a cool right foot, which could indicate a vascular complication from the procedure.\n3. Upon examination, she has a pulsatile mass in her right groin with loss of distal pulses and a bruit over the femoral artery access site, which suggests a femoral artery pseudoaneurysm.\n\n4. The clinical trial is comparing the MynxGrip vascular closure device to manual compression for closure after femoral artery access angiography procedures.\n\n5. The inclusion criteria are:\n   - Age > 18 years (the patient is 67, so meets this)\n   - Able to provide informed consent\n   - Undergoing coronary angiography, possibly with FFR, IVUS, OCT or NIRS\n\n6. This patient underwent a cardiac catheterization via the femoral artery, which is the type of procedure included in this trial.\n\n7. Her complication of a suspected femoral pseudoaneurysm is directly relevant to evaluating vascular closure devices like the MynxGrip.\n\nBased on the information provided, this patient seems highly relevant for this clinical trial comparing femoral artery closure devices after undergoing a femoral angiography procedure and developing a vascular complication.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "191": {
        "output": "To determine the patient's eligibility for the clinical trial \"Safety and Performance Study of Large Hole Vascular Closure Device\", let's go through the inclusion criteria one by one:\n\n1. Over 18 years of age: The patient is 67 years old, so this criterion is met.\n\n2. Each patient, or his or her guardian or legal representative, is willing to give informed consent: This information is not provided in the patient note, but we can assume that the patient would be willing to give informed consent if referred to the trial.\n\n3. Clinically indicated for an endovascular procedure involving access through the femoral artery, with an access puncture of 18 - 24 French (F): The patient note mentions that the patient underwent cardiac catheterization via the right femoral artery, which would involve an access puncture within the specified range.\n\n4. Females who are not pregnant or lactating, and not planning to become pregnant in \u2264 12 months: This criterion is not applicable since the patient is a 67-year-old woman.\n\nBased on the information provided in the patient note and the inclusion criteria, this patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "192": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent cardiac catheterization via the right femoral artery earlier in the day.\n2. She is now complaining of a cool right foot, and upon examination, she has a pulsatile mass in her right groin with loss of distal pulses and a bruit over the point where the right femoral artery was entered.\n3. The clinical trial is investigating the duration and adverse events of non-cuffed catheters in patients with hemodialysis.\n4. The inclusion criteria for the trial are:\n   - Chronic renal failure requiring hemodialysis\n   - No medical history of central vena catheterization\n   - Maintenance hemodialysis after central vena catheterization\n   - Signed informed consent\n\nBased on the information provided, this patient does not appear to meet the inclusion criteria for this clinical trial. The patient's condition is related to a complication from cardiac catheterization, not hemodialysis or chronic renal failure.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "193": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n2. She is now complaining of a cool right foot, which suggests potential vascular complications from the catheterization procedure.\n3. Upon examination, she has a pulsatile mass in her right groin with loss of distal pulses and a bruit over the femoral artery puncture site. This indicates a possible pseudoaneurysm or arteriovenous fistula formation at the catheterization site.\n\nThe clinical trial is titled \"Randomized Clinical Trial of Polyester vs. Polyurethane Patch for Carotid Endarterectomy.\" The inclusion criteria state:\n\n\"Carotid stenosis > 60% NASCET criteria\"\n\nBased on the patient note, there is no mention of carotid artery stenosis or any indication that the patient would require a carotid endarterectomy procedure. The patient's presenting issue appears to be a complication from the cardiac catheterization procedure involving the femoral artery, which is not relevant to the inclusion criteria for this particular clinical trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "194": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery earlier that day.\n2. She is now complaining of a cool right foot, which suggests potential vascular complications from the procedure.\n3. Upon examination, she has a pulsatile mass in her right groin with loss of distal pulses and a bruit over the femoral artery puncture site. This indicates a potential pseudoaneurysm or arteriovenous fistula complication.\n\n4. The clinical trial is comparing the use of a negative pressure incision management system (Prevena) versus standard dressing after vascular surgery involving groin incisions.\n\n5. The inclusion criteria state that eligible patients must be undergoing vascular surgery that includes a groin incision, such as femoral artery bypass, endarterectomy, or procedures involving the common femoral, profunda, or proximal superficial femoral arteries.\n\n6. This patient did not undergo a planned vascular surgery procedure but rather developed a complication (likely pseudoaneurysm) after a cardiac catheterization procedure involving the femoral artery.\n\n7. While the patient's condition involves the femoral artery and groin region, she does not meet the specific inclusion criteria of undergoing a planned vascular surgery procedure with a groin incision.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the patient does not currently meet the inclusion criteria, her condition may potentially require vascular surgery involving a groin incision to treat the suspected pseudoaneurysm or arteriovenous fistula complication. Further investigation and discussion with the study team would be warranted to determine if she could potentially become eligible for enrollment after undergoing the necessary vascular procedure.",
        "label": 1
    },
    "195": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now experiencing symptoms of a potential complication from the procedure, including a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery access site.\n3. The clinical trial is evaluating the effect of surgical safety checklists on perioperative complications in children undergoing non-cardiac surgery in Ontario, Canada.\n4. The inclusion criteria specify that participants must be surgical admissions for non-cardiac surgical interventions, and be between 28 days and 18 years of age.\n\nGiven that this patient is an adult who underwent a cardiac catheterization procedure, which is not included in the trial's inclusion criteria, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "196": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day. She is now presenting with symptoms suggestive of a femoral artery pseudoaneurysm, which is a potential complication of the catheterization procedure.\n\nThe clinical trial is studying the use of intracardiac echocardiography (ICE) during atrial flutter ablation procedures. The only inclusion criterion listed is \"indication for atrial flutter ablation\".\n\nSince the patient's current condition is related to a complication from a cardiac catheterization procedure rather than atrial flutter, she would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "197": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, here is my assessment of the patient's eligibility:\n\nThe patient note describes a 67-year-old woman who underwent a cardiac catheterization procedure via the right femoral artery and is now experiencing complications related to that procedure, including a pulsatile mass in the right groin and loss of distal pulses.\n\nThe clinical trial titled \"Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty\" is studying the effectiveness of different types of nerve blocks for pain management and early rehabilitation after total knee replacement surgery.\n\nThe key inclusion criterion for this trial is \"Able to consent to regional anesthesia and having primary total knee arthroplasty/replacement.\"\n\nBased on the information provided in the patient note, there is no indication that this patient is undergoing or scheduled for a total knee replacement surgery. The note describes complications related to a cardiac catheterization procedure, which is unrelated to the focus of this clinical trial.\n\nTherefore, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "198": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day via the right femoral artery.\n\n2. She is now complaining of a cool right foot, and upon examination, there is a pulsatile mass in her right groin with loss of distal pulses and a bruit over the entry point of the femoral artery.\n\n3. The clinical trial is comparing two types of arteriovenous fistulas (AVFs) for hemodialysis patients - the brachiocephalic AVF (BCAVF) and a modified non-transposed brachiobasilic AVF (mNT-BBAVF).\n\n4. The inclusion criteria are:\n   - Age 18-75 years\n   - Radial artery diameter < 2.0 mm or cephalic vein diameter in forearm < 2.5 mm\n   - Brachial artery diameter \u2265 2 mm\n\n5. Based on the patient note, this 67-year-old woman does not seem to require hemodialysis or have any issues with her upper extremity vessels that would make her eligible for this AVF clinical trial.\n\n6. Her current issue appears to be a complication from the cardiac catheterization procedure involving the femoral artery, which is not relevant to the trial studying upper extremity AVFs.\n\nTherefore, Trial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "199": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who underwent a cardiac catheterization procedure earlier in the day.\n2. She is now experiencing symptoms of a potential complication from the procedure, including a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These symptoms suggest the possibility of a femoral artery pseudoaneurysm, which is a known complication of cardiac catheterization procedures.\n\n4. The clinical trial is studying pulmonary artery denervation for the treatment of pulmonary arterial hypertension.\n5. The key inclusion criteria are:\n   - Patients with pulmonary arterial hypertension\n   - Age over 18 years\n   - NYHA class III or IV heart failure\n   - Uncontrolled hypertension despite optimal medical management\n\n6. Based on the patient note, there is no mention of the patient having pulmonary arterial hypertension or meeting the other key inclusion criteria for this trial.\n7. The patient's current medical issue appears to be related to a complication from the cardiac catheterization procedure rather than pulmonary hypertension.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "200": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who recently underwent a cardiac catheterization procedure via the right femoral artery.\n2. She is now experiencing symptoms like a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These symptoms suggest a potential complication from the cardiac catheterization procedure, such as a pseudoaneurysm or arteriovenous fistula.\n\n4. The clinical trial is studying the effect of CPAP treatment on sleep disordered breathing in patients with precapillary pulmonary hypertension (PAH or CTEPH).\n\n5. The inclusion criteria require:\n   - Age \u2265 18 years\n   - Diagnosed with PAH or non-operable/post-operative CTEPH with persistent pulmonary hypertension\n   - PAH diagnosis confirmed by cardiac catheterization\n   - CTEPH diagnosis confirmed by specific imaging tests\n   - Recent diagnosis of sleep disordered breathing (AHI > 15 on polysomnography within 3 months)\n   - Stable clinical condition for at least 3 months\n\n6. Based on the provided patient note, there is no information about the patient having precapillary pulmonary hypertension (PAH or CTEPH) or a recent diagnosis of sleep disordered breathing.\n\n7. The patient's current condition appears to be related to a complication from the cardiac catheterization procedure rather than the conditions being studied in this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "201": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who recently underwent a cardiac catheterization procedure via the right femoral artery.\n2. She is now experiencing a cool right foot and has a pulsatile mass in her right groin with loss of distal pulses and a bruit over the entry point of the femoral artery.\n3. The clinical trial is focused on preventing recurrence of chronic venous leg and diabetic foot ulcers by using a cooling intervention.\n4. One of the inclusion criteria is having a newly healed leg or diabetic foot ulcer within the past 7-14 days.\n5. The patient note does not mention any leg or foot ulcers, only complications from the cardiac catheterization procedure.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial as she does not have a newly healed leg or diabetic foot ulcer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "202": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 67-year-old woman who recently underwent a cardiac catheterization procedure via the right femoral artery.\n2. She is now presenting with symptoms of a potential complication from the procedure, including a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery puncture site.\n3. These findings are suggestive of a femoral artery pseudoaneurysm, which is a known complication of femoral artery catheterization procedures.\n4. The clinical trial is studying the use of neuromuscular electrical stimulation in patients with critical limb ischemia due to non-reconstructable arterial disease.\n5. One of the key inclusion criteria is a diagnosis of non-reconstructable arterial disease and critical limb ischemia.\n6. While the patient does have a vascular issue involving the femoral artery, it appears to be an iatrogenic complication from the recent procedure rather than underlying non-reconstructable arterial disease.\n7. Additionally, the patient does not seem to meet the criteria of having critical limb ischemia at this point, as the symptoms are acute and related to the procedural complication.\n\nBased on the information provided, this patient would likely not be eligible for this particular clinical trial studying neuromuscular electrical stimulation in critical limb ischemia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "203": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which falls within the age range of 18-60 years specified in the inclusion criteria.\n\n2. There is no information provided about her handedness or smoking status, so we cannot determine if she meets those criteria.\n\n3. She is presenting with excruciating pain in her right arm, but the inclusion criteria specifically mentions facial pain or neuralgia. Arm pain does not seem to meet this criterion.\n\n4. The duration of her pain is only 1 hour, while the inclusion criteria requires continuous pain for more than 3 months.\n\n5. There is no information provided about the severity of her pain or the presence of allodynia.\n\nBased on the information given, this patient does not seem to meet several of the key inclusion criteria for this clinical trial on neuropathic facial pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "204": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history of diabetes. The trial is specifically looking for patients with diabetic peripheral neuropathic pain (DPNP).\n\n2. The patient's presenting complaint is excruciating pain in her right arm that started 1 hour prior, which does not seem to be related to diabetic neuropathy.\n\n3. There is no mention of the patient having diabetes or peripheral neuropathy in the patient note.\n\n4. The inclusion criteria specifically state that patients must \"Have pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes with the pain beginning in the feet and present for at least 6 months.\"\n\nBased on the information provided in the patient note and the inclusion criteria, this patient would not be eligible for the clinical trial on duloxetine for diabetic peripheral neuropathic pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "205": {
        "output": "To determine the patient's eligibility for the clinical trial \"Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia\", let's go through the inclusion criteria:\n\n1. Documented silent myocardial ischemia type I\nThe patient note does not mention any evidence of silent myocardial ischemia. This criterion is not met.\n\n2. At least one cardiovascular risk factor\nThe patient note does not provide information about the presence of any cardiovascular risk factors.\n\nSince the patient note does not indicate that the patient meets either of the inclusion criteria, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "206": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which falls within the age range of 15-45 years specified in the inclusion criteria.\n\n2. The patient is presenting with excruciating pain in her right arm, not chronic or recurrent right lower abdominal quadrant pain as required by the inclusion criteria.\n\n3. The trial is specifically studying the effects of laparoscopic appendectomy on chronic right lower abdominal pain, which does not seem to be the case for this patient.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial titled \"Laparoscopic Appendectomy for Chronic Right Lower Abdominal Pain\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "207": {
        "output": "Based on the patient note provided, the 40-year-old woman presents with excruciating pain in her right arm without any history of trauma or discoloration/movement limitation in the arm. The clinical trial you provided is focused on assessing brain injury and clinical outcomes in patients with moderate brain trauma using magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI).\n\nGiven that the patient's symptoms do not indicate any brain trauma or injury, she would not meet the inclusion criteria for this clinical trial, which specifically requires patients with acute moderate brain trauma.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "208": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which falls within the age range of 50-75 years specified in the inclusion criteria.\n2. However, there is no mention of the patient having Type 2 diabetes mellitus, which is a key inclusion criterion for this clinical trial.\n\nSince the patient does not meet one of the essential inclusion criteria (having Type 2 diabetes mellitus), I would not consider referring this patient for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "209": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which falls within the age range of 18-65 years specified in the inclusion criteria.\n\n2. The patient presents with excruciating pain in her right arm, which could potentially be classified as \"muscular-skeletal pain\" or \"acute pain\" in the neck/shoulder region, as per the inclusion criteria.\n\n3. However, there is no mention of restricted range of motion, fibrosis/scar tissue, inflammation, altered function, or muscle strains specifically in the neck/shoulder region.\n\n4. Additionally, there is no rating provided on the 0-100 Visual Analog Scale (VAS) pain scale, which is a requirement for inclusion.\n\nBased on the information provided, there is not enough evidence to definitively determine if the patient meets all the inclusion criteria for this clinical trial. Some additional investigation may be needed to assess the specific location and nature of the pain, as well as to obtain a VAS pain rating.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "210": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which meets the age criteria of being > 18 years old for the clinical trial.\n\n2. However, the patient does not have a diagnosis of angina pectoris, unstable angina pectoris, or documented silent ischemia. The inclusion criteria specifically require one of these diagnoses.\n\n3. The patient also did not have a drug-eluting stent implanted, which is another key inclusion criteria.\n\n4. Based on the information provided in the patient note, this patient would not be eligible for the \"Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "211": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, presenting with excruciating pain in her right arm that started 1 hour prior to admission. She denies trauma.\n\n2. The clinical trial is a study on the efficacy and safety of Privigen in subjects with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).\n\n3. The inclusion criteria for the trial are:\n   - For IVIG-untreated subjects:\n     - Newly diagnosed CIDP (developing over at least 2 months) or IVIG treatment interruption for at least 1 year with progressive disease (deteriorating in the last 2 months)\n     - Actual diagnosis of CIDP with progressive or relapsing dysfunction from motor and sensory or symmetric motor nerve only in at least 1 limb\n     - Age \u226518 years\n     - Male or female\n     - Written informed consent\n   - For IVIG-pretreated subjects:\n     - Being treated regularly with IVIG on a fixed cycle length of 2 to 6 weeks \u00b1 5 days in the last 6 months, on a fixed dosage of \u00b1 20 % in the last 6 months and deteriorating by at least 1 INCAT score point during the Washout Period of up to 10 weeks\n     - Historic diagnosis of CIDP with progressive or relapsing dysfunction from motor and sensory or symmetric motor nerve only in at least 1 limb\n     - Age \u226518 years\n     - Male or female\n     - Written informed consent\n\n4. Based on the patient note, there is no mention of the patient having CIDP or any neuropathy. The patient is presenting with acute arm pain, which does not seem to fit the inclusion criteria for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "212": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, which meets the age criteria for the trial.\n\n2. She presents with excruciating pain in her right arm, tachypnea, tachycardia, and hypotension (80/60 mmHg), which could be signs of septic shock.\n\n3. The trial's inclusion criteria state \"ventilated patient in sinus rhythm with septic shock requiring a hemodynamic assessment.\"\n\n4. While the patient note does not explicitly mention ventilation or sinus rhythm, her vital sign abnormalities and lack of trauma suggest possible septic shock.\n\n5. Therefore, she may potentially meet the inclusion criteria, but further investigation would be needed to confirm the diagnosis of septic shock and the need for hemodynamic assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "213": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history.\n2. She presented to the ER with excruciating pain in her right arm that started 1 hour prior, with no history of trauma.\n3. On examination, she is pale, in moderate discomfort, tachypneic, tachycardic, with normal temperature and low blood pressure (80/60).\n4. Her right arm has no discoloration or movement limitation.\n\nThe clinical trial is titled \"DEPITAC: Short Screening Scale for Psychotraumatic Disorders After Motor Vehicle Accident\" and aims to screen for PTSD in road traffic accident victims.\n\nThe inclusion criteria are:\n1. Road traffic accident victims hospitalized in surgical department less than 2 weeks\n2. Can be called by phone\n\nBased on the information provided, this patient does not seem to be a victim of a road traffic accident. She presented with arm pain of unknown etiology, but there is no mention of a motor vehicle accident.\n\nTherefore, she does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "214": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which meets the age criteria of \u226518 years old for the clinical trial.\n\n2. The patient has no reported cancer diagnosis or treatment with capecitabine or sunitinib, which are required for inclusion in this trial studying palmar-plantar erythrodysesthesia (PPE) related to those treatments.\n\n3. There is no mention of the patient having PPE or any skin changes on her palms or soles, which is a requirement for this trial.\n\n4. The patient's presenting symptoms of excruciating right arm pain, pale appearance, tachypnea, tachycardia, and hypotension suggest a potentially serious acute condition unrelated to PPE.\n\n5. The trial has additional inclusion criteria regarding adequate organ function and performance status, but these are not assessable from the provided patient note.\n\nBased on the information given, this patient does not appear to meet the key inclusion criteria for this clinical trial studying topical sildenafil for PPE related to capecitabine or sunitinib treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "215": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history presenting with severe right arm pain, tachypnea, tachycardia, and hypotension. This suggests a possible septic shock presentation.\n\n2. The clinical trial is looking at comparing different hemodynamic protocols in septic shock patients.\n\n3. The inclusion criteria for the trial are:\n   - 2 or more SIRS criteria (which the patient likely meets with tachypnea and tachycardia)\n   - Documented or suspected infection (not mentioned in the note, but a possibility given the presentation)\n   - Shock requiring vasopressor treatment (the patient has hypotension which may require vasopressors)\n\n4. The exclusion criteria don't seem to apply to this patient based on the limited information provided.\n\n5. While there are some gaps in information, such as confirmed infection source and need for vasopressors, this patient's presentation is concerning for septic shock which meets the broad inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "216": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, so she meets the age criteria of \u226518 years.\n\n2. She does not present with stable angina pectoris or silent ischemia (positive stress test without chest pain). The note mentions excruciating pain in her right arm, which is not indicative of angina.\n\n3. She is not scheduled for coronary angiography or percutaneous coronary intervention (PCI).\n\n4. There is no mention of her being on aspirin and clopidogrel, or being able to tolerate dual anti-platelet therapy.\n\n5. There is no information about her willingness to conform to the study requirements or sign an informed consent.\n\n6. Based on the limited information provided, there is no indication that she has an illness or condition that would impair the results of the study.\n\n7. There is no information about her pregnancy status.\n\nOverall, while she meets the age criteria, she does not seem to meet several other key inclusion criteria for this clinical trial, such as having stable angina or silent ischemia, being scheduled for PCI, and being on dual anti-platelet therapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "217": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history.\n2. She presents to the ER with excruciating pain in her right arm that started 1 hour prior.\n3. She denies trauma.\n4. On examination, she is pale, in moderate discomfort, tachypneic, and tachycardic.\n5. Her body temperature is normal, and her blood pressure is 80/60.\n6. Her right arm has no discoloration or movement limitation.\n\nLooking at the inclusion criteria for the clinical trial:\n1. Patients must be diagnosed with septic shock, acute respiratory distress syndrome (ARDS), or both.\n2. Specific criteria are provided for the diagnosis of septic shock and ARDS.\n\nBased on the information provided in the patient note, there is no indication that the patient has septic shock or ARDS. The note mentions pain in the right arm, but no other symptoms or conditions that would meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "218": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which falls within the age range of 18-60 specified in the inclusion criteria.\n\n2. There is no mention of the patient having PTSD or fulfilling the DSM-IV criteria for PTSD, which is a key inclusion criterion for this clinical trial.\n\n3. The patient's presenting complaint is excruciating pain in her right arm, with no history of trauma. This does not align with the clinical trial's focus on PTSD.\n\n4. There is no information provided about the patient's CAPS score, which is another inclusion criterion.\n\nBased on the information given, this patient does not appear to meet the key inclusion criteria of having a diagnosis of PTSD and a CAPS score of at least 40.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "219": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, presenting with excruciating right arm pain that started 1 hour prior. She has no trauma, is pale, tachypneic, tachycardic, with low blood pressure.\n\n2. The clinical trial \"Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease\" is studying the use of implantable cardiac monitors in patients with Chagas disease and certain electrical/arrhythmic disorders.\n\n3. The key inclusion criteria are:\n- Confirmed Chagas disease\n- Evidence of certain electrical disorders like bradycardia, conduction blocks, arrhythmias (but not severe enough to require pacemaker/ablation)\n- Asymptomatic or minimal symptoms \n- Left ventricular ejection fraction > 35%\n- Age > 21 years\n\n4. Based on the patient note, there is no mention of the patient having Chagas disease or any of the specified electrical/arrhythmic disorders. Her symptoms seem more acute in nature.\n\nTherefore:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "220": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: Patients with signs or symptoms in favor of PTE who come to Emergency department of Alzahra General Hospital.\n\nThe patient is a 40-year-old woman who presented to the ER with excruciating pain in her right arm, tachypnea, and tachycardia. While the symptoms could potentially be related to a pulmonary thromboembolism (PTE), the information provided does not explicitly mention signs or symptoms specifically favoring PTE.\n\nBased on the limited information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient's presenting symptoms could potentially be related to PTE, but more information would be needed to determine if the signs and symptoms specifically favor a diagnosis of PTE, as required by the inclusion criteria. Further investigation, such as additional diagnostic tests or a more detailed medical history, may help clarify the patient's eligibility for this clinical trial.",
        "label": 2
    },
    "221": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 40-year-old woman presenting with excruciating right arm pain that started 1 hour prior, with no history of trauma. Her vital signs show tachypnea, tachycardia, and hypotension, suggesting a possible acute medical issue.\n\nThe clinical trial is evaluating the efficacy of the HEART pathway for identifying high-risk vs low-risk patients with acute chest pain in the emergency department.\n\nLooking at the inclusion criteria:\n1) Age \u2265 21 years - The patient is 40 years old, so meets this criteria.\n2) Chest discomfort or other symptoms consistent with possible acute coronary syndrome (ACS) - While the patient has arm pain rather than chest pain, arm pain can be a symptom of ACS, so this may potentially meet the criteria upon further investigation.\n3) The treating physician feels the patient could be discharged home if cardiac disease was excluded - This is unclear from the provided information and would require input from the treating physician.\n\nOverall, based on the information provided, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the age criteria and has symptoms that could potentially represent ACS, which would make them eligible. However, more information is needed from the treating physician regarding their assessment of potentially discharging the patient if cardiac disease is excluded. Further evaluation of the patient's symptoms and risk factors for ACS would also be warranted before definitively determining eligibility.",
        "label": 0
    },
    "222": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which meets the age criteria of being 18 years or older for the clinical trial.\n\n2. However, the clinical trial is specifically looking at women who have had a vaginal delivery complicated by genital trauma and anal incontinence. \n\n3. The patient note does not mention anything about the patient having a recent vaginal delivery or any genital trauma/anal incontinence issues.\n\n4. The patient is presenting with excruciating pain in her right arm, which is unrelated to the focus of the clinical trial.\n\nBased on the information provided, this patient does not meet the key inclusion criteria for the \"Physical Therapy for Women With Obstetric Trauma and Anal Incontinence\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "223": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history.\n2. She presents to the ER with excruciating pain in her right arm that started 1 hour prior.\n3. On examination, she is pale, in moderate discomfort, tachypneic, and tachycardic. Her blood pressure is 80/60.\n4. Her right arm has no discoloration or movement limitation.\n\nThe key inclusion criterion for this clinical trial is \"Reported pain greater than or equal to 3 out of 10\".\n\nGiven that the patient presents with \"excruciating pain\" in her right arm, it is highly likely that her reported pain level would be greater than or equal to 3 out of 10.\n\nTherefore, based on the information provided, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "224": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial \"Transcranial Magnetic Stimulation for Focal Hand Dystonia\" step-by-step:\n\nThe patient note states:\n\"A 40-year-old woman with no past medical history presents to the ER with excruciating pain in her right arm that had started 1 hour prior to her admission. She denies trauma. On examination she is pale and in moderate discomfort, as well as tachypneic and tachycardic. Her body temperature is normal and her blood pressure is 80/60. Her right arm has no discoloration or movement limitation.\"\n\nThe inclusion criteria for the trial are:\n- Confirmed diagnosis of focal hand dystonia (patients only)\n- Between age 18 and 70 years\n- Able to give informed consent  \n- Right handed\n- Agrees to not drink caffeine or alcohol for 48 hours before study session\n- No open scalp wounds or scalp infections\n\nThe exclusion criteria include:\n- Drug use that may affect study results\n- Excessive alcohol use\n- Abnormal neurological exam findings (other than dystonia)\n- History of brain tumor, stroke, traumatic brain injury, epilepsy/seizures\n- Major depression or other major mental disorders\n- Neurological disorder other than dystonia\n- Head injury with loss of consciousness\n- Pacemaker, implants, metal objects in eye/skull\n- Hearing loss\n- Pregnancy\n- Certain medications that lower seizure threshold\n\nBased on the information provided in the patient note, there is no indication that this 40-year-old woman has focal hand dystonia or meets any of the inclusion criteria. The note also does not provide enough information to determine if she meets any of the exclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "225": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient is a 40-year-old woman presenting with excruciating pain in her right arm, tachypnea, tachycardia, and hypotension. The clinical trial is focused on assessing fluid responsiveness in patients with septic shock using various hemodynamic measurements.\n\nThe inclusion criteria for the trial are:\n1. Written informed consent by patient or relative\n2. Time in ICU < 48 hours\n3. Septic shock\n4. Pulmonary artery catheter and radial arterial catheter\n5. Age 18 - 75 years\n6. Sinus rhythm\n7. Need for norepinephrine over 0.1 ug/kg/min but otherwise hemodynamically stable\n8. Mechanical ventilation with sedation\n9. Pwcp <18 mmHg\n\nBased on the information provided in the patient note, there is no indication that the patient has septic shock or is in the ICU. Therefore, the patient does not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "226": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, presenting with excruciating pain in her right arm that started 1 hour prior to admission. She denies trauma.\n\n2. On examination, she is pale, in moderate discomfort, tachypneic, and tachycardic. Her body temperature is normal, and her blood pressure is 80/60. Her right arm has no discoloration or movement limitation.\n\n3. The clinical trial is titled \"Evaluation of Lung Doppler Signals in Pulmonary Hypertension\" and aims to evaluate the lung Doppler signals in patients with pulmonary hypertension who undergo or have undergone right heart catheterization.\n\n4. The inclusion criteria for the prospective arm are:\n   - Man or woman aged over 18\n   - With suspicion or diagnosis of pulmonary hypertension\n   - Scheduled to undergo right heart catheterization\n   - Able and willing to give informed consent\n\n5. The inclusion criteria for the retrospective arm are:\n   - Man or woman aged over 18\n   - With diagnosis of pulmonary hypertension confirmed by right heart catheterization in the past\n   - Able and willing to give informed consent\n\n6. Based on the patient note, there is no mention of pulmonary hypertension or any suspicion of it. The patient's presenting symptoms seem unrelated to the clinical trial's focus.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "227": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient is a 40-year-old woman presenting with severe arm pain, but no history of trauma is mentioned. The clinical trial is focused on venous thromboembolism (VTE) in trauma patients. Since there is no indication of trauma or injuries in the patient note, it is unlikely that this patient would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "228": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age 29 days to less than 18 years of age\nThe patient is 40 years old, so this criterion is not met.\n\n2a) Patient has Persistent Signs of Shock including one or more of the following: \ni) Vasoactive Medication Dependence - Not mentioned\nii) Hypotension (Systolic Blood Pressure and/or Mean Blood Pressure less than the 5th percentile for age) - Blood pressure is 80/60 which is low\niii) Abnormal Perfusion (2 or more of: abnormal capillary refill, tachycardia, decreased level of consciousness, decreased urine output) - The patient is tachypneic and tachycardic, so this criterion is partially met.\n\n2b) Suspected or Confirmed Septic Shock (Shock due to Suspected or Confirmed Infectious Cause) - There is no mention of suspected or confirmed septic shock.\n\n2c) Patient has received initial fluid resuscitation criteria - Not mentioned.\n\n3. Patient has Fluid Refractory Septic Shock as defined by the Presence of all of 2a, 2b, and 2c - Since 2b and 2c are not met, this is also not met.\n\nBased on the information provided, the patient does not meet the key inclusion criteria of being a pediatric patient with suspected or confirmed septic shock that is fluid refractory.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "229": {
        "output": "To determine the trial-level eligibility for this patient, let's go through the inclusion criteria for the clinical trial \"Diagnosing Pneumonia Under Low-resource Conditions\":\n\nInclusion criteria: All children below 5 exceeding WHO age-dependent tachypnea criteria.\n\nBased on the patient note provided, the key details are:\n- The patient is a 40-year-old woman, so she does not meet the age criteria of being a child below 5 years old.\n- There is no mention of tachypnea (rapid breathing) or any respiratory symptoms.\n\nSince the patient does not meet the age requirement and there is no indication of tachypnea or respiratory distress, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "230": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which falls outside the age range of 18-30 years specified in the inclusion criteria.\n\n2. The patient is presenting with excruciating pain in her right arm, which suggests she is not asymptomatic as required by the inclusion criteria.\n\n3. The trial is evaluating the hypoalgesic (pain-relieving) effects of neural mobilization techniques in asymptomatic subjects.\n\nBased on the information provided, this patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "231": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history.\n2. She presents to the ER with excruciating pain in her right arm that started 1 hour prior.\n3. She denies any trauma.\n4. On examination, she is pale, in moderate discomfort, tachypneic, and tachycardic.\n5. Her blood pressure is 80/60, which is low.\n6. Her right arm has no discoloration or movement limitation.\n\nLooking at the inclusion criteria for the clinical trial:\n1. Patients presenting to the emergency department (chest pain unit) - This patient presented to the ER with arm pain, so this criterion is met.\n2. Typical angina pectoris - The patient's symptoms (arm pain, low BP) could be indicative of angina, but it's not explicitly stated as \"typical angina pectoris\".\n3. Absence of symptoms since presentation - The patient's symptoms started 1 hour prior, so this criterion is met.\n4. At least 18 years - The patient is 40 years old, so this criterion is met.\n5. Low GRACE risk score (<140 points) - The GRACE risk score is not provided in the patient note.\n6. Informed consent, signed agreement - This is not mentioned in the patient note.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation (Trial-level eligibility: 1). While some criteria are met, there are uncertainties around whether the patient's symptoms constitute \"typical angina pectoris\" and what their GRACE risk score is. Additionally, informed consent is not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "232": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Signed informed consent prior to any study-mandated procedure. \n   - This cannot be assessed from the patient note provided.\n\n2. Healthy Caucasian male subjects aged between 18 and 45 years (inclusive) at screening.\n   - The patient is a 40-year-old woman, so she does not meet this criteria.\n\n3. Subjects must agree to use reliable methods of contraception.\n   - This cannot be assessed from the patient note.\n\n4. No clinically significant findings on physical examination at screening. \n   - The patient presents with excruciating arm pain, which would likely be considered a clinically significant finding.\n\n5. Body mass index (BMI) between 18.0 and 30.0 kg/m^2 (inclusive) at screening.\n   - BMI is not provided in the patient note.\n\n6. Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and pulse rate (PR) 45-90 bpm (inclusive) measured at screening.\n   - The patient's blood pressure is 80/60 mmHg, which is below the required range. Heart rate is not provided.\n\n7. 12-lead ECG without clinically relevant abnormalities, measured at screening.\n   - No ECG results are provided.\n\n8. Body temperature (T\u00b0) 35.5-37.5\u00b0C at screening and prior to (first) dosing.\n   - The patient's body temperature is stated to be normal.\n\n9. Total and differential white blood cell (WBC) count strictly within the normal ranges at screening and on Day -1.\n   - No WBC count is provided.\n\n10. C-reactive protein (CRP) levels below 5 mg/L.\n    - No CRP level is provided.\n\n11. Hematology and clinical chemistry results (other than total and differential WBC count and CRP) not deviating from the normal range to a clinically relevant extent at screening.\n    - No hematology or clinical chemistry results are provided.\n\n12. Coagulation and urinalysis test results not deviating from the normal range to a clinically relevant extent at screening.\n    - No coagulation or urinalysis results are provided.\n\n13. Non smokers, defined as never smoked or achieved cessation for \u2265 6 months at screening.\n    - Smoking status is not provided.\n\n14. Negative results from urine drug screen at screening. \n    - No urine drug screen results are provided.\n\n15. Subjects allowing the conduct of genetic analyses on whole blood consisting of measuring the levels of messenger ribonucleic acid (mRNA) expression of mechanistic biomarkers of N-formyl-peptide receptor 2 (FPR2) and proteins involved in inflammation.\n    - This cannot be assessed from the patient note.\n\n16. Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study.\n    - This cannot be assessed from the patient note.\n\nBased on the information provided in the patient note, the patient does not meet at least criteria 2 (gender and age) and 6 (blood pressure). There are also several criteria that cannot be assessed.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "233": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which falls within the age range of 45-80 years old specified in the inclusion criteria.\n\n2. The patient does not have a clinical diagnosis of osteoarthritis in the knee, which is a key requirement for this trial. The patient's complaint is excruciating pain in the right arm.\n\n3. There is no mention of the patient having knee pain, morning stiffness, crepitus, or osteophytes on radiograph related to osteoarthritis of the knee.\n\n4. The patient does not meet the criteria of having symptoms associated with osteoarthritis of the knee for at least 6 months prior to screening.\n\n5. There is no indication that the patient required NSAID or other therapy for knee pain associated with osteoarthritis for at least 15 days during the preceding month.\n\n6. There is no radiographic evidence provided for the patient regarding osteoarthritis of the knee.\n\nSince the patient does not meet several key inclusion criteria related to having a clinical diagnosis of osteoarthritis in the knee, as well as knee pain and radiographic evidence of osteoarthritis, I would not consider referring this patient to this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "234": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which does not violate the inclusion criteria provided.\n\n2. However, the inclusion criteria specifically mention \"Patients needing venous blood sampling or insertion of an intravenous canula\". The patient note does not indicate that the patient needs either of those procedures.\n\n3. The inclusion criteria also state \"Normal development according to parents\". Since this is an adult patient, that criteria is not applicable.\n\n4. Overall, based on the information given, this patient does not meet the key inclusion criteria of needing venous blood sampling or IV insertion.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "235": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, which meets the inclusion criteria of being a healthy volunteer.\n\n2. The clinical trial is studying the use of an index called iHAT to predict hypovolemia (blood loss) in a simulated hemorrhage model using a Lower Body Negative Pressure (LBNP) chamber.\n\n3. The patient's presenting symptoms of excruciating pain in the right arm, pale appearance, tachypnea, tachycardia, and hypotension are not consistent with the expected findings in a simulated hemorrhage model in healthy volunteers.\n\n4. There is no indication that the patient is being considered for participation in this specific clinical trial.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "236": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, presenting with severe right arm pain without any trauma or discoloration/movement limitation. This does not seem to be related to a percutaneous coronary intervention (PCI) procedure.\n\n2. The clinical trial is studying the efficacy of a femoral compression device versus manual compression in achieving hemostasis after a PCI procedure via femoral artery puncture.\n\n3. The inclusion criteria specify that patients must be between 18-85 years old and scheduled to undergo an elective PCI via femoral artery puncture.\n\nSince the patient in the given note is not scheduled for a PCI procedure and is presenting with arm pain unrelated to the intervention being studied, she would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "237": {
        "output": "Unfortunately, without the title and inclusion criteria for the clinical trial, I cannot make an assessment of the patient's eligibility. Please provide the details of the clinical trial, including the title and inclusion criteria, so that I can compare the patient's information against the trial requirements and provide a trial-level eligibility assessment.\n\nTrial-level eligibility: I cannot determine the eligibility without the clinical trial details.",
        "label": 0
    },
    "238": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, presenting with severe right arm pain without trauma or discoloration/limitation of movement. This does not seem to match the inclusion criteria for the adolescent idiopathic scoliosis trial.\n\n2. The trial is specifically looking for adolescent females between 14-16 years old with right thoracic scoliosis of 20-40 degrees Cobb angle or healthy controls with no scoliosis.\n\n3. The patient note does not mention anything about scoliosis or being an adolescent.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "239": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, which meets the age criteria of 18-65 years for both TB and non-TB subjects in this clinical trial.\n\n2. The patient presents with excruciating pain in her right arm, tachypnea, and tachycardia, but no other symptoms related to tuberculosis or lung disease are mentioned. This does not seem to meet the inclusion criteria for either TB or non-TB subjects with lung disease.\n\n3. There is no mention of the patient having a diagnosis of tuberculosis or any other lung disease, which are required for the inclusion criteria.\n\n4. There is no information provided about the patient's consent or willingness to comply with follow-up, which are also part of the inclusion criteria.\n\nBased on the information provided in the patient note, it does not appear that this patient meets the inclusion criteria for this clinical trial on recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "240": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which meets the age criteria of \u226518 years old.\n2. She presents to the ER with excruciating pain in her right arm, which could be considered a trauma.\n3. However, the inclusion criteria specifically mentions \"Trauma patients of all severity stages including poly traumatized patients admissioned through the emergency room.\"\n4. Based on the information provided, this seems to be a single trauma (pain in right arm) rather than a poly-trauma or severe trauma case.\n5. There is no mention of hypothermia or temperature issues with this patient yet.\n\nGiven the limited information and that the trial seems focused on more severe trauma cases, I would assess this patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "241": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman, which meets the age criteria of being above 18 years old for the clinical trial.\n\n2. The clinical trial is focused on patients with ankle fractures who undergo surgery. The patient note does not mention an ankle fracture or any fracture at all. The presenting complaint is excruciating pain in the right arm without any trauma.\n\n3. Since the patient does not have an ankle fracture, which is a key inclusion criteria for this clinical trial, she would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "242": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient is a 40-year-old woman presenting with severe arm pain, which does not align with the trial's focus on women who have recently undergone an emergency cesarean section.\n\n2. There is no mention of the patient giving birth or having a cesarean section in the patient note.\n\n3. The trial aims to study the prevention of intrusive memories and posttraumatic stress symptoms after an emergency cesarean section, which is not relevant to the patient's current condition.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "243": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, which fits the age criteria for both the patient and control groups in the trial.\n\n2. The trial is looking for patients with familial hypercholesterolemia (FH), but the patient note does not mention FH or any lipid disorders. This is a key exclusion criterion.\n\n3. The trial also requires patients to be asymptomatic, but the patient presented to the ER with excruciating arm pain, which would exclude her.\n\n4. The trial excludes patients with a personal history of cardiovascular disease, and while the note doesn't explicitly state this, the arm pain could potentially be related to a cardiovascular issue.\n\n5. The trial excludes patients with diabetes mellitus, and the note doesn't mention the patient's diabetes status.\n\nBased on the information provided, this patient would likely not be eligible for this particular clinical trial due to the lack of familial hypercholesterolemia diagnosis, the presence of symptoms (arm pain), and the potential for an underlying cardiovascular condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "244": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 40-year-old woman with no past medical history, presenting with severe right arm pain without trauma or discoloration/limitation of movement. This does not seem to match the inclusion criteria for the tuberculosis clinical trial, which is looking for patients with confirmed or suspected tuberculosis.\n\n2. The clinical trial inclusion criteria specifically mention:\n- Tuberculosis patients (pulmonary or extrapulmonary)\n- Non-TB patients with lung disease but not tuberculosis\n- Suspected TB patients with lung disease\n\n3. The patient note does not mention any symptoms, signs, or diagnosis of tuberculosis or other lung disease.\n\n4. Therefore, based on the information provided, this patient would not be eligible for this particular clinical trial on tuberculosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "245": {
        "output": "To determine the patient's eligibility for the clinical trial \"Prevention of Weight Gain\", let's go through the inclusion criteria:\n\nInclusion criteria: Body mass index of 21 through 30\n\nThe patient note does not provide enough information to calculate the patient's body mass index (BMI). BMI is calculated using height and weight measurements.\n\nWithout knowing the patient's BMI, it is difficult to definitively assess their eligibility for this trial based on the provided inclusion criteria.\n\nHowever, the patient note mentions that the 25-year-old woman has experienced weight gain in the previous 6 months. This could potentially put her BMI within the eligible range of 21 through 30.\n\nGiven the limited information available, I would consider the following assessment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo make a more definitive assessment, additional information would be needed, such as the patient's height and weight measurements to calculate their BMI and determine if it falls within the eligible range specified in the inclusion criteria.",
        "label": 0
    },
    "246": {
        "output": "To determine the patient's eligibility for the \"Thyroxine Titration Study\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. Male or female subjects >18 years of age\n   - The patient is a 25-year-old woman, so she meets this criterion.\n\n2. Primary hypothyroidism \u22656 months duration arising from autoimmune hypothyroidism, thyroidectomy or radioiodine treatment\n   - The patient note does not explicitly state the cause of her hypothyroidism, but it mentions a \"prominent, soft, uniform anterior cervical mass at the midline,\" which could be indicative of an enlarged thyroid gland (goiter) due to autoimmune hypothyroidism (Hashimoto's thyroiditis).\n\n3. Thyroxine dose \u2265100 mcg/day\n   - The patient note does not mention if the patient is currently taking thyroxine or the dosage.\n\n4. No change in thyroxine dose in past 2 months\n   - Again, the patient note does not provide information about the patient's thyroxine treatment.\n\n5. Serum TSH of 0.1-4.8 mU/L\n   - The patient note does not include any laboratory values for TSH.\n\n6. Adequate contraceptive measures for women of childbearing age\n   - The patient note does not provide information about the patient's contraceptive measures.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for the \"Thyroxine Titration Study\" clinical trial. While the patient's age and presenting symptoms (fatigue, hair loss, change in voice, weight gain, cold intolerance, and possible goiter) are consistent with hypothyroidism, there is no information about the duration of her condition, current thyroxine treatment, TSH levels, or contraceptive measures.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "247": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months. She also has a prominent, soft, uniform anterior cervical mass at the midline on examination.\n\nThe clinical trial is studying the effects of modafinil on waking function and sleep in individuals with primary insomnia.\n\nThe key inclusion criteria for the trial are:\n1) Age 25 or older\n2) Meet diagnostic criteria for psychophysiological insomnia according to ICSD\n3) Complaint of fatigue and/or sleepiness at intake\n4) Live in the Greater Rochester NY area\n\nBased on the information provided, the patient meets the age criteria (25 years old) and complains of fatigue, which could potentially qualify under the fatigue/sleepiness criterion. However, there is no mention of the patient having insomnia or meeting the diagnostic criteria for psychophysiological insomnia.\n\nAdditionally, the patient's symptoms (hair loss, change in voice, weight gain, cold intolerance, and anterior cervical mass) suggest a potential underlying thyroid condition rather than primary insomnia.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to determine if the patient meets the diagnostic criteria for psychophysiological insomnia and to rule out any underlying medical conditions that could be causing the reported symptoms.",
        "label": 0
    },
    "248": {
        "output": "Based on the patient note provided, the 25-year-old woman is presenting with symptoms suggestive of a thyroid disorder, such as hypothyroidism, including fatigue, hair loss, change in voice, weight gain, and cold intolerance. The note also mentions a prominent, soft, uniform anterior cervical mass at the midline, which could be indicative of an enlarged thyroid gland (goiter).\n\nHowever, the clinical trial titled \"Sleep Apnea in Look AHEAD (Action for Health in Diabetes)\" is focused on assessing the effects of weight loss on sleep-disordered breathing (SDB) in obese patients with type 2 diabetes and obstructive sleep apnea (OSA).\n\nThe inclusion criteria for this trial are:\n1. Enrollment in the Look AHEAD study\n2. Type II Diabetes\n3. Sleep Apnea\n\nBased on the information provided in the patient note, there is no mention of the patient having type 2 diabetes or sleep apnea. Therefore, the patient does not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "249": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria of 18-50 years old for the clinical trial.\n\n2. The patient's chief complaint is prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance. These symptoms could potentially be related to obesity or metabolic syndrome, which the trial is investigating.\n\n3. However, the patient's BMI is not provided, and the trial has a specific BMI inclusion criteria of 29-55. Without knowing the patient's BMI, it's difficult to determine if she meets this criteria.\n\n4. The trial also requires chronic sleep deprivation, defined as regularly sleeping \u2264 6.5 hours per night for at least 6 months. The patient note states that she sleeps an average of 8 hours per night, which would exclude her from the trial.\n\n5. The patient note does not mention any other medical conditions that would exclude her based on the listed exclusion criteria.\n\nBased on the information provided, the patient does not meet the sleep deprivation criteria and her BMI is unknown, so I cannot definitively determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her BMI and confirmation that she does not meet the chronic sleep deprivation criteria.",
        "label": 0
    },
    "250": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which does not violate any of the inclusion criteria provided for the clinical trial.\n\n2. The patient is presenting with symptoms of fatigue, hair loss, change in voice, weight gain, and cold intolerance. These symptoms are suggestive of a thyroid disorder, not type 2 diabetes.\n\n3. The inclusion criteria specifically mention a diagnosis of type 2 diabetes, an HbA1C <= 12.0% within the past 12 months, BMI <= 45.0 kg/m2, and initiation/addition/change/continuation of basal insulin therapy with insulin detemir.\n\n4. Based on the information provided in the patient note, there is no mention of a diagnosis of type 2 diabetes or any details about HbA1C levels, BMI, or insulin therapy.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria for the clinical trial titled \"Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "251": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms are suggestive of a thyroid disorder.\n\nThe clinical trial is studying the effects of selenium treatment in patients with autoimmune thyroiditis (AIT).\n\nThe inclusion criteria for the trial are:\n1. Clinically approved AIT patients\n2. Not using any medication other than levothyroxine (LT4) to keep TSH in the lower half of normal range.\n\nBased on the information provided in the patient note, it seems likely that this patient has AIT or another thyroid disorder, given her symptoms and the cervical mass. However, it is not explicitly stated that she has been clinically diagnosed with AIT.\n\nAdditionally, there is no information provided about whether she is taking any medications, including levothyroxine.\n\nTherefore, with the limited information available, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore details would be needed to confirm the diagnosis of AIT and her medication status to determine if she meets the inclusion criteria for this trial.",
        "label": 2
    },
    "252": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"hypopituitarism of at least 3 axes (TSH plus gonadotropin, somatotropin, corticotropin or ADH deficiency)\"\n   - The patient note mentions symptoms suggestive of hypothyroidism (fatigue, hair loss, change in voice, weight gain, cold intolerance, and a cervical mass), which could indicate TSH deficiency. However, there is no explicit mention of deficiencies in other pituitary axes.\n\n2. \"termination of surgical or radiation treatment of pituitary tumors at least six month before study entry\"\n   - There is no information provided about any previous surgical or radiation treatment for a pituitary tumor.\n\n3. \"BMI of 20 - 39.9 kg/m2\"\n   - The patient's BMI is not provided, so it is unclear if they meet this criterion.\n\n4. \"non-smoking status\"\n   - The patient's smoking status is not mentioned.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for the clinical trial. While the symptoms suggest hypothyroidism, which is the target condition, there is not enough information to determine if the patient meets the other criteria related to pituitary deficiencies, previous treatment, BMI, and smoking status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "253": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months. On examination, she has a prominent, soft, uniform anterior cervical mass at the midline.\n\n2. The clinical trial is focused on the diagnosis and follow-up of patients with subclinical hypothyroidism.\n\n3. The inclusion criteria for the trial are:\n   - Hypothyroidism: TSH > 40 mU/L and T3 and T4 below the reference range, or TSH > 40 mU/L, T3 normal and T4 below the reference range\n   - Subclinical hypothyroidism: TSH \u2265 20 mU/L, T3 and T4 normal or low-normal, or TSH > 5.6 mU/L and < 20 mU/L on initial determination and on follow-up, or TSH levels increase on follow-up and/or gradually declining T4 levels.\n\n4. Based on the patient's symptoms (fatigue, hair loss, change in voice, weight gain, cold intolerance) and the presence of an anterior cervical mass, it is highly suggestive of hypothyroidism or subclinical hypothyroidism.\n\n5. However, without specific laboratory values for TSH, T3, and T4, it is difficult to determine if the patient meets the exact inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of thyroid function tests (TSH, T3, T4) to confirm if she meets the inclusion criteria for hypothyroidism or subclinical hypothyroidism.",
        "label": 2
    },
    "254": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, so she does not meet the age criteria for the clinical trial, which is for preterm infants.\n\n2. There is no information provided about her birth weight or gestational age, which are required inclusion criteria.\n\n3. While she has symptoms suggestive of hypothyroidism (fatigue, hair loss, voice change, weight gain, cold intolerance, goiter), there are no specific lab values provided for her free thyroxine or thyroid stimulating hormone levels to determine if she meets those inclusion criteria.\n\n4. She is not between 2-4 weeks of age after birth, which is another inclusion criteria.\n\nBased on the information provided in the patient note, this 25-year-old woman would not be eligible for the \"Supplemental Thyroxine Treatment for Preterm Infants With Hypothyroxinemia\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "255": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which does not violate any of the inclusion criteria provided for the clinical trial.\n\n2. The patient is complaining of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months. These symptoms could be indicative of an underlying condition, but do not directly relate to the inclusion criteria for this sleep disorder clinical trial.\n\n3. The clinical examination notes a \"prominent, soft, uniform anterior cervical mass at the midline.\" This finding could potentially indicate an underlying thyroid condition, which may impact sleep patterns, but is not specifically mentioned in the inclusion criteria.\n\n4. The inclusion criteria focus on delayed sleep phase syndrome, insomnia with difficulty falling asleep at the desired bedtime, and other sleep-related factors. There is no mention of the patient's specific sleep patterns or complaints related to delayed sleep phase syndrome in the provided note.\n\nBased on the information given, there is not enough evidence to determine if the patient meets the inclusion criteria for this specific clinical trial on delayed sleep phase syndrome and insomnia.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their sleep patterns and potential delayed sleep phase syndrome diagnosis.",
        "label": 0
    },
    "256": {
        "output": "To determine the patient's eligibility for the \"Weight Gain Prevention\" clinical trial, let's go through the inclusion criteria one by one:\n\nAge 18-35: The patient is 25 years old, which meets this criterion.\n\nBody mass index between 23 and 30: The patient's BMI is not provided, but the note mentions weight gain in the previous 6 months, which could potentially put her BMI in the eligible range.\n\nInterested in preventing weight gain: The patient's primary complaint is not related to weight gain, but the note does mention weight gain as one of her symptoms.\n\nBased on the information provided, the patient meets the age criterion and potentially meets the BMI criterion, but it is unclear if she is interested in preventing weight gain. Therefore, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo make a more definitive assessment, it would be helpful to have the patient's current BMI and to inquire about her interest in preventing further weight gain. If her BMI falls within the eligible range and she expresses interest in preventing weight gain, she could potentially be a good candidate for this trial.",
        "label": 2
    },
    "257": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria of 18-80 years for the clinical trial.\n\n2. The patient does not have a diagnosis of essential tremor, which is a key inclusion criterion for this trial. The main complaint is prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance.\n\n3. The examination finding of a \"prominent, soft, uniform anterior cervical mass at the midline\" suggests a potential thyroid issue, which is not directly relevant to the inclusion criteria for this essential tremor trial.\n\n4. There is no mention of the patient having a history of seizures, which is allowed per the inclusion criteria.\n\n5. Overall, while the patient's age meets the criteria, the lack of an essential tremor diagnosis and the presence of symptoms potentially related to a thyroid condition make this patient unlikely to be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "258": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 25-year-old woman, which meets the age inclusion criteria of 25-50 years for this clinical trial on the role of dairy products in weight maintenance.\n\nHowever, some key details that would likely make her ineligible:\n1. Her BMI is not provided, but the clinical trial requires a BMI of 30-39.9 kg/m2 at baseline. The patient does not seem to be obese based on the note.\n2. The patient is presenting with symptoms like fatigue, hair loss, change in voice, weight gain, and cold intolerance, which could indicate an underlying thyroid condition. The trial excludes people with certain medical conditions.\n3. The trial requires participants to have recently completed a weight loss program and lost 10kg. There is no mention of the patient having done a weight loss program.\n\nGiven this information in the patient note, it does not seem like she would meet the key inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "259": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Premenopausal women: The patient is a 25-year-old woman, so she meets this criterion.\n\n2. Overt primary hypothyroidism (reduced T4 concentration accompanied by increased TSH concentration at the time of initial diagnosis): The patient note does not explicitly mention the patient's T4 and TSH levels at the time of diagnosis. However, the symptoms described (fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent anterior cervical mass) are consistent with hypothyroidism.\n\n3. Did not receive thyroid hormones: The patient note does not mention if the patient has received any thyroid hormone treatment.\n\nBased on the information provided, it is possible that the patient meets the inclusion criteria for the clinical trial, but further investigation is needed to confirm the diagnosis of overt primary hypothyroidism and whether the patient has received any prior thyroid hormone treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "260": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria of 18-64 years old for the clinical trial.\n\n2. The patient is presenting with symptoms of fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months. These symptoms could potentially be related to a thyroid disorder, which is not directly relevant to the clinical trial focused on weight gain induced by serotonergic medications.\n\n3. The clinical trial is specifically looking at preventing weight gain caused by serotonergic medications initiated on psychiatric inpatient units. There is no mention of the patient being admitted to a psychiatric inpatient unit or being prescribed serotonergic medications.\n\n4. The inclusion criteria state that the patient must be receiving or scheduled to receive a new or changed serotonergic psychotropic agent for a psychiatric condition, or be on a stable regimen without weight gain in the last 3 months. Based on the information provided, there is no indication that the patient meets this criterion.\n\nGiven the lack of information about the patient being prescribed serotonergic medications or being admitted to a psychiatric inpatient unit, and the symptoms potentially pointing to a different underlying condition, I would assess the eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "261": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\nAge range: 21 years and older\n- The patient is 25 years old, so she meets this criterion.\n\nBody mass index between 25.0-39.9 kg/m2\n- The patient's BMI is not provided, so we cannot determine if she meets this criterion.\n\nWeight stable (< 4.5 kg (10 lbs) weight gain or loss within last 6 months)\n- The patient reports weight gain during the previous 6 months, so she may not meet this criterion.\n\nBody fat >25% (assessed by skinfold and plethysmography (if needed))\n- The patient's body fat percentage is not provided, so we cannot determine if she meets this criterion.\n\nNon-smoking (within the last 6 months)\n- The patient's smoking status is not provided, so we cannot determine if she meets this criterion.\n\nConstant habitual activity patterns (within last 3 months)\n- The patient's activity patterns are not provided, so we cannot determine if she meets this criterion.\n\nClinically normal blood profiles (specifically, normal liver and kidney function; fasting blood glucose <110 mg/dl)\n- The patient's blood profiles are not provided, so we cannot determine if she meets this criterion.\n\nNot taking medications known to influence appetite or metabolism\n- The patient's medication status is not provided, so we cannot determine if she meets this criterion.\n\nNon-diabetic\n- The patient's diabetic status is not provided, so we cannot determine if she meets this criterion.\n\nBased on the information provided in the patient note, there are several inclusion criteria that we cannot determine if the patient meets or not. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "262": {
        "output": "To determine the patient's eligibility for the clinical trial, I will go through the inclusion criteria one by one:\n\nInclusion Criteria:\nFibromyalgia using ACR diagnosis\n\nThe patient note does not mention a diagnosis of fibromyalgia. Instead, it describes symptoms that could potentially indicate a thyroid disorder, such as fatigue, hair loss, change in voice, weight gain, and cold intolerance, along with a finding of a cervical mass on examination.\n\nSince the patient does not have a diagnosis of fibromyalgia, which is the only inclusion criterion mentioned, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "263": {
        "output": "To determine the patient's eligibility for the clinical trial \"Overnight Weight Loss and Sleep Structure\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\n- normal and obese volunteers\n\nBased on the patient note, there is no mention of the patient's weight or body mass index (BMI) to determine if they are normal weight or obese. The note only states that the patient is a 25-year-old woman presenting with fatigue, hair loss, change in voice, weight gain, cold intolerance, and a cervical mass.\n\nWithout information on the patient's weight or BMI, it is difficult to determine if they meet the inclusion criteria of being a normal or obese volunteer.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their weight/BMI status.",
        "label": 0
    },
    "264": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria of being between 18-85 years old for this rheumatoid arthritis clinical trial.\n\n2. However, the patient note does not mention that she has been diagnosed with rheumatoid arthritis or meets the American College of Rheumatology revised criteria for rheumatoid arthritis.\n\n3. The symptoms mentioned are prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms are more suggestive of a thyroid disorder rather than rheumatoid arthritis.\n\n4. There is no mention of the patient being on any disease-modifying antirheumatic drugs (DMARDs) or TNF antagonists, which are part of the inclusion criteria.\n\nBased on the information provided in the patient note, this patient does not appear to meet the key inclusion criteria of having a diagnosis of rheumatoid arthritis. The symptoms described are more indicative of a thyroid disorder.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "265": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria of \"25 years and older\" for the clinical trial.\n\n2. The clinical trial is for obese and morbidly obese women with a BMI between 30-50. The patient's BMI is not provided, so we cannot determine if she meets this criteria.\n\n3. The patient does not mention having metabolic syndrome or diabetes, which are required for inclusion in the trial.\n\n4. The patient's main complaints seem to be fatigue, hair loss, change in voice, weight gain, and cold intolerance. These symptoms could potentially be related to an underlying thyroid condition rather than obesity.\n\n5. The clinical trial is specifically for patients undergoing laparoscopic gastric bypass surgery, but there is no mention of the patient being scheduled for or considering this procedure.\n\nBased on the information provided, the patient does not clearly meet all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her BMI, metabolic status, and potential plans for gastric bypass surgery.",
        "label": 0
    },
    "266": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria of being over 18 years old.\n\n2. The patient does not have a confirmed diagnosis of lung adenocarcinoma, which is required for inclusion in this trial. The presenting symptoms suggest a potential thyroid issue rather than lung cancer.\n\n3. There is no information provided about the clinical stage or ECOG performance status, which are required for inclusion.\n\n4. There is no mention of any prior anticancer treatment, measurable lesions, or life expectancy, which are also required inclusion criteria.\n\nBased on the information provided in the patient note, this patient does not appear to meet the key inclusion criteria for this clinical trial of erlotinib versus docetaxel/cisplatin in previously untreated stage IIIB/IV lung adenocarcinoma with EGFR mutations.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "267": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Recently diagnosed hypothyroid subject (either during the inclusion period, or within the 6 previous months) for whom, data related to the diagnosis is available if the diagnosis was not carried out initially by the investigating doctor\"\n\nThe patient note mentions that the 25-year-old woman presents with symptoms suggestive of hypothyroidism, such as fatigue, hair loss, change in voice, weight gain, and cold intolerance. Additionally, it states that she has a \"prominent, soft, uniform anterior cervical mass at the midline,\" which could indicate a thyroid issue. Although the note does not explicitly state that she has been diagnosed with hypothyroidism, the symptoms and physical examination findings strongly suggest that she likely has hypothyroidism or is being evaluated for it.\n\n2. \"Subject, who has given his/her oral consent for participation\"\n\nThe patient note does not mention whether the patient has provided consent for participation in the clinical trial.\n\nBased on the information provided, it seems that the patient meets the first inclusion criterion or is highly likely to meet it upon further evaluation and diagnosis. However, we do not have information about whether she has provided consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "268": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the inclusion criteria of being an adult patient.\n\n2. However, the patient is not diagnosed with major depressive disorder. The note mentions prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a cervical mass - which points more towards a potential thyroid disorder rather than depression.\n\n3. The inclusion criteria specifically states that patients must be diagnosed with major depressive disorder and treated with pharmacotherapy.\n\nSince this patient does not have a diagnosis of major depressive disorder, they would not meet the inclusion criteria for this clinical trial on the use of desvenlafaxine (Pristiq) for treating depression.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "269": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent anterior cervical mass.\n\n2. The clinical trial is studying the association of costimulatory molecules and PPAR-polymorphisms with autoimmune thyroid disease.\n\n3. One of the inclusion criteria is \"Autoimmune thyroid patients\".\n\n4. Based on the patient's symptoms of fatigue, hair loss, voice change, weight gain, cold intolerance, and cervical mass, it is highly suggestive of an autoimmune thyroid disorder like Hashimoto's thyroiditis or Graves' disease.\n\n5. Therefore, this patient would likely meet the inclusion criteria of being an autoimmune thyroid patient.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "270": {
        "output": "To determine the patient's eligibility for the clinical trial \"Central Hypothyroidism, a Novel Laboratory Measurement\", I will go through the inclusion criteria one by one:\n\n1. Clinical evidence of central hypothyroidism: status post pituitary surgery and/or radiotherapy plus laboratory documentation of central hypothyroidism, with or without concurrent hormonal deficiencies in other axes, such as ACTH, LH, FSH\n\nThe patient note does not mention any history of pituitary surgery or radiotherapy. However, the patient presents with symptoms suggestive of hypothyroidism, such as fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms could indicate central hypothyroidism, but the note does not provide laboratory documentation of central hypothyroidism or mention any concurrent hormonal deficiencies.\n\nBased on the information provided, I would consider referring this patient to this clinical trial upon further investigation to confirm the diagnosis of central hypothyroidism and rule out other potential causes of the symptoms.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "271": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria for this clinical trial (no specific age limits mentioned).\n\n2. The patient does not have a confirmed diagnosis of melanoma, which is required for this trial. The presenting symptoms (fatigue, hair loss, change in voice, weight gain, cold intolerance, anterior cervical mass) are more suggestive of a thyroid disorder rather than melanoma.\n\n3. The trial specifically requires patients to have metastatic melanoma with measurable disease, which this patient does not appear to have.\n\n4. The other inclusion criteria related to lab values, performance status, prior therapies, etc. are not relevant since the patient does not have the target disease (melanoma) for this trial.\n\nTherefore, based on the information provided, this patient would not be eligible for the melanoma vaccine therapy trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "272": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months. On examination, she has a prominent, soft, uniform anterior cervical mass at the midline.\n\nThe clinical trial is studying the effectiveness and safety of minoxidil foam versus placebo foam for androgenetic alopecia (male pattern baldness) in men aged 18-70.\n\nThe key inclusion criteria are:\n1) Male\n2) Age 18-70 years old \n3) Exhibits male androgenetic alopecia based on Hamilton-Norwood Scale III vertex to VI\n\nSince the patient is a 25-year-old female with symptoms suggestive of a thyroid disorder rather than male pattern baldness, she would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "273": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)\", let's go through the inclusion criteria:\n\n1. Adults 18-70 years of age: The patient is 25 years old, which falls within this range.\n\n2. Having positive antibodies against thyroid peroxidase: The patient note does not mention any information about antibodies against thyroid peroxidase.\n\n3. Having sonographic evidence consistent with a diagnosis of Hashimoto's thyroiditis: The patient note mentions that the patient has a \"prominent, soft, uniform anterior cervical mass at the midline\", which could be consistent with Hashimoto's thyroiditis, but there is no explicit mention of sonographic evidence.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for the clinical trial. While the patient's age falls within the specified range, there is no information about positive antibodies against thyroid peroxidase, and the sonographic evidence is not explicitly mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "274": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months. On examination, she has a prominent, soft, uniform anterior cervical mass at the midline.\n\n2. The clinical trial is titled \"Central Hypothyroidism and Cardiovascular Risk\" and is studying the effects of levothyroxine (T4) replacement on cardiovascular risk factors in patients with pituitary insufficiency/hypopituitarism.\n\n3. The inclusion criteria for the trial is \"All patients with pituitary hypopituitarism\".\n\n4. Based on the patient's symptoms (fatigue, hair loss, voice change, weight gain, cold intolerance) and the anterior cervical mass, this patient likely has hypothyroidism due to pituitary insufficiency/hypopituitarism.\n\n5. Therefore, this patient meets the inclusion criteria of having pituitary hypopituitarism for the \"Central Hypothyroidism and Cardiovascular Risk\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "275": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which does not meet the age inclusion criteria of 6-18 months for this clinical trial on Down syndrome in young children.\n\n2. There is no mention of the patient having Down syndrome or a trisomy 21 karyotype, which is a key inclusion criteria.\n\n3. There is no mention of the patient undergoing a cardiac ultrasound to rule out severe heart disease, which is another inclusion criteria.\n\nBased on the information provided in the patient note, this patient would not be eligible for the clinical trial titled \"Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "276": {
        "output": "To determine the patient's eligibility for the clinical trial \"Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment\", let's go through the inclusion criteria:\n\n1. Age: The patient is 25 years old, which falls within the age range of 18 to 65 years.\n\n2. Primary hypothyroidism: The patient presents with symptoms suggestive of hypothyroidism, such as fatigue, hair loss, change in voice, weight gain, and cold intolerance. Additionally, the presence of a prominent, soft, uniform anterior cervical mass at the midline could indicate an enlarged thyroid gland, which is often seen in hypothyroidism.\n\n3. On levothyroxine for at least 6 months: The patient note does not explicitly mention if the patient is currently taking levothyroxine or for how long. However, given the presentation of hypothyroid symptoms, it is reasonable to assume that the patient may be a candidate for levothyroxine treatment.\n\nBased on the available information, the patient meets the age criterion and appears to have primary hypothyroidism, which are two of the inclusion criteria. However, it is unclear if the patient has been on levothyroxine for at least 6 months.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding the duration of levothyroxine treatment, if any.",
        "label": 0
    },
    "277": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria of \u226518 years for the clinical trial.\n\n2. The patient does not have a confirmed diagnosis of breast cancer or metastatic breast cancer, which is a key inclusion criterion for this trial. \n\n3. The clinical presentation with prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and an anterior cervical mass is more suggestive of a thyroid disorder like hypothyroidism rather than breast cancer.\n\n4. There is no mention of HER2 positivity, which is another key inclusion criterion for this breast cancer trial evaluating trastuzumab and pertuzumab.\n\n5. The patient does not seem to meet the main inclusion criteria of having histologically confirmed HER2-positive metastatic breast cancer.\n\nTherefore, based on the provided patient note and inclusion criteria, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "278": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria for the trial (no specific age range given in the inclusion criteria).\n\n2. The patient has symptoms suggestive of thyroid disease, including fatigue, hair loss, change in voice, weight gain, cold intolerance, and a palpable anterior cervical mass. This suggests she may have differentiated thyroid cancer, which is one of the inclusion criteria.\n\n3. The patient note does not explicitly state if she has been treated with thyroidectomy and radioactive iodine ablation, which are required per the inclusion criteria. However, it is reasonable to assume these treatments may have been done given her symptoms and presentation.\n\n4. The patient note does not provide information on her current TSH level, which needs to be < 4 mIU/L per the inclusion criteria.\n\nBased on the available information, there are some key details missing to definitively determine eligibility, such as confirmation of her thyroid cancer diagnosis, treatment history, and current TSH level.\n\nHowever, given her symptoms and presentation suggestive of thyroid disease, I would consider referring this patient to the clinical trial upon further investigation to confirm she meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "279": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism\", let's go through the inclusion criteria:\n\n1. Age: The patient is a 25-year-old woman, which falls within the age range of 40-75 years old specified in the inclusion criteria.\n\n2. Diagnosis of overt or subclinical hypothyroidism: The patient presents with symptoms suggestive of hypothyroidism, such as fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent, soft, uniform anterior cervical mass at the midline, which could indicate an enlarged thyroid gland. However, the note does not explicitly state that the patient has been diagnosed with overt or subclinical hypothyroidism on two occasions with a minimum interval period of three months, as required by the inclusion criteria.\n\nBased on the information provided in the patient note, it is unclear if the patient meets the diagnostic criteria for hypothyroidism specified in the inclusion criteria. Therefore, further investigation would be needed to confirm the diagnosis and determine if the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "280": {
        "output": "Based on the provided patient note and the clinical trial information, here is my assessment:\n\nThe patient note describes a 25-year-old woman presenting with symptoms of fatigue, hair loss, change in voice, weight gain, and cold intolerance, along with a finding of a prominent, soft, uniform anterior cervical mass at the midline. These symptoms are suggestive of a thyroid disorder, such as hypothyroidism.\n\nThe clinical trial titled \"Comparison of Biomarkers of Stress in Emergency Physicians Working a 24-hour Shift or a 14-hour Night Shift - the JOBSTRESS Randomized Trial\" is focused on studying stress biomarkers in emergency physicians working different shift patterns.\n\nThe inclusion criteria for this trial specifically state \"emergency physician.\"\n\nSince the patient in the provided note is not an emergency physician, she would not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "281": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the inclusion criteria of being a woman with breast cancer.\n\n2. However, the note does not mention that she has been newly diagnosed with breast cancer stage 1-2. The note only states that she has prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a cervical mass. These symptoms could potentially be indicative of thyroid issues rather than breast cancer.\n\n3. The note also does not mention that she is planning to undergo neoadjuvant or adjuvant chemotherapy, which is a key inclusion criterion for this trial.\n\n4. Without confirmation of a breast cancer diagnosis and planned chemotherapy regimen, it is difficult to determine if she meets the other inclusion criteria related to chemotherapy type and dosing.\n\nBased on the information provided in the patient note, there is not enough evidence to conclude that this patient would be eligible for the \"Scalp Cooling to Prevent Chemo-induced Hair Loss\" clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her diagnosis and planned treatment regimen.",
        "label": 0
    },
    "282": {
        "output": "To determine the patient's eligibility for the clinical trial \"Physical Activity for Advanced Stage Cancer Patients\", let's go through the inclusion criteria one by one:\n\n1. Have stage III or IV cancer diagnosis: The patient note does not mention any cancer diagnosis, so this criterion is not met.\n\n2. Able to understand English: Assuming the patient can understand English since no language barrier is mentioned.\n\n3. Have a Karnofsky Performance Status (KPS) score of 60% (able to care for most of the personal needs): The patient note does not provide information about the patient's performance status or ability to care for personal needs.\n\n4. Have fatigue and/or two other target symptoms: The patient complains of prolonged fatigue, which meets this criterion.\n\n5. Have been cleared by their provider to engage in low to moderate intensity physical activities: The patient note does not mention whether the patient has been cleared for physical activity.\n\nSince the patient note does not indicate a stage III or IV cancer diagnosis, which is a key inclusion criterion, and there is no information about the patient's performance status or clearance for physical activity, it is unlikely that this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "283": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which falls within the age range of 25-65 years specified in the inclusion criteria.\n\n2. The patient complains of weight gain during the previous 6 months, which suggests she may be overweight or obese. However, her BMI is not explicitly stated.\n\n3. There is no mention of her ability to walk without assistance, which is one of the inclusion criteria.\n\n4. There is no mention of her commitment to a schedule of assessment visits, which is another inclusion criterion.\n\nBased on the information provided, there are some missing details that would be needed to fully assess eligibility. However, her age and potential overweight/obesity status make her a potential candidate worth further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "284": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria of 18 years or older for the clinical trial.\n\n2. The patient does not have a confirmed diagnosis of asthma mentioned in the note. The note mentions prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a cervical mass, which are symptoms suggestive of a thyroid disorder rather than asthma.\n\n3. The clinical trial is specifically for patients with moderate to severe asthma exacerbation, which is not mentioned in the patient note.\n\n4. There is no information provided about the patient being enrolled in another clinical trial.\n\nBased on the information given in the patient note and the inclusion criteria for the clinical trial, this patient does not appear to be eligible for the \"Thyroid Hormones Treatment in Asthma Exacerbation\" trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "285": {
        "output": "To determine the patient's eligibility for the clinical trial \"Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women With Hypothyroidism\", let's go through the inclusion criteria:\n\nInclusion Criteria: Consecutive pregnant women with L-T4 treated hypothyroidism followed at the outpatient clinic at the Endocrinology Unit, Herlev Hospital, Denmark during 2012\n\nFrom the patient note, we know that the patient is:\n- A 25-year-old woman (meets age criteria)\n- Presenting with symptoms suggestive of hypothyroidism (fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent anterior cervical mass)\n- However, there is no mention of the patient being pregnant or receiving levothyroxine (L-T4) treatment for hypothyroidism.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this specific clinical trial, as pregnancy and levothyroxine treatment for hypothyroidism are required.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "286": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the inclusion criteria of being an adult (age \u2265 18 years).\n\n2. The patient has symptoms suggestive of Hashimoto's thyroiditis, including fatigue, hair loss, change in voice, weight gain, cold intolerance, and a palpable thyroid mass on examination. This aligns with the inclusion criteria of having newly diagnosed Hashimoto's thyroiditis within 1 year.\n\n3. The note does not mention the patient's thyroid function tests (free T4 and TSH levels), so it is unclear if she meets the inclusion criteria of being euthyroid.\n\n4. The note does not provide information about the exclusion criteria, such as pregnancy, renal or liver dysfunction, hematologic diseases, G6PD deficiency, porphyria, allergy to 4-aminoquinoline compounds, retinopathy, or current immunosuppression therapy.\n\nBased on the available information, I would consider referring this patient to this clinical trial upon further investigation of her thyroid function tests and exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "287": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the age criteria of being 18 years or older.\n\n2. The patient is presenting with symptoms that could indicate a thyroid disorder, such as fatigue, hair loss, change in voice, weight gain, cold intolerance, and a cervical mass.\n\n3. The clinical trial is looking at the prevalence of thyroid disorders in Malaysia, including hypothyroidism and hyperthyroidism.\n\n4. The inclusion criteria only require the participant to be 18 years or older and a Malaysian citizen.\n\nBased on the information provided, this patient seems to fit the inclusion criteria for the clinical trial, as she is over 18 years old and is presenting with symptoms that could indicate a thyroid disorder, which is the focus of the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "288": {
        "output": "To determine the patient's eligibility for the \"My Health Coach Study\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. Adults age 21 and over: The patient is 25 years old, which meets this criterion.\n\n2. Referred by primary care physician for health coaching: The patient note does not mention if she was referred by her primary care physician for health coaching. We would need more information to determine if this criterion is met.\n\n3. Have telephone for follow-up: The patient note does not provide information about whether the patient has a telephone for follow-up. We would need more information to determine if this criterion is met.\n\n4. English speaking: The patient note does not specify the patient's language, but we can assume she is English speaking since the note is written in English.\n\nBased on the information provided in the patient note, we cannot definitively determine if the patient meets all the inclusion criteria. While she meets the age and language criteria, we do not have enough information about whether she was referred by her primary care physician for health coaching or if she has a telephone for follow-up.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "289": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which falls within the age range of 21-80 years old specified in the inclusion criteria.\n\n2. The patient does not report any insomnia or sleep difficulties, which is a key inclusion criterion for this trial on insomnia disorder. \n\n3. There is no information provided about the patient's score on the Insomnia Severity Index, Epworth Sleepiness Scale, or Hyperarousal Scale.\n\n4. The main complaint seems to be prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance - which points more towards a potential thyroid disorder rather than insomnia.\n\nBased on the information provided, this patient does not seem to meet the key inclusion criteria of having insomnia disorder.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "290": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months. On examination, she has a prominent, soft, uniform anterior cervical mass at the midline.\n\nThe clinical trial is for the Hairstetics\u2122 Anchoring System in female patients with female pattern hair loss (FPHL).\n\nLooking at the inclusion criteria:\n1) Age \u2265 19 years - The patient is 25 years old, so she meets this criterion.\n2) Female patients with androgenetic alopecia (FPHL) - The patient is experiencing hair loss, which could potentially be FPHL, so she may meet this criterion pending further investigation.\n3) Pre-treatment hematology and coagulation values within specified limits - There is no information provided about the patient's lab values, so this cannot be assessed.\n4) A life expectancy at least of the duration of the trial - No information is provided about the patient's life expectancy.\n5) Signed informed consent and post-implantation protocol - This would be obtained if the patient is enrolled in the trial.\n\nBased on the information provided, the patient meets at least one of the inclusion criteria (age) and potentially meets another (FPHL), but there is not enough information to definitively determine eligibility for all criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "291": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months. On examination, she has a prominent, soft, uniform anterior cervical mass at the midline.\n\nThe clinical trial is titled \"Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth\" and aims to study the effect of a positional therapy device called PrenaBelt on reducing stillbirth and low birth weight in pregnant women.\n\nThe inclusion criteria for the trial are:\n1. Age \u2265 18 years old\n2. Low-risk singleton pregnancy\n3. Entering the last trimester of pregnancy (26-30 weeks of gestation)\n4. Residing in the Greater Accra Metropolitan Area or area served by the Korle Bu Teaching Hospital\n5. Fluent in English, Twi, or Ga\n\nBased on the patient note, the 25-year-old woman does not appear to be pregnant, and her symptoms suggest a potential thyroid disorder. Therefore, she would not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "292": {
        "output": "To determine the trial-level eligibility for this patient, let's go through the inclusion criteria for the clinical trial:\n\nInclusion Criteria:\n1. Participants will be men of European or South Asian origin.\nThe patient is a 25-year-old woman, so she does not meet this criterion.\n\n2. BMI <25 kg.m-2\nThe patient's BMI is not provided, so we cannot assess this criterion.\n\n3. Weight stable (\u00b1 2 kg) for >6 months\nThe patient's weight history is not provided, so we cannot assess this criterion.\n\nSince the patient does not meet at least one of the inclusion criteria (gender), and we do not have enough information to assess the other criteria, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "293": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent anterior cervical mass.\n\nThe clinical trial is studying DNA methylation in autoimmune thyroid diseases like Hashimoto's Thyroiditis (HT) and Graves' Disease (GD).\n\nFor inclusion in the HT arm, the criteria are:\n1) Positive anti-TPO or anti-Tg antibodies\n2) At least one of: abnormal thyroid function requiring levothyroxine, goiter, or thyroid morphological changes on ultrasound\n\nFor inclusion in the GD arm, the criteria are:\n1) Positive anti-TSI antibodies\n2) Decreased TSH and increased free T4 or T3 levels\n\nThe patient's symptoms like fatigue, hair loss, voice change, weight gain, and cold intolerance are suggestive of hypothyroidism, possibly due to HT. The anterior cervical mass could represent a goiter.\n\nHowever, we don't have any information about her antibody levels or thyroid function tests to definitively diagnose HT or determine if she meets the HT inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her antibody levels and thyroid function tests to see if she meets the HT inclusion criteria.",
        "label": 1
    },
    "294": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which meets the inclusion criteria of being an adult patient.\n\n2. She has a prominent, soft, uniform anterior cervical mass at the midline, which could potentially be a head and neck cancer that was treated with surgery. However, the note does not explicitly state that she was diagnosed with head and neck cancer or received surgery for it.\n\n3. The note mentions symptoms like fatigue, hair loss, change in voice, weight gain, and cold intolerance, which are consistent with hypothyroidism.\n\n4. However, the note does not provide any thyroid function test results to confirm if she has subclinical hypothyroidism as defined by the trial's inclusion criteria (TSH 4-10mIU/L and free T4 10-24pmol/L).\n\nBased on the information provided in the patient note, there is not enough evidence to definitively determine if the patient meets all the inclusion criteria for the clinical trial. More information is needed regarding her specific diagnosis, treatment history, and thyroid function test results.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "295": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman presenting with prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months. On examination, she has a prominent, soft, uniform anterior cervical mass at the midline.\n\n2. The clinical trial is titled \"The Influence of Psychobiological Adversity to Children and Adolescents With Type 1 Diabetes\" and aims to study the susceptibility to stress in patients with Type 1 Diabetes (T1D) and its influence on diabetes management, as well as developing strategies for assessment and treatment.\n\n3. The inclusion criteria for the trial are:\n   - Informed consent signed by a parent/legal guardian and informed assent signed by the study participant prior to study entry\n   - Diagnosed with Type 1 Diabetes prior to signing the consent\n   - Age between 8-15 years old (inclusive) at the time of signing the consent\n   - Treated by the investigator's center prior to signing the consent (for the T1D group)\n   - Willing to undergo all study procedures\n\n4. Based on the patient note, there is no mention of the patient having Type 1 Diabetes. The symptoms described (fatigue, hair loss, change in voice, weight gain, cold intolerance, and anterior cervical mass) are more suggestive of a thyroid disorder, such as hypothyroidism.\n\n5. Since the patient does not appear to have Type 1 Diabetes, which is a key inclusion criterion for this clinical trial, it is highly unlikely that this patient would be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "296": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Patients aged 20 to 80 years\n\nThe patient is 25 years old, which falls within the age range specified in the inclusion criteria.\n\n2. Scheduled to receive neck dissection due to head and neck cancer\n\nThe patient note mentions a \"prominent, soft, uniform anterior cervical mass at the midline\", which could potentially be a head and neck cancer requiring neck dissection. However, there is no explicit mention of the patient being scheduled for neck dissection or having a confirmed diagnosis of head and neck cancer.\n\nBased on the information provided, the patient meets the age criterion but does not clearly meet the criterion of being scheduled for neck dissection due to head and neck cancer.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient's age meets the inclusion criteria, but additional information is needed to confirm if the patient has a diagnosis of head and neck cancer and is scheduled for neck dissection. Further investigation into the patient's condition and planned treatment would be necessary to determine eligibility for this specific clinical trial.",
        "label": 0
    },
    "297": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 25-year-old woman, which does not meet the age criteria for the clinical trial (children younger than 18 years old and older than 2 years old).\n\n2. The patient presents with prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent, soft, uniform anterior cervical mass at the midline. These symptoms are not indicative of obstructive sleep apnea/hypopnea syndrome (OSAHS), which is the target condition for the clinical trial.\n\n3. There is no mention of the patient having symptoms of snoring or undergoing a polysomnography to confirm OSAHS.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient does not appear to be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "298": {
        "output": "To determine the patient's eligibility for the clinical trial \"Acupuncture for Shortness of Breath in Cancer Patients\", let's go through the inclusion criteria one by one:\n\n1. Diagnosis of local or metastatic breast or lung cancer\nThe patient note does not mention any cancer diagnosis, so this criterion is not met.\n\n2. Shortness of breath with onset after cancer diagnosis\nThe patient is experiencing shortness of breath, but there is no mention of a cancer diagnosis, so this criterion is also not met.\n\n3. Life expectancy of at least 4 weeks\nThere is no information provided about the patient's life expectancy, but since there is no mention of a terminal illness, we can assume this criterion is likely met.\n\nHowever, since the first two inclusion criteria are not met, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "299": {
        "output": "To determine the patient's eligibility for the clinical trial \"BNP Testing in Patients With SOB on Presentation to ED\", let's go through the inclusion criteria:\n\n1. Presenting to the ED with shortness of breath: The patient note mentions that the 30-year-old woman presented with shortness of breath, so this criterion is met.\n\n2. Over 40 years old: The patient is 30 years old, which does not meet this criterion.\n\n3. Emergency department triage category of 3 or higher: The patient note does not provide information about the triage category.\n\nSince the patient does not meet the age criterion and there is no information about the triage category, I would assess the eligibility as follows:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "300": {
        "output": "To determine the patient's eligibility for the clinical trial \"Study of Diagnosis and Pathophysiology of Pulmonary Embolism (APE 1 Trial)\", let's go through the inclusion criteria:\n\n1. Referred from clinical departments at Odense University Hospital\n   - The patient note does not mention the hospital, so we cannot confirm this criterion.\n\n2. Referred to the Departments of Nuclear Medicine or Radiology for diagnostic evaluation of suspected pulmonary embolism\n   - The patient note mentions that the patient presented with shortness of breath, which could be a symptom of pulmonary embolism. However, it does not explicitly state that the patient was referred for diagnostic evaluation of suspected pulmonary embolism.\n\n3. Referred for lung scintigraphy, spiral computer tomography, or pulmonary angiography\n   - There is no mention of the patient being referred for any of these diagnostic tests in the patient note.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for the clinical trial. The note suggests that the patient may be experiencing symptoms consistent with pulmonary embolism, but it does not confirm that the patient has been referred for diagnostic evaluation or specific tests related to pulmonary embolism.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "301": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her oxygen saturation is 92% which is slightly low.\n4. The clinical trial is studying the use of inhaled prostacyclin for adult respiratory distress syndrome (ARDS) and pulmonary hypertension.\n5. The inclusion criteria are:\n   - Patients admitted to the ICU with pulmonary hypertension (mean PA > 35 mmHg)\n   - Patients in the ICU with post-operative pulmonary hypertension (mean PA > 35 mmHg)\n   - Patients with ARDS (PaO2/FiO2 < 200, arterial hypoxemia, bilateral infiltrates on chest X-ray, and wedge pressure < 20 mmHg)\n\nBased on the information provided, this patient does not seem to meet the inclusion criteria for this clinical trial. While she is experiencing shortness of breath and slightly low oxygen saturation, there is no mention of her having pulmonary hypertension or ARDS. Additionally, she is not currently admitted to the ICU.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "302": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her vital signs show tachypnea, tachycardia, but normal blood pressure and oxygen saturation.\n4. Physical exam is otherwise unremarkable, and her chest x-ray and CBC are normal.\n\nLooking at the inclusion criteria for the Multi MERCI clinical trial:\n\n1. It requires angiographically confirmed large vessel ischemic stroke, which this patient does not appear to have based on the provided information.\n2. The intervention needs to be performed within 8 hours of symptom onset, which may be satisfied given her shortness of breath started 2 hours prior.\n3. The patient is over 18 years of age.\n4. There is no mention of an NIHSS score or failed IV tPA treatment, which are also inclusion criteria.\n\nBased on the information provided, this patient does not seem to meet the key inclusion criteria of having a confirmed large vessel ischemic stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "303": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is studying uterine regression after pregnancy, specifically looking at the loss of fibroids (uterine leiomyomas) during this process.\n3. The inclusion criteria state that participants must be 18 years or older, pregnant, enrolled by 10 weeks of gestation, planning to carry pregnancy to term, no plans to move before delivery, and English speaking. Additionally, those found to have fibroids at either their 7-week or 22-week ultrasound examination are eligible.\n4. There is no mention of the patient having fibroids or undergoing any ultrasound examinations during her pregnancy in the provided note.\n5. The patient's current presentation of shortness of breath 2 hours before admission does not seem directly relevant to the clinical trial's focus on uterine regression and fibroids.\n\nBased on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets some of the basic criteria (age, recent pregnancy), but there is no information provided about whether she had fibroids detected during her pregnancy, which is a key inclusion criterion for this specific trial. Further investigation into her pregnancy details and any ultrasound findings would be needed to determine full eligibility.",
        "label": 0
    },
    "304": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is called \"Family Spirit Study\" and is focused on evaluating an in-home parenting education program for Native American pregnant teens or young women.\n3. Looking at the inclusion criteria:\n   - The patient is not a Native American pregnant teen or young woman aged 12-22 at the time of conception.\n   - She is also not pregnant, as she recently gave birth 3 weeks ago.\n   - She does not meet the other criteria of being an enrolled tribal member or residing in the specified area.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the \"Family Spirit Study\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "305": {
        "output": "To determine the patient's eligibility for the clinical trial \"Echo-Cardiographic Assessment of Cardiovascular Characteristics During Pregnancy and Postpartum Periods\", let's go through the inclusion criteria:\n\n1. Healthy women: The patient note states that the patient is a \"30-year-old generally healthy woman\", which meets this criterion.\n\n2. First trimester of a normal pregnancy: The patient note mentions that the patient \"had given birth to a healthy child 3 weeks before\", which means she is in the postpartum period and not in the first trimester of pregnancy. This criterion is not met.\n\n3. Normal baseline echocardiogram: There is no information provided about the patient's baseline echocardiogram.\n\nSince the patient does not meet the second inclusion criterion of being in the first trimester of a normal pregnancy, and there is no information about her baseline echocardiogram, I would assess her eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "306": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is about studying the effects of targeting lower arterial oxygen saturations on the development of control of breathing in very preterm infants.\n3. The inclusion criteria for the trial are:\n   - Gestational age 23 0/7 - 27 6/7 weeks\n   - Enrolled in the COT trial at specific hospitals in Winnipeg\n   - Postnatal age between 21 days and 70 days\n   - Informed written consent obtained from at least one parent\n\n4. Based on the patient note, this patient does not meet the inclusion criteria for gestational age or postnatal age, as she is a full-term adult who recently gave birth.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "307": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her oxygen saturation is 92% on room air.\n4. The clinical trial is looking at the effectiveness of long-term oxygen therapy for COPD patients with moderately low oxygen levels at rest or desaturation during exercise.\n\nLooking at the inclusion criteria:\n- Age at least 40 years (The patient is 30, so does not meet this criteria)\n- COPD diagnosis (The patient does not have a COPD diagnosis mentioned)\n- Dyspnea score of at least 1 on MMRC scale (Not mentioned for this patient)\n- Meet specific FEV1 criteria for COPD (No pulmonary function tests mentioned)\n- Oxygen saturation 89-93% at rest or desaturation <90% with exercise (The patient's resting O2 sat is 92%, which meets this criteria. However, no exercise desaturation test was done)\n\nOverall, while the patient meets one of the oxygen saturation criteria, there is not enough information provided to definitively determine if she meets all the other inclusion criteria related to COPD diagnosis, symptoms, and pulmonary function tests.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "308": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is studying the effects of X-ray computed tomography (CT) scans on reactive oxygen species (ROS) levels in the blood.\n3. The inclusion criteria state that participants must be undergoing a scheduled X-ray CT scan of the lungs or heart as part of a health check program at the hospital.\n\nSince the patient note does not mention the patient undergoing or being scheduled for a X-ray CT scan, she would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "309": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is studying the relationship between postpartum anemia and postpartum depression in women who have delivered by elective term cesarean section.\n3. The inclusion criteria for the trial is \"Women after term elective cesarean section\".\n4. Based on the patient note, it mentions that the patient gave birth to a healthy child 3 weeks before, but it does not specify the mode of delivery.\n\nSince the mode of delivery (whether it was an elective term cesarean section or not) is not clearly stated in the patient note, I cannot definitively determine if the patient meets the inclusion criteria for this clinical trial.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo confirm eligibility, I would need to clarify whether the patient delivered via elective term cesarean section or not. If she did, then she would likely be eligible for the trial. If not, then she would not be eligible based on the given inclusion criteria.",
        "label": 1
    },
    "310": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her medical history only includes 2 natural abortions in the past.\n4. On examination, she appears apprehensive, tachypneic, tachycardic, with a blood pressure of 110/70 and oxygen saturation of 92%.\n5. Her chest x-ray and CBC are normal.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\nInclusion Criteria for healthy controls:\n- Normal lung function (FVC > 80%, FEV1 > 80%, FEV1/FVC > 0.75)\n- Oxygen saturation > 94% and normal blood pressure\n- Symptom score \u2264 6 (out of 24)\n- Negative methacholine challenge\n- Negative pregnancy test for females\n- Negative allergy skin test\n\nInclusion criteria for allergic asthmatics:\n- History of episodic wheezing, chest tightness, or shortness of breath consistent with asthma\n- Positive methacholine test\n- FEV1 \u2265 80% and FEV1/FVC \u2265 0.70\n- Allergic sensitization confirmed by positive allergy skin test\n\nBased on the information provided, this patient does not meet all the inclusion criteria for healthy controls due to her oxygen saturation of 92% (criteria requires > 94%). There is also no information provided about her lung function tests, symptom score, methacholine challenge, or allergy skin test results.\n\nAdditionally, she does not meet the criteria for allergic asthmatics as there is no mention of a history of asthma symptoms or positive methacholine/allergy tests.\n\nTherefore, with the limited information available:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "311": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She presents with shortness of breath that started 2 hours before admission.\n3. Her vital signs show tachypnea, tachycardia, but normal blood pressure and oxygen saturation.\n4. Her chest x-ray and CBC are normal.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. Diagnosis of acute pulmonary embolism (PE) with symptoms present <14 days, confirmed by CT angiography.\n2. Systolic blood pressure (SBP) > 89 mmHg at enrollment.\n3. Oxygen saturation (SaO2) > 80% at enrollment. \n4. Borg dyspnea score > 4/10.\n\nBased on the patient note, there is no confirmed diagnosis of acute PE yet, as the CT angiography results are not mentioned. However, the shortness of breath starting 2 hours prior could potentially be due to an acute PE.\n\nThe patient meets the criteria for SBP > 89 mmHg and SaO2 > 80% at presentation.\n\nThe Borg dyspnea score is not explicitly stated, but the presence of shortness of breath suggests it could potentially be > 4/10.\n\nOverall, this patient may be eligible for the clinical trial upon further investigation to confirm the diagnosis of acute PE by CT angiography.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "312": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"All preterm (28 to 34 week gestation) very low birth weight (birth weight 750-1500grams.) infants born at AIIMS would be eligible for enrollment in the study.\"\n   - The patient note does not mention the gestational age or birth weight, so this criterion cannot be evaluated.\n\n2. Cases: \"Preterm (28 to 34 week gestation) infants with birth weight between 750 and 1500 grams with shock in the first week of life requiring vasopressor therapy (dopamine or dobutamine or both in a dose of > 10 mcg/kg/min)\"\n   - The patient is a 30-year-old woman, not a preterm infant, so she does not meet the criteria for the case group.\n\n3. Controls: \"Stable preterm (28 to 34 week gestation) infants with birth weight between 750 and 1500 grams who are matched for gestational age, birth weight, postnatal-age.\"\n   - Again, the patient is an adult, not a preterm infant, so she does not meet the criteria for the control group either.\n\nBased on the information provided in the patient note, this 30-year-old woman would not be eligible for this clinical trial, which is focused on preterm infants with very low birth weight.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "313": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients who were treated with fondaparinux pre-, peri- and/or postpartum for more than 7 days for VTE prophylaxis or treatment: The patient note does not mention the patient being treated with fondaparinux, so this criterion is not met.\n\n2. Especially those with a history of abortion, and/or stillbirth: The patient note mentions that the patient had 2 natural abortions in the past, so this criterion is met.\n\n3. VTE: The patient note does not mention the patient having a venous thromboembolism (VTE), so this criterion is not met.\n\n4. Severe fetal and maternal complications during pregnancy: The patient note does not mention any severe complications during the recent pregnancy, so this criterion is not met.\n\n5. Severe inherited or acquired thrombophilias: The patient note does not mention any thrombophilias, so this criterion is not met.\n\n6. Long-term anticoagulation (e.g., patients with mechanical heart valves): The patient note does not mention any need for long-term anticoagulation, so this criterion is not met.\n\n7. Intolerance to heparins or heparinoids or heparin-induced thrombocytopenia (HIT): The patient note does not mention any intolerance to heparins or HIT, so this criterion is not met.\n\nOverall, the patient meets only one of the inclusion criteria (history of abortion). Therefore, based on the information provided, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "314": {
        "output": "To determine the patient's eligibility for the clinical trial \"Safety and Feasibility Study of a Mechanical Ventilation Computerized Protocol: Intellivent\", let's go through the inclusion criteria one by one:\n\n1. The attending physician thinks that the patient will be able to breathe spontaneously or the patient is already breathing spontaneously.\n- The patient note does not mention whether the patient is on mechanical ventilation or not. This criterion cannot be evaluated based on the given information.\n\n2. No vasopressor or inotropic medication, unless the patient is receiving some digitalin or small doses of dopamine or dobutamine (\u2264 5 \u00b5g/kg/min)\n- The patient note does not mention any medications the patient is taking. This criterion cannot be evaluated based on the given information.\n\n3. Slight or no endotracheal tube gas-leakage ((Vti - Vte)/Vti \u2264 20%)\n- The patient note does not provide any information about endotracheal tube gas-leakage. This criterion cannot be evaluated based on the given information.\n\n4. Mechanical ventilation with a plateau pressure \u2264 25 cmH2O over PEEP\n- The patient note does not mention whether the patient is on mechanical ventilation or any information about plateau pressure or PEEP. This criterion cannot be evaluated based on the given information.\n\n5. PEEP \u2264 8 cmH2O\n- The patient note does not provide any information about PEEP. This criterion cannot be evaluated based on the given information.\n\n6. FiO2 \u2264 60% in order to obtain pulse oxymetry \u2265 95%\n- The patient note mentions that the patient's oxygen saturation is 92%, which is below the required 95%. However, it does not provide information about the FiO2 level. This criterion cannot be fully evaluated based on the given information.\n\n7. PaCO2 < 70 mmHg on the last blood gases\n- The patient note does not provide any information about the patient's PaCO2 levels. This criterion cannot be evaluated based on the given information.\n\n8. Extubation not expected the day of inclusion\n- The patient note does not mention whether the patient is intubated or not. This criterion cannot be evaluated based on the given information.\n\n9. Gap between ETPCO2 and PCO2 < 7 mmHg on last blood gas.\n- The patient note does not provide any information about the patient's ETPCO2 or PCO2 levels. This criterion cannot be evaluated based on the given information.\n\nOverall, based on the limited information provided in the patient note, it is not possible to determine the patient's eligibility for this clinical trial with certainty. Most of the inclusion criteria cannot be evaluated due to lack of relevant details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "315": {
        "output": "To determine the patient's eligibility for the clinical trial \"Pulmonary Embolism Response to Fragmentation, Embolectomy, & Catheter Thrombolysis: PERFECT\", let's go through the inclusion criteria:\n\n1. Must be Age greater than or equal to 18\nThe patient is 30 years old, so this criterion is met.\n\n2. Obtain informed written consent.\nThis is not mentioned in the patient note, but it is a standard requirement for clinical trials that can be obtained if the patient is eligible and willing to participate.\n\n3. Diagnosed with acute pulmonary embolism (PE) (< 14 days)\nThe patient presents with shortness of breath that started 2 hours before admission, which could be a symptom of acute pulmonary embolism. However, a definitive diagnosis is not mentioned in the patient note.\n\n4. Catheter-directed therapy (CDT) was performed to treat acute PE\nThere is no mention of the patient receiving catheter-directed therapy in the patient note.\n\nBased on the information provided, the patient meets the age criterion, but there is not enough information to determine if they have been diagnosed with acute pulmonary embolism or if they have received catheter-directed therapy. Therefore, further investigation would be needed to assess their eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "316": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age greater than 21 years\nThe patient is 30 years old, so this criterion is met.\n\n2. Patients scheduled for a procedure that requires analgesia and/or sedation by any route (intravenous, intramuscular, oral, epidural or intrathecal).\nThe patient note does not mention any scheduled procedure requiring analgesia or sedation, so this criterion is not met.\n\n3. Patients with an anticipated length of sedation greater than or equal to one hour.\nThere is no information about anticipated sedation length, so this criterion cannot be evaluated.\n\n4. Patients in the ASA category I through III.\nThere is no information about the patient's ASA category, so this criterion cannot be evaluated.\n\n5. Patients who only receive propofol, benzodiazepines, and opioids.\nThere is no information about the patient receiving these medications, so this criterion cannot be evaluated.\n\nOverall, while the patient meets the age criterion, there is not enough information provided to determine if the other inclusion criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "317": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is looking to identify early predictors of fetomaternal hemorrhage (FMH), which is when fetal blood crosses over to the maternal circulation during pregnancy.\n3. One of the inclusion criteria is \"Women admitted for term delivery (delivery between 37 0/7 and 41 6/7 weeks from the last menstrual period) to the Mount Sinai Medical Center\"\n4. Since the patient note states she gave birth 3 weeks ago, she would have been admitted for term delivery around 3 weeks prior.\n5. However, the trial seems to be recruiting women at the time of admission for delivery, not after they have already delivered.\n\nGiven this information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the criteria of being a woman admitted for term delivery recently, but some additional clarification may be needed on if they would consider enrolling women who have already delivered within the last few weeks. If they would allow that, then the eligibility could potentially be raised to a 2) Highly likely to refer.",
        "label": 0
    },
    "318": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is studying the use of carbetocin to prevent post-partum hemorrhage in elective cesarean deliveries.\n3. The inclusion criteria state that all patients planned for elective cesarean delivery under spinal anesthesia and who give written informed consent are eligible.\n\nSince the patient recently gave birth 3 weeks ago via a presumably non-elective delivery, she would not meet the inclusion criteria of being planned for an elective cesarean delivery.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "319": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago. She is presenting with shortness of breath that started 2 hours before admission.\n\nLooking at the inclusion criteria for the PROSPER clinical trial:\n\n1. She does not have a known low-risk thrombophilia or immobilization, so she does not meet that first criteria.\n\n2. For the second criteria of having any two of the listed reasons, she potentially meets the following:\n   - Postpartum infection (fever, clinical signs of infection, elevated neutrophil count) - The note does not mention fever, signs of infection, or elevated neutrophil count, so this is unlikely.\n   - Postpartum hemorrhage (>1000 ml blood loss) - Not mentioned, so unlikely.\n   - Pre-pregnancy BMI >25 kg/m2 - Not mentioned, so unknown.\n   - Emergency cesarean birth - Not mentioned, so unknown. \n   - Smoking >5 cigarettes per day prior to pregnancy - Not mentioned, so unknown.\n   - Preeclampsia - Not mentioned, so unlikely.\n   - Small for gestational age infant - Not mentioned, so unknown.\n\nBased on the information provided, there is not enough evidence to definitively say she meets the inclusion criteria of having two of the listed risk factors.\n\nIn summary, while she is a postpartum woman presenting with shortness of breath, the limited information provided does not clearly indicate she meets the specified inclusion criteria for being at high risk for thromboembolism.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "320": {
        "output": "To determine the patient's eligibility for the clinical trial \"Venous Thromboembolism Prophylaxis Post Cesarean Section\", let's go through the inclusion criteria:\n\n1. Age > 18 years old: The patient is 30 years old, so she meets this criterion.\n\n2. Delivered by cesarean section (emergency or planned): The patient note does not mention whether she delivered by cesarean section or not. This is a crucial piece of information that is missing.\n\n3. Signed, informed consent: This cannot be determined from the patient note.\n\n4. Ready access to a local health service: This cannot be determined from the patient note.\n\n5. Capable of using Tinzaparin: This cannot be determined from the patient note.\n\nSince the patient note does not explicitly state whether the patient delivered by cesarean section, which is a key inclusion criterion for this trial, I cannot definitively determine her eligibility. However, based on the information provided, I would consider referring this patient to this clinical trial upon further investigation to confirm if she had a cesarean delivery.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "321": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. The clinical trial is titled \"Carbetocin at Elective Cesarean Delivery Part 2\" and is studying the use of carbetocin to prevent post-partum hemorrhage in women undergoing elective cesarean delivery.\n4. One of the key inclusion criteria is \"All patients planned for elective cesarean delivery under spinal anesthesia.\"\n5. Based on the patient note, there is no mention of the patient undergoing or planning for an elective cesarean delivery. She recently gave birth 3 weeks ago, so it seems unlikely she would be scheduled for another elective cesarean delivery so soon after.\n\nGiven this information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "322": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath, which started 2 hours before admission.\n3. The clinical trial is about timing of postpartum depot medroxyprogesterone acetate (DMPA) administration on breastfeeding, contraceptive continuation, and depression.\n4. The inclusion criteria state that the participant must be:\n   - Age > 18 years old and > 24 0/7 weeks pregnant at time of enrollment\n   - Planning to deliver at Magee-Womens Hospital and to breastfeed\n   - Plans to use DMPA for postpartum contraception for at least 6 months\n   - Willing and able to provide informed consent in English and to comply with study protocol\n\n5. Based on the information provided, the patient meets the age criteria (30 years old) and has recently given birth 3 weeks ago, so she would likely meet the pregnancy criteria as well.\n6. However, there is no information provided about whether she plans to breastfeed, use DMPA for contraception, or deliver at Magee-Womens Hospital.\n7. Additionally, her current medical condition (shortness of breath) may potentially exclude her from the study, depending on the severity and underlying cause.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "323": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nThe trial is studying the effects of different breathing procedures on peripheral oxygen saturation at high altitude.\n\nThe inclusion criteria state:\n\"Exclusion Criteria: acute clinically significant inter-current diseases\"\n\nFrom the patient note, we know that the patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago. The only concerning symptom mentioned is shortness of breath that started 2 hours before admission.\n\nWhile shortness of breath could potentially be an acute condition, there is no clear indication that it is a clinically significant disease. The patient's vital signs seem relatively stable, and her chest x-ray and CBC are normal.\n\nGiven the limited information provided, it does not appear that the patient has an acute clinically significant disease that would exclude her from the trial.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "324": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her vital signs show tachypnea, tachycardia, and mild hypoxemia (oxygen saturation 92%).\n4. The clinical trial is studying high-flow oxygen therapy versus standard therapy in bronchiolitis.\n5. One of the inclusion criteria is \"All children under 18 months of age with a clinical diagnosis of bronchiolitis requiring admission to hospital for observation and oxygen.\"\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial for the following reasons:\n\n1. The trial is specifically for children under 18 months of age, while this patient is a 30-year-old adult.\n2. There is no mention of a diagnosis of bronchiolitis in the patient note. The shortness of breath could be due to other causes in the postpartum period.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "325": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her vital signs show tachypnea, tachycardia, and slightly low oxygen saturation.\n4. The clinical trial is looking at detecting air embolism during ERCP procedures using echocardiography.\n5. The inclusion criteria are:\n    - Subject is undergoing ERCP as part of their medical care\n    - Subject will be of age 19 or older\n\nBased on the information provided, this patient is not undergoing an ERCP procedure. She is presenting with shortness of breath 3 weeks after giving birth, which could be indicative of a postpartum complication like pulmonary embolism.\n\nTherefore, this patient does not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "326": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago to a healthy child.\n2. The clinical trial is studying the impact of a video communication system on maternal anxiety and mother-child relationships for mothers who are separated from their premature babies after birth.\n3. One of the key inclusion criteria is \"The patient has given birth this day to a premature child (< 36 weeks of gestation and/or < 2 kg birthweight)\".\n4. Based on the patient note, the patient gave birth 3 weeks ago to a healthy child, not a premature child.\n\nTherefore, this patient would not meet the key inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "327": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluation of Breastfeeding Support After Short Time Hospitalization\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n- pregnant women (gestational week 35-36)\n\nBased on the patient note, the patient is a 30-year-old woman who has given birth to a healthy child 3 weeks before. This means she is no longer pregnant and does not meet the inclusion criteria of being in gestational week 35-36.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "328": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her vital signs show tachypnea, tachycardia, but normal blood pressure and oxygen saturation.\n4. Her physical exam is otherwise unremarkable, and her chest x-ray and CBC are normal.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. The trial is looking for men aged 18-30 or 55-92 years old. This patient is a 30-year-old woman, so she does not meet the age/gender criteria.\n2. The trial excludes current smokers and those who have smoked within the last 10 years. The patient's smoking status is not mentioned, so we cannot determine if she meets this criterion.\n3. The trial requires participants to agree to volunteer and sign an informed consent form. We don't have information about whether the patient has agreed to this.\n4. The trial requires negative screening tests for respiratory diseases, cardiac conditions, normal spirometry, normal impedance oscillometry, and exhaled nitric oxide levels within specified ranges. We don't have this information for the patient.\n\nBased on the information provided, the key exclusion criterion is that the patient is a woman, and the trial is only enrolling men.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "329": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is a bioequivalence study for felodipine extended-release tablets under fasting conditions.\n3. The key inclusion criteria are:\n   - Healthy males within the age range of 18 to 50 years\n   - No significant diseases or abnormal lab values\n   - No history of allergies, psychiatric disorders, or drug dependence\n   - Not consumed certain foods/drinks prior to the study\n\n4. Based on the patient note, this 30-year-old woman does not meet several of the key inclusion criteria:\n   - She is female, while the trial requires male participants\n   - She recently gave birth, which may affect her health status\n   - Her shortness of breath and tachycardia suggest potential health issues\n\nTherefore, based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "330": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is focused on smoking cessation for postpartum women.\n3. The inclusion criteria for the trial are:\n   - First or second trimester of pregnancy\n   - Age 18 or older\n   - Self-reported tobacco use in the past 90 days or nicotine-dependence in the past year\n\nBased on the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial because:\n\n- She is not currently pregnant (the trial requires being in the first or second trimester of pregnancy).\n- There is no mention of her being a smoker or having nicotine dependence in the past year.\n\nTherefore, based on the given information, I would assess the eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "331": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is looking for healthy pregnant women less than 17 weeks gestation with a pre-pregnancy BMI < 40 kg/m2.\n3. Since the patient has already given birth, she would not meet the inclusion criteria of being pregnant and less than 17 weeks gestation.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "332": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Men and women aged between 18 and 35 years\nThe patient is a 30-year-old woman, so she meets this criterion.\n\n2. Nonsmokers\nThe patient note does not mention if she is a smoker or not, so we cannot determine if she meets this criterion based on the information provided.\n\n3. Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant\nThe patient note mentions that she is generally healthy, with no health problems in the past besides 2 natural abortions. Her physical examination is also unremarkable, except for shortness of breath, tachypnea, tachycardia, and slightly low oxygen saturation. These abnormalities could be related to her recent childbirth, so an investigator may consider them clinically irrelevant.\n\n4. Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant\nThe patient's CBC is normal, and no other laboratory values are mentioned.\n\n5. Normal ophthalmic findings, ametropy < 3 Dpt.\nThe patient note does not provide any information about her ophthalmic findings or ametropy.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there are also some criteria that cannot be determined from the patient note. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "333": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her examination shows she is apprehensive, tachypneic, tachycardic, with a blood pressure of 110/70 and oxygen saturation of 92%.\n4. Her chest x-ray and CBC are normal.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. Age \u2265 18 years (the patient is 30 years old, so she meets this criteria)\n2. Investigator judges caval filtration clinically indicated for prevention of pulmonary embolism in patient with venous thromboembolic disease or at high risk for venous thromboembolic disease.\n\nThe patient does not have a confirmed diagnosis of venous thromboembolism or pulmonary embolism at this point. However, her recent pregnancy and current shortness of breath put her at potential risk for pulmonary embolism.\n\nBased on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther testing like a CT angiogram or VQ scan would be needed to evaluate if she has a pulmonary embolism, which would then make her eligible for the trial based on the inclusion criteria. Her recent pregnancy also puts her at higher risk. But more information is required before definitively referring her to this particular trial.",
        "label": 1
    },
    "334": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. The clinical trial is comparing two different doses of low-molecular-weight heparin (LMWH) to prevent recurrent venous thromboembolism (VTE) in pregnant patients with a history of previous VTE.\n4. The inclusion criteria are:\n   - Age 18 years or older (the patient is 30, so meets this criteria)\n   - Pregnancy confirmed by urinary pregnancy test (the patient recently gave birth, so was pregnant)\n   - Gestational age < 14 weeks (not mentioned, but she gave birth 3 weeks ago, so likely meets this)\n   - Previous objectively confirmed VTE (not mentioned in the patient note)\n\nSince the patient note does not mention if the patient had a previous VTE, which is one of the key inclusion criteria, I cannot definitively determine if she would be eligible for this trial based on the information provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether she had a previous VTE.",
        "label": 0
    },
    "335": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her examination shows she is apprehensive, tachypneic, tachycardic, with a normal blood pressure and oxygen saturation of 92%.\n4. Her chest x-ray and CBC are normal.\n\nThe clinical trial is for the treatment of Transient Tachypnea of the Newborn (TTN) in late preterm and term infants using inhaled corticosteroids.\n\nThe inclusion criteria are:\n1. Late preterm and term infants (post-menstrual age \u2265 34 weeks)\n2. Diagnosis of TTN\n3. Parents signed informed consent\n\nWhile the patient is a 30-year-old woman and not an infant, her recent delivery 3 weeks ago and presentation with shortness of breath and tachypnea could potentially indicate TTN.\n\nHowever, there are a few factors that make her eligibility uncertain:\n1. She is not an infant, which is explicitly stated in the inclusion criteria.\n2. There is no definitive diagnosis of TTN mentioned in the patient note.\n\nGiven these uncertainties, I would consider referring this patient to the clinical trial upon further investigation to confirm if she indeed has TTN.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "336": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her medical history does not mention chronic obstructive pulmonary disease (COPD).\n4. The clinical trial is studying nocturnal breathing and sleep in patients with COPD, specifically GOLD grade 2-3.\n5. One of the inclusion criteria is having COPD, GOLD grade 2-3.\n\nBased on the information provided in the patient note, there is no mention of the patient having COPD or any lung disease. Therefore, she would not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "337": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. The clinical trial is studying the efficacy of low dose (30ml) vs full dose (100ml) contrast CT pulmonary angiography in detecting pulmonary emboli.\n4. The inclusion criteria for the trial is: \"Patients referred for CT pulmonary angiogram to exclude pulmonary embolus\"\n5. Given that the patient is presenting with shortness of breath and is being evaluated for potential pulmonary embolism, she meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "338": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her vital signs show tachypnea, tachycardia, but normal blood pressure and oxygen saturation.\n4. Her physical exam is otherwise unremarkable, and her chest x-ray and CBC are normal.\n\nThe clinical trial is studying the effects of high frequency oscillatory ventilation (HFOV) combined with intermittent sigh breaths on blood oxygenation and stability in infants.\n\nThe key inclusion criteria are:\n1. Infants at 24-36 weeks corrected gestational age\n2. Already ventilated with high frequency ventilation\n3. Requiring FiO2=21%-70% to maintain adequate oxygen saturation\n4. Clinically stable on current ventilator settings\n5. Parent(s) or guardian able and willing to provide informed consent\n\nBased on the patient note, this 30-year-old woman does not meet the inclusion criteria for this clinical trial, as she is an adult and not an infant on high frequency ventilation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "339": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Using Nasal High Flow From Birth in Premature Infants - a Pilot Study\", this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient is a 30-year-old woman, while the trial includes premature infants born between 24+0 to 30+0 weeks gestation.\n2. The patient has given birth 3 weeks ago, indicating she is not a premature infant.\n3. The trial aims to study the use of nasal high flow therapy from birth in premature infants, which does not apply to this patient.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "340": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is studying the effect of a father inclusive psychoeducation program on postnatal depression.\n3. The inclusion criteria for the trial are:\n   - Aged 18 or above (the patient is 30, so meets this criteria)\n   - First-time parents (the note mentions she had 2 natural abortions before, but this is her first successful pregnancy/childbirth, so she likely meets this criteria)\n   - Able to speak and read Chinese language (no information given, so cannot determine if met)\n   - Hong Kong resident (no information given, so cannot determine if met)\n\n4. The main factor that makes the patient potentially ineligible is that the presenting complaint of shortness of breath 2 hours before admission is likely unrelated to postnatal depression, which is the focus of this trial.\n\nBased on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "341": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is studying the effects of postpartum vitamin A supplementation on breastmilk and infant health.\n3. One of the key inclusion criteria is \"Pregnant women >-18 years of age with low-risk obstetric\"\n4. Since the patient has recently given birth 3 weeks ago, she meets this inclusion criteria.\n\nBased on the information provided, this patient appears eligible for the clinical trial studying postpartum vitamin A supplementation.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "342": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is studying neurocognitive and immunological development in infants fed a new infant formula compared to a standard formula.\n3. One of the key inclusion criteria is \"Full-term newborns (>37 weeks and <41 weeks gestation)\". Since the patient recently gave birth 3 weeks ago, her newborn would likely meet this criteria.\n4. Another inclusion criteria is \"Inclusion age: from 0 to 2 months (60 days) in the formula fed groups\". Since the patient's newborn is 3 weeks old (around 21 days), the newborn would meet this age criteria for the formula fed group.\n5. The patient note doesn't mention if she is breastfeeding or formula feeding, but the trial allows up to 30 days of exclusive breastfeeding before switching to formula.\n\nBased on the information provided, it seems highly likely that this patient's newborn would be eligible for this clinical trial studying infant formula and development.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "343": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her examination shows she is apprehensive, tachypneic, tachycardic, with a blood pressure of 110/70 and oxygen saturation of 92%.\n4. Her chest x-ray and CBC are normal.\n\nLooking at the inclusion criteria for the clinical trial:\n1. Precapillary pulmonary hypertension, or interstitial lung disease - The patient note does not mention either of these conditions.\n2. New York Heart Association class 2-3 - There is no information about the patient's NYHA class.\n3. Residence at low altitude (<800m) - There is no information about the patient's place of residence/altitude.\n\nBased on the information provided in the patient note, there is no clear indication that the patient meets the inclusion criteria for this clinical trial on pulmonary hypertension or interstitial lung disease at altitude.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "344": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago. This meets the age criteria of 18-45 years old for the clinical trial.\n\n2. She is not breastfeeding, which is an exclusion criteria for the medication groups.\n\n3. She has no history of depression, mood disorders, or psychiatric disorders mentioned, which meets the inclusion criteria.\n\n4. There is no mention of any conditions that would contraindicate the use of oral contraceptives, such as thrombophlebitis, pulmonary embolism, cerebrovascular disease, diabetes, migraines, renal disease, hypertension, jaundice, breast/endometrial cancer, liver disease, thyroid disorders, or recent alcohol/drug use.\n\n5. She is not a smoker, which meets the criteria for non-smokers under 35.\n\n6. There is no mention of any history of non-compliance with taking medication.\n\nBased on the information provided in the patient note, this patient appears to meet the eligibility criteria for the clinical trial studying the effects of oral contraceptives on postpartum depression and sexual function.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "345": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago to a healthy child. This matches the inclusion criteria of being age 18 or above at time of delivery and delivery of a live born infant at estimated gestational age \u226537 weeks.\n\n2. She is a postpartum primiparous patient (first-time mother) within the first 48 hours after delivery, which matches the inclusion criteria.\n\n3. It is stated that she had given birth to a healthy child 3 weeks before, so it can be inferred that she intended to breastfeed and initiated breastfeeding within 48 hours of delivery, matching those inclusion criteria.\n\n4. There is no information provided about whether the infant is continuously rooming in with the mother, her language, ability to read/complete surveys, anticipated discharge from military system/Tricare benefits, or willingness to provide informed consent.\n\nBased on the information provided, I would consider referring this patient to this clinical trial upon further investigation to confirm the remaining inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "346": {
        "output": "To determine the patient's eligibility for the nuMoM2b Heart Health Study, let's go through the inclusion criteria:\n\n1. Interval Contact:\n   - Agreed to contact for future studies during nuMoM2b and not subsequently withdrawn from the cohort: Unknown from the given information.\n   - Have pregnancy outcome data from the nuMoM2b study: Unknown from the given information.\n   - At least 18 years of age: The patient is 30 years old, so this criterion is met.\n   - Provision of verbal consent for telephone interview or acknowledgment of consent with completion of the web-based self-administered questionnaire: Unknown from the given information.\n\n2. In-clinic Visit:\n   - Consented for participation in interval contacts and not subsequently withdrawn: Unknown from the given information.\n   - Between 2 and 3.5 years after the nuMoM2b pregnancy ended: The patient gave birth 3 weeks ago, so this criterion is not met.\n   - Self-report at least 6 months postpartum from any subsequent pregnancy: The patient gave birth 3 weeks ago, so this criterion is not met.\n   - Self-report not currently pregnant: The patient is not currently pregnant, so this criterion is met.\n   - Able to provide informed consent: Assuming the patient is competent, this criterion is likely met.\n   - Provision of written, signed, informed consent for the 2 to 3.5 year in-clinic assessment: Unknown from the given information.\n   - Not currently pregnant by urine pregnancy test administered in the clinic following consent: The patient is not currently pregnant, so this criterion is met.\n\n3. In-home Sleep Breathing Assessment after the In-Clinic Visit:\n   - Participation in the in-clinic visit: This criterion is not met since the patient does not meet the criteria for the in-clinic visit.\n   - Participation in the sleep breathing substudy of nuMoM2b with at least one sleep breathing assessment providing valid data: Unknown from the given information.\n   - Not currently using positive airway pressure (PAP) therapy or other approved treatments for sleep apnea such as oral appliances and nasal therapy patch (Provent): Unknown from the given information.\n   - Not currently on continuous oral steroid therapy for 14 days or more to treat asthma: Unknown from the given information.\n   - Not currently using oxygen supplementation to treat a medical condition: Unknown from the given information.\n   - Able to provide informed consent and deemed likely to return equipment in a reasonable period: Assuming the patient is competent, this criterion is likely met.\n   - Provision of written, signed, informed consent for the sleep breathing assessment for the nuMoM2b Heart Health Study: Unknown from the given information.\n\nBased on the available information, the patient does not meet the criteria for the in-clinic visit due to the timing of her recent pregnancy. Therefore, she would not be eligible for the in-home sleep breathing assessment either.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "347": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago. This meets the age criteria of at least 18 years old.\n\n2. She is presenting with shortness of breath, which could potentially be related to a pulmonary embolism, one of the conditions the trial is investigating.\n\n3. She is undergoing no surgical intervention at this time, whereas the trial inclusion criteria specify patients undergoing major lung resection surgery.\n\n4. There is no mention of her being diagnosed with lung cancer or metastatic lung disease, which is an inclusion criterion.\n\n5. She does not meet any of the exclusion criteria listed.\n\nBased on the information provided, while she could potentially be at risk for venous thromboembolism due to her recent pregnancy, she does not meet the key inclusion criteria of having a diagnosed lung cancer/metastatic disease and undergoing major lung resection surgery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "348": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Elective cesarean delivery under spinal anesthesia.\nThe patient note does not mention whether this is an elective cesarean delivery or the type of anesthesia used. More information is needed to determine if this criterion is met.\n\n2. Written informed consent to participate in this study.\nThe patient note does not indicate whether the patient has provided written informed consent. This is usually obtained after determining initial eligibility.\n\n3. Term pregnancy\nThe patient note states that the woman gave birth to a healthy child 3 weeks before, indicating that this was a term pregnancy.\n\nBased on the limited information provided in the patient note, I would consider referring this patient to this clinical trial upon further investigation to determine if the first inclusion criterion is met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "349": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. She had no major health issues in the past except for 2 natural abortions.\n4. Her vital signs show tachypnea, tachycardia, normal blood pressure, and slightly low oxygen saturation.\n5. Her physical exam is otherwise unremarkable, and her chest x-ray and CBC are normal.\n\nThe clinical trial is studying the use of magnesium sulfate during the postpartum period in women with severe preeclampsia.\n\nThe key inclusion criteria are:\n1. Severe preeclampsia or severe preeclampsia with chronic hypertension\n2. Gestational age > 24 weeks\n3. Treated with 4-6 grams of magnesium sulfate for at least 8 hours continuously before delivery\n4. The study begins at termination of pregnancy\n\nBased on the information provided in the patient note, there is no mention of the patient having severe preeclampsia or being treated with magnesium sulfate before delivery.\n\nTherefore, based on the available information, this patient would not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "350": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is about involving men in maternity care in Burkina Faso.\n3. The inclusion criteria for the trial are:\n   - Age 16-18, married, or\n   - Age 18+, in a co-habiting relationship\n   - Pregnant 24-36 weeks\n   - No obstetric risk factors requiring hospital delivery\n   - Lives no more than one hour away on foot, not planning to move from the city\n   - Gives informed consent\n\n4. Based on the patient note, the woman is 30 years old, which does not meet the age criteria for the trial.\n5. Additionally, she is not currently pregnant, as she recently gave birth 3 weeks ago, which does not meet the pregnancy criteria of 24-36 weeks.\n6. There is no information provided about her marital status or living situation.\n\nTherefore, based on the information given, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "351": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. The clinical trial is looking at amoxicillin vs placebo for treatment of fast breathing pneumonia in children.\n4. The inclusion criteria specify:\n    - History of cough or difficult breathing < 14 days\n    - Respiratory rate \u2265 50 breaths per minute in children 2 to <12 months \n    - Respiratory rate \u2265 40 breaths per minute in children 12-59 months\n    - Written informed consent by legal guardian\n\nBased on the information provided, this patient would not meet the inclusion criteria for this clinical trial for a few reasons:\n1. The trial is focused on children, while this patient is an adult woman.\n2. There is no mention of the patient's respiratory rate, which is a key inclusion criteria.\n3. The patient's shortness of breath started only 2 hours prior, while the criteria specifies a history of cough/difficult breathing < 14 days.\n\nTherefore, given the mismatch between the patient details and the trial inclusion criteria, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "352": {
        "output": "To determine the patient's eligibility for the clinical trial \"Dental Support Device During Breastfeeding as a Mean for Pain Control\", let's go through the inclusion criteria:\n\n1. Maternal age 18-45 years.\nThe patient is a 30-year-old woman, which meets this criterion.\n\n2. Normal vital signs.\nThe patient's blood pressure is 110/70, which is within the normal range. Her oxygen saturation is 92%, which is slightly low but not critically abnormal. The note mentions that her physical examination is otherwise unremarkable.\n\nBased on the provided information, the patient appears to meet the inclusion criteria for this clinical trial.\n\nHowever, it's important to note that the patient's chief complaint is shortness of breath, which started 2 hours before admission. While the cause of her shortness of breath is not specified, it could potentially be related to a postpartum complication or other underlying condition that may affect her eligibility for the trial.\n\nTherefore, I would consider referring this patient to this clinical trial upon further investigation of the cause and severity of her shortness of breath, as well as any other potential exclusion criteria that may apply.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "353": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman presenting with shortness of breath 3 weeks after giving birth to a healthy child.\n2. The clinical trial is studying the effects of sonic pressure oscillations on pulmonary gas exchange in healthy volunteers.\n3. The inclusion criteria state that the trial is looking for \"Healthy male or female volunteers in the age group.\"\n\nSince the patient is described as generally healthy and within the appropriate age group, and her symptoms of shortness of breath are likely related to her recent pregnancy/childbirth rather than an underlying chronic condition, she would potentially be eligible for this trial.\n\nHowever, given that her symptoms are acute and she is only 3 weeks postpartum, I would want to investigate her condition further before definitively referring her to ensure there are no complications from childbirth causing her shortness of breath.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "354": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath and tachypnea, which could potentially be signs of sepsis in the postpartum period.\n3. The clinical trial is studying the use of sodium lactate Ringer's injection in patients with septic shock.\n4. The only inclusion criteria listed is \"diagnosis in patients with septic shock\".\n\nBased on the limited information provided in the patient note, there is not enough evidence to definitively diagnose septic shock. The shortness of breath and tachypnea could have other potential causes in the postpartum period.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional testing and evaluation would be needed to determine if this patient meets the criteria for septic shock before definitively referring them to this particular clinical trial. More information about potential sources of infection, vital signs, lab values, etc. would help clarify the diagnosis and eligibility.",
        "label": 0
    },
    "355": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath and tachypnea, which could be indicative of anemia.\n3. The clinical trial is looking at treatment options for postpartum anemia, defined as hemoglobin < 9.5 g/dL.\n4. The inclusion criteria specifically state:\n   - Women above 18 years old after giving birth\n   - Women who suffer from iron deficiency anemia, defined as hemoglobin < 9.5 g/dL\n\nWhile the patient's hemoglobin level is not provided, her recent postpartum status and shortness of breath symptoms suggest she may have postpartum anemia.\n\nTherefore, based on the information provided, I would consider referring this patient to this clinical trial upon further investigation of her hemoglobin levels.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "356": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. She is presenting with shortness of breath that started 2 hours before admission.\n3. Her vital signs show tachypnea, tachycardia, and slightly low oxygen saturation of 92%.\n4. Her physical exam is otherwise unremarkable, and her chest x-ray and CBC are normal.\n\nLooking at the inclusion criteria for the clinical trial:\n1. Age 18-70 years - The patient is 30 years old, so she meets this criterion.\n2. Male and female volunteers - The patient is female, so she meets this criterion.\n3. ASA physical status I, II, and III - Based on the information provided, the patient seems to be generally healthy aside from the current shortness of breath episode, so she likely falls into ASA class I or II and meets this criterion.\n4. Capable and willing to provide written informed consent in English - This is not mentioned in the patient note, but we can assume she is capable of providing consent.\n\nOverall, based on the information provided, the patient seems to meet all the inclusion criteria for this clinical trial on comparing different oxygen delivery masks.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "357": {
        "output": "To determine the patient's eligibility for the clinical trial \"The Impact of Creative Interventions on Symptoms of Postnatal Depression (Cohort Study)\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\nWomen who are more than 28 weeks pregnant OR up to 9 months post-birth\n\nBased on the patient note, the patient is a 30-year-old woman who gave birth to a healthy child 3 weeks before presenting with shortness of breath. Since she is within the 9 months post-birth period, she meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "358": {
        "output": "To determine the patient's eligibility for the clinical trial \"Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial\", let's go through the details:\n\nThe patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago. She is currently hospitalized with shortness of breath.\n\nThe inclusion criteria for the trial is \"All pregnant women hospitalized.\"\n\nSince the patient has recently given birth and is currently hospitalized, she meets the inclusion criteria of being a hospitalized pregnant woman.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "359": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 30-year-old generally healthy woman who recently gave birth 3 weeks ago.\n2. The clinical trial is focused on pediatric patients between 1-18 years old who require intubation.\n3. Since the patient is an adult and does not require intubation, she does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "360": {
        "output": "To determine the patient's eligibility for the clinical trial \"Computed Tomography CT Venography During Postpartum Venous Thromboembolism\", let's go through the inclusion criteria one by one:\n\n1. \"Women with clinically suspected pulmonary embolism (PE) during the first 6 weeks postpartum, without any sign of severe PE (shock, hypotension), referred for CT angiography\"\n   - The patient is a 30-year-old woman who presented with shortness of breath 3 weeks after giving birth, which could be a sign of pulmonary embolism. She does not seem to have signs of severe PE like shock or hypotension. This criterion is likely met.\n\n2. \"Absence of contraindication to iodinated contrast medium injection (Previous allergic reaction to iodinated contrast medium, renal insufficiency with creatine clearance less than 30mL/mn, uncontrolled hyperthyroidism)\"\n   - There is no information provided about any contraindications to contrast medium injection for this patient. We can assume this criterion is met unless stated otherwise.\n\n3. \"Age > 18 years\"\n   - The patient is 30 years old, so this criterion is met.\n\n4. \"Health insurance\"\n   - No information is provided about the patient's health insurance status.\n\n5. \"Possibility to have 3-month follow-up\"\n   - No information is provided about the possibility of follow-up for this patient.\n\n6. \"Obtention of written informed consent (ability to give consent)\"\n   - No information is provided about the patient's ability to give consent.\n\nBased on the information provided, the patient meets at least one of the inclusion criteria (suspected pulmonary embolism in the postpartum period) and does not seem to violate any of the other criteria explicitly stated. However, there is not enough information to confirm that all criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "361": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient is an 85-year-old man, which does not meet the inclusion criteria of females aged 25-75 years. Additionally, the patient's condition involves a gradual decrease in consciousness and inability to walk or eat, which suggests a potential neurological or medical issue unrelated to the study's focus on vitamin D, fingernail thickness, and bone density.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "362": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which is outside the age range of 60-80 years specified in the inclusion criteria for this clinical trial on early Alzheimer's disease.\n\n2. The patient's education level is not mentioned, so we cannot determine if he meets the minimum 12 years of education criteria.\n\n3. The patient is exhibiting a gradual decrease in level of consciousness and inability to walk or eat by himself over the past 3 days. This suggests potential cognitive impairment beyond the \"within normal limits\" specified in the inclusion criteria.\n\n4. No information is provided about the patient's Global Deterioration Scale (GDS) score or performance on neuropsychological tests like the WMS-R delayed memory index to assess if he meets the \"within normal limits\" criteria.\n\nBased on the available information, particularly the patient's age being outside the specified range and the suggestion of more advanced cognitive impairment, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "363": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of 65 or older.\n2. The patient is being admitted to the hospital, but the inclusion criteria specifically mentions being admitted for surgical repair of hip fracture. There is no mention of a hip fracture in the patient note.\n3. There is no evidence of delirium at admission mentioned in the patient note.\n4. The patient's MMSE score is not provided, so we cannot assess if they meet the criteria of a score below 24.\n5. There is no mention of the patient providing consent to participate in the study.\n\nBased on the information provided, there are some criteria that are met (age) and some that are unclear or not met (reason for admission, MMSE score, consent). More investigation would be needed to fully determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "364": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, so he does not meet the age inclusion criteria for this trial which likely requires younger participants.\n\n2. There is no mention of the patient having a driving license or driving experience, which are required inclusion criteria.\n\n3. There is no information provided about the patient's vision, handedness, or language fluency to determine if he meets those inclusion criteria.\n\n4. The trial is focused on the effects of pain on driving performance and cognition, but the patient note does not mention any chronic pain condition. The decrease in consciousness level seems to be due to an unspecified cause potentially related to the previous car accident.\n\nBased on the information provided in the patient note and the inclusion criteria listed for this clinical trial, it does not appear that this patient would be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "365": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of being over 55 years old for this clinical trial on the use of beta blockers in elderly trauma patients.\n\n2. The patient was brought to the ER due to a gradual decrease in level of consciousness and inability to walk or eat by himself in the last 3 days. This suggests he may have suffered some kind of trauma or injury, though the details are not provided.\n\n3. It is mentioned that he was involved in a car accident 3 weeks prior and had a normal head CT at that time, indicating a potential traumatic injury.\n\n4. The inclusion criteria specifically state that all trauma patients admitted to the ICU over 55 years old with a primary diagnosis of injury will be screened as study candidates.\n\nBased on the information provided, this 85-year-old patient seems to meet the age criteria and has a history of potential trauma/injury from the recent car accident. However, more details would be needed to confirm if he was admitted to the ICU and if the primary diagnosis was related to an injury.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "366": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. One week following: Traumatic Brain Injury or Cerebro-Vascular Accident\n   - The patient note mentions that the patient was involved in a car accident 3 weeks prior, which could potentially be a traumatic brain injury. However, the time frame of \"one week following\" is not met.\n\n2. Subsequent brain CT showed cerebral cortex injury.\n   - The patient note does not mention any findings from a recent brain CT scan, so we cannot confirm if there is a cerebral cortex injury.\n\nBased on the information provided in the patient note, the inclusion criteria are not fully met. The time frame of one week following the potential traumatic brain injury is not satisfied, and there is no confirmation of a cerebral cortex injury on a recent brain CT scan.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo make a more definitive assessment, we would need additional information, such as the results of a recent brain CT scan and the exact date of the car accident or traumatic brain injury event. If these details align with the inclusion criteria, the patient may be eligible for the clinical trial.",
        "label": 2
    },
    "367": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which does not meet the age criteria of 0-15 years old for the clinical trial.\n\n2. The clinical trial is specifically for asymptomatic pediatric trauma patients, but this patient is presenting with a gradual decrease in level of consciousness and inability to walk or eat, which suggests he is symptomatic.\n\n3. There is no mention of any recent trauma or injury that would qualify this patient for a trauma-related clinical trial.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial titled \"the Role of Total Body Imaging in Asymptomatic Pediatric Trauma Patients\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "368": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Age: The patient is 85 years old, which meets the age requirement of 65 years or older.\n\n2. Diagnosed with dementia: The patient note does not explicitly state that the patient has been diagnosed with dementia. However, the gradual decrease in level of consciousness and inability to walk or eat by himself could be indicative of dementia.\n\n3. Mini-Mental State Examination (MMSE) score: The patient note does not provide the MMSE score.\n\n4. Capable of participating at least once a week for 6 weeks: The patient note does not provide information about the patient's ability to participate in the study.\n\nBased on the available information, the patient meets the age criterion, but there is not enough information to determine if the patient has been diagnosed with dementia, has an MMSE score of 23 or less, or is capable of participating in the study for 6 weeks.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "369": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Valid Ontario driver's license: The patient note does not mention whether the patient has a valid driver's license or not.\n2. Active driver (greater than or equal to three times per week): The patient note does not provide any information about the patient's driving habits.\n3. Written, informed consent: This criterion cannot be assessed based on the provided information.\n4. Lives in Toronto/Thunder Bay: The patient note does not specify the patient's location.\n5. Healthy: The patient note indicates that the patient's level of consciousness has gradually decreased, and he has stopped walking and eating by himself, which suggests that he is not healthy.\n6. Male between 65-75 years old: The patient note states that the patient is an 85-year-old man, which does not meet the age criterion.\n\nBased on the available information, the patient does not meet at least two of the inclusion criteria (age and health status). Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "370": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER due to a gradual decrease in level of consciousness over the past 3 days. He stopped walking and eating by himself.\n\n2. The clinical trial is titled \"Delirium Recall in Advanced Cancer Patients\" and aims to determine the proportion of patients who experience recall of delirium symptoms and the associated distress levels for both patients and caregivers.\n\n3. One of the key inclusion criteria is \"Presence of advanced cancer, defined as local recurrent and/or metastatic.\" The patient note does not mention any cancer diagnosis, so this criterion is not met.\n\n4. Another inclusion criterion is \"History of an episode of delirium during the patient's current inpatient admission, diagnosis of delirium will be made by one of the palliative care specialists according to DSM-IV-TR criteria.\" While the patient's decreased level of consciousness could potentially be delirium, there is no explicit mention of a delirium diagnosis in the patient note.\n\n5. Other inclusion criteria, such as the ability to communicate in English, the presence of a caregiver, and written informed consent, are not addressed in the patient note.\n\nBased on the information provided, it is unlikely that this patient would be eligible for the clinical trial, as the key inclusion criteria of advanced cancer and a confirmed delirium episode are not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "371": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who has experienced a gradual decrease in level of consciousness and stopped walking and eating by himself in the last 3 days.\n\n2. The clinical trial is aimed at reducing falls incidence rate in frail elderly people.\n\n3. One of the key inclusion criteria is \"At least one fall in the last 6 months\". The patient note does not explicitly mention any falls in the last 6 months.\n\n4. Another inclusion criterion is \"Ability to walk 15 meters independently (use of a walking aid is permitted)\". The patient note states that the patient has stopped walking by himself, which suggests he may not meet this criterion.\n\n5. The other inclusion criteria like living at home/aged home, availability of a caregiver, and life expectancy of more than 6 months are not clearly addressed in the patient note.\n\nBased on the available information, it is unclear if the patient fully meets the inclusion criteria for this clinical trial. More investigation may be needed to determine if the patient had any falls in the last 6 months and to assess their ability to walk 15 meters independently.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "372": {
        "output": "To determine the patient's eligibility for the clinical trial \"Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus\", let's go through the inclusion criteria one by one:\n\n1. Walking difficulties in both legs which has developed gradually, not explained by other conditions, either in combination with mental impairment and urinary incontinence:\n   - The patient note mentions that the 85-year-old man stopped walking by himself in the last 3 days, which suggests walking difficulties. However, it does not explicitly state that the walking difficulties developed gradually or were present in both legs.\n\n2. Brain CT or MRI findings of enlarged ventricles compared to established standards (minimum Evans ratio of 0.30 as measured by reviewing films):\n   - The patient note does not provide any information about brain imaging findings or the Evans ratio.\n\n3. Mental impairment must be mild to moderate, emerging with or after the walking difficulties:\n   - The patient note mentions a gradual decrease in the level of consciousness, which could indicate mental impairment. However, the severity of the impairment is not specified.\n\n4. Age > or = 18 years old:\n   - The patient is 85 years old, so this criterion is met.\n\n5. MMSE (Mini-mental status exam): < or = 10:\n   - The patient note does not provide the MMSE score.\n\n6. Urinary incontinence:\n   - The patient note does not mention urinary incontinence.\n\nBased on the information provided in the patient note, some of the inclusion criteria are potentially met, while others are unclear or not met. More investigation would be needed to determine the patient's eligibility with certainty.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "373": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which falls outside the age range of 18-65 years specified in the inclusion criteria.\n\n2. The patient has experienced a traumatic brain injury (TBI) from a car accident 3 weeks prior, which meets the inclusion criteria of having a mild-moderate TBI at least 1 year old after 9/11/2001.\n\n3. There is no information provided about intracranial neurosurgery post-TBI, disability rating scale, alcohol/drug abuse screening, pregnancy status, or the percent back to normal rating scale.\n\n4. Based on the limited information provided, the patient's age is a major exclusion factor, but the TBI history potentially meets some of the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "374": {
        "output": "To determine the patient's eligibility for the clinical trial \"Analysis of Balance in the Aging Process\", let's go through the inclusion criteria:\n\nInclusion Criteria: Absence of the basic pathology that interferes directly in the balance\n\nThe patient note mentions that the 85-year-old man has experienced a gradual decrease in his level of consciousness and stopped walking and eating by himself in the last 3 days. This could potentially interfere with his balance and ability to perform the balance tests required for the clinical trial.\n\nHowever, the note also mentions that the patient had a normal head CT after a car accident 3 weeks prior, suggesting that there may not be an underlying pathology directly affecting his balance.\n\nGiven the limited information provided, it is difficult to determine with certainty whether the patient meets the inclusion criteria or not.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "375": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER with a gradual decrease in level of consciousness over the past 3 days. He stopped walking and eating by himself.\n\n2. The clinical trial is titled \"International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage\" and is studying treatments for intracerebral hemorrhage (ICH) in patients on vitamin K antagonists (VKA) like warfarin.\n\n3. The inclusion criteria for the trial are:\n   - Spontaneous ICH or subdural hematoma diagnosed by CT scan \u2264 12 hours after symptom onset\n   - Receiving VKA therapy\n   - INR \u2265 2\n   - Signed informed consent\n\n4. Based on the patient note, there is no mention of the patient being on VKA therapy or having an elevated INR. There is also no mention of an ICH or subdural hematoma being diagnosed on CT scan within 12 hours.\n\n5. While the patient's decreased level of consciousness could potentially be due to an ICH, there is not enough information provided to determine if he meets the inclusion criteria for this specific trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "376": {
        "output": "To determine the patient's eligibility for the clinical trial \"Neural Correlates of Cognitive Rehabilitation in Post-Traumatic Stress Disorder (PTSD)\", let's go through the inclusion criteria:\n\n1. OEF/OIF Veteran: The patient note does not mention whether the patient is a veteran or not, so this criterion cannot be evaluated.\n\n2. Meets DSM-IV criteria for PTSD: The patient note does not provide any information about the patient meeting the criteria for PTSD, so this criterion cannot be evaluated either.\n\n3. Control group does not meet criteria for PTSD: This criterion is for the control group, not the patient group.\n\nSince the patient note does not provide enough information to determine if the patient meets the inclusion criteria for PTSD and veteran status, I cannot make a definitive assessment of eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "377": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER due to a gradual decrease in consciousness, stopped walking and eating by himself in the last 3 days.\n2. He had a car accident 3 weeks prior but had a normal head CT at that time.\n3. The clinical trial is studying the use of advanced imaging techniques to diagnose traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD).\n4. The inclusion criteria are: at least 18 years of age, non-active duty, and either normal (no history of head injury) or having a TBI since January 1, 2002.\n\nGiven the information provided, this patient seems to meet the age criteria (85 years old) and the non-active duty criteria. However, it is unclear if he has a TBI or not. The note mentions a car accident 3 weeks prior with a normal head CT at that time, but his current symptoms of decreased consciousness, inability to walk or eat could potentially be related to a TBI from that accident.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "378": {
        "output": "To determine the patient's eligibility for the clinical trial \"Delirium in the Emergency Department: Novel Screening\", let's go through the inclusion criteria:\n\n1. Age: The patient is 85 years old, which meets the age criteria of 65 years or greater.\n\n2. In the Emergency Department for less than 12 hours at the time of enrollment: The patient note does not specify how long the patient has been in the ER, so we cannot definitively confirm this criterion.\n\nHowever, based on the information provided, the patient appears to be exhibiting symptoms consistent with delirium, such as a gradual decrease in level of consciousness, stopping walking and eating by himself, and no apparent underlying medical condition (fever, cough, rash, or diarrhea) that could explain these symptoms.\n\nGiven the patient's age and presenting symptoms, which align with the study's focus on delirium in older ED patients, I would consider referring this patient to this clinical trial upon further investigation to confirm the time spent in the ED.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "379": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Between the ages of 65-85: The patient is 85 years old, which meets this criterion.\n\n2. Independent in activities of daily living: The note mentions that the patient has stopped walking and eating by himself in the last 3 days, which suggests he is not currently independent in activities of daily living. This does not meet the criterion.\n\n3. Able to walk without assistance for at least 10 minutes: The note states that the patient stopped walking by himself, which implies he is unable to walk without assistance for 10 minutes. This does not meet the criterion.\n\n4. Cognitively intact (Mini Mental State Exam \u226524): There is no information provided about the patient's cognitive status or Mini Mental State Exam score.\n\n5. Reported 2 or more falls within 6 months prior to the beginning of the study: There is no information provided about the patient's fall history.\n\nBased on the information given in the patient note, the patient does not meet at least two of the inclusion criteria (independence in activities of daily living and ability to walk without assistance for 10 minutes). There is also not enough information to determine if the patient meets the cognitive status and fall history criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "380": {
        "output": "To determine the patient's eligibility for the \"Imaging of Traumatic Brain Injury\" clinical trial, let's go through the inclusion criteria:\n\n1. Age 18 or older: The patient is 85 years old, so this criterion is met.\n\n2. Evidence of external head injury or facial trauma, or mechanism of injury consistent with brain trauma, including loss of consciousness or altered mental status: The patient was involved in a car accident 3 weeks prior and has experienced a gradual decrease in level of consciousness, suggesting a potential traumatic brain injury. This criterion is likely met.\n\n3. Residence within 90 minutes driving time of University of Maryland Medical Center, and willingness to attend follow-up appointments: There is no information provided about the patient's residence or willingness to attend follow-up appointments.\n\nBased on the available information, the patient meets at least two of the three inclusion criteria. However, there is not enough information to determine if the patient meets the third criterion regarding residence and willingness to attend follow-up appointments.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding their residence and willingness to attend follow-up appointments.",
        "label": 2
    },
    "381": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of \u226575 years for the clinical trial.\n\n2. The patient is brought to the ER because of a gradual decrease in consciousness and inability to walk or eat by himself in the last 3 days. This suggests a potential hip fracture or other injury that may require hip fracture surgery.\n\n3. The inclusion criteria state that the patient should be willing and able to complete the requirements of the study, including signing informed consent. The patient's current decreased level of consciousness may make it difficult for him to provide informed consent.\n\n4. The inclusion criteria also specify that the hip fracture surgery should be planned within 48 hours after the hip fracture. The patient note does not provide information on when the potential hip fracture occurred or when surgery is planned.\n\nBased on the available information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to determine if the patient has a hip fracture requiring surgery within the 48-hour window, and if the patient's level of consciousness improves to the point where they can provide informed consent for the study.",
        "label": 0
    },
    "382": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, so he meets the age criteria for most clinical trials.\n\n2. However, the clinical trial is specifically for patients who have been involved in or witnessed a car accident at least 6 months ago and have developed PTSD or distress/impairment following the accident.\n\n3. The patient note mentions that the patient was involved in a car accident 3 weeks prior to admission, but there is no mention of him developing PTSD or any distress/impairment related to the accident.\n\n4. The main issue described in the patient note is a gradual decrease in the patient's level of consciousness and inability to walk or eat by himself in the last 3 days, which does not seem directly related to the car accident.\n\n5. Based on the information provided, there is no clear indication that the patient meets the inclusion criteria for this specific clinical trial on PTSD following a car accident.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "383": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of \"aged over 75 years\" for the clinical trial.\n\n2. However, the patient is not being admitted for a scheduled surgery, which is one of the inclusion criteria. He is being brought to the ER due to a gradual decrease in level of consciousness.\n\n3. There is no mention of the patient agreeing to participate in the trial.\n\nBased on the information provided in the patient note, this patient would not meet all the inclusion criteria for the \"Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "384": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age inclusion criteria of being 65 years or older.\n\n2. There is no information provided about the patient's residence, so we cannot determine if he meets the inclusion criteria of residing in Greve in Chianti or Bagno A Ripoli, Italy.\n\n3. There is no information provided about the patient's cognitive status, so we cannot determine if he meets the inclusion criteria related to moderate cognitive problems.\n\n4. The patient does not appear to be a child, so he meets the exclusion criteria.\n\nBased on the limited information provided, I would consider referring this patient to this clinical trial upon further investigation to determine if he meets the residence and cognitive status criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "385": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of \u226565 years old for the clinical trial.\n\n2. However, the patient is not described as healthy. He is brought to the ER because of a gradual decrease in his level of consciousness and inability to walk or eat by himself in the last 3 days. This suggests he is not in a healthy condition.\n\n3. The inclusion criteria specifically state \"Japanese healthy elderly male and female\" as a requirement.\n\n4. Since the patient does not appear to be in a healthy condition based on the provided information, he would likely not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "386": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of \u226575 years for the clinical trial.\n\n2. However, the patient note does not mention any olecranon fracture or forearm fracture. The note states that the patient had a normal head CT after a car accident 3 weeks prior.\n\n3. The clinical trial is specifically for patients with an isolated olecranon fracture within two weeks of the fracture.\n\n4. Since there is no mention of an olecranon fracture in the patient note, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "387": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER with a gradual decrease in consciousness over the past 3 days. He stopped walking and eating by himself.\n\n2. The clinical trial is looking at whether discontinuing aspirin treatment after mild head trauma decreases the incidence of chronic subdural hematoma.\n\n3. The key inclusion criteria for the trial are:\n   - Age \u2265 50 years (the patient is 85, so meets this criteria)\n   - Sustained mild head trauma with visit to the ER within 24 hours (the patient had a car accident 3 weeks prior, so does not meet this criteria)\n   - On low-dose aspirin (75-100mg) at time of head trauma (no information given about aspirin use)\n   - Admission non-contrast head CT with no evidence of intracranial hemorrhage or skull fracture (the patient had a normal head CT 3 weeks ago after the accident)\n\n4. While the patient meets the age criteria, the key issue is that he did not present to the ER within 24 hours of the mild head trauma from the car accident 3 weeks ago. \n\n5. There is also no information provided about whether he was on low-dose aspirin at the time of the accident.\n\nBased on the information given, I would assess the eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "388": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, so he meets the age criteria of being 18 years or older.\n\n2. There is no information provided about the patient's kidney function or GFR, so we cannot determine if he meets the criteria of having CKD stage 3.\n\n3. There is no information about whether the patient has had stable plasma creatinine levels in the last 2 months.\n\n4. The patient is not mentioned as being scheduled for an elective computed tomography (CT) scan with contrast. The note only mentions a previous normal head CT after a car accident.\n\nSince there is not enough information to definitively determine if the patient meets all the inclusion criteria, especially regarding kidney function and scheduled contrast CT scan, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "389": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Age \u2265 70 years old: The patient is 85 years old, so this criterion is met.\n\n2. Undergoing any lumbar spine surgery, posterior cervical spine surgery, or anterior cervical spine surgery > 2 levels: The patient note does not mention any upcoming spine surgery, so this criterion is not met.\n\nSince the patient does not meet one of the key inclusion criteria (undergoing spine surgery), it is unlikely that they would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "390": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER due to a gradual decrease in level of consciousness and inability to walk or eat by himself in the last 3 days.\n\n2. The clinical trial is titled \"The Neuromarker S-100B in Patients With Different Types of Intracranial Injury\" and is studying the use of the S-100B marker to predict neuronal damage caused by traumatic brain injury.\n\n3. The inclusion criteria for the trial is \"all patients with traumatic brain injury\".\n\n4. Given that the patient had a car accident 3 weeks prior and had a normal head CT at that time, but is now experiencing a decrease in consciousness and inability to walk/eat, it is possible that he has suffered a traumatic brain injury.\n\n5. Therefore, based on the inclusion criteria of \"all patients with traumatic brain injury\", this patient would likely be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "391": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER due to a gradual decrease in consciousness and inability to walk or eat by himself over the past 3 days.\n\n2. The clinical trial is about evaluating the role of follow-up CT scans in the management of chronic subdural hematoma after neurosurgical evacuation.\n\n3. One of the key inclusion criteria is \"Newly diagnosed chronic subdural hematoma by CT scan or MRI, operated within the last 48 hours\".\n\n4. From the patient note, it is mentioned that the patient had a normal head CT 3 weeks prior to admission after a car accident. There is no mention of a recent diagnosis of chronic subdural hematoma or a recent surgery for it.\n\n5. Therefore, based on the available information, this patient does not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "392": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of \"Over 60 year old\" for the clinical trial.\n\n2. The patient is exhibiting signs of delirium, such as a gradual decrease in level of consciousness, stopped walking and eating by himself, which could potentially meet the criteria of \"Delirium according to the CAM-ICU (Confusion Assessment Method for Intensive Care Unit)\".\n\n3. It is not explicitly stated whether informed consent from legal representatives has been obtained, but this could potentially be arranged if the patient is deemed eligible.\n\nBased on the information provided, it seems that this patient may be eligible for the clinical trial \"Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial\", but further investigation would be needed to confirm the diagnosis of delirium and obtain informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "393": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer\", this 85-year-old man would not be eligible for the trial. The key reasons are:\n\n1. The trial is specifically for patients with breast cancer, while the patient note does not mention any breast cancer diagnosis.\n\n2. The trial has strict inclusion criteria related to breast cancer characteristics, such as hormone receptor status, HER2 status, tumor size, lymph node involvement, and prior treatments like chemotherapy and radiation therapy. None of these details are provided in the patient note.\n\n3. The trial excludes patients with metastatic breast cancer (stage IV disease), which is not mentioned in the patient note.\n\n4. The trial has specific requirements for laboratory values, performance status, and comorbidities, which are not addressed in the patient note.\n\n5. The trial excludes patients with certain prior malignancies, but the patient note does not provide any information about the patient's cancer history.\n\nTherefore, based on the limited information provided in the patient note, this patient would not meet the eligibility criteria for this specific breast cancer clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "394": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Adult patients admitted for cardiac surgery at department of cardiothoracic surgery, Rigshospitalet, Denmark\n\nBased on the patient note, the 85-year-old man was brought to the emergency room, and there is no mention of him being admitted for cardiac surgery. Therefore, he does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "395": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which is outside the age range of 18-50 specified in the inclusion criteria for this clinical trial on PTSD development.\n\n2. The patient was brought to the ER due to a gradual decrease in consciousness over the past 3 days, not immediately after a traumatic event as required by the inclusion criteria.\n\n3. There is no mention of the patient experiencing a traumatic event that would meet the criteria for PTSD in the DSM-IV-TR (criteria A1, A2, and at least 1 from criteria B).\n\n4. The clinical trial is specifically looking at predictors of PTSD development after a recent traumatic event, which does not seem to be the case for this 85-year-old patient with decreasing consciousness.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial on using hair cortisol levels to predict PTSD development.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "396": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER with a gradual decrease in consciousness over the past 3 days. He stopped walking and eating by himself during this time.\n\n2. The clinical trial is titled \"Non-invasive Measuring of Cerebral Perfusion After Severe Brain Injury With Near-infrared-spectroscopy and ICG\". The purpose is to detect secondary ischemic events in patients with severe brain injury or cerebral hemorrhage using non-invasive near-infrared spectroscopy.\n\n3. The inclusion criteria for the trial are:\n   - Patients over 18 years old\n   - Onset of clinical symptoms of subarachnoid or intracranial hemorrhage or trauma suffered less than 72 hours\n   - Indication for implanting a tissue oxygen and intracranial pressure probe\n   - Signed informed consent by the patient or legal guardian\n\n4. Based on the patient note, the 85-year-old man meets the age criteria (over 18 years old). However, there is no mention of a subarachnoid or intracranial hemorrhage or trauma within the past 72 hours. The note only states that he was involved in a car accident 3 weeks prior, with a normal head CT at that time.\n\n5. Without clear evidence of a recent brain injury or hemorrhage, it is unlikely that this patient would meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "397": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER due to a gradual decrease in consciousness, stopped walking and eating by himself in the last 3 days.\n\n2. The clinical trial is titled \"Continuous Video- EEG Monitoring in the Acute Phase in Patients With a Cerebrovascular Attack- Randomisation of a Subpopulation Regarding Treatment Strategy\".\n\n3. The trial aims to study the occurrence of subclinical epileptiform discharges in patients with ischemic or hemorrhagic cerebrovascular attacks and their impact on functional outcome and mortality.\n\n4. The inclusion criteria specifically mention \"Patients with ischemic arteria cerebri media infarct and spontaneous intraparenchymal bleeding\".\n\n5. Based on the limited information provided in the patient note, it is unclear if the patient had an ischemic stroke or a hemorrhagic stroke.\n\n6. The patient note mentions a history of a car accident 3 weeks prior, but no details are provided about any potential head injury or stroke at that time.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "398": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Patient at least 18 years of age presenting with a symptomatic chronic subdural hematoma\"\n   - The patient is 85 years old, which meets the age requirement.\n   - The patient is presenting with a gradual decrease in level of consciousness, which could be a symptom of a chronic subdural hematoma.\n\n2. \"Chronic subdural hematoma verified on cranial CT or MRI\"\n   - The patient note does not explicitly mention a CT or MRI scan confirming the presence of a chronic subdural hematoma.\n\nBased on the information provided, the patient meets the age requirement and has symptoms that could be indicative of a chronic subdural hematoma. However, there is no confirmation of the diagnosis through imaging studies.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation, specifically a cranial CT or MRI scan to verify the presence of a chronic subdural hematoma.",
        "label": 1
    },
    "399": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, while the inclusion criteria specify \"Female 50 or older\". So the patient does not meet the gender requirement.\n\n2. There is no mention of the patient having a diagnosis of overactive bladder (OAB), which is one of the inclusion criteria.\n\n3. The other inclusion criteria like English literacy, ability to swallow oral medication, and cognitive ability to give consent are not clearly stated for this patient.\n\nBased on the information provided, this 85-year-old man does not seem to meet the key inclusion criteria of being a female aged 50 or older with a diagnosis of overactive bladder.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "400": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: All male and female patients who have been prescribed for the first time either Rivaroxaban or standard of care from the date of market authorization of rivaroxaban to Dec 31, 2017\n\nBased on the patient note provided, there is no mention of the patient being prescribed Rivaroxaban or any other anticoagulant medication. The note focuses on the patient's gradual decrease in consciousness level and inability to walk or eat in the last 3 days.\n\nSince the inclusion criteria specifically require patients who have been prescribed Rivaroxaban or a standard anticoagulant for the first time, and there is no information about the patient receiving such medication, it is unlikely that this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "401": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man presenting with a gradual decrease in level of consciousness and inability to walk or eat by himself over the past 3 days.\n\n2. The clinical trial is titled \"Memory Aid - Working Memory Training in Patients With Mild Cognitive Impairment.\"\n\n3. The inclusion criteria for the trial are:\n   - Patients who meet the Peterson diagnostic criteria of MCI\n   - Memory complaints (preferably confirmed by an informant)\n   - Memory impairment according to age and education\n   - Preserved general cognitive function\n   - Intact activities of daily living\n   - Absence of dementia\n\n4. Based on the patient note, the 85-year-old man is presenting with a decrease in level of consciousness and inability to perform activities of daily living like walking and eating. This suggests a more severe cognitive impairment than mild cognitive impairment (MCI).\n\n5. Additionally, the patient's symptoms seem to have an acute onset over the past 3 days, which is not typical of MCI.\n\n6. Therefore, this patient would likely not meet the inclusion criteria for the \"Memory Aid - Working Memory Training in Patients With Mild Cognitive Impairment\" trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "402": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of being an adult \u2265 18 years old, but exceeds the upper age limit of < 76 years old for this trial.\n\n2. The patient is admitted to the ER, which is not one of the specified units (MICU, SICU) for this trial.\n\n3. There is no mention of a surrogate being present to provide informed consent.\n\n4. There is no RASS score or CAM assessment mentioned to determine if the patient meets the criteria of RASS >-3, < +1 and being CAM positive.\n\n5. It is not specified if the patient has enteral access.\n\nBased on the information provided, there are several inclusion criteria that are not met or cannot be determined from the patient note. The patient's age exceeds the upper limit, and it is unclear if they meet the other criteria related to delirium assessment, unit admission, and enteral access.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "403": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of \u226518 years for the clinical trial.\n\n2. The patient is not currently intubated or on mechanical ventilation, which is a requirement for the trial. However, the note mentions a gradual decrease in consciousness, which could potentially lead to intubation and mechanical ventilation.\n\n3. There is no information provided about the expected time on a ventilator, but the gradual decrease in consciousness suggests it may be longer than 24 hours if intubation is required.\n\n4. There is no mention of whether informed consent has been obtained or is possible to obtain.\n\nBased on the information provided, it is unclear if the patient would meet all the inclusion criteria for the clinical trial. More information is needed regarding intubation status, expected time on mechanical ventilation, and ability to provide informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "404": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, so he meets the age criteria for most clinical trials.\n\n2. However, the clinical trial you provided is specifically looking at cough symptoms and mechanisms related to cough. The patient note does not mention any cough or respiratory symptoms.\n\n3. The inclusion criteria state that patients must demonstrate significant cough symptoms by scoring greater than 20/70 on the Hull Airways Reflux Questionnaire. There is no information provided about the patient's score on this questionnaire.\n\n4. The inclusion criteria also require patients to be current non-smokers, have stable medication for at least one month, be able to attend the trials unit on multiple occasions, have normal lung function, and be able to provide informed consent.\n\n5. The patient note does not provide enough information to determine if the patient meets these additional inclusion criteria related to smoking status, medication, ability to attend the trial, lung function, or ability to provide consent.\n\nBased on the information provided, it does not seem likely that this 85-year-old patient with a gradual decrease in consciousness and no reported cough or respiratory symptoms would be eligible for this specific clinical trial investigating the mechanism of inhalation cough challenge.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "405": {
        "output": "To determine the patient's eligibility for the clinical trial \"Cognitive Impairment and Balance in Elderly\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n- Nursing home residents.\n\nBased on the patient note, there is no mention of the patient being a nursing home resident. The note states that an 85-year-old man was brought to the ER, but it does not specify if he is a nursing home resident or not.\n\nWithout having information about the patient's living situation, it is difficult to determine if he meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo make a more definitive assessment, we would need additional information about whether the patient is a nursing home resident or not. If he is a nursing home resident, then he would likely be eligible for the trial. However, if he is not a nursing home resident, then he would not meet the inclusion criteria based on the information provided.",
        "label": 0
    },
    "406": {
        "output": "To determine the patient's eligibility for the clinical trial \"The DETEcT Study - Delirium in Elderly paTiEnts Admitted to Trauma\", let's go through the inclusion criteria:\n\nInclusion criteria: Patients with any medical condition with an age of 65 years and older\n\nThe patient note states that the patient is an 85-year-old man, which meets the age requirement of 65 years and older.\n\nBased on the information provided in the patient note, the patient seems to be eligible for this clinical trial as he meets the inclusion criteria of being 65 years or older.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "407": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which does not meet the age criteria for any of the groups in the inclusion criteria. The age ranges specified are 21-45 for cognitively normal subjects, \u226550 for clinically diagnosed AD/possible AD, \u226560 for MCI, and \u226575 for at-risk elderly subjects.\n\n2. The patient's cognitive status is not clearly stated, but it is mentioned that he has had a gradual decrease in level of consciousness and stopped walking/eating by himself in the last 3 days. This suggests some form of cognitive impairment, but it's unclear if it meets criteria for dementia/AD or MCI.\n\n3. No MMSE score is provided to assess cognitive function based on the trial's MMSE criteria.\n\n4. No information is given about the patient's ApoE4 carrier status.\n\nBased on the limited information provided, it does not seem highly likely that this 85-year-old patient would meet all the inclusion criteria for any of the specified groups in this trial focused on calibrating florbetapir PET imaging to the centiloid scale across different cognitive states.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "408": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of being over 60 years old for this clinical trial on postoperative delirium in elderly patients.\n\n2. The patient's condition of gradual decrease in level of consciousness and stopping walking/eating could potentially be related to postoperative delirium, which is the focus of this study.\n\n3. However, the inclusion criteria specifically state that patients must be undergoing scheduled surgery. The patient note does not mention any upcoming scheduled surgery.\n\n4. The patient note also does not provide information about the patient's ASA physical status or whether they can provide informed consent.\n\nBased on the information provided, there are some factors that could make the patient eligible (age, potential delirium symptoms), but the lack of details around an upcoming scheduled surgery makes it difficult to definitively assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether they are scheduled for an upcoming surgery and can provide informed consent.",
        "label": 0
    },
    "409": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which falls outside of the age range (18-55 years) specified in the inclusion criteria for this clinical trial.\n\n2. The trial is looking for healthy, non-pregnant subjects who are able to run 5km within a certain time frame based on their age and gender. This patient's gradual decrease in level of consciousness and inability to walk or eat by himself suggests he would not meet the \"healthy\" criteria or be able to complete the 5km run requirement.\n\n3. There is no mention of the patient taking any supplements or medications that would exclude him, but his overall health status makes him ineligible regardless.\n\n4. The trial is specifically studying the effects of a nutritional supplement on athletic performance and oxidative damage in runners. This patient's condition does not align with the goals of the study.\n\nBased on the provided patient note and inclusion/exclusion criteria for the clinical trial, this patient would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "410": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, so he does not meet the inclusion criteria of being a post-stroke patient within 2 months of a cerebrovascular attack.\n\n2. There is no mention of the patient having upper limb apraxia or any other stroke-related symptoms. The symptoms described (gradual decrease in consciousness, stopped walking and eating) seem more indicative of a different condition unrelated to stroke.\n\n3. The inclusion criteria specifically require upper limb apraxia lasting at least 2 months and a score less than 9 on the Apraxia Screen of TULIA, but there is no information provided about the patient meeting these criteria.\n\nBased on the information given, this patient does not appear to meet the key inclusion criteria for the \"Functional Rehabilitation of Upper Limb Apraxia in Patients Poststroke\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "411": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of \u226565 years for the clinical trial.\n\n2. The patient is brought to the ER because of a gradual decrease in consciousness and inability to walk or eat by himself in the last 3 days. This suggests a potential hip fracture or other condition requiring hip fracture surgery.\n\n3. The patient is willing to complete the study, as there is no information indicating otherwise.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to meet all the listed criteria for participation.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "412": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of being elderly (>65 years old) for the clinical trial.\n\n2. The clinical trial is looking for frail elderly patients undergoing non-cardiac surgery under anesthesia lasting for >60 minutes. The patient note does not mention any upcoming surgery, so this inclusion criterion is not met.\n\n3. The patient is experiencing a gradual decrease in level of consciousness and stopped walking and eating by himself in the last 3 days. This could potentially indicate frailty, but more information would be needed to confirm if he meets the criteria for being considered \"frail\" for this study.\n\n4. The patient is willing and able to complete the requirements of the study. However, since he has a decreased level of consciousness, it is unclear if he would be able to complete the study requirements.\n\nBased on the information provided, there are some uncertainties around whether this patient fully meets the inclusion criteria for the clinical trial on postoperative delirium in frail elderly patients undergoing non-cardiac surgery.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "413": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which does not meet the age inclusion criteria of 18-55 years old for this clinical trial on post-traumatic stress disorder (PTSD).\n\n2. There is no mention of the patient having PTSD or any trauma exposure in the patient note. The note describes a gradual decrease in consciousness and stopping walking/eating, which seems unrelated to PTSD.\n\n3. The exclusion criteria specifically exclude medical or neurological illnesses likely to affect physiology or anatomy, which the patient seems to have based on the gradual decrease in consciousness and functional abilities.\n\n4. There is no information provided about the patient meeting any of the other inclusion criteria for PTSD patients or healthy controls.\n\nBased on the available information, this 85-year-old patient with a gradual decrease in consciousness and functional abilities does not appear eligible for this clinical trial on PTSD due to not meeting the age criteria and having a potentially confounding medical condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "414": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which falls outside the age range of 40-85 years specified in the inclusion criteria.\n\n2. There is no mention of the patient participating in contact sports or having a history of concussions, which is a key inclusion criterion.\n\n3. The patient is not described as having mild cognitive impairment (MCI) or being a healthy control.\n\n4. There is no mention of the patient having a study partner.\n\nBased on the information provided in the patient note, this patient does not meet the key inclusion criteria for the clinical trial on amyloid and tauopathy PET imaging in acute and chronic traumatic brain injury.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "415": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which does not meet the age inclusion criteria of 60 years or older for this cardiac surgery trial.\n\n2. There is no mention of the patient undergoing or planning to undergo cardiac surgery like CABG or valve replacement.\n\n3. The patient's presenting symptoms of gradual decrease in consciousness, stopping walking and eating, with no fever, cough, rash or diarrhea, do not seem directly related to the trial's focus on postoperative delirium after cardiac surgery.\n\n4. The trial is specifically looking at using dexmedetomidine to prevent postoperative delirium in cardiac surgery patients, which does not appear relevant to this patient's current condition.\n\nBased on the information provided, this 85-year-old patient with altered mental status and functional decline does not meet the key inclusion criteria for this cardiac surgery delirium prevention trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "416": {
        "output": "To determine the patient's eligibility for the clinical trial \"Postoperative Delirium in Hip Arthroplasty Patients\", let's go through the inclusion criteria one by one:\n\n1. Male or female: The patient is male, so this criterion is met.\n2. Between 30 and 80 years of age: The patient is 85 years old, which is outside the specified age range. This criterion is not met.\n3. ASA I, II or III: There is no information provided about the patient's ASA (American Society of Anesthesiologists) physical status classification, so it is unclear if this criterion is met or not.\n4. Capable and willing to consent: There is no information provided about the patient's ability to consent, so it is unclear if this criterion is met or not.\n5. Participants literate in English language: There is no information provided about the patient's literacy in English, so it is unclear if this criterion is met or not.\n\nBased on the information given, the patient does not meet the age criterion for this clinical trial. Additionally, there is not enough information to determine if the other criteria are met or not.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "417": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of being 75 years or older for this clinical trial on elderly patients with acute abdominal pain.\n\n2. However, the patient is not presenting with acute abdominal pain. The note mentions a gradual decrease in level of consciousness and stopping walking/eating, but no abdominal pain symptoms.\n\n3. The note also does not indicate any traumatic pain or mention the duration of symptoms being less than a week, so the exclusion criteria are not clearly met or violated.\n\n4. Overall, while the patient's age fits the inclusion criteria, the lack of acute abdominal pain being the chief complaint makes them ineligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "418": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man presenting with a gradual decrease in level of consciousness over the past 3 days, along with stopping walking and eating by himself.\n\n2. The clinical trial is titled \"Comparison of Dexmedetomidine and Propofol on the Delirium and Neuroinflammation in Patients With SIRS.\"\n\n3. The summary mentions assessing the effects of dexmedetomidine and propofol on delirium and neuroinflammation in patients with systemic inflammatory response syndrome (SIRS) using the CAM-ICU scale and serum protein S100b.\n\n4. The only inclusion criterion provided is the presence of delirium.\n\n5. Based on the patient note, there is no explicit mention of delirium or SIRS. The gradual decrease in level of consciousness could potentially indicate delirium, but more information would be needed to confirm this.\n\nGiven the limited information provided in the patient note and the specific inclusion criterion of the presence of delirium, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "419": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion criteria: presence of delirium\n\nFrom the patient note, it mentions that the 85-year-old man has a \"gradual decrease in his level of consciousness\" and \"stopped walking and eating by himself\" in the last 3 days. These symptoms suggest that the patient may be experiencing delirium.\n\nHowever, the note does not explicitly state that the patient has been diagnosed with delirium. More information would be needed to confirm if the patient meets the inclusion criteria of \"presence of delirium.\"\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "420": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of 60 years and older for the clinical trial.\n\n2. The patient is described as having a gradual decrease in level of consciousness, stopped walking and eating by himself, which could indicate frailty, meeting that inclusion criteria.\n\n3. The patient is being brought to the ER, so it's unclear if he is undergoing elective surgery, which is an inclusion criteria for the trial.\n\n4. It's also unclear if the patient is expected to remain admitted for at least 2 postoperative days, another inclusion criteria.\n\nBased on the information provided, there are some uncertainties around whether the patient meets all the inclusion criteria, specifically regarding undergoing elective surgery and expected length of stay.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "421": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER due to a gradual decrease in level of consciousness, stopped walking and eating by himself in the last 3 days.\n\n2. The clinical trial is titled \"Intelligent Intensive Care Unit\" and is studying delirium detection using movement data from wearable sensors and facial recognition systems in ICU patients.\n\n3. The inclusion criteria for ICU patients are:\n   - Intensive care unit patient\n   - 18 years of age or older\n\n4. The patient meets the age criteria (85 years old) but it's not explicitly stated if he is an ICU patient or not.\n\n5. Based on the information provided, it seems likely that an 85-year-old man brought to the ER with a decreased level of consciousness would be admitted to the ICU.\n\nTherefore, considering the patient's age and the likelihood of being admitted to the ICU, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "422": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which does not meet the age inclusion criteria of \"children aged 2 through 17 years (17 years included)\".\n\n2. The patient does not have a suspected long bone fracture, which is a requirement based on the inclusion criteria \"suspected fracture of a long bone requiring morphine analgesia\".\n\n3. The trial is studying the analgesic efficacy of different drug combinations for long bone fractures in children, which does not seem relevant to the patient's gradual decrease in consciousness.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "423": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which does not meet the age criteria of 12-36 months for this clinical trial on using modified ride-on cars to improve mobility and socialization in young children with disabilities.\n\n2. There is no information provided about the patient having any motor delays or impairments that prevented functional independent mobility like rolling, crawling or walking. \n\n3. The patient's presenting complaint seems to be a gradual decrease in level of consciousness over the past 3 days, which is likely unrelated to the goals of this pediatric clinical trial.\n\n4. Based on the information given, this 85-year-old patient would not be eligible for enrollment in this particular clinical trial focused on young children with motor delays/impairments.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "424": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who was brought to the ER due to a gradual decrease in consciousness and inability to walk or eat by himself in the last 3 days.\n\n2. The clinical trial is titled \"Clinical Relevance of Microbleeds In Stroke\" and is studying patients with non-valvular atrial fibrillation (AF) who are starting oral anticoagulants after a cardioembolic stroke.\n\n3. The inclusion criteria for the trial are:\n   - Adult (\u226518y; no upper limit) patients with a clinical diagnosis of non-valvular AF (verified by ECG)\n   - Previous ischemic stroke or TIA diagnosed by treating clinician\n   - Able to have GRE MRI before (or within 1 week) of starting best practice oral anticoagulant\n\n4. Based on the patient note, there is no mention of the patient having atrial fibrillation or a previous ischemic stroke/TIA. The note only states that the patient had a normal head CT 3 weeks prior after a car accident.\n\n5. Without meeting the key inclusion criteria of having non-valvular AF and a previous ischemic stroke/TIA, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "425": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. ICU patients aged \u226518 years: The patient is 85 years old, so this criterion is met.\n\n2. Surgical, medical, neurology/neurosurgical, or trauma patients: The patient is a medical patient brought to the ER due to a gradual decrease in consciousness level, so this criterion is likely met.\n\nBased on the provided information, the patient seems to meet the inclusion criteria for the clinical trial titled \"DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "426": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man who has experienced a gradual decrease in level of consciousness and stopped walking and eating by himself in the last 3 days.\n\n2. The clinical trial is about examining the feasibility of combining modified ride-on cars with bimanual training on mobility, socialization, and motor function in toddlers with disabilities aged between 12-36 months.\n\n3. The inclusion criteria for the trial specifically mention:\n   - Motor delays (sd>1.5) resulting in impaired functional independent mobility\n   - Aged between 12-36 months\n   - Able to tolerate sitting with support for 30 minutes\n   - Able to reach objects with one or two hands\n   - Parental consent\n\n4. Given that the patient is an 85-year-old man and the trial is focused on toddlers aged 12-36 months with motor delays, this patient clearly does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "427": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of \u226575 years for the clinical trial.\n\n2. The patient was brought to the ER because of a gradual decrease in his level of consciousness and stopped walking and eating by himself in the last 3 days. This could potentially indicate acute dyspnea, which is one of the inclusion criteria.\n\n3. However, the patient note does not explicitly mention breathe rate, PaO2, SpO2, or PaCO2 levels, which are required to confirm acute dyspnea based on the inclusion criteria.\n\n4. The patient note also does not mention if the patient was in sinus rhythm at admission, which is another inclusion criterion.\n\n5. Without the specific vital sign information and rhythm status, it is difficult to definitively determine if the patient meets all the inclusion criteria for acute dyspnea.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of vital signs and rhythm status at admission.",
        "label": 1
    },
    "428": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of being 65 years or older for the clinical trial.\n\n2. The patient is being hospitalized, which implies they would be eligible to be hospitalized at the Acute Geriatric Unit where the trial is taking place.\n\n3. There is no mention of whether informed consent was obtained, so we cannot definitively say if this inclusion criteria is met or not.\n\n4. The key factor is that the patient is presenting with a gradual decrease in level of consciousness over the past 3 days, which could potentially be delirium - the main condition the trial is trying to study interventions for.\n\nGiven that the patient meets the age criteria, is hospitalized which implies they could be at the trial site, and their symptoms are potentially related to delirium which is the focus of the trial, I would assess:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWe would need more information to definitively determine if informed consent could be obtained, as well as get a formal delirium assessment done. But based on the available information, this patient seems like they could potentially be eligible and should be considered for the trial after some additional evaluation.",
        "label": 0
    },
    "429": {
        "output": "To determine the patient's eligibility for the clinical trial \"Ramelteon Prevention of Delirium - RCT\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n- from designated nursing units\n\nThe patient note does not mention if the patient is from a designated nursing unit or not. However, it states that the 85-year-old man was brought to the emergency room (ER), which suggests he is likely admitted to the hospital.\n\nGiven the limited information provided in the inclusion criteria, and the fact that the patient is an 85-year-old hospitalized individual, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "430": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which does not meet the age criteria for the severe trauma population (age \u226518 to 54) or the elective hip repair population (age \u226518). However, the trial does allow for adults aged 55 and older in the severe trauma population if certain criteria are met.\n\n2. The patient was brought to the ER due to a gradual decrease in level of consciousness and stopped walking/eating in the last 3 days. This does not seem to be related to a severe traumatic injury.\n\n3. The patient was involved in a car accident 3 weeks prior, but had a normal head CT at that time. This suggests he did not sustain severe injuries requiring operative repair from that accident.\n\n4. There is no mention of long bone/pelvic fractures, hemorrhagic shock, or an injury severity score in the patient note.\n\nBased on the information provided, this 85-year-old patient does not appear to meet the inclusion criteria for this clinical trial on hematopoietic stem cell dysfunction after severe injury.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "431": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of \u226555 years for this clinical trial on surgical treatment of low energy pelvic fractures in the elderly.\n\n2. The patient was brought to the ER due to a gradual decrease in level of consciousness and inability to walk/eat by himself over the past 3 days. This could potentially be related to a pelvic fracture from the car accident 3 weeks prior.\n\n3. However, the patient note does not explicitly mention a pelvic fracture or any details about injuries from the car accident. More information is needed to determine if he sustained a pelvic ring fracture affecting the posterior ring or both posterior and anterior rings.\n\n4. The inclusion criteria also specifies that patients must have been ambulatory before surgery. The note does not provide information about the patient's ambulatory status prior to this current decline.\n\nBased on the limited information provided in the patient note, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore details are needed about any pelvic/ring fractures from the prior car accident, as well as the patient's pre-injury ambulatory status, in order to definitively determine eligibility for this surgical pelvic fracture trial in the elderly.",
        "label": 0
    },
    "432": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 85-year-old man, which meets the age criteria of being over 18 years old for the clinical trial.\n\n2. The patient is being admitted to the ER, which suggests he may need intensive care, making him potentially eligible for admission to the ICU.\n\n3. However, the clinical trial is specifically studying delirium in the ICU setting, and there is no mention of the patient having delirium or being admitted to the ICU yet.\n\n4. The information provided is not sufficient to determine if the patient will definitely be admitted to the ICU and develop delirium there.\n\nTherefore, based on the limited information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "433": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Written informed consent: This is not mentioned in the patient note, so we cannot make a determination.\n\n2. \u2265 65 years of age: The patient is 85 years old, so this criterion is met.\n\n3. Scheduled to undergo elective cardiac surgery (coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery) with the use of CPB: There is no mention of the patient being scheduled for cardiac surgery in the patient note.\n\n4. Both genders: The patient's gender is not specified, but this criterion is likely met.\n\nSince we do not have information about whether the patient is scheduled for cardiac surgery or has provided informed consent, we cannot definitively determine eligibility based on the given information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "434": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 36-year-old woman, which meets the inclusion criteria of being an adult patient.\n\n2. The patient has a suspected gestational trophoblastic neoplasia (vesicular mole or fibroid degeneration), which is the target condition for this clinical trial.\n\n3. The patient has not received any prior chemotherapy for gestational trophoblastic neoplasia, meeting that inclusion criteria.\n\n4. The patient's lab values (complete blood count and biochemical profile) are within the specified limits for the trial.\n\n5. The ultrasound findings of an enlarged uterus with cystic areas are consistent with the condition being studied in the trial.\n\n6. The patient has undergone at least one uterine curettage, as required by the inclusion criteria.\n\nBased on the information provided, this patient appears to meet all the major inclusion criteria for the clinical trial studying methotrexate versus dactinomycin for gestational trophoblastic neoplasia.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "435": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 36-year-old woman, which falls within the age range of 33-50 specified in the inclusion criteria.\n\n2. She is presenting with symptoms suggestive of a uterine fibroid, including amenorrhea, vaginal spotting, abdominal tenderness, nausea, and vomiting. The ultrasound also shows an enlarged uterus with cystic areas, which is consistent with the differential diagnosis of a vesicular mole or fibroid degeneration.\n\n3. The inclusion criteria specifically state that women with a history of uterine fibroids causing symptoms of bleeding, pressure, or pain are eligible for the trial.\n\n4. The patient does not appear to meet any of the exclusion criteria listed, such as pregnancy, lactation, recent use of hormonal medications, or a history of malignancy.\n\n5. However, the patient's desire for fertility is not mentioned, and the inclusion criteria state that participants should have no desire for fertility and be willing to undergo a hysterectomy.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation of her fertility desires and willingness to undergo a hysterectomy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "436": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 36-year-old premenopausal woman, which meets the age and premenopausal criteria for the clinical trial.\n\nShe has a diagnosis of uterine fibroids confirmed by ultrasound, which meets one of the key inclusion criteria.\n\nHer menstrual history is not explicitly stated, but the 12 weeks of amenorrhea suggests her cycles were likely in the 17-42 day range prior to this episode.\n\nThe other health details provided don't indicate any exclusionary conditions. Her scheduled hysterectomy at the end of the treatment period also meets an inclusion criteria.\n\nThe negative pregnancy test is noted, meeting that criteria. Contraception agreement and Pap test results are not mentioned.\n\nThe endometrial biopsy results are not provided, but the differential diagnosis suggests no significant histological disorder is likely.\n\nOverall, based on the information given, this patient appears to meet most of the key inclusion criteria for the uterine fibroid clinical trial evaluating asoprisnil.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of a few remaining criteria like contraception agreement, Pap test results, and endometrial biopsy findings.",
        "label": 1
    },
    "437": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women that have completed 6 months of treatment in study C02-037 with no more than a 7-day interruption in their treatment\n- The patient note does not mention if the patient was part of the previous study C02-037, so this criterion cannot be evaluated.\n\n2. Otherwise good health\n- The patient note states that apart from the current symptoms, the complete blood count and biochemical profile are normal, suggesting the patient is otherwise in good health.\n\n3. Premenopausal based on Estrogen and Follicle Stimulating Hormone levels\n- The patient is a 36-year-old woman, which suggests she is likely premenopausal, but her hormone levels are not provided.\n\n4. Agrees to double-barrier method of contraception\n- There is no information about the patient's willingness to use contraception.\n\n5. Adequate endometrial biopsy with no significant histological disorder\n- No information is provided about an endometrial biopsy for this patient.\n\nOverall, while the patient seems to have uterine fibroids or a related condition based on the ultrasound findings, there is not enough information provided to definitively determine if she meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "438": {
        "output": "To determine the patient's eligibility for the clinical trial \"Detection of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Hydatidiform Mole\n2. Choriocarcinoma\n3. Gestational Trophoblastic Neoplasms\n\nBased on the patient note, the differential diagnosis includes vesicular mole or fibroid degeneration. A vesicular mole is a type of hydatidiform mole, which is one of the inclusion criteria for this clinical trial.\n\nWhile the diagnosis is not confirmed yet, the patient's presentation with amenorrhea, vaginal spotting, enlarged uterus with cystic areas, and negative pregnancy test is highly suggestive of a gestational trophoblastic disease like a hydatidiform mole.\n\nTherefore, considering the strong suspicion of a condition that meets the inclusion criteria, I would assess the patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "439": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subject with uterine fibroids, who desire pregnancy within 12 months and has the one of the following criteria: \n   - The patient is a 36-year-old woman, which falls within the age range of 20-40 years.\n   - The patient desires pregnancy, as evidenced by the 12 weeks of amenorrhea.\n\n2. Use or non-use of non-steroidal treatments for excessive vaginal bleeding has been maintained for the three months prior and the patient has agreed to maintain this through the 6-month follow-up period.\n   - There is no mention of the patient using any non-steroidal treatments.\n\n3. Clinically normal PAP smear within timing of National Guidelines in the country of the clinical site.\n   - There is no information provided about the patient's PAP smear results.\n\n4. Able and willing to give consent and able to attend all study visits\n   - Assuming the patient is willing to give consent and attend study visits, this criterion is likely met.\n\n5. Able to communicate sensations during the MRgFUS procedure\n   - There is no information provided about the patient's ability to communicate sensations.\n\n6. Having uterine fibroids that are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone).\n   - The ultrasound report mentions an enlarged uterus with multiple cystic areas, which could be indicative of uterine fibroids.\n\n7. Tumor(s) are clearly visible on non-contrast MRI.\n   - There is no information provided about an MRI scan.\n\n8. Largest fibroid 8 cm in diameter or 12 cm if receiving GnRH\n   - The ultrasound report mentions the uterus being 12 cm x 9 cm x 7 cm, which could potentially meet this criterion.\n\nBased on the information provided, there are some criteria that are potentially met (age, desire for pregnancy, possible uterine fibroids), but there are also several criteria for which there is not enough information to make a definitive assessment (PAP smear results, ability to communicate sensations, MRI visibility, fibroid size).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "440": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Persistent or recurrent low risk Gestational Trophoblastic Tumor (GTT)\n- The patient has an enlarged uterus with cystic areas, which could potentially be a gestational trophoblastic disease like a vesicular mole. However, it's not definitively diagnosed as a GTT yet. This criterion is possibly met but needs further investigation.\n\n2. WHO score 2-6 (re-evaluated at the time of relapse)\n- There is no information provided about the WHO score for this patient.\n\n3. Histologically confirmed complete or partial moles on initial evacuation\n- No information is provided about whether the patient had an evacuation procedure or histological confirmation of a mole.\n\n4. Patients with mild to moderate renal insufficiency should avoid taking NSAIDs...\n- This is just providing guidance about NSAID use, not an inclusion criterion.\n\n5. Folic Acid (350-1000 micrograms) must be given daily...\n- This is just stating requirements for folic acid supplementation if enrolled, not an inclusion criterion.\n\n6. Vitamin B12 (1000 micrograms) will be administered...\n- This is just stating requirements for vitamin B12 supplementation if enrolled, not an inclusion criterion.\n\nBased on the limited information provided in the patient note, it's difficult to definitively determine eligibility for this trial. More diagnostic information is needed to confirm if the patient has a gestational trophoblastic tumor and assess risk status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "441": {
        "output": "Based on the patient note provided, the 36-year-old woman is presenting with symptoms suggestive of a possible gestational trophoblastic disease (GTD) such as a vesicular mole or fibroid degeneration. However, the clinical trial titled \"The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy\" is focused on improving skin self-examination accuracy for detecting skin lesions or moles.\n\nSince the patient's condition is not related to skin lesions or moles, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "442": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient is a 36-year-old woman presenting with symptoms suggestive of a possible molar pregnancy or fibroid degeneration, which does not seem to be related to the clinical trial for treating recurrent herpes labialis.\n\nThe inclusion criteria for the clinical trial specify:\n1. Patients aged 18 years or older (the patient meets this criterion)\n2. A history typical for recurrent herpes labialis with at least 3 episodes in the last 12 months, prodromal symptoms, and vesicular lesions (the patient note does not mention any history of herpes labialis)\n3. Good general health without serious medical conditions (the patient seems to have a potential gynecological condition that needs further evaluation)\n4. Appropriate contraceptive use for women of childbearing potential (not mentioned in the patient note)\n5. Negative pregnancy test for women of childbearing potential (the patient had a negative pregnancy test, but this may be due to the early gestational age or a possible molar pregnancy)\n\nBased on the information provided, the patient does not seem to meet the inclusion criteria for this clinical trial, as there is no mention of a history of recurrent herpes labialis, which is a key requirement.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "443": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 36-year-old woman presenting with vaginal bleeding, abdominal tenderness, nausea, and vomiting. The ultrasound shows an enlarged uterus with cystic areas, and the differential diagnosis includes a vesicular mole or fibroid degeneration.\n\nThe clinical trial is studying the treatment of uterine fibroids, comparing laparoscopic occlusion of uterine vessels to uterine fibroid embolization.\n\nThe key inclusion criterion for this trial is \"Menorrhagia and/or bulk symptoms associated with uterine fibroids\".\n\nWhile the patient is experiencing vaginal bleeding and abdominal symptoms, the differential diagnosis includes a vesicular mole, which is not a uterine fibroid. Additionally, the ultrasound findings of cystic areas in the uterus are more suggestive of a molar pregnancy rather than fibroids.\n\nTherefore, based on the information provided, this patient does not clearly meet the inclusion criteria for this clinical trial on uterine fibroids.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "444": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Natural History Study of Moles and Suspicious Melanoma\", this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient is a 36-year-old woman presenting with symptoms related to a potential pregnancy complication (vesicular mole or fibroid degeneration), which is not relevant to the study of moles and melanoma.\n\n2. The inclusion criteria specifically mention infants/children with large congenital melanocytic nevus, adults with multiple moles (\u2265100 moles >2mm), or adults with a suspicious pigmented lesion for melanoma. This patient does not meet any of these criteria.\n\nTherefore, based on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "445": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 36-year-old woman, which meets the age criteria of being at least 18 years old and premenopausal.\n\n2. The patient has an enlarged uterus (12 cm x 9 cm x 7 cm) with multiple cystic areas, which could indicate the presence of uterine leiomyomas (fibroids). However, the differential diagnosis also includes a vesicular mole.\n\n3. The inclusion criteria specifically state that the patient must have a confirmed diagnosis of leiomyoma by ultrasound, and at least one leiomyoma must be equal to or greater than 2 cm in diameter, with the uterus enlarged to the size typical during the eighth week of pregnancy.\n\n4. While the patient's uterus is enlarged, there is no definitive confirmation of leiomyomas yet, as the differential diagnosis includes a vesicular mole.\n\n5. Based on the available information, it is unclear if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to confirm the presence of leiomyomas and rule out other conditions like a vesicular mole.",
        "label": 1
    },
    "446": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 36-year-old woman, which falls within the age range of 30-50 years old specified in the inclusion criteria.\n\nShe is presenting with symptoms caused by a potential uterine fibroid, including vaginal bleeding, abdominal tenderness, nausea, and vomiting. The ultrasound shows an enlarged uterus with cystic areas, which could be indicative of uterine fibroids. This matches the inclusion criteria of \"Symptoms caused by uterine fibroids, such as heavy bleeding (menorrhagia) and/or bulk-related complaints such as urinary frequency, constipation or pelvic pain.\"\n\nThe patient has fibroids confirmed by ultrasound, although an MRI is not explicitly mentioned in the patient note. However, this could potentially be ordered for further confirmation.\n\nThere is no mention of kidney function in the patient note, but this could be assessed if needed.\n\nThe patient is presenting to the emergency department, so her willingness and ability to undergo follow-up imaging at 3 and 6 months post-procedure is not explicitly stated.\n\nBased on the information provided, it seems that this patient could potentially be eligible for the clinical trial, but further investigation may be needed to confirm the diagnosis of uterine fibroids via MRI, assess kidney function, and determine the patient's willingness and ability to undergo follow-up imaging.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "447": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female presenting with symptoms like spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia after returning from a trip where she attended a stray animal recovery campaign.\n\n2. The clinical trial titled \"Human Movement Database\" is collecting information on different ways people control limb and body movements, including those with diseases that affect movement patterns.\n\n3. The inclusion criteria for this trial is very broad - \"Any volunteer of any age from birth to old age who is deemed medically fit to participate and is willing to provide their informed consent will be included in the study.\"\n\n4. Given the patient's presenting symptoms and the broad inclusion criteria of the trial, it seems highly likely that this patient could be referred for participation in this \"Human Movement Database\" trial.\n\nHer abnormal movement patterns and symptoms would provide valuable data for the study's goal of developing a database on adaptive movements in those with diseases affecting movement.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "448": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing and marked hydrophobia.\n\n2. The clinical trial is focused on idiopathic familial voice disorders, specifically spasmodic dysphonia and vocal fold paralysis.\n\n3. The inclusion criteria for the trial require symptoms present during speech but not at rest, symptoms less evident during whisper/singing/falsetto, symptoms worsening with prolonged speaking/practice/anxiety, and reflexive/emotional aspects of voice function unaffected.\n\n4. The exclusion criteria rule out airway obstruction history, structural laryngeal abnormalities, reduced vocal fold movement range during non-speech tasks, smoking/tobacco use, and psychiatric disorders.\n\n5. Based on the patient's presenting symptoms, which seem to be more systemic and not specifically related to voice/speech issues, they do not appear to meet the inclusion criteria for this voice disorder study.\n\n6. Additionally, the symptoms of spastic arm movements, sweating, agitation/anxiety, malaise, difficulty swallowing and hydrophobia would likely exclude the patient under the psychiatric disorder exclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "449": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of being 21 years or older for the clinical trial.\n\n2. The patient does not have a diagnosis of essential tremor, which is a requirement for the clinical trial. The patient's symptoms (spastic arm movements, sweating, agitation, malaise, difficulty swallowing, and hydrophobia) are more indicative of a different condition, possibly an infection or neurological disorder.\n\n3. The patient's medical history and current condition are not clearly described as being related to essential tremor or any other neurological disease besides the tremor-like symptoms.\n\n4. There is no information provided about the patient's medication history or whether they meet the criteria of not taking medications for essential tremor or any other medical condition for at least 2 weeks.\n\n5. There is no information provided about the patient's alcohol consumption or whether they meet the criteria of not consuming alcohol or cold medications containing alcohol for at least 24 hours prior to the study.\n\n6. There is no information provided about the patient's pregnancy or lactation status, or their use of birth control if they are of childbearing age.\n\n7. There is no information provided about the patient's thyroid, liver, kidney, or chronic lung disease status.\n\nBased on the limited information provided, it is unlikely that this patient would be eligible for the clinical trial on 1-octanol for essential tremor.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "450": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which does not violate any of the inclusion/exclusion criteria listed for this clinical trial on constraint-based therapy for children with cerebral palsy.\n\n2. However, the patient note does not mention a diagnosis of cerebral palsy or hemiparetic cerebral palsy, which is a key inclusion criterion.\n\n3. The symptoms described (neck/shoulder pain, paresthesias, tremors, spasticity, spastic arm movements, sweating, agitation, malaise, difficulty swallowing, hydrophobia) are more consistent with a potential diagnosis of rabies rather than cerebral palsy.\n\n4. There is no indication that the patient has one arm/side significantly more impaired than the other, which is a core premise of constraint-induced movement therapy.\n\n5. The patient does not appear to be a pediatric case, as the trial specifies treatment for children with cerebral palsy.\n\nGiven this analysis, the appropriate assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "451": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of being 21 years or older for the clinical trial.\n\n2. The patient does not have a diagnosis of essential tremor, which is a requirement for the clinical trial. Her symptoms (spastic arm movements, sweating, agitation, malaise, difficulty swallowing, and hydrophobia) are more indicative of a different condition, possibly an infection or neurological disorder.\n\n3. The clinical trial excludes patients with chronic medical conditions, and while the patient's condition is not explicitly stated as chronic, her symptoms suggest a potentially serious medical issue.\n\n4. The clinical trial excludes patients of Asian or Pacific Islander descent, and the patient's ethnicity is not specified.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial on essential tremor, and her symptoms suggest a potentially serious medical condition that would likely exclude her from participating.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "452": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of being an adult (>21 years old) for the clinical trial.\n\n2. The clinical trial is studying the bioavailability of 1-octanol in adults with ethanol-responsive essential tremor. The patient note does not mention essential tremor or any tremor at all. The symptoms described (neck and shoulder pain, left hand and arm paresthesias, spastic arm movements, sweating, agitation, malaise, difficulty swallowing, and hydrophobia) do not seem consistent with essential tremor.\n\n3. The inclusion criteria specifically state \"Patients with alcohol-responsive Essential Tremor\" and \"Limb involvement should be a prominent feature of the Essential tremor\". Based on the patient note, there is no indication that the patient has essential tremor or that their symptoms respond to alcohol.\n\n4. The exclusion criteria also list \"Patients with abnormalities other than tremor on neurological exam\", which seems to apply to this patient who is exhibiting various neurological symptoms beyond just tremor.\n\nBased on the information provided, this patient does not appear to meet the key inclusion criteria for the clinical trial and exhibits some exclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "453": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) \"They must be at least six months post-stroke.\" - The patient note does not mention a stroke, so this criterion is not met.\n\n2) \"18 years of age or older with a clinical diagnosis of hemiparesis (as verified by medical record and a medical expert).\" - The patient is 28 years old, but there is no mention of hemiparesis or a stroke diagnosis.\n\n3) \"They have voluntary control with a low to medium range of motion function (UE-FT<5) and a muscle tone.\" - There is no information about the patient's range of motion function or muscle tone.\n\n4) \"They are functionally stable (no significant changes in motor function over a week) and are able to tolerate being seated upright for 90 minutes.\" - No information is provided about the patient's functional stability or ability to be seated upright for 90 minutes.\n\n5) \"They report no excessive pain the impaired arm.\" - The patient note does not mention any impaired arm or excessive pain.\n\n6) \"If left neglect or spasticity is detected in the impaired arm, these levels must not interfere with the ability to cognitively complete the tasks or turn a wheel.\" - No information is provided about left neglect, spasticity, or the ability to complete tasks or turn a wheel.\n\n7) \"They must not be participating in any experimental rehabilitation or drug therapies.\" - No information is provided about the patient participating in any experimental therapies.\n\n8) \"If subjects are receiving chemical injections for spasticity, they must be at least 3-months away from their last treatment.\" - No information is provided about the patient receiving chemical injections for spasticity.\n\n9) \"They must have driven prior to stroke.\" - The patient note does not mention a stroke or the patient's driving history.\n\n10) \"They are not clinically depressed (as measured by the Geriatric Depression Scale (GDS) short form (Sheikh and Yesavage, 1986).\" - No information is provided about the patient's depression status or GDS score.\n\nBased on the lack of information provided in the patient note that matches the inclusion criteria for this clinical trial, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "454": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of \u226518 years old for the clinical trial.\n\n2. The patient does not have a history of stroke, which is a key inclusion criterion for this trial investigating post-stroke spasticity of the upper limb.\n\n3. The patient's symptoms (spastic arm movements, sweating, agitation, difficulty swallowing, hydrophobia) are more indicative of a potential viral infection like rabies rather than post-stroke spasticity.\n\n4. There is no mention of the patient having any prior botulinum toxin treatments, which is an exclusion criterion for treatment-naive patients in this trial.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial investigating incobotulinumtoxinA for post-stroke upper limb spasticity.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "455": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of being 18 years or older.\n\n2. The patient does not have a diagnosis of multiple sclerosis or any other condition that would cause upper extremity spasticity. The symptoms described (spastic arm movements, sweating, agitation, difficulty swallowing, hydrophobia) are more consistent with a possible viral infection like rabies.\n\n3. The inclusion criteria specifically require unilateral upper limb spasticity of at least 6 months duration, as well as meeting criteria for a certain level of hand impairment. This patient's symptoms are acute and do not appear to be related to upper limb spasticity or hand impairment.\n\n4. The other inclusion criteria regarding ability to answer yes/no questions, follow instructions, use birth control if applicable, etc. cannot be determined from the provided patient note.\n\nBased on the information given, this patient does not meet the key inclusion criteria of having upper extremity spasticity and hand impairment related to a chronic neurological condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "456": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of 18-70 years old for the clinical trial.\n\n2. The patient's symptoms (spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia) do not seem to be related to a stroke, which is a requirement for this clinical trial focused on post-stroke spasticity.\n\n3. There is no mention of the patient having a history of stroke or any unilateral, upper-limb focal spasticity pattern of the wrist and fingers, which is another key inclusion criterion.\n\n4. The patient's symptoms seem to be more indicative of a potential viral or infectious condition, rather than a post-stroke condition.\n\n5. Based on the information provided, this patient does not meet the key inclusion criteria of having a history of stroke and post-stroke spasticity in the wrist and fingers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "457": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria for most clinical trials.\n\n2. The clinical trial is for treating alcohol withdrawal with oral baclofen. However, the patient note does not mention any alcohol use or withdrawal symptoms.\n\n3. The patient is exhibiting symptoms like spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia, which are not typical of alcohol withdrawal.\n\n4. The patient's symptoms seem more consistent with a neurological condition or possible infection, rather than alcohol withdrawal syndrome.\n\n5. The inclusion criteria specifically state that participants must meet the DSM-IV criteria for alcohol withdrawal syndrome and have an alcohol withdrawal score sufficient to trigger benzodiazepine therapy.\n\nBased on the information provided, this patient does not appear to meet the inclusion criteria for this particular clinical trial on treating alcohol withdrawal with oral baclofen.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "458": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Subjects free of obvious health-problems or with stable condition\"\n   - The patient is exhibiting symptoms of a potential rabies infection, which is a serious health problem. This criterion is not met.\n\n2. \"Male or female subjects aged \u226519 to \u226465 years\"\n   - The patient is 28 years old, which falls within the age range. This criterion is met.\n\n3. \"BMI between \u226518 and \u226430 kg/m2\"\n   - There is no information provided about the patient's BMI, so we cannot determine if this criterion is met or not.\n\nGiven the patient's symptoms, which are highly suggestive of a potential rabies infection, and the fact that the clinical trial is evaluating a treatment for rabies, it is highly likely that this patient would be eligible for the trial.\n\nHowever, one of the inclusion criteria (BMI) cannot be fully assessed due to lack of information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "459": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range of 12-18 months specified in the inclusion criteria. However, the trial is looking for toddlers, not adults.\n\n2. The patient is presenting with symptoms consistent with rabies infection, such as spastic arm movements, sweating, agitation, difficulty swallowing, and hydrophobia.\n\n3. The trial is focused on pre-exposure rabies vaccination in healthy toddlers, not treatment for active rabies infection.\n\n4. There is no mention of the patient being in good health or available for follow-up visits, as required by the inclusion criteria.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "460": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria for the malaria vaccine trial (1-4 years old).\n2. However, the patient does not appear to be from Mali or the surrounding area of Bancoumana, which is an inclusion criteria for this trial.\n3. The patient is exhibiting symptoms like spastic arm movements, sweating, agitation, malaise, difficulty swallowing, and hydrophobia, which could indicate a neurological or infectious disease. These would likely exclude the patient from the trial based on the exclusion criteria.\n4. There is no mention of the patient having malaria or being at risk for malaria, which is the target disease for this vaccine trial.\n\nBased on the information provided, this patient does not meet the key inclusion criteria for the malaria vaccine trial and exhibits potential exclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "461": {
        "output": "Based on the patient note provided, the 28-year-old female patient does not appear to have any symptoms related to chronic functional constipation in children, which is the focus of the clinical trial titled \"Physiotherapeutic Intervention in Children With Chronic Functional Constipation.\"\n\nThe patient's presenting symptoms, such as neck and shoulder pain, left hand and arm paresthesias, spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia, are not consistent with the inclusion criteria for this clinical trial, which specifically mentions symptoms like infrequent defecation, fecal incontinence, retentive behavior, pain during defecation, and hard stools.\n\nTherefore, based on the information provided, this patient would not be eligible for the clinical trial on physiotherapeutic intervention for chronic functional constipation in children.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "462": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age inclusion criteria of 18-60 years old for this rabies vaccine clinical trial.\n\n2. The patient is exhibiting symptoms consistent with a potential rabies infection, including spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. This suggests she may have been exposed to rabies during the stray animal recovery campaign in California.\n\n3. The inclusion criteria state that participants should not have received any previous rabies vaccination, which is not mentioned for this patient.\n\n4. There are no other clear exclusion criteria mentioned for this patient based on the note provided.\n\n5. Given the patient's symptoms suggestive of potential rabies exposure, her age meeting the criteria, and no clear exclusions, she would likely be a good candidate for this clinical trial evaluating a new rabies vaccine.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "463": {
        "output": "Okay, let's go through the inclusion criteria for the \"Brain Computer Interface (BCI) Based Robotic Rehabilitation for Stroke\" clinical trial and assess the eligibility of the patient based on the given note.\n\nDemographics: 21 to 65 years, within 12 months of first, single clinical stroke (ischaemic or haemorrhagic).\n- The patient note does not mention a stroke, so this criterion is not met.\n\nModerate to severe upper extremity (UE) weakness post stroke.\n- Since there is no mention of a stroke, this criterion is also not met.\n\nFugly-Meyer motor score of the upper limb < 40.\n- No Fugly-Meyer motor score is provided in the patient note.\n\nUpper limb motor power MRC grade 3 or less /5 in at least 1 arm region.\n- The patient note mentions left hand and arm paresthesias (abnormal sensations), but no specific information about motor power or weakness is given.\n\nAble to give own consent and understand simple instructions and learn through practice.\n- This criterion is likely met based on the information provided.\n\nResting brain states determined by FMRI criteria\n- No information about FMRI criteria is provided in the patient note.\n\nOverall, based on the information given in the patient note, it does not appear that this patient would be eligible for the \"Brain Computer Interface (BCI) Based Robotic Rehabilitation for Stroke\" clinical trial, as there is no mention of a stroke or upper extremity weakness resulting from a stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "464": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the inclusion criteria of being an adult (age \u2265 18 years).\n\n2. The patient's race/ethnicity is not explicitly stated, but the inclusion criteria specify \"African American (3 of 4 grandparents are of African Descent)\". We cannot determine if the patient meets this criteria based on the information provided.\n\n3. There is no information about the patient's residence or plans to move, so we cannot assess if she meets the criteria of \"Lives in designated census area\" and \"No plans to move in the next two years\".\n\n4. The patient does not seem to have a medical condition that would limit participation in moderate intensity exercise, based on the information provided.\n\n5. There is no information about the patient's availability to participate in measures and intervention activities over the next 2 years.\n\nGiven the incomplete information about the patient's race/ethnicity, residence, and availability, I would consider referring this patient to the clinical trial upon further investigation to determine if she meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "465": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of being 18 years or older.\n\n2. The patient is exhibiting symptoms that could potentially be related to rabies exposure, such as spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia.\n\n3. The inclusion criteria specifically mention that laboratory personnel, epidemiologists, EISOs, veterinary students, interns, and other first responders at CDC, as well as other CDC employees and healthy volunteer adults who report occupational exposure to rabies, will be selected for the study.\n\n4. While the patient note does not explicitly state that the patient had an occupational exposure to rabies, her recent attendance at a stray animal recovery campaign in California could potentially put her at risk for rabies exposure.\n\n5. The inclusion criteria also require participants to be in good health, able to understand and comply with study procedures, provide informed consent, and have health insurance.\n\nBased on the information provided, there are some potential indicators that the patient may be eligible for this clinical trial, such as her age and possible rabies exposure. However, there are also some uncertainties, such as whether her attendance at the stray animal recovery campaign would be considered an occupational exposure and whether she meets the other health-related criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "466": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of >=2 months to <18 years for this pediatric trial.\n\n2. There is no mention of the patient being pregnant or having childbearing potential, so we can assume she meets that inclusion criteria.\n\n3. The patient recently returned from a trip to California, which is not an area where Japanese Encephalitis (JE) is endemic. The trial requires that subjects plan to travel to a JE endemic area after completing the vaccination schedule.\n\n4. There is no information provided about whether the patient plans to travel to a JE endemic area in the future.\n\nGiven the limited information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her future travel plans to JE endemic areas.",
        "label": 0
    },
    "467": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range (18-50 years) specified in the inclusion criteria.\n\n2. The patient initially presented with neck and shoulder pain, left hand and arm paresthesias, which are not exclusionary conditions for this trial.\n\n3. However, the patient was later hospitalized with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia. These symptoms are not consistent with the ETEC infection that the vaccine is intended to prevent.\n\n4. The inclusion criteria specify that participants should be in general good health without clinically significant medical history or physical examination findings. The patient's symptoms upon hospitalization suggest a significant medical condition that would likely preclude participation.\n\n5. Additionally, the exclusion criteria state that the presence of a significant medical or psychiatric condition that precludes participation is grounds for exclusion.\n\nBased on the information provided, the patient's symptoms upon hospitalization suggest a significant medical condition that would likely exclude them from participating in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "468": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Postoperative Distress and Cosmetic Outcomes After Open Versus Robotic Thyroidectomy\", it appears that the patient does not have a thyroid condition or cancer. The patient's symptoms suggest a possible neurological condition or infection, which is not relevant to the inclusion criteria of the thyroid surgery trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "469": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria for the trial.\n2. The patient does not have a diagnosis of multiple sclerosis (MS). The trial requires a diagnosis of non-relapsing MS (primary progressive or secondary progressive).\n3. The patient's symptoms (spastic arm movements, sweating, agitation, difficulty swallowing, hydrophobia) do not seem to be related to MS, but rather suggest a different condition.\n4. There is no mention of the patient having reduced use of one hand due to MS, which is an inclusion criterion for the trial.\n5. The other inclusion criteria, such as the ability to travel to the treatment location, undergo treatment for 2 weeks, and undergo an MRI scan, are not addressed in the patient note.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of having a diagnosis of non-relapsing MS and reduced use of one hand due to MS.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "470": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age inclusion criteria of 18-55 years old.\n\n2. The patient's symptoms (spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia) are consistent with a potential rabies virus infection after attending a stray animal recovery campaign and traveling to California. \n\n3. The clinical trial is evaluating the safety and efficacy of a monoclonal antibody cocktail (CL184) in combination with rabies vaccines for post-exposure prophylaxis in healthy adults.\n\n4. While the patient's current condition is serious and requires immediate treatment, if she recovers and meets the other inclusion criteria (free of obvious health problems, BMI 18-30 kg/m^2, able to use contraception, etc.), she could potentially be eligible for this trial after receiving initial treatment.\n\nTherefore, based on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "471": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Trial of Levodopa in Angelman Syndrome\", let's go through the inclusion criteria one by one:\n\n1. Age between 4 years and 12 years (i.e., before the 13th birthday)\nThe patient note states that the patient is a 28-year-old female, which does not meet this age criterion.\n\n2. Molecular confirmation of the diagnosis of AS, which may include abnormal methylation studies or UBE3A mutation analyses - only subjects with a molecular diagnosis will be allowed to enroll\nThere is no mention of the patient having Angelman syndrome (AS) or any molecular confirmation of this diagnosis in the patient note.\n\n3. Not on LD, CD, or any dopamine agonists in the 2 weeks prior to participation\nThere is no information provided about the patient's current medications or treatments.\n\nBased on the information given in the patient note, the patient does not seem to meet the inclusion criteria for this clinical trial, as the age and diagnosis requirements are not fulfilled.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "472": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range of 18-60 years specified in the inclusion criteria.\n\n2. The patient note mentions that she attended a stray animal recovery campaign, which could potentially expose her to rabies. However, there is no explicit mention of her receiving a primary rabies immunization in the past.\n\n3. The clinical trial is looking for HIV-infected patients who have previously received a primary rabies vaccination, to study the immune response after a booster vaccination.\n\n4. While the patient note does not confirm whether she has HIV or not, her symptoms of spastic arm movements, sweating, agitation, malaise, difficulty swallowing, and hydrophobia are consistent with potential rabies infection.\n\n5. However, without confirmation of her HIV status and previous primary rabies vaccination, it is difficult to definitively determine her eligibility for this specific trial.\n\nBased on the available information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to confirm the patient's HIV status, whether she received a primary rabies vaccination in the past, and potentially rule out or confirm an active rabies infection. With this additional information, her eligibility could be reassessed.",
        "label": 1
    },
    "473": {
        "output": "Based on the patient note provided, this appears to be a case of suspected rabies infection, given the symptoms of spastic arm movements, sweating, agitation, difficulty swallowing, and hydrophobia (fear of water) following potential exposure to a stray animal.\n\nThe clinical trial you provided is for evaluating malaria vaccine candidates in healthy adults and children in a malaria-endemic region.\n\nGiven that the patient is exhibiting symptoms consistent with a suspected rabies infection, which is not related to malaria, they would not meet the inclusion criteria for this malaria vaccine trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "474": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the \"adult patients\" criteria for the trial.\n\n2. The patient is experiencing spasticity in her left arm and hand, which aligns with the trial's focus on \"upper limb adult spasticity\".\n\n3. However, the patient's spasticity does not seem to be caused by a stroke, which is a requirement stated in the inclusion criteria \"Adult patients with upper limb spasticity following a stroke\".\n\n4. Additionally, the patient has not received any previous botulinum toxin Type A therapy, which meets the \"No previous botulinum toxin Type A therapy\" criteria.\n\nBased on the information provided, while the patient meets some of the inclusion criteria, the fact that her spasticity is not caused by a stroke would likely make her ineligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "475": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria (40-80 years old) for the healthy control group, but not the stroke patient group.\n\n2. The patient does not appear to have had a stroke based on the note. The symptoms described (neck/shoulder pain, paresthesias, tremors, spasticity, agitation, difficulty swallowing, hydrophobia) are more consistent with a potential infectious process like rabies than a stroke.\n\n3. The trial is specifically looking at enriched environments for upper limb stroke rehabilitation. Since this patient does not seem to have had a stroke, she would not be eligible for the stroke patient arm of the study.\n\n4. However, she could potentially meet criteria for the healthy control group if she has no other neurological or orthopedic problems that may interfere with interpretation of results (which is not clearly stated in the note).\n\nIn summary, while the patient may meet criteria for the healthy control group pending further evaluation, she would not be eligible for the stroke patient arm of this particular clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation (as a potential healthy control subject).",
        "label": 0
    },
    "476": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age inclusion criteria of 18-60 years old.\n\n2. The patient's symptoms (spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia) suggest a possible infection or reaction related to her recent travel and exposure to stray animals. \n\n3. The clinical trial is evaluating the safety and immunogenicity of travel vaccines when given alone or with another vaccine (MenACWY-CRM).\n\n4. One of the inclusion criteria is that the participants must be healthy. Given the patient's current symptoms and hospitalization, she would likely not be considered healthy at this time.\n\n5. Another inclusion criterion is availability for all study visits and calls. With the patient's current condition requiring hospitalization, her availability is uncertain.\n\nBased on the information provided, while the patient's age meets the criteria, her current health status and uncertain availability make her ineligible for this particular clinical trial at the moment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "477": {
        "output": "Okay, let's think through this step-by-step:\n\n1. The patient is a 28-year-old female presenting with symptoms consistent with rabies infection, including spastic arm movements, sweating, agitation, difficulty swallowing, and hydrophobia.\n\n2. The clinical trial is studying the immune response to a new rabies vaccine (SPEEDA) as pre-exposure prophylaxis (PrEP) and simulated post-exposure prophylaxis (PEP) in healthy adults.\n\n3. The inclusion criteria for the trial are:\n   - Healthy\n   - Can visit according to the protocol\n\n4. Given the patient's symptoms strongly indicative of rabies infection, she would not meet the \"healthy\" inclusion criteria for this vaccine trial.\n\n5. Additionally, her current medical condition would likely prevent her from being able to visit according to the protocol schedule.\n\nTherefore, based on the provided information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "478": {
        "output": "Based on the patient note provided, this 28-year-old female appears to be exhibiting symptoms consistent with rabies infection, such as spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia (fear of water). The note mentions that she attended a stray animal recovery campaign in California, which could have potentially exposed her to rabies.\n\nGiven that the clinical trial you provided is for a malaria vaccination strategy in infants and children aged 5-17 months in Burkina Faso, this patient would not be eligible for this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "479": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which does not violate any of the inclusion criteria provided.\n\n2. The patient does not have a spinal cord injury, which is a key requirement for this clinical trial. The patient's symptoms (neck and shoulder pain, left hand and arm paresthesias, spastic arm movements, sweating, agitation, malaise, difficulty swallowing, and hydrophobia) are not indicative of spinal cord injury.\n\n3. The inclusion criteria specifically state \"Incomplete traumatic Spinal Cord Injury (at least 18 months prior and stable for 6 months)\" and \"Moderate to severe lower-limb spasticity\". The patient does not meet these criteria.\n\nBased on the information provided, this patient would not be eligible for the clinical trial titled \"Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "480": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the inclusion criteria of being an adult (age \u2265 18 years).\n\n2. The patient does not have a diagnosis of stroke or any other neurological condition mentioned in the note. The note describes symptoms like spastic arm movements, sweating, agitation, difficulty swallowing, and hydrophobia, which are more indicative of a potential infection or disease like rabies rather than a stroke.\n\n3. The inclusion criteria specifically state \"first episode of unilateral stroke\" and \"time since stroke less than 3 months, i.e., acute or subacute stage\". Based on the patient note, there is no mention of the patient having a stroke.\n\n4. The other inclusion criteria like initial motor part of upper limb FMA score and Mini Mental State Exam score cannot be evaluated from the given patient note.\n\nTherefore, based on the information provided, this patient would not be eligible for the clinical trial titled \"Effects of Intensive Robot-assisted Therapy in Patients With Subacute Stroke\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "481": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female presenting with symptoms like spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia after returning from a trip where she attended a stray animal recovery campaign.\n\n2. The clinical trial is about evaluating the protective effect of a rabies vaccine called Speeda\u00ae.\n\n3. The inclusion criteria for the trial are:\n   - Parent/legal representatives willing to provide informed consent for children, or adult participants able to provide consent themselves\n   - Participant considered in good health based on medical history and physical examination, living locally for at least 12 months before the injury\n   - The animal that caused the injury can be found and tested for the rabies virus\n\n4. Based on the patient's symptoms like hydrophobia, spastic movements, and the context of attending a stray animal recovery campaign, it is highly likely that the patient has been exposed to rabies.\n\n5. The patient meets the inclusion criteria of being an adult able to provide consent, being in relatively good health before the incident, and living locally for at least 12 months.\n\n6. The only potential issue is whether the animal that caused the exposure can be found and tested, but given the severity of the patient's symptoms, it is reasonable to assume rabies exposure.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "482": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range of 2-17 years specified in the inclusion criteria for this clinical trial. So this criterion is not met.\n\n2. The patient is exhibiting symptoms consistent with a potential rabies infection, such as spastic arm movements, sweating, agitation, difficulty swallowing, and hydrophobia. \n\n3. The clinical trial is studying the immunogenicity and safety of a rabies vaccine in healthy children and adolescents aged 2-17 years who have not been exposed to rabies.\n\n4. Since this patient is exhibiting symptoms of a potential rabies infection, she would likely not be eligible for a pre-exposure prophylaxis trial of a rabies vaccine.\n\nTherefore, based on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "483": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range of 18-80 years specified in the inclusion criteria.\n\n2. The patient is exhibiting symptoms of tremors, spasticity, agitation, anxiety, and difficulty swallowing, which could potentially be related to a movement disorder like essential tremor (ET).\n\n3. However, the inclusion criteria specifically state that the diagnosis of ET should be confirmed by a movement disorder neurologist based on clinical history and examination. The patient note does not mention an official diagnosis of ET.\n\n4. Additionally, the inclusion criteria require that the patient's tremor should be refractory to at least two medications, one of which should be either propranolol or primidone. The patient note does not provide any information about previous medication trials for tremor.\n\n5. The inclusion criteria also require that the Vim nucleus of the thalamus should be apparent on MRI for targeting with the ExAblate device. The patient note does not mention any MRI findings or the suitability of the patient's brain anatomy for the procedure.\n\n6. While the patient is exhibiting some symptoms that could potentially be related to ET, there is not enough information provided in the patient note to determine if they meet all the specific inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "484": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the inclusion criteria of being an adult patient who has suffered a stroke.\n\n2. However, the patient note does not mention that she has suffered a stroke. Instead, it describes symptoms that seem more consistent with rabies, such as hydrophobia, spastic arm movements, and agitation.\n\n3. The inclusion criteria specifically state that patients must have a history of acute stroke within the past 12 months, and this patient does not appear to have had a stroke.\n\n4. Additionally, the trial is focused on hand rehabilitation after stroke, but this patient's symptoms seem to be affecting her entire upper limb and body.\n\n5. Based on the information provided, this patient does not meet the inclusion criteria for this particular clinical trial on robot-assisted hand rehabilitation after stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "485": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which fits the age criteria for the Phase Ia part of the trial (18-45 years).\n\n2. However, the patient note mentions symptoms like spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. These symptoms are not consistent with being in \"general good health\", which is an inclusion criterion.\n\n3. The trial is specifically looking at a malaria vaccine candidate, but the patient's symptoms seem to be unrelated to malaria and more indicative of another condition like rabies or a neurological disorder.\n\n4. There is no mention of the patient living in a malaria-endemic area or having any history of malaria exposure.\n\nBased on the information provided, this patient does not seem eligible for this particular malaria vaccine trial due to her current medical condition and lack of relevant exposure history.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "486": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female presenting with symptoms like spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia after returning from a trip where she attended a stray animal recovery campaign.\n\n2. The clinical trial is evaluating the safety and efficacy of BOTOX (botulinum toxin Type A) in patients treated for primary axillary hyperhidrosis, focal spasticity, or moderate to severe glabellar lines.\n\n3. The inclusion criteria specifically mention patients treated with BOTOX for focal spasticity, which seems to match the patient's symptoms of spastic arm movements.\n\n4. However, the patient's symptoms also suggest a possible infection or exposure to something during the stray animal recovery campaign, which may not be covered by this trial focused on BOTOX safety and efficacy.\n\n5. Given the uncertainty around the underlying cause of the patient's symptoms, I would consider referring this patient to this clinical trial upon further investigation into the diagnosis and ruling out any potential infections or exposures.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "487": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"ASIS for Botox in Upper Limb Spasticity\", here is my assessment:\n\nThe patient is a 28-year-old female presenting with spastic arm movements, tremors, and spasticity, which could potentially be related to upper limb spasticity resulting from a condition like stroke. However, the note does not explicitly mention a history of stroke or confirm the cause of her symptoms.\n\nThe inclusion criteria require adults with a history of stroke resulting in unilateral upper limb focal spasticity, specific Ashworth Scale scores for wrist and finger flexor tone, ability to understand verbal directions, functional disability ratings on the Disability Assessment Scale (DAS), and specific functional task score criteria.\n\nWhile the patient's symptoms suggest upper limb spasticity, the note lacks details on the underlying cause, severity scores, functional disability assessments, and task performance scores required by the inclusion criteria.\n\nTherefore, based on the information provided, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional details regarding the patient's medical history, stroke diagnosis (if applicable), spasticity severity assessments, functional disability evaluations, and task performance scores would be needed to determine definitive eligibility for this specific clinical trial.",
        "label": 0
    },
    "488": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of \"Adult male or female over 40 years of age\" for the clinical trial.\n\n2. However, the patient does not have myopic macular degeneration (MMD), which is a key inclusion criterion for this trial. The patient's symptoms (neck and shoulder pain, left hand and arm paresthesias, spastic arm movements, sweating, agitation, malaise, difficulty swallowing, and hydrophobia) are not consistent with MMD.\n\n3. The trial is specifically looking for patients with MMD, a degenerative disease of the retina, to evaluate the safety and efficacy of transplanting retinal pigment epithelial (RPE) cells derived from stem cells.\n\n4. Since the patient does not have MMD or any other retinal degenerative disease mentioned in the trial summary, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "489": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female who recently returned from a trip to California where she attended a stray animal recovery campaign. This puts her at potential risk for exposure to rabies from handling stray animals.\n\n2. She initially presented with symptoms like neck and shoulder pain, left hand and arm paresthesias, which could be early signs of rabies infection.\n\n3. Her symptoms then progressed to spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and marked hydrophobia (fear of water), which are classic signs of rabies infection.\n\n4. The clinical trial is studying the safety and immunogenicity of two intradermal rabies vaccine regimens, with or without rabies immunoglobulin, in subjects aged 1 year and older.\n\n5. The inclusion criteria for the trial are: healthy males and females aged 1 year or older, individuals/parents/legal guardians who have given written consent, individuals in good health, and individuals who can comply with study procedures.\n\n6. Based on the patient's symptoms and potential exposure to rabies from handling stray animals, she would likely meet the inclusion criteria for this clinical trial studying rabies vaccines.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "490": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of being 16 or older for the clinical trial.\n\n2. The patient does not have a confirmed diagnosis of spastic cerebral palsy, which is a key inclusion criterion for the trial. The symptoms described (spastic arm movements, sweating, agitation, difficulty swallowing, hydrophobia) are more indicative of a potential rabies infection rather than cerebral palsy.\n\n3. The other inclusion criteria such as unilateral or predominantly unilateral motor disability, speech troubles, normal or slightly sub-normal IQ, and no psychiatric disorders cannot be definitively assessed based on the provided patient note.\n\nGiven that the patient does not have a confirmed diagnosis of spastic cerebral palsy, which is a critical inclusion criterion for this particular clinical trial, I would not recommend referring this patient for enrollment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "491": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the inclusion criteria of being an adult.\n2. The patient has symptoms that could potentially be related to rabies exposure, such as spastic arm movements, sweating, agitation, difficulty swallowing, and hydrophobia.\n3. The inclusion criteria do not specify any particular disease or condition, but rather focus on the safety and tolerability of the investigational drug (CV8102) and its combination with a rabies vaccine.\n4. The patient's symptoms and potential rabies exposure make her a relevant candidate for a trial involving a rabies vaccine.\n5. However, the inclusion criteria also mention requirements related to physical examination, laboratory results, BMI, and contraceptive use, which are not provided in the patient note.\n\nBased on the information given, I would consider referring this patient to this clinical trial upon further investigation to determine if she meets the other inclusion criteria related to physical examination, laboratory results, BMI, and contraceptive use.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "492": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range of 18-40 years specified in the inclusion criteria.\n\n2. The patient initially presented with neck and shoulder pain, left hand and arm paresthesias, which are not directly relevant to the rabies vaccine trial.\n\n3. However, the patient later developed symptoms such as spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia, which are consistent with rabies infection.\n\n4. The trial is specifically looking for healthy adults, and the patient's current condition with suspected rabies infection would likely exclude her from participating.\n\n5. While the patient's initial symptoms may have been considered for further investigation, her subsequent development of severe symptoms strongly suggests she would not be eligible for this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "493": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range of 1-15 years specified in the inclusion criteria. However, the inclusion criteria specifically mentions \"healthy children\", and this patient appears to have some concerning symptoms like spastic arm movements, sweating, agitation, difficulty swallowing, and hydrophobia.\n\n2. The patient's symptoms seem to be consistent with a potential rabies exposure, which is relevant to this clinical trial studying a rabies vaccine regimen.\n\n3. The inclusion criteria do not explicitly exclude patients with suspected rabies exposure or symptoms, as long as they are children aged 1-15 years and their parents provide informed consent.\n\n4. However, the patient's symptoms appear quite severe, and she has already been hospitalized. This may make it difficult for her to participate in the study and receive the vaccine regimen as planned.\n\nConsidering these factors, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the patient's age and potential rabies exposure make her relevant for this trial, her severe symptoms and hospitalization status would require further evaluation to determine if she can safely participate and adhere to the study protocol. Additional information from her treating physicians would be needed to make a more definitive assessment.",
        "label": 0
    },
    "494": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which does not violate any of the inclusion criteria provided.\n\n2. The patient does not appear to have had a stroke based on the information given. The symptoms described (spastic arm movements, sweating, agitation, malaise, difficulty swallowing, hydrophobia) are more indicative of a potential infection or neurological condition, rather than a stroke.\n\n3. The inclusion criteria specifically state that participants must have had a first focal unilateral stroke 1-12 months prior to enrollment.\n\n4. There is no mention of the patient being rated on the Chedoke McMaster Stroke Assessment Impairment Inventory, which is another requirement for inclusion.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of having had a stroke within the specified time frame and being rated on the required assessment scale.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "495": {
        "output": "To determine the patient's eligibility for the clinical trial \"Robot Aided Rehabilitation - Multi-joint Evaluations\", let's go through the inclusion criteria one by one:\n\n1. \"First focal unilateral lesion, ischemic or hemorrhagic\"\n   - The patient note does not mention whether the patient had a stroke or the type of lesion, so this criterion cannot be evaluated.\n\n2. \"Had a stroke less than a month prior to enrollment\"\n   - The patient note does not explicitly state that the patient had a stroke, so this criterion cannot be evaluated.\n\n3. \"Rated between stages 1-4 on the Chedoke McMaster Stroke Assessment Impairment Inventory: Stage of Recovery of the Arm\"\n   - The patient note does not provide information about the Chedoke McMaster Stroke Assessment Impairment Inventory score for the arm, so this criterion cannot be evaluated.\n\n4. \"Rated between stages 1-4 on the Chedoke McMaster Stroke Assessment Impairment Inventory: Stage of Recovery of the Hand\"\n   - The patient note does not provide information about the Chedoke McMaster Stroke Assessment Impairment Inventory score for the hand, so this criterion cannot be evaluated.\n\nBased on the information provided in the patient note, it is not possible to determine if the patient meets the inclusion criteria for the clinical trial. The note does not explicitly mention that the patient had a stroke, which is a key requirement for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "496": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of 18-60 years old for the clinical trial.\n\n2. The patient is exhibiting symptoms of rabies infection, such as spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. These symptoms suggest she may have been exposed to rabies during the stray animal recovery campaign in California.\n\n3. The clinical trial is studying the immunogenicity and effectiveness of different dosing schedules and administration routes for rabies pre-exposure prophylaxis.\n\n4. Since the patient is potentially infected with rabies and exhibiting symptoms, she would not be eligible for a pre-exposure prophylaxis trial, as she has likely already been exposed.\n\n5. The inclusion criteria state that participants must be in good health based on medical history and physical examination, which this patient does not meet due to her rabies-like symptoms.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "497": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range of 18-85 years specified in the inclusion criteria.\n\n2. The patient does not have a diagnosis of essential tremor, which is a key inclusion criterion for this clinical trial. The symptoms described (spastic arm movements, sweating, agitation, difficulty swallowing, hydrophobia) are more suggestive of a condition like rabies rather than essential tremor.\n\n3. The trial is specifically for deep brain stimulation (DBS) surgery for essential tremor, and the patient does not have this condition.\n\n4. There is no mention of the patient's motor skills or ability to complete evaluations, which is another inclusion criterion.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial on DBS for essential tremor.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "498": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range of 2-100 specified in the inclusion criteria.\n\n2. The patient is exhibiting symptoms such as spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. These symptoms are not consistent with cervical dystonia or spasmodic torticollis, which is the target condition for this clinical trial.\n\n3. The inclusion criteria specifically state that the patient must have a clinical diagnosis of cervical dystonia or spasmodic torticollis, which this patient does not appear to have.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial titled \"Effect of Osteopathic Manipulative Medicine on Motor Function and Quality of Life in Cervical Dystonia.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "499": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female presenting with symptoms like spastic arm movements, sweating, agitation, difficulty swallowing, and hydrophobia after returning from a trip where she attended a stray animal recovery campaign.\n\n2. The clinical trial titled \"Palestinian Perineum and Birth Complication Study\" is focused on assessing complications associated with pregnancy and delivery, as well as interventions used during labor.\n\n3. The inclusion criteria for this trial are:\n   - All midwives and physicians working on the labor ward in the participating hospitals\n   - All women giving birth in the participating hospitals\n   - Both genders are included in the staff and among the newborns\n\n4. Based on the patient note provided, this patient does not seem to be pregnant or giving birth. Her symptoms also do not appear to be related to pregnancy or delivery complications.\n\n5. Therefore, this patient would not meet the inclusion criteria for the \"Palestinian Perineum and Birth Complication Study\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "500": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which falls within the age range of 10-60 years old specified in the inclusion criteria.\n\n2. The patient appears to be exhibiting symptoms consistent with rabies infection, such as spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia.\n\n3. The trial is specifically for evaluating the safety and immunogenicity of a rabies vaccine in healthy Chinese subjects.\n\n4. While the patient's current condition is likely due to a rabies infection, the trial is looking for healthy subjects to test the vaccine's safety and efficacy.\n\n5. Given the patient's current symptomatic state, she would not be considered a healthy subject suitable for this particular trial.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "501": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of 18-60 years old for the clinical trial.\n\n2. The patient is exhibiting symptoms that could be indicative of rabies infection, such as spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. These symptoms suggest a potential rabies exposure.\n\n3. The inclusion criteria for the clinical trial require HIV-infected patients who have previously received primary rabies immunization.\n\n4. While the patient note does not explicitly state that the patient is HIV-positive, it also does not rule out this possibility.\n\n5. The patient note does not mention whether the patient has received primary rabies immunization in the past.\n\nGiven the information provided, there are some uncertainties regarding the patient's eligibility for this clinical trial. However, based on the patient's age and potential rabies exposure, it would be reasonable to consider referring this patient to the clinical trial upon further investigation of their HIV status and previous rabies immunization history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "502": {
        "output": "Analyzing the patient note and the clinical trial inclusion criteria:\n\nThe patient is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. These symptoms do not align with the inclusion criteria of the clinical trial, which requires individuals without a current or past history of neck pain and the ability to lie on their back or stomach without difficulty.\n\nThe patient's symptoms suggest a potential neurological condition or infection, which would exclude her from participating in a trial evaluating the effects of cervicothoracic manipulation and passive stretching on individuals without recent neck pain complaints.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "503": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 28-year-old female, which meets the age criteria of \u226518 to \u226460 years old.\n\n2. The patient is exhibiting symptoms consistent with a potential rabies exposure, such as spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia.\n\n3. The trial is evaluating the effect of antimalarial drugs on the immune response to the rabies vaccine when given for post-exposure prophylaxis.\n\n4. The inclusion criteria state that participants must be in good general health based on medical history and physical exam. While the patient's current symptoms are concerning, her medical history prior to this incident is not provided.\n\n5. The other inclusion criteria of providing informed consent and being willing to comply with study procedures cannot be assessed from the given information.\n\nBased on the available information, it seems reasonable to consider referring this patient to the clinical trial upon further investigation into her medical history and overall health status prior to the potential rabies exposure.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "504": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Effectiveness of Radial Extracorporeal Shockwave Therapy on Tennis Elbow\", this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient's symptoms (spastic arm movements, sweating, agitation, malaise, difficulty swallowing, and hydrophobia) do not align with the condition of interest, which is tennis elbow or lateral epicondylitis.\n\n2. The inclusion criteria specifically mention lateral elbow pain lasting for more than 3 months, pain induced by compression on the lateral epicondyle or common extensor tendon, and pain with certain wrist and elbow movements. The patient's symptoms do not seem to match these criteria.\n\nTherefore, based on the information provided, this patient would not be a suitable candidate for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "505": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male with common variable immunodeficiency (CVID), which is a primary immunodeficiency disorder.\n\n2. The clinical trial is studying primary immunodeficiency diseases, including trying to identify genetic mutations and evaluating the course of these diseases over time.\n\n3. One of the key inclusion criteria is \"Patients with a clinical history or signs and symptoms suggestive of a primary immune deficiency syndrome and their family members are eligible for inclusion in this study.\"\n\nSince the patient has CVID, which is a primary immunodeficiency disorder, he meets this key inclusion criteria.\n\n4. There are no clear exclusion criteria that would exclude this patient based on the information provided.\n\nTherefore, based on the patient having a confirmed primary immunodeficiency disorder (CVID) and meeting the key inclusion criteria, I would assess:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "506": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Epi Cystic Hydatid Disease Peru\", this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient's condition is related to a ruptured liver abscess, which is not relevant to the cystic hydatid disease caused by the Echinococcus granulosus parasite that the trial is studying.\n\n2. The inclusion criteria specify that participants should be living in the study area (Cooperative Tupac Amaru) and be older than five years old. There is no information provided about the patient's location or age that would meet these criteria.\n\nTherefore, based on the available information, this patient does not seem to be a suitable candidate for the \"Epi Cystic Hydatid Disease Peru\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "507": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male with common variable immunodeficiency (CVID), which matches one of the key inclusion criteria for the clinical trial.\n\n2. The patient presented with acute abdominal pain, fever, and dehydration, which led to the discovery of a ruptured liver abscess that required surgical drainage. This does not seem to be directly related to the gut inflammation associated with CVID that the trial is studying.\n\n3. The inclusion criteria specify that patients must have chronic diarrhea or involuntary weight loss of more than 5% over the past year. The patient note does not mention either of these symptoms.\n\n4. The exclusion criteria rule out patients with certain clinical chemistry values, low blood cell counts, active infections requiring IV antibiotics, and a history of certain conditions like cancer, hepatitis, HIV, and tuberculosis. The patient note does not provide enough information to determine if the patient meets these exclusion criteria.\n\n5. Overall, while the patient has CVID which is a key inclusion criterion, there is not enough information provided to definitively determine if they meet all the inclusion criteria or none of the exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "508": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID). This matches the inclusion criteria of the clinical trial, which includes patients with \"disorders of immunoglobulin production\" such as CVID.\n\n2. The patient presented with acute abdominal pain, fever, and dehydration, which required exploratory laparotomy and drainage of a ruptured liver abscess. While this is a serious condition, it does not necessarily exclude the patient from the clinical trial.\n\n3. The clinical trial aims to investigate gene abnormalities in Primary Immune Deficiency (PID) disorders, including CVID, to improve diagnosis and treatment. The patient's CVID diagnosis makes them a potential candidate for this study.\n\n4. The inclusion criteria state that there is no limit on age, sex, race, or disability, and the patient meets these criteria.\n\n5. The exclusion criteria mention acquired abnormalities like HIV, chemotherapy, and malignancy, which do not apply to this patient's case.\n\nBased on the information provided, this patient meets the inclusion criteria for the clinical trial and does not have any apparent exclusion criteria.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "509": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the age criteria of 18-90 years old.\n\n2. The patient has a ruptured liver abscess that required surgical drainage, which meets the inclusion criteria of \"Abscess formation or abdominal cyst scheduled to drainage.\"\n\n3. There is no information provided about the patient's plasma creatinine level, so we cannot confirm if they meet that criteria or not.\n\n4. There is also no information provided about whether the patient provided written informed consent.\n\nBased on the information given, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWe would need to confirm the patient's plasma creatinine level and obtain written informed consent before definitively referring them to the trial. However, the patient does meet some of the key inclusion criteria based on the details provided.",
        "label": 1
    },
    "510": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the inclusion criteria of being 18 years or older.\n\n2. The patient does not have a diagnosis of biliary tract cancer. The note mentions a history of common variable immunodeficiency (CVID) and a ruptured liver abscess.\n\n3. The inclusion criteria specifically require a diagnosis of unresectable biliary tract cancer that is amenable to radiotherapy and without visceral metastases.\n\n4. Since the patient does not have biliary tract cancer, they would not meet the disease characteristics inclusion criteria for this clinical trial.\n\n5. The other inclusion criteria related to performance status, lab values, prior therapies, etc. are not relevant since the primary disease criterion is not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "511": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which does not match the inclusion criteria of being a child with ruptured appendicitis.\n\n2. The patient has a history of common variable immunodeficiency (CVID) and presented with acute abdominal pain, fever, and dehydration.\n\n3. Imaging showed hepatomegaly and free intraperitoneal fluid, and exploratory surgery revealed a ruptured liver abscess, not a ruptured appendicitis.\n\n4. Based on the information provided, this patient does not meet the inclusion criteria for the clinical trial on ruptured appendicitis in children.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "512": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 48-year-old male with common variable immunodeficiency (CVID), which is a primary humoral immunodeficiency. This matches one of the key inclusion criteria for the clinical trial.\n\nThe patient has not received any prior immunoglobulin substitution therapy, which is another key inclusion criterion.\n\nThe patient's IgG level is not mentioned, but it is stated that he has CVID, which typically results in low IgG levels. This suggests he likely meets the inclusion criterion of IgG level < 5 g/L at screening.\n\nThere is no mention of the patient having any serious infections, bleeding disorders, secondary immune disorders, or conditions that would interfere with the study. So he does not seem to meet any of the key exclusion criteria.\n\nBased on the information provided, this patient appears to meet the key eligibility criteria for the clinical trial on Vivaglobin\u00ae in previously untreated patients with primary immunodeficiency.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "513": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which falls within the age range (18-75 years) specified in the inclusion criteria.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not explicitly mentioned in the inclusion criteria. However, the criteria state that patients with at least one focal liver lesion, either identified or suspected, are eligible.\n\n3. The patient presented with acute abdominal pain, fever, and dehydration, and an exploratory laparotomy revealed a ruptured liver abscess, which was surgically drained.\n\n4. A liver abscess can be considered a focal liver lesion, as mentioned in the inclusion criteria under \"Abscess\".\n\n5. The patient underwent an exploratory laparotomy and surgical drainage of the liver abscess, which aligns with the inclusion criterion of patients who have undergone or are scheduled to undergo the defined procedure for the standard of care within one month before or after the study MRI.\n\nBased on the information provided, this patient meets the key inclusion criteria for the clinical trial, as they have a focal liver lesion (liver abscess) and have undergone a procedure related to the standard of care.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "514": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 48-year-old white male, which meets the age criteria of being an adult patient (>18 years).\n\nHe has a ruptured liver abscess, which required surgical intervention (exploratory laparotomy and drainage). This falls under the inclusion criteria of \"Intra-abdominal abscess (including of liver and spleen)\".\n\nThe patient required surgical intervention within 24 hours of diagnosis, as the note mentions he was taken to the ICU after surgery for the ruptured liver abscess.\n\nBased on the information provided, this patient seems to meet the key inclusion criteria for the T.E.A. Study clinical trial comparing ertapenem vs ampicillin-sulbactam for community-acquired intra-abdominal infections of mild to moderate severity.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "515": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which meets the age criteria of being older than 15 years.\n\n2. The patient has a ruptured liver abscess, which was diagnosed through physical examination, ultrasound, and exploratory laparotomy. This meets the inclusion criteria of having a clinical and ultrasonographic diagnosis of an amebic liver abscess.\n\n3. The inclusion criteria do not specify any gender restrictions.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "516": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male presenting with acute abdominal pain, fever, and dehydration. This matches the inclusion criteria of \"All consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness\".\n\n2. The physical exam findings of tenderness and positive Murphy's sign indicate abdominal tenderness, which is also part of the inclusion criteria.\n\n3. The abdominal ultrasound and exploratory laparotomy findings of a ruptured liver abscess explain the source of the abdominal pain and tenderness.\n\n4. There are no exclusion criteria mentioned that would disqualify this patient.\n\nBased on the information provided, this patient meets all the stated inclusion criteria for the clinical trial \"Correlation of Location of Abdominal Tenderness With Acute CT Abnormalities in Emergency Department Patients\".\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "517": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which falls within the age range of 12-80 years old specified in the inclusion criteria.\n\n2. The patient does not have perforated appendicitis, which is a key requirement for this clinical trial. Instead, the patient has a ruptured liver abscess.\n\n3. The patient's presenting symptoms (acute abdominal pain, fever, dehydration) and findings on physical exam (tenderness, positive Murphy's sign) and imaging (hepatomegaly, intraperitoneal fluid) are consistent with a ruptured liver abscess, not perforated appendicitis.\n\n4. The inclusion criteria specifically state that patients must have a clinical picture and imaging findings suggestive of perforated appendicitis.\n\nBased on the information provided, this patient does not meet the key inclusion criteria for this clinical trial on perforated appendicitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "518": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the age criteria for the trial (no specific age range given in the inclusion criteria).\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not mentioned in the inclusion criteria. However, the trial is focused on the effects of intraperitoneal local anesthetic in colonic surgery, and the patient's CVID may not directly impact their eligibility.\n\n3. The patient is undergoing exploratory laparotomy and surgical drainage of a ruptured liver abscess, which is not a colonic resection as specified in the inclusion criteria.\n\n4. The trial is specifically for patients undergoing open colonic resection as part of an enhanced recovery after surgery (ERAS) program, which is not the case for this patient.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of undergoing an open colonic resection as part of an ERAS program.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "519": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: patients with gallbladder stones and laparoscopic cholecystectomy\n\nThe patient note does not mention gallbladder stones or a cholecystectomy procedure. Instead, it states that the patient had a ruptured liver abscess, which was surgically drained.\n\nSince the patient does not meet the inclusion criteria for this clinical trial, which is specifically for patients who have undergone laparoscopic cholecystectomy for gallbladder stones, I would not refer this patient for this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "520": {
        "output": "Based on the given patient note and the clinical trial information, the patient does not have gastric cancer or any condition related to the trial. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "521": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male with common variable immunodeficiency (CVID). The clinical trial is about laparoscopic cholecystectomy in cirrhotic patients with gallstones.\n\n2. The patient does not have cirrhosis or gallstones mentioned in the note. The acute issue is a ruptured liver abscess requiring surgery.\n\n3. Based on the information provided, this patient does not meet the inclusion criteria of having liver cirrhosis with symptomatic gallbladder stones.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "522": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the age criteria of \u2265 21 years for the clinical trial.\n\n2. The patient does not have a confirmed diagnosis of dengue fever, which is one of the inclusion criteria for the trial. The note mentions a history of common variable immunodeficiency (CVID) and acute abdominal pain, fever, and dehydration, but no specific diagnosis of dengue.\n\n3. The patient's platelet count is not mentioned in the note, so it is unclear if they meet the criteria of platelets \u2264 20x103/\u03bcL.\n\n4. Based on the information provided, there is not enough evidence to definitively determine if the patient meets all the inclusion criteria for the dengue platelet study.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information would be needed, such as confirming a diagnosis of dengue fever and obtaining the patient's platelet count, to fully assess eligibility for this specific trial. However, the patient's age and presenting symptoms could potentially make them a candidate if the other criteria are met.",
        "label": 0
    },
    "523": {
        "output": "Let's go through the inclusion criteria for the clinical trial \"Perforated Appendicitis With Delayed Presentation\" and assess the eligibility of the given patient note.\n\nInclusion criteria:\n1. All children with a delayed diagnosis of perforated appendicitis. Delayed diagnosis will be defined as symptoms for 4 or more days. Duration of symptoms will be defined as the time pain started.\n- The patient note does not mention the duration of symptoms or a diagnosis of perforated appendicitis. This criterion is not met.\n\n2. Confirmed diagnosis of perforated appendicitis. The diagnosis of perforated appendicitis will be based on diagnostic imaging (CT scan or ultrasound), showing an established appendiceal abscess or phlegmon.\n- The patient note mentions a ruptured liver abscess, not a perforated appendicitis or appendiceal abscess. This criterion is not met.\n\n3. Consent to participate\n- There is no information about the patient's consent to participate in the trial.\n\nBased on the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial \"Perforated Appendicitis With Delayed Presentation\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "524": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male or female, from 18 to 90 years of age, inclusive\nThe patient is a 48-year-old male, so he meets this criterion.\n\n2. One of the following diagnoses with evidence of intraperitoneal infection:\n(a) Cholecystitis with rupture, perforation, or progression beyond gallbladder wall\n(b) Diverticular disease with perforation or abscess\n(c) Appendiceal perforation or periappendiceal abscess\n(d) Acute gastric or duodenal perforation, if operated on >24 hours after perforation\n(e) Traumatic perforation of intestine, if operated on >12 hours after perforation\n(f) Peritonitis due to perforated viscus, postoperative or spread from other infection focus\n(g) Intraabdominal abscess (including liver and spleen)\n\nThe patient has a ruptured liver abscess, which falls under criterion (g), so he meets this requirement.\n\n3. Requires surgical intervention within 24 hours before or after first dose of study drug\nThe patient underwent an exploratory laparotomy where the liver abscess was drained surgically, so he meets this criterion.\n\n4. If enrolled preoperatively, must have radiographic evidence of bowel perforation or intraabdominal abscess\nThis criterion is not applicable since the patient was enrolled post-operatively.\n\n5. Subjects who failed prior antibacterial treatment can be enrolled if they have a positive culture and require surgical intervention\nThere is no mention of prior failed antibacterial treatment, so this criterion is not applicable.\n\n6. Willing and able to comply with study procedures and restrictions\nThere is no information provided about the patient's willingness to comply, so we cannot definitively assess this criterion.\n\n7. Willing and able to provide written informed consent\nAgain, there is no information about the patient's ability to provide informed consent.\n\nOverall, based on the information provided, the patient meets the key inclusion criteria of having a complicated intra-abdominal infection requiring surgical intervention. However, there are two criteria (6 and 7) that cannot be assessed due to lack of information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding willingness to comply with study procedures and ability to provide informed consent.",
        "label": 1
    },
    "525": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Prophylactic Fenestration of the Peritoneum in Kidney Transplantation\", the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.\n\nThe key reasons are:\n\n1. The patient in the note is not a kidney transplant recipient. The note mentions a ruptured liver abscess and exploratory laparotomy, but does not indicate a kidney transplant.\n\n2. The inclusion criteria specifically states \"Adult recipients of kidney transplants from deceased donors\" as the only eligibility criterion mentioned.\n\nSince the patient does not meet this key inclusion criterion of being a kidney transplant recipient, they would not be eligible for this particular clinical trial. The note does not provide any information suggesting the patient meets the inclusion criteria.",
        "label": 0
    },
    "526": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which meets the age criteria of 18-70 years old for the clinical trial.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not mentioned in the inclusion criteria. However, the inclusion criteria do not explicitly exclude patients with immunodeficiency disorders.\n\n3. The patient presented with acute abdominal pain, fever, and dehydration, which led to the discovery of a ruptured liver abscess during exploratory laparotomy. This does not align with the inclusion criteria, which specifically mentions patients with colorectal adenocarcinoma and a high risk of developing peritoneal carcinomatosis.\n\n4. The patient underwent exploratory laparotomy and surgical drainage of the liver abscess, but there is no mention of receiving systemic adjuvant chemotherapy, which is one of the inclusion criteria.\n\n5. The patient's current condition and treatment do not seem to match the inclusion criteria for this specific clinical trial, which is focused on colorectal cancer patients at high risk of developing peritoneal carcinomatosis after receiving adjuvant chemotherapy.\n\nBased on the information provided, it is unlikely that this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "527": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which does not match the inclusion criteria of pregnant women aged 14 years and over at \u2265 24 weeks' viable gestation.\n\n2. The patient has a history of common variable immunodeficiency (CVID) and underwent an exploratory laparotomy for a ruptured liver abscess. There is no mention of pregnancy or an upcoming cesarean section.\n\n3. The clinical trial is studying the effectiveness and safety of azithromycin-based extended-spectrum antibiotic prophylaxis to prevent post-cesarean infection.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial, as he is not a pregnant woman undergoing a cesarean section.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "528": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which does not meet the age inclusion criteria of 6-15 years old for this clinical trial on streptococcal pharyngitis.\n\n2. The patient has a history of common variable immunodeficiency (CVID) and presented with acute abdominal pain, fever, dehydration, tachycardia, and hypotension. There is no mention of symptoms related to streptococcal pharyngitis like sore throat, fever, erythema or exudate of tonsils, or enlarged lymph nodes.\n\n3. The patient underwent exploratory laparotomy for a ruptured liver abscess and was taken to the ICU after surgery. This is not related to streptococcal pharyngitis.\n\n4. There is no mention of a positive throat culture for Group A \u03b2-hemolytic Streptococcus, which is an inclusion criterion.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial on streptococcal pharyngitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "529": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which meets the age criteria of 18 years and older.\n\n2. The patient does not have polycystic liver disease (PLD) or autosomal dominant polycystic kidney disease (ADPKD). The patient has common variable immunodeficiency (CVID) and a ruptured liver abscess.\n\n3. The inclusion criteria specifically require a liver volume \u2265 4 liters and \u2265 20 liver cysts, which are symptoms of PLD or ADPKD. The patient does not have these criteria.\n\n4. The inclusion criteria also require the patient to be symptomatic with at least 2 out of 5 specific symptoms related to mass effect from PLD/ADPKD. The patient's symptoms (acute abdominal pain, fever, dehydration) are likely due to the ruptured liver abscess rather than PLD/ADPKD.\n\nBased on the information provided, this patient does not meet the key inclusion criteria for this clinical trial on lanreotide for symptomatic polycystic liver disease.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "530": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which meets the age criteria of being over 18 years old.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not mentioned in the inclusion criteria. However, this does not necessarily exclude the patient from the trial.\n\n3. The patient presented with acute abdominal pain, fever, and dehydration, which led to the discovery of a ruptured liver abscess during exploratory laparotomy.\n\n4. The inclusion criteria specifically state \"patients diagnosed with de novo FLL at standard ultrasound\", where FLL stands for focal liver lesion.\n\n5. The patient's abdominal ultrasound showed hepatomegaly (enlarged liver) and abundant free intraperitoneal fluid, but it does not explicitly mention a de novo focal liver lesion.\n\n6. The exploratory laparotomy revealed a ruptured liver abscess, which could potentially be considered a focal liver lesion, but it is not clear if this was detected on the initial ultrasound or if it qualifies as a \"de novo\" lesion.\n\nBased on the information provided, it is unclear if the patient meets the specific inclusion criteria of having a de novo focal liver lesion diagnosed on standard ultrasound. Additional information may be needed to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "531": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which meets the age criteria of being over 18 years old for the clinical trial.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not explicitly mentioned in the inclusion criteria. However, the trial is focused on assessing the immune response in patients with severe intra-abdominal sepsis, and the patient's condition seems to fit this description.\n\n3. The patient presented with acute abdominal pain, fever, dehydration, and signs of sepsis (tachycardia and hypotension). An exploratory laparotomy revealed a ruptured liver abscess, which was surgically drained.\n\n4. The inclusion criteria specifically mention \"30 patients with severe abdominal sepsis in order to form the study group.\"\n\nBased on the information provided, this patient seems to meet the key inclusion criteria of being an adult with severe intra-abdominal sepsis, as evidenced by the ruptured liver abscess and subsequent surgical intervention.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "532": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the age criteria of >18 years for the clinical trial.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not directly related to liver cirrhosis. However, the patient presented with acute abdominal pain, fever, and dehydration, and was found to have a ruptured liver abscess during exploratory laparotomy.\n\n3. The clinical trial is specifically for the treatment of advanced liver cirrhosis, and the inclusion criteria require a clinically diagnosed liver cirrhosis confirmed by imaging or biopsy.\n\n4. While the patient had a ruptured liver abscess, there is no explicit mention of a diagnosis of liver cirrhosis in the patient note.\n\n5. The MELD (Model for End-Stage Liver Disease) score, which is used to assess the severity of liver disease, is not provided in the patient note.\n\nBased on the information provided, it is unclear if the patient meets the inclusion criteria for this clinical trial, as there is no explicit mention of a diagnosis of liver cirrhosis or the MELD score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information regarding the diagnosis of liver cirrhosis and the MELD score would be required to make a more definitive assessment of the patient's eligibility for this specific clinical trial.",
        "label": 0
    },
    "533": {
        "output": "Let's go through the inclusion criteria for the clinical trial \"Antibiotics Versus Surgery in Acute Appendicitis\" and assess the eligibility of the given patient.\n\nInclusion criteria:\n1. Patients between 18 and 65 years old\nThe patient is 48 years old, so this criterion is met.\n\n2. First episode of suspected acute appendicitis diagnosed by Andersson's score or combination with abdominal ultrasound\nThe patient note does not mention acute appendicitis or any diagnostic criteria related to it. Instead, it mentions a ruptured liver abscess, which is a different condition.\n\nSince the patient does not seem to have acute appendicitis, which is the target condition for this clinical trial, they would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "534": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Proteomics & Glyco-Proteomic Analysis of Follicular Fluid\", this 48-year-old male patient with common variable immunodeficiency (CVID) would not be eligible for this trial.\n\nThe key reasons are:\n\n1. The trial is specifically recruiting female patients undergoing controlled ovarian hyperstimulation, transvaginal oocyte aspiration, and saline infused sonography for follicular fluid collection.\n\n2. The patient is a male, and the trial excludes male partners.\n\n3. The trial is focused on studying the follicular fluid proteome and glyco-proteome in relation to ovarian function and polycystic ovary syndrome (PCOS), which is not relevant to this patient's condition.\n\nTherefore, based on the provided information, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "535": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which meets the \"Caucasian volunteers\" inclusion criteria for the clinical trial.\n\n2. There is no information provided about whether the patient is a smoker or not, so we cannot determine if he meets the \"No smoker\" criteria.\n\n3. The patient has a history of common variable immunodeficiency (CVID), which is not mentioned in the inclusion criteria. However, the inclusion criteria only specify normal biological parameters, which we do not have information about for this patient.\n\n4. There is no information provided about whether the patient has health insurance or not.\n\n5. There is no information provided about whether the patient has signed an informed consent form or not.\n\nBased on the limited information provided, we cannot definitively determine if the patient meets all the inclusion criteria for the clinical trial. Some key information is missing, such as smoking status, biological parameters, health insurance status, and informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "536": {
        "output": "Based on the given patient note and the clinical trial information, here is my assessment of the patient's eligibility for the trial:\n\nThe patient note describes a 48-year-old male with common variable immunodeficiency (CVID) who developed a ruptured liver abscess requiring surgical drainage. The clinical trial is studying the role of connective tissue growth factor (CTGF) in peritoneal metastasis of gastric cancer.\n\nSince the patient does not have gastric cancer, and the trial is specifically focused on gastric cancer patients eligible for curative surgery, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "537": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the age criteria of \u226518 years old for the clinical trial.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not mentioned in the inclusion criteria. However, the inclusion criteria do not explicitly exclude patients with immunodeficiencies.\n\n3. The patient presented with acute abdominal pain, fever, and dehydration, which led to the discovery of a ruptured liver abscess that was surgically drained. This suggests that the patient has a liver space occupying lesion (LOE) that required an extended hepatic resection, which is one of the inclusion criteria.\n\n4. The patient's laboratory values are not provided, so it is unclear if they meet the criteria for leukocytes, neutrophils, platelets, liver enzymes, and creatinine levels.\n\n5. It is not mentioned if the patient provided written informed consent for participation in the study.\n\nBased on the information provided, there are some uncertainties regarding the patient's eligibility for this clinical trial. While the patient appears to meet the age criteria and have a liver condition that may require an extended hepatic resection, there are missing details about their laboratory values and consent for participation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their laboratory values and willingness to provide informed consent.",
        "label": 1
    },
    "538": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Operative Treatment of Endometriosis Patients in Turku University Hospital\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient is a 48-year-old male, while the trial is focused on endometriosis, which is a condition that affects females.\n\n2. The patient's condition is related to a ruptured liver abscess, which is not relevant to the trial's focus on endometriosis.\n\n3. The inclusion criteria specifically mention \"Endometriosis\", \"Adnexal finding\", and \"Laparoscopic sterilization\", none of which apply to this patient's case.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "539": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which falls within the age range of 18-75 specified in the inclusion criteria.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not chronic granulomatous disease (CGD) as required by the inclusion criteria.\n\n3. The patient has a ruptured liver abscess, which was surgically drained. The trial is specifically looking for patients with liver abscesses that cannot be treated with surgery.\n\n4. There is no mention of the patient's liver abscess being caused by a specific microorganism susceptible to radiofrequency ablation (RFA).\n\n5. There is no information provided about the patient's willingness to return for follow-up visits or undergo testing/procedures associated with the trial.\n\nBased on the information provided, the patient does not meet several key inclusion criteria, such as having CGD, having a liver abscess that cannot be treated with surgery, and having a confirmed microorganism susceptible to RFA.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "540": {
        "output": "Let's go through the eligibility assessment step-by-step:\n\n1. The patient is a 48-year-old male, which meets the general age criteria for most clinical trials.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not directly relevant to the clinical trial on laparoscopic cholecystectomy drainage.\n\n3. The patient presented with acute abdominal pain, fever, and dehydration, which could be related to an acutely inflamed gallbladder.\n\n4. The exploratory laparotomy revealed a ruptured liver abscess, which was surgically drained. This condition is not directly related to the clinical trial's focus on laparoscopic cholecystectomy drainage.\n\n5. The inclusion criteria for the clinical trial specifically mention \"acutely inflamed gallbladder.\"\n\nBased on the information provided, there is no clear indication that the patient had an acutely inflamed gallbladder, which is the primary inclusion criterion for the clinical trial.\n\nTherefore, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "541": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male with a history of common variable immunodeficiency (CVID). This matches the inclusion criteria of the trial, which does not specify any age or gender restrictions.\n\n2. The patient has a pyogenic liver abscess, which was surgically drained after rupture. This directly matches the inclusion criteria of \"Pyogenic liver abscess radiologically and bacteriologically diagnosed\".\n\n3. There is no mention of colon cancer or any colonic lesions in the patient note.\n\nBased on the information provided, this patient meets the sole inclusion criteria of having a pyogenic liver abscess. While the trial aims to evaluate the prevalence of colon cancer in such patients, the inclusion criteria do not require the presence of colon cancer.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "542": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which falls within the age range (18-70 years) specified in the inclusion criteria.\n\n2. The patient does not have a liver cyst or any indication for aspiration and sclerotherapy. Instead, the patient has a ruptured liver abscess, which required surgical drainage.\n\n3. The clinical trial is specifically studying the efficacy of combining pasireotide with aspiration sclerotherapy for reducing the volume of hepatic cysts. Since the patient does not have a hepatic cyst, they would not be eligible for this trial.\n\nTherefore, based on the information provided, this patient would not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "543": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which meets the age criteria of being over 18 years old for the clinical trial.\n\n2. However, the patient does not have esophagogastric-junction cancer, which is a key inclusion criteria for this trial. The patient has a ruptured liver abscess related to common variable immunodeficiency (CVID).\n\n3. Since the patient does not have the target disease of esophagogastric-junction cancer required for this trial, they would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "544": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which falls within the age range of 21-80 years old specified in the inclusion criteria.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not mentioned in the inclusion criteria. However, the inclusion criteria do not explicitly exclude patients with other medical conditions.\n\n3. The patient presented with acute abdominal pain, fever, and dehydration, which led to the discovery of a ruptured liver abscess during exploratory laparotomy.\n\n4. The clinical trial is focused on extensive peritoneal lavage after curative gastrectomy for gastric cancer.\n\n5. The inclusion criteria specifically mention patients with T3 (subserosal) or T4 (serosal) gastric cancer who are undergoing gastrectomy with curative intent.\n\n6. Based on the information provided, the patient does not have gastric cancer and is not undergoing gastrectomy. Instead, the patient had a ruptured liver abscess, which required surgical drainage.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "545": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism\", the patient does not seem to meet the inclusion criteria for this trial.\n\nThe patient note mentions that the patient has a history of common variable immunodeficiency (CVID) and presented with acute abdominal pain, fever, dehydration, and a ruptured liver abscess that required surgical drainage. However, there is no mention of liver cirrhosis or hypersplenism, which are the two inclusion criteria for the clinical trial.\n\nTherefore, based on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "546": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the age criteria of being 18 years or older.\n\n2. The patient underwent an exploratory laparotomy due to a ruptured liver abscess, which necessitated a damage control laparotomy. This meets the inclusion criteria of being a trauma patient who sustained trauma necessitating a damage control laparotomy.\n\n3. There are no exclusion criteria mentioned in the trial information provided.\n\nBased on the information given, this patient meets all the stated inclusion criteria for the clinical trial \"Use of Hypertonic Saline After Damage Control Laparotomy to Improve Early Primary Fascial Closure\".\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "547": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the age criteria of being 18 years or older for this clinical trial.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not breast cancer. This clinical trial is specifically for patients with oligometastatic breast cancer.\n\n3. There is no mention of the patient having breast cancer or oligometastatic lesions in the patient note.\n\n4. The patient presented with acute abdominal pain, fever, dehydration, and a ruptured liver abscess, which required surgical drainage. This condition is unrelated to the clinical trial's focus on oligometastatic breast cancer.\n\nBased on the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial titled \"Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "548": {
        "output": "Based on the provided patient note and the clinical trial information, this patient would not be eligible for the trial. The key reasons are:\n\n1. The trial is focused on using a new nanotechnology material (Buckypaper) for surgical procedures and cancer treatment in an animal model (New Zealand female rabbits).\n\n2. The patient is a 48-year-old human male, not a New Zealand female rabbit, which is required by the inclusion criteria of the trial.\n\n3. The trial does not appear to be related to the patient's medical condition of common variable immunodeficiency (CVID) or the ruptured liver abscess.\n\nTherefore, based on the mismatch between the patient's characteristics and the trial's inclusion criteria, I would not refer this patient for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "549": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient is a 48-year-old male, while the trial requires pregnant women.\n2. The patient has a history of common variable immunodeficiency (CVID) and a ruptured liver abscess, which are not relevant to the trial's focus on preterm premature rupture of membranes (PPROM) during pregnancy.\n3. The trial's inclusion criteria specifically state \"singleton pregnancy with a definite history of current PPROM for the study group\", which does not apply to this patient.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "550": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male with common variable immunodeficiency (CVID). The clinical trial is for evaluating a vascular reconstruction device for treating intracranial aneurysms.\n\n2. The inclusion criteria for the clinical trial are:\n- Subject \u2265 18 years old (the patient meets this criterion)\n- Subjects with non-ruptured or ruptured intracranial aneurysm that is referred for endovascular treatment (the patient does not have an intracranial aneurysm, so this criterion is not met)\n- Parent vessel with a diameter of \u2265 2.0 mm and \u2264 4 mm (not applicable since the patient does not have an intracranial aneurysm)\n- Subject understands the nature of the procedure and provides voluntary written informed consent (unknown from the patient note)\n- Subject is willing to participate in follow-ups (unknown from the patient note)\n\n3. Since the patient does not have an intracranial aneurysm, which is a key inclusion criterion for this clinical trial, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "551": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the age inclusion criteria of 12 years or above.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is one of the underlying disease processes listed as putting someone at risk for noncirrhotic portal hypertension (NCPH).\n\n3. There is no mention of the patient having cirrhosis, hepatitis B/C, primary sclerosing cholangitis, primary biliary cirrhosis, Wilson's disease, autoimmune hepatitis, hemochromatosis, bile duct obstruction, hepatocellular carcinoma, or cholangiocarcinoma - which are all exclusion criteria.\n\n4. There is no indication that the patient has active substance abuse within the past year.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria and does not have any of the clearly stated exclusion criteria for this clinical trial on the natural history of noncirrhotic portal hypertension.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "552": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old male, which meets the age criteria of being > 18 years old for the clinical trial.\n\n2. The patient has a history of common variable immunodeficiency (CVID), which is not mentioned in the inclusion criteria. However, the inclusion criteria do not explicitly exclude patients with immunodeficiency disorders.\n\n3. The patient presented with acute abdominal pain, fever, and dehydration, which led to the discovery of a ruptured liver abscess during exploratory laparotomy. This condition is not directly related to the peritoneal surface malignancy that is the focus of the clinical trial.\n\n4. The inclusion criteria specifically mention histologically confirmed peritoneal carcinomatosis from appendiceal, colorectal, ovarian, or primary mesothelioma, with no systemic metastases. The patient note does not mention any of these conditions.\n\n5. The inclusion criteria also require evidence of low-volume peritoneal disease defined by a PCI < 10 based on cross-sectional imaging or diagnostic laparoscopy findings. The patient note does not provide any information about the extent of peritoneal disease or PCI score.\n\n6. The inclusion criteria have several other requirements related to the patient's performance status, liver and kidney function, hematological parameters, and absence of certain comorbidities. The patient note does not provide enough information to assess these criteria.\n\nBased on the available information, it is unlikely that this patient would be eligible for the clinical trial, as the patient's condition does not appear to be related to peritoneal surface malignancy, and there is insufficient information to determine if the patient meets the other inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "553": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 48-year-old white male with common variable immunodeficiency (CVID). This matches one of the inclusion criteria for the clinical trial, which is \"Common Variable Immunodeficiency (CVID)\".\n\nHowever, the patient note describes an acute medical issue of abdominal pain, fever, dehydration, and a ruptured liver abscess requiring surgery. The clinical trial appears to be focused on studying the role of DNA repair mechanisms in immune deficiencies, rather than treating acute medical conditions.\n\nWhile the patient has CVID, which meets one inclusion criteria, the acute medical issue described in the patient note suggests that the patient may not be an ideal candidate for this particular trial at this time.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe key reason is that while the patient meets the CVID inclusion criteria, the acute medical condition may need to be stabilized before considering enrollment in a trial focused on studying the underlying genetic/molecular mechanisms of CVID. Further investigation into the patient's overall clinical status and suitability for this particular trial would be warranted.",
        "label": 1
    },
    "554": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 48-year-old white male, which meets the age criteria of \u226518 years old for the clinical trial.\n\n2. However, the patient does not have a perianal abscess. Instead, the patient has a ruptured liver abscess, which required surgical drainage.\n\n3. The clinical trial is specifically for the treatment of perianal abscesses, either through aspiration or surgical incision.\n\n4. Since the patient does not have a perianal abscess, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "555": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the inclusion criteria of being 18 years of age or older.\n\n2. There is no mention of the patient having systemic lupus erythematosus (SLE) or meeting the American Rheumatism Association criteria for SLE diagnosis.\n\n3. While the patient has abnormal urinalysis findings, there is no information provided about a renal biopsy showing class III or IV lupus nephritis.\n\n4. The patient's serum creatinine of 1.3 mg/dL suggests impaired renal function, which is an exclusion criterion for severe proliferative lupus nephritis.\n\n5. There is no information provided about the patient's previous immunosuppressive therapy or other medical conditions that may exclude them from the trial.\n\nBased on the information provided, this 6-month-old infant patient does not meet the key inclusion criteria of being 18 years or older, having a diagnosis of SLE, and having biopsy-proven lupus nephritis. Additionally, the impaired renal function would likely exclude the patient from this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "556": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDisease Characteristics:\n- The patient does not fall into Group 1 (patients on chronic hemodialysis)\n- The patient does not fall into Group 2 (patients at high risk of developing acute renal failure after cadaveric renal transplantation)\n- The patient seems to fall into Group 3 (patients with ischemic acute renal failure due to hypotension, surgery, or trauma)\n  - ARF severity index is not provided but creatinine clearance of 12-14 mL/min matches\n  - Rising creatinine of at least 0.5 mg/dL per day for 2 days without evidence of recovery despite standard supportive care (details not provided)\n  - No drug or contrast induced renal failure (not specified)\n  - No oliguric renal failure (creatinine clearance 3-4 mL/min)\n  - No prior chronic renal failure (not specified)\n  - Baseline creatinine greater than 2.5 mg/dL for males (creatinine 1.3 mg/dL)\n  - No ARF due to bacterial/fungal sepsis, nephrotoxins, etc. (not specified)\n\nPrior/Concurrent Therapy:\n- No details provided on prior/concurrent therapy\n\nPatient Characteristics:\n- No details provided on recent infection, allergy to study drugs, prisoner status, pregnancy/nursing status, or mental impairment\n- No severe nonrenal medical condition that would interfere with the study (not specified)\n\nBased on the limited information provided, it seems this 6-month-old infant patient may potentially meet some of the inclusion criteria for Group 3, but several key details are missing.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "557": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which meets the age criteria of less than 12 months for Part I of the trial.\n\n2. The patient is undergoing major surgery, which is an inclusion criterion.\n\n3. There is no mention of prenatal opiate exposure, which is required.\n\n4. The surgery does not seem to involve pneumonectomy, tracheal or bronchial stenosis reconstruction, diaphragmatic hernia repair, or closure of large gastroschisis or omphalocele defects, which are exclusion criteria.\n\n5. There is no mention of hepatic or renal transplantation, which are exclusion criteria.\n\n6. The patient's renal function tests (BUN and creatinine) are provided, but it is not clear if they are within normal limits, which is an inclusion criterion.\n\n7. There is no mention of pulmonary disease causing baseline hypercarbia or pulmonary hypertension contraindicating use of 5% CO2 in rebreathing studies, which are exclusion criteria.\n\n8. There is no mention of allergy to morphine or severe developmental delay, which are exclusion criteria.\n\nBased on the information provided, there are some potential concerns regarding the patient's renal function, but overall, the patient seems to meet most of the key inclusion criteria for Part I of the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "558": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the inclusion criteria of being an adult patient with IgA nephropathy diagnosed within the past 3 years.\n\n2. The patient's condition appears to be related to post-surgical complications and acute kidney injury, rather than IgA nephropathy specifically.\n\n3. The clinical trial is focused on studying the progression of IgA nephropathy and the effects of enalapril on renal function in these patients.\n\n4. Based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "559": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant undergoing major surgery, which fits the inclusion criteria of being scheduled for surgery.\n\n2. However, the patient note does not mention the specific diagnosis. The inclusion criteria lists several congenital heart diseases like ventricular septal defect, coarctation of the aorta, transposition of the great arteries, tetralogy of Fallot, complete atrioventricular canal defect, and hypoplastic left heart.\n\n3. Without knowing the specific diagnosis, it's difficult to definitively determine eligibility based on the inclusion criteria.\n\n4. The patient note mentions signs of acute kidney injury like oliguria, edema, elevated BUN/creatinine, and abnormal urinalysis findings. This could potentially exclude the patient if it's considered an \"additional defect\" based on the exclusion criteria.\n\n5. Given the lack of information on the specific diagnosis and the potential exclusion due to acute kidney injury, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "560": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which meets the age criteria of 1-45 days at surgery.\n\n2. The patient is undergoing major surgery, but the type of surgery is not specified. The inclusion criteria mention specific types of congenital heart defects that qualify.\n\n3. The patient has signs of acute kidney injury with oliguria, elevated BUN/creatinine, and abnormal urinalysis findings. The exclusion criteria state that patients with significant non-cardiac organ dysfunction such as renal failure should be excluded.\n\n4. There is no mention of the patient having any other exclusion criteria like prior cardiac arrest, infection, chromosomal abnormalities, etc.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation into the type of congenital heart defect and surgery being performed. The acute kidney injury is concerning, but may be transient in the post-operative period.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "561": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique\", the patient does not meet the inclusion criteria.\n\nThe key points are:\n\n1. The patient is a 6-month-old male infant, while the inclusion criteria specify children aged 8-12 years.\n2. The patient note does not mention any Schistosoma haematobium infection, which is the target disease for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "562": {
        "output": "Let's go through the inclusion criteria for this clinical trial:\n\n\"Inclusion Criteria: Healthy children, free of medication\"\n\nBased on the patient note provided, this 6-month-old infant does not seem to meet the inclusion criteria for this clinical trial. The note mentions that the infant has undergone major surgery, has generalized edema, and has abnormal laboratory values suggesting acute kidney injury.\n\nTherefore, this infant cannot be considered a healthy child free of medication, as they are likely receiving medical treatment and medications following the surgery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "563": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Cessation of hemofiltration: The patient note does not mention whether the patient was on hemofiltration or not. So, this criterion cannot be evaluated.\n\n2. Mechanical ventilation: The patient note does not mention whether the patient is on mechanical ventilation or not. So, this criterion cannot be evaluated either.\n\n3. Written informed consent: The patient note does not provide any information about obtaining written informed consent. This criterion cannot be evaluated based on the given information.\n\nSince two out of the three inclusion criteria cannot be evaluated from the provided patient note, it is difficult to make a definitive assessment of the patient's eligibility for the clinical trial.\n\nHowever, based on the information provided, the patient appears to be a 6-month-old infant with acute kidney injury (AKI) after major surgery, as evidenced by oliguria, elevated BUN and creatinine, and the presence of casts and hematuria on urinalysis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation, particularly regarding the cessation of hemofiltration, mechanical ventilation status, and the ability to obtain written informed consent.",
        "label": 1
    },
    "564": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 6-month-old male infant, so he does not meet the age criteria of being greater than 18 years old.\n\nThe note does not mention diabetes or the need for insulin/oral hypoglycemic agents, so the diabetes criteria is not met.\n\nThe serum creatinine of 1.3 mg/dL falls within the range specified for non-diabetic subjects (140-300 \u03bcmol/L or 1.57-3.36 mg/dL). However, the note mentions that the patient recently underwent major surgery, so the renal function may not be stable as required.\n\nBased on the information provided, this patient does not seem to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "565": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, while the clinical trial inclusion criteria specify ages 18-40 years. So the patient does not meet the age criteria.\n\n2. The patient has signs of acute kidney injury after major surgery, with oliguria, edema, elevated BUN/creatinine, and abnormal urinalysis findings. The clinical trial is studying enteroaggregative E. coli and its role in causing diarrhea in healthy adults.\n\n3. The patient's current medical condition of acute kidney injury after surgery is not relevant to the clinical trial, which is looking for healthy adults without any acute illnesses.\n\n4. There are no details provided about the patient meeting any of the other specific inclusion criteria like IL-8 genotype, negative serologies, normal lab values at screening, etc.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial studying enteroaggregative E. coli in healthy adults.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "566": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Evaluating the Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis\", this patient does not appear to have a diagnosis of gastroschisis. The note describes a 6-month-old male infant with signs of acute kidney injury after major surgery, but does not mention gastroschisis.\n\nSince the inclusion criteria specifically require a diagnosis of gastroschisis, as well as a birth weight \u2265 1500 grams and gestational age \u2265 34 weeks, this patient does not meet the eligibility criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "567": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 6-month-old male infant who has recently undergone major surgery. Some key points from the note:\n\n- Low urine output (<0.2 mL/kg/hr) suggesting acute kidney injury\n- Generalized edema\n- Elevated blood urea nitrogen and creatinine\n- Hematuria and casts in urine sediment\n\nThe clinical trial is studying the use of levosimendan vs milrinone for preventing low cardiac output syndrome (LCOS) in infants after open heart surgery.\n\nThe key inclusion criteria are:\n1) Age younger than one year\n2) Corrective open heart surgery with biventricular repair, except tetralogy of Fallot\n\nThis patient meets both criteria:\n1) He is 6 months old, which is younger than 1 year\n2) He has recently undergone major surgery, which implies he had corrective open heart surgery with biventricular repair\n\nGiven that the patient meets all the stated inclusion criteria and has just undergone the type of surgery being studied, he would be an excellent candidate for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "568": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n- First time recipient of deceased donor liver transplant - Satisfied based on the patient note.\n- Age 18-70 - Not satisfied as the patient is a 6-month-old infant.\n- Hepatitis C virus (HCV) positive recipients - No information provided about HCV status.\n- For Long-term extension study-Subjects who have completed one year of study treatment (through Week 52) - Not applicable as this is the initial enrollment.\n\nExclusion Criteria:\n- Donor Exclusions (a-f) - Not applicable as these relate to donor characteristics.\n- Recipient Exclusions:\n    g) Subjects with a history of hypercoagulable state - No information provided.\n    h) Subjects with fulminant hepatic failure - No information provided.\n    i) Subjects receiving a split or reduced liver - No information provided.\n    j) Subjects who are Epstein-Barr virus (EBV) negative - No information provided.\n- Medical History and Concurrent Diseases:\n    - Subjects who have received 2 or more consecutive weeks of dialysis 1 month prior to enrollment OR anticipated to have prolonged dialysis post-transplantation - No information provided.\n    - Subjects with known intrinsic renal disease (e.g., a urine protein/ creatinine ratio > 150 mg/g or the presence of an abnormal number of red blood cells (RBCs) or granular casts in the urine) AND calculated GFR < 40 ml/min/1.73 m^2 body surface area (BSA) (abbreviated Modification of Diet in Renal Disease [MDRD]). Subjects must have a calculated GFR assessment within 1 month prior to enrollment. - Potentially excluded based on the presence of RBCs and granular casts in the urine, but no information provided on GFR.\n    - Subjects with known HIV - No information provided.\n    - Subjects with any prior or concurrent solid organ (e.g., heart, kidney, pancreas) or cell (e.g., islet, bone marrow) transplant or subjects deemed likely to have a second solid organ or cell transplant (e.g., islet, bone marrow) within the next 3 years - No information provided.\n    - Subjects with a history of cancer within the last 5 years - No information provided.\n- Allergies and Adverse Drug Reactions:\n    a) Hypersensitivity to any medications that will be used in the protocol - No information provided.\n- Prohibited Treatments and/or Therapies:\n    - Subjects receiving immunosuppressive agent(s) (e.g., methotrexate, abatacept, infliximab, etanercept, chemotherapy, etc.) within the past 6 months for other indications such as an autoimmune disease - No information provided.\n    - Subjects who received maintenance corticosteroids at a dose of > 5 mg/day of prednisone (or equivalent) for at least 7 consecutive days within the prior year for an underlying chronic inflammatory or autoimmune disease - No information provided.\n    - Subjects who have used any investigational drug within 30 days prior to the Day 1 visit - No information provided.\n    - Subjects previously treated with belatacept - No information provided.\n\nBased on the information provided, the patient does not meet the age inclusion criteria and may potentially be excluded based on the presence of RBCs and granular casts in the urine, but there is not enough information to make a definitive determination.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "569": {
        "output": "To determine the patient's eligibility for the clinical trial \"Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery\", let's go through the inclusion criteria one by one:\n\n1. Age over 18 years: The patient is a 6-month-old infant, so this criterion is not met.\n\n2. Planned CABG or valvular surgery with cardiopulmonary bypass: The patient note does not mention the type of surgery, so it's unclear if this criterion is met.\n\n3. Serum creatinine available (within 30 days): The patient's serum creatinine is provided (1.3 mg/dL), so this criterion is met.\n\n4. Estimated GFR 15-90ml/min using the abbreviated MDRD formula (CKD stages 2-4): The patient's GFR is not provided, but based on the serum creatinine of 1.3 mg/dL, it's likely that the GFR is below 90 ml/min, which would meet this criterion.\n\nHowever, since the patient is a 6-month-old infant and the inclusion criteria specifically state \"Age over 18 years\", it's highly unlikely that this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "570": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 6-month-old male infant who has recently undergone major surgery. He is showing signs of acute kidney injury with oliguria (urine output < 0.2 mL/kg/hr), generalized edema, elevated BUN and creatinine, and abnormal urinalysis findings.\n\nThe clinical trial is looking at the use of fenoldopam and ketanserin for preventing acute kidney failure after cardiac surgery in high-risk patients.\n\nThe inclusion criteria are:\n1) Undergoing cardiac surgery\n2) At least one risk factor for acute renal failure, which includes:\n    a) Oliguria < 0.5 mL/kg/hour for over 3 hours despite adequate fluid resuscitation and furosemide\n    b) Requiring at least 60 mg furosemide/12 hours IV to maintain diuresis > 1 mL/kg/hour\n\nThis patient meets the first inclusion criteria of undergoing major surgery (which could potentially include cardiac surgery).\n\nHe also meets the second criteria of having at least one risk factor for acute renal failure, which is oliguria < 0.2 mL/kg/hr despite likely adequate fluid resuscitation (normal BP).\n\nTherefore, based on the information provided, this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "571": {
        "output": "To determine the patient's eligibility for the clinical trial \"Acute Kidney Injury in Neonates\", let's go through the inclusion criteria:\n\nInclusion Criteria: Families of infants (birthweight >1500g) be asked to participate in the study.\n\nGiven information:\n- The patient is a 6-month-old male infant.\n- No information is provided about the birthweight.\n\nSince the birthweight is not mentioned, we cannot definitively determine if the patient meets the inclusion criteria of having a birthweight greater than 1500g. However, the patient does seem to be exhibiting signs of acute kidney injury, which is the focus of the clinical trial.\n\nBased on the available information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo make a more definitive assessment, we would need to know the patient's birthweight to confirm if they meet the inclusion criteria. Additional details about the clinical trial, such as any exclusion criteria, would also be helpful in determining eligibility.",
        "label": 1
    },
    "572": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Proteinuria over 0.25 g/mmol of creatinine with hypoalbuminemia below 30g/L for the case\n- The patient note does not mention proteinuria or albumin levels, so this criterion cannot be evaluated.\n\n2. No history of renal disease\n- The patient note mentions the patient is a 6-month-old infant who recently underwent major surgery, but does not specify if there is a history of renal disease.\n\n3. Normal C3 and negativity for hepatitis B and C\n- The patient note does not provide information about C3 levels or hepatitis B/C status.\n\nSince several key pieces of information are missing from the patient note to definitively assess eligibility for this particular trial, I would provide the following assessment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information needed would include details on proteinuria, albumin levels, history of renal disease, C3 levels, and hepatitis B/C status to fully evaluate eligibility per the stated inclusion criteria. With the limited information provided in just this patient note, the patient cannot be definitively ruled in or out for this particular clinical trial.",
        "label": 1
    },
    "573": {
        "output": "Let's go through the inclusion criteria for this clinical trial:\n\n\"Infants aged 6 to 36 months admitted to the Intensive Care-Sophia after craniofacial surgery\"\n\nThe patient note mentions a 6-month-old male infant, which falls within the age range specified in the inclusion criteria. However, there is no mention of the infant being admitted to the Intensive Care-Sophia or undergoing craniofacial surgery.\n\nBased on the information provided in the patient note, it is unclear if the infant meets the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "574": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which meets the minimum birth weight inclusion criteria of 500g.\n\n2. The patient has undergone major surgery and has a urine output of less than 0.2 mL/kg/hr, suggesting potential kidney issues. However, the trial is focused on zinc and copper absorption in infants with ostomies/bilious losses.\n\n3. There is no mention of the patient having an ostomy or bilious losses in the patient note.\n\n4. The trial inclusion criteria specifically state \"Presence of ileostomy due to any disease or condition (i.e., necrotizing enterocolitis, intestinal atresias, gastroschisis, or intestinal perforations)\".\n\nSince the patient note does not indicate the presence of an ileostomy or bilious losses, which is a key inclusion criteria for this trial, I would assess the eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "575": {
        "output": "To determine the trial-level eligibility for this patient, let's go through the inclusion criteria for the clinical trial:\n\nInclusion criteria: Infants born at >28 weeks gestation will be eligible for enrollment in this study.\n\nThe patient note states that the patient is a 6-month-old male infant, which implies that the infant was born at term (around 40 weeks gestation). Since the inclusion criteria require infants born at greater than 28 weeks gestation, this patient meets the inclusion criteria.\n\nHowever, it's important to note that the clinical trial is focused on studying the relationship between gestational age and urine concentration of S100B in preterm and term infants during the first week of life. The patient note does not provide any information about the urine concentration of S100B or the timing of the clinical presentation (whether it's within the first week of life or not).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "576": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which meets the age criteria of 0 days to 6 months for the clinical trial.\n\n2. The clinical trial is focused on infants undergoing stage I palliation (Norwood procedure) for hypoplastic left heart syndrome or similar left-sided obstructive lesions in the setting of single-ventricle physiology.\n\n3. The patient note does not mention the specific diagnosis or planned surgery, so it is unclear if the patient meets this key inclusion criteria.\n\n4. However, the patient is described as having undergone \"major surgery\" and having signs of acute kidney injury (oliguria, elevated BUN/creatinine, hematuria, and granular casts on urinalysis).\n\n5. The trial aims to evaluate the use of phenoxybenzamine to reduce afterload and improve systemic perfusion in these high-risk infants undergoing cardiac surgery.\n\n6. Given the patient's age, recent major surgery, and acute kidney injury (which could be related to low cardiac output/perfusion), they may potentially benefit from the intervention being studied.\n\nBased on the available information, I would assess this case as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their specific cardiac diagnosis and planned surgical procedure.",
        "label": 0
    },
    "577": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant undergoing major surgery, which meets the inclusion criteria for children \"Undergoing open heart surgery\".\n\n2. The patient has signs of acute kidney injury (AKI) after surgery, with low urine output, elevated BUN and creatinine, and abnormal urinalysis findings. This is relevant to the trial which is examining new diagnostic tests for AKI after heart surgery.\n\n3. There is no information provided that would exclude the patient based on the listed exclusion criteria.\n\nTherefore, based on the information provided, this patient would likely be eligible for the clinical trial examining new diagnostic tests for acute kidney injury after heart surgery in children.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "578": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Aged 18-45 years.\nThe patient note states that the patient is a 6-month-old male infant, which does not meet this age criterion.\n\n2. Were neither overweight nor underweight for his height as per the Life Insurance Corporation of India height/weight chart for non-medical cases.\nThere is no information provided about the patient's weight or height, so it is unclear if this criterion is met.\n\n3. Had voluntarily given written informed consent to participate in this study.\nAs an infant, the patient would not be able to provide voluntary written informed consent.\n\n4. Were of normal health as determined by medical history and physical examination of the subjects performed within 21 days prior to the commencement of the study.\nThe patient note indicates that the infant has recently undergone major surgery, has generalized edema, oliguria, elevated blood urea nitrogen and serum creatinine, and abnormal urinalysis findings. This suggests that the patient is not in normal health.\n\nBased on the information provided, this 6-month-old infant patient would not meet the inclusion criteria for this clinical trial, which is specifically designed for healthy adult male subjects.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "579": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age inclusion criteria of 18-45 years for this clinical trial.\n\n2. The patient has just undergone major surgery and is showing signs of acute kidney injury (oliguria, elevated BUN/creatinine, hematuria, proteinuria, granular casts). Patients with significant medical conditions like this would likely be excluded from a bioavailability study.\n\n3. There is no mention of the patient's weight status, but as an infant, it is unlikely they would meet the weight criteria based on standard adult height/weight charts.\n\n4. The patient is male, so the criteria regarding female participants are not applicable.\n\nBased on the provided information, this 6-month-old infant patient with acute kidney injury after major surgery would not be eligible for this bioavailability study of metformin in healthy adults.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "580": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 6-month-old male infant undergoing major surgery, which likely involved cardiopulmonary bypass. This matches the inclusion criteria of \"Patient undergoing heart surgery on cardiopulmonary bypass.\"\n\nHowever, there are some concerning signs that the patient may have acute kidney injury (AKI):\n- Low urine output (<0.2 mL/kg/hr)\n- Generalized edema\n- Elevated BUN (33 mg/dL) and creatinine (1.3 mg/dL)\n- Abnormal urinalysis findings (hematuria, casts)\n\nThe clinical trial is investigating the use of remote ischemic preconditioning to prevent AKI after cardiac surgery involving cardiopulmonary bypass.\n\nGiven that this infant patient is undergoing major surgery likely involving cardiopulmonary bypass and may be developing AKI based on the clinical presentation, they would be an appropriate candidate for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "581": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which meets the age criteria of 1 year to <18 years for the clinical trial.\n\n2. The patient has thrombocytopenia (low platelet count) shortly after undergoing major surgery, which could potentially be related to chronic ITP (idiopathic thrombocytopenic purpura). However, the note does not explicitly confirm a diagnosis of chronic ITP.\n\n3. The patient's platelet count is not provided, but the inclusion criteria requires a platelet count <30 Gi/L on Day 1 or within 48 hours prior.\n\n4. The patient has not received any prior ITP therapies mentioned in the inclusion criteria, such as immunoglobulins, corticosteroids, azathioprine, splenectomy, rituximab, or cyclophosphamide.\n\n5. The patient's laboratory values (BUN, creatinine, urinalysis) suggest potential kidney injury or acute kidney injury, which is not mentioned in the inclusion/exclusion criteria.\n\nBased on the information provided, there are some uncertainties regarding the patient's eligibility for this clinical trial:\n\n- The diagnosis of chronic ITP is not explicitly confirmed.\n- The patient's platelet count is not provided, which is a key inclusion criterion.\n- The potential kidney injury or acute kidney injury may or may not be an exclusion criterion.\n\nTherefore, I would consider the following assessment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "582": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age inclusion criteria of \"Neonates Age </= 1 month\".\n\n2. The patient is undergoing major surgery, which could potentially involve cardiopulmonary bypass, but this is not explicitly stated.\n\n3. The patient's inpatient status is not mentioned, so we cannot determine if they meet the criteria of being an inpatient at MUSC for at least 8 hours prior to planned surgery.\n\nBased on the information provided, the patient does not clearly meet all of the inclusion criteria for this clinical trial. However, there are some missing details that could potentially make them eligible upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "583": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age inclusion criteria of being \u226518 years old for this clinical trial studying a monoclonal antibody in healthy volunteers.\n\n2. The patient has just undergone major surgery and has signs of acute kidney injury with oliguria, elevated BUN and creatinine, and abnormal urinalysis findings. This indicates the patient is not in general good health as required by the inclusion criteria.\n\n3. The laboratory values provided show the creatinine is elevated above the allowed 1.1 x upper limit of normal specified in the inclusion criteria.\n\nBased on the information provided, this 6-month-old infant patient with acute kidney injury after major surgery would not be eligible for this phase 1 clinical trial evaluating a monoclonal antibody in healthy adult volunteers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "584": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the gestational age criteria of 28-34 weeks for inclusion in this trial.\n\n2. The patient's birth weight is not provided, so we cannot determine if they meet the 750-1500 gram birth weight criteria.\n\n3. The patient is described as having undergone major surgery and having signs of shock (low urine output, generalized edema, elevated heart rate), which could potentially meet the \"shock in the first week of life requiring vasopressor therapy\" criteria for cases.\n\n4. However, it is not explicitly stated if the patient required vasopressor therapy or met the dosage threshold specified.\n\nGiven the incomplete information and the patient's age being outside the gestational age range, I would assess:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWe would need more details on the patient's birth weight, gestational age at birth, and whether vasopressor therapy at the specified dosage was required to make a definitive determination. But the signs of shock post-surgery make them a potential candidate if they meet the other criteria.",
        "label": 1
    },
    "585": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 6-month-old male infant with signs of acute kidney injury after major surgery, including oliguria, edema, elevated BUN and creatinine, and abnormal urinalysis findings.\n\nThe clinical trial is looking to define normal citrulline levels in premature infants (<32 weeks gestational age) as a potential screening tool for gastrointestinal disease.\n\nSince the patient is 6 months old and was not premature, he does not meet the inclusion criteria of gestational age <32 weeks for this particular trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "586": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age inclusion criteria of 18-80 years old for this clinical trial on minimal change nephritic syndrome in adults.\n\n2. The patient has generalized edema, low urine output, elevated blood urea nitrogen and serum creatinine levels, which suggest acute kidney injury rather than minimal change nephritic syndrome.\n\n3. The urinalysis shows hematuria (red blood cells) and casts, which are not typical findings in minimal change disease.\n\n4. There is no mention of a kidney biopsy confirming the diagnosis of minimal change disease, which is an inclusion criteria.\n\n5. The urine protein/creatinine ratio and serum albumin level are not provided, so it's unclear if the patient meets those inclusion criteria.\n\nBased on the information provided, this 6-month-old infant with acute kidney injury and atypical urinalysis findings does not appear to be eligible for this adult clinical trial specifically studying minimal change nephritic syndrome.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "587": {
        "output": "Let's go through the inclusion criteria for this clinical trial:\n\n1. 18 years or older\n   - The patient is a 6-month-old infant, so this criterion is not met.\n\n2. Male\n   - The patient is a male infant, so this criterion is met.\n\n3. Signed informed consent\n   - There is no information provided about whether informed consent was obtained or not.\n\n4. Negative urine multistix\n   - The patient's urinalysis shows abnormal findings (RBCs, WBCs, and casts), so this criterion is likely not met.\n\nOverall, while the patient meets the gender criterion, they do not meet the age or negative urine multistix criteria. Additionally, there is no information provided about informed consent.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "588": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age criteria of at least 18 years old for this clinical trial.\n\n2. The patient has cirrhosis and ascites, which meets one of the inclusion criteria.\n\n3. The patient has a serum creatinine of 1.3 mg/dL, which does not meet the criteria of serum creatinine \u2265 2.5 mg/dL.\n\n4. There is no information provided about whether the patient's serum creatinine has doubled within 2 weeks or if the patient has had no sustained improvement in renal function after diuretic withdrawal and albumin administration.\n\nSince the patient does not meet the age criteria and the serum creatinine criteria, and there is not enough information about the other criteria related to the progression of renal function, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "589": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age inclusion criteria of 18 years to 90 years old for this clinical trial.\n\n2. The patient has signs of acute kidney injury after major surgery, with oliguria, elevated BUN/creatinine, and abnormal urinalysis findings. This could potentially qualify as a \"proteinuric disease state\" which is one of the inclusion criteria.\n\n3. However, the trial specifically states it is looking at patients with newly diagnosed kidney disease who require a kidney biopsy. This infant's acute kidney injury is likely due to the recent major surgery rather than a newly diagnosed chronic kidney disease process.\n\n4. There is no mention of the infant undergoing or requiring a kidney biopsy, which is a key inclusion criteria for this trial evaluating inflammatory mediators in kidney biopsy tissue.\n\nIn summary, while the infant has some signs of acute kidney injury, they do not meet the age criteria and do not appear to have a newly diagnosed chronic kidney disease process requiring a kidney biopsy per the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "590": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 6-month-old male infant who has recently undergone major surgery. He is showing signs of acute kidney injury (AKI), including:\n- Low urine output (<0.2 mL/kg/hr)\n- Generalized edema\n- Elevated blood urea nitrogen (33 mg/dL) and serum creatinine (1.3 mg/dL)\n- Abnormal urinalysis findings (hematuria, pyuria, granular casts)\n\nThe clinical trial is studying the use of urinary NGAL (neutrophil gelatinase-associated lipocalin) as an early predictive marker of AKI after cardiac surgery in neonates and infants.\n\nThe key inclusion criteria are:\n1) Term neonates and infants undergoing heart surgery with cardiopulmonary bypass\n2) Parents received written information and did not oppose participation\n\nThis patient meets the first inclusion criteria, as he is a 6-month-old infant who has recently undergone major surgery (likely involving cardiopulmonary bypass, given the context).\n\nRegarding the second criteria, there is no information provided about whether the parents received written information or opposed participation.\n\nOverall, based on the information given, this patient is likely eligible for the clinical trial, as he meets the key inclusion criteria of being a neonate/infant who has undergone cardiac surgery and is showing signs of AKI. However, parental consent would need to be confirmed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of parental consent.",
        "label": 1
    },
    "591": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age criteria of 18-50 years old for this clinical trial.\n\n2. There is no mention of the patient having a documented diagnosis of autosomal dominant polycystic kidney disease (ADPKD), which is a key inclusion criteria.\n\n3. The total kidney volume is not provided, but the patient is described as having generalized edema and oliguria (low urine output), which suggests kidney dysfunction rather than enlarged polycystic kidneys.\n\n4. The patient's serum creatinine of 1.3 mg/dL indicates reduced kidney function, with an estimated GFR likely below the required 60 mL/min/1.73m2 for this trial.\n\nBased on the information provided, this 6-month-old patient with acute kidney injury and no documented ADPKD diagnosis does not meet the key inclusion criteria for this bosutinib clinical trial in ADPKD.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "592": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Gestational age <29 weeks: The patient note does not mention the gestational age, so this criterion cannot be evaluated.\n2. An echocardiographic evidence of significant PDA: The patient note does not mention any information about a patent ductus arteriosus (PDA), so this criterion cannot be evaluated.\n3. An age of 12 to 24 hours: The patient note states that the patient is a 6-month-old infant, which does not meet this criterion.\n4. RDS necessitating respiratory support: The patient note does not mention any information about respiratory distress syndrome (RDS) or the need for respiratory support, so this criterion cannot be evaluated.\n\nExclusion Criteria:\n1. Major congenital anomalies: The patient note does not mention any congenital anomalies, so this exclusion criterion is not applicable.\n2. Life-threatening infection or hydrops fetalis: The patient note does not mention any life-threatening infection or hydrops fetalis, so this exclusion criterion is not applicable.\n3. Pulmonary hypertension: The patient note does not mention any information about pulmonary hypertension, so this exclusion criterion cannot be evaluated.\n4. Death before the conclusion of the first course of ibuprofen: This exclusion criterion is not applicable since the patient has not received any ibuprofen treatment yet.\n5. Urine output below 1 ml per kilogram of body weight per hour during the preceding 12 hours (with the exception of the first dose): The patient note states that the patient has a urine output of less than 0.2 mL/kg/hr, which meets this exclusion criterion.\n6. A serum creatinine concentration of >1.5 mg/dL (129 \u03bcmol per liter): The patient note states that the patient's serum creatinine is 1.3 mg/dL, which does not meet this exclusion criterion.\n7. A platelet count of <50,000/mm3: The patient note does not mention any information about the patient's platelet count, so this exclusion criterion cannot be evaluated.\n8. A tendency to bleed, as revealed by hematuria, blood in the endotracheal aspirate, gastric aspirate, or stools, and oozing from puncture sites: The patient note mentions that the urinalysis shows 18 RBCs per HPF, which may indicate hematuria and a tendency to bleed, meeting this exclusion criterion.\n\nBased on the information provided in the patient note, the patient does not meet the age criterion for inclusion and meets at least one exclusion criterion (low urine output and possible hematuria/tendency to bleed). Therefore, the patient is unlikely to be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "593": {
        "output": "Let's go through the inclusion criteria for this clinical trial:\n\n1. Age birth to 18 years\nThe patient is a 6-month-old infant, which falls within this age range.\n\n2. Cardiac surgery with planned cardiopulmonary bypass\nThe patient note does not explicitly mention that the patient is undergoing cardiac surgery with planned cardiopulmonary bypass. However, it states that the patient has undergone \"major surgery\" and is exhibiting signs of acute kidney injury shortly after the surgery.\n\nSince the trial is investigating the effects of remote ischemic preconditioning on post-operative acute kidney, myocardial, and lung injury, it is possible that this patient may be eligible if the \"major surgery\" involved cardiopulmonary bypass.\n\nHowever, without more specific information about the type of surgery the patient underwent, it is difficult to determine eligibility with certainty.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "594": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which falls within the age range of < 6 months specified in the inclusion criteria.\n\n2. The patient has undergone major surgery, which is a requirement for this clinical trial studying postoperative pain management in infants.\n\n3. The patient's urine output is less than 0.2 mL/kg/hr, which could indicate acute kidney injury, a potential safety concern for the use of ketorolac, a non-steroidal anti-inflammatory drug (NSAID).\n\n4. The patient's blood urea nitrogen and serum creatinine levels are elevated, further suggesting acute kidney injury.\n\n5. The urinalysis findings of hematuria (18 RBCs/HPF) and granular casts could also be indicative of acute kidney injury.\n\nBased on the information provided, there are concerns about the patient's kidney function, which could potentially increase the risk of adverse effects from ketorolac. However, the trial aims to study the safety and pharmacokinetics of ketorolac in this age group, and the patient meets the age and postoperative criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the severity and cause of the acute kidney injury, as well as a discussion of the potential risks and benefits with the patient's caregivers.",
        "label": 2
    },
    "595": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age criteria of 14-60 years for this clinical trial on refractory nephrotic syndrome.\n\n2. The patient has a urine output of less than 0.2 mL/kg/hr and generalized edema, which suggests nephrotic syndrome. However, the trial specifically excludes secondary causes of nephrotic syndrome, and this patient's nephrotic syndrome appears to be secondary to recent major surgery.\n\n3. The patient's eGFR is not provided, so it's unclear if they meet the criteria of eGFR \u2265 60 ml/min/1.73 m2.\n\n4. There is no information provided about whether this patient has tried and failed steroid or other immunosuppressive therapy for nephrotic syndrome, which is a key inclusion criteria.\n\nOverall, based on the age not meeting criteria and the likely secondary cause of the nephrotic syndrome, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "596": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which meets the age criteria of < 18 years for the clinical trial.\n\n2. The patient has acute kidney injury requiring renal replacement therapy, as evidenced by the low urine output, elevated BUN and creatinine, and presence of casts and hematuria on urinalysis. This meets the inclusion criteria of \"Acute kidney injury as defined by pRIFLE classification requiring extra renal replacement therapy, whatever is the method.\"\n\nSince the patient meets both of the listed inclusion criteria for this pediatric acute kidney injury clinical trial, I would assess the eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "597": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age inclusion criteria of \">12 years\" for this clinical trial on severe malaria.\n\n2. There is no mention of the patient having malaria or a positive blood smear for Plasmodium falciparum, which is required by the inclusion criteria.\n\n3. The patient's temperature is not provided, so we cannot determine if they meet the fever criteria.\n\n4. There is no information about consent being provided.\n\nBased on the information given, this 6-month-old infant patient would not be eligible for this clinical trial on severe malaria due to not meeting the age criteria and lacking evidence of having malaria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "598": {
        "output": "Based on the patient note provided, the patient is a 6-month-old male infant who has recently undergone major surgery and is exhibiting signs of acute kidney injury (AKI), such as oliguria (low urine output), elevated serum creatinine, and the presence of red blood cells and casts in the urine.\n\nThe clinical trial titled \"Plasma and Hemodynamic Markers During Hepatectomy\" is focused on studying the effects of liver resection (hepatectomy) on renal function and liver regeneration in patients with neoplastic liver tumors.\n\nConsidering the inclusion criteria of the clinical trial, which states \"Patient with neoplastic liver tumors undergoing elective hepatectomy,\" the 6-month-old infant patient does not appear to meet this criterion as there is no mention of a neoplastic liver tumor or a planned hepatectomy in the patient note.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "599": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Sodium Supplementation and Growth in Very Low Birth Weight Infants\", here is my assessment:\n\nThe patient note describes a 6-month-old male infant with signs of acute kidney injury (oliguria, elevated BUN and creatinine, hematuria, and granular casts in urine) shortly after undergoing major surgery. The infant does not meet the inclusion criteria of being born at less than 32 weeks postmenstrual age for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "600": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age inclusion criteria of \"> 18 years\" for this clinical trial.\n\n2. The patient has generalized edema, low urine output, elevated blood urea nitrogen and serum creatinine levels, which suggest kidney dysfunction. This would likely exclude the patient based on the exclusion criteria of \"Evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations\" and \"Presence of values, which are significantly different from normal reference ranges and/or judged clinically significant for serum creatinine, blood urea nitrogen...\"\n\n3. The urinalysis shows hematuria (blood in urine) and casts, which would exclude the patient based on the exclusion criteria \"Clinically abnormal chemical and microscopic examination of urine defined as presence of red blood cells, white blood cells (>4/High Power Field [HPF]), glucose (positive) or protein (positive)\".\n\nBased on the information provided, this 6-month-old infant with kidney dysfunction and abnormal urinalysis would not be eligible for this phase 1 clinical trial assessing the ocular safety and tolerability of an eye drop formulation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "601": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: Adult deceased brain dead kidney donors and recipients scheduled for renal transplantation\n\nThe patient note describes a 6-month-old male infant undergoing major surgery, with signs of acute kidney injury (oliguria, elevated BUN and creatinine, and abnormal urinalysis findings). The patient is not an adult deceased brain dead kidney donor or recipient scheduled for renal transplantation.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "602": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not match the inclusion criteria of patients undergoing cardiac surgery.\n\n2. The patient has low urine output, generalized edema, elevated blood urea nitrogen and serum creatinine levels, indicating potential kidney dysfunction or acute kidney injury after major surgery.\n\n3. The inclusion criteria specify patients undergoing cardiac surgery between 2007 and 2011 at a specific hospital (Charit\u00e9 hospital).\n\nBased on the information provided, this patient does not meet the inclusion criteria for this particular clinical trial investigating the renal effects of levosimendan in cardiac surgery patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "603": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age criteria of 18-65 years old for any of the groups in the inclusion criteria.\n\n2. The patient has undergone major surgery and is showing signs of acute kidney injury with oliguria, elevated BUN and creatinine, and abnormal urinalysis findings. There is no mention of nephrolithiasis or the need for nephrolithotomy.\n\n3. The patient does not appear to have normal renal function or be a candidate for radical nephrectomy or emergency kidney resection.\n\nBased on the information provided, this 6-month-old infant patient with acute kidney injury does not meet any of the inclusion criteria for this clinical trial on screening and identification of microRNA regulating the urate transporter hURAT1 in relation to uric acid stone formation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "604": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not match the inclusion criteria of the clinical trial which is for adult patients with cirrhosis.\n\n2. The patient has signs of acute kidney injury (AKI) with low urine output, elevated BUN and creatinine, and abnormal urinalysis findings. However, the clinical trial is specifically looking at AKI in patients with cirrhosis.\n\n3. There is no mention of the patient having cirrhosis or any liver disease in the patient note.\n\nBased on the information provided, this 6-month-old infant patient would not be eligible for this particular clinical trial on AKI in cirrhotic patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "605": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 6-month-old male infant, which meets the age criteria of \u226418 years for the clinical trial.\n\nThe patient is undergoing major surgery, which implies they will be undergoing cardiac surgery with cardiopulmonary bypass, meeting that inclusion criteria.\n\nThe patient has signs of acute kidney injury with oliguria (urine output <0.2 mL/kg/hr), elevated BUN and creatinine, hematuria, and granular casts on urinalysis.\n\nBased on the information provided, this patient meets all of the stated inclusion criteria for the clinical trial \"Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery\".\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "606": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which fits the inclusion criteria of patients undergoing surgery for congenital heart disease.\n\n2. The patient has signs of acute kidney injury (AKI) after undergoing major surgery, as evidenced by low urine output, elevated BUN and creatinine, and abnormal urinalysis findings.\n\n3. The clinical trial is specifically studying the incidence, risk factors, and risk model of AKI in pediatric patients undergoing surgery for congenital heart disease.\n\nBased on the information provided, this patient appears to be an excellent candidate for this clinical trial, as they meet the inclusion criteria and have developed the condition of interest (AKI) after congenital heart surgery.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "607": {
        "output": "To determine the patient's eligibility for the clinical trial \"Predicting Acute Kidney Injury After Coronary Artery Bypass Graft\", let's go through the inclusion criteria:\n\nInclusion criteria: \"patients who underwent coronary artery bypass surgery during between 2010 and 2012 in Samsung Medical Center\"\n\nBased on the provided patient note, there is no information indicating that this 6-month-old infant underwent coronary artery bypass surgery or was treated at Samsung Medical Center between 2010 and 2012.\n\nThe patient note describes a 6-month-old male infant with signs of acute kidney injury shortly after undergoing major surgery, but the type of surgery is not specified.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "608": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes a 6-month-old male infant with signs of acute kidney injury (oliguria, elevated BUN and creatinine, hematuria, and granular casts in urine) shortly after undergoing major surgery. However, the clinical trial is focused on evaluating the influence of tidal volume during mechanical ventilation on postoperative clinical outcomes in pediatric patients undergoing congenital heart surgery.\n\nWhile the patient note mentions that the infant underwent major surgery, there is no information provided about whether the surgery was related to congenital heart disease or if the patient required mechanical ventilation. Additionally, the inclusion criteria specifically state that the study is looking at patients who underwent surgery for congenital heart disease with cardiopulmonary bypass at a specific medical center (Samsung Medical Center) between 2009 and 2013.\n\nGiven the lack of information about the type of surgery and the medical center where it was performed, as well as the absence of details about mechanical ventilation, it is difficult to determine if this patient would be eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "609": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age inclusion criteria of \">18 years\" for this clinical trial.\n\n2. There is no mention of the patient having cirrhosis of the liver, which is one of the inclusion criteria.\n\n3. While the patient does have acute kidney injury based on the details provided (low urine output, elevated BUN/creatinine, abnormal urinalysis), the clinical trial specifically requires the patients to be hospitalized at the University of Virginia Medical Center. There is no information given about where this patient is hospitalized.\n\nBased on the information provided in the patient note, this infant would not be eligible for the clinical trial evaluating renal blood flow using contrast-enhanced ultrasound in cirrhotic patients with acute kidney injury.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "610": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the age criteria of \u2265 18 years for this clinical trial.\n\n2. The patient has a Foley catheter and urine collection system in place, which meets one of the inclusion criteria.\n\n3. There is no information provided about the estimated length of placement of the Foley catheter, so we cannot determine if the patient meets that criteria.\n\n4. The patient does not have a burn injury, which is a requirement for inclusion in this trial.\n\n5. Since the patient is an infant, they would not be able to provide informed consent, and it is not specified if a legally authorized representative is available to provide consent.\n\nBased on the information provided, the patient does not meet several of the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "611": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 6-month-old male infant, so he does not meet the inclusion criteria of being a post-menopausal woman.\n\nAdditionally, while the patient does have microscopic hematuria (18 RBCs per HPF), this is likely due to the recent major surgery and acute kidney injury, rather than being asymptomatic microscopic hematuria.\n\nTherefore, this patient would not be eligible for the clinical trial titled \"Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "612": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not match the inclusion criteria of age \u2265 18 years.\n\n2. The patient has undergone major surgery and is showing signs of acute kidney injury (oliguria, elevated BUN/creatinine, hematuria, and granular casts in urine). This matches the intent of the trial to study acute kidney function decrease after non-cardiac surgery.\n\n3. However, the inclusion criteria specifically state \"43 patients who had non-cardiac surgery in Seoul Paik Hospital.\" Since there is no mention of this patient being treated at Seoul Paik Hospital, we cannot definitively confirm eligibility.\n\nBased on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of whether they were treated at Seoul Paik Hospital.",
        "label": 0
    },
    "613": {
        "output": "To determine the patient's eligibility for the clinical trial \"Pharmacology of Aminophylline for Acute Kidney Injury in Neonates\", let's go through the inclusion criteria one by one:\n\n1. Neonate < 3 months post natal age\nThe patient is a 6-month-old male infant, which meets this criterion.\n\n2. Diagnosed with acute kidney injury (AKI)\nThe patient has a urine output of less than 0.2 mL/kg/hr, elevated blood urea nitrogen and serum creatinine levels, and the presence of RBCs and granular casts in the urine, which are indicative of acute kidney injury.\n\n3. Receiving aminophylline for AKI treatment as per local standard of care.\nThe patient note does not mention whether the patient is receiving aminophylline for AKI treatment.\n\nBased on the information provided, the patient meets two out of the three inclusion criteria. However, since there is no mention of the patient receiving aminophylline for AKI treatment, it is unclear if the patient fully meets the eligibility criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding the use of aminophylline for AKI treatment.",
        "label": 0
    },
    "614": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not match the inclusion criteria of age \u2265 18 years for the clinical trial.\n\n2. The patient does not have a diagnosis of IgA nephropathy or Henoch-Schonlein purpura, which are required for inclusion in this trial.\n\n3. The patient's serum creatinine of 1.3 mg/dL suggests a creatinine clearance/GFR below 30 ml/min/1.73m2, which is an exclusion criterion.\n\n4. The patient's hemoglobin level is not provided, so it's unclear if they meet the inclusion criteria of hemoglobin \u2265 8.5 g/dL.\n\n5. The patient's platelet count is not provided, so it's unclear if they meet the inclusion criteria of platelets \u2265 100,000/mm3.\n\n6. The patient's AST and ALT levels are not provided, so it's unclear if they meet the inclusion criteria of AST/ALT \u2264 2.5 times the upper limit of normal.\n\nBased on the information provided, this patient does not meet several key inclusion criteria and potentially meets some exclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "615": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which meets the age criteria for the study (children who were born prematurely).\n\n2. The patient has a low urine output of less than 0.2 mL/kg/hr shortly after undergoing major surgery, suggesting potential acute kidney injury (AKI).\n\n3. The patient's blood urea nitrogen and serum creatinine levels are elevated, further indicating kidney dysfunction.\n\n4. The urinalysis shows hematuria (blood in urine), pyuria (white blood cells in urine), and granular casts, which are consistent with AKI.\n\n5. The fractional excretion of sodium is 3.3%, which is elevated and suggests acute tubular necrosis, a type of AKI.\n\nBased on the information provided, this patient appears to have experienced AKI, which is one of the inclusion criteria for the \"Premature AKI Study group\" in this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "616": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fed Conditions\", it is unlikely that this 6-month-old infant patient would be eligible for the trial.\n\nThe key reasons are:\n\n1. The inclusion criteria specifically mention that the study is looking for healthy adult male volunteers aged 18-45 years. The patient is a 6-month-old infant, which does not meet the age or gender criteria.\n\n2. The patient note indicates that the infant has recently undergone major surgery and is exhibiting signs of acute kidney injury (oliguria, elevated BUN and creatinine, hematuria, and granular casts in urine). This would exclude the patient from being considered \"normal health\" as required by the inclusion criteria.\n\n3. The study is assessing the bioequivalence of an extended-release felodipine formulation, which is typically used for the treatment of hypertension in adults. It is unlikely that a 6-month-old infant would be an appropriate participant for such a study.\n\nTherefore, based on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "617": {
        "output": "To determine the patient's eligibility for the clinical trial \"Delayed Renal Allograft Function and Furosemide Treatment\", let's go through the inclusion criteria one by one:\n\nAge \u2265 18 years: The patient is a 6-month-old infant, so this criterion is not met.\n\nPatient with ESRD who has been on RRT (Hemodialysis or Peritoneal dialysis): There is no information provided about the patient being on renal replacement therapy, so this criterion cannot be evaluated.\n\nRecipient of deceased donor kidney transplant: There is no information provided about the patient receiving a kidney transplant, so this criterion cannot be evaluated.\n\nUrine output less than 0.5 mL/kg/h before transplant: The patient's urine output is mentioned as less than 0.2 mL/kg/hr, which meets this criterion.\n\nPatient consents to the study: There is no information provided about the patient or their legal guardian consenting to the study, so this criterion cannot be evaluated.\n\nPatient is not allergic to furosemide or sulfa: There is no information provided about the patient's allergies, so this criterion cannot be evaluated.\n\nEnglish or Spanish speaking patient: There is no information provided about the patient's language, so this criterion cannot be evaluated.\n\nPatient is oliguric (urine output less than 0.5mL/kg/h, as per AKIN criteria) or anuric (urine output less than 10 mL in 6 hours post-transplant or 2 mL/h) in the first 6 hours post kidney transplant: The patient's urine output is mentioned as less than 0.2 mL/kg/hr, which meets this criterion.\n\nBased on the information provided, the patient meets at least two of the inclusion criteria (urine output and oliguria/anuria criteria). However, there are several criteria that cannot be evaluated due to lack of information, such as the patient's renal replacement therapy status, kidney transplant status, consent, allergies, and language.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "618": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Narrow Band Imaging in Flexible Cystocopy\", here is my assessment:\n\nThe patient note describes a 6-month-old male infant with signs of acute kidney injury (oliguria, elevated BUN/creatinine, hematuria, and granular casts in urine) shortly after undergoing major surgery. \n\nThe inclusion criteria for the clinical trial state that patients undergoing flexible cystoscopy because of hematuria or previous non-muscle invasive bladder cancer (NMIBC) are eligible.\n\nWhile the patient does have hematuria, the note does not mention any indication for cystoscopy or bladder-related conditions. The patient's acute kidney injury and post-operative status suggest that the hematuria is likely related to these factors rather than a bladder condition that would warrant cystoscopy.\n\nTherefore, based on the information provided, this patient would not be eligible for the \"Narrow Band Imaging in Flexible Cystocopy\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "619": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the inclusion criteria of \"adult patients\".\n\n2. The patient has oliguria (urine output < 0.2 mL/kg/hr) shortly after major surgery, which meets the inclusion criteria of \"acute oliguric renal failure\".\n\n3. The details provided do not specify if the patient is critically ill or within 6 hours of presentation.\n\nBased on the information provided, I would consider referring this patient to this clinical trial upon further investigation to determine if the patient meets the remaining inclusion criteria of being critically ill and within 6 hours of presentation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "620": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the inclusion criteria of \"old patients scheduled to undergo orthopaedic surgery\".\n\n2. The trial is evaluating the nephrotoxicity (kidney toxicity) of a particular fluid (6% hydroxyethyl starch 130/0.4) used during surgery. \n\n3. The patient note indicates the infant has signs of acute kidney injury after major surgery, with oliguria (low urine output), edema, elevated BUN/creatinine, hematuria (blood in urine), and granular casts in the urine.\n\n4. However, the trial's inclusion criteria specifies \"old patients\" and does not mention evaluating acute kidney injury in infants/children after surgery.\n\n5. Therefore, based on the provided information, this 6-month-old infant patient would likely not be eligible for this particular clinical trial evaluating nephrotoxicity in elderly orthopedic surgery patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "621": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant who recently underwent major surgery.\n2. He has signs of acute kidney injury with oliguria, edema, elevated BUN/creatinine, and abnormal urinalysis findings.\n3. The clinical trial is studying optimal postoperative feeding regimens following pyloromyotomy surgery for pyloric stenosis.\n4. The inclusion criteria state that subjects must be infants diagnosed with pyloric stenosis who will undergo pyloromyotomy.\n\nBased on the information provided, this patient does not have a diagnosis of pyloric stenosis and did not undergo pyloromyotomy surgery. His presentation is more consistent with acute kidney injury in the postoperative period following a different type of major surgery.\n\nTherefore, this patient would not meet the inclusion criteria for the clinical trial studying postoperative feeding after pyloromyotomy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "622": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which meets the inclusion criteria of being an infant admitted to a level 2 or 3 NICU.\n\n2. The patient has received intravenous fluids, as evidenced by the mention of \"undergoing major surgery\" and having a urine output of less than 0.2 mL/kg/hr, which suggests the need for intravenous fluid administration.\n\n3. The patient has signs of acute kidney injury (AKI), such as oliguria (low urine output), elevated serum creatinine, and the presence of granular casts in the urine.\n\n4. The study aims to assess the epidemiology of AKI in neonates, develop a standardized definition of neonatal AKI, evaluate risk factors, and investigate the impact of fluid provision/balance on outcomes.\n\nBased on the information provided, this patient meets the inclusion criteria for the clinical trial, as the patient is an infant admitted to a NICU, has received intravenous fluids for more than 48 hours, and has signs of AKI, which is the primary condition being studied.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "623": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not meet the inclusion criteria of being an adult patient scheduled for coronary and/or peripheral angiography and/or angioplasty.\n\n2. The patient has an estimated GFR of less than 45 ml/min/1.73 m2, based on the serum creatinine of 1.3 mg/dL, which meets one of the inclusion criteria.\n\n3. However, there is no information provided about the patient's Mehran's score or Gurm's score, which are also part of the inclusion criteria.\n\n4. Overall, while the patient meets one of the inclusion criteria (low eGFR), there is not enough information to determine if they meet the other criteria related to risk scores.\n\nTherefore, based on the information provided, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their Mehran's score and Gurm's score.",
        "label": 0
    },
    "624": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. ASA physical status grade I and II infants (1-12month).\nThe patient note mentions a 6-month-old male infant, which falls within the age range of 1-12 months. However, there is no information provided about the ASA physical status grade.\n\n2. undergoing elective cataract surgery in one eye under general anesthesia.\nThe patient note does not mention anything about the patient undergoing cataract surgery or general anesthesia. It appears to be describing a postoperative state after a major surgery, but the type of surgery is not specified.\n\nSince the patient does not meet the second inclusion criterion and there is insufficient information to determine if the first criterion is met, I would not consider referring this patient for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "625": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment\", this 6-month-old male infant would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The inclusion criteria specify that participants should be lifelong residents of the area where the study is being conducted, but no information is provided about the patient's residence.\n\n2. The inclusion criteria require participants to be negative for schistosomes, hookworm, Trichuris, and Ascaris, but the patient's parasitological status is not mentioned in the note.\n\n3. The inclusion criteria state that participants should have frequent contact with infective water, but no information is provided about the patient's water exposure.\n\n4. The patient is a 6-month-old infant, while the trial seems to be focused on children who are old enough to provide urine and stool samples for parasitological examination.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "626": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not match the inclusion criteria of being an adult cancer patient admitted to the ICU after major surgery.\n\n2. The patient has low urine output, generalized edema, elevated blood urea nitrogen and serum creatinine, suggesting acute kidney injury. However, the cause is not clearly stated as being due to ischemia-reperfusion injury from major surgery.\n\n3. The patient's fractional excretion of sodium is 3.3%, which is not very high and does not strongly suggest acute tubular necrosis from ischemia.\n\n4. There is no mention of the patient having cancer or undergoing major surgery recently.\n\nBased on the information provided, this patient does not seem to meet the key inclusion criteria for the clinical trial, which requires adult cancer patients who have undergone major surgery and are at risk of ischemic acute kidney injury.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "627": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 6-month-old male infant, which does not match the inclusion criteria of patients with a history of bladder cancer in follow-up for tumor recurrence.\n\n2. The patient's presenting symptoms (low urine output, edema, elevated BUN/creatinine) suggest acute kidney injury, likely related to the recent major surgery. There is no mention of bladder cancer or tumors.\n\n3. The urinalysis findings (hematuria, casts) are non-specific and could be related to the acute kidney injury rather than bladder cancer.\n\nTherefore, based on the information provided in the patient note, this patient would not be eligible for the clinical trial studying blue light cystoscopy for detection of bladder cancer recurrence.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "628": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 6-month-old male infant who has recently undergone major surgery. Some key points from the note:\n\n- Low urine output (<0.2 mL/kg/hr) suggesting acute kidney injury\n- Generalized edema\n- Elevated blood urea nitrogen and serum creatinine\n- Abnormal urinalysis findings (hematuria, casts)\n\nThe clinical trial is looking at the effect of hydroxyethyl starch on kidney injury in pediatric cardiac surgery patients.\n\nThe inclusion criteria are:\n1) Children aged less than 7 years old\n2) ASA physical status 1-3\n\nThis patient meets the age criteria as he is 6 months old. However, there is no information provided about his ASA physical status.\n\nGiven the acute kidney injury findings and the fact that he just had major surgery, it is highly likely that his ASA status would be at least 3 if not higher.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his ASA physical status.",
        "label": 1
    },
    "629": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking, describing progressive dysphagia (difficulty swallowing) that began several months ago. He has lost 25 pounds.\n\nThe clinical trial is for treating patients with cancer of the esophagus using combination chemotherapy and radiation therapy.\n\nLooking at the inclusion criteria:\n- It requires histologically confirmed epidermoid carcinoma or adenocarcinoma of the esophagus, which is not explicitly stated in the patient note. However, the progressive dysphagia and weight loss are suggestive of esophageal cancer.\n- The disease must be limited to the esophagus, without invasion into surrounding structures like the trachea or pleura, which is not clearly stated.\n- The patient must have adequate hematologic, hepatic, and renal function, as well as an acceptable performance status, which are not provided.\n- The patient should not have received prior chemotherapy or radiotherapy, which is not mentioned.\n\nBased on the information provided, there are some key details missing to definitively determine eligibility, such as the cancer type, stage, and extent of disease, as well as the patient's overall health status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "630": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. This matches the age criteria of 18-75 years old.\n\nHe describes progressive dysphagia (difficulty swallowing) that began several months ago, progressing from solid foods to liquids. This suggests he likely has esophageal cancer.\n\nThe clinical trial is for patients with stage II or III esophageal squamous cell cancer. While the patient's stage is not explicitly stated, the progressive dysphagia and weight loss of 25 pounds are concerning for locally advanced esophageal cancer.\n\nThe inclusion criteria specify histologically confirmed squamous cell carcinoma of the esophagus, stage T2-3 N0 M0 (stage II or III). The patient's histology is not provided, but squamous cell is the most common type of esophageal cancer.\n\nThere are no other major exclusion criteria listed that would rule out this patient.\n\nOverall, while we don't have complete staging information, this patient's presentation is highly suggestive of locally advanced esophageal cancer that could potentially meet the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation (e.g. biopsy, staging).",
        "label": 1
    },
    "631": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is describing progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids over several months. He has lost 25 pounds.\n\nThe clinical trial is for patients with lung and esophageal cancers that may be removed by surgery. The key inclusion criteria are:\n\n1. Histologically confirmed esophageal or non-small cell lung carcinoma\n2. For esophageal cancer: Biopsy proven and considered acceptable for curative resection\n3. For lung cancer: Stages IA-IIIB without pleural effusion, candidates for induction chemo followed by surgical resection\n4. Age 18 and over\n5. Adequate performance status and organ function\n\nWhile the patient's symptoms of progressive dysphagia and weight loss are concerning for an esophageal malignancy, there is no confirmation yet of a cancer diagnosis or staging information provided. More diagnostic workup would be needed.\n\nGiven the limited information provided, I would assess this patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "632": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He has progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids as well. He has lost 25 pounds.\n\nThe clinical trial is for treating esophageal cancer with combination chemotherapy and radiation therapy.\n\nLooking at the inclusion criteria:\n- Histologically confirmed adenocarcinoma, squamous cell, adenosquamous, or undifferentiated carcinoma of the esophagus or gastroesophageal junction - This patient likely has esophageal cancer based on the symptoms, but it is not explicitly confirmed histologically yet.\n- Potentially resectable disease - Not mentioned if the disease is resectable or not.\n- No malignant celiac node involvement - Not mentioned.\n- No cervical esophageal carcinoma - Location not specified, but symptoms point to lower esophageal cancer.\n- Age 18 and over - The patient is 52, so meets this criteria.\n- ECOG performance status 0-2 - Not mentioned.\n- Adequate hematologic, hepatic, and renal function - Not mentioned.\n- No other recent malignancies - Not mentioned.\n- No significant medical or psychiatric illness that would preclude study - Not mentioned.\n- Not pregnant/nursing and using contraception if fertile - Likely not an issue for a 52-year-old man.\n- No prior chemotherapy, thoracic radiotherapy, or surgical resection for esophageal cancer - Meets this criteria based on information given.\n\nOverall, the patient meets some of the key inclusion criteria like being over age 18 and not having had prior treatment for esophageal cancer. However, there are several criteria that are not mentioned or confirmed, such as histologic confirmation of cancer type, disease resectability, performance status, and adequate organ function.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to confirm eligibility based on the unmentioned criteria.",
        "label": 1
    },
    "633": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. The clinical trial is looking for smokers between 18-60 years old with a minimum 2-year history of smoking and currently smoking >10 cigarettes per day.\n3. The patient meets the age criteria (52 years old) and likely meets the smoking history criteria given his \"heavy smoking\" history.\n4. However, there is no information provided about his current smoking level (>10 cigarettes per day).\n5. The trial also excludes people being treated for serious physical disorders, which the patient note does not mention.\n\nGiven the available information, I would consider referring this patient to the clinical trial upon further investigation into his current smoking level.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "634": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Biopsy proven Carcinoma of the oesophagus: The patient note does not explicitly mention a biopsy confirming esophageal cancer, but it describes progressive dysphagia (difficulty swallowing) which is a common symptom of esophageal cancer.\n\n2. Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness: The patient note does not provide information about the stage of the cancer or presence of metastases.\n\n3. Symptomatic patients with dysphagia scores of \u2265 1 i.e. able to eat only some solids: The patient note mentions that the patient initially had difficulty swallowing meat, which then progressed to other solid foods, soft foods, and liquids, indicating a dysphagia score of at least 1.\n\n4. Performance status ECOG \u2264 2: The patient note does not provide information about the patient's performance status.\n\n5. Patients must begin treatment within 2 weeks of randomization: The patient note does not provide information about the timeline for starting treatment.\n\n6. Patient is at least 18 years old: The patient note states that the patient is 52 years old, which meets this criterion.\n\n7. Adequate haematological function to undergo chemotherapy: The patient note does not provide information about the patient's hematological function.\n\n8. Adequate renal function, Creatinine - Calculated clearance \u2265 50 ml/min: The patient note does not provide information about the patient's renal function.\n\n9. Patients capable of childbearing are using adequate contraception: The patient note does not provide information about the patient's childbearing status or use of contraception.\n\n10. Written informed consent of patient: The patient note does not provide information about whether the patient has provided written informed consent.\n\nBased on the information provided in the patient note, there are some criteria that are met (dysphagia, age), some that are unclear (stage of cancer, performance status, hematological and renal function, childbearing status, informed consent), and some that are not met (no mention of a biopsy confirming esophageal cancer).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "635": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients aged 18-90 presenting with dysphagia or food impaction\nThe patient note mentions that the 52-year-old man is presenting with progressive dysphagia, which started with difficulty swallowing meat and progressed to other solid foods, soft foods, and liquids. This meets the inclusion criterion of presenting with dysphagia.\n\n2. Ability to undergo esophagogastroduodenoscopy and biopsies\nThere is no information provided about any contraindications for the patient to undergo an esophagogastroduodenoscopy (EGD) and biopsies.\n\n3. No significant cardiopulmonary disease, or other contraindication to EGD\nAgain, there is no information provided about any significant cardiopulmonary disease or other contraindications for the patient to undergo an EGD.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to meet all the listed criteria.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "636": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the age inclusion criteria of 20-90 years old for the clinical trial.\n\n2. The patient has a history of heavy smoking and drinking, which is not listed as an exclusion criterion.\n\n3. The patient describes progressive dysphagia (difficulty swallowing) that began several months ago, progressing from solid foods to liquids. This matches the inclusion criterion of \"Evidence of pharyngeal phase dysphagia following the brain injury that places the patient at risk for aspiration.\"\n\n4. The patient is able to locate the point where food is obstructed at the lower end of his sternum, which suggests pharyngeal phase dysphagia.\n\n5. The patient has lost 25 pounds, which is not listed as an exclusion criterion but may be related to the dysphagia.\n\n6. There is no mention of a history of brain injury, which is an inclusion criterion. However, the progressive dysphagia suggests a potential underlying neurological cause.\n\n7. There is no information provided about the patient's cognitive status, medical stability, or presence of other exclusion criteria such as epilepsy, cardiac conditions, or metal implants.\n\nBased on the information provided, the patient appears to meet some of the key inclusion criteria for the clinical trial, such as age and evidence of pharyngeal phase dysphagia. However, there are still some missing details that would need further investigation to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "637": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which does not meet the age and gender criteria of \"Non-pregnant, non-breastfeeding females; 18- 45 years old\".\n\n2. The patient has a history of heavy smoking and drinking, which could potentially affect the study results, but is not explicitly listed as an exclusion criterion.\n\n3. The patient describes progressive dysphagia (difficulty swallowing) and has lost 25 pounds, which is an alarm indicator and an exclusion criterion (\"No alarm indicators on clinical assessment (weight loss of more than 7kg, bleeding, recent recurrent vomiting, progressive dysphagia)\").\n\n4. There is no mention of a history suggestive of small bowel obstruction, which meets that inclusion criterion.\n\nBased on the information provided, the patient does not meet multiple key inclusion criteria and has at least one explicit exclusion criterion (progressive dysphagia and significant weight loss).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "638": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nLooking at the inclusion criteria for the clinical trial:\n1. Age 18 years or older - The patient is 52, so he meets this criterion.\n2. Ability to understand the protocol and willing to provide written informed consent - This is not mentioned in the patient note, but we can assume he has the ability to understand and provide consent.\n3. Membership in one of the sub-cohorts:\n   - The patient does not have any of the listed cancer types (oral cavity, oropharyngeal, laryngeal, hypopharyngeal, colon, rectal, breast, non-small cell lung, or B-cell Non-Hodgkin's lymphoma).\n   - However, his symptoms of progressive dysphagia and weight loss could potentially be indicative of an underlying cancer that is not specified in the note.\n\nBased on the information provided, the patient's eligibility for this clinical trial is unclear. While he meets some of the inclusion criteria, his specific condition is not mentioned as one of the targeted cancer types.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "639": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nLooking at the inclusion criteria for the clinical trial:\n1. It is for patients with either stage I, II, or IIIa non-small cell lung cancer (NSCLC) who have undergone surgical resection, or stage I or II head and neck squamous cell carcinoma (HNSCC) who have undergone definitive local treatment (surgery or radiation therapy).\n2. For HNSCC patients, the definitive local treatment must have been within 12 months prior to trial enrollment.\n3. For NSCLC patients, the surgery must have been within 12 months prior to trial enrollment.\n4. There should be no evidence of residual cancer.\n5. Age >= 18 years.\n6. Performance status of 0-2 (Zubrod scale).\n7. No contraindications for undergoing bronchoscopy.\n8. No active pulmonary infections.\n9. Specific blood level requirements (granulocyte count, platelet count, bilirubin, creatinine).\n10. Willing to undergo bronchoscopy and endobronchial biopsy for biomarker studies.\n11. Smoking history of at least 10 pack-years (current or former smoker).\n12. Legally capable of providing consent.\n13. For HNSCC patients, no contraindications for undergoing laryngoscopy.\n\nBased on the information provided, this patient does not seem to have a confirmed diagnosis of NSCLC or HNSCC. The progressive dysphagia and weight loss could be indicative of a head and neck cancer, but there is no definitive diagnosis mentioned.\n\nTherefore, based on the available information:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "640": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is describing progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids. He can locate the point of obstruction at the lower end of his sternum, and he has lost 25 pounds.\n\nThe clinical trial is titled \"Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients\". The inclusion criteria state that participants must be:\n\n1. 18 years or older (the patient is 52, so he meets this criteria)\n2. Diagnosed with head and neck cancer including the lip, oral cavity, salivary glands, paranasal sinuses, oropharynx, nasopharynx, hypopharynx, larynx, and thyroid (the patient's note does not explicitly state a cancer diagnosis, but his symptoms of progressive dysphagia and weight loss are concerning for a head and neck cancer)\n3. All histological types of cancer\n4. All tumor stages according to American Joint Committee for Cancer (AJCC) Staging\n5. All forms of RT including standard or investigational and/or concurrent standard or investigational chemotherapy for head and neck cancers (the patient's note does not mention any treatment yet)\n6. Alert and mentally competent (no information provided to suggest otherwise)\n7. English speaking (assumed based on the note)\n\nBased on the information provided, the patient meets some of the key inclusion criteria, such as age and symptoms concerning for a head and neck cancer. However, a definitive cancer diagnosis is not stated in the note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to confirm a head and neck cancer diagnosis.",
        "label": 1
    },
    "641": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes a 52-year-old African American man with a history of heavy smoking and drinking, who is experiencing progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to include liquids as well. He has lost 25 pounds in weight.\n\nThe clinical trial titled \"Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat\" has the following inclusion criteria:\n\n1. The patient must have a diagnosis of pharyngitis with objective findings of tonsillo-pharyngitis.\n2. The patient is willing to take nothing by mouth, including inhaled treatments, except the trial medication during the two hours while at the site and following trial drug administration.\n\nWhile the patient is experiencing difficulty swallowing, which could be related to a sore throat or pharyngitis, the note does not explicitly mention a diagnosis of pharyngitis or tonsillo-pharyngitis. Additionally, there is no information provided about the patient's willingness to take nothing by mouth except the trial medication for the required duration.\n\nTherefore, based on the available information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to confirm the diagnosis of pharyngitis and the patient's willingness to follow the trial protocol regarding oral intake.",
        "label": 0
    },
    "642": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nLooking at the inclusion criteria for the clinical trial:\n1. Age \u2265 18 years (the patient is 52, so he meets this criteria)\n2. Must have persistent, recurrent or progressive ovarian cancer or primary peritoneal cancer after prior treatment with platinum and taxol compounds (the patient does not have ovarian or peritoneal cancer, he seems to have some kind of esophageal/swallowing issue)\n3. Various other criteria related to ovarian/peritoneal cancer staging, lab values, prior treatments, etc.\n\nBased on the information provided, this patient does not seem to meet the key inclusion criteria of having ovarian or peritoneal cancer. His symptoms point to a different condition entirely.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "643": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is titled \"Smoking Status and Body Image in Oral Cancer Patients\" and is looking at smoking behaviors, body image, and quality of life in patients with oral cavity cancer before and after surgical procedures.\n\nThe inclusion criteria are:\n- 18 years of age or older (the patient is 52, so he meets this criterion)\n- Able to provide written informed consent to participate (not mentioned, but we can assume he can)\n- Diagnosis of head and neck malignancy involving an oral cavity site without previous treatment (the patient is describing symptoms consistent with an oral cavity malignancy, and there is no mention of previous treatment)\n- Current treatment plan includes surgical intervention (not explicitly stated, but surgical intervention would likely be recommended based on the symptoms described)\n- English speaking (not mentioned, but we can assume he is)\n\nBased on the information provided, the patient appears to meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "644": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. This matches the inclusion criteria of recruiting smokers, non-smokers, and those exposed to second-hand smoke.\n\nHe describes progressive dysphagia (difficulty swallowing) that began several months ago, progressing from solid foods to liquids. This suggests he may have lung cancer causing esophageal compression/obstruction.\n\nThe trial is specifically for non-small cell lung cancer (NSCLC) with malignant pleural effusion (fluid buildup around the lungs from cancer). The patient note doesn't mention a confirmed diagnosis of NSCLC or pleural effusion yet.\n\nThe other key inclusion criteria are:\n- Stage IIIB or IV NSCLC \n- Measurable disease\n- No prior chemo for metastatic/recurrent disease\n- Adequate blood counts and organ function\n- Age > 18\n- No recent heart issues\n- Able to consent\n- Negative for breast/ovarian cancer if female\n\nWithout a confirmed NSCLC diagnosis and staging information, it's difficult to fully assess eligibility. However, based on the presenting symptoms of progressive dysphagia in a smoker, he could potentially meet the eligibility criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to confirm the diagnosis and stage the disease.",
        "label": 1
    },
    "645": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking, describing progressive dysphagia (difficulty swallowing) that began several months ago. He first noticed difficulty swallowing meat, which then progressed to other solid foods, soft foods, and liquids. He can locate the point where food is obstructed at the lower end of his sternum, and he has lost a total of 25 pounds.\n\nThe clinical trial is studying the effects of intensity-modulated radiotherapy (IMRT) with chemotherapy on swallowing function in patients with previously untreated Stage III or IV oral, laryngeal, and pharyngeal cancer.\n\nThe inclusion criteria specifically state that the target population is patients with stages III or IV squamous cell lesions of the oral cavity, oropharynx, pharynx, or larynx, or unknown primary.\n\nGiven the patient's progressive dysphagia and weight loss, it is highly likely that he has a lesion or cancer in the oral cavity, oropharynx, pharynx, or larynx area, which would make him eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "646": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He describes progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. Patients having a sore throat with acute viral pharyngitis.\n2. Female and male ambulant patients between the ages of 18 and 65.\n3. The throat pain intensity is rated at least severe on the VRS (PI).\n4. Written Informed Consent is given by the patient.\n5. Compliance by the patient seems guaranteed.\n\nThe exclusion criteria are:\n1. Patients with symptoms of primarily bacterial pharyngitis or bacterial secondary infection.\n2. First indication of symptoms of acute pharyngitis occurred more than 3 days ago already.\n3. Counting of white blood cell in blood routine examination exceeds 10?109/L.\n4. Patients who suffered from acute viral or bacterial pharyngitis in the past 4 weeks.\n5. Broncho-motor disorders or concomitant diseases with relatively large quantities of secretion.\n6. Known hypersensitivity to Ambroxol or to auxiliary substances contained in the tablet.\n7. Previous and/or existing tumour condition.\n8. Pregnancy and/or breast-feeding.\n9. Alcohol, and/or drug abuse.\n10. Simultaneous participation in another clinical trial.\n\nBased on the information provided, this patient does not seem to meet the inclusion criteria for this clinical trial. The main issue is that the patient is experiencing progressive dysphagia, which is not a symptom of acute viral pharyngitis (sore throat). Additionally, the patient has a history of heavy smoking and drinking, which could be considered alcohol and/or drug abuse, an exclusion criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "647": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. The clinical trial is focused on assessing smoking cessation interventions in dental clinic smokers.\n3. One of the inclusion criteria is \"Active smokers (active smoking as self-reported regular use of at least 10 cigarettes per day)\".\n4. The patient note mentions that the patient has a history of heavy smoking, which likely meets the criteria of smoking at least 10 cigarettes per day.\n5. However, the primary concern described in the patient note is progressive dysphagia (difficulty swallowing) and weight loss, which does not seem directly related to the focus of the smoking cessation trial.\n\nBased on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the patient meets the criteria of being an active smoker, their primary medical concern appears to be unrelated to smoking cessation. Further investigation may be needed to determine if the patient's dysphagia and weight loss would preclude them from participating in the trial or if they could still be eligible despite these additional medical issues.",
        "label": 0
    },
    "648": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is presenting with progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids as well. He has lost 25 pounds.\n\nThe clinical trial is for patients with stage III or stage IV head and neck squamous cell carcinoma. The key inclusion criteria are:\n\n1. Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx\n2. Locoregionally confined stage III (excluding T1-2, N1) or stage IV disease\n3. No distant metastases\n4. Appropriate for definitive non-operative management with curative intent\n5. ECOG performance status 0-1\n6. Meeting certain lab value criteria\n7. No prior definitive surgery, radiotherapy or systemic therapy for this cancer\n\nBased on the patient's presenting symptoms of progressive dysphagia and weight loss, it is highly suggestive of a head and neck cancer, likely a squamous cell carcinoma given the patient's smoking history. However, the note does not provide information on the stage, location of the primary tumor, or spread of disease.\n\nAdditionally, the note lacks details about the patient's performance status and lab values to fully assess eligibility.\n\nTherefore, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the tumor stage, location, extent of disease, performance status and lab values to definitively determine eligibility.",
        "label": 1
    },
    "649": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is studying biological factors in predicting response to treatment in patients with esophageal cancer or rectal cancer.\n\nThe inclusion criteria state:\n- Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or rectum\n- Planning to receive neoadjuvant treatment, including radiotherapy or chemoradiotherapy\n\nBased on the patient's symptoms of progressive dysphagia and weight loss, it is highly suggestive of esophageal cancer, though a histological confirmation is not provided in the note.\n\nSince the patient's condition and planned treatment are not explicitly stated, it would be premature to definitively determine eligibility. However, given the strong clinical suspicion of esophageal cancer, it would be reasonable to consider referring this patient to this clinical trial upon further investigation and confirmation of diagnosis and planned treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "650": {
        "output": "Let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note describes a 52-year-old African American man with progressive dysphagia (difficulty swallowing) over several months, affecting solids, soft foods, and liquids. He has lost 25 pounds.\n\nThe clinical trial is studying the efficacy and safety of valdecoxib (a COX-2 inhibitor) for treating sore throat pain.\n\nThe key inclusion criteria are:\n1) Moderate to severe sore throat pain, measured by a specific scale (STPIS \u226566 mm on 100-mm VAS)\n2) Minimum Tonsillo-Pharyngitis Score of 4 on a 10-point scale\n3) No coughing or mouth-breathing\n\nBased on the patient note, this patient does not seem to have a sore throat. Rather, they are experiencing progressive dysphagia likely due to an underlying condition like esophageal cancer. They do not meet the key inclusion criteria of having moderate to severe sore throat pain.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "651": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the age criteria of being 18 years or older.\n\n2. The patient has progressive dysphagia (difficulty swallowing) which began several months ago, progressing from solid foods to liquids. This suggests a possible head and neck cancer, though a diagnosis is not explicitly stated.\n\n3. The inclusion criteria specify \"Patients with newly diagnosed, previously untreated squamous cell carcinoma of the head and neck (SCCHN)\". While the patient note doesn't confirm a diagnosis, the symptoms are suggestive of a possible head and neck cancer.\n\n4. The other inclusion criteria like ability to provide informed consent, ability to read/write/speak English, and being a U.S. resident are not addressed in the patient note.\n\n5. There is no mention of the patient agreeing to have tumor tissue tested for HPV, which is one of the inclusion criteria.\n\nBased on the information provided, I would assess this case as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets some of the key criteria like age and suggestive symptoms, but further confirmation of diagnosis, ability to provide consent, agree to HPV testing, etc. would be needed before definitively referring them to this particular trial.",
        "label": 1
    },
    "652": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluation of Polyflex Stenting in Esophageal Cancer Patients\", let's go through the inclusion criteria one by one:\n\n1. 18 years of age and older: The patient is 52 years old, so this criterion is met.\n\n2. Willing and able to provide informed consent: There is no information about this in the patient note, but we can assume that the patient is willing and able to provide informed consent if referred to the trial.\n\n3. Willing to comply with follow-up requirements: Again, there is no information about this, but we can assume the patient is willing to comply if referred.\n\n4. Biopsy-confirmed esophageal cancer (adenocarcinoma or squamous cell carcinoma) in mid or distal esophagus (clinical stage 3 or less): The patient note mentions that the patient has progressive dysphagia (difficulty swallowing) and has lost 25 pounds, which are common symptoms of esophageal cancer. However, there is no specific mention of a biopsy confirmation or the stage of the cancer.\n\n5. Indicated for chemotherapy and/or radiation therapy: The patient note does not mention if the patient is indicated for chemotherapy or radiation therapy.\n\n6. Ability to dilate stricture to 15mm diameter at extent of disease evaluation: There is no information about this in the patient note.\n\n7. Placement of at least 18 x 23mm diameter and 120mm length PolyFlex stent: There is no information about this in the patient note.\n\nBased on the information provided in the patient note, there are some key details missing to determine if the patient meets all the inclusion criteria for this clinical trial. However, the patient's symptoms and history are suggestive of esophageal cancer, which is the target condition for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "653": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which falls within the age range of 18-75 years old specified in the inclusion criteria.\n\n2. The patient does not have a confirmed diagnosis of oculopharyngeal muscular dystrophy (OPMD), which is a requirement for this trial. The note mentions a history of heavy smoking and drinking, but does not indicate a genetic diagnosis of OPMD.\n\n3. The patient is experiencing progressive dysphagia (difficulty swallowing) which started with solid foods and has progressed to liquids as well. This aligns with the inclusion criteria of \"UES dysfunction\" and \"salivary or alimentary stasis at fibroscopy of swallowing above the UES\".\n\n4. There is no mention of a videofluoroscopy of swallowing being performed to assess decreased opening of the UES or decreased pharyngeal propulsion.\n\n5. The note does not indicate whether the patient has provided written consent.\n\nBased on the information provided, there are some criteria that are met (age range, dysphagia symptoms) and some that are unclear or not met (confirmed OPMD diagnosis, videofluoroscopy findings, written consent).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "654": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 52-year-old African American man, which meets the age criteria of > 18 years old.\n\nHe has a history of progressive dysphagia (difficulty swallowing) that started with solid foods and progressed to liquids, along with a 25 pound weight loss. This suggests he likely has esophageal cancer, which matches the trial for esophageal squamous cell carcinoma.\n\nThe note does not specify if it is metastatic/recurrent disease, which is an inclusion criteria. However, the severe dysphagia and weight loss suggest advanced/inoperable disease.\n\nThere is no mention of prior chemotherapy treatment, which meets the criteria of no previous palliative chemotherapy.\n\nHis performance status is not stated, but the dysphagia symptoms imply he is likely ECOG 0-2 as required.\n\nNo details are provided about his organ function (bone marrow, renal, liver), but presumably he would meet those criteria if being considered for chemotherapy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of disease stage/metastasis and organ function.",
        "label": 1
    },
    "655": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. Histologically confirmed primary cancer of the esophagus\n   - The patient note does not explicitly state this, but the progressive dysphagia and point of obstruction suggest esophageal cancer.\n2. Must be dysphagia caused by esophageal cancer\n   - This criterion is met based on the patient's symptoms.\n3. Without esophageal fistulas\n   - No mention of fistulas in the patient note.\n4. Must be an inpatient\n   - The patient note does not specify if the patient is an inpatient or not.\n5. Life expectancy is over 6 months\n   - No information provided about life expectancy.\n\nBased on the information given, this patient appears to meet some of the key inclusion criteria, such as having dysphagia likely caused by esophageal cancer. However, there are a few criteria that are not clearly met or not mentioned, such as being an inpatient and having a life expectancy over 6 months.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "656": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He has progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids as well. He has lost 25 pounds in weight.\n\nThe clinical trial is studying the addition of cetuximab (a monoclonal antibody) and radiotherapy to standard chemotherapy for resectable (operable) esophageal adenocarcinoma.\n\nThe key inclusion criteria are:\n1. Histologically proven resectable adenocarcinoma of the lower esophagus and gastro-esophageal junction\n2. Tumor stage T2-3 N0-1 M0 (localized disease without distant metastases)\n3. Age > 18 years\n4. Weight loss < 10% in last 6 months\n5. Good performance status (0-1)\n6. No prior chemo or radiotherapy\n\nThis patient meets criteria 1, 3, and potentially 5 based on the limited information provided. However, the tumor stage is not mentioned, so criteria 2 cannot be assessed. Importantly, the weight loss of 25 pounds is likely more than 10% of his baseline weight, violating criteria 4.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of tumor stage and performance status, but the significant weight loss makes him ineligible unless it was less than 10% of baseline weight.",
        "label": 1
    },
    "657": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically proven adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the esophagus - Meets this criteria based on the progressive dysphagia symptoms\n- Locally advanced disease (any T, N0 or N1, M0 or M1a) - Likely meets this criteria based on the progressive symptoms, but staging is not provided\n- No metastatic disease, except for allowed exceptions - Appears to meet this criteria as no metastatic disease is mentioned\n- No other exclusion criteria for disease characteristics are mentioned\n\nPATIENT CHARACTERISTICS:\n- ECOG performance status 0-2 - Not mentioned, so cannot evaluate\n- Life expectancy \u2265 3 months - Likely meets this based on the provided information\n- Meets laboratory criteria (counts, creatinine, bilirubin, etc.) - Not enough information provided to evaluate\n- Not pregnant or nursing - Likely meets this criteria as it's not mentioned\n- Fertile patients must use effective contraception - Likely meets this criteria as it's not mentioned\n- Caloric intake sufficient - Potentially does not meet this criteria due to 25 lb weight loss\n- No weight loss > 20% normal body weight within the past 3 months - Potentially does not meet this criteria due to 25 lb weight loss\n- No complete dysphagia - Likely meets this criteria based on description of progressive dysphagia\n- No other exclusion criteria for patient characteristics are mentioned\n\nPRIOR CONCURRENT THERAPY:\n- No prior treatment for esophageal cancer - Meets this criteria \n- No other exclusion criteria for prior/concurrent therapy are mentioned\n\nBased on the provided information, the main potential issues are the 25 lb weight loss potentially not meeting the caloric intake/weight loss criteria and the lack of staging information to confirm locally advanced disease. However, many criteria are likely met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "658": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. The inclusion criteria for the clinical trial require participants to be:\n   - Heavy smokers (\u226510 cigarettes per day) and heavy drinkers (>25 drinks per week for males)\n   - OR heavy smokers and social drinkers (<14 drinks per week for males)\n3. The patient note does not specify the exact number of cigarettes smoked per day or the number of alcoholic drinks consumed per week.\n4. However, it does mention that the patient has a history of heavy smoking and drinking.\n\nBased on the information provided, it is unclear whether the patient meets the specific criteria for being a heavy smoker/heavy drinker or a heavy smoker/social drinker. Additional information would be needed to determine their exact smoking and drinking levels.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "659": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is describing progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids over several months. He has lost 25 pounds.\n\nThe clinical trial is studying the efficiency of esophageal dilation (stretching) on patients with eosinophilic esophagitis, a condition that causes swallowing difficulties.\n\nThe inclusion criteria for the trial are:\n1) Male and female volunteers aged 18 years or older\n2) Patients with known or suspected eosinophilic esophagitis\n3) Patients undergoing upper endoscopy for recent food impaction or complaint of dysphagia\n\nThis patient meets all the inclusion criteria:\n1) He is 52 years old, so meets the age requirement\n2) While not definitively diagnosed, his symptoms of progressive dysphagia suggest he may have eosinophilic esophagitis\n3) He is experiencing dysphagia and would likely be undergoing an upper endoscopy\n\nBased on the information provided, this patient appears to be a good candidate for this clinical trial studying esophageal dilation for eosinophilic esophagitis.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "660": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the age criteria of being over 45 years old.\n\n2. He has a history of heavy smoking and drinking, which aligns with the inclusion criteria of being a current smoker with > 30 pack years.\n\n3. There is no mention of him having airflow obstruction, lung cancer, or a prior history of head and neck or bronchogenic carcinoma, which meets the other inclusion criteria.\n\n4. The only potential issue is that the trial is looking for non-smokers and current smokers to be age-matched with a previously enrolled cohort, and we don't have information about that cohort's ages.\n\nOverall, based on the information provided, this patient seems to largely meet the inclusion criteria for the clinical trial on biomarkers in smokers and non-smokers.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into the age-matching requirement.",
        "label": 0
    },
    "661": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is describing progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids. He can locate the point of obstruction at the lower end of his sternum, and he has lost 25 pounds.\n\nThe clinical trial is titled \"Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery.\" The key inclusion criteria are:\n\n1. Diagnosis of adenocarcinoma of the esophagus\n2. Stage I-IV disease\n3. Received cisplatin-based treatment on clinical trial ECOG-1201\n\nBased on the patient's symptoms of progressive dysphagia and weight loss, it is highly suggestive of esophageal cancer, which meets the first inclusion criterion. However, there is no information provided about the stage of the disease or whether the patient has received prior cisplatin-based treatment on the specified clinical trial.\n\nWithout additional details regarding the stage and prior treatment, it is difficult to definitively determine eligibility. However, given the strong indication of esophageal cancer based on the symptoms, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "662": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nLooking at the inclusion criteria for the clinical trial:\n1. It is looking for healthy adults aged 18-54 years old.\n2. The patient is 52 years old, which falls within the age range.\n3. However, the trial excludes individuals with chronic medical conditions, except for well-controlled hypertension.\n4. The patient's progressive dysphagia and 25-pound weight loss suggest an underlying medical condition, which would likely exclude him from this trial.\n\nTherefore, based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "663": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is titled \"Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat\" and is studying the effectiveness of triamcinolone paste in reducing sore throat after tracheal intubation.\n\nThe inclusion criteria for the trial are:\n1. ASA physical status I-II (healthy or mild systemic disease)\n2. Aged between 20 and 70 years\n3. Scheduled for elective laparoscopic cholecystectomy under general anesthesia with endotracheal intubation\n\nBased on the patient note, this patient does not meet the inclusion criteria for this clinical trial. His symptoms (progressive dysphagia, weight loss) are not related to the study's focus on postoperative sore throat. Additionally, he is not scheduled for the specific surgery (laparoscopic cholecystectomy) required by the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "664": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. The clinical trial is looking at the efficacy and safety of varenicline for smoking cessation in HIV-infected patients.\n3. One of the inclusion criteria is that the patient must be HIV-infected.\n4. The patient note does not mention whether the patient is HIV-infected or not.\n5. Another inclusion criterion is that the patient must be a regular smoker (at least 10 cigarettes a day during the last year).\n6. The patient note mentions that the patient has a history of heavy smoking, so this criterion is likely met.\n7. However, without knowing the HIV status of the patient, it is difficult to determine eligibility with certainty.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their HIV status.",
        "label": 0
    },
    "665": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the age inclusion criteria of 18-50 years old for this clinical trial.\n\n2. The patient has a history of heavy smoking and drinking, but the inclusion criteria do not explicitly exclude patients with these conditions as long as they are in general good health.\n\n3. The patient describes progressive dysphagia (difficulty swallowing) that began several months ago, which is not directly related to the inclusion criteria for this trial.\n\n4. The inclusion criteria state that participants should be in general good health, which may be a concern given the patient's progressive dysphagia and 25-pound weight loss.\n\n5. However, the inclusion criteria do not explicitly exclude patients with dysphagia or weight loss, as long as they can ingest the study drug orally.\n\n6. The other inclusion criteria, such as willingness to prevent pregnancy, comply with the protocol, and provide informed consent, cannot be determined from the given patient note.\n\nBased on the available information, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the age criteria and does not have any explicitly stated exclusion criteria, but their general health status and ability to ingest the study drug orally would need further evaluation due to the progressive dysphagia and weight loss. Additional information about their overall health, willingness to comply with the protocol, and ability to provide informed consent would also be needed to make a final determination.",
        "label": 0
    },
    "666": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is looking for patients with advanced non-small cell lung cancer (NSCLC) who have not received previous chemotherapy or radiotherapy.\n\nBased on the information provided in the patient note, there is no mention of the patient having lung cancer or being diagnosed with NSCLC. The symptoms described (progressive dysphagia and weight loss) could potentially be caused by a different condition, such as esophageal cancer or another gastrointestinal issue.\n\nTherefore, based on the available information, this patient would not meet the inclusion criteria for the clinical trial on K-RAS oncogene mutation in advanced NSCLC patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "667": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. The clinical trial is titled \"Post Operative Sore Throat and Dexamethasone\" and is studying the effects of dexamethasone on postoperative sore throat.\n3. The inclusion criteria for the trial are:\n   - Female patients undergoing outpatient laparoscopic gynecologic surgery\n   - ASA PS I and II\n   - Age between 18 and 64 years\n   - Fluent in English\n\nBased on the patient note and the inclusion criteria, this patient would not be eligible for this clinical trial because:\n- The patient is male, but the trial requires female patients.\n- The patient is not undergoing laparoscopic gynecologic surgery, which is required for the trial.\n- The patient's age (52 years) is outside the specified age range of 18-64 years.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "668": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He describes progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nThe clinical trial inclusion criteria are:\n1. Endoscopically and histologically confirmed cancer of the esophagus\n2. Progressive dysphagia caused by esophageal cancer, and the dysphagia grade of level III or IV\n3. Severe stricture of the cancer making it difficult for barium to pass through on barium swallow study\n4. The bulk and shape of the esophageal cancer displayed by CT three-dimensional reconstruction\n5. Patients with clear consciousness, cooperation, and ECOG performance status of 0, 1, and 3\n6. Informed consent provided\n\nBased on the information provided, this patient meets several of the key inclusion criteria:\n- He has progressive dysphagia, which is a primary symptom for this trial\n- His dysphagia has progressed to the point where he has difficulty swallowing liquids, suggesting a severe grade (likely III or IV)\n- His weight loss of 25 pounds indicates a significant impact from the dysphagia\n\nHowever, there are a few key pieces of information missing to definitively determine eligibility:\n- Confirmation of esophageal cancer diagnosis by endoscopy and histology\n- Results of barium swallow study and CT scan to assess stricture and tumor characteristics\n- ECOG performance status and ability to provide informed consent\n\nGiven the available information, I would assess this patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "669": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago.\n3. He first noticed difficulty swallowing meat, then it progressed to other solid foods, soft foods, and liquids.\n4. He can locate the point where food is obstructed at the lower end of his sternum.\n5. He has lost a total of 25 pounds.\n\nThe clinical trial is titled \"Comparison Between Two Methods of Throat Swabbing\" and is studying different methods of throat swabbing for diagnosing strep pharyngitis.\n\nThe inclusion criteria for this trial are: \"patients with sore throat, classified 2-3 according to Cantor's criteria\"\n\nBased on the patient note, there is no mention of a sore throat or any classification according to Cantor's criteria. The patient is describing progressive dysphagia and weight loss, which are not part of the inclusion criteria for this trial.\n\nTherefore:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "670": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the age criteria of being over 18 years old.\n\n2. The patient has progressive dysphagia (difficulty swallowing) and has lost 25 pounds, which could be indicative of an underlying cancer, but the note does not explicitly state that the patient has been diagnosed with lung adenocarcinoma.\n\n3. The note does not mention the clinical stage of the patient's potential cancer.\n\n4. The note does not mention the patient's ECOG performance status.\n\n5. The note does not mention if the patient has received any prior anticancer treatment, radiation, or surgery.\n\n6. The note does not mention if the patient has any measurable lesions.\n\n7. The note does not mention if the patient has provided written informed consent.\n\nBased on the information provided in the patient note, there are several inclusion criteria that are not clearly met or addressed, such as the specific diagnosis of lung adenocarcinoma, the clinical stage, ECOG performance status, prior treatment history, presence of measurable lesions, and provision of informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to determine if the remaining inclusion criteria are met.",
        "label": 0
    },
    "671": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He describes progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum (breastbone).\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is for the treatment of thoracic esophageal cancer, which seems to match the patient's symptoms of progressive dysphagia and weight loss.\n\nThe inclusion criteria are:\n- Age \u2264 70 years old (the patient is 52, so he meets this criteria)\n- Karnofsky Performance Status \u2265 80 (not mentioned in the patient note, so cannot determine eligibility for this)\n- Pathological diagnosis of squamous cell carcinoma of the thoracic esophagus, treated initially (the patient has not been diagnosed yet, so does not meet this criteria)\n- Clinical stage cT1-3N0-1 based on endoscopic ultrasound, CT scans, etc. (no staging information provided)\n- Able to tolerate surgery and chemotherapy based on preoperative evaluation (no information provided)\n- Able to understand and sign informed consent (not mentioned)\n- Meeting certain laboratory test criteria (no lab values provided)\n\nBased on the information given, the patient seems to potentially meet some of the inclusion criteria, but there are several key criteria that cannot be determined from the note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "672": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Experiencing progressive dysphagia (difficulty swallowing) that began several months ago\n- Initially had trouble swallowing meat, then progressed to other solid foods, soft foods, and liquids\n- Can locate the point of obstruction at the lower end of his sternum\n- Has lost a total of 25 pounds\n\nThe inclusion criteria for the clinical trial state:\n- Ages 18-35 years old\n- BMI > 22 kg/m^2\n- Self-report smoking > 10 cigarettes per day\n- Have access to telephone and internet\n- Demonstrate ability to access a website and receive/respond to emails\n- Willing to accept random assignment\n- Intending to be available for 24 month intervention \n- At risk for weight gain (e.g. plan to quit smoking)\n\nBased on the information provided, this 52-year-old patient with dysphagia and 25 lb weight loss does not meet several of the key inclusion criteria:\n1) He is outside the 18-35 year age range\n2) There is no mention of him planning to quit smoking\n3) His weight loss of 25 lbs suggests he is not at risk for weight gain\n\nTherefore, I would assess his trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "673": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nLooking at the inclusion criteria for the clinical trial:\n1. The trial is for patients with esophageal cancer or gastroesophageal junction tumors, including adenocarcinoma and squamous cell cancer subtypes.\n2. The patient must have failed no more than 2 prior chemotherapy regimens and 1 chemoradiation course.\n3. The patient must have measurable or evaluable disease by CT scan.\n4. The patient must have a WHO performance status of 0-2 and meet certain lab value criteria.\n5. The patient must be able to take oral tablets.\n\nBased on the information provided in the patient note, this patient appears to have symptoms consistent with esophageal cancer, such as progressive dysphagia and weight loss. However, there is no specific mention of a confirmed diagnosis or prior treatment history.\n\nGiven the limited information, I would assess this patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information needed would include a confirmed diagnosis of esophageal cancer or gastroesophageal junction tumor, details on any prior chemotherapy or radiation treatments, and assessment of performance status and lab values to fully determine eligibility.",
        "label": 1
    },
    "674": {
        "output": "To determine the patient's eligibility for the clinical trial \"Lidocaine: Effect of Lidocaine in Chronic Cough\", let's go through the inclusion criteria:\n\n1. Male and female subjects, age 18 years and over.\nThe patient is a 52-year-old man, so he meets this criterion.\n\n2. History of cough for more than 8 weeks.\nThe patient describes progressive dysphagia (difficulty swallowing) that began several months ago, which suggests a chronic condition lasting more than 8 weeks. However, the inclusion criterion specifically mentions a history of cough, not dysphagia.\n\n3. Normal chest x ray\nThere is no information provided about the patient's chest x-ray results.\n\n4. Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers.\nThe patient's note does not mention any specific diagnosis or triggers for the dysphagia, so it is unclear if this criterion is met.\n\nBased on the information provided, the patient meets the age criterion but does not clearly meet the other inclusion criteria. The main issue is that the trial is focused on chronic cough, while the patient's primary symptom is dysphagia (difficulty swallowing).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information would be needed, such as whether the patient also experiences chronic cough, the results of a chest x-ray, and whether the dysphagia is idiopathic or resistant to treatment. If the patient does have a chronic cough in addition to dysphagia, and meets the other criteria, then he could potentially be eligible for the trial.",
        "label": 0
    },
    "675": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He describes progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is titled \"Adjunctive Neuromuscular Electrical Stimulation for the Rehabilitation of Swallowing\" and aims to investigate the effect of neuromuscular electrical stimulation (NMES) therapy for dysphagia upon recovery of swallowing function following stroke.\n\nThe inclusion criteria are:\n1. Stroke identified by neurological and radiological examination\n2. Oropharyngeal dysphagia as confirmed by clinical and radiological examination\n3. No prior history of oropharyngeal dysphagia by patient and/or caregiver report\n4. No previous head/neck surgery or trauma that may impact swallowing ability\n5. No other/concomitant neurological disorders (e.g. Parkinson's disease) that would impact oropharyngeal swallowing ability. This does not include post-stroke deficits.\n6. Physician and patient/family agreement to participate.\n\nBased on the information provided, the patient meets criteria 2 (oropharyngeal dysphagia) and 3 (no prior history of oropharyngeal dysphagia). However, there is no mention of a stroke, which is required by criteria 1. Additionally, there is no information provided about whether the patient meets criteria 4, 5, and 6.\n\nTherefore, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "676": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 52-year-old African American man, which meets the age criteria of 70-85 years old. However, the trial is specifically for esophageal cancer patients, and the patient note mentions progressive dysphagia (difficulty swallowing) as the main symptom without explicitly stating esophageal cancer as the diagnosis.\n\nThe inclusion criteria require a histologically documented diagnosis of esophageal cancer. Since the patient note does not confirm this diagnosis, it is unclear if the patient meets this key eligibility criterion.\n\nOther inclusion criteria like performance status, lab values, and organ function are not mentioned in the patient note, so it's difficult to assess if the patient meets those criteria.\n\nIn summary, while the patient's age falls within the eligible range, the lack of a confirmed esophageal cancer diagnosis makes it uncertain if the patient qualifies for this particular clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to confirm the diagnosis of esophageal cancer and assess other eligibility criteria.",
        "label": 0
    },
    "677": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nLooking at the inclusion criteria for the clinical trial:\n1. It requires patients to have a confirmed diagnosis of advanced, measurable or evaluable, non-resectable and/or metastatic non-hematologic malignancy that has shown progression in the last 6 months.\n2. The patient's symptoms suggest a possible esophageal or gastric malignancy, which would fit the non-hematologic malignancy criteria.\n3. However, there is no explicit confirmation of a cancer diagnosis or staging information provided.\n\nBased on the limited information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional diagnostic testing and staging would be needed to confirm a cancer diagnosis and determine if it meets the criteria of advanced, measurable/evaluable, non-resectable and/or metastatic disease that has progressed in the last 6 months. More clinical details are required to make a definitive assessment of eligibility.",
        "label": 0
    },
    "678": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He describes progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease not amenable to curative therapy.\n   - The patient note does not mention a confirmed diagnosis of adenocarcinoma of the stomach or gastro-oesophageal junction.\n2. Measurable disease, according to the Response Evaluation Criteria in Solid Tumours (RECIST), assessed using imaging techniques (CT or MRI)\n   - The patient note does not mention any imaging or measurable disease.\n3. ECOG Performance status 0, 1 or 2\n   - The patient note does not mention the patient's performance status.\n4. Life expectancy of at least 3 months\n   - This is not mentioned in the patient note.\n5. Male or female age \u2265 18 years.\n   - The patient is 52 years old, so he meets this criterion.\n6. Signed informed consent.\n   - This is not mentioned in the patient note.\n7. Assessment of HER2 status (primary tumour or metastasis) by the central laboratory prior to initiation of study treatment\n   - The patient note does not mention HER2 status.\n8. Able to swallow and retain oral medication.\n   - The patient note mentions that the patient has difficulty swallowing, so he may not meet this criterion.\n9. LVEF \u2265 50% assessed by multigated radionucleotide angiography (MUGA) or cardiac ultrasound.\n   - The patient note does not mention LVEF or cardiac assessment.\n\nBased on the information provided in the patient note, there are several inclusion criteria that are not met or cannot be determined. The main concern is the lack of a confirmed diagnosis of adenocarcinoma of the stomach or gastro-oesophageal junction, as well as the patient's difficulty swallowing, which may prevent him from taking oral medication.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "679": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is presenting with progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids over several months. He has lost 25 pounds.\n\nThe clinical trial is titled \"Optimal Management of Malignant Dysphagia\" and is studying the effectiveness of adding brachytherapy (a type of radiation therapy) to patients with severe dysphagia who have already received a self-expanding metallic stent.\n\nThe key inclusion criteria are:\n1) Age \u226518 years (the patient is 52, so he meets this)\n2) Confirmed esophageal/gastroesophageal cancer of any histology on biopsy (the note doesn't confirm a cancer diagnosis, but the progressive dysphagia and weight loss are concerning for a malignancy like esophageal cancer)\n3) Dysphagia score \u22652 (the patient has progressive dysphagia to liquids, so he likely meets this)\n4) Stage IV cancer/Metastatic disease (the note doesn't provide staging information)\n\nBased on the available information, the patient meets some of the key inclusion criteria like age and presence of dysphagia. However, there is no confirmed cancer diagnosis or staging provided. More diagnostic testing would likely be needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "680": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy.\n   - The patient note does not mention a confirmed diagnosis of adenocarcinoma of the stomach or gastro-oesophageal junction.\n\n2. Measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST), assessed using imaging techniques (CT or MRI).\n   - The patient note does not mention any imaging or measurable disease.\n\n3. HER2 positive tumour (primary tumour or metastasis) defined as either IHC2+ and FISH+ or IHC3+ according to the gastric cancer scoring system for HER2\n   - The patient note does not mention HER2 status.\n\n4. ECOG Performance status 0, 1 or 2\n   - The patient note does not mention ECOG Performance status.\n\n5. Life expectancy of at least 3 months.\n   - This is not explicitly stated in the patient note.\n\n6. Male or female. Age over 20 year.\n   - The patient is a 52-year-old male, so he meets this criterion.\n\n7. Signed informed consent.\n   - This is not mentioned in the patient note.\n\nBased on the information provided in the patient note, there are several inclusion criteria that are not met or cannot be determined. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "681": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He describes progressive dysphagia (difficulty swallowing) that began several months ago.\n3. He first noticed difficulty swallowing meat, then it progressed to other solid foods, soft foods, and liquids.\n4. He can locate the point where food is obstructed at the lower end of his sternum.\n5. He has lost a total of 25 pounds.\n\nThe clinical trial is studying the efficacy and safety of an oral suspension (Alginos) for treating laryngopharyngeal reflux (LPR).\n\nThe inclusion criteria are:\n1. Age 12-75 years old (the patient is 52, so he meets this criterion)\n2. At least one LPR symptom like hoarseness, throat clearing, throat pain, globus sensation, or chronic cough for \u22654 weeks (the patient has progressive dysphagia, which could be a symptom of LPR)\n3. Reflux Symptom Index (RSI) score >10\n4. Reflux Finding Score (RFS) >5 based on laryngoscopic exam\n5. Signed informed consent\n\nBased on the information provided, the patient seems to potentially meet the age criterion and have a symptom consistent with LPR (dysphagia). However, we don't have information about his RSI or RFS scores, which are required for inclusion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his RSI and RFS scores, as well as obtaining informed consent.",
        "label": 0
    },
    "682": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient is experiencing progressive dysphagia (difficulty swallowing) which is not related to sore throat pain or upper respiratory tract infection as required by the inclusion criteria.\n\n2. The patient's symptoms are related to a potential underlying condition (e.g., esophageal or gastrointestinal issue) rather than a sore throat due to an upper respiratory tract infection.\n\n3. The inclusion criteria specifically require the presence of sore throat pain due to an upper respiratory tract infection, a baseline sore throat pain intensity score of \u226560 mm, and a Tonsillopharyngitis Assessment score of \u22655, none of which are mentioned in the patient note.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the clinical trial evaluating the time of pain relief for sore throat pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "683": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is describing progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids over several months. He has lost 25 pounds.\n\nThe clinical trial is looking at quality of life and dysphagia following palliative stenting in esophageal cancer patients.\n\nThe key inclusion criteria are:\n1) Patients with end stage inoperable esophageal cancer\n2) Deemed candidates for intraluminal esophageal palliative stent insertions\n\nBased on the patient note, it seems highly likely that this patient has esophageal cancer causing the progressive dysphagia and weight loss. The note doesn't explicitly state it is end-stage or inoperable, but the severe symptoms suggest it may be advanced disease.\n\nGiven this information, I would assess this patient as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "684": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is describing progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids as well. He has lost 25 pounds.\n\nThe clinical trial is studying the effects of functional confections (strawberry gummies) on oral health. \n\nLooking at the inclusion criteria:\n- The patient would meet the smoking criteria as a habitual smoker.\n- There is no mention of the patient having any metabolic/digestive disorders that would exclude him.\n- His BMI is not provided but the 25 pound weight loss suggests he may fall within the 20-35 kg/m^2 range.\n\nHowever, some of the exclusion criteria raise concerns:\n- The patient has dysphagia (difficulty swallowing), which is an explicit exclusion criteria.\n- His heavy alcohol use (>15 glasses/week) would also exclude him.\n\nGiven the dysphagia and heavy alcohol use, which are both exclusion criteria for this trial, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "685": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the age criteria of being over 45 years old for the clinical trial.\n\n2. However, the clinical trial is studying a tumor marker (DCAMLK1) in lung cancer patients, and the patient note does not mention anything about the patient having lung cancer or a suspected lung disease.\n\n3. The patient note describes progressive dysphagia (difficulty swallowing) that the patient has been experiencing, along with weight loss. This could potentially be a symptom of an esophageal or gastric cancer, but there is no clear indication of lung cancer specifically.\n\n4. Without any mention of lung cancer or a suspected lung disease, it is unlikely that this patient would be eligible for a clinical trial studying a tumor marker in lung cancer patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "686": {
        "output": "Based on the patient note provided, the 52-year-old African American man is describing symptoms of progressive dysphagia (difficulty swallowing) that started with solid foods and progressed to liquids, along with a 25-pound weight loss. These symptoms do not align with the inclusion criteria for the clinical trial titled \"Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI.\"\n\nThe inclusion criteria for this clinical trial require the patient to have symptoms of an upper respiratory tract infection (URTI), such as mild to moderate body pain, headache, fever, sore throat, nasal congestion, runny nose, or sneezing. The patient's symptoms of dysphagia and weight loss are not indicative of an URTI and do not meet the inclusion criteria.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "687": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluation of Two Different Thickening Products in Patients With Dysphagia\", let's go through the inclusion criteria one by one:\n\n1. History of dysphagia necessitating a dynamic fluoroscopic swallow study\nThe patient note mentions that the 52-year-old man has progressive dysphagia, which started with difficulty swallowing meat and progressed to other solid foods, soft foods, and liquids. This meets the inclusion criterion of having a history of dysphagia.\n\n2. Age > 18 years\nThe patient is 52 years old, which meets the age criterion.\n\n3. Ability to complete a comprehensive dynamic fluoroscopic swallow study\nThere is no information provided about the patient's ability to complete such a study, but it can be assumed that if he is able to provide a detailed history, he would likely be able to complete the required study.\n\n4. Ability to provide informed consent for study participation\nAgain, there is no specific information about the patient's ability to provide informed consent, but it can be reasonably assumed that he would be able to do so based on the provided details.\n\nOverall, based on the information provided in the patient note, this patient appears to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "688": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histological or cytologic diagnosis of Esophageal squamous cell carcinoma\n   - The patient note mentions progressive dysphagia (difficulty swallowing) which could be a symptom of esophageal cancer, but does not confirm a diagnosis. More investigation would be needed.\n\n2. ECOG performance status 0-2\n   - The patient's performance status is not mentioned, so this cannot be evaluated from the note.\n\n3. Age: 18-70 years\n   - The patient is 52 years old, which meets this criteria.\n\n4. Joined the study voluntarily and signed informed consent form\n   - This has not occurred yet, so cannot be evaluated.\n\n5. Patients must not have received any prior anticancer therapy\n   - The note does not mention any prior cancer treatment, so this criteria is likely met.\n\n6. Resectable disease, Stage IIA-IIIC, T2N0M0-T3N1M0 (AJCC 2009)\n   - The stage and resectability are not provided in the patient note.\n\n7. Target lesions can be measured according to RECIST criteria\n   - This requires further testing/imaging to evaluate.\n\n8. No serious system dysfunction and immuno-deficiency, Adequate organ function...\n   - The patient's organ function levels are not provided.\n\n9. Use of an effective contraceptive for adults to prevent pregnancy\n   - This may not apply since the patient is male.\n\n10. Life expectancy of more than 3 months\n    - This is not mentioned in the note.\n\nIn summary, while some of the criteria are potentially met based on the limited information provided, several key criteria cannot be evaluated from this patient note alone.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "689": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 52-year-old African American man, which meets the age criteria of 18-75 years old for the clinical trial.\n\nHe has a history of progressive dysphagia (difficulty swallowing) that started several months ago, progressing from solid foods to liquids. This suggests he likely has esophageal cancer, which is the target disease for this clinical trial.\n\nThe patient note does not mention any prior treatments, so he would likely meet the criteria of no prior palliative treatment or an interval of at least 6 months from prior treatments.\n\nThe note mentions he has lost 25 pounds, suggesting he has measurable disease progression which meets the criteria of having at least one tumor mass \u226510mm diameter.\n\nHis expected life expectancy is not mentioned, but the progressive dysphagia and 25 pound weight loss imply his condition is serious enough that a 3 month life expectancy is reasonable to assume.\n\nHis performance status is not provided, so this would need further investigation to determine if he meets the \u226580 Karnofsky criteria.\n\nHis lab values and cardiac history are not provided, so these criteria cannot be evaluated from the note.\n\nOverall, based on the available information, this patient appears to potentially meet many of the key inclusion criteria for the esophageal cancer clinical trial. However, some additional details like performance status, lab values, and cardiac history would need to be investigated further.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "690": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which does not match the inclusion criteria of being an infant.\n\n2. The patient has progressive dysphagia (difficulty swallowing) that began several months ago, which could potentially match the inclusion criteria of having severe dysphagia.\n\n3. However, the inclusion criteria specifically state \"Infants with severe dysphagia on VFFS as defined by dysphagia resulting in aspiration with swallow of at least 2 food textures (e.g. thin and thick liquid).\" There is no mention of the patient's dysphagia being evaluated using VFFS (Videofluoroscopic Swallow Study) or resulting in aspiration with at least two food textures.\n\n4. The inclusion criteria also state \"We will include children with dysphagia due to a central neurologic deficit. The neurologic diagnosis will be based on the diagnosis from the treating physician.\" There is no information provided about the cause of the patient's dysphagia or any neurologic diagnosis.\n\nBased on the information provided, the patient does not clearly meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "691": {
        "output": "To determine the patient's eligibility for the clinical trial \"Satiety Innovation- Study 793. University of Aberdeen\", let's go through the inclusion criteria one by one:\n\n1. \"Males and females\" - The patient is a 52-year-old man, so he meets this criterion.\n\n2. \"18-65 years old\" - The patient is 52 years old, which falls within this age range.\n\n3. \"Body Mass Index (BMI) 27-35kg/m2\" - The patient's BMI is not provided in the note, so we cannot determine if he meets this criterion.\n\n4. \"Overall healthy\" - The patient is described as having a history of heavy smoking and drinking, which may impact his overall health status. However, the note does not provide enough information to definitively determine if he is considered \"overall healthy\" or not.\n\n5. \"Weight Stable (<3 kg change in the past 4 months, before the trial)\" - The patient has lost a total of 25 pounds (approximately 11.3 kg), which suggests significant weight loss. However, the timeframe of this weight loss is not specified.\n\nBased on the information provided in the patient note, we cannot definitively determine if the patient meets all the inclusion criteria for this clinical trial. While he meets the age and gender criteria, there is not enough information about his BMI, overall health status, and recent weight stability.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "692": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 52-year-old African American man, which meets the age criteria of 20-85 years old.\n\nHe has progressive dysphagia (difficulty swallowing) that began several months ago, which aligns with the inclusion criteria of having dysphagia for more than 3 weeks.\n\nThe note does not mention if the patient had a stroke, which is a key inclusion criterion. However, it does state that the dysphagia is progressive, suggesting a potential neurological cause.\n\nThere is no information provided about the patient's cognitive status, mental state, or FOIS score.\n\nBased on the available information, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information needed would be confirmation of a stroke diagnosis, the patient's cognitive and mental status, and their current diet level/FOIS score. If these criteria are met, the patient could potentially be eligible for the trial targeting stroke-related dysphagia.",
        "label": 0
    },
    "693": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effects of Chemotherapy on Muscle Mass and Exercise Performance in Patients With Oesophageal Cancer\", let's go through the inclusion criteria:\n\n1. Oesophageal cancer: The patient note mentions that the 52-year-old man has progressive dysphagia (difficulty swallowing), which is a common symptom of oesophageal cancer. However, the note does not explicitly state that the patient has been diagnosed with oesophageal cancer.\n\n2. Multidisciplinary team decision to offer neoadjuvant chemotherapy prior to surgery: The patient note does not provide any information about the treatment plan or whether the patient will receive neoadjuvant chemotherapy before surgery.\n\nBased on the information provided in the patient note, it is unclear if the patient meets the inclusion criteria for this clinical trial. While the symptoms suggest the possibility of oesophageal cancer, there is no definitive diagnosis or treatment plan mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "694": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\n5. The clinical trial is studying the efficacy of intensity modulated radiation therapy after surgery in early stage esophageal carcinoma (squamous cell carcinoma).\n\n6. The key inclusion criteria are:\n   - Stage T2-3N0M0 disease of thoracic esophageal squamous cell carcinoma (TESCC)\n   - Patients who received R0 operations (complete surgical resection) at a specific hospital\n   - KPS (performance status) \u226570 before radiotherapy\n   - No neoadjuvant or adjuvant treatment received\n   - No clear recurrent or metastatic lesions before radiotherapy\n   - Willing to receive intensity modulated radiation therapy (IMRT)\n   - Able to follow up regularly\n\n7. Based on the patient's symptoms of progressive dysphagia and weight loss, it is highly suggestive of esophageal cancer, potentially meeting the disease criteria.\n\n8. However, there is no information provided about the patient's disease stage, whether they have undergone surgery, their performance status, or treatment history.\n\nTherefore, based on the limited information provided:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "695": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum (breastbone).\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is studying the effect of Caphosol\u00ae on the development of esophagitis (inflammation of the esophagus) in patients with small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) who are receiving concurrent chemoradiotherapy.\n\nThe inclusion criteria for the trial are:\n1. Age 18 years or older\n2. Patients with histologically proven (N)SCLC (all histological subtypes), treated with concurrent chemo- and radiotherapy\n3. Ability to understand the protocol and willing to provide written informed consent\n\nBased on the information provided, the patient does not have a confirmed diagnosis of SCLC or NSCLC, which is a requirement for this trial. Additionally, there is no mention of the patient receiving concurrent chemoradiotherapy, which is another inclusion criterion.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "696": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the inclusion criteria of being at least 18 years old.\n\n2. The patient has a history of heavy smoking and drinking, which aligns with the inclusion criteria of being a current smoker with at least 5 years of smoking history.\n\n3. There is no mention of the patient being pregnant, having major periodontal disease, cancer, or using antibiotics in the last 3 months, which would exclude them from the trial.\n\n4. The patient's age, gender, and ethnicity can likely be matched with a non-smoker control group based on the information provided about the clinic's demographics.\n\nBased on the information provided in the patient note and the inclusion/exclusion criteria for the clinical trial, this patient appears to be eligible for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "697": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which does not match the inclusion criteria of being a premature infant.\n\n2. The patient has progressive dysphagia (difficulty swallowing) that started several months ago, which could potentially be related to pharyngeal phase dysphagia mentioned in the inclusion criteria.\n\n3. However, the trial specifically mentions that it is studying the effects of cold liquids on swallowing mechanisms in premature infants, not adults.\n\n4. The patient does not meet the key inclusion criterion of being a premature infant referred for a videofluoroscopic swallow study (VFSS) due to suspected pharyngeal phase dysphagia.\n\nTherefore, based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "698": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the age criteria of 18 years or older.\n\n2. The patient is described as having a history of heavy smoking, which meets the criteria of using 10 cigarettes per day or more.\n\n3. There is no mention of the patient's BMI, so we cannot confirm if they meet the BMI criteria of 18.5 or above.\n\n4. There is no mention of the patient having a history of anorexia or bulimia, which is good.\n\n5. However, the main issue here is that the patient is describing progressive dysphagia (difficulty swallowing) and a 25-pound weight loss, which suggests an underlying medical condition that may exclude them from this particular trial.\n\nBased on the information provided, I would consider referring this patient to this clinical trial upon further investigation into their medical condition and BMI.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "699": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which falls within the age range of 30-80 specified in the inclusion criteria.\n\n2. The patient's BMI is not mentioned, so we cannot determine if he meets the BMI criteria of 30-45 prior to starting Weight Watchers.\n\n3. There is no information provided about the patient's recent weight loss history or if he has lost at least 5kg in the past 4-6 months before enrolling, which is an inclusion criterion.\n\n4. The patient's health status is not explicitly stated, but the progressive dysphagia (difficulty swallowing) and 25-pound weight loss suggest potential health issues that may affect his eligibility for the trial.\n\nBased on the information provided, we cannot definitively determine the patient's eligibility for this clinical trial. While his age falls within the specified range, there is insufficient information about his BMI, recent weight loss history, and overall health status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "700": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. The clinical trial is for comparing the effects of magnesium sulfate and dexamethasone on postoperative sore throat after spinal surgery in prone position with tracheal intubation.\n3. The inclusion criteria for the trial are:\n   - ASA I-II patients (American Society of Anesthesiologists physical status classification system, indicating a healthy or mild systemic disease patient)\n   - Aged between 20 and 65 years\n   - Undergoing 1 or 2 level posterior spinal fusion in prone position with tracheal intubation\n\n4. The patient note does not mention any spinal surgery or plans for spinal surgery. The note is focused on the patient's progressive dysphagia (difficulty swallowing) and weight loss.\n\n5. Based on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "701": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. The clinical trial is looking for U.S. participants aged 18-25 years who are never smokers or former smokers (have not smoked in the past 30 days).\n3. The patient's age (52 years) does not meet the inclusion criteria of 18-25 years.\n4. The patient's smoking history is not clearly stated as being a former smoker who has not smoked in the past 30 days or a never smoker.\n\nBased on the information provided, this patient does not meet the inclusion criteria for age and smoking status is unclear.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "702": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the general criteria of being an adult patient.\n\n2. However, the patient's chief complaint is progressive dysphagia (difficulty swallowing) that began several months ago. He is having trouble swallowing solids, soft foods, and liquids. This does not align with the inclusion criteria of having a primary diagnosis of pharyngitis (sore throat) confirmed by a Tonsillo-Pharyngitis Assessment score \u2265 5.\n\n3. The patient's symptoms of dysphagia and weight loss of 25 pounds suggest a more serious underlying condition, such as esophageal or gastric cancer, rather than a simple sore throat or pharyngitis.\n\n4. The other inclusion criteria, such as having moderate or severe sore throat pain, a baseline Sore Throat Scale (STS) \u2265 6, and willingness to remain at the study center for 3 hours, are not applicable or relevant given the patient's presenting symptoms.\n\nTherefore, based on the information provided, this patient would not be eligible for the placebo-controlled onset-of-action study of flurbiprofen for pharyngitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "703": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is describing progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids as well. He has lost 25 pounds.\n\nThe clinical trial is studying the relationship between smoking and pancreatic insufficiency (decreased production of pancreatic enzymes leading to malabsorption).\n\nThe key inclusion criteria are:\n1) Male or female at least 30 years of age (the patient is 52, so meets this)\n2) Able to provide informed consent \n3) Either negligible smoking history (<=5 pack-years and no smoking for 7 years) OR at least 20 pack-year smoking history\n\nThe patient note mentions a history of heavy smoking, which suggests he likely meets the 20 pack-year criteria. His symptoms of progressive dysphagia and 25 lb weight loss are consistent with potential pancreatic insufficiency.\n\nWhile we don't have full details to definitively conclude eligibility, based on the available information, I would assess his trial eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "704": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\n5. The clinical trial is evaluating the safety and efficacy of an oral spray called Colflex on the frequency/duration of colds and sore throats, as well as dental and oral health changes.\n\n6. The inclusion criteria for the trial are:\n   - Availability to give written consent\n   - Age 18-60, men and women (who are not pregnant or nursing)\n   - People in good health\n   - Able to follow protocol\n   - Must be experiencing a sore throat or cold at least once a year\n\n7. Based on the patient note, this patient does not seem to be experiencing a sore throat or cold. Instead, he is experiencing progressive dysphagia, which is difficulty swallowing.\n\n8. Therefore, this patient would not be eligible for this particular clinical trial, as he does not meet the inclusion criteria of experiencing a sore throat or cold at least once a year.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "705": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nLooking at the inclusion criteria for the clinical trial:\n1. The trial is recruiting adults aged 21 years and older.\n2. It is specifically looking for patients with precancerous lesions or growths in the mouth, as well as patients with head and neck cancer.\n3. Patients younger than 21 years and those with a history of head and neck cancer are excluded.\n\nBased on the information provided, this patient does not seem to have any precancerous lesions or growths in the mouth mentioned. His symptoms (dysphagia and weight loss) could potentially be indicative of head and neck cancer, but this is not explicitly stated.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the age criteria, and his symptoms could potentially be related to head and neck cancer, which is the focus of the trial. However, more information would be needed to confirm if he has a precancerous lesion or head and neck cancer to definitively determine his eligibility for this specific trial.",
        "label": 0
    },
    "706": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. The clinical trial is looking for healthy individuals between 18-35 years old.\n3. The patient's age of 52 does not meet the inclusion criteria of 18-35 years old.\n4. Additionally, the patient has a history of heavy smoking and drinking, which may exclude them from being considered \"healthy\".\n5. The patient's primary complaint is progressive dysphagia (difficulty swallowing), which is not relevant to the clinical trial investigating the effects of a carbohydrate drink.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "707": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point of obstruction at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nLooking at the inclusion criteria for the clinical trial:\n1. Histologically proven adenocarcinoma of the gastro-oesophageal junction\n   - The patient note does not mention a confirmed diagnosis, only symptoms suggestive of an esophageal/gastric cancer.\n2. Age 18 years or older\n   - The patient is 52 years old, so he meets this criterion.\n3. International Union Against Cancer (UICC) T2-4 N0-2 M0, potentially resectable disease treated by the CROSS regimen\n   - The patient note does not provide information about the cancer stage or potential resectability.\n4. WHO 0-2\n   - The patient note does not provide information about the patient's performance status.\n\nBased on the information provided in the patient note, there is not enough evidence to confirm that the patient meets all the inclusion criteria for the clinical trial. However, the symptoms described are concerning for a potential esophageal or gastric cancer, which would make the patient a candidate for further evaluation and possible enrollment in the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "708": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking. He is describing progressive dysphagia (difficulty swallowing) that started with solid foods and has progressed to liquids as well. He has lost 25 pounds in weight.\n\nThe clinical trial is about assessing the impact of the size of the gastric sleeve on weight loss after bariatric surgery for morbid obesity.\n\nThe key inclusion criteria are:\n1) Age between 18-65 years (the patient is 52, so meets this)\n2) BMI > 40 kg/m2 or > 35 kg/m2 with comorbidities likely to improve after weight loss (no BMI given for the patient)\n3) Morbid obesity established for at least 5 years (duration not specified for the patient)\n4) Failure of supervised conservative treatments (not mentioned for the patient)\n5) Absence of endocrine disorders causing the obesity (not mentioned)\n6) Psychological stability - no substance abuse, major psychiatric disorders etc. (The patient has a history of heavy smoking and drinking which may exclude him)\n\nBased on the information provided, there are some criteria the patient seems to meet like age, but several key criteria are missing information like BMI, duration of obesity, failure of conservative treatments, psychological stability etc.\n\nSo in summary:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "709": {
        "output": "To determine the patient's eligibility for the clinical trial \"Biomarker Feedback for Smoking Cessation\", let's go through the inclusion criteria one by one:\n\n1. \"Male or female cigarette smokers, 18-75 years\"\nThe patient note mentions that the patient is a 52-year-old African American man, so he meets this criterion.\n\n2. \"Smoked an average of less than 10 cigarettes per day during past month\"\nThe patient note does not provide information about the patient's smoking habits or the number of cigarettes smoked per day. Therefore, we cannot determine if he meets this criterion.\n\n3. \"A personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.\"\nThis criterion is not relevant for determining eligibility based on the patient note alone. It would be addressed during the informed consent process if the patient is referred to the trial.\n\nSince we do not have enough information to determine if the patient meets the second inclusion criterion regarding the number of cigarettes smoked per day, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "710": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He describes progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum (breastbone).\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is studying the safety and efficacy of a device called the Swallow Expansion Device (SED) for improving swallowing in patients.\n\nThe key inclusion criteria are:\n- Profound oropharyngeal feeding tube dependent dysphagia of greater than 12 months duration\n- Must be receiving 100% of nutritional requirements by enterogastric tube\n- Age 18 years or older\n- Diminished upper esophageal sphincter opening on fluoroscopic swallow study\n- Failure of > 3 months of dysphagia therapy within 3 months of study enrollment\n- No history of noncompliance with feeding recommendations\n- Cognition within normal limits\n- Manual dexterity within normal limits\n- Physical strength to pull the SED forward\n- Ability to understand informed consent and comply with follow-up\n- Bilateral vocal fold mobility or unilateral vocal fold immobility with ability to attain complete glottic closure\n\nBased on the information provided, this patient meets several of the key criteria, including being over 18 years old, having progressive dysphagia, and likely having diminished upper esophageal sphincter opening given his symptoms.\n\nHowever, there are some criteria that are unclear, such as whether he has been receiving 100% of his nutrition via a feeding tube for over 12 months, whether he has failed over 3 months of dysphagia therapy, his cognitive status, manual dexterity, physical strength, and vocal fold mobility.\n\nTherefore, I would assess this patient as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "711": {
        "output": "Based on the patient note provided, the 52-year-old African American man with a history of heavy smoking and drinking is describing symptoms of progressive dysphagia (difficulty swallowing) that started with solid foods and progressed to liquids, along with a 25-pound weight loss. This patient does not appear to have thyroid cancer or be scheduled for thyroid surgery, which is the inclusion criterion for the clinical trial titled \"Dexamethasone and Wound Healing After Thyroid Surgery.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "712": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He describes progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum (breastbone).\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is studying the effects of oropharyngeal strengthening exercises on dysphagia in patients post-stroke.\n\nThe inclusion criteria are:\n1. Clinical diagnosis of unilateral ischemic stroke within 6 months\n2. Score of 3 or higher on the Penetration-Aspiration scale OR score of 2 on the Residue scale from a videofluoroscopic swallowing study\n3. Age between 21 and 95\n4. Ability to perform the exercises independently or with caregiver assistance\n5. Physician approval of medical stability\n6. Decision-making capacity to provide informed consent\n7. Phone access\n8. Ability to return for follow-up appointments\n\nWhile the patient does have dysphagia, there is no mention of a stroke diagnosis in the patient note. The dysphagia seems to be from a different underlying cause.\n\nTherefore, based on the information provided, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "713": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He describes progressive dysphagia (difficulty swallowing) that began several months ago.\n3. He first noticed difficulty swallowing meat, then it progressed to other solid foods, soft foods, and liquids.\n4. He can locate the point where food is obstructed at the lower end of his sternum.\n5. He has lost a total of 25 pounds.\n\nThe clinical trial is titled \"DYsphAgia In Mechanically Ventilated ICU patientS\" and is an observational analysis aimed at elucidating the incidence and impact of dysphagia on the clinical course of a mixed population of ICU patients post invasive mechanical ventilation.\n\nThe inclusion criteria for the trial are: \"all adult ICU patients post mechanical ventilation (observational analysis)\".\n\nBased on the information provided, this patient meets the inclusion criteria of being an adult with dysphagia. However, the trial specifically mentions including patients who are post mechanical ventilation in the ICU, and there is no indication that this patient has been in the ICU or received mechanical ventilation.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "714": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Pathologically confirmed esophageal carcinoma\n   - The patient note mentions progressive dysphagia (difficulty swallowing) which could be a symptom of esophageal cancer, but there is no explicit mention of a pathological confirmation of esophageal carcinoma. This criterion is not clearly met.\n\n2. Stage I\uff5eIva By EUS and CT/MRI, without contraindication for radical radiotherapy\n   - The patient note does not provide any information about the disease stage or whether the patient is a candidate for radical radiotherapy.\n\n3. Aged \u2265 70 and < 85 years, behavioral status evaluation ECOG scores 0-2\n   - The patient is 52 years old, which does not meet the age criteria for this trial.\n\n4. In 7 days after being screened, subjects should follow the status: WBC \u2265 3.0 x 10^9/L; ANC \u2265 1.5x 10^9/L; PLT \u2265 80 x 10^9/L; Hb \u2265 90 g/L; serum Cr \u2264 ULN; serum bilirubin \u2264 1.5 ULN; ALT/AST \u2264 1.5 ULN\n   - The patient note does not provide any information about the patient's laboratory values or organ function.\n\n5. Subjects should sign for the informed consent\n   - This is a procedural requirement that cannot be assessed based on the provided information.\n\n6. Subjects should perform good compliance\n   - This is a subjective criterion that cannot be assessed based on the provided information.\n\nBased on the available information in the patient note, the patient does not clearly meet the inclusion criteria for this clinical trial, primarily due to the age criterion and the lack of confirmed esophageal cancer diagnosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "715": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago. It started with difficulty swallowing meat, then progressed to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is studying the effect of zinc lozenges on postoperative sore throat syndrome in patients undergoing general anesthesia and intubation.\n\nThe inclusion criteria state:\n- Men and women ages 18 and older (the patient is 52, so he meets this)\n- ASA physical status I and II (healthy or mild systemic disease) - the patient's health status is not mentioned, so this cannot be definitively assessed\n- Coming for elective surgery requiring general anesthesia (the patient is not described as coming for surgery)\n- Staying for at least 24 hours postoperatively (not applicable since the patient is not described as coming for surgery)\n- Providing informed consent (not mentioned)\n- Surgery duration >1 hour and <6 hours (not applicable)\n\nBased on the information provided, the patient does not seem to meet the key inclusion criteria of coming for elective surgery requiring general anesthesia and intubation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "716": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients \u2265 18 years: The patient is 52 years old, so this criterion is met.\n\n2. Histologically confirmed inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction: The patient note mentions progressive dysphagia (difficulty swallowing) and a 25-pound weight loss, which are common symptoms of gastric cancer. However, there is no explicit mention of a confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.\n\n3. ECOG (Eastern Cooperative Oncology Group) performance status 0-2: There is no information provided about the patient's performance status.\n\n4. Adequate renal, hepatic, and hematologic function: There is no information provided about the patient's renal, hepatic, or hematologic function.\n\n5. Measurable or nonmeasurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST): There is no information provided about the patient's disease status according to RECIST criteria.\n\nBased on the information provided in the patient note, there is not enough evidence to confirm that the patient meets all the inclusion criteria for the clinical trial. However, the symptoms described are suggestive of gastric cancer, which is the target disease for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "717": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nLooking at the inclusion criteria for the clinical trial \"Brain Regulation of Appetite in Twins\":\n\n1. The ability and willingness to come with their twin to the University of Washington (Seattle) - This criterion is not met as there is no mention of the patient having a twin.\n2. Additional criteria for Aim 1 random sample only: Member of randomly selected MZ pair or - Not applicable as the patient does not have a twin.\n3. Additional criteria for Aim 2 random sample only: One member of MZ or same-sex DZ pair with BMI of at least 30 kg/m^2 - Not applicable as the patient does not have a twin.\n4. Additional criteria for Aim 3 sample only: Member of randomly selected MZ pair, and not BMI discordant \u2265 5 kg/m^2 - Not applicable as the patient does not have a twin.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial \"Brain Regulation of Appetite in Twins\" as the trial requires participants to be twins.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "718": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. The clinical trial is looking at the effect of saline lubrication on post-intubation complications.\n3. The inclusion criteria for the trial are patients aged between 20-80 years who are scheduled for surgery under general anesthesia requiring orotracheal intubation.\n\nBased on the information provided in the patient note, there is no mention of the patient being scheduled for surgery under general anesthesia requiring orotracheal intubation. The note only mentions the patient's progressive dysphagia (difficulty swallowing) and weight loss.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "719": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man with a history of heavy smoking and drinking.\n2. He is describing progressive dysphagia (difficulty swallowing) that began several months ago, starting with difficulty swallowing meat and progressing to other solid foods, soft foods, and liquids.\n3. He can locate the point where food is obstructed at the lower end of his sternum.\n4. He has lost a total of 25 pounds.\n\nThe clinical trial is titled \"Brief Tobacco Cessation Intervention\" and aims to evaluate the effect of a brief smoking cessation counseling intervention among patients in busy clinic settings.\n\nThe inclusion criteria for the trial are:\n1. Outpatients aged 18 years or above\n2. Smoke on at least 1 day in the past 30 days\n3. Chinese residents able to communicate in Chinese (Mandarin or Cantonese)\n4. Has a telephone\n\nBased on the patient note, this patient meets the following inclusion criteria:\n1. He is an outpatient (not specified, but implied)\n2. He has a history of heavy smoking, so he likely smoked in the past 30 days\n\nHowever, the patient note does not provide information about whether he meets the other two inclusion criteria (being a Chinese resident able to communicate in Chinese and having a telephone).\n\nGiven that the patient meets at least two of the inclusion criteria and his smoking history is relevant to the trial, I would consider referring this patient to this clinical trial upon further investigation to determine if he meets the remaining criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "720": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 52-year-old African American man with a history of heavy smoking and drinking, describing progressive dysphagia (difficulty swallowing) that began several months ago. This matches the inclusion criteria of \"Histologically verified adenocarcinoma of the esophagus\".\n\nThe patient's symptoms of difficulty swallowing solids, soft foods, liquids, and weight loss of 25 pounds suggest an advanced stage of esophageal cancer, potentially meeting the criteria of \"Pre-treatment stage cT1N+, M0 or cT2-4a, N0/+, M0\".\n\nThe patient's age of 52 years meets the criteria of \"Age \u226518 years\".\n\nThere is no mention of prior abdominal or thoracic radiotherapy, so the patient likely meets the criteria of \"No prior abdominal or thoracic radiotherapy\".\n\nThe note does not provide information about the patient's ECOG Performance status, cardiac function, bone marrow function, respiratory function, renal function, or liver function. Therefore, it is unclear if the patient meets these criteria without further investigation.\n\nOverall, based on the information provided, the patient appears to meet some of the key inclusion criteria for this clinical trial, but further investigation would be needed to confirm eligibility for the remaining criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "721": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 52-year-old African American man, which meets the age criteria of 18-75 years old for the clinical trial.\n\n2. The patient has progressive dysphagia (difficulty swallowing) that started several months ago, which could be a symptom of esophageal cancer. However, the note does not explicitly state that the patient has been diagnosed with esophageal cancer.\n\n3. The inclusion criteria require a pathological or cytological diagnosis of stage II-III esophageal carcinoma or stage IV thoracic segment carcinoma with supraclavicular lymph node metastasis. The patient note does not provide this specific diagnostic information.\n\n4. The other inclusion criteria, such as measurable lesion, ECOG performance status \u22642, expected survival \u22653 months, and no serious organ diseases, cannot be fully assessed based on the information provided in the patient note.\n\nBased on the available information, it is difficult to determine with certainty whether the patient meets all the inclusion criteria for the clinical trial. More diagnostic information would be needed to confirm the presence and stage of esophageal cancer.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "722": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age criteria of being 13 years or older for this HIV clinical trial.\n\n2. There is no mention of the patient being HIV-positive in the note, which is a key inclusion criteria.\n\n3. The clinical presentation seems to be related to a respiratory illness with fever, cough, and lung infiltrates after a recent travel, rather than HIV-related symptoms.\n\nBased on the information provided in the patient note and the inclusion criteria for this HIV clinical trial, this patient would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "723": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of \"Over 18\" for this clinical trial studying recurrent glioblastoma multiforme in adults.\n\n2. The patient's presenting symptoms (fever, dyspnea, cough, loose stools) and chest x-ray findings (bilateral lung infiltrates) suggest a respiratory infection, not a brain tumor like glioblastoma multiforme.\n\n3. There is no mention of the patient having a prior history of glioblastoma multiforme or receiving prior treatment for it.\n\n4. The inclusion criteria specifically require histological or cytological confirmation of glioblastoma multiforme, recurrent disease documented by MRI after prior radiotherapy, and at least one measurable target lesion \u2265 2 cm, none of which are present in this patient note.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial studying erlotinib versus temozolomide or carmustine in recurrent glioblastoma multiforme.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "724": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of being 10 years or older for this sickle cell disease clinical trial.\n\n2. There is no mention of the patient having sickle cell disease or any hemoglobinopathy in the patient note. The note describes symptoms of fever, cough, and lung infiltrates, which are more indicative of a respiratory infection.\n\n3. The patient does not present with a vaso-occlusive crisis (VOC), which is an inclusion criterion for this trial studying treatment for sickle cell pain crises.\n\nBased on the information provided in the patient note, this patient would not be eligible for the nitric oxide inhalation clinical trial for treating sickle cell pain crises.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "725": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Non-pregnant subjects >/= 18 years of age\n   - The patient is an 8-year-old male, so he does not meet this criteria.\n\n2. Admission to the ICU during the preceding 3 days (minimum of 2 days in ICU) and expected to stay in the ICU a minimum of 2 additional days\n   - The note does not mention if the patient was admitted to the ICU or expected length of stay, so this cannot be determined.\n\n3. Subjects must have at least 1 of the following:\n   a) Received at least one other dose of any systemic antibiotic on any one of the ICU days before study entry and continue to receive antibiotics at the time of enrollment\n      - The note does not mention if the patient received antibiotics.\n   b) Presence of a central venous catheter at the time of enrollment and for one additional day during the current ICU stay\n      - The note does not mention a central venous catheter.\n   c) At least 2 of the following:\n      i) Use of total parenteral nutrition on any of Days 1-4 of ICU stay\n         - Not mentioned in the note.\n      ii) Any type of dialysis on any of Days 1-4 of ICU stay\n         - Not mentioned in the note.  \n      iii) Any in-patient surgery done under general anesthesia or epidural block in the 7 days prior to or on ICU admission*\n         - Not mentioned in the note.\n      iv) Pancreatitis in the 7 days prior to or on ICU admission\n         - Not mentioned in the note.\n      v) More than 1 dose of systemic steroids in the 7 days prior to or on ICU admission\n         - Not mentioned in the note.\n      vi) Use of more than 1 dose of other systemic immunosuppressive agents in the 7 days prior to or on ICU admission\n         - Not mentioned in the note.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if this patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "726": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male child, while the clinical trial is looking to recruit HIV infected individuals.\n2. There is no mention of the patient being HIV positive in the patient note.\n3. The patient seems to be presenting with a respiratory illness with fever, cough, and lung infiltrates on chest x-ray, likely an acute respiratory infection.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the trial as there is no indication that the patient is HIV infected.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "727": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the inclusion criteria of being an adult outpatient.\n\n2. The patient has a fever, cough, dyspnea, and bilateral lung infiltrates on chest X-ray, which could potentially indicate community-acquired pneumonia (CAP). However, the inclusion criteria specifically state that patients must be 18 years or older for CAP.\n\n3. There is no mention of the patient having a history of chronic bronchitis or meeting the criteria for acute exacerbation of chronic bronchitis (AECB).\n\n4. Based on the information provided, this 8-year-old patient does not meet the inclusion criteria for this clinical trial, which is focused on adult outpatients with AECB or CAP.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "728": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which falls within the age range of 1 to 6 years specified in the inclusion criteria.\n2. However, the patient is presenting with fever, dyspnea, cough, and bilateral lung infiltrates, which suggests he is not clinically healthy as required by the inclusion criteria.\n3. There is no information provided about whether the legal representative understands the nature of the study, agrees to its provisions, gives written informed consent, or agrees to keep a Volunteer Diary.\n\nBased on the information provided, the patient does not fully meet the inclusion criteria due to not being clinically healthy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "729": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which falls within the age range of 6-16 years specified in the inclusion criteria.\n\n2. The patient is presenting with fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray, indicating he is not clinically healthy at the time of presentation. The inclusion criteria specifies that participants must be clinically healthy.\n\n3. There is no information provided about whether the legal representative understands the nature of the study, agrees to its provisions, gives written informed consent, or agrees to keep a volunteer diary.\n\n4. There is no information provided about pregnancy status or birth control measures for female participants, as this patient is male.\n\nBased on the information provided, the main exclusion factor is that the patient is not clinically healthy at the time of presentation due to his acute respiratory illness.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "730": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of 16-65 years for this clinical trial.\n\n2. The clinical trial is a safety study for a tick-borne encephalitis (TBE) vaccine, while the patient presents with fever, dyspnea, cough, and bilateral lung infiltrates, which are not related to TBE.\n\n3. The inclusion criteria require the participants to be clinically healthy, but this patient is clearly ill with a respiratory infection.\n\nBased on the information provided, this patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "731": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which meets the age criteria of 1 year to < 16 years for this clinical trial.\n\n2. The patient presents with fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray, indicating he is not clinically healthy at the time of presentation.\n\n3. There is no information provided about whether the parents/legal guardians understand the nature of the study, have provided written informed consent, or agree to keep a volunteer diary.\n\n4. The patient's gender (male) is not an exclusion criterion.\n\nBased on the information provided, the main exclusion criterion appears to be that the patient is not clinically healthy at the time of presentation due to his acute respiratory illness.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "732": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not match the inclusion criteria of being 1-15 years old at the time of the first vaccination in the previous study (209).\n\n2. There is no information provided about whether this patient participated in the previous study 209 and received the TBE vaccinations, which is a key inclusion criteria.\n\n3. There is no information about the patient's TBE antibody levels or neutralizing antibody titers from the previous study.\n\n4. The current clinical presentation appears to be an acute respiratory illness, which is not relevant to the study about TBE antibody persistence and booster vaccination.\n\nBased on the information provided, this patient does not meet the stated inclusion criteria for this clinical trial about TBE vaccine antibody persistence.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "733": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male child presenting with fever, cough, dyspnea, and bilateral lung infiltrates on chest X-ray after returning from a trip to Colorado.\n\n2. The clinical trial is studying the immunogenicity and safety of a third dose of the FSME-IMMUN 0.5 mL vaccine in subjects previously vaccinated with 2 doses on a rapid schedule.\n\n3. The key inclusion criteria are:\n   - Received 2 vaccinations with FSME-IMMUN 0.5 mL during a previous study\n   - Clinically healthy\n   - Negative pregnancy test for females of childbearing potential\n   - Agree to use birth control during the study for females of childbearing potential\n   - Agree to keep a subject diary\n\n4. This patient does not meet the inclusion criteria as they are an 8-year-old child with an acute respiratory illness, and the trial is specifically looking at adults who previously received the FSME-IMMUN vaccine.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "734": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male child presenting with fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray. This does not seem to match the inclusion criteria for the given clinical trial.\n\n2. The clinical trial is studying the persistence of TBE virus antibodies approximately 3 years after a booster vaccination with FSME-IMMUN 0.25 mL JUNIOR in children.\n\n3. The key inclusion criteria are:\n   - Male and female children who participated in Study 146A\n   - Received the complete 3-immunization primary vaccination series with either 0.5 ml or 0.25 ml TicoVac in Study 146A\n   - Received FSME-IMMUN 0.25 ml Junior for their first booster vaccination approximately 3 to 4 years after their third vaccination in Study IMAG-146A\n\n4. Based on the information provided in the patient note, there is no indication that this patient participated in Study 146A or received the required vaccinations. The patient's current presentation appears to be an acute respiratory illness, which is not relevant to the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "735": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the inclusion criteria of being an adult (age \u2265 18 years).\n\n2. The patient presents with fever, dyspnea, cough, and bilateral lung infiltrates on chest X-ray, which are symptoms of a respiratory illness, not tick-borne relapsing fever.\n\n3. There is no mention of suspected exposure to ticks, tick bites, or being in an area endemic for tick-borne relapsing fever.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial on post-exposure treatment with doxycycline for the prevention of relapsing fever, this patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "736": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which falls within the age range of 1 to 10 years specified in the inclusion criteria.\n\n2. The inclusion criteria state that the participants should be \"healthy\" children. However, the patient note mentions that the child presented with fever, dyspnea, cough, and bilateral lung infiltrates, indicating an active respiratory illness.\n\n3. There is no mention of the child having any prior history of tick-borne encephalitis (TBE) or receiving any TBE vaccines, which is the focus of this clinical trial.\n\nBased on the information provided, the patient does not meet the \"healthy\" criteria due to the active respiratory illness. Additionally, there is no indication that the trial is related to the patient's current condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "737": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male child, while the clinical trial is for HIV/AIDS patients enrolled in the SMART study.\n2. There is no mention of the patient having HIV/AIDS or being enrolled in the SMART study.\n3. The inclusion criteria specifically state that participants must be co-enrolled in the SMART study.\n\nBased on the information provided, this patient does not meet the inclusion criteria for this particular clinical trial on anti-HIV drug regimens.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "738": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male child presenting with fever, cough, dyspnea and bilateral lung infiltrates on chest x-ray after returning from a trip to Colorado. This appears to be a case of community-acquired pneumonia.\n\n2. The clinical trial titled \"Effects of Two Anti-HIV Drug Regimens on HIV Transmission Risk Behavior Among SMART Study Participants\" is studying the effects of different HIV drug regimens on transmission risk behavior.\n\n3. The inclusion criteria for this trial are:\n   - Coenrollment in the SMART study\n   - Parent/guardian willing to provide informed consent, if applicable\n\n4. Based on the patient note provided, there is no mention of the patient having HIV or being enrolled in the SMART study.\n\n5. Therefore, this patient would not meet the inclusion criteria for this particular HIV clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "739": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Effects of Anti-HIV Therapy on Nervous System Function\", it is unlikely that this patient would be eligible for the trial. The key reasons are:\n\n1. The patient is an 8-year-old male, while the trial inclusion criteria specifically mention coenrollment in the SMART study, which is likely a study involving adults with HIV.\n\n2. The patient note does not mention any HIV diagnosis or anti-HIV therapy, which is the focus of the clinical trial.\n\n3. The patient's presenting symptoms (fever, dyspnea, cough, and loose stools) appear to be related to a respiratory illness or infection, rather than HIV or nervous system function.\n\nTherefore, based on the available information, this patient would not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "740": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient is an 8-year-old male presenting with fever, dyspnea, cough, and bilateral lung infiltrates on chest X-ray, which is consistent with severe pneumonia. The clinical trial is studying the management of severe pneumonia in children aged 2-59 months through either day-care or hospitalized treatment.\n\nWhile the patient meets the criteria of having severe pneumonia, he is outside the age range specified in the inclusion criteria (2-59 months). Therefore, he would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "741": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of being >= 16 years old for this clinical trial.\n\n2. The clinical trial is studying the immunogenicity and safety of a vaccine (FSME-IMMUN 0.5 mL) in adults previously vaccinated on a rapid schedule. \n\n3. The patient's presenting symptoms (fever, dyspnea, cough, loose stools) suggest an acute illness, which would likely exclude them from participating as the inclusion criteria state participants must be \"clinically healthy\".\n\n4. There is no mention of the patient previously receiving the FSME-IMMUN vaccine on a rapid schedule, which is a requirement for this trial.\n\nBased on the provided patient note and inclusion criteria, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "742": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of 18-55 years for this clinical trial on a typhoid fever vaccine.\n\n2. The patient is presenting with fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray, which suggests he has an acute respiratory illness, likely pneumonia. This is not consistent with the trial looking for healthy subjects.\n\n3. There is no mention of the patient having typhoid fever or being at risk for typhoid fever in the patient note.\n\nTherefore, based on the provided patient note and inclusion criteria for the typhoid fever vaccine trial, this patient would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "743": {
        "output": "Based on the provided patient note and the clinical trial information, this patient would not be eligible for the \"TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)\" clinical trial.\n\nThe key reasons are:\n\n1. The patient is an 8-year-old male, while the inclusion criteria specify that participants must have received the first booster vaccination with FSME-IMMUN 0.5ml during the course of study 223, which was likely a previous adult study.\n\n2. There is no mention of the patient having received any prior TBE (Tick-borne encephalitis) vaccinations or being part of the referenced Study 223.\n\n3. The patient's presenting symptoms (fever, dyspnea, cough, and loose stools) appear to be unrelated to TBE or the purpose of this vaccine study.\n\nTherefore, based on the information provided, this patient would not be eligible for referral to this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "744": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which falls outside the age range of 9-36 months specified in the inclusion criteria.\n\n2. The patient presents with fever, dyspnea, cough, and bilateral lung infiltrates on chest X-ray, which could potentially indicate a respiratory tract infection.\n\n3. However, the trial specifically focuses on Cryptosporidium infection causing diarrhea and respiratory symptoms. While the patient had loose stools prior to the fever and cough, there is no mention of a confirmed Cryptosporidium infection.\n\n4. The inclusion criteria also require the presence of acute or persistent diarrhea, which is not clearly stated for this patient.\n\nBased on the information provided, this patient does not meet all the inclusion criteria for the clinical trial on Cryptosporidium transmission and respiratory tract involvement.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "745": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which falls outside the age range of 6 months to 5 years specified in the inclusion criteria.\n\n2. However, the patient does present with fever (up to 39\u00b0C), cough, and difficult breathing (dyspnea), which matches the inclusion criteria of \"present with history of fever or reported fever\" and \"present with cough or difficult breathing\".\n\n3. Given that the patient meets some but not all of the inclusion criteria, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "746": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US\", it is clear that the patient does not meet the eligibility criteria for this trial.\n\nThe key reasons are:\n\n1. The patient is an 8-year-old male, while the inclusion criteria specify an age range of 18 to 45 years.\n2. The patient is presenting with fever, dyspnea, cough, and bilateral lung infiltrates, indicating an acute respiratory illness, which goes against the requirement of being \"healthy\" as per the inclusion criteria.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "747": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age criteria of 32-75 years for this clinical trial.\n\n2. The patient does not have a diagnosis of diarrhea-predominant irritable bowel syndrome (IBS) or meet the Rome III criteria for it. The note mentions loose stools prior to the fever and cough, but this seems to be an acute gastrointestinal illness rather than a chronic condition.\n\n3. There is no mention of the patient serving in the military or reserves during Operation Desert Storm, which is an inclusion criteria.\n\n4. The other inclusion criteria like normal endoscopic appearance, negative celiac/IBD markers, normal thyroid/calcium levels are not addressed in this brief note.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of age, diarrhea-predominant IBS diagnosis, and military service during the Gulf War.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "748": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Human Immune Responses to Yellow Fever Vaccination\", here is my assessment:\n\nThe patient is an 8-year-old male, which does not meet the age inclusion criteria of 18-45 years for this clinical trial. Additionally, there is no information provided about the patient's ability to understand and give informed consent.\n\nTherefore, based on the available information, I would not refer this patient for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "749": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which meets the criteria of being a patient.\n2. The patient presents with fever, dyspnea (shortness of breath), and cough, which meets the inclusion criteria of \"Patients with cough or shortness of breath\".\n3. The patient has bilateral lung infiltrates on chest x-ray, indicating a respiratory condition.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "750": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of 18-45 years for this dengue vaccine trial.\n\n2. There is no mention of the patient's health status, so we cannot determine if he meets the \"healthy\" inclusion criteria.\n\n3. The patient presented with fever, dyspnea, cough, and lung infiltrates on chest x-ray, suggesting an acute respiratory illness. This would likely exclude him from participating due to the exclusion criteria of \"chronic illness at a stage that could interfere with trial conduct or completion.\"\n\n4. There is no information provided about any previous flavivirus infections, vaccinations, or travel history, so we cannot determine eligibility based on those exclusion criteria.\n\nBased on the available information, the young age and acute respiratory illness would make this patient ineligible for this particular dengue vaccine trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "751": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which meets the age inclusion criteria of 1-11 years old for this clinical trial on TBE vaccines in children.\n\n2. The patient presented with fever, dyspnea, cough, and loose stools prior to the fever and cough. This suggests he likely has an acute respiratory illness, possibly pneumonia based on the chest x-ray findings.\n\n3. The inclusion criteria state that participants should be \"generally healthy\" and that the physician would have no reservations vaccinating with a TBE vaccine outside the scope of the clinical study.\n\n4. Given that the patient has an acute respiratory illness with fever and pneumonia, he would not be considered \"generally healthy\" at this time. Vaccinating him while acutely ill could potentially worsen his condition or lead to adverse effects.\n\n5. Therefore, based on the inclusion criteria requiring generally healthy participants, I would not recommend referring this patient for enrollment in this particular TBE vaccine clinical trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "752": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Children aged 2 to 59 months attending the outpatient's clinics of participating sites\n   - The patient is an 8-year-old male, which is outside the age range of 2-59 months. This criterion is not met.\n\n2. WHO defined non-severe pneumonia\n   - The patient presents with fever, dyspnea, cough, and bilateral lung infiltrates on chest X-ray, which suggests a more severe form of pneumonia. This criterion is not clearly met.\n\n3. Accessibility for follow-up\n   - No information is provided about the patient's accessibility for follow-up.\n\n4. Written informed consent by a parent or legal guardian\n   - No information is provided about obtaining consent.\n\nSince the patient does not meet the age criterion and the severity of pneumonia is unclear, it is unlikely that this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "753": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which meets the inclusion criteria of being a child/adolescent.\n\n2. However, the clinical trial is specifically about tick-borne encephalitis (TBE) and assessing antibody persistence after a TBE vaccine booster. \n\n3. The patient note does not mention anything about the patient receiving a TBE vaccine or being part of the precursor Study 700401.\n\n4. The patient presents with fever, cough, dyspnea and lung infiltrates - which points to a respiratory illness like pneumonia rather than tick-borne encephalitis.\n\n5. Therefore, this patient would not be eligible for this particular clinical trial about TBE vaccine antibody persistence.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "754": {
        "output": "To determine the patient's eligibility for the clinical trial \"Chest Physiotherapy in Pediatrics Patients With Pneumonia\", let's go through the inclusion criteria:\n\n1. Children aged 1 to 12 years: The patient is an 8-year-old male, which falls within this age range.\n\n2. Acute community-acquired pneumonia: The patient presents with fever, dyspnea, cough, and bilateral lung infiltrates on chest X-ray, which are consistent with pneumonia. The note mentions that the symptoms started 2 days ago, suggesting an acute onset.\n\n3. Cough, tachypnea (rapid breathing), fever: The patient has cough, fever up to 39\u00b0C, and dyspnea (shortness of breath), which can indicate tachypnea.\n\n4. Chest radiography with lobar, segmental or bronchopneumonia within the first 48 hours: The patient has bilateral lung infiltrates on chest X-ray, which is consistent with pneumonia.\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria for the clinical trial \"Chest Physiotherapy in Pediatrics Patients With Pneumonia\".\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "755": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age greater than or equal to 18 years\nThe patient note states that the patient is an 8-year-old male, which does not meet this inclusion criteria.\n\n2. Written informed consent by the patients\nThere is no information provided about whether informed consent was obtained from the patient or their parents/guardians.\n\n3. Medical condition necessitating the administration of antipyretic or analgesic medications\nThe patient note mentions that the patient presented with fever up to 39\u00b0C, which would likely necessitate the administration of an antipyretic medication.\n\nBased on the information provided, the patient does not meet the age requirement for this clinical trial. Additionally, there is no information about whether informed consent was obtained.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "756": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the inclusion criteria of \"Adults, equal to or more than 18 years years of age\".\n\n2. The patient presents with fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray, which could potentially be classified as \"mild community-acquired pneumonia\" under the inclusion criteria.\n\n3. However, the patient's age of 8 years old is a clear exclusion criterion for this trial.\n\nTherefore, based on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "757": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age criteria of \"above 55 years of age\" for this clinical trial on probiotics for preventing antibiotic-associated diarrhea.\n\n2. The patient is being treated as an inpatient and is receiving antibiotics, which meets some of the inclusion criteria.\n\n3. However, there is no information provided about whether the patient can take medication orally or has given informed consent, which are also required inclusion criteria.\n\n4. Additionally, the primary focus of this clinical trial seems to be on preventing Clostridium difficile infection in older adults taking antibiotics, whereas this patient's main issue appears to be a respiratory infection with bilateral lung infiltrates.\n\nBased on the information provided, this patient does not fully meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "758": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male presenting with fever, cough, dyspnea, and bilateral lung infiltrates on chest X-ray after returning from a trip to Colorado. This suggests a possible respiratory infection like pneumonia.\n\n2. The clinical trial is focused on reducing inappropriate antibiotic prescribing by primary care clinicians for common outpatient infections.\n\n3. The inclusion criteria state that the study will monitor antibiotic prescribing patterns for conditions like upper respiratory infections, bronchitis, pharyngitis, sinusitis, otitis media, cystitis, cellulitis, and community-acquired pneumonia.\n\n4. Since the patient has symptoms and radiographic findings suggestive of pneumonia, which is one of the conditions being studied, he would likely be eligible for inclusion in this trial.\n\n5. However, the inclusion criteria also mention that the study is focused on primary care clinics and outpatient settings. Since this patient presented to the emergency room, there is some uncertainty about whether he would meet the inclusion criteria based on the setting.\n\nIn summary, while the patient's clinical presentation aligns with the conditions being studied, the fact that he presented to the ER rather than an outpatient primary care clinic introduces some ambiguity regarding his eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether ER presentations are included in the study settings.",
        "label": 1
    },
    "759": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of 18-45 years for this clinical trial.\n\n2. The patient presented with fever, dyspnea, cough, and bilateral lung infiltrates on chest X-ray, suggesting a respiratory illness rather than being healthy as required by the inclusion criteria.\n\n3. There is no information provided about the patient's comprehension, consent, or ability to comply with the study protocol.\n\n4. There is no information about the patient's laboratory values to assess if they meet the normal screening criteria.\n\n5. There is no information about the patient's childbearing potential or birth control methods.\n\nBased on the information provided in the patient note, this patient would not be eligible for the Phase I Study of ETEC Vaccine due to not meeting the age criteria and having an active respiratory illness.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "760": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which meets the age criteria of \"at least 12 weeks of age\" for the clinical trial.\n\n2. The patient was admitted to the ER with severe gastroenteritis symptoms (fever, dyspnea, cough, and loose stools), which aligns with the inclusion criteria of being \"admitted to the study clinics/hospitals for severe gastroenteritis during the study period.\"\n\n3. The onset of symptoms was 2 days prior to admission, which meets the criteria of \"onset of severe gastroenteritis \u2264 14 days prior to admission.\"\n\n4. There is no information provided about a laboratory-confirmed rotavirus positive stool sample or written informed consent from the parent/guardian.\n\nBased on the available information, the patient meets some of the key inclusion criteria for being a potential case in this clinical trial. However, there are still some missing pieces of information needed to fully determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "761": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which meets the age criteria of less than 5 years old for the clinical trial.\n\n2. The patient presented with fever, dyspnea, cough, and loose stools, which could potentially indicate acute gastroenteritis.\n\n3. However, the patient also had respiratory symptoms like dyspnea, cough, and bilateral lung infiltrates on chest X-ray, which are not typical of acute gastroenteritis alone.\n\n4. The inclusion criteria specifically state that the patient must be admitted to the study hospital for acute gastroenteritis.\n\n5. Based on the information provided, it is unclear if the patient was admitted primarily for acute gastroenteritis or for a respiratory illness with secondary gastrointestinal symptoms.\n\nConsidering these points, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information regarding the primary reason for admission and the severity of the gastrointestinal symptoms would be needed to make a more definitive assessment of eligibility for this particular clinical trial on acute rotavirus gastroenteritis.",
        "label": 0
    },
    "762": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which meets the age criteria of being under 6 years old.\n\n2. The patient presented with fever, dyspnea, cough, and loose stools, which could indicate gastroenteritis.\n\n3. The patient was hospitalized, which meets the inclusion criteria of being hospitalized with acute gastroenteritis or rotavirus gastroenteritis.\n\nBased on the information provided, this patient seems to meet the inclusion criteria for the clinical trial on the burden of rotavirus gastroenteritis in children under 6 years old in Japan.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "763": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of being between 21-40 years old for this clinical trial.\n\n2. The clinical trial is studying the effects of probiotics on intestinal barrier function and inflammation caused by an Enterotoxigenic Escherichia coli (ETEC) challenge. \n\n3. The patient presented with fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray, which are symptoms of a respiratory illness rather than an intestinal infection.\n\n4. There is no mention of the patient being challenged with ETEC or having any intestinal symptoms besides a brief report of loose stools prior to the fever and cough.\n\n5. The inclusion criteria specifically state that participants must be healthy based on a health questionnaire, physical exam, and lab tests. This patient presented to the ER with an acute illness.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial studying intestinal barrier function and probiotics.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "764": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which meets the age criteria of being under 5 years old.\n\n2. The patient presented to the ER with fever, dyspnea, cough, and loose stools, which could indicate acute gastroenteritis.\n\n3. The inclusion criteria state that the patient should either be hospitalized for acute gastroenteritis, visit the ER for acute gastroenteritis, or have rotavirus positive laboratory results and develop acute gastroenteritis at least 48 hours after hospitalization.\n\n4. In this case, the patient visited the ER with symptoms suggestive of acute gastroenteritis, which meets one of the inclusion criteria.\n\nBased on the information provided, this patient appears to meet the inclusion criteria for the clinical trial on rotavirus gastroenteritis in children under 5 years of age.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "765": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not violate the inclusion criteria for age or gender.\n\n2. The patient presented with fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray, which suggests pneumonitis. This aligns with the inclusion criteria of \"Presence of respiratory symptoms and/or signs at presentation\".\n\n3. There is no mention of paraffin (kerosene) ingestion in the patient note, which is a key inclusion criteria for this trial.\n\n4. The other inclusion criteria regarding informed consent and ability to follow up are not addressed in the patient note.\n\nBased on the information provided, the lack of confirmed paraffin ingestion makes the patient ineligible for this particular clinical trial on antibiotic efficacy in paraffin-induced pneumonitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "766": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male child presenting with fever, cough, dyspnea, and loose stools after returning from a vacation in Colorado.\n2. The clinical trial is studying the etiology of diarrhea in Guinea-Bissau and Finland.\n3. One of the inclusion criteria is \"With diarrhea: the first 10 children and 10 adults presenting each month at the health facility\".\n4. Since the patient is a child presenting with loose stools (diarrhea), he meets this inclusion criteria.\n\nHowever, there are a few potential issues:\na) The trial is being conducted in Guinea-Bissau and Finland, while this patient is from Colorado, USA.\nb) The trial seems to be focused on diarrhea specifically, while this patient also has respiratory symptoms like fever, cough, and dyspnea which could indicate a different underlying condition.\n\nGiven this information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the criteria of being a child with diarrhea, but further clarification may be needed on whether patients outside of Guinea-Bissau/Finland are eligible, and whether the respiratory symptoms exclude the patient or not. More investigation into the full eligibility criteria would be warranted before making a final decision.",
        "label": 1
    },
    "767": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is an 8-year-old male, which fits the age criteria of 6 months to 6 years old for the clinical trial.\n\nThe patient has a fever up to 39\u00b0C, which meets the inclusion criteria of having an axillary temperature above 37.5\u00b0C.\n\nThe patient's weight is not mentioned, but the inclusion criteria state a minimum weight of 5 kg. Most 8-year-olds would likely meet this weight requirement.\n\nBased on the information provided in the patient note, this patient appears to meet the key inclusion criteria for the clinical trial on comparing fever medications in children.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "768": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age criteria of \u2265 18 years for this clinical trial.\n\n2. The patient presented with fever, dyspnea, cough, and loose stools, which are not specifically gastrointestinal symptoms lasting more than 10 days as required by the inclusion criteria.\n\n3. There is no mention of Blastocystis hominis being identified in the patient's stool specimens.\n\n4. The patient's symptoms and chest x-ray findings suggest a respiratory infection, which would likely exclude them from this trial focused on gastrointestinal symptoms and Blastocystis hominis infection.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial titled \"Is it Effective to Treat Patients With Blastocystis Hominis Infection?\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "769": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not exclude him based on the inclusion criteria provided.\n\n2. The patient does not have a confirmed diagnosis of sickle cell disease (Hemoglobin SS, SC, SB0thal, or SBthal), which is required for inclusion.\n\n3. The patient meets some of the clinical criteria for acute chest syndrome (ACS) with fever, dyspnea, cough, and bilateral lung infiltrates on chest x-ray.\n\n4. However, there is no information provided about whether the patient is eligible for a simple transfusion based on hypoxemia, low hemoglobin, or increased work of breathing.\n\n5. Without a confirmed diagnosis of sickle cell disease and meeting all the criteria for ACS and transfusion eligibility, I cannot definitively determine if this patient would be eligible for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into their sickle cell disease status and transfusion eligibility criteria.",
        "label": 0
    },
    "770": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age criteria of \u226540 years for this COPD trial.\n\n2. The patient does not have a diagnosis of COPD or meet the spirometry criteria listed.\n\n3. There is no mention of the patient having cardiovascular disease, a prior cardiovascular event, or the listed cardiovascular risk factors required for inclusion.\n\n4. The patient's presenting symptoms (fever, cough, dyspnea, loose stools) seem more consistent with an acute respiratory illness rather than COPD exacerbation.\n\nBased on the information provided, this 8-year-old patient with an acute respiratory illness does not meet the key inclusion criteria for this COPD clinical trial evaluating an inhaled medication in patients with or at risk for cardiovascular disease.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "771": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age criteria of 40-75 years for this lung cancer screening trial.\n\n2. There is no information provided about the patient's smoking history or family history of lung cancer, which are key inclusion criteria.\n\n3. The patient presents with fever, cough, and lung infiltrates on chest x-ray, which suggests an acute respiratory illness rather than lung cancer.\n\nBased on the information provided in the patient note, this patient would not be eligible for the \"Chest Imaging, Breath, and Biomarkers in a Screening Trial\" as they do not meet the age or risk factor criteria for lung cancer screening.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "772": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of \"Men / Women aged 18 and over\" for this clinical trial on preventing relapse of Clostridium difficile associated diarrhea.\n\n2. There is no mention of the patient being successfully treated for C. diff associated diarrhea using standard therapy like metronidazole or vancomycin, which is another inclusion criteria.\n\n3. The patient's symptoms (fever, dyspnea, cough, loose stools) seem more indicative of a respiratory infection rather than C. diff colitis specifically.\n\nBased on the information provided in the patient note, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "773": {
        "output": "To determine the patient's eligibility for the clinical trial, I will need the title and inclusion criteria for the trial. Without that information, I cannot make an assessment. Please provide the missing details about the clinical trial, and I will evaluate the patient's eligibility based on the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "774": {
        "output": "To determine the patient's eligibility for the clinical trial \"Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis\", let's go through the inclusion criteria one by one:\n\n1. Subjects must be 18 years of age or older.\nThe patient is an 8-year-old male, so he does not meet this criterion.\n\n2. Ability to provide written informed consent.\nSince the patient is a minor, he would not be able to provide written informed consent himself.\n\n3. Likely to complete all study visits.\nThere is no information provided about the patient's ability to complete all study visits.\n\n4. Subjects must have one eye that with a diagnosis of infectious keratitis.\nThe patient note does not mention any diagnosis of infectious keratitis. The patient presents with fever, dyspnea, cough, and bilateral lung infiltrates, which suggests a respiratory infection rather than an eye infection.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient does not appear to be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "775": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of 18-45 years for this clinical trial.\n\n2. The patient presents with fever, dyspnea, cough, and bilateral lung infiltrates, which suggests an acute respiratory illness. This clinical trial is studying a vaccine candidate for enterotoxigenic E. coli (ETEC), which causes diarrheal illness. The patient's symptoms do not align with the target disease of this trial.\n\n3. There is no information provided about whether the patient meets the other inclusion criteria, such as being in general good health, having normal laboratory values, demonstrating comprehension of the study procedures, and agreeing to the required restrictions.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial due to not meeting the age criteria and having symptoms inconsistent with the target disease.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "776": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age inclusion criteria of \u2265 18 years old for this clinical trial on community-acquired pneumonia.\n\n2. However, the patient does have an infiltrate on chest X-ray, which meets one of the inclusion criteria.\n\n3. The patient also has cough, fever, and pathologic lung auscultation (bronchial respiratory sounds on the left), which meet the other inclusion criteria of cough, production of purulent sputum, pathologic lung auscultation, or fever.\n\n4. Since the patient meets some but not all of the inclusion criteria, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "777": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male presenting with fever, dyspnea (shortness of breath), cough, and bilateral lung infiltrates on chest X-ray.\n\n2. The clinical trial is looking at the usefulness of point-of-care lung ultrasound in evaluating patients presenting to the emergency department with cough, wheezing, and/or dyspnea (shortness of breath).\n\n3. The inclusion criteria for the trial are:\n   - Presenting to the Emergency Department with cough, wheezing and/or dyspnea (shortness of breath)\n   - Referred for CXR and/or CT scan\n\n4. The patient meets both of these inclusion criteria:\n   - He presented to the ER with cough, dyspnea, and fever.\n   - He had a chest X-ray done which showed bilateral lung infiltrates.\n\nTherefore, based on the information provided, this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "778": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Children aged 6 months to 10 years presenting with CAP will be eligible.\nThe patient is an 8-year-old male, which falls within this age range. However, it is not explicitly stated that he has community-acquired pneumonia (CAP).\n\n2. CAP will be defined if all of the four following numeric criteria are met:\n   a) fever (>37.5 C axillary, > 37.7 C oral, or >38 C rectal) recorded in the ED or at home in the 48h prior to presentation;\n      The patient had a fever up to 39 C, which meets this criterion.\n   b) any one of: tachypnoea, cough, increased work of breathing, or auscultatory findings consistent with pneumonia;\n      The patient had dyspnea (difficulty breathing) and cough, which meets this criterion.\n   c) infiltrates on chest radiograph consistent with bacterial CAP as judged by the ED physician;\n      The patient had bilateral lung infiltrates on chest x-ray, which suggests pneumonia.\n   d) the attending ED physician diagnoses the child with primary CAP.\n      This is not explicitly stated in the patient note.\n\n3. Participants must be well enough to be treated as outpatients.\n   The patient was brought to the ER, but it is not mentioned if they were admitted or discharged.\n\n4. No evidence of empyaema or necrotizing pneumonia on chest radiograph.\n   This is not mentioned in the patient note.\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria. More investigation would be needed to determine if the ED physician diagnosed primary CAP and if the patient was well enough for outpatient treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "779": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the age criteria of \u226518 years to <60 years for this clinical trial on yellow fever vaccination.\n\n2. There is no mention of the patient being on methotrexate therapy or being a healthy control, which are required for this study.\n\n3. The patient's symptoms (fever, dyspnea, cough, loose stools) suggest an acute respiratory illness, possibly pneumonia, rather than being a traveler seeking a yellow fever vaccination.\n\nBased on the information provided in the patient note, this patient would not be eligible for the yellow fever vaccination clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "780": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not meet the inclusion criteria of being 18 years or older for this clinical trial on typhoid vaccination.\n\n2. There is no information provided that indicates the patient is a traveler attending a travel vaccination clinic.\n\n3. There is no information that the patient is eligible for or recommended to receive the typhoid vaccination according to standard practice.\n\n4. The patient presented to the emergency room with fever, cough, and lung infiltrates, suggesting an acute illness rather than being a healthy traveler seeking pre-travel vaccination.\n\nBased on the information provided in the patient note, this 8-year-old male with an acute respiratory illness would not meet the inclusion criteria for this phase 4 clinical trial assessing the safety of a typhoid vaccine in healthy adult travelers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "781": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male child, which fits the inclusion criteria of having at least one child under 5 years old in the household.\n\n2. However, the clinical trial is focused on assessing the health impact of a water and sanitation intervention in rural Odisha, India. The patient note does not mention anything about the patient being from rural Odisha or participating in the specific intervention being studied.\n\n3. The patient's symptoms (fever, dyspnea, cough, loose stools, lung infiltrates) seem to be indicative of an acute respiratory illness, which is not directly relevant to the water and sanitation intervention being studied.\n\n4. Without more information about the patient's location, household, and participation in the specific intervention, it is difficult to determine their eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "782": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male, which does not violate any of the inclusion criteria provided.\n\n2. The patient presents with fever up to 39\u00b0C, which meets the inclusion criterion of having a temperature higher than 38\u00b0C.\n\n3. The fever has been present for 2 days, which is less than one week. This does not meet the inclusion criterion of having fever for more than one week.\n\n4. The patient has undergone a physical examination and chest X-ray, but no definitive diagnosis has been made yet.\n\nBased on the information provided, the patient partially meets the inclusion criteria for this clinical trial. While the patient has a high fever and has undergone some diagnostic tests without a definitive diagnosis, the duration of fever is less than one week as required by the inclusion criteria.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "783": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old male child presenting with fever, dyspnea, cough, and loose stools after returning from a vacation in Colorado.\n2. The clinical trial is about evaluating the effectiveness and patient satisfaction with pre-travel consultations provided by a pharmacist with specialty training in travel medicine.\n3. The inclusion criteria for the trial is: \"Receiving a pre-travel consultation at the Travel Health Network clinic in St. Albert, Alberta, Canada\"\n4. Based on the patient note, this patient did not receive a pre-travel consultation, as they are presenting with symptoms after returning from their trip.\n\nTherefore, this patient does not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "784": {
        "output": "Based on the given patient note and the clinical trial information, this patient does not meet the inclusion criteria for the \"Preventing Chronic Whiplash Pain\" trial. The key reasons are:\n\n1. The patient has sustained multiple injuries including upper and lower extremity fractures, which are not related to whiplash injury.\n2. The patient's injuries are from a recent car accident, not specifically a whiplash injury from a motor vehicle accident within the past 4-10 weeks as required by the inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "785": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman admitted to the ER following a car accident. This matches the inclusion criteria of being a driver admitted as a result of a motor vehicle accident.\n\n2. The exclusion criteria state that drivers aged < 18 years are excluded. Since the patient is 32 years old, she meets this criteria.\n\n3. There is no information provided about whether the patient has any sleep disorders or not. The trial is looking to ascertain the prevalence of sleep disorders in drivers involved in motor vehicle accidents.\n\nBased on the information provided, this patient could potentially be eligible for the clinical trial, but further investigation would be needed to determine if she has any underlying sleep disorders.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "786": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was involved in a car accident and sustained multiple injuries including fractures.\n2. The clinical trial is titled \"ED Intervention to Reduce Risky Behaviors in Drivers\" and aims to test the effectiveness of a brief intervention to limit risky driving behaviors and problem drinking in drivers during an ED visit.\n3. One of the inclusion criteria for the trial is to \"Screen Positive for a drinking problem in the ED\".\n4. The patient note does not mention anything about the patient having a drinking problem or being screened for one in the ED.\n\nBased on the information provided in the patient note and the inclusion criteria, there is not enough evidence to determine if the patient would be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "787": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, so her age is not specified in the inclusion criteria.\n2. There is no mention of whether she has a driving license, driving experience, normal vision, or is right-handed and fluently Dutch speaking.\n3. The clinical trial is about the effects of pain on driving performance and cognition, but the patient note does not mention any chronic pain condition.\n4. The patient has sustained multiple injuries from a car accident, but this does not necessarily mean she has chronic pain or cognitive impairment that would affect driving performance.\n\nBased on the information provided, there is not enough evidence to determine if this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "788": {
        "output": "Based on the provided patient note and the clinical trial information, this patient would not be eligible for the \"Ischemic Preconditioning of Liver in Cadaver Donors\" clinical trial.\n\nThe key reasons are:\n\n1. The patient is not a deceased liver donor. The trial specifically includes \"Deceased donor livers allocated to adult (> 18 years of age) recipients at the research site.\"\n\n2. The patient's condition is related to injuries sustained from a car accident, and there is no mention of liver disease or the need for a liver transplant.\n\nTherefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "789": {
        "output": "Based on the provided patient note and the clinical trial information, this patient would not be eligible for the clinical trial titled \"Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort\". The key reasons are:\n\n1. The patient is a 32-year-old woman who has been admitted to the ER following a car accident with multiple injuries, including fractures and potential internal injuries (tender abdomen, guarding, rebound tenderness, and no bowel sounds). \n\n2. The inclusion criteria for the clinical trial specify an age range of 21-75 years old, which the patient meets. However, the trial is studying the effects of aircraft cabin altitude on passenger comfort and discomfort, and it excludes individuals with specified acute or chronic medical conditions.\n\n3. The patient's current medical condition, involving multiple traumatic injuries from a car accident, would likely exclude her from participating in this clinical trial, as her injuries and potential complications could interfere with the study's objectives and measurements.\n\nTherefore, based on the available information, I would not refer this patient for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "790": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which does not meet the age inclusion criteria of 15 years 0 months to 16 years 6 months for this clinical trial on driver education for teens.\n\n2. The clinical trial is specifically studying the efficacy of a driver education program, and this patient was admitted to the ER following a car accident, which is not relevant to the trial's aims.\n\n3. There is no mention of the patient being enrolled in a driver education course, which is an inclusion criterion.\n\nBased on the information provided, this patient would not be eligible for the Michigan Driver Education Study clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "791": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Effect of Experience on Driving Performance in New Teenage Drivers\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient is a 32-year-old woman, while the trial is recruiting newly licensed teenage drivers aged 16-17 years old.\n\n2. The patient has sustained multiple injuries, including fractures, from a car accident. The trial requires participants to be able to legally drive and have at least 20/40 correctable vision, which may not be the case for this patient given her injuries.\n\n3. The trial is focused on evaluating driving performance and experience, whereas this patient's situation involves a car accident and injuries, which are not relevant to the trial's objectives.\n\nTherefore, based on the information provided, this patient would not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "792": {
        "output": "Based on the given patient note and the clinical trial information, this patient would not be eligible for the \"Severe Post Partum Haemorrhage (PPH): A Randomized Trial on Transversal Intervention in 6 French Perinatal Networks\" trial. The key reasons are:\n\n1. The patient is a 32-year-old woman admitted to the ER following a car accident, not a pregnant woman or a woman who has recently given birth.\n\n2. The trial is specifically focused on postpartum hemorrhage (PPH) and interventions to manage PPH, which is not relevant to the patient's current condition.\n\n3. The inclusion criteria explicitly state that eligible participants are \"All women delivering at a gestational age greater than 22 weeks, in one of the participating maternity unit during the study period.\"\n\nTherefore, based on the information provided, this patient would not meet the eligibility criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "793": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Intra Ocular Pressure During Robotic Prostatectomy\", this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient is a 32-year-old woman, while the inclusion criteria specify that participants must be male.\n2. The patient is admitted to the ER following a car accident and has sustained multiple injuries, including fractures. The trial is specifically looking at patients scheduled for robotic prostatectomy surgery.\n3. The trial is studying the relationship between intraocular pressure and visual deficiencies/vision loss after robotic prostatectomy surgery, which is not relevant to the patient's current condition.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "794": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation\", this patient would not be eligible for the trial.\n\nThe patient note describes a 32-year-old woman who was admitted to the ER following a car accident, sustaining multiple injuries including fractures and abdominal trauma. There is no mention of any nasal symptoms or conditions related to vasomotor rhinitis or nonallergic rhinitis.\n\nThe inclusion criteria for the clinical trial specifically require participants to have a significant history of chronic and/or recurrent nasal symptoms (rhinorrhea, blockage, sneezing, or pruritus) in response to changes in temperature and/or humidity (physical triggers) or nonspecific irritant triggers (perfumes, cleaning products, smoke, etc.) for at least two years.\n\nSince the patient note does not indicate any relevant nasal symptoms or conditions, and the patient's presentation is related to a traumatic injury, she would not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "795": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Hospitalized men or women >/=18 years of age\nThe patient is a 32-year-old woman admitted to the ER, so this criterion is met.\n\n2. Expected duration of treatment with intravenous antibiotics anticipated to be >/= 5 full days but not exceeding 14 days\nThere is no information provided about the expected duration of treatment, so this criterion cannot be evaluated.\n\n3. Ability to provide documented and signed written informed consent\nThere is no information provided about the patient's ability to provide informed consent, so this criterion cannot be evaluated.\n\n4. Confirmed or suspected intra abdominal infection defined as follows:\n   a) For a confirmed intra abdominal infection, a surgical procedure must have been performed within 24 hours prior to enrollment and reveal at least one of the following:\n      - Gross peritoneal inflammation with purulent exudates (i.e. peritonitis)\n      - Intra abdominal abscess\n      - Macroscopic intestinal perforation with localized or diffuse peritonitis\n   b) Subjects enrolled on the basis of a suspected intra abdominal infection must have:\n      - Radiological evidence of gastrointestinal perforation or intra-abdominal abscess\n      - Symptoms referable to the abdominal cavity (e.g. anorexia, nausea, vomiting or pain), lasting for at least 24 hours\n      - Tenderness (with or without rebound), involuntary guarding, absent or diminished bowel sounds, or abdominal wall rigidity\n      - At least two of the SIRS criteria (fever, tachycardia, tachypnea, leukocytosis or leukopenia)\n      - The subject must be scheduled for a surgical procedure within 24 hours of enrollment\n\nThe patient has a tender abdomen with guarding and rebound in all four quadrants, and no bowel sounds, which suggests a suspected intra-abdominal infection. However, there is no information provided about radiological evidence, duration of symptoms, or SIRS criteria.\n\n5. The subject must be scheduled for a surgical procedure (laparotomy or laparoscopy) within 24 hours of enrollment of the study\nThere is no information provided about whether the patient is scheduled for a surgical procedure within 24 hours.\n\nBased on the information provided, some of the inclusion criteria are met, but there are several criteria that cannot be evaluated due to lack of information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "796": {
        "output": "Based on the provided patient note and the clinical trial information, here is my assessment of the patient's eligibility for the trial:\n\nThe patient note describes a 32-year-old woman who was involved in a car accident and sustained multiple injuries, including fractures. The clinical trial is focused on enhancing driving performance in individuals with Attention-Deficit/Hyperactivity Disorder (ADHD) using stimulant medication.\n\nThe patient note does not mention any diagnosis of ADHD or any history of ADHD symptoms. Additionally, the inclusion criteria for the clinical trial specifically require an ADHD diagnosis, a valid driver's license, not taking any medication for ADHD, having access to a car as the primary driver, a history of approximately two driving collisions or citations, and a history of responsiveness to methylphenidate.\n\nBased on the information provided in the patient note, there is no indication that the patient meets the inclusion criteria for this clinical trial. The note does not mention any ADHD diagnosis or related symptoms, and the patient's injuries and circumstances do not align with the trial's focus on evaluating driving performance in individuals with ADHD.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "797": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which falls within the age range of 18-60 specified in the inclusion criteria.\n\n2. The patient is described as being fully awake and alert, suggesting no neurological or psychiatric conditions that would exclude her from the trial.\n\n3. However, the patient has sustained multiple injuries, including upper and lower extremity fractures, from a car accident. This suggests she may not be able to safely operate a vehicle for the driving simulation portion of the trial.\n\n4. Additionally, the patient has signs of abdominal trauma (tender abdomen, guarding, rebound tenderness, no bowel sounds), which could indicate a serious medical condition that would exclude her from participating.\n\n5. The inclusion criteria specifically state that participants should be \"neurologically normal\" and without \"chronic medical or psychiatric conditions\" that could impact driving performance independent of the study drug.\n\nGiven the patient's recent injuries and potential abdominal trauma, I would not consider her eligible for this particular clinical trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "798": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman admitted to the ER following a car accident with multiple injuries including fractures. This meets the inclusion criteria of being an emergency department patient undergoing abdominal CT.\n\n2. However, the inclusion criteria specifically excludes patients with traumatic abdominal pain and tenderness. Since this patient's abdominal pain and tenderness are due to the car accident trauma, she would likely be excluded from this study.\n\n3. The study is looking at correlating the location of abdominal tenderness with acute CT abnormalities in non-traumatic cases.\n\nTherefore, based on the inclusion/exclusion criteria provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "799": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries including upper and lower extremity fractures.\n\n2. The clinical trial is titled \"Plating of Humeral Shaft Fractures in Multiple Trauma Patients.\" The summary indicates that the study is reviewing the operative management of acute diaphyseal fractures of the humerus (upper arm bone) in multiple trauma patients.\n\n3. One of the inclusion criteria is \"patients with past (acute) traumatic humeral shaft fracture(s) treated with open reduction and internal fixation (ORIF).\"\n\n4. Based on the patient note, it is not explicitly stated that the patient sustained a humeral shaft fracture. The note only mentions \"upper and lower extremity fractures.\"\n\n5. Without more specific information about the type and location of the upper extremity fracture(s), it is difficult to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "800": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was in a car accident and sustained multiple injuries including fractures. This does not align with the inclusion criteria of being 50 years or older with non-traumatic osteoporotic vertebral fractures.\n\n2. The patient's injuries are from a traumatic event (car accident), whereas the trial is looking for non-traumatic osteoporotic fractures.\n\n3. There is no mention of the patient having a vertebral fracture specifically, which is a key inclusion criterion.\n\n4. The patient's presentation with abdominal tenderness, guarding, and lack of bowel sounds suggests an acute abdominal issue, which would likely preclude her from undergoing an elective procedure like vertebroplasty or kyphoplasty at this time.\n\nBased on the information provided, this patient would not be eligible for the clinical trial comparing balloon kyphoplasty and vertebroplasty for subacute osteoporotic vertebral fractures.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "801": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries including upper and lower extremity fractures.\n\n2. The clinical trial is a feasibility study of balloon kyphoplasty in traumatic vertebral fractures needing surgical fixation.\n\n3. Looking at the inclusion criteria for the trial:\n   - The patient must be 18 years or older (the patient is 32, so she meets this criterion).\n   - The patient must have one or two traumatic vertebral fractures located between T11 and L5, classified as A3.2, A3.3, B1, or C1 in the MAGERL classification, with a regional kyphotic angle > 15\u00b0, and treated by osteosynthesis through a posterior surgical approach with or without spinal decompression.\n\n4. The patient note does not mention any specific details about vertebral fractures or their classification. It only states that she sustained upper and lower extremity fractures.\n\n5. Without more information about the presence and nature of any vertebral fractures, it is difficult to determine if the patient meets the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "802": {
        "output": "To determine the patient's eligibility for this clinical trial, let's go through the inclusion criteria:\n\n1. Primary diagnosis of post-traumatic stress disorder (PTSD)\nThe patient note does not mention a diagnosis of PTSD. It only states that the patient was involved in a car accident and sustained multiple injuries.\n\n2. Involved in motor vehicle accident that occurred at least 3 months ago\nThe patient note indicates that the patient was admitted to the ER following a car accident, but it does not specify when the accident occurred.\n\nSince the patient note does not provide enough information to confirm that the patient meets both inclusion criteria, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "803": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which falls within the age range of 16-60 years specified in the inclusion criteria.\n\n2. The patient note does not mention an ankle sprain, which is a key requirement for this clinical trial on ankle manual therapy for ankle sprains.\n\n3. The patient has sustained multiple injuries from a car accident, including upper and lower extremity fractures, but there is no specific mention of an ankle sprain.\n\n4. The patient's symptoms, such as tender abdomen with guarding and rebound in all four quadrants and absence of bowel sounds, suggest a potential abdominal injury rather than an ankle sprain.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the \"Ankle Manual Therapy for Ankle Sprains\" trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "804": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries including upper and lower extremity fractures, suggesting potential rib fractures as well.\n\nThe clinical trial is focused on chest wall repair of rib fractures after trauma.\n\nLooking at the inclusion criteria:\n1) The patient is over 18 years old (she is 32), so she meets this criterion.\n2) The patient likely has rib fractures given the car accident and multiple extremity fractures, but the note does not specify the number of rib fractures or presence of a flail segment. More information is needed to determine if she meets this criterion.\n3) The note does not mention a pulmonary hernia, so this criterion is unclear.\n4) The note does not specify the severity of associated injuries beyond the extremity fractures.\n5) The note does not mention failure of pain control measures.\n\nBased on the available information, I would consider referring this patient to the clinical trial upon further investigation of the specific rib fracture details and associated injuries.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "805": {
        "output": "Based on the provided patient note and the clinical trial information, this patient would not be eligible for the \"Maastricht Neck Study: Cervical Range of Motion in Whiplash Patients\" trial. The key reasons are:\n\n1. The patient has sustained multiple injuries from a car accident, including upper and lower extremity fractures, but there is no mention of a whiplash injury or neck complaints.\n\n2. The trial's inclusion criteria specifically state that patients must have had a measurement of the cervical range of motion, which is not mentioned in the patient note.\n\n3. The trial is focused on investigating the natural course of cervical range of motion and its relation to chronic whiplash syndrome, which does not seem relevant to this patient's condition.\n\nTherefore, based on the available information, this patient would not be a suitable candidate for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "806": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which falls within the age range of 21-35 years old specified in the inclusion criteria.\n\n2. There is no information provided about the patient's BMI, body weight, smoking status, or visual/hearing abilities, so we cannot determine if she meets those criteria.\n\n3. The patient was involved in a car accident, suggesting she is a driver and likely possesses a valid driver's license for at least 3 years, as required by the inclusion criteria.\n\n4. However, the patient has sustained multiple injuries, including upper and lower extremity fractures, and has a tender abdomen with guarding and rebound in all four quadrants, suggesting a potential abdominal injury. These injuries may affect her ability to participate in a driving simulator study safely.\n\n5. Additionally, the study requires participants to be considered reliable and mentally capable of adhering to the protocol. The patient's mental status is not explicitly stated, but being fully awake and alert after a car accident is a positive sign.\n\nBased on the available information, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the patient meets some of the inclusion criteria, her injuries and overall medical condition would need to be evaluated further to determine if she can safely participate in a driving simulator study. Additional information about her BMI, body weight, smoking status, visual/hearing abilities, and mental capacity to follow the protocol would also be needed to make a more definitive assessment of eligibility.",
        "label": 2
    },
    "807": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries including upper and lower extremity fractures.\n\n2. The clinical trial is titled \"An Adhesion Reduction Plan in the Management of the Surgical Open Abdomen\" and is focused on trauma patients with an open abdomen after initial laparotomy.\n\n3. The patient's physical examination reveals a tender abdomen with guarding and rebound in all four quadrants, and she has no bowel sounds. This suggests she may have sustained abdominal injuries requiring surgical intervention.\n\n4. The inclusion criteria for the clinical trial specifically mention trauma patients with an open abdomen after initial laparotomy.\n\n5. While the patient note does not explicitly state that the patient underwent an initial laparotomy, the abdominal findings strongly suggest the need for surgical exploration and potential open abdomen management.\n\nBased on the information provided, this patient appears to meet the inclusion criteria for the clinical trial, as she is a trauma patient who may require an open abdomen after initial laparotomy.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "808": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman admitted to the ER following a car accident with multiple injuries including fractures.\n2. The clinical trial is studying the peritoneal/serum lactate ratio in patients undergoing abdominal surgery or with signs of sepsis/hypoperfusion in the post-operative period.\n3. The inclusion criteria specifically mention:\n   - Post-operative period of abdominal surgery (elective or urgent laparotomy)\n   - Patients with signs of sepsis in the post-operative period\n   - Patients with signs of systemic hypoperfusion in the post-operative period\n\n4. Based on the patient note, this patient has just been admitted to the ER following a car accident and has not undergone any abdominal surgery yet. There is no mention of sepsis or systemic hypoperfusion either.\n\nTherefore, this patient does not currently meet the inclusion criteria for this clinical trial studying peritoneal/serum lactate ratio in post-operative abdominal surgery patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "809": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Safety and Efficacy of Autologous Bone Marrow Stem Cells in Treating Spinal Cord Injury,\" the patient does not appear to meet the eligibility criteria for this trial.\n\nThe key reasons are:\n\n1. The patient is a 32-year-old woman who was admitted to the ER following a car accident. The inclusion criteria specify that the patients should have a spinal cord injury, but there is no mention of a spinal cord injury in the patient note.\n\n2. The inclusion criteria specify that the patients should be between 20-55 years of age, which the patient meets.\n\n3. However, the inclusion criteria also state that the patients should have a complete spinal cord transection at a level between C4 and T12, and the injury should be at least 6 months old for chronic patients, less than 2 weeks for acute patients, or between 2-8 weeks for subacute patients.\n\nSince the patient note does not mention a spinal cord injury or the duration of the injury, it is unlikely that the patient would be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "810": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was involved in a car accident and sustained multiple injuries including fractures.\n2. The clinical trial is focused on screening for psychotraumatic disorders like PTSD after a motor vehicle accident.\n3. One of the key inclusion criteria is that the patient must be a victim of a road traffic accident and hospitalized in a surgical department for less than 2 weeks.\n\nThis patient meets that key inclusion criteria, as she was admitted to the ER following a car accident and likely will be hospitalized for treatment of her injuries.\n\nHowever, there are a couple potential concerns:\n1) The patient's mental status is not clearly described, so we don't know if she would be able to complete the screening questionnaire.\n2) It's not specified if she will be admitted to a surgical unit or just treated in the ER.\n\nGiven that she meets the core inclusion criteria of being a recent road traffic accident victim, but there are some potential uncertainties, I would assess her eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "811": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which does not meet the inclusion criteria of birth gestational age between 25 and 32 weeks and corrected gestational age less than 34 weeks for this neonatal trial.\n\n2. There is no information provided about the patient being a preterm infant or having any feeding intolerance issues, which are key criteria for this trial.\n\n3. The patient's presenting condition is related to injuries from a car accident, which is not relevant to this trial focused on feeding intolerance in preterm infants.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria for this neonatal clinical trial, this patient would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "812": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman admitted to the ER following a car accident with multiple injuries including fractures. This matches the inclusion criteria of being an adult patient requiring a CT abdomen for clinical purposes.\n\n2. However, the clinical trial specifically mentions patients with inflammatory bowel disease (IBD), and there is no mention of the patient having IBD in the provided note.\n\n3. The purpose of the trial is to validate the use of low-dose CT protocols for patients with IBD, which this patient does not have based on the information given.\n\n4. While the patient requires a CT abdomen due to the injuries sustained in the car accident, they do not seem to fit the specific inclusion criteria of having IBD.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "813": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Driving Simulator Performance After Intake of Zopiclone Sleeping Pills,\" the patient would not be eligible for this trial.\n\nThe patient is a 32-year-old woman who was involved in a car accident and sustained multiple injuries, including fractures. The inclusion criteria for the clinical trial specify that participants must be male, Caucasian, aged between 25-35 years, and have possessed a driver's license for at least five years.\n\nThe patient does not meet the gender, age, or ethnicity requirements for this trial. Additionally, her current medical condition and injuries would likely preclude her from participating in a driving simulator study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "814": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was involved in a car accident and sustained multiple injuries including fractures.\n2. The clinical trial is for psychological treatment (Prolonged Exposure Therapy) for children and adolescents suffering from post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) due to a motor vehicle accident.\n\n3. The inclusion criteria for the trial are:\n   - Age 6 to 18 years old\n   - Speaks Hebrew or Arabic\n   - Diagnosed with PTSD\n   - Car accident event within the past 3 years\n   - For mTBI group: \n      - Symptoms like loss of consciousness, confusion, headache, etc. during/after the accident\n      - Diagnosed with mTBI within 3 years, confirmed by CT/MRI/fMRI\n      - Glasgow Coma Scale score < 15\n\n4. Based on the information provided, this 32-year-old patient does not meet the age criteria (she is an adult, not a child/adolescent aged 6-18 years).\n\n5. There is also no mention of her having PTSD or mTBI diagnosed, which are required for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "815": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was involved in a car accident and sustained multiple injuries including fractures.\n2. The clinical trial is the \"Teenage Driving Safety Study\" which aims to educate and evaluate the impact of an educational program on distracted driving behaviors among teenage drivers.\n3. One of the inclusion criteria is \"Teenagers perceived to be students driving near school property.\"\n4. Another inclusion criterion is \"Teenagers perceived to be of driving age.\"\n5. The patient is 32 years old, so she does not meet the criteria of being a teenager or perceived to be of driving age for a high school student.\n6. There is no information provided that suggests the patient was driving near a school property.\n\nBased on the information given, this patient does not meet the inclusion criteria for the \"Teenage Driving Safety Study\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "816": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which meets the age criteria of being 18 years or older.\n\n2. The patient has sustained multiple injuries including upper and lower extremity fractures following a car accident. However, the inclusion criteria specifically mentions \"radiographic evidence of tibial plateau fracture\".\n\n3. The patient note does not explicitly state that the patient has a tibial plateau fracture, only that she has sustained upper and lower extremity fractures.\n\n4. Without confirmation of a tibial plateau fracture, it is difficult to definitively determine eligibility for this specific clinical trial.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to confirm the presence of a tibial plateau fracture.",
        "label": 0
    },
    "817": {
        "output": "Okay, let's go through the inclusion criteria for the \"WalkMore Walking Interventions for Overweight/Obese Postmenopausal Women\" clinical trial and assess the eligibility of the patient based on the given note.\n\nThe inclusion criteria are:\n1. Woman between 45-74 years of age\n   - The patient is a 32-year-old woman, so she does not meet this criterion.\n\n2. Have not had a menstrual period for at least 12 months\n   - There is no information provided about the patient's menstrual status.\n\n3. Are not regularly physically active (self-reported non-exerciser for previous 6 months)\n   - No information is provided about the patient's physical activity level.\n\n4. Have a body mass index (BMI) between 25-45 kg/m^2\n   - No information is provided about the patient's BMI.\n\n5. Have high normal blood pressure or (systolic pressure of 130-179 mmHg or a diastolic pressure of 85-99 mmHg)\n   - The patient's blood pressure is reported as 134/74 mm Hg, which does not meet the criterion for high normal blood pressure or the specified systolic/diastolic ranges.\n\n6. Not limited in your ability to walk\n   - The patient has sustained multiple injuries, including upper and lower extremity fractures, which may limit her ability to walk.\n\n7. Understand these criteria\n   - There is no information provided about the patient's ability to understand the criteria.\n\n8. Are willing to provide informed consent\n   - There is no information provided about the patient's willingness to provide informed consent.\n\n9. Willing to be randomized to either type of walking intervention or a control group being studied, and are willing to follow the protocol for the group to which they have been assigned\n   - There is no information provided about the patient's willingness to be randomized or follow the protocol.\n\nBased on the information provided in the patient note, the patient does not meet at least two of the inclusion criteria (age and blood pressure). Additionally, there is not enough information to determine if the patient meets several other criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "818": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which meets the inclusion criteria of being a child (under 18 years old).\n\n2. She was involved in a car accident, which is considered a blunt trauma resulting from a significant mechanism of injury (motor vehicle collision).\n\n3. She has sustained multiple injuries including upper and lower extremity fractures, which meets the inclusion criteria of \"multiple long bone fractures (e.g., tibia and humerus fracture)\".\n\n4. Her physical examination reveals a tender abdomen with guarding and rebound in all four quadrants and no bowel sounds, which is suggestive of intra-abdominal injury following blunt torso trauma.\n\nBased on the information provided, this patient meets multiple inclusion criteria for the clinical trial titled \"Utility of Abdominal Ultrasound in the Evaluation of Children With Blunt Trauma\".\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "819": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which meets the age criteria of 18-70 years for the clinical trial.\n\n2. There is no mention of the patient having Type 1 diabetes or taking insulin, which are key inclusion criteria for this trial.\n\n3. The other inclusion criteria like being a legal driver, driving more than 5,000 miles per year, having regular internet access, and being an English speaker are not addressed in the patient note.\n\n4. The patient note focuses on injuries sustained from a car accident, which is not relevant to the clinical trial on identifying driving risk factors in Type 1 diabetes.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if this patient meets the inclusion criteria for the \"Identifying Driving Risk Factors in Type 1 Diabetes and Their Reduction Via Internet Program (DiabetesDriving.Com)\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "820": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries including fractures.\n\n2. The clinical trial is studying the effects of Seprafilm adhesion barrier on patients undergoing open abdomen damage control management for traumatic injuries.\n\n3. The inclusion criteria for the trial are:\n   - Trauma patients undergoing damage control/open abdomen (DC/OA) management for traumatic injury\n   - Age 18 or older\n   - Life expectancy longer than 48 hours\n\n4. Based on the information provided, this patient meets the inclusion criteria:\n   - She is a trauma patient who was in a car accident (traumatic injury)\n   - She is 32 years old, which meets the age requirement of 18+\n   - There is no indication that her life expectancy is less than 48 hours\n\n5. Therefore, this patient is likely eligible for the clinical trial studying Seprafilm in open abdomens for trauma damage control patients.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "821": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was admitted to the ER following a car accident. She has sustained multiple injuries including fractures.\n\n2. The clinical trial is titled \"Individualized Fortification of Breast Milk\" and is focused on investigating individualized fortification of breast milk for preterm infants.\n\n3. The inclusion criteria for the trial state that participants must have a gestational age < 32 weeks, be tolerating an enteral intake of \u2265 100 ml/kg/d for \u2265 24h, be anticipated to receive the intervention for \u2265 3 consecutive weeks after full enteral feeding, and have written informed consent from the infant's legal representative.\n\n4. Based on the patient note provided, this patient does not meet the inclusion criteria for the clinical trial as she is not a preterm infant, nor is she tolerating enteral feeding or requiring breast milk fortification.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "822": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries including fractures.\n\n2. The clinical trial is titled \"Physical Activity for Campus Employees\" and aims to evaluate the effects of a worksite wellness program on physical activity and cardiovascular disease risk factors among university employees.\n\n3. The inclusion criteria for the trial is being an employee of Washington University in St. Louis.\n\nBased on the information provided in the patient note, there is no mention of the patient being an employee of Washington University in St. Louis. The patient note focuses on the injuries sustained from the car accident.\n\nTherefore, based on the given information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "823": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Pain Management in Geriatric Hip Fracture\", here is my assessment:\n\nThe patient is a 32-year-old woman who has sustained multiple injuries, including upper and lower extremity fractures, following a car accident. However, the inclusion criteria for the clinical trial specifically mention that the participants should be aged 65 or above and have a traumatic non-pathological fracture of the neck of femur, trochanteric, or subtrochanteric region requiring operative intervention.\n\nWhile the patient has sustained fractures, the details provided do not indicate that she has a hip fracture meeting the specific criteria mentioned in the trial. Additionally, her age of 32 years does not meet the age requirement of being over 65 years old.\n\nTherefore, based on the information provided, I would not refer this patient for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "824": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which falls within the age range of 19-65 years specified in the inclusion criteria.\n\n2. The patient's blood pressure (134/74 mm Hg) and pulse (87/min) suggest that she is hemodynamically stable, which would likely qualify her as ASA PS 1 or 2 (American Society of Anesthesiologists physical status).\n\n3. However, the patient has sustained multiple injuries from a car accident, including upper and lower extremity fractures, a tender abdomen with guarding and rebound in all four quadrants, and no bowel sounds. These findings suggest significant trauma and possible intra-abdominal injury, which would likely preclude her from undergoing an elective colonoscopy at this time.\n\n4. Additionally, the patient is being admitted to the emergency room, not scheduled for an elective procedure, which is one of the inclusion criteria for this clinical trial.\n\nBased on the information provided, this patient would not be eligible for the clinical trial at this time due to her acute injuries and unstable condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "825": {
        "output": "Based on the given patient note and the clinical trial information, this patient would not be eligible for the \"Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis\" trial.\n\nThe key reasons are:\n\n1. The patient has not undergone an ERCP (endoscopic retrograde cholangiopancreatography) procedure, which is a requirement for this trial studying the prevention of post-ERCP pancreatitis.\n\n2. The patient has sustained injuries from a car accident and has signs of potential abdominal trauma or internal bleeding, which would likely exclude her from participating in this trial.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "826": {
        "output": "Based on the given patient note and the clinical trial information, this patient would not be eligible for the trial examining microcirculation of the caput humeri after proximal humerus fracture.\n\nThe key reasons are:\n\n1. The patient note does not mention any fracture of the proximal humerus, which is a requirement for inclusion in this trial.\n\n2. The patient has sustained multiple injuries from a car accident, including upper and lower extremity fractures, but the specific location and nature of these fractures are not provided.\n\n3. The trial focuses on examining microcirculation during surgical treatment of proximal humerus fractures, but there is no indication that this patient will undergo surgery for a humerus fracture.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "827": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not appear to be eligible for this trial. The key reasons are:\n\n1. The clinical trial is focused on temporomandibular joint (TMJ) disorders and related pain management, while the patient note describes a 32-year-old woman admitted to the ER following a car accident with multiple injuries, including upper and lower extremity fractures, abdominal tenderness, and no bowel sounds.\n\n2. The inclusion criteria specifically mention TMJ arthralgia, masticatory myalgia, TMJ sounds, and a history of at least 6 weeks of occlusal appliance therapy, none of which are mentioned in the patient note.\n\nTherefore, based on the available information, this patient would not be eligible for the clinical trial titled \"Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "828": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 32-year-old woman, which falls within the age range of 3-60 years specified in the inclusion criteria.\n\nShe was evaluated for blunt trauma following a car accident, which aligns with the requirement of being evaluated for blunt trauma.\n\nHer Glasgow Coma Scale (GCS) score is not explicitly stated, but she is described as \"fully awake and alert,\" which suggests a GCS score of 15 (the highest possible score, indicating no impairment of consciousness).\n\nThe inclusion criteria state that a CT abdomen and pelvis imaging order is required. While the patient note does not explicitly mention an imaging order, it does describe physical examination findings suggestive of intra-abdominal injury (tender abdomen with guarding and rebound in all four quadrants, no bowel sounds), which would likely prompt imaging.\n\nBased on the information provided, this patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "829": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries including upper and lower extremity fractures. Her vital signs are stable, but she has abdominal tenderness, guarding, rebound tenderness, and no bowel sounds, suggesting an acute abdomen that may require an open abdomen procedure.\n\nThe clinical trial is studying the use of enteral feeding (EN) in patients with a traumatic bowel injury requiring an open abdomen, compared to keeping them nil per os (NPO). \n\nThe key inclusion criterion is \"All patients with a post-injury open abdomen.\"\n\nBased on the patient's presentation of an acute abdomen that may require an open abdomen procedure, she would likely meet this key inclusion criterion if she undergoes that procedure.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient appears to potentially meet the main inclusion criterion, but further details about her injuries, the need for an open abdomen, and any other potential exclusion criteria would need to be investigated before definitively referring her to this trial.",
        "label": 1
    },
    "830": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries including fractures.\n\n2. The clinical trial is titled \"Open Abdomen: Vacuum Pack Versus Sylo Bag and Mesh Protocol\" and is studying different techniques for managing an open abdomen in trauma and acute care patients.\n\n3. The only inclusion criterion listed is \"Open Abdomen\".\n\n4. Based on the patient note, it mentions that the patient has a tender abdomen with guarding and rebound in all four quadrants, and no bowel sounds. This suggests that the patient likely has an open abdomen due to trauma from the car accident.\n\nTherefore, based on the information provided, this patient would meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "831": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 32-year-old woman who was admitted to the ER following a car accident. She has sustained multiple injuries including upper and lower extremity fractures, but there is no mention of a spinal cord injury.\n\nThe clinical trial is focused on preventing orthostatic hypotension in patients with acute spinal cord injury (SCI) above the T6 level.\n\nThe key inclusion criteria for this trial are:\n1) Inpatients\n2) Positive diagnosis of orthostatic hypotension\n3) Acute traumatic spinal cord injury\n4) Lesion level above T6\n5) AIS (American Spinal Injury Association Impairment Scale) grade A, B or C\n\nBased on the patient note provided, there is no indication that this patient has sustained a spinal cord injury, let alone one above the T6 level. Additionally, there is no mention of orthostatic hypotension.\n\nTherefore, this patient would not meet the key inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "832": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries including fractures, but there is no mention of her taking glucocorticoids or having osteoporosis.\n\n2. The clinical trial is studying the efficacy and safety of eldecalcitol compared to alfacalcidol in patients with glucocorticoid-induced osteoporosis.\n\n3. The key inclusion criteria are:\n   - Currently taking or planning to take oral glucocorticoids for 3 months or longer\n   - Having an existing insufficiency fracture, low bone mineral density, or taking a high dose of glucocorticoids\n   - Aged between 20 and 85 years\n   - Able to walk without assistance\n   - Provided consent to participate\n\n4. Based on the information provided in the patient note, there is no indication that the patient meets the inclusion criteria for this clinical trial. She does not appear to be taking glucocorticoids or have glucocorticoid-induced osteoporosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "833": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which meets the age criteria of being 18 years or older for the clinical trial.\n\n2. The patient has sustained trauma from a car accident, which meets one of the inclusion criteria for the trial.\n\n3. However, the patient note does not mention any visual impairment or loss of vision, which is a key requirement for this clinical trial aimed at improving vision after trauma or certain eye conditions.\n\n4. Without any information about the patient's visual status or impairment, it is difficult to determine if she would be eligible for this particular trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her visual status and any potential vision loss or impairment from the trauma.",
        "label": 0
    },
    "834": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, so she meets the age criteria of being an adult.\n\n2. However, the clinical trial is specifically for obstetric patients with severe hypertension during pregnancy or up to 72 hours postpartum. This patient note does not mention that the patient is pregnant or recently gave birth. Instead, it states that she was admitted to the ER following a car accident with multiple injuries.\n\n3. The inclusion criteria also specify that patients must have a systolic BP \u2265160 mmHg or diastolic BP \u2265110 mmHg. This patient's BP is 134/74 mmHg, which does not meet the hypertension criteria.\n\n4. Based on the information provided, this patient does not seem to meet the key inclusion criteria for this obstetric hypertension clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "835": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock\", let's go through the inclusion criteria one by one:\n\n1. Age \u226516 years of age or estimated weight \u226550kgs if age is unknown: The patient is 32 years old, so this criterion is met.\n\n2. Victim of blunt or penetrating trauma: The patient was involved in a car accident, which qualifies as blunt trauma, so this criterion is met.\n\n3. Hemorrhagic shock defined as:\n   a) One or more episodes of systolic blood pressure \u226490mmHg at any time prior to enrollment into the study: The patient's blood pressure is 134/74 mm Hg, which does not meet this criterion.\n   b) An identified source of blood loss (abdomen, chest, pelvis/retroperitoneum, extremities, external): The patient has a tender abdomen with guarding and rebound in all four quadrants, which could indicate internal bleeding or injury to the abdomen. This criterion is potentially met.\n   c) Blood products (RBC, Platelets, Plasma, etc.) have been ordered to the trauma room: There is no information provided about blood products being ordered, so this criterion is not met.\n\n4. Admitted to St. Michael's Hospital directly from the scene of injury within 3 hours of the injury: There is no information provided about the hospital or the time since the injury, so it is unclear if this criterion is met.\n\n5. Application and completion of Remote Ischemic Conditioning (RIC) within 4 hours of the injury: There is no information provided about the application of RIC, so it is unclear if this criterion is met.\n\nBased on the information provided, the patient potentially meets some of the inclusion criteria, but there are also some criteria that are unclear or not met. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "836": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was involved in a car accident and sustained multiple injuries including fractures.\n2. The clinical trial is studying the association between low cortisol levels and whiplash syndrome in victims of motor vehicle accidents.\n3. The inclusion criteria for the trial are: victims of motor vehicle accidents and signed informed consent.\n\nGiven the information provided, this patient meets the inclusion criteria of being a victim of a motor vehicle accident.\n\nHowever, there are a few potential concerns:\n- The patient has sustained multiple injuries, including fractures, which could complicate the assessment of whiplash syndrome.\n- There is no mention of whether the patient has provided informed consent or not.\n\nConsidering these factors, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the primary inclusion criteria of being a victim of a motor vehicle accident. However, further investigation would be needed to determine if her injuries would interfere with the assessment of whiplash syndrome and to obtain informed consent.",
        "label": 0
    },
    "837": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which meets the age criteria of >=18 years old for the clinical trial.\n\n2. The patient is admitted to the ER following a car accident and has sustained multiple injuries including upper and lower extremity fractures. This suggests that she may have an ankle fracture requiring internal fixation surgery, which would make her eligible for the trial.\n\n3. The trial is specifically looking at postoperative pain profiles and rebound pain after nerve block anesthesia for ankle fracture surgery.\n\n4. The patient's ability to read and understand Danish is not mentioned, but this is likely not a strict requirement if she can give informed oral and written consent in her native language.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial on peripheral nerve block anesthesia for ankle fracture surgery.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "838": {
        "output": "Based on the provided patient note and the clinical trial information, here is my assessment of the patient's eligibility for the trial:\n\nThe patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries, including upper and lower extremity fractures. The clinical trial is focused on investigating the effect of withholding feeds during red blood cell transfusion on the development of transfusion-related acute gut injury (TRAGI) in premature infants.\n\nThe inclusion criteria for the trial specify that participants should be premature babies with a gestational age of less than 32 weeks or birth weight less than 1500 grams, and at least 7 days old. Additionally, they should be fed enterally well at the time of the planned transfusion.\n\nSince the patient in the given note is an adult woman who was involved in a car accident, she does not meet the inclusion criteria for this clinical trial, which is specifically focused on premature infants.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "839": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which meets the age criteria of \u226518 years for the clinical trial.\n\n2. The patient was admitted to the ER following a car accident and has sustained multiple injuries including fractures. There is no mention of end-stage renal disease or the need for hemodialysis, which are key inclusion criteria for this trial.\n\n3. The trial is specifically looking at preventing intra-dialytic hypotension (IDH) during hemodialysis sessions using an abdominal compression device.\n\n4. Based on the information provided in the patient note, there is no indication that this patient would be eligible for a trial focused on hemodialysis patients with end-stage renal disease.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "840": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which meets the age criteria of 21-80 years old for the iStride stroke rehabilitation clinical trial.\n\n2. There is no mention of the patient having a stroke or any cerebral strokes in the patient note. The note indicates she was in a car accident and sustained multiple injuries including fractures.\n\n3. Since the patient does not have a history of stroke, she would not meet the inclusion criteria of \"one or more cerebral strokes, but all strokes on same side\" and \"a stroke at least 6 months prior to enrollment\".\n\n4. There is no information provided about the patient's gait asymmetry, cognitive impairment, or home environment to assess the other inclusion criteria.\n\nBased on the information given in the patient note, this patient would not be eligible for the iStride stroke rehabilitation clinical trial as she does not have a history of stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "841": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was involved in a car accident and sustained multiple injuries including fractures.\n2. She meets the age criteria of being 18 years or older for the clinical trial.\n3. She has sustained blunt trauma to the thorax (tender abdomen with guarding and rebound) and abdomen (no bowel sounds), which meets the inclusion criteria of \"blunt or penetrating trauma to the thorax or abdomen\".\n4. She is being transported by ambulance to the hospital, which meets the inclusion criteria.\n5. Her transport time is not specified, but it is reasonable to assume it will take longer than 10 minutes given the severity of her injuries.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial involving the use of prehospital ultrasound for thoracoabdominal trauma.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "842": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which meets the age criteria for this trauma trial (no specific age cutoffs given in the inclusion criteria).\n\n2. She was involved in a car accident and sustained multiple injuries including fractures, indicating significant trauma. \n\n3. Her blood pressure on admission was 134/74 mmHg. The inclusion criteria specify a systolic BP \u2264 100 mmHg at any time from injury until 30 minutes after admission. Her initial BP does not meet this, but it's possible her BP dropped lower at some point that is not captured in this brief note.\n\n4. She has abdominal tenderness, guarding, and no bowels sounds - suggesting internal bleeding/hemorrhage. \n\n5. The trauma team has not yet ordered a red blood cell transfusion based on this note. But her symptoms suggest she is at risk of requiring one.\n\nSo in summary, she meets the broad criteria of being a trauma patient at risk of significant bleeding based on her injuries and symptoms. However, the blood pressure and lack of ordered transfusion at this point are not definitively met per the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her initial blood pressure, whether a transfusion was ordered, and monitoring her clinical status.",
        "label": 1
    },
    "843": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Is male or female, 18 years of age or older\nThe patient note states that the patient is a 32-year-old woman, so she meets this criterion.\n\n2. Has provided written informed consent or has surrogate consent provided by a Legally Authorized Representative (LAR)\nThere is no information provided about consent, so we cannot determine if this criterion is met or not.\n\n3. Has experienced abdominal trauma, blunt or penetrating, requiring open abdominal laparotomy with primary closure or Has experienced acute surgical abdomen requiring open abdominal laparotomy with primary closure\nThe patient note states that the patient was admitted to the ER following a car accident and has sustained multiple injuries including upper and lower extremity fractures. It also mentions that she has a tender abdomen with guarding and rebound in all four quadrants and no bowel sounds, which suggests an acute surgical abdomen requiring an open abdominal laparotomy.\n\nBased on the information provided, this patient seems to meet the key inclusion criteria for this clinical trial, but we cannot be certain about the consent requirement.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "844": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman who was involved in a car accident and sustained multiple injuries including fractures.\n2. The clinical trial is investigating the effectiveness of a device (Q-collar) in mitigating traumatic brain injury (TBI) in high school athletes playing collision or contact sports.\n3. The inclusion criteria for the trial are:\n   - Normal healthy volunteer\n   - Able to provide written consent\n   - Must be 14 years or older and a participant on a competitive and organized sports program\n   - Neck circumference of 15 \u00bd - 16 \u00bd inches\n\n4. Based on the patient note, this patient does not meet the inclusion criteria for the trial as she is not a healthy volunteer, nor is she a participant in a competitive and organized sports program.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "845": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 32-year-old woman who was admitted to the ER following a car accident. She has sustained multiple injuries including upper and lower extremity fractures, which matches the inclusion criteria of \"Fractures and fracture/dislocations of the foot, ankle, tibia, fibula, elbow, forearm, wrist and hand\".\n\nThe inclusion criteria also state that patients must be at least 18 years old, which the patient meets at 32 years old.\n\nThe trial is open to all genders and racial/ethnic groups, so the patient would be eligible in that regard.\n\nThe patient is opting for surgical treatment of her fractures, as evidenced by her admission to the ER following the accident.\n\nThere is no information provided about whether the patient consented to be randomized or is willing to follow up for 52 weeks, but those criteria could potentially be met upon further investigation.\n\nBased on the information provided, I would consider referring this patient to this clinical trial upon further investigation to determine if she meets the remaining inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "846": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Safety Skills Training: Parents of School-Aged Children\", this patient would not be eligible for the trial.\n\nThe patient note describes a 32-year-old woman who was involved in a car accident and sustained multiple injuries, including fractures and abdominal trauma. The clinical trial, however, is focused on training parents or guardians of school-aged children (aged 6-11) on safety practices to prevent injuries in their children.\n\nSince the patient in the given note is not a parent or guardian of a school-aged child, she does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "847": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Safety in Seconds 2.0: An App to Increase Car Seat Use\", I would assess the trial-level eligibility as follows:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.\n\nThe patient note describes a 32-year-old woman who was involved in a car accident and sustained multiple injuries, including fractures and abdominal trauma. The clinical trial is focused on increasing the use of car seats for children aged 4-7 years by providing tailored injury prevention education to parents or guardians.\n\nThe patient in the given note does not meet the inclusion criteria for this clinical trial, as she is not a parent or guardian of a child aged 4-7 years. Additionally, the trial requires participants to be residents of Baltimore City, MD or Little Rock, AR, and the patient's location is not specified in the note.\n\nTherefore, based on the available information, I would not refer this patient for the \"Safety in Seconds 2.0: An App to Increase Car Seat Use\" clinical trial.",
        "label": 0
    },
    "848": {
        "output": "Based on the provided patient note and the inclusion criteria for the \"Check Yourself Study\" clinical trial, the patient would not be eligible for this trial.\n\nThe key reasons are:\n\n1. The patient is a 32-year-old woman, while the inclusion criteria specify that eligible participants should be between 13-18 years old.\n\n2. The patient was admitted to the ER following a car accident and has sustained multiple injuries, including fractures. The trial is focused on adolescents receiving primary health care services, and this patient's condition does not align with the trial's purpose.\n\n3. The trial aims to evaluate the effectiveness of an app in reducing health risk behaviors and improving quality of care among adolescents. The patient's current condition and the nature of the trial do not match.\n\nTherefore, based on the information provided, this patient would not be eligible for the \"Check Yourself Study\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "849": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, so she meets the age criteria of being at least 18 years old.\n\n2. She is awake and alert, which meets the inclusion criteria of being awake and alert.\n\n3. However, the patient has sustained multiple injuries from a car accident, including upper and lower extremity fractures. This suggests she may not be able to access the gut for enteral feeding, which is an exclusion criterion.\n\n4. Additionally, the patient has a tender abdomen with guarding and rebound in all four quadrants, and no bowel sounds. This could indicate diffuse peritonitis, which is an exclusion criterion.\n\n5. There is no information provided about whether she is pregnant or not.\n\nBased on the available information, there are some potential exclusion criteria that may apply, such as not being able to access the gut for enteral feeding and the possibility of diffuse peritonitis. However, more information would be needed to make a definitive determination.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "850": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Way to Safety Cellphone Blocking\", the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.\n\nThe patient note describes a 32-year-old woman who was involved in a car accident and sustained multiple injuries, including fractures and abdominal trauma. The clinical trial's inclusion criteria specifically require participants to be high school students aged 16 or 17, have a valid driver's license, live with their parents/guardians, drive to school, primarily drive one car, have a compatible smartphone, and admit to texting while driving at least once in the last 30 days.\n\nBased on the information provided in the patient note, this patient does not meet the age, student status, living situation, or driving behavior criteria for the clinical trial. Therefore, it is highly unlikely that this patient would be eligible for referral to this particular clinical trial.",
        "label": 0
    },
    "851": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Severe traumatic brain injury, GCS 8 or less\nThe patient note does not mention any details about a traumatic brain injury or the Glasgow Coma Scale (GCS) score. Therefore, we cannot confirm if this criterion is met.\n\n2. Craniofacial fracture\nThe patient note does not mention any craniofacial fractures. It only states that the patient sustained upper and lower extremity fractures.\n\nSince the patient note does not provide enough information to confirm if either of the inclusion criteria is met, we cannot definitively determine the patient's eligibility for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "852": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Evaluation of a Neck Strengthening Program to Reduce the Risk of Sport-related Concussion,\" this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient is a 32-year-old woman who was involved in a car accident, not a contact/collision sport athlete, which is a requirement for inclusion in this trial.\n\n2. The patient has sustained multiple injuries, including upper and lower extremity fractures, and has a tender abdomen with guarding and rebound in all four quadrants, indicating potential internal injuries. These injuries are not related to the focus of the trial, which is evaluating a neck strengthening program for reducing the risk of sport-related concussions.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "853": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman presenting to the ER following a car accident with multiple injuries including fractures. This does not seem directly relevant to the clinical trial on diagnosing acute appendicitis.\n\n2. However, the patient is reported to have a tender abdomen with guarding and rebound tenderness in all four quadrants, as well as absent bowel sounds. These findings raise suspicion for an acute abdominal process like appendicitis.\n\n3. The inclusion criteria for the trial are: 1) Patient presented with the complaint of right lower abdominal pain, and 2) Suspected acute appendicitis.\n\n4. While the patient did not specifically complain of right lower quadrant pain, her abdominal exam findings are concerning for an acute process like appendicitis.\n\n5. Given her concerning abdominal exam, it would be reasonable to include her in the trial evaluating bedside ultrasound for suspected appendicitis to further investigate the cause of her abdominal pain and tenderness.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "854": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which falls within the age range of 2-17 years specified in the inclusion criteria. However, the trial is specifically for children, so her age may be a potential issue.\n\n2. She has sustained multiple injuries including upper and lower extremity fractures. The trial is for long-bone fractures, so this criterion is likely met.\n\n3. She is fully awake and alert, which suggests she can provide informed consent or have a parent/guardian provide it.\n\n4. There is no information provided about her pain level or whether she requires morphine analgesia, which is a key inclusion criterion.\n\n5. There is no information about the time elapsed since her injury, but the criteria specify within the first 12 hours.\n\n6. Her insurance status is not mentioned, which is another inclusion criterion.\n\nOverall, while some criteria are potentially met, there are several key pieces of information missing, such as her pain level, time since injury, and insurance status. Additionally, her age may be a potential issue since the trial is specifically for children.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "855": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient is a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries, including upper and lower extremity fractures. The clinical trial is focused on comparing the regain of gastrointestinal motility after general anesthesia versus spinal anesthesia in cesarean section.\n\nThe inclusion criteria for the trial are:\n1. Patients set for planned cesarean section under general or spinal anesthesia\n2. Age from 18 to 37 years\n3. Full term (37-41 weeks)\n4. Singleton pregnancy\n5. Hemoglobin level more than 11 gm/dl\n\nSince the patient is not pregnant and was not admitted for a planned cesarean section, she does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "856": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 32-year-old woman, which meets the age criteria of 12-36 months for the clinical trial.\n2. However, the patient does not have any reported motor delays or impairments that prevented functional independent mobility like rolling, crawling or walking. The patient note mentions injuries from a car accident, but no pre-existing motor delays.\n3. The patient is fully awake and alert, so she would likely be able to tolerate sitting with support for 30 minutes and reach objects with her hands, meeting those inclusion criteria. \n4. However, there is no mention of parental consent, which is a key inclusion criteria for this pediatric clinical trial.\n\nOverall, while the patient meets some of the criteria like age range and being able to sit/reach, the crucial criteria of having a motor delay/impairment and parental consent are not met based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "857": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes a 32-year-old woman who was admitted to the ER following a car accident. She sustained multiple injuries, including fractures, and has signs of abdominal tenderness, guarding, and lack of bowel sounds, which could indicate an acute abdomen.\n\nThe clinical trial titled \"Abdomen CT and Open Appendicectomy: New Diagnostic and Surgical Procedures\" is studying new approaches to diagnosing and treating acute appendicitis.\n\nThe inclusion criteria for this trial are \"patients with a clinical diagnosis of acute appendicitis.\"\n\nWhile the patient's abdominal findings could potentially indicate acute appendicitis, the note does not explicitly state a diagnosis of acute appendicitis. Additionally, the patient's injuries appear to be related to a traumatic event (car accident) rather than a primary abdominal condition.\n\nTherefore, based on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther diagnostic workup, such as an abdominal CT scan, would be needed to determine if the patient meets the inclusion criteria of a clinical diagnosis of acute appendicitis before considering referral to this specific trial.",
        "label": 0
    },
    "858": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Web-Based Adolescent Motivational Enhancement Study\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient is a 32-year-old woman, while the inclusion criteria specify that eligible participants should be between 13-18 years old.\n\n2. The patient note does not mention any information about alcohol use, which is a crucial inclusion criterion for this trial. The trial is specifically focused on moderate to high-risk alcohol users.\n\n3. The patient note describes injuries sustained from a car accident, which is not relevant to the focus of this clinical trial.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria for the \"Web-Based Adolescent Motivational Enhancement Study\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "859": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis\" and assess the eligibility of the patient based on the provided note.\n\nThe patient is a 21-year-old female, which meets the age criterion of being 18 years or older.\n\nThe patient has a positive ANA and anti-dsDNA, along with proteinuria, hematuria, and RBC casts in the urine, which suggests active lupus nephritis. This likely meets the criterion of having a renal biopsy showing active WHO Class III, IV, or mixed membranous and proliferative SLE glomerulonephritis within the past 5 years.\n\nThe patient's lab results show normocytic anemia and thrombocytopenia, which are not exclusion criteria.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria for this clinical trial.\n\nHowever, there are some additional criteria that cannot be assessed from the provided note, such as:\n\n- Proteinuria level (must be \u2265 1.0 g/day at screening)\n- Complement C3 level\n- Absence of certain medical disorders or conditions (e.g., active infection, neoplasm, rapidly progressive glomerulonephritis, fibrinoid necrosis/cellular crescents affecting >25% of glomeruli)\n- Hepatitis B, C, and HIV status\n- CD4 count\n- Recent treatment with certain medications (e.g., cyclophosphamide, IV methylprednisolone, cyclosporine, high-dose prednisone)\n- Pregnancy status and contraceptive use (if applicable)\n- Enrollment in other clinical studies\n\nConsidering the information available, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "860": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female presenting with symptoms suggestive of systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine findings of proteinuria and RBC casts.\n\n2. The clinical trial is studying the incidence, pathogenesis, and risk factors for thrombotic events and coronary artery disease in patients with SLE.\n\n3. The inclusion criteria for the trial states \"No eligibility criteria\", meaning any patient with SLE can be included.\n\n4. Given that this patient has clear clinical and laboratory evidence of SLE, and the trial has no specific exclusion criteria, this patient would be eligible for enrollment in this lupus cohort study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "861": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria (\u226518 years) for the clinical trial.\n\n2. The patient has symptoms and laboratory findings consistent with systemic lupus erythematosus (SLE), which is one of the autoimmune diseases included in the trial.\n\n3. The patient meets several of the specific criteria for SLE listed in the inclusion criteria, including malar rash, photosensitivity, arthritis, hematologic disorder (anemia, thrombocytopenia), immunologic disorder (positive ANA, anti-dsDNA), and renal disorder (proteinuria, RBC casts).\n\n4. The inclusion criteria state that the patient must have at least 4 of the 7 variables on the lupus activity scale measured, which is not provided in the patient note. However, the note suggests active disease with multi-organ involvement.\n\n5. The patient's performance status is not mentioned, but the inclusion criteria allow for ECOG 0-2 if symptoms are related to the autoimmune disease.\n\n6. There is no information provided about the patient's prior treatment history or refractoriness to conventional therapy, which is part of the inclusion criteria.\n\nBased on the information provided, I would consider this patient for the clinical trial upon further investigation into disease activity, prior treatment history, and performance status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "862": {
        "output": "To determine the patient's eligibility for the clinical trial \"Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus\", I will analyze the patient note against the inclusion criteria provided.\n\nThe inclusion criteria states:\n\"A diagnosis of systemic lupus erythematosus\"\n\nFrom the patient note, we can see that the 21-year-old female patient presents with symptoms consistent with systemic lupus erythematosus (SLE), including:\n\n- Arthralgias (joint pain)\n- Malaise\n- Alopecia (hair loss)\n- Rash on the face\n- Purpura (small hemorrhages) on the calves\n- Swelling and tenderness of wrists and ankles\n- Normocytic anemia\n- Thrombocytopenia\n- Positive ANA (antinuclear antibody) and anti-dsDNA (anti-double stranded DNA antibody)\n- Proteinuria and RBC casts in urine\n\nThese clinical and laboratory findings are highly suggestive of a diagnosis of SLE, which meets the sole inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "863": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of 18-70 years old for the clinical trial.\n\n2. The patient has symptoms and lab findings consistent with systemic lupus erythematosus (SLE), including a positive ANA and anti-dsDNA, as well as organ involvement (kidney with proteinuria and RBC casts).\n\n3. The inclusion criteria state that patients must have SLE for at least 6 months prior to screening. The note does not specify how long the patient has had SLE, so this would need further investigation.\n\n4. The patient has active SLE disease based on the symptoms and lab findings described.\n\n5. The patient has organ involvement (kidney), which meets one of the inclusion criteria.\n\n6. The note does not mention any failed standard therapies or immunosuppressive agents, so this criterion cannot be evaluated from the information given.\n\n7. The note does not provide any specific lab values, so whether the patient meets the protocol's lab value criteria is unknown.\n\n8-9. The note does not mention any current medications, so whether the patient meets the criteria regarding immunosuppressive agents or corticosteroids is unclear.\n\n10. The patient has an elevated autoantibody level (anti-dsDNA), meeting this inclusion criterion.\n\nOverall, the patient appears to potentially meet several of the key inclusion criteria based on the information provided, but there are some unclear areas that would need further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "864": {
        "output": "To determine the patient's eligibility for the \"Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Meets American College of Rheumatology (ACR) revised diagnostic guidelines for SLE\"\n   - The patient is described as having a positive ANA, anti-dsDNA, and clinical manifestations consistent with SLE (rash, arthritis, nephritis), so this criterion is likely met.\n\n2. \"Weight of 25 kg (55 lbs) or more\"\n   - The patient's weight is not provided, but as a 21-year-old, it is reasonable to assume they weigh at least 55 lbs.\n\n3. \"Outpatient\"\n   - No information is provided about the patient's inpatient/outpatient status, but this is likely met.\n\n4. \"Ability to complete self-report questionnaires in either English or Spanish\"\n   - No information is provided about the patient's language abilities, but English is assumed.\n\n5. \"Willingness to comply with recommended diet\"\n   - No information is provided about the patient's willingness to comply with a diet.\n\n6. \"Acceptable methods of contraception\"\n   - As a 21-year-old female, this criterion is likely applicable, but no information is provided about contraceptive use.\n\nBased on the information provided, the patient meets at least one of the key inclusion criteria (ACR diagnostic guidelines for SLE), and there is no clear exclusion. However, some important details are missing, such as weight, language abilities, willingness to comply with a diet, and contraceptive use.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "865": {
        "output": "To determine the patient's eligibility for the \"Lupus Genetics Studies\" clinical trial, let's go through the inclusion criteria:\n\nInclusion criteria: Families in which one or more living members have been diagnosed with systemic lupus erythematosus\n\nBased on the patient note, the 21-year-old female patient is presenting with symptoms suggestive of systemic lupus erythematosus (SLE), including alopecia, rash, purpura, arthritis, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts in the urine.\n\nWhile a definitive diagnosis is not provided, the clinical presentation is highly indicative of SLE. Therefore, this patient would likely meet the inclusion criteria of having a diagnosis of systemic lupus erythematosus.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "866": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female with symptoms suggestive of systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, rash, purpura, joint swelling/tenderness, anemia, thrombocytopenia, positive ANA/anti-dsDNA, and urine findings.\n\n2. The clinical trial is studying the safety and efficacy of belimumab (an approved SLE treatment) in patients with active SLE disease.\n\n3. The key inclusion criteria are:\n   - Clinical diagnosis of SLE\n   - Active SLE disease \n   - On stable SLE treatment regimen\n   - History of measurable autoantibodies\n\n4. The patient meets all of these key inclusion criteria based on the note.\n\n5. Some of the key exclusion criteria that the patient does not seem to meet are:\n   - Recent non-FDA approved investigational agent\n   - Recent cyclosporine, IVIG, plasmapheresis\n   - Active lupus nephritis requiring hemodialysis/cyclophosphamide/high-dose prednisone\n   - Active CNS lupus \n   - Renal transplant\n   - Recent/active infections\n   - HIV, hepatitis B/C\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "867": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female presenting with arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts in urine.\n\n2. The clinical trial is titled \"The Research Registry for Neonatal Lupus\" and is studying women with antibodies to SSA/Ro, SSB/La, or ribonucleoproteins (RNP) and their children who may develop neonatal lupus.\n\n3. The inclusion criteria specifically mention including mothers with antibodies to SSA/Ro, SSB/La, or RNP, children of such mothers who develop neonatal lupus, fathers of affected children, grandparents of affected children, aunts/uncles of affected children, and unaffected siblings.\n\n4. Based on the patient's clinical presentation which is highly suggestive of systemic lupus erythematosus (SLE), it is likely that she may have the antibodies mentioned in the inclusion criteria, though this is not explicitly stated.\n\n5. However, since she is not pregnant or a mother yet, she would not currently meet the strict inclusion criteria for this particular registry.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her autoantibody status, as she is a potential candidate if she has the relevant antibodies and becomes pregnant in the future.",
        "label": 0
    },
    "868": {
        "output": "To determine the patient's eligibility for the clinical trial \"Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone\", let's go through the inclusion criteria:\n\n1. Participants must be diagnosed with SLE and be experiencing an active lupus flare in at least one of three organ systems: skin (discoid lesions), inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints within 14 days of a screening visit (arthritis).\n\nThe patient note mentions that the 21-year-old female patient has a rash mainly distributed on the bridge of her nose and her cheeks, swelling and tenderness of her wrists and ankles, and positive ANA and anti-dsDNA tests, which are indicative of SLE. The patient is also experiencing arthritis (swelling and tenderness of wrists and ankles).\n\n2. Stable dose of prednisone (<30mg) for at least one month.\n\nThe patient note does not mention if the patient is currently taking prednisone or any other medication.\n\nBased on the information provided, the patient meets the first inclusion criterion of being diagnosed with SLE and experiencing an active lupus flare with arthritis. However, it is unclear if the patient meets the second inclusion criterion regarding prednisone dosage.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding prednisone dosage and stability.",
        "label": 1
    },
    "869": {
        "output": "To determine the patient's eligibility for the clinical trial \"Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis\", let's go through the inclusion criteria one by one:\n\n1. Fulfill the revised American College of Rheumatology criteria for SLE\n   - The patient has a positive ANA and anti-dsDNA, along with clinical manifestations like rash, arthritis, and nephritis, which fulfills the criteria for SLE.\n\n2. Have biopsy-proven membranous nephropathy secondary to SLE\n   - The patient note does not mention a biopsy, but it does state that the patient has proteinuria and RBC casts in the urine, which is suggestive of lupus nephritis.\n\n3. Nephrotic syndrome with proteinuria (> 3 g/day) and serum albumin < 30 g/dl, with or without active urinary sediments despite steroid therapy (with or without cytotoxic agents)\n   - The patient note does not provide information about the exact amount of proteinuria or serum albumin levels.\n\n4. Age over 18 with informed consent\n   - The patient is 21 years old, so she meets the age criteria.\n\n5. Female patients of child-bearing age and male patients who agree to maintain effective birth control practice during the study\n   - The patient is a 21-year-old female, so she would need to agree to maintain effective birth control practice during the study.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria, but there are a few key pieces of information missing, such as the exact amount of proteinuria, serum albumin levels, and whether a biopsy has been performed to confirm membranous nephropathy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "870": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female presenting with arthralgias, malaise, alopecia, rash, purpura, joint swelling/tenderness, normocytic anemia, thrombocytopenia, positive ANA/anti-dsDNA, and proteinuria/hematuria.\n\n2. The clinical trial is studying genetic polymorphisms of the DcR3 gene in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and healthy controls.\n\n3. The inclusion criteria are: SLE, RA, or healthy.\n\n4. Based on the clinical presentation of rash, arthritis, anemia, thrombocytopenia, positive ANA/anti-dsDNA, and renal involvement, this patient likely meets criteria for SLE.\n\n5. Since the trial includes patients with SLE as one of the inclusion criteria, this patient would be eligible.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "871": {
        "output": "To determine the patient's eligibility for the clinical trial \"Memantine in Systemic Lupus Erythematosus\", I will go through the inclusion criteria one by one:\n\n1. Clinical diagnosis of SLE\nThe patient note mentions that the 21-year-old female patient has a positive ANA and anti-dsDNA, along with other symptoms like rash, alopecia, and arthritis, which are consistent with a clinical diagnosis of Systemic Lupus Erythematosus (SLE). This inclusion criterion is met.\n\n2. Self-reported cognitive impairment\nThe patient note does not explicitly mention any cognitive impairment or related symptoms. However, the trial summary states that cognitive dysfunction is prevalent in NPSLE patients.\n\nSince the patient has a clinical diagnosis of SLE and cognitive impairment is common in these patients, it would be reasonable to consider referring this patient to the trial upon further investigation of her cognitive function.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "872": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of being between 18-60 years old for this chronic fatigue syndrome trial.\n\n2. However, the patient does not have a diagnosis of chronic fatigue syndrome based on the 1988 CDC case definition, which is an inclusion criteria. Instead, the patient appears to have symptoms suggestive of lupus or another autoimmune condition (alopecia, rash, purpura, arthralgias, positive ANA/anti-dsDNA, anemia, thrombocytopenia, proteinuria).\n\n3. The trial specifically excludes patients with a positive ANA or anti-dsDNA, which this patient has.\n\n4. There are no details provided about the patient's quality of life score (KPS 40-60 required), ability to walk on a treadmill, thyroid status, or other lab values required.\n\nBased on the information provided, this patient would not be eligible for this chronic fatigue syndrome trial due to not meeting the diagnostic criteria for CFS and having positive autoimmune serology which is an exclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "873": {
        "output": "Okay, let's go through the inclusion criteria for the \"Cutaneous Lupus Erythematosus and Elidel\" clinical trial and assess the eligibility of the patient based on the provided note.\n\n1. \"Female and male patients aged 18-65 years (females of childbearing potential may be enrolled provided they are routinely using adequate contraception in the assessment of the investigator).\"\n   - The patient is a 21-year-old female, which falls within the age range.\n\n2. \"Patients with histologically defined dLE or scLE.\"\n   - The patient note does not explicitly mention a histological diagnosis of discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE). However, the clinical presentation with a rash, alopecia, and positive ANA and anti-dsDNA suggests a possible diagnosis of lupus erythematosus.\n\n3. \"The test sites (lupus erythematosus plaques) must be on the face only, and have a total sign score of 4 or more (sum of erythema, induration and scaling scores) and must be the same within a given patient (ie not differing in the sum for erythema, induration or scaling).\"\n   - The patient note mentions a rash \"mainly distributed on the bridge of her nose and her cheeks,\" which suggests the presence of facial lesions.\n\n4. \"The patients must receive a baseline medication with chloroquine.\"\n   - The patient note does not mention any current medication, including chloroquine.\n\n5. \"Patients must have been informed about the study procedures and medication and must have given their written Informed Consent.\"\n   - This criterion cannot be assessed based on the provided information.\n\n6. \"Patients expected to be available for the duration of the study and able to comply with the study visits.\"\n   - This criterion cannot be assessed based on the provided information.\n\nBased on the available information, the patient meets some of the inclusion criteria, such as age and the presence of facial lesions suggestive of lupus erythematosus. However, there is no explicit mention of a histological diagnosis of dLE or scLE, and the use of chloroquine is not specified. Additionally, some criteria cannot be assessed due to lack of information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "874": {
        "output": "To determine the patient's eligibility for the \"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. Age between 18 and 60 years, inclusive: The patient is 21 years old, which meets this criterion.\n\n2. Meet at least 4 of 11 American College of Rheumatology (ACR) Revised Classification Criteria for SLE: The patient has alopecia, a rash, purpura, arthritis, anemia, thrombocytopenia, positive ANA, and positive anti-dsDNA, which likely meets this criterion.\n\n3. Have at least one of the following conditions defining severe steroid refractory disease:\n   a) Lupus nephritis: The patient has proteinuria and RBC casts, which suggests lupus nephritis.\n   b) Visceral organ involvement other than nephritis: Not mentioned.\n   c) Cytopenias that are immune-mediated: The patient has anemia and thrombocytopenia, which could be immune-mediated.\n   d) Mucocutaneous disease: The patient has a rash and alopecia, which could be mucocutaneous manifestations.\n   e) Arthritis/myositis: The patient has arthritis.\n\n4. Ability and willingness to provide written informed consent: Not mentioned, but likely able to provide consent.\n\n5. Must be ANA positive: The patient is ANA positive.\n\nBased on the information provided, the patient meets the age criterion, likely meets the ACR criteria for SLE, and has at least one condition defining severe steroid refractory disease (lupus nephritis, cytopenias, mucocutaneous disease, and arthritis). Therefore, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "875": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Role of DcR3 in T Cell Activation in SLE and RA\", here is my assessment:\n\nThe patient is a 21-year-old female presenting with symptoms suggestive of systemic lupus erythematosus (SLE), including alopecia, rash, purpura, arthritis, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts in urine.\n\nThe inclusion criteria for the clinical trial are patients with SLE or rheumatoid arthritis (RA).\n\nGiven that this patient appears to have SLE based on the clinical presentation, she would meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "876": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Diagnosis of systemic lupus erythematosus (SLE) according to current American College of Rheumatology (ACR) criteria.\nThe patient note mentions that the patient has a positive ANA and anti-dsDNA, which are diagnostic criteria for SLE. Additionally, the patient has symptoms like rash, arthritis, and nephritis, which are common in SLE. Therefore, this criterion is likely met.\n\n2. Diagnosis of International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV lupus nephritis (LN), with either active or active/chronic disease.\nThe patient note mentions that the patient has proteinuria and RBC casts in the urine, which are indicative of active lupus nephritis. However, the specific class of lupus nephritis is not mentioned.\n\n3. Proteinuria.\nThe patient note explicitly states that the patient has proteinuria, so this criterion is met.\n\n4. 16-75 years of age.\nThe patient is a 21-year-old female, which falls within the age range specified in the inclusion criteria.\n\nBased on the information provided in the patient note, the patient meets criteria 1, 3, and 4. However, there is not enough information to determine if criterion 2 is met, as the specific class of lupus nephritis is not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to determine the class of lupus nephritis.",
        "label": 1
    },
    "877": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of >18 and <60 years old.\n\n2. The patient is described as having alopecia, a rash, purpura, arthritis, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria and RBC casts in the urine. These findings are consistent with a diagnosis of systemic lupus erythematosus (SLE), which fulfills the inclusion criteria of \"Fulfill ACR Classification Criteria for SLE\".\n\n3. There is no mention of cognitive dysfunction or functional difficulties due to cognitive issues in the patient note. However, the inclusion criteria state that the patient must endorse \u22656 items on the Cognitive Symptoms Inventory (CSI) questionnaire. This is not assessed in the provided note.\n\n4. The other inclusion criteria regarding English proficiency, having a treating rheumatologist, estimated premorbid verbal IQ, physical/mental disabilities, ability to read/hear, blood pressure, ECG findings, and adequate contraception are not addressed in the patient note.\n\nBased on the information provided, I would consider this patient for the clinical trial upon further investigation into their cognitive symptoms and the other inclusion criteria not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "878": {
        "output": "To determine the patient's eligibility for the clinical trial \"Lupus Nephritis: Role of Environmental and Occupational Exposures\", let's go through the inclusion criteria:\n\n1. Have renal biopsy proven Lupus Nephritis (with the biopsy-based diagnosis date no earlier than January 1, 1995).\n\nThe patient note does not explicitly mention a renal biopsy, but it does state that the patient has \"positive for protein and RBC casts\" in their urine, which is indicative of lupus nephritis. However, without a confirmed renal biopsy, this criterion cannot be fully satisfied.\n\n2. Reside within designated counties of eastern North Carolina and South Carolina.\n\nThe patient note does not provide any information about the patient's residence, so this criterion cannot be evaluated.\n\nBased on the available information in the patient note, it is unclear if the patient meets the inclusion criteria for this clinical trial. Further investigation would be needed to confirm the renal biopsy diagnosis and the patient's residence.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "879": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of \u226518 years.\n2. There is no mention of the patient being prescribed Tarceva (erlotinib) or having non-small cell lung cancer (NSCLC). The patient seems to have symptoms suggestive of lupus.\n3. The patient does not have a rash on the face related to Tarceva treatment, which is a key inclusion criterion.\n4. There is no information provided about the patient's ECOG performance status or life expectancy.\n\nBased on the information given, this patient does not meet the key inclusion criteria of being on Tarceva treatment and having a Tarceva-related facial rash.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "880": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female presenting with arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine with protein and RBC casts. These findings are consistent with systemic lupus erythematosus (SLE).\n\n2. The clinical trial is studying genetic polymorphisms related to clearance of apoptotic cells in autoimmune diseases like SLE and rheumatoid arthritis (RA).\n\n3. One of the inclusion criteria is having SLE or RA.\n\n4. Since this patient has clinical findings consistent with SLE, she would likely meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "881": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of >18 years old for the clinical trial.\n\n2. The patient has symptoms and lab findings consistent with systemic lupus erythematosus (SLE), including a positive ANA, anti-dsDNA, rash, arthritis, and renal involvement (proteinuria and RBC casts). This meets the inclusion criteria of fulfilling at least 4 of the ACR criteria for SLE diagnosis.\n\n3. The patient has renal function impairment based on the proteinuria, which is one of the listed risk factors for inclusion.\n\n4. The patient does not appear to have any of the other listed risk factors like diabetes, hypertension, hyperlipidemia, obesity, smoking history, or antiphospholipid antibodies mentioned.\n\nBased on meeting the age criteria, SLE diagnosis criteria, and having at least one risk factor of renal impairment, this patient would likely be eligible for the clinical trial studying aspirin and statins for atherosclerosis prevention in SLE.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "882": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of being 48 years or older for inclusion in the trial.\n\n2. However, the patient does not seem to be menopausal based on the information provided. There is no mention of amenorrhea, elevated FSH levels, or menopausal symptoms.\n\n3. The patient has systemic lupus erythematosus (SLE) with various manifestations like arthralgia, rash, anemia, thrombocytopenia, proteinuria, and hematuria. The trial is specifically looking at the effect of hormone replacement therapy (HRT) on lupus activity in menopausal women with SLE.\n\n4. Since the patient is not menopausal, she would not meet the key inclusion criteria for this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "883": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"The Reduction of Systemic Lupus Erythematosus Flares: Study PLUS\" and assess the eligibility of the patient based on the provided note.\n\nInclusion criteria:\n1) Age of 18 and above\nThe patient is 21 years old, so this criterion is met.\n\n2) Diagnosis of Systemic Lupus Erythematosus (SLE) according to the American College of Rheumatology (ACR) Classification Criteria.\nThe patient is described as having a positive ANA and anti-dsDNA, along with other symptoms suggestive of SLE, so this criterion is likely met.\n\n3) Treatment with HCQ for at least 6 months, without modification of HCQ dosage for 2 months\nThere is no information provided about the patient's treatment history or current medications, so it is unclear if this criterion is met.\n\n4) Stable dosage of HCQ from one day to another (200 g x 2/day or 400 mg once a day or 200 mg once a day)\nAgain, there is no information about the patient's current medication dosage, so it is unclear if this criterion is met.\n\n5) No increase in the steroids dosage during the 3 previous weeks\n6) Steroids dosage lower or equal to 0.5 mg/kg/day of prednisone equivalent\nThere is no information provided about the patient's current steroid dosage or any recent changes, so it is unclear if these criteria are met.\n\n7) No modifications of a possible immunosuppressor during the 2 previous months\nThere is no information provided about the patient's use of immunosuppressants, so it is unclear if this criterion is met.\n\n8) SELENA-SLEDAI \u2264 12\nThe SELENA-SLEDAI score, which is a measure of disease activity in SLE, is not provided for the patient, so it is unclear if this criterion is met.\n\n9) Signature of the consent of participation\nThis criterion cannot be assessed based on the provided information.\n\nIn summary, while the patient's age and likely diagnosis of SLE meet some of the inclusion criteria, there is not enough information provided about the patient's treatment history, medication dosages, disease activity, and willingness to participate to determine their overall eligibility for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "884": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis\" and assess the eligibility of the patient based on the provided note.\n\n1. \"Systemic Lupus Erythematosus (SLE) as defined by meeting at least 4 of the 11 classification criteria of the American College of Rheumatology for the classification of Systemic Lupus Erythematosus, either sequentially or coincident. The 4 criteria need not be present at study entry\"\n\nThe patient note mentions that the patient has a 4/4 positive ANA and anti-dsDNA, which are two of the criteria for SLE. Additionally, the note mentions that the patient has a rash, alopecia, and arthritis, which are also criteria for SLE. Therefore, this criterion is likely met.\n\n2. \"Renal biopsy within 12 months prior to screening visit indicating active proliferative lupus glomerulonephritis (met ISN/RPS Class III or IV classification criteria [2003], excluding Class III [C], IV-S [C] and IV-G [C], or the World Health Organization Class III or IV classification criteria [1982], excluding Class IIIc, IVd). If the renal biopsy was performed >3 months but \u226412 months prior to screening visit, at least 1 of the following 3 serologies (performed locally) must have been abnormal prior to screening visit: complement (C3 or C4) level below normal range OR anti-dsDNA >upper limit of normal range.\"\n\nThe patient note does not mention a renal biopsy or the specific class of lupus nephritis. However, it does mention that the patient has proteinuria and RBC casts in the urine, which are indicative of active lupus nephritis. Additionally, the note mentions that the patient has a positive anti-dsDNA, which meets the serological criteria if the renal biopsy was performed more than 3 months ago.\n\n3. \"A stable serum creatinine \u22643 mg/dL\"\n\nThe patient note does not provide information about the serum creatinine level.\n\nBased on the available information, the patient meets at least one of the inclusion criteria (SLE diagnosis) and potentially meets the second criterion (active lupus nephritis) based on the urinary findings and positive anti-dsDNA. However, there is not enough information to determine if the patient meets the third criterion regarding serum creatinine.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "885": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 21-year-old female, which meets the age criteria of 18 years and above.\n\nShe has been diagnosed with systemic lupus erythematosus (SLE) based on her clinical presentation (rash, arthritis, anemia, thrombocytopenia, positive ANA and anti-dsDNA) and laboratory findings (proteinuria, hematuria), meeting the inclusion criteria of having a diagnosis of SLE.\n\nHer disease appears to be active based on the progressive arthralgias, rash, and other symptoms, likely meeting the SLAM score requirement of at least 8.\n\nThere is no mention of end-organ damage or SLICC/ACR damage index score, but assuming it is \u226415 based on her young age and recent disease onset.\n\nThe note does not mention her current medications, but it can be assumed she would be eligible as long as she meets the stable dosing requirements for 4 weeks prior.\n\nAssuming she can understand English or French and provide informed consent.\n\nBased on the information provided, this patient appears to meet all of the key inclusion criteria for the clinical trial studying methotrexate in lupus erythematosus.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "886": {
        "output": "To determine the patient's eligibility for the clinical trial \"Myfortic Versus Azathioprine in Systemic Lupus Erythematosus\", let's go through the inclusion criteria one by one:\n\n1. Males or females, aged 18 years and over\nThe patient is a 21-year-old female, so this criterion is met.\n\n2. Patients meeting the diagnostic criteria for SLE (Appendix 2), according to ACR guidelines (including screening for anti-dsDNA (antibody to native DNA in abnormal titer))\nThe patient has a positive ANA and anti-dsDNA, along with other symptoms like alopecia, rash, purpura, arthritis, and hematuria, which are consistent with the diagnosis of systemic lupus erythematosus (SLE). This criterion is met.\n\n3. SLEDAI > 6\nThe SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) score is not provided, but the patient is described as having active disease with progressive symptoms, suggesting a SLEDAI score greater than 6. This criterion is likely met.\n\n4. Patients treated with maintenance therapy including azathioprine.\nThe patient's current treatment is not mentioned, so it is unclear if this criterion is met.\n\n5. Patients who are willing and able to participate in the study and from whom written informed consent has been obtained\nThis criterion cannot be assessed based on the provided information.\n\nOverall, the patient meets at least 3 out of the 5 inclusion criteria, and potentially 4 out of 5 if she is currently on azathioprine maintenance therapy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "887": {
        "output": "To determine the patient's eligibility for the Duke Lupus Registry clinical trial, let's go through the inclusion criteria:\n\n1. Diagnosis of Systemic Lupus Erythematosus or Cutaneous Lupus:\nBased on the patient note, the 21-year-old female patient presents with symptoms suggestive of Systemic Lupus Erythematosus (SLE), including arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts in the urine. These findings are consistent with a diagnosis of SLE, meeting this inclusion criterion.\n\n2. Patient of a rheumatologist at Duke University Medical Center:\nThe patient note does not specify if the patient is being seen at Duke University Medical Center. However, since this is a requirement for the Duke Lupus Registry, we can assume that if the patient is being evaluated at Duke, they would meet this criterion.\n\nBased on the information provided, the patient appears to meet the primary inclusion criterion of having a diagnosis of Systemic Lupus Erythematosus. If the patient is being seen at Duke University Medical Center, they would likely be eligible for the Duke Lupus Registry clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "888": {
        "output": "To determine the patient's eligibility for the clinical trial \"Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis\", let's go through the inclusion criteria one by one:\n\n1. Age at least 18 years: The patient is 21 years old, so this criterion is met.\n\n2. Diagnosis of SLE by ACR criteria: The patient has a positive ANA and anti-dsDNA, which are consistent with a diagnosis of SLE, so this criterion is likely met.\n\n3. Diagnosis of proliferative lupus nephritis (ISN/RPS class III or IV): The patient has proteinuria and RBC casts in the urine, which suggests lupus nephritis. However, the specific class (III or IV) is not mentioned, so further investigation may be needed to confirm this criterion.\n\n4. Currently on prednisolone (5 to 20 mg/day): The patient's current medication regimen is not mentioned, so it is unclear if this criterion is met.\n\n5. In partial or complete remission for at least 3 months: The patient's disease status (active or in remission) is not mentioned, so it is unclear if this criterion is met.\n\nBased on the information provided, some of the inclusion criteria are likely met, while others require further investigation or clarification.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "889": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age inclusion criteria of being less than 21 years at baseline exam.\n\n2. The patient has a positive ANA and anti-dsDNA, along with other symptoms like rash, arthritis, and hematuria, which suggests a diagnosis of systemic lupus erythematosus (SLE).\n\n3. The inclusion criteria specifies five diagnostic categories based on aPL (anti-phospholipid antibody) positivity, APS (anti-phospholipid antibody syndrome) criteria, and SLE criteria.\n\n4. Based on the information provided, this patient likely falls into the category of \"SLE with aPL, but without manifestations of APS\" since there is no mention of blood clots or other APS manifestations.\n\n5. Therefore, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "890": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria step-by-step:\n\n1. Systemic Lupus Erythematosus subjects 4/11 of the American College of Rheumatology criteria for SLE (23)\n   - The patient is described as having a positive ANA, anti-dsDNA, rash, arthritis, and hematologic disorder (anemia and thrombocytopenia), which meets at least 4 of the 11 criteria for SLE.\n\n2. Age less than 22 years\n   - The patient is described as a 21-year-old female, which meets this criterion.\n\nSince the patient meets both inclusion criteria for the clinical trial, which is studying osteoporosis in children and adolescents with systemic lupus erythematosus, I would assess the eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "891": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) Age 18 to 65 years\nThe patient is 21 years old, which falls within this range.\n\n2) SLE as defined by the ACR classification\nThe patient has a positive ANA and anti-dsDNA, along with clinical symptoms like rash, arthritis, and renal involvement, which are consistent with a diagnosis of SLE.\n\n3) Stable SLE (treatment not modified during the 2 months preceding the inclusion date W0)\nNo information is provided about recent treatment changes.\n\n4) SLE treated by immunosuppressant only or systemic corticosteroids at a dose \u2265 5 mg/j or systemic corticosteroids at any dose associated with one or more immunosuppressive drugs\nNo information is provided about the patient's current treatment.\n\n5) SLE treated by hydroxychloroquine only\nNo information about hydroxychloroquine use.\n\n6) 31 months following\nThis appears to be a typo in the criteria and is unclear.\n\n7) Females must have an effective method of contraception during the first 7 months of the study and with a negative serum or urinary pregnancy test\nThe patient is female, but no information is provided about contraception or pregnancy status.\n\n8) Females not wishing to have a child during the 7 months following W0\nNo information provided.\n\n9) Physical examination\nPresumably this would be done if the patient was referred.\n\n10) Signed written and informed consent\nPresumably this would be done if the patient was referred.\n\nIn summary, while the patient meets some of the key criteria like age and SLE diagnosis, there is not enough information provided about recent treatment, contraception status, or pregnancy plans to fully assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "892": {
        "output": "To determine the patient's eligibility for the clinical trial \"Leflunomide in Systemic Lupus Erythematosus\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Fulfill the revised ACR criteria for SLE with either evidence of active disease according to SLE Disease Activity Index (SLEDAI)\n\nBased on the patient note, the 21-year-old female patient presents with symptoms that suggest Systemic Lupus Erythematosus (SLE), such as alopecia, rash, purpura, arthralgias, positive ANA and anti-dsDNA, and evidence of kidney involvement (proteinuria and RBC casts in urine). These findings fulfill the revised ACR criteria for SLE and indicate active disease.\n\nSince the patient meets the inclusion criteria for this clinical trial, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "893": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Written Informed consent. (Not mentioned in patient note)\n2. Age >18 yrs. (Patient is 21 years old, meets criteria)\n3. SLE meeting ACR criteria for at least 6 months. (Patient has positive ANA, anti-dsDNA, and clinical manifestations suggestive of SLE, meets criteria)\n4. Stable disease activity as evidenced by no change in immunosuppressive therapy in the past 1 month. (Not mentioned in patient note)\n5. If female of childbearing potential must use an effective method of birth control (Not mentioned in patient note)\n\nExclusion Criteria:\n1. Renal disease (creatinine >1.5 mg/dL, dialysis, 2+ or more proteinuria) (Patient has proteinuria and RBC casts, may meet this exclusion)\n2. Previous or current history of peptic ulcer disease or gastrointestinal bleed. (Not mentioned)\n3. Previous or current thromboembolic or ischemic cardiovascular event (stroke, myocardial infarction, angina) - can do aspirin part of study. (Not mentioned)\n4. Currently taking an anticoagulant or antiplatelet agent (besides aspirin). (Not mentioned)\n5. Thrombocytopenia (platelet count <135,000) (Patient has thrombocytopenia, meets this exclusion)\n6. Pregnancy (Not mentioned)\n7. Allergy to aspirin, NSAIDs (Not mentioned)\n8. NSAIDs in the previous week (Not mentioned)\n\nBased on the information provided, the patient meets some of the inclusion criteria for SLE, but also meets at least two of the exclusion criteria (renal disease and thrombocytopenia).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "894": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female presenting with arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness. Lab findings show normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine with protein and RBC casts.\n\n2. The clinical trial is for evaluating the safety and effectiveness of infliximab in patients with ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, and psoriasis.\n\n3. The inclusion criteria mention participants with rheumatoid arthritis who show insufficient response to DMARDs like methotrexate.\n\n4. Based on the patient's presentation with arthralgias, rash, positive autoantibodies, and evidence of kidney involvement, this appears to be a case of systemic lupus erythematosus (SLE) rather than rheumatoid arthritis.\n\n5. Therefore, this patient would not meet the inclusion criteria for this particular clinical trial evaluating infliximab.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "895": {
        "output": "Okay, let's go through the patient note and inclusion criteria for the clinical trial step-by-step:\n\nPatient Note:\n- 21-year-old female\n- Progressive arthralgias and malaise\n- Alopecia, rash on face, purpura on calves\n- Swelling and tenderness of wrists and ankles\n- Normocytic anemia, thrombocytopenia\n- Positive ANA and anti-dsDNA\n- Proteinuria and RBC casts in urine\n\nClinical Trial:\nTitle: Prospective Study of Rapamycin for the Treatment of SLE\n\nInclusion Criteria:\nFor SLE Subjects:\n- SLE patients with SLEDAI >= 4 (disease activity)\n- SLE patients on >= 10 mg/day prednisone \n- Age >= 18 years\n- Updated vaccinations\n- Effective contraception for males\n\nThe patient meets several of the key inclusion criteria:\n- Diagnosed with SLE based on clinical manifestations and lab findings\n- Age 21 years, meeting >= 18 years criteria\n- Likely has active disease based on symptoms/lab findings, suggesting SLEDAI >= 4\n- No mention of prednisone use, so unclear if meeting that criteria\n\nOverall, this patient appears highly likely to be eligible for this SLE clinical trial studying rapamycin, pending confirmation of a few criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "896": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. SLE patients that on prednisolone more than 30 mg/day\n   - The patient note does not mention the patient's current treatment or dosage of prednisolone, so this criterion cannot be evaluated.\n\n2. Normal liver faction: AST and ALT < 80 mg/dl\n   - The patient note does not provide any information about the patient's liver function tests, so this criterion cannot be evaluated.\n\n3. Normal muscle enzyme: CPK < 100 U/L\n   - The patient note does not provide any information about the patient's CPK levels, so this criterion cannot be evaluated.\n\n4. LDL cholesterol level > 100 mg/dl\n   - The patient note does not provide any information about the patient's LDL cholesterol levels, so this criterion cannot be evaluated.\n\nBased on the information provided in the patient note, it is not possible to determine with certainty whether the patient meets all the inclusion criteria for the clinical trial. However, the patient note does indicate that the patient has been diagnosed with systemic lupus erythematosus (SLE), which is the target disease for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "897": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subjects between 1 year and <18 years of age at Day 1.\n   - The patient is 21 years old, so this criterion is not met.\n\n2. Written informed consent from subject's guardian and accompanying informed assent from subject (for children over 6 years old).\n   - This is a procedural requirement that cannot be assessed from the patient note.\n\n3. Confirmed diagnosis of chronic ITP, according to the American Society of Hematology / British Committee for Standards in Haematology (ASH/BCSH) guidelines [George, 1996; BCSH, 2003]. In addition, a peripheral blood smear or bone marrow examination should support the diagnosis of ITP with no evidence of other causes of thrombocytopenia.\n   - The patient note mentions thrombocytopenia, but also suggests the presence of systemic lupus erythematosus (SLE) based on the positive ANA, anti-dsDNA, and other clinical findings. Therefore, the thrombocytopenia may not be due to ITP alone.\n\n4. Subjects who are refractory or have relapsed after at least one prior ITP therapy or are not eligible, for a medical reason, for other treatments.\n   - The patient note does not mention any prior ITP therapy, so this criterion cannot be assessed.\n\n5. Day 1 (or within 48 hours prior) platelet count <30 Gi/L.\n   - The patient note mentions thrombocytopenia, but does not provide the specific platelet count.\n\n6. Previous therapy for ITP with immunoglobulins (IVIg and anti-D) must have been completed at least 2 weeks prior to Day 1 or have been clearly ineffective.\n   - The patient note does not mention any prior ITP therapy, so this criterion cannot be assessed.\n\n7. Subjects treated with concomitant ITP medication (e.g. corticosteroids or azathioprine) must be receiving a dose that has been stable for at least 4 weeks prior to Day 1.\n   - The patient note does not mention any ITP medication, so this criterion cannot be assessed.\n\n8. Previous treatment for ITP with splenectomy, rituximab and cyclophosphamide must have been completed at least 4 weeks prior to Day 1 or have clearly been ineffective.\n   - The patient note does not mention any prior ITP therapy, so this criterion cannot be assessed.\n\n9. Subjects must have prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) within 80 to 120% of the normal range.\n   - The patient note does not provide information about PT/INR or aPTT.\n\n10. Subjects must have a complete blood count (CBC) not suggestive of another hematological disorder.\n    - The patient note suggests the presence of SLE, which could be the underlying cause of the thrombocytopenia and other hematological abnormalities.\n\n11. The following clinical chemistries for the subjects MUST NOT exceed the upper limit of normal (ULN) reference range by more than 20%: creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and alkaline phosphatase. In addition, total albumin must not be below the lower limit of normal (LLN) by more than 10%.\n    - The patient note does not provide information about these laboratory values.\n\n12. For subjects of child-bearing potential (after menarche): subject must not be sexually active or is practicing an acceptable method of contraception (documented in chart). Female subjects (or female partners of male subjects) must use one of the following highly effective methods of contraception (i.e., Pearl Index <1.0%) from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:\n    - The patient note does not provide information about the patient's sexual activity or contraceptive use.\n\nBased on the information provided in the patient note, there are several inclusion criteria that are not met or cannot be assessed. The presence of SLE and the possibility of thrombocytopenia being secondary to SLE rather than primary ITP would likely exclude the patient from this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient",
        "label": 0
    },
    "898": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which falls within the age range of 19-60 years specified in the inclusion criteria.\n\n2. The patient does not have a diagnosis of PTSD, which is a requirement for this clinical trial. The note mentions symptoms like arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria/hematuria, which are more suggestive of a systemic autoimmune condition like lupus rather than PTSD.\n\n3. There is no mention of the patient's pregnancy status or contraceptive use, which is another inclusion criteria.\n\n4. There is no information provided about the patient's current medications or ability to understand/comply with the study protocol.\n\nBased on the information given, this patient does not meet the key inclusion criteria of having a diagnosis of PTSD. There are also some missing details about pregnancy/contraception and medications/ability to comply with the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "899": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Persons aged 18 and above.\"\nThe patient is 21 years old, so this criterion is met.\n\n2. \"Persons fulfill the diagnostic criteria of the 1997 American College of Rheumatology for systemic lupus erythematosus in the patient group.\"\nThe patient note mentions that the patient has a positive ANA and anti-dsDNA, along with other symptoms such as alopecia, rash, purpura, arthritis, and hematuria, which are consistent with the diagnostic criteria for systemic lupus erythematosus (SLE).\n\nSince the patient meets both inclusion criteria, it is highly likely that this patient would be eligible for the clinical trial studying the metabolic syndrome in patients with SLE.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "900": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\nAge > 18 years at the time of signing the informed consent form\nThe patient is 21 years old, so this criterion is met.\n\nFulfil at least 4 criteria for SLE as defined by the American College of Rheumatology (ACR)\nThe patient has alopecia, a rash, purpura, arthritis, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts. These symptoms fulfill multiple ACR criteria for SLE, so this criterion is met.\n\nPresent with active SLE disease with at least one of the following symptoms:\ni) Arthritis - > 2 joints with pain and signs of inflammation (i.e. tenderness, swelling, or effusion)\nii) Inflammatory-type skin rash\niii) Oral ulcers\nThe patient has arthritis with swelling and tenderness of the wrists and ankles, as well as a rash, so this criterion is met.\n\nLaboratory values as follows\nHemoglobin \u2265 100 g/L\nAbsolute neutrophil count \u2265 1.0 x 109/L\nTotal bilirubin \u2264 1.5 x upper limit of normal (ULN)\nAST (SGOT) / ALT (SGPT) \u2264 2.5 x ULN\nThe patient's laboratory values for these criteria are not provided, so it is unclear if they meet these criteria.\n\nAbility to take and retain oral medication\nAbility to sign and date a written informed consent prior to entering the study\nWillingness and ability to comply with the protocol for the duration of the study\nThese criteria are not addressed in the patient note, but they are generally assumed to be met unless stated otherwise.\n\nBased on the information provided, the patient meets several key inclusion criteria for the clinical trial, including age, fulfilling ACR criteria for SLE, and presenting with active SLE symptoms of arthritis and rash. However, some laboratory values are missing, which could potentially exclude the patient.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the missing laboratory values.",
        "label": 1
    },
    "901": {
        "output": "To determine the patient's eligibility for the clinical trial \"An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)\", let's go through the inclusion criteria one by one:\n\n1. Diagnosis of systemic lupus erythematosus (SLE)\nThe patient note mentions that the patient has a positive ANA and anti-dsDNA, along with other symptoms like alopecia, rash, purpura, arthritis, and hematuria, which are consistent with a diagnosis of SLE. This criterion is met.\n\n2. Disease duration: 6 months or longer\nThe patient note does not specify the disease duration, so we cannot confirm if this criterion is met or not.\n\n3. Stable, mild to moderately active systemic lupus erythematosus (SLE)\nThe patient note describes progressive arthralgias and malaise, suggesting active disease. However, the severity is not specified. This criterion may or may not be met.\n\n4. Receiving stable maintenance therapy\nThe patient note does not mention if the patient is receiving any treatment for SLE. This criterion cannot be confirmed.\n\nBased on the information provided in the patient note, the patient meets at least one of the inclusion criteria (diagnosis of SLE) and potentially meets another criterion (disease activity). However, there is not enough information to confirm if the patient meets the other two criteria (disease duration and receiving stable maintenance therapy).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "902": {
        "output": "To determine the patient's eligibility for the clinical trial \"QT Dispersion in Patients With Systemic Lupus Erythematosus (SLE)\", let's go through the inclusion criteria:\n\n1. No administration of drugs that would potentially influence QT duration except hydroxychloroquine.\nThe patient note does not mention any medications, so this criterion is likely met.\n\n2. No history of ischemic heart disease, congestive heart failure, atrial fibrillation, bundle branch block or abnormal serum electrolytes.\nThe patient note does not mention any of these conditions, so this criterion is likely met.\n\n3. Normal resting ECG and a good-quality ECG recording to measure the QT interval.\nThe patient note does not provide information about the patient's ECG, so it is unclear if this criterion is met.\n\nBased on the available information, the patient seems to meet the first two inclusion criteria. However, without information about the patient's ECG, it is difficult to determine if they meet the third criterion.\n\nTherefore, I would consider referring this patient to this clinical trial upon further investigation of their ECG results.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "903": {
        "output": "To determine the patient's eligibility for the clinical trial \"Autoimmunity in Sisters of Lupus Patients\", I will go through the inclusion criteria one by one:\n\n1. \"Proband must be a female and have documented SLE that meets ACR criteria.\"\nThe patient note does not mention a proband (a patient with SLE). Instead, it describes a 21-year-old female patient with symptoms suggestive of lupus, such as a positive ANA and anti-dsDNA, rash, arthritis, and renal involvement. However, the note does not explicitly state that she meets the ACR criteria for SLE.\n\n2. \"SLE must be diagnosed by and including age 40.\"\nThe patient is 21 years old, which meets this criterion.\n\n3. \"Proband must have at least one biological sister \u2265 10 years of age and \u2264 45 who is available and willing to donate a blood sample and enroll in a longitudinal study. Both full and half siblings qualify.\"\nThe patient note does not mention whether the patient has a sister or not.\n\nBased on the information provided in the patient note, it is unclear if the patient meets the inclusion criteria for this clinical trial. While her age and symptoms are consistent with SLE, the note does not explicitly state that she meets the ACR criteria for SLE diagnosis. Additionally, there is no information about whether she has a sister who would be eligible to participate in the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "904": {
        "output": "To determine the patient's eligibility for the \"Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Female SLE patients\": The patient note mentions that the 21-year-old patient is female and has symptoms suggestive of systemic lupus erythematosus (SLE), such as alopecia, rash, purpura, arthritis, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts in the urine. This criterion is met.\n\n2. \"Age 18-60 years\": The patient is 21 years old, which falls within the age range specified in the inclusion criteria.\n\n3. \"If premenopausal using a reliable method of contraception\": The patient's menopausal status is not mentioned, but at 21 years old, she is likely premenopausal. However, there is no information provided about her using a reliable method of contraception.\n\n4. \"Clinically stable disease\": The patient note does not provide enough information to determine if her disease is clinically stable or not.\n\n5. \"Taking hydroxychloroquine and up to 15mgs of prednisolone daily\": There is no information provided about the patient's current medications.\n\nBased on the available information, the patient meets some of the inclusion criteria, but there are uncertainties regarding her menopausal status, use of contraception, clinical stability of the disease, and current medications. Further investigation would be needed to clarify these points.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "905": {
        "output": "To determine the patient's eligibility for the clinical trial \"Development and Evaluation of Modified Yoga in Systemic Lupus Erythematosus (SLE)\", let's go through the inclusion criteria:\n\n1. Age 18-65: The patient is 21 years old, which meets this criterion.\n\n2. Diagnosis of SLE based on ACR criteria: The patient has a positive ANA and anti-dsDNA, along with symptoms like rash, arthritis, and renal involvement (proteinuria and RBC casts), which are consistent with a diagnosis of SLE based on the ACR criteria.\n\nSince the patient meets both inclusion criteria, they would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "906": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which matches the inclusion criteria of \"Subject must be female\" and \"Subject must be aged 10 and over\" for the clinical trial titled \"Drug Use Investigation for Cervarix\u00ae\".\n\n2. However, the clinical trial is investigating the safety and efficacy of the Cervarix\u00ae vaccine, which is a vaccine against human papillomavirus (HPV) infection.\n\n3. The patient note describes symptoms consistent with systemic lupus erythematosus (SLE), such as arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts.\n\n4. Since the patient does not appear to have any condition related to HPV infection or the need for the Cervarix\u00ae vaccine, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "907": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)\", let's go through the inclusion criteria one by one:\n\n1. Diagnosis must have been before the patient's 16th birthday\n   - The patient's age is not mentioned, but she is described as a 21-year-old female, so this criterion is likely not met.\n\n2. Disease duration of at least 6 months before study entry\n   - The duration of the disease is not mentioned, so it's unclear if this criterion is met.\n\n3. Must have 5 or more joints with active arthritis\n   - The patient is described as having swelling and tenderness of her wrists and ankles, which suggests active arthritis in at least 4 joints.\n\n4. Must be taking a stable dose of methotrexate 10-30 mg/meter squared (patients with body surface area [BSA] 1.67 square meter or more must be taking a minimum of 15 mg/week of methotrexate)\n   - There is no mention of the patient taking methotrexate.\n\n5. May take a stable dose of prednisone less than 10 mg/day 4 weeks prior to entry or may take a stable dose of NSAIDS (non-steroidal anti-inflammatory drugs) 2 weeks prior to entry\n   - There is no mention of the patient taking prednisone or NSAIDs.\n\n6. Must have qualifying laboratory values at the first visit.\n   - The patient's lab results are mentioned, but it's unclear if they meet the qualifying values for the trial.\n\nBased on the information provided, it seems unlikely that the patient meets all the inclusion criteria for this clinical trial. However, some key details are missing, such as the patient's age, disease duration, and whether she meets the laboratory value requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "908": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female presenting with arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine findings of proteinuria and RBC casts.\n\n2. The clinical trial is titled \"Cutaneous Lupus Registry\" and is studying the genetic factors contributing to cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).\n\n3. The inclusion criteria are:\n   - Diagnosed with CLE and/or SLE by clinical, laboratory, and histopathological findings\n   - Ability to speak and read English or Spanish at a 6th grade level\n   - Ability to give written informed consent\n\n4. Based on the patient's presenting symptoms and positive autoantibodies, she likely meets criteria for a diagnosis of SLE.\n\n5. The trial is specifically looking to enroll patients with CLE and/or SLE.\n\n6. There are no exclusions mentioned based on the provided information about the patient's age, language abilities, or ability to consent.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "909": {
        "output": "To determine the patient's eligibility for the clinical trial \"Levothyroxine in Pregnant SLE Patients\", let's go through the inclusion criteria:\n\n1. All SLE (Systemic Lupus Erythematosus) pregnant women (aged 18 - 45 years) before 14 weeks of gestation: The patient note mentions that the patient is a 21-year-old female, which falls within the age range. However, there is no mention of pregnancy or gestational age.\n\n2. With autoimmune thyroid antibodies: The patient note does not mention any information about thyroid antibodies or thyroid function.\n\nSince the patient note does not provide information about the patient's pregnancy status or thyroid antibody status, which are both required by the inclusion criteria, I would not be able to determine eligibility based on the given information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of pregnancy status and thyroid antibody status.",
        "label": 0
    },
    "910": {
        "output": "To determine the patient's eligibility for the clinical trial \"Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children\", let's go through the inclusion criteria:\n\nThe patient is a 21-year-old female, which falls within the age range of 5-21 years old for both SLE subjects and control subjects.\n\nThe patient note mentions that she has a positive ANA and anti-dsDNA, along with other symptoms like alopecia, rash, purpura, arthralgia, and proteinuria with RBC casts in the urine. These findings are consistent with a diagnosis of systemic lupus erythematosus (SLE).\n\nThe inclusion criteria specifically mention that SLE subjects should be drawn from the rheumatology clinic at Children's Hospital of Philadelphia. Since the patient note does not provide information about where the patient is being evaluated, it is unclear if she meets this specific requirement.\n\nAdditionally, the inclusion criteria state that SLE subjects should have no known vertebral compression fracture of L2. The patient note does not mention any information about vertebral compression fractures.\n\nBased on the available information, the patient meets some of the inclusion criteria for the SLE group, such as age and diagnosis of SLE. However, there are uncertainties regarding the requirement of being evaluated at the specific rheumatology clinic and the absence of vertebral compression fractures.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "911": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subjects who gave consent to this study participation and signed into informed consent form.\n   - This is not mentioned in the patient note, so we cannot make a determination.\n\n2. Subjects who are at least 20 years of age at Screening visit.\n   - The patient is 21 years old, so this criterion is met.\n\n3. Have a clinical diagnosis of Systemic Lupus Erythematosus (SLE) according to the American College of Rheumatology (ACR) classification criteria, with 4 or more of the 11 ACR criteria present, serially or simultaneously during any interval or observation.\n   - The patient has alopecia, rash, purpura, arthritis, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine abnormalities, which likely meets at least 4 of the ACR criteria for SLE diagnosis.\n\n4. Be on either no SLE medication or a stable SLE treatment regimen of any medication (e.g., low-dose prednisone, NSAIDs; alone or in combination) for a period of at least 2 months prior to the Screening visit.\n   - The patient's medication status is not mentioned, so we cannot make a determination.\n\n5. Gender and reproductive status criteria.\n   - The patient is a 21-year-old female, so she would likely meet one of the reproductive criteria listed.\n\n6. The subject is positive test for anti-nuclear antibody (ANA) or anti-dsDNA antibody in serum.\n   - The patient has a positive ANA and anti-dsDNA, so this criterion is met.\n\nBased on the information provided, the patient appears to meet several key inclusion criteria for the clinical trial, including age, SLE diagnosis, and positive autoantibodies. However, there are some criteria that cannot be determined from the patient note, such as consent, medication status, and reproductive status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "912": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria (\u226518 years) for the clinical trial.\n\n2. The patient does not have a diagnosis of systemic scleroderma (SSc) mentioned in the note. The note describes symptoms and lab findings suggestive of systemic lupus erythematosus (SLE) rather than SSc.\n\n3. Since the patient does not have SSc, they would not meet any of the inclusion criteria groups 1-6 for this SSc clinical trial.\n\nTherefore, based on the information provided in the patient note, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "913": {
        "output": "To determine the patient's eligibility for the clinical trial \"Vitamin D Supplementation in Systemic Lupus Erythematosus\", let's go through the inclusion criteria one by one:\n\n1. Systemic lupus erythematosus: The patient is described as having symptoms consistent with systemic lupus erythematosus (SLE), such as alopecia, rash, purpura, arthritis, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts. This meets the inclusion criterion.\n\n2. Age > 18 years: The patient is described as a 21-year-old female, which meets the age requirement.\n\n3. Serum vitamin D levels [25(OH)D] < 30 ng/mL: There is no information provided about the patient's vitamin D levels, so this criterion cannot be definitively assessed.\n\n4. Low to moderate active disease without modification of associated treatments: The patient is described as having progressive symptoms, suggesting active disease. However, there is no information about the severity of the disease or any current treatments.\n\nOverall, based on the information provided, the patient meets at least two of the inclusion criteria (SLE diagnosis and age), but there is not enough information to determine if they meet the other two criteria (vitamin D levels and disease activity/treatment status).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their vitamin D levels and disease activity/treatment status.",
        "label": 2
    },
    "914": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 21-year-old female presenting with arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts.\n\nThe clinical trial is for hair-sparing whole brain radiotherapy in patients with brain metastases.\n\nThe key inclusion criteria are:\n1. Brain metastases\n2. Age \u2265 18 years\n3. Signed informed consent\n4. Recursive Partitioning Analysis (RPA) class III patients \n5. RPA class I-II patients and >3 brain metastases\n6. Patients with small cell lung cancer extended disease eligible for prophylactic whole-brain radiotherapy\n\nBased on the patient note, there is no mention of brain metastases. The patient seems to have symptoms suggestive of a systemic autoimmune condition like lupus. Therefore, this patient would not meet the key inclusion criteria for this brain radiotherapy trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "915": {
        "output": "To determine the patient's eligibility for the clinical trial \"Atacicept Demonstrating Dose RESponSe\", let's go through the inclusion criteria one by one:\n\n1. Male or female of \u226518 years of age: The patient is a 21-year-old female, so this criterion is met.\n\n2. Written informed consent: This is not mentioned in the patient note, but it can be obtained if the patient is eligible and willing to participate.\n\n3. Diagnosis of SLE satisfying at least 4 out of the 11 ACR criteria during the course of their illness: The patient has alopecia, a rash, purpura, arthritis, normocytic anemia, thrombocytopenia, positive ANA, positive anti-dsDNA, and proteinuria with RBC casts in the urine. These findings suggest that the patient meets at least 4 of the ACR criteria for SLE.\n\n4. Disease duration of at least 6 months: The duration of the disease is not mentioned in the patient note.\n\n5. SLEDAI-2K score \u2265 6 at screening: The SLEDAI-2K score is not provided in the patient note.\n\n6. Positive test results for antinuclear antibody (ANA) (HEp-2 ANA \u22651:80) and/or anti-double-stranded deoxyribonucleic acid (dsDNA) (\u226530 IU/mL) at screening: The patient has a positive ANA and positive anti-dsDNA, meeting this criterion.\n\n7. Negative serum pregnancy test and highly effective method of contraception for woman of childbearing potential: This information is not provided in the patient note.\n\nBased on the available information, the patient meets some of the inclusion criteria, but there are a few criteria that cannot be determined from the provided patient note, such as disease duration, SLEDAI-2K score, pregnancy status, and contraceptive use.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "916": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which does not violate any of the inclusion criteria provided.\n\n2. However, the patient note mentions that she has \"normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA\", which indicates that she has an autoimmune disorder, likely systemic lupus erythematosus (SLE). This would violate the inclusion criterion of having \"biological parameters (haematological, biochemical, renal and hepatic) in normal range\".\n\n3. Additionally, the patient note mentions that her \"urine is positive for protein and RBC casts\", which further suggests that she has an underlying medical condition that would exclude her from this clinical trial.\n\n4. The other inclusion criteria, such as being a Caucasian volunteer, non-smoker, having health insurance, and signing informed consent, cannot be determined from the patient note provided.\n\nTherefore, based on the information given, this patient would likely not be eligible for this clinical trial due to her underlying autoimmune disorder and abnormal laboratory findings.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "917": {
        "output": "To determine the patient's eligibility for the clinical trial \"CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n- Patients with systemic Lupus erythematosus\n\nBased on the patient note, the 21-year-old female patient is presenting with symptoms suggestive of systemic lupus erythematosus (SLE), such as alopecia, rash, purpura, arthritis, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts in the urine.\n\nGiven that the patient appears to have systemic lupus erythematosus and meets the sole inclusion criterion for this clinical trial, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "918": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients older than 18 years old: The patient is 21 years old, so this criterion is met.\n\n2. Immune Thrombopenia according to the American Society of Hematology (ASH) guidelines 2011: The patient has thrombocytopenia (low platelet count), which is a key feature of immune thrombocytopenia (ITP). However, the note does not explicitly state that the patient meets the ASH guidelines for ITP diagnosis.\n\n3. Positive antinuclear antibodies > 1/160e on Hep2 cells: The patient has a positive ANA (antinuclear antibodies), which meets this criterion.\n\nBased on the information provided, the patient meets criteria 1 and 3, but it is unclear if they meet criterion 2 (diagnosis of ITP according to ASH guidelines). Therefore, further investigation may be needed to confirm the ITP diagnosis and determine if the patient fully meets the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "919": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the inclusion criteria of being 18 years or older.\n\n2. The patient has symptoms consistent with systemic lupus erythematosus (SLE), including a positive ANA and anti-dsDNA, as well as clinical manifestations like rash, arthritis, and renal involvement.\n\n3. The trial is specifically looking at patients with cutaneous lupus erythematosus (CLE) or SLE with active skin lesions, which this patient appears to have based on the rash description.\n\n4. There is no mention of the patient's current corticosteroid dose, but the exclusion criteria state patients on >15mg/day prednisone equivalent would be excluded. We can assume the patient is either not on steroids or on a lower dose for now.\n\n5. The CLASI activity score, which measures skin disease activity, is not provided but is required to be \u22654 for inclusion. However, the rash description suggests significant skin involvement.\n\nBased on the information provided, this patient meets the key inclusion criteria of age, SLE diagnosis, and likely active skin disease. The only potential exclusion is a high dose of corticosteroids, which is unclear.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their current medication doses and CLASI skin score.",
        "label": 0
    },
    "920": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria for this lupus trial (no specific age cutoffs given).\n\n2. The clinical presentation with arthralgias, rash, purpura, joint swelling/tenderness, anemia, thrombocytopenia, positive ANA/anti-dsDNA, and urine findings are all consistent with systemic lupus erythematosus (SLE).\n\n3. The trial is specifically for patients with SLE.\n\n4. The key inclusion criteria are:\n   - Having completed the previous BEL113750 trial in Northeast Asia through Week 48\n   - OR having completed the open-label extension of trial C1115 in Japan\n   \n   This patient note does not mention if the patient completed either of those prior trials.\n\n5. Since the patient's SLE diagnosis meets the broad disease criteria, but there is no information about completing the required prior trials, I would assess this case as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "921": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Age >= 18 years: The patient is 21 years old, so meets this criteria.\n2. Self-identified black race: No information provided about race.\n3. Clinical diagnosis of SLE according to ACR criteria: The patient has symptoms suggestive of SLE (alopecia, rash, purpura, arthritis, anemia, thrombocytopenia, positive ANA/anti-dsDNA, proteinuria/hematuria).\n4. SELENA SLEDAI score >= 8: No SLEDAI score provided.\n5. Positive ANA and/or anti-dsDNA: The patient has positive ANA and anti-dsDNA.\n6. On stable SLE treatment for >=30 days: No information provided about current treatment.\n7. Female subject criteria: The patient is a 21-year-old female.\n\nExclusion Criteria:\n1. Prior belimumab treatment: No information provided.\n2. Certain biologics/investigational agents within specified timeframes: No information provided.\n3. >=3 courses steroids for other conditions in past year: No information provided.\n4. Certain medications within specified timeframes: No information provided. \n5. Severe lupus nephritis: Possible based on proteinuria/hematuria, but details lacking.\n6. Severe active CNS lupus: No information provided.\n7. History of major organ transplant: No information provided.\n8. Unstable acute/chronic diseases: No information provided.\n9. Planned surgery or other contraindications: No information provided.\n10. Malignancy in past 5 years: No information provided.\n11. Certain infections/treatments: No information provided.\n12. Suicide risk: No information provided.\n13. Substance abuse: No information provided.\n14. Positive HIV, hepatitis B/C: No information provided.\n15. IgA deficiency: No information provided.\n16. Certain grade 3/4 lab abnormalities: Possible based on anemia/thrombocytopenia, but details lacking.\n17. Anaphylaxis history to proteins/antibodies: No information provided.\n\nIn summary, while the patient appears to meet some key inclusion criteria based on the provided note (age, likely SLE diagnosis, positive autoantibodies, female), there is insufficient information to definitively determine eligibility as several important criteria are not addressed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "922": {
        "output": "To determine the patient's eligibility for the \"Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. 5 years to 17 years of age at enrollment\n   - The patient is 21 years old, which does not meet this criterion.\n\n2. Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) classification criteria.\n   - The patient is described as having alopecia, a rash, purpura, arthritis, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts in the urine, which are consistent with a diagnosis of systemic lupus erythematosus (SLE).\n\n3. Have active SLE disease (SELENA SLEDAI score \u2265 6).\n   - While the SELENA SLEDAI score is not provided, the presence of active symptoms suggests active disease.\n\n4. Have positive anti-nuclear antibody (ANA) test results.\n   - The patient is described as having a 4/4 positive ANA, meeting this criterion.\n\n5. Are on a stable SLE treatment regimen at a fixed dose for a period of at least 30 days prior to Day 0.\n   - No information is provided about the patient's current treatment regimen.\n\n6. Females of childbearing age are willing to use appropriate contraception.\n   - As the patient is a 21-year-old female, this criterion would need to be met if she is referred to the trial.\n\n7. Subject age appropriate assent and parent or legal guardian informed consent to participate.\n   - As the patient is 21 years old, she would be able to provide her own informed consent.\n\nBased on the information provided, the patient meets some of the key inclusion criteria, such as having a diagnosis of SLE, active disease, and positive ANA. However, her age falls outside the specified range of 5 to 17 years old, which is a major exclusion criterion. Additionally, there is no information provided about her current treatment regimen.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the patient's age is a significant barrier, further investigation into her current treatment regimen and willingness to use contraception (if applicable) may provide more clarity on her overall eligibility. If her age were within the specified range, she would likely be a strong candidate based on the provided information.",
        "label": 0
    },
    "923": {
        "output": "To determine the patient's eligibility for the clinical trial \"An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)\", let's go through the inclusion criteria one by one:\n\n1. Men and women (not pregnant and not nursing): The patient is a 21-year-old female, so this criterion is met.\n\n2. Subjects with SLE meeting the American College of Rheumatology (ACR) criteria, with a disease duration of at least 6 months: The patient is described as having a positive ANA and anti-dsDNA, along with symptoms consistent with SLE (alopecia, rash, purpura, arthritis, and renal involvement). While the disease duration is not explicitly stated, the progressive nature of her symptoms suggests it has been present for some time. This criterion is likely met.\n\n3. Subjects with clinically active SLE defined as a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of at least 6 and positive for antinuclear antibody (ANA) and/or Anti-double-stranded DNA antibody (anti-dsDNA): The patient is positive for both ANA and anti-dsDNA, and her symptoms suggest active disease. This criterion is likely met.\n\n4. If taken, background medication must be stable: No information is provided about the patient's current medications.\n\nBased on the information provided, the patient appears to meet most of the key inclusion criteria for this clinical trial. However, there is some uncertainty regarding the disease duration and current medication status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "924": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial on systemic lupus erythematosus (SLE) treatment and assess if the patient meets them:\n\n1. The American College of Rheumatology criteria for SLE classification:\n   - Malar rash (rash on cheeks) - Yes, the patient has a rash on her cheeks\n   - Discoid rash - No mention\n   - Serositis - No mention \n   - Oral ulcers - No mention\n   - Arthritis - Yes, the patient has swelling and tenderness of wrists and ankles\n   - Photosensitivity - No mention\n   - Blood disorder - Yes, the patient has normocytic anemia and thrombocytopenia\n   - Renal disorder - Yes, the patient has proteinuria and RBC casts in urine\n   - Antinuclear antibody positive - Yes, 4/4 positive ANA\n   - Anti-dsDNA positive - Yes\n   - Neurologic disorder - No mention\n\nThe patient meets at least 4 of the 11 criteria (malar rash, arthritis, blood disorder, renal disorder, ANA positive, anti-dsDNA positive).\n\n2. HIV negative - Not mentioned but can be further investigated\n3. Signed informed consent - Not mentioned but can be obtained\n4. Taking contraceptive measures during treatment period - The patient is female, so this would apply if enrolled\n\nBased on the information provided, the patient seems to meet the key inclusion criteria for this SLE clinical trial. Some additional details may need to be confirmed, but overall:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "925": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 21-year-old female with symptoms suggestive of systemic lupus erythematosus (SLE) like arthralgias, rash, alopecia, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine findings of proteinuria and RBC casts.\n\nThe clinical trial is studying the safety of belimumab (a monoclonal antibody against B-lymphocyte stimulator) in adults with active SLE.\n\nThe key inclusion criteria are:\n1) Clinical diagnosis of SLE by ACR criteria - This patient meets this criteria based on her symptoms and lab findings.\n2) Active SLE disease - The patient seems to have active disease based on her symptoms.\n3) Autoantibody positive - The patient is positive for ANA and anti-dsDNA.\n4) On stable SLE treatment regimen - It's not mentioned if the patient is on any SLE treatment yet.\n\nThe key exclusion criteria don't seem to apply based on the information given.\n\nSo based on the inclusion criteria provided, this patient would likely be eligible for the trial if she meets any treatment criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding her current treatment regimen.",
        "label": 1
    },
    "926": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of being 18 years or older.\n\n2. She has a clinical diagnosis of systemic lupus erythematosus (SLE), as evidenced by the arthralgias, rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine findings.\n\n3. She is autoantibody-positive (positive ANA and anti-dsDNA).\n\n4. It is not explicitly stated if she is currently on SLE therapy, but given the severity of her presentation, it is highly likely she will be started on SLE therapy soon.\n\n5. There is no information provided about her ability to understand study requirements, provide consent, and comply with data collection procedures. However, given her age, this is likely not an issue.\n\nBased on the information provided, this patient meets most of the key inclusion criteria for the BENLYSTA clinical trial in SLE. The only potential issue is whether she will be started on SLE therapy soon, which is a requirement.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding initiation of SLE therapy.",
        "label": 1
    },
    "927": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female presenting with arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness, normocytic anemia, thrombocytopenia, positive ANA and anti-dsDNA, and proteinuria with RBC casts in urine.\n\n2. The clinical trial is studying hydroxychloroquine for primary thrombosis prevention in patients with persistent antiphospholipid antibody positivity but no history of thrombosis or systemic autoimmune diseases.\n\n3. The key inclusion criteria are:\n   - Persistent antiphospholipid antibody positivity (aCL, anti-\u03b22GPI, or lupus anticoagulant)\n   - No history of thrombosis\n   - No systemic autoimmune disease diagnosis like SLE\n\n4. The key exclusion criteria are:\n   - History of thrombosis\n   - SLE diagnosis\n   - Other systemic autoimmune diseases\n   - Current hydroxychloroquine or antimalarial treatment\n   - Current anticoagulant treatment\n\n5. This patient meets the inclusion criteria of persistent antiphospholipid antibody positivity (positive ANA, anti-dsDNA) and no clear history of thrombosis mentioned.\n\n6. However, the patient has findings suggestive of a systemic autoimmune disease like lupus (rash, arthritis, anemia, thrombocytopenia, proteinuria), which would be an exclusion criterion.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation to clarify if she meets criteria for a systemic autoimmune disease diagnosis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "928": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Non-drug Study Profiling Cutaneous Lupus\", let's go through the inclusion criteria one by one:\n\n1. \"have active DLE or active SCLE confirmed by histological analysis\"\nThe patient note does not explicitly mention DLE (discoid lupus erythematosus) or SCLE (subacute cutaneous lupus erythematosus), but it does mention a rash on the bridge of the nose and cheeks, which could potentially be consistent with these conditions. However, there is no mention of histological confirmation.\n\n2. \"have a confirmed diagnosis of SLE with SLE Disease Activity Index (SLEDAI) of >6 and current or historical positive ANA or anti-dsDNA\"\nThe patient note mentions a positive ANA and anti-dsDNA, which are consistent with a diagnosis of SLE (systemic lupus erythematosus). However, there is no information provided about the SLEDAI score.\n\n3. \"have an active skin lesion that can be biopsied\"\nThe patient note mentions a rash, which could potentially be biopsied.\n\n4. \"if using hydroxychloroquine or chloroquine, must be on stable doses for at least 2 months prior to screening.\"\nThere is no information provided about the patient's medication use.\n\nBased on the available information, it is unclear if the patient meets all the inclusion criteria. While some criteria are potentially met (positive ANA and anti-dsDNA, presence of a rash), there is no confirmation of the specific type of cutaneous lupus (DLE or SCLE) through histological analysis, and the SLEDAI score is not provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "929": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female presenting with arthralgias, malaise, alopecia, rash, purpura, joint swelling and tenderness. Her labs show anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine with protein and RBC casts.\n\n2. The clinical trial is for evaluating minoxidil 1% for eyebrow enhancement in patients with hypotrichosis (hair loss) of the eyebrows.\n\n3. The inclusion criteria for the trial are:\n   - Male or female aged 18-60 years (the patient meets this at 21 years old)\n   - Hypotrichosis of eyebrows (the patient has alopecia which could include eyebrow hair loss, but it's not explicitly stated)\n   - Healthy (the patient does not seem healthy based on her symptoms/labs)\n   - Informed consent obtained (not mentioned if this has happened)\n\n4. Based on the information provided, the patient does not seem to be an ideal candidate for this particular trial as:\n   - Her symptoms suggest an underlying autoimmune or systemic condition rather than just isolated eyebrow hypotrichosis\n   - She does not meet the \"healthy\" inclusion criteria\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "930": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients 18 years or older with underlying diagnosis of metastatic colorectal cancer or head and neck squamous cell carcinoma including newly diagnosed patient\"\n- The patient note does not mention colorectal cancer or head and neck cancer, so this criterion is not met.\n\n2. \"Patients must provide written informed consent to participate in the study\"\n- There is no information about whether the patient has provided consent, so this cannot be evaluated.\n\n3. \"Anticipated initiation of cetuximab treatment with or without additional chemotherapy.\"\n- The patient note does not mention cetuximab treatment, so this criterion is not met.\n\n4. \"Able to self-administer topical interventions or provide for another person to apply the topical interventions\"\n- There is no information about the patient's ability to self-administer topical interventions, so this cannot be evaluated.\n\nSince the patient note does not indicate that the patient has colorectal cancer, head and neck cancer, or is anticipated to receive cetuximab treatment, the key inclusion criteria for this clinical trial are not met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "931": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Able and willing to give written informed consent and comply with requirements of the study - This is not mentioned in the patient note, but we can assume the patient is able to provide consent.\n\n2. Age 18 - 70 years, inclusive, at randomization - The patient is 21 years old, which meets this criterion.\n\n3. Diagnosis of SLE, per the American College of Rheumatology (ACR) criteria - The patient has a positive ANA, anti-dsDNA, and clinical manifestations consistent with SLE, so this criterion is likely met.\n\n4. m-SLEDAI score < 4 at screening visit (SLEDAI score without serologies) - This score is not provided in the patient note.\n\n5. Physician Global Assessment (0-3) score of 1 or less at screening visit - This score is not provided.\n\n6. On a stable dose of MMF (1000-3000 mg/day) for at least 12 weeks prior to randomization - The patient note does not mention MMF treatment.\n\n7. Total duration of stable or decreasing MMF therapy must be at least: two years for renal indications or one year for extra-renal indications - Not applicable since MMF treatment is not mentioned.\n\n8. Corticosteroid dose criteria - The patient note does not mention corticosteroid treatment.\n\n9. If history of B cell depleting therapy, presence of CD19 positive cells documented - This is not mentioned.\n\n10. On maintenance HCQ or chloroquine for at least 12 weeks - This is not mentioned.\n\nBased on the information provided, some key inclusion criteria are likely met (age, SLE diagnosis), but several others cannot be determined from the patient note, such as disease activity scores and treatment history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "932": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of 18-75 years old for the alopecia areata clinical trial.\n\n2. The patient is described as having alopecia, which is one of the key inclusion criteria for this trial on alopecia areata.\n\n3. While the exact percentage of scalp hair loss is not provided, the note mentions that the patient has alopecia distributed on the bridge of her nose and cheeks, suggesting significant hair loss that would likely meet the >30% and <95% total scalp hair loss criteria.\n\n4. The duration of hair loss is not explicitly stated, but the progressive nature of her symptoms implies it has been going on for at least 3 months, meeting that inclusion criteria.\n\n5. There is no mention of the patient receiving any prior treatments for alopecia areata, so she could be treatment-naive or have failed prior treatments, both of which are allowed per the inclusion criteria.\n\nBased on the information provided in the patient note, this 21-year-old female with significant alopecia and no explicit exclusion criteria mentioned appears to meet all the key inclusion criteria for the alopecia areata clinical trial evaluating ruxolitinib.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "933": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female presenting with symptoms suggestive of systemic lupus erythematosus (SLE), including arthralgias, malaise, alopecia, rash, purpura, joint swelling/tenderness, anemia, thrombocytopenia, positive ANA/anti-dsDNA, and urine abnormalities.\n\n2. The clinical trial is studying the genetic and immunologic abnormalities in pediatric SLE patients, including those with syndromic or familial forms of lupus.\n\n3. The inclusion criteria specifically state that patients of any age with SLE onset before 18 years old are eligible. This patient at 21 years old likely had pediatric-onset SLE.\n\n4. The criteria also allow for syndromic lupus cases, familial/consanguineous cases, and first-degree relatives of lupus patients. While not explicitly stated for this patient, these additional criteria expand eligibility.\n\n5. Overall, given the young age of onset and clinical presentation consistent with SLE, this patient appears to meet the key inclusion criteria for this pediatric lupus study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "934": {
        "output": "To determine the patient's eligibility for the clinical trial \"Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)\", let's go through the inclusion criteria one by one:\n\n1. Complete immunization history must be available at time of enrollment\n   - The patient note does not mention the immunization history, so this criterion cannot be evaluated.\n\n2. Patients will be aged 8-18 years at time of enrollment\n   - The patient is 21 years old, so this criterion is not met.\n\n3. Patient will have stable disease activity (no changes in SLEDAI >2 points) during the 3 months preceding enrollment.\n   - The patient note does not provide information about the disease activity or SLEDAI score, so this criterion cannot be evaluated.\n\n4. Patients can be enrolled as soon as the seasonal IIV is available and prior to the onset of influenza activity in the community. Generally, this will be between September 2013-January 2014.\n   - The patient note does not provide the date, so this criterion cannot be evaluated.\n\nSince the patient is 21 years old and does not meet the age criterion, it is unlikely that they would be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "935": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers\", let's go through the inclusion criteria one by one:\n\n1. \"Have Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) with or without a diagnosis of Systemic Lupus Erythematosus (SLE)\"\n   - The patient note mentions that the patient has a rash on her nose and cheeks, which could be indicative of DLE or SCLE. Additionally, the positive ANA and anti-dsDNA results suggest a diagnosis of SLE.\n\n2. \"Active DLE or active SCLE confirmed by histological analysis (for participants with DLE or SCLE without SLE)\"\n   - The patient note does not mention a histological analysis being performed, but it does state that the patient has active cutaneous lupus lesions.\n\n3. \"Confirmed diagnosis of SLE using American College of Rheumatology criteria and has current or historical positive antinuclear antibodies (ANA) or anti double-stranded deoxyribonucleic acid (anti-dsDNA) (for participants with DLE or SCLE with SLE)\"\n   - The patient note mentions that the patient has a positive ANA and anti-dsDNA, which suggests a diagnosis of SLE.\n\n4. \"An active skin lesion that can be biopsied (for participants with lupus erythematosus)\"\n   - The patient note mentions that the patient has an active rash on her nose and cheeks, which could potentially be biopsied.\n\nBased on the information provided in the patient note, it appears that the patient meets most of the inclusion criteria for the clinical trial. However, it is unclear if a histological analysis has been performed to confirm the diagnosis of DLE or SCLE.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "936": {
        "output": "To determine the patient's eligibility for the clinical trial \"CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis\", let's go through the inclusion criteria one by one:\n\n1. Fulfill at least 4 diagnostic criteria for SLE defined by American College of Rheumatology\nThe patient note mentions that the patient has alopecia, a rash, purpura, arthritis, normocytic anemia, thrombocytopenia, positive ANA, and positive anti-dsDNA, which fulfills several diagnostic criteria for SLE.\n\n2. Positive antinuclear antibodies (ANA) and/or anti-double stranded DNA (anti-dsDNA)\nThe patient note specifically mentions that the patient has a 4/4 positive ANA and positive anti-dsDNA.\n\n3. Active SLE disease as defined by SELENA-SLEDAI score \u226510 despite on-going stable corticosteroid therapy\nThe patient note does not mention the SELENA-SLEDAI score or whether the patient is on corticosteroid therapy.\n\n4. Subjects with stable nephritis may be enrolled\nThe patient note mentions that the patient's urine is positive for protein and RBC casts, which could indicate nephritis.\n\n5. 18 years of age or older\nThe patient note states that the patient is 21 years old, which meets this criterion.\n\nBased on the information provided in the patient note, the patient meets several of the inclusion criteria, including positive ANA and anti-dsDNA, and being 18 years or older. However, there is not enough information to determine if the patient meets the criteria for active SLE disease with a SELENA-SLEDAI score \u226510 despite corticosteroid therapy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "937": {
        "output": "To determine the patient's eligibility for the clinical trial \"Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)\", let's go through the inclusion criteria one by one:\n\n1. \"Four or more American College of Rheumatology (ACR) criteria for the classification of SLE or 4 or more of the SLICE criteria\"\nThe patient note mentions that the patient has a 4/4 positive ANA and anti-dsDNA, which are two of the ACR criteria for SLE. Additionally, the patient has arthritis, rash, and hematologic involvement (anemia and thrombocytopenia), which are also ACR criteria. Therefore, this criterion is likely met.\n\n2. \"Involvement of one or more of the following organ systems: renal, neurologic, hematologic, cardiac, pulmonary, gastrointestinal\"\nThe patient note mentions hematologic involvement (anemia and thrombocytopenia) and renal involvement (proteinuria and RBC casts in urine). Therefore, this criterion is met.\n\n3. \"A lack of response to corticosteroids in moderate-to-high doses, and to either an equivalent degree of immunosuppression with azathioprine, methotrexate, cyclosporin, tacrolimus, belimumab, rituximab, mycophenolate mofetil, and/or appropriate other treatment\"\nThe patient note does not provide information about the patient's treatment history or response to treatments. Therefore, it is unclear if this criterion is met or not.\n\n4. \"Patients should be eligible for transplantation according to the BMT Policy Manual\"\nThe patient note does not provide information about the patient's eligibility for transplantation according to the BMT Policy Manual. Therefore, it is unclear if this criterion is met or not.\n\nBased on the information provided, the patient meets at least two of the inclusion criteria (criteria 1 and 2). However, there is not enough information to determine if the patient meets criteria 3 and 4.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "938": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of being 18 years or older.\n\n2. The patient has symptoms and lab findings consistent with systemic lupus erythematosus (SLE), including a positive ANA and anti-dsDNA, as well as clinical manifestations like rash, arthritis, and renal involvement.\n\n3. However, the inclusion criteria specifically state that patients must have received at least 6 months of therapy with belimumab 10 mg/kg in a current SLE belimumab continuation study.\n\n4. There is no information provided about whether this patient has previously received belimumab therapy or participated in a belimumab continuation study.\n\n5. For the control group and belimumab treatment holiday group, patients need to have a SELENA SLEDAI score of 3 or less after at least 6 months of belimumab therapy. The patient's SELENA SLEDAI score is not provided.\n\n6. For the long-term discontinuation group, patients must have voluntarily withdrawn from their continuation studies, which is not mentioned for this patient.\n\nBased on the information provided, there is not enough evidence to determine if this patient meets all the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "939": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of being 12 years or older.\n\n2. The patient has been diagnosed with cutaneous lupus based on the symptoms described (alopecia, rash on face, purpura on calves, joint swelling and tenderness) and positive lab results (positive ANA, anti-dsDNA, proteinuria, and RBC casts in urine).\n\n3. There is no information provided about the patient's ability to understand and provide informed consent or comply with study instructions, but we can assume she is capable unless stated otherwise.\n\nBased on the information provided, this patient meets the key inclusion criteria of having a diagnosis of cutaneous lupus by a dermatologist and being 12 years or older.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "940": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old female, which meets the age criteria of being 18 years or older for the clinical trial.\n\n2. The patient does not have cancer and is not receiving Cetuximab or Panitumumab, which are required for inclusion in this clinical trial.\n\n3. The patient's condition appears to be related to systemic lupus erythematosus (SLE) based on the symptoms of alopecia, rash, purpura, arthritis, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine findings.\n\n4. This clinical trial is specifically for evaluating a topical foam for preventing skin toxicity from EGFR inhibitor cancer drugs in patients receiving those drugs.\n\n5. Since the patient does not have cancer and is not receiving the relevant cancer drugs, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "941": {
        "output": "To determine the patient's eligibility for the clinical trial \"Rituximab and Belimumab for Lupus Nephritis\", let's go through the inclusion criteria one by one:\n\n1. Diagnosis of Systemic Lupus Erythematosus (SLE) by American College of Rheumatology (ACR) criteria.\nThe patient note mentions that the patient has a positive ANA and anti-dsDNA, which are criteria for SLE diagnosis. This criterion is likely met.\n\n2. Positive antinuclear antibody (ANA) or positive anti-ds DNA test results at visit -1 or any time within 14 days before visit -1.\nThe patient note states that the patient has a positive ANA and anti-dsDNA. This criterion is met.\n\n3. Active proliferative lupus nephritis, as defined by either of the following:\n   a. Kidney biopsy documentation within the last 3 months of International Society of Nephrology/Renal Pathology Society (ISN/RPS) proliferative nephritis: Class III, Class IV, or Class V in combination with Class III or IV.\n   b. Active urinary sediment and kidney biopsy documentation within the last 12 months of ISN/RPS proliferative nephritis: Class III, Class IV, or Class V in combination with Class III or IV. Active urinary sediment is defined as any one of the following:\n      - >5 RBC/hpf in the absence of menses and infection;\n      - >5 White blood cell per high powered field (WBC/hpf) in the absence of infection; or\n      - Cellular casts limited to RBC or WBC casts.\n\nThe patient note mentions that the patient's urine is positive for protein and RBC casts, which suggests active urinary sediment. However, there is no information about a kidney biopsy or the specific class of lupus nephritis. This criterion may or may not be met, and further investigation would be needed.\n\n4. Urine protein-to-creatinine ratio (UPCR) >1 at study entry based on a 24-hour collection.\nThe patient note mentions that the patient's urine is positive for protein, but there is no specific information about the UPCR value. This criterion may or may not be met, and further investigation would be needed.\n\n5. Ability to provide informed consent.\nThere is no information about the patient's ability to provide informed consent, but this is generally assumed unless stated otherwise.\n\nBased on the available information, some of the inclusion criteria are met, while others require further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "942": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Synergetic B-cell Immodulation in SLE\" and assess the eligibility of the patient based on the provided note.\n\nThe inclusion criteria are:\n1. Age 18 years or older\n   - The patient is 21 years old, so this criterion is met.\n\n2. American College of Rheumatology (ACR) diagnosis of SLE (1997 revised criteria)\n   - The patient has a positive ANA, anti-dsDNA, and other symptoms consistent with SLE, so this criterion is likely met.\n\n3. Severe SLE flare at screening, defined by one or more of the following:\n   - Increase in SLEDAI with 12 or more points (not enough information provided)\n   - New or worse SLE-related activity of major organs (the patient has nephritis, which is mentioned)\n   - Refractory disease (not enough information provided)\n\n4. ANA seropositivity (\u22651:80) before and at screening\n   - The patient has a positive ANA, so this criterion is met.\n\n5. Anti-dsDNA seropositivity (\u226530 IU/mL) before and at screening\n   - The patient has a positive anti-dsDNA, so this criterion is met.\n\n6. Immune-complex mediated complement usage, defined by low C3, low C4, or reduced classical pathway activation\n   - No information is provided about complement levels or classical pathway activation.\n\n7. Use of effective contraception\n   - No information is provided about contraception use.\n\nBased on the provided information, the patient meets several of the key inclusion criteria, such as age, SLE diagnosis, positive ANA and anti-dsDNA, and likely has a severe SLE flare with nephritis. However, there is not enough information to definitively determine if all criteria are met, particularly regarding complement levels, contraception use, and the specific details of disease activity/severity.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "943": {
        "output": "To determine the patient's eligibility for the clinical trial \"Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE\", let's go through the inclusion criteria one by one:\n\n1. \"Patients fulfilled the 1997 ACR modified or SLICC classification criteria of SLE\"\n   - The patient note mentions positive ANA and anti-dsDNA, which are consistent with SLE. The other symptoms like rash, arthritis, and renal involvement also support an SLE diagnosis.\n   - This criterion is likely met.\n\n2. \"New onset thrombocytopenia: platelet count <30X109/L(by both routine test and citric acid anti-coagulated blood count test) within 3 months\"\n   - The patient note mentions thrombocytopenia, which meets this criterion.\n   - However, the exact platelet count is not provided, so we cannot confirm if it is <30X109/L.\n\nOverall, based on the information provided, the patient seems to meet the first inclusion criterion for SLE diagnosis. However, there is not enough information to confirm if the thrombocytopenia meets the severity threshold required by the second criterion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the platelet count and confirmation of meeting all inclusion criteria.",
        "label": 0
    },
    "944": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"man and women over 18 Years old.\"\nThe patient is a 21-year-old female, so this criterion is met.\n\n2. \"suffering from SLE (American College of Rheumatology criteria).\"\nThe patient has a positive ANA and anti-dsDNA, along with other symptoms like rash, arthritis, and hematuria, which are consistent with the diagnosis of systemic lupus erythematosus (SLE). This criterion is likely met.\n\n3. \"without SLE flare for 3 months.\"\nThe note does not mention the duration of the patient's symptoms, so it is unclear if this criterion is met or not.\n\n4. \"with a signed consent and social security affiliation (required in France).\"\nThe note does not provide information about consent or social security affiliation.\n\nBased on the available information, the patient meets at least two of the inclusion criteria (age and SLE diagnosis). However, there is not enough information to determine if the patient meets the criteria for being without an SLE flare for 3 months and having signed consent and social security affiliation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "945": {
        "output": "To determine the patient's eligibility for the clinical trial \"Long-term Immunogenicity of a HPV Vaccine in SLE\", let's go through the inclusion criteria:\n\n1. SLE patients: The patient note mentions that the 21-year-old female patient has a positive ANA and anti-dsDNA, which are indicative of systemic lupus erythematosus (SLE). This criterion is met.\n\n2. Female patients aged 18-35 years: The patient is a 21-year-old female, which falls within the age range specified in the inclusion criteria.\n\n3. Fulfilling the American College of Rheumatology (ACR) criteria for the classification of SLE: While the patient note does not explicitly state that the ACR criteria are met, the presence of a positive ANA, anti-dsDNA, and clinical manifestations such as rash, arthritis, and hematological abnormalities strongly suggest that the patient meets the ACR criteria for SLE.\n\n4. Having participated in the investigators' original HPV study in 2010: There is no information provided about the patient's participation in a previous HPV study.\n\n5. Able to give written informed consent: Assuming the patient is competent to provide informed consent, this criterion is likely met.\n\nBased on the information provided in the patient note, the patient meets criteria 1, 2, and 3, and potentially meets criterion 5. However, there is no information about criterion 4 (participation in a previous HPV study).\n\nGiven the lack of information about the patient's participation in a previous study, the most appropriate assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "946": {
        "output": "To determine the patient's eligibility for the \"Web-based Genetic Research on Lupus\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"diagnosed with lupus by a qualified physician.\"\nThe patient note mentions that the patient has a positive ANA and anti-dsDNA, which are indicative of lupus. Additionally, the patient has symptoms such as alopecia, rash, purpura, arthralgia, and proteinuria with RBC casts, which are consistent with lupus. Therefore, this criterion is likely met.\n\n2. \"consents to have 23andMe (via a partner) contact the physician to obtain medical record information\"\nThis criterion cannot be assessed based on the provided information.\n\n3. \"willing to submit a saliva sample for DNA testing and complete online surveys related to condition\"\nThis criterion cannot be assessed based on the provided information.\n\n4. \"at least 6 years old (minors under 18 require parental consent to enroll)\"\nThe patient is 21 years old, so this criterion is met.\n\n5. \"access to the internet\"\nThis criterion cannot be assessed based on the provided information.\n\n6. \"resides in the United States\"\nThis criterion cannot be assessed based on the provided information.\n\nBased on the information provided, the patient meets at least one of the inclusion criteria (diagnosed with lupus by a qualified physician) and is of eligible age. However, there are several criteria that cannot be assessed due to lack of information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "947": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age \u2265 18 and \u2264 75 years: The patient is 21 years old, which meets this criterion.\n\n2. Diagnosed SLE (defined by \u2265 4 of the 11 American College of Rheumatology (ACR) classification criteria for SLE) for at least 3 months before screening: The patient has alopecia, a rash, purpura, arthritis, anemia, thrombocytopenia, positive ANA and anti-dsDNA, and urine abnormalities, which likely meets at least 4 of the ACR criteria for SLE diagnosis. However, the duration of diagnosis is not specified.\n\n3. Moderate to severe SLE disease activity demonstrated by SLEDAI-2K total score \u2265 6, including skin and joint involvement: The patient has skin and joint involvement, but the SLEDAI-2K score is not provided.\n\n4. CLASI Activity score \u2265 5 or at least 5 of 66/68 joints with pain and signs of inflammation: The patient has swelling and tenderness of wrists and ankles, which suggests at least 4 joints with inflammation, but the CLASI score is not provided.\n\n5. Positive anti-nuclear antibodies (ANA) test at screening: The patient has a positive ANA, meeting this criterion.\n\n6. No change in concomitant medication for SLE activity maintenance and symptom control regarding type of medication and dose level for at least 8 weeks prior to baseline (for steroids and NSAIDs/pain medication 2 weeks): No information is provided about the patient's medications.\n\n7. Normal electrocardiogram (ECG): No information is provided about the patient's ECG.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there are several criteria for which information is lacking (duration of diagnosis, SLEDAI-2K score, CLASI score, medication history, and ECG). Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "948": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus\", let's go through the inclusion criteria one by one:\n\n1. \"Patients with SLE according to the ACR revised criteria.\"\nThe patient is described as having a positive ANA and anti-dsDNA, along with symptoms like rash, arthritis, and renal involvement (proteinuria and RBC casts), which are consistent with the diagnosis of systemic lupus erythematosus (SLE) based on the ACR criteria.\n\n2. \"Quiescent disease without flare since at least one year (SELENA SLEDAI < or equal to 4, BILAG C, D or E, PGA 0)\"\nThe patient's disease activity is not explicitly mentioned, but the description suggests an active flare with progressive symptoms like arthralgias, malaise, and new-onset rash and renal involvement.\n\n3. \"Treatment with 5 milligrams/day of prednisone since at least 1 year\"\nThere is no information provided about the patient's current treatment or treatment history.\n\nBased on the available information, the patient seems to have an active flare of SLE and does not meet the inclusion criteria of quiescent disease without a flare for at least one year.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "949": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment\", let's go through the inclusion criteria:\n\n1. Men and women, age 18-60 with AGA\n   - The patient is a 21-year-old female, which falls within the age range.\n   - However, the patient note does not mention androgenetic alopecia (AGA) specifically. It states that she has alopecia, but the cause is not specified.\n\n2. Completed informed consent form\n   - This criterion cannot be evaluated based on the given information.\n\n3. Ludwig stage 1-2 for women\n   - The patient note does not provide information about the Ludwig stage of her alopecia.\n\n4. Norwood Hamilton Stage 3 to 5 for men\n   - This criterion is not applicable since the patient is a woman.\n\nBased on the available information, it is unclear if the patient's alopecia is specifically due to androgenetic alopecia, which is a key inclusion criterion for this trial. Additionally, the severity of her alopecia (Ludwig stage) is not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the age criterion, but more information is needed to determine if her alopecia is androgenetic in nature and to assess its severity according to the Ludwig scale. Further investigation would be required to make a definitive decision about her eligibility for this specific trial.",
        "label": 0
    },
    "950": {
        "output": "To determine the patient's eligibility for the clinical trial \"Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)\", let's go through the inclusion criteria one by one:\n\n1. Patients between 18 and 65 years old, male or female, of any race\nThe patient is a 21-year-old female, so she meets this criterion.\n\n2. Historical presence of at least 4 of 11 of the ACR Classification Criteria\nThe patient note mentions alopecia, rash, purpura, arthritis, and positive ANA and anti-dsDNA, which are consistent with several of the ACR Classification Criteria for SLE. However, the note does not explicitly state that she meets at least 4 of the 11 criteria.\n\n3. Evidence of a positive ANA (\u22651:80 titer) or positive dsDNA antibody test within 6 months of screening\nThe patient note mentions a 4/4 positive ANA and positive anti-dsDNA, so she meets this criterion.\n\n4. Clinically active SLE determined by SLEDAI score \u22656 and the presence of at least one BILAG A or BILAG B at screening, despite standard-of-care therapy\nThe patient note does not provide information about the SLEDAI score or BILAG scores, so it is unclear if she meets this criterion.\n\n5. If the patient has a BILAG A or BILAG B score in the renal organ system, he/she must have completed at least 6 months of therapy for the current episode of nephritis prior to Screening. Therapy must include at least 6 months of mycophenolate or at least 3 months of cyclophosphamide followed by mycophenolate or azathioprine\nThe patient note mentions proteinuria and RBC casts, which could indicate renal involvement, but there is no information about her treatment history.\n\n6. Able and willing to give written informed consent\nThere is no information about this in the patient note.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there are several criteria for which there is not enough information to determine eligibility. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "951": {
        "output": "To determine the patient's eligibility for the clinical trial \"Appendicitis With Medical Treatment\", let's go through the inclusion criteria:\n\nInclusion Criteria: patients with appendicitis, not receiving operation\n\nBased on the patient note, the key points are:\n\n1. The 15-year-old girl presents with symptoms suggestive of appendicitis (abdominal pain localizing to the right lower quadrant, loss of appetite, rebound tenderness on examination).\n2. An abdominal ultrasound shows a markedly edematous appendix, which is a radiological finding consistent with appendicitis.\n3. There is no mention of the patient receiving an operation for appendicitis.\n\nSince the patient meets the inclusion criteria of having appendicitis and not receiving an operation, she would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "952": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl presenting with symptoms of acute appendicitis (abdominal pain, loss of appetite, tenderness in the right lower quadrant, and ultrasound showing an edematous appendix).\n\n2. The clinical trial is studying the safety and efficacy of two different antibiotic regimens (levofloxacin/metronidazole vs. piperacillin/tazobactam) for treating complicated appendicitis.\n\n3. The inclusion criteria for the trial are:\n   - Two or more symptoms of acute appendicitis for at least 24 hours or radiologic evidence of complicated appendicitis\n   - Able to take medicine orally after recovering from surgery\n   - If female, using birth control\n\n4. Based on the patient note, the 15-year-old girl meets the first inclusion criterion of having symptoms and radiologic evidence of complicated appendicitis.\n\n5. However, there is no information provided about whether she would be able to take oral medication after surgery or if she is using birth control.\n\nGiven the limited information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information would be needed regarding her ability to take oral medication post-surgery and her use of birth control to fully determine eligibility.",
        "label": 2
    },
    "953": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients with acute appendicitis: Based on the patient note, the 15-year-old girl presents with symptoms suggestive of acute appendicitis, such as abdominal pain localizing to the right lower quadrant, rebound tenderness, and a markedly edematous appendix seen on ultrasound. This criterion is met.\n\n2. Patients with acute gastroenteritis: The patient note does not mention any symptoms or diagnosis of acute gastroenteritis. This criterion is not met.\n\n3. Patients older than 15 years of age: The patient is a 15-year-old girl, which meets this age criterion.\n\nSince the patient meets two out of the three inclusion criteria (acute appendicitis and age), and there is no information suggesting any exclusion criteria, it is highly likely that this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "954": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl, which falls within the age range of 12-80 years old specified in the inclusion criteria.\n\n2. The patient presents with abdominal pain that localized to the right lower quadrant, which is a common symptom of appendicitis.\n\n3. The abdominal ultrasound showed a markedly edematous appendix, which is a sign of acute appendicitis.\n\n4. The inclusion criteria specifically mention that patients with a clinical examination favoring the diagnosis of perforated acute appendicitis and abdominal imaging showing signs of acute appendicitis and intra-abdominal fluid accumulation should be included.\n\nBased on the information provided, this patient meets the inclusion criteria for the clinical trial on laparoscopic operation for perforated appendicitis.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "955": {
        "output": "To determine the patient's eligibility for the clinical trial \"Magnetic Resonance Imaging (MRI) of Appendicitis in Children\", let's go through the inclusion criteria:\n\nAge 8-18 years: The patient is a 15-year-old girl, which falls within the age range.\n\nReferred from emergency department for suspected appendicitis: The patient presented to the ER with abdominal pain, localized rebound tenderness, and an ultrasound showing a markedly edematous appendix, which suggests suspected appendicitis.\n\nReceiving either CT scan or ultrasound of the abdomen for diagnosis: The patient received an abdominal ultrasound, which meets this criterion.\n\nBased on the provided information, the patient meets all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "956": {
        "output": "To determine the patient's eligibility for the clinical trial \"Open Versus Laparoscopic Appendectomy\", let's go through the inclusion criteria one by one:\n\n1. Age over 15 years: The patient is a 15-year-old girl, which meets this criterion.\n\n2. Suspected acute appendicitis: The patient presents with abdominal pain localized to the right lower quadrant, loss of appetite, and tenderness on examination. An ultrasound also shows a markedly edematous appendix, which strongly suggests acute appendicitis. This criterion is met.\n\n3. Suitability for laparoscopy: There is no information provided about any contraindications for laparoscopy in this patient. Assuming no other factors preclude laparoscopy, this criterion is likely met.\n\nSince all the inclusion criteria are met based on the information provided, this patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "957": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl presenting with symptoms suggestive of acute appendicitis (abdominal pain, loss of appetite, tenderness in the right lower quadrant, and ultrasound findings of an edematous appendix).\n\n2. The clinical trial is studying wound healing after emergency appendectomy in adult patients.\n\n3. One of the inclusion criteria for the trial is \"Adult patient with acute appendicitis\".\n\nSince the patient is 15 years old and not an adult, she would not meet this inclusion criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "958": {
        "output": "Let's go through the inclusion criteria for this clinical trial:\n\n1. Age range from 18 to 60 years\nThe patient is a 15-year-old girl, which does not meet the age criteria of 18-60 years.\n\n2. CT scan diagnosed uncomplicated acute appendicitis\nThe patient had an abdominal ultrasound showing a markedly edematous appendix, which suggests acute appendicitis. However, the criteria specifically requires a CT scan diagnosis.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "959": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 15-year-old girl presenting with signs and symptoms consistent with acute appendicitis, including abdominal pain localizing to the right lower quadrant, lack of appetite, and tenderness on examination. An ultrasound confirmed an edematous appendix.\n\nThe clinical trial is comparing two different laparoscopic appendectomy techniques in patients undergoing appendectomy.\n\nLooking at the inclusion criteria:\n1. Patients will be at least 18 years of age. - The patient is 15 years old, so she does not meet this criteria.\n2. Male or female (excluding pregnant females). - The patient is a non-pregnant female, so she meets this criteria. \n3. Patients with ASA \u2266 3. - No ASA score is provided, so unable to assess this criteria.\n4. Patients informed about the study, and will have read; understood and signed the patient informed consent. Patients will be willing and able to submit to postoperative follow-up evaluations. - These criteria cannot be assessed from the provided information.\n\nSince the patient does not meet the age criteria, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "960": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 15-year-old girl presenting with symptoms suggestive of acute appendicitis, which was confirmed on ultrasound.\n\nThe clinical trial is studying the use of warm humid gas insufflation during laparoscopic appendectomy in children aged 8-14 years.\n\nOne of the key inclusion criteria is \"Healthy volunteers aged 8-14 years presenting to Starship Children's Hospital (Auckland, New Zealand) within the study period diagnosed clinically with acute appendicitis requiring diagnostic laparoscopy +/- appendicectomy.\"\n\nThe patient meets the age criteria (15 years old) and has been diagnosed with acute appendicitis requiring appendectomy.\n\nHowever, there are a couple of potential issues:\n1) The trial specifies \"healthy volunteers\", and while the patient note doesn't mention any significant comorbidities, it's unclear if she would be considered a \"healthy volunteer\".\n2) The trial is being conducted at Starship Children's Hospital in Auckland, New Zealand, and the patient note doesn't specify the location.\n\nGiven these uncertainties, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "961": {
        "output": "To determine the patient's eligibility for the clinical trial \"Perforated Appendicitis With Delayed Presentation\", let's go through the inclusion criteria one by one:\n\n1. \"All children with a delayed diagnosis of perforated appendicitis. Delayed diagnosis will be defined as symptoms for 4 or more days. Duration of symptoms will be defined as the time pain started.\"\n   - The patient note does not specify the duration of symptoms, but it mentions that the abdominal pain \"appeared gradually and was periumbilical at first, localizing to the right lower quadrant over hours\". This suggests that the symptoms may not have been present for 4 or more days, but we cannot be certain.\n\n2. \"Confirmed diagnosis of perforated appendicitis. The diagnosis of perforated appendicitis will be based on diagnostic imaging (CT scan or ultrasound), showing an established appendiceal abscess or phlegmon.\"\n   - The patient note mentions that an abdominal ultrasound was performed, and it showed \"a markedly edematous appendix\". This suggests that the appendix may be perforated or close to perforation, but it does not explicitly confirm a perforated appendicitis or the presence of an abscess or phlegmon.\n\n3. \"Consent to participate\"\n   - The patient note does not mention whether the patient or their legal guardian has provided consent to participate in the clinical trial.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for the clinical trial. While the ultrasound findings suggest a potential perforated appendicitis, the duration of symptoms and the presence of an abscess or phlegmon are not clearly stated. Additionally, consent to participate is not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "962": {
        "output": "To determine the patient's eligibility for the clinical trial \"Non Operative Treatment for Acute Appendicitis\", let's go through the inclusion criteria one by one:\n\nAge >14 years\nThe patient is a 15-year-old girl, so she meets this criterion.\n\nLower / RIF Abdominal Pain\nThe patient presents with abdominal pain that localized to the right lower quadrant, which meets this criterion.\n\nClinical Suspicion of Acute Appendicitis:\ni.e.\nAlvarado Score 5-6 (equivocal for acute appendicitis)\nAlvarado Score 7-8 (probably appendicitis)\nAlvarado Score 9-10 (highly likely appendicitis)\n\nThe patient's Alvarado score is not explicitly mentioned, but the clinical presentation strongly suggests acute appendicitis, with localized rebound tenderness in the right lower quadrant and an edematous appendix seen on ultrasound.\n\nInformed consent (patient or legal representative)\nThis criterion is not addressed in the patient note, but it is a requirement that can be obtained if the patient is deemed eligible for the trial.\n\nBased on the information provided, the patient meets the key inclusion criteria of age, abdominal pain location, and clinical suspicion of acute appendicitis. Therefore, she is likely eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "963": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: patients with diagnosis of acute appendicitis with intraoperative finding of a gangrenous appendix who accepted to enter the study\n\nBased on the patient note provided, the 15-year-old girl presents with symptoms suggestive of acute appendicitis, including abdominal pain localizing to the right lower quadrant, loss of appetite, and tenderness on examination. The ultrasound also shows a markedly edematous appendix, which could indicate a gangrenous appendix.\n\nHowever, the inclusion criteria specifically mentions an \"intraoperative finding of a gangrenous appendix.\" Since the patient has not undergone surgery yet, this criterion cannot be definitively confirmed at this point.\n\nAdditionally, the inclusion criteria requires the patient to accept entering the study, which is not mentioned in the provided patient note.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would involve confirming the diagnosis of acute gangrenous appendicitis during surgery and obtaining the patient's consent to participate in the study.",
        "label": 1
    },
    "964": {
        "output": "To determine the patient's eligibility for the \"Pediatric Appendicitis Pathway Study\" clinical trial, let's go through the details:\n\nPatient Information:\n- A 15-year-old girl\n- Presenting with abdominal pain that localized to the right lower quadrant\n- No appetite since yesterday\n- Localized rebound tenderness over the right lower quadrant on examination\n- Abdominal ultrasound showed a markedly edematous appendix\n\nInclusion Criteria for the Clinical Trial:\n- Chief complaint of acute appendicitis\n\nBased on the patient's symptoms, physical examination findings, and the ultrasound results indicating an edematous appendix, this patient meets the inclusion criteria of having a chief complaint of acute appendicitis.\n\nTherefore, considering the information provided, this patient is highly likely to be eligible for the \"Pediatric Appendicitis Pathway Study\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "965": {
        "output": "To determine the patient's eligibility for the clinical trial \"The Value of Pancreatic Stone Protein in Predicting Acute Appendicitis\", let's go through the inclusion criteria:\n\n1. Age >18 years of age (subject to the current ethics approval protocol, may change)\nThe patient note states that the patient is a 15-year-old girl, which does not meet the age requirement of being over 18 years old.\n\n2. Clinical suspicion of appendicitis as the primary or differential diagnoses\nThe patient note mentions that the patient presents with abdominal pain that localized to the right lower quadrant, and an ultrasound showed a markedly edematous appendix, which is consistent with a clinical suspicion of appendicitis.\n\n3. Patients able to provide informed consent\nThere is no information provided about the patient's ability to provide informed consent.\n\nBased on the information given, the patient meets one of the inclusion criteria (clinical suspicion of appendicitis) but does not meet the age requirement. Additionally, there is no information about the patient's ability to provide informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding the patient's ability to provide informed consent and any potential changes to the age requirement in the ethics approval protocol.",
        "label": 0
    },
    "966": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl, which falls within the age range of 1-14 years specified in the inclusion criteria.\n\n2. She has abdominal pain that localized to the right lower quadrant, along with rebound tenderness in that area on examination. An ultrasound showed a markedly edematous appendix.\n\n3. The inclusion criteria specify that patients must have complicated appendicitis, defined as appendix perforation, peri-appendicular abscess, or free fluid with signs of diffuse peritoneal irritation in the right lower quadrant.\n\n4. The ultrasound findings of an edematous appendix suggest complicated appendicitis, likely with impending perforation or early perforation.\n\n5. Therefore, this patient meets the key inclusion criteria of being a child aged 1-14 years with complicated appendicitis.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "967": {
        "output": "To determine the patient's eligibility for the clinical trial \"Diagnostic Accuracy of Serum Bilirubin in the Prediction of Perforated Appendicitis\", let's go through the inclusion criteria:\n\nInclusion criteria: \"all patients undergoing appendectomy for suspected appendicitis\"\n\nBased on the patient note, the 15-year-old girl presents with symptoms suggestive of appendicitis (abdominal pain, localized tenderness in the right lower quadrant, and an edematous appendix seen on ultrasound). It is likely that she will undergo an appendectomy.\n\nTherefore, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "968": {
        "output": "To determine the patient's eligibility for the clinical trial \"Inflammatory Response in Appendicitis\", let's go through the inclusion criteria:\n\nInclusion Criteria: Patients with appendicitis\n\nBased on the patient note, the 15-year-old girl presents with symptoms suggestive of appendicitis, including abdominal pain localizing to the right lower quadrant, loss of appetite, and rebound tenderness on examination. Additionally, an abdominal ultrasound showed a markedly edematous appendix, which is a strong indicator of appendicitis.\n\nGiven that the only inclusion criterion is patients with appendicitis, and the patient note clearly describes a case of appendicitis, this patient meets the eligibility criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "969": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 15-year-old girl presenting with signs and symptoms consistent with acute appendicitis, which was confirmed on ultrasound.\n\nThe clinical trial is studying the use of ultrasound-guided abdominal wall nerve blocks for post-operative pain management in adults undergoing laparoscopic appendectomy for acute appendicitis.\n\nOne of the key inclusion criteria is \"Age above 18 years\". Since the patient is only 15 years old, she does not meet this criteria.\n\nAnother inclusion criteria is \"Patients undergoing diagnostic laparoscopy for acute appendicitis\". While the patient likely needs an appendectomy based on the clinical picture, it's not explicitly stated if a laparoscopic approach is planned.\n\nGiven that the patient does not meet the age criteria, and it's unclear if she meets the laparoscopic surgery criteria:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "970": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Emergency department visit with suspected symptoms and signs of acute appendicitis\n   - The patient presented to the ER with abdominal pain localizing to the right lower quadrant, which is a symptom of acute appendicitis. This criterion is met.\n\n2. Intravenous contrast-enhanced computed tomography examination requested due to suspicion of appendicitis\n   - The patient had an abdominal ultrasound, which showed a markedly edematous appendix, suggesting appendicitis. While a CT scan is not explicitly mentioned, it is a common diagnostic test for suspected appendicitis. This criterion is likely met.\n\n3. Willing to provide telephone or cell phone numbers for follow-up\n   - This information is not provided in the patient note, but it can be obtained if the patient is eligible and agrees to participate in the trial.\n\n4. Signed informed consent provided prior to study entry\n   - This is a requirement that can be fulfilled if the patient is eligible and agrees to participate in the trial.\n\nBased on the information provided, the patient meets the key clinical criteria of suspected acute appendicitis, and the other criteria can potentially be met if the patient is willing to participate.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "971": {
        "output": "To determine the patient's eligibility for the clinical trial \"Importance of Peritoneal Free Fluid Cultures in Acute Appendicitis\", let's go through the inclusion criteria:\n\n1. Appendicitis (Perforated/ Non-perforated): Based on the patient note, the patient has a markedly edematous appendix seen on ultrasound, which indicates acute appendicitis. This criterion is met.\n\n2. Free fluid: The patient note does not explicitly mention the presence of free fluid, but it is common to have free fluid in cases of acute appendicitis.\n\n3. Age: 6 - 90y: The patient is a 15-year-old girl, which falls within the age range specified in the inclusion criteria.\n\nSince the patient meets the criteria for appendicitis and age, and the presence of free fluid is likely in this case, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "972": {
        "output": "To determine the patient's eligibility for the clinical trial \"Study of the Preservation of the Left Colic Artery on Rectum Cancer Surgery\", let's go through the inclusion criteria one by one:\n\n1. \"Patients coming to FirstJilinU diagnosed rectum cancer by endoscopy and pathology.\"\nThe patient note does not mention a diagnosis of rectal cancer, only that the patient presented with abdominal pain and an edematous appendix was seen on ultrasound. This criterion is not met.\n\n2. \"The rectum cancer is the first malignant neoplasm the patient has got.\"\nSince the patient is not diagnosed with rectal cancer, this criterion is not applicable.\n\n3. \"The cancer is solitary, and is 3cm to 20cm to the anus.\"\nAgain, since there is no mention of rectal cancer, this criterion is not applicable.\n\n4. \"The surgical method is limited to Dixon.\"\nThis criterion is related to the surgical procedure and is not relevant for determining eligibility based on the patient note.\n\nSince the patient is not diagnosed with rectal cancer, which is a key inclusion criterion for this clinical trial, the patient would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "973": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl, which does not meet the age criteria of 18-75 years old for this clinical trial.\n\n2. The clinical trial is specifically for patients undergoing laparoscopic surgery, but the patient note does not mention any planned laparoscopic surgery. It only states that she presented to the ER with abdominal pain and an ultrasound showed an edematous appendix, suggesting appendicitis.\n\n3. The clinical trial is focused on reducing post-laparoscopic shoulder pain, which is not relevant to this patient's condition of suspected appendicitis.\n\nBased on the information provided, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "974": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl presenting with symptoms suggestive of appendicitis (abdominal pain, loss of appetite, tenderness in the right lower quadrant, and an edematous appendix seen on ultrasound).\n\n2. The clinical trial is studying geographic influences on outcomes after appendectomy surgery.\n\n3. The inclusion criteria for the trial is: \"All patients, of all ages, undergoing appendicectomy (OPCS code H01) during the time period January 2001 - December 2010.\"\n\n4. This patient meets the inclusion criteria of being a patient undergoing an appendectomy.\n\n5. There are no other exclusion criteria mentioned that would make the patient ineligible.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "975": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 15-year-old girl presenting with symptoms suggestive of acute appendicitis - abdominal pain localizing to the right lower quadrant, loss of appetite, and tenderness on examination. An ultrasound also showed an edematous appendix.\n\nThe clinical trial is looking at outcomes of appendectomy (appendix removal surgery) based on hospital procedural volume over a 10-year period from 2001-2010. \n\nThe inclusion criteria states \"All patients, of all ages, undergoing appendicectomy (OPCS code H01) during the time period January 2001 - December 2010.\"\n\nSince this patient is presenting with a likely case of acute appendicitis requiring appendectomy, and the trial is including all patients undergoing that procedure during 2001-2010, this patient would be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "976": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl, which does not meet the age criteria of \u226518 years for this clinical trial.\n\n2. However, she presents with symptoms suggestive of acute appendicitis (abdominal pain localizing to the right lower quadrant, lack of appetite, rebound tenderness on exam, edematous appendix on ultrasound).\n\n3. The clinical trial is specifically studying the use of a laparoscopic scoring system to diagnose appendicitis and reduce negative appendectomy rates.\n\n4. Given that this patient has a high clinical suspicion for appendicitis and would likely undergo a diagnostic laparoscopy, she could potentially be enrolled in this trial to validate the laparoscopic scoring system.\n\nWhile she does not meet the strict age criteria, her clinical presentation is highly relevant to the trial aims. Therefore, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "977": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 15-year-old girl presenting with symptoms suggestive of acute appendicitis - abdominal pain localizing to the right lower quadrant, loss of appetite, and tenderness on examination. An ultrasound confirmed an edematous appendix.\n\nThe clinical trial is comparing outcomes of appendectomies performed on children aged 2-12 years old at pediatric surgery centers versus general surgical centers in Scotland.\n\nThe key inclusion criteria are:\n1) Age 2-12 years old\n2) Underwent an appendectomy procedure coded as H01 (Emergency excision of appendix) between 2001-2010\n\nThis patient meets the age criteria as she is 15 years old. And based on the clinical presentation and ultrasound findings, it is highly likely she will undergo an appendectomy coded as H01.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "978": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age >3 months and <16 years\nThe patient is a 15-year-old girl, which falls within this age range.\n\n2. Clinical suspicion of dengue hemorrhagic fever. (Revised WHO Classification System)\nThe patient note does not mention any suspicion of dengue fever. The symptoms described (abdominal pain, loss of appetite, tenderness in the right lower quadrant, edematous appendix on ultrasound) are more consistent with acute appendicitis rather than dengue fever.\n\n3. Not a prisoner or ward of the state\nThere is no information provided about the patient's legal status, but we can assume they are not a prisoner or ward of the state unless stated otherwise.\n\n4. Parents able and willing to give consent. Children older then 7 able and willing to give assent\nThere is no information provided about the parents' ability or willingness to give consent, or the child's willingness to give assent.\n\nBased on the information provided in the patient note, this patient does not meet the key inclusion criterion of clinical suspicion of dengue hemorrhagic fever. The symptoms and findings are more consistent with acute appendicitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "979": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl, which falls within the age range of 5-18 years old specified in the inclusion criteria.\n\n2. She has a diagnosis of appendicitis and is scheduled for an appendectomy, which meets the second inclusion criterion.\n\n3. The ultrasound findings indicate a \"markedly edematous appendix\", which suggests suppurative appendicitis, meeting the third inclusion criterion of intraoperative findings of suppurative appendicitis.\n\nSince the patient meets all three inclusion criteria for this clinical trial on fast track appendectomy for suppurative appendicitis, I would assess her eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "980": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl presenting with abdominal pain that localized to the right lower quadrant, loss of appetite, and tenderness on examination in the right lower quadrant. An ultrasound showed an edematous appendix, suggestive of appendicitis.\n\n2. The clinical trial is looking at improving appendix identification and appendicitis diagnosis using oral contrast medium in patients presenting to the emergency department with right lower quadrant pain.\n\n3. The inclusion criteria for the trial is \"patients in emergency department with right lower quadrant pain\".\n\n4. This patient meets that criteria, as she presented to the ER with right lower quadrant abdominal pain and findings suggestive of appendicitis on ultrasound.\n\nTherefore:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "981": {
        "output": "To determine the patient's eligibility for the clinical trial \"Multi-institutional Trial of Non-operative Management of Appendicitis\", let's go through the inclusion criteria one by one:\n\n1. English and non-English speaking patients: The patient note does not mention the patient's language, so we can assume this criterion is met.\n\n2. Age: 8-17 years: The patient is a 15-year-old girl, which falls within this age range.\n\n3. US or CT confirmed early appendicitis with US showing hyperemia, \u2264 1.1 cm in diameter, compressible or non-compressible, no abscess, no fecalith, no phlegmon or CT showing hyperemia, fat stranding, \u2264 1.1 cm in diameter, no abscess, no fecalith, no phlegmon: The patient note mentions that an abdominal ultrasound showed a \"markedly edematous appendix\", which indicates early appendicitis. However, the size of the appendix is not specified.\n\n4. White Blood Cell count > 5,000/\u00b5L and \u2264 18,000/\u00b5L: The patient note does not provide any information about the patient's white blood cell count.\n\n5. Abdominal pain \u2264 48 hours prior to receiving antibiotics: The patient note states that the abdominal pain appeared gradually and localized to the right lower quadrant over hours, which suggests the duration of pain is within 48 hours. However, it is not explicitly mentioned if the patient has received antibiotics yet.\n\nBased on the information provided in the patient note, some of the inclusion criteria are met, while others are unclear or not mentioned. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "982": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl, which does not meet the age inclusion criteria of being between 18 and 80 years old for this clinical trial on laparoscopic cholecystectomy.\n\n2. The patient presents with symptoms of acute appendicitis (abdominal pain, loss of appetite, tenderness in the right lower quadrant, edematous appendix on ultrasound). This is not related to symptomatic gallstones, which is an inclusion criteria.\n\n3. There is no mention of the patient's ASA class or any previous anesthetic complications.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "983": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl presenting with abdominal pain, loss of appetite, and tenderness in the right lower quadrant. An ultrasound showed an edematous appendix, suggesting appendicitis.\n\n2. The clinical trial is a Phase II study of concurrent chemoradiotherapy and local hyperthermia versus chemoradiotherapy alone for locally advanced pancreatic cancer.\n\n3. Looking at the inclusion criteria, the key points are:\n- Patients with locally advanced pancreatic cancer with specific criteria like venous infiltration, arterial encasement, lymph node metastasis, etc.\n- Histologically proven ductal adenocarcinoma of the pancreas\n- ECOG performance status 0-1\n- Age 18-80 years\n- Primary tumor or lymph nodes >4cm on CT scan\n- No distant metastasis\n- Adequate organ function\n\n4. This 15-year-old patient with suspected appendicitis does not have pancreatic cancer, which is the target disease for this clinical trial. She does not meet any of the key inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "984": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Adult or child ages \u22655 years\nThe patient is a 15-year-old girl, so she meets this criterion.\n\n2. Diagnosis of acute uncomplicated appendicitis, confirmed by CT, ultrasound and/or MRI performed within 24 hours of consent, as read by an attending radiologist, and confirmed by consultation of an attending surgeon\nThe patient has a markedly edematous appendix seen on abdominal ultrasound, which suggests acute appendicitis. It's not explicitly stated that this was confirmed by a radiologist and surgeon, but it seems likely given the clinical presentation.\n\n3. Ability to provide written informed consent (and for subjects ages 5-17, consent from their parent/guardian and assent if applicable)\nSince the patient is 15 years old, she would need consent from her parent/guardian to participate, which is not mentioned in the note.\n\n4. Negative pregnancy test for subjects who are women of childbearing potential\nThe patient is a 15-year-old girl, so a negative pregnancy test would likely be required, but this is not mentioned in the note.\n\nOverall, while the patient appears to meet some of the key inclusion criteria based on the provided information, there are a couple of potential issues regarding confirmation of diagnosis and consent/pregnancy testing that would need further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "985": {
        "output": "Let's go through the inclusion criteria for this clinical trial:\n\n1. Patients referred to the radiology department for an abdominal ultrasound\n- The patient note mentions that an abdominal ultrasound was performed, so this criterion is met.\n\n2. Age > 18 years\n- The patient note states that the patient is a 15-year-old girl, so this criterion is not met.\n\nSince the patient does not meet the age criterion, they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "986": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl, which meets the age inclusion criteria of 0-18 years old.\n\n2. She is presenting to the pediatric emergency department with right lower abdominal pain and suspected appendicitis. \n\n3. The clinical diagnostic plan includes an abdominal ultrasound, which is one of the required imaging modalities listed in the inclusion criteria.\n\n4. Based on the information provided, this patient appears to meet all of the listed inclusion criteria for the clinical trial titled \"Point of Care 3D Ultrasound for Pediatric Appendicitis: a Pilot Study.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "987": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl presenting with abdominal pain, loss of appetite, and tenderness in the right lower quadrant. An ultrasound showed an edematous appendix, suggesting appendicitis.\n\n2. The clinical trial is studying the use of probiotics and corticosteroids for treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) in children aged 1-12 years.\n\n3. The inclusion criteria for the trial are:\n   - Diagnosis or confirmation of PFAPA diagnosis\n   - Undergoing treatment for PFAPA at the study site\n   - Agrees to consent/assent forms\n   - Age between 1 and 12 years\n\n4. Based on the patient note, this 15-year-old girl does not have a diagnosis of PFAPA. She appears to have appendicitis, which is a different condition.\n\n5. Therefore, she would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "988": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 15-year-old girl presenting with symptoms suggestive of acute appendicitis - abdominal pain localizing to the right lower quadrant, loss of appetite, and tenderness on examination. An ultrasound also showed an edematous appendix.\n\nThe clinical trial is studying a new diagnostic and surgical approach for acute appendicitis, comparing traditional open appendectomy to a modified incision approach guided by abdominal CT scan.\n\nThe key inclusion criteria is \"patients with a clinical diagnosis of acute appendicitis\".\n\nGiven the clinical presentation and ultrasound findings, this patient meets the inclusion criteria of having a clinical diagnosis of acute appendicitis.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "989": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 15-year-old girl, which falls within the age range of 7-18 years old specified in the inclusion criteria.\n\n2. The patient is presenting with symptoms of acute appendicitis, which is an uncomplicated condition that meets the inclusion criteria of \"uncomplicated appendicitis\" and \"diagnosed to have simple acute appendicitis by intraoperative laparoscopy\".\n\n3. The patient is scheduled for a laparoscopic appendectomy surgery, which meets the inclusion criteria of \"Patients scheduled for laparoscopic appendectomy surgery\".\n\n4. There is no information provided about the patient's ASA score or hemodynamic stability, but given that she is a previously healthy 15-year-old girl presenting with acute appendicitis, it is reasonable to assume that she would likely meet the ASA Score I or II criteria and be hemodynamically stable.\n\n5. There is no information provided about whether the patient or caregiver has provided written informed assent/consent, but this is a requirement that could potentially be met.\n\nBased on the information provided, this patient appears to meet most of the key inclusion criteria for the clinical trial. However, there are a few criteria that cannot be definitively confirmed or ruled out based on the information given.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "990": {
        "output": "To determine the trial-level eligibility for this patient, let's go through the inclusion criteria one by one:\n\n1. \"children and adolescents ages 5-20 years with abdominal pain\"\nThe patient is a 15-year-old girl presenting with abdominal pain, so she meets this criterion.\n\n2. \"internal med, family med, or emergency med trained providers at participating EDs\"\nThis criterion is about the providers, not the patient, so it is not relevant for determining the patient's eligibility.\n\nSince the patient meets the only relevant inclusion criterion, which is being a child or adolescent aged 5-20 years with abdominal pain, she is likely eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "991": {
        "output": "To determine the patient's eligibility for the clinical trial \"Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)\", let's go through the inclusion criteria one by one:\n\n1. Age greater than or equal to 40 years: The patient is 63 years old, so this criterion is met.\n\n2. Cigarette smoking greater than or equal to 30 pack years: The patient has a history of heavy smoking, which likely meets this criterion, although the exact pack-year history is not provided.\n\n3. Obstructive Spirometry: The patient has symptoms of cough, shortness of breath, and diffuse rales on lung examination, which are suggestive of obstructive lung disease. However, spirometry results are not provided in the patient note.\n\n4. First degree relative with smoking history willing to participate: There is no information provided about the patient's family members or their smoking history.\n\nBased on the available information, the patient meets at least two of the inclusion criteria (age and smoking history), but there is not enough information to confirm obstructive spirometry or the availability of a first-degree relative with a smoking history willing to participate.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "992": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Hospitalized male and female subjects with clinically documented nosocomial pneumonia proven to be due to methicillin-resistant staphylococcus aureus.\"\n   - The patient note does not mention that the pneumonia is caused by methicillin-resistant Staphylococcus aureus (MRSA). It only states that the patient has a productive cough and shortness of breath.\n\n2. \"Chest X-ray at baseline/screen or within 48 hours of treatment consistent with the diagnosis of pneumonia.\"\n   - The patient note mentions that the chest X-ray is notable for hyperinflation with no consolidation, which is consistent with the diagnosis of pneumonia.\n\n3. \"Suitable sputum specimen defined as having less than 10 squamous epithelial cells and greater or equal 25 leukocytes or have a culture taken by an invasive technique within 24 hours of study entry.\"\n   - The patient note does not provide any information about the sputum specimen or culture results.\n\nBased on the information provided in the patient note, it is unclear if the patient meets the first and third inclusion criteria for the clinical trial. While the chest X-ray findings are consistent with pneumonia, there is no mention of the specific causative organism (MRSA) or the sputum specimen characteristics required for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "993": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggestive of an acute exacerbation of chronic obstructive pulmonary disease (COPD). His past medical history includes heavy smoking, which is a major risk factor for COPD.\n\nThe clinical trial is studying the effects of roflumilast, a medication used to treat COPD, on lung function parameters indicative of hyperinflation in COPD patients.\n\nLooking at the inclusion criteria:\n- The patient is over 40 years old (meets criteria)\n- He likely has an FEV1/FVC ratio \u2264 70% and FEV1 \u2264 65% predicted based on his COPD diagnosis (meets criteria, though exact values not provided)\n- His chest X-ray findings of hyperinflation suggest he may meet the FRC \u2264 120% predicted criteria\n\nLooking at the key exclusion criteria:\n- He has not had a COPD exacerbation requiring systemic steroids in the last 4 weeks (meets criteria)\n- He is a former heavy smoker with likely >10 pack-year history (meets criteria)\n- No other significant lung diseases like asthma mentioned (meets criteria)\n- Not on long-term home oxygen therapy (meets criteria)\n- No other significant contraindications like HIV, hepatitis, cancer, etc. mentioned (appears to meet criteria)\n\nOverall, based on the information provided, this patient appears to potentially meet the key inclusion/exclusion criteria for the roflumilast COPD trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of precise lung function values and ruling out any other exclusion criteria.",
        "label": 1
    },
    "994": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man, which does not meet the age criteria of 2-12 months for this pediatric clinical trial on bronchiolitis.\n\n2. The patient's symptoms (cough, shortness of breath, productive cough with purulent sputum) and examination findings (cyanosis, tachypnea, barrel-shaped chest, diffuse rales) are more consistent with an acute exacerbation of chronic obstructive pulmonary disease (COPD) rather than bronchiolitis.\n\n3. There is no mention of the patient meeting the bronchiolitis diagnostic criteria listed in the inclusion criteria.\n\n4. The trial specifically requires testing for respiratory syncytial virus (RSV) infection after enrollment, which has not been done for this patient yet.\n\nBased on the information provided, this 63-year-old patient with likely COPD exacerbation does not meet the key inclusion criteria for this pediatric bronchiolitis trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "995": {
        "output": "To determine the patient's eligibility for the clinical trial \"Placebo Versus Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)\", let's go through the inclusion criteria:\n\n1. Acute exacerbation of COPD type I or II according to GOLD\n   - The patient note mentions that the 63-year-old man presents with cough, shortness of breath, and productive purulent sputum, which are symptoms of an acute exacerbation of COPD. The chest x-ray also shows hyperinflation, which is consistent with COPD.\n\n2. Ability to perform lung function tests\n   - The patient note does not explicitly mention whether the patient can perform lung function tests, but it is generally assumed that patients can undergo necessary tests unless stated otherwise.\n\n3. Ability to take oral medication\n   - The patient note does not indicate any issues with the patient's ability to take oral medication.\n\nBased on the information provided in the patient note, the patient appears to meet the inclusion criteria for the clinical trial. However, it would be prudent to investigate further to confirm the patient's COPD status and ability to perform lung function tests.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "996": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting a respiratory infection or exacerbation.\n\n2. He has a history of heavy smoking, which puts him at risk for chronic obstructive pulmonary disease (COPD).\n\n3. The clinical trial is studying the use of macrolide antibiotics to prevent exacerbations of asthma and COPD.\n\n4. One of the inclusion criteria is \"Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation\".\n   - While the patient note doesn't explicitly state a diagnosis of COPD, his smoking history and respiratory symptoms are highly suggestive of a COPD exacerbation.\n\n5. Another inclusion criteria is \"Evidence of airflow obstruction on spirometry (FEV1/FVC<70%)\".\n   - The patient note doesn't provide spirometry results, so this criteria cannot be definitively assessed.\n\n6. The other inclusion criteria of being admitted to the inpatient service and being 18 years or older are likely met based on the information provided.\n\nOverall, while the patient seems to potentially meet some of the key inclusion criteria, the lack of confirmed spirometry results makes it difficult to definitively determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation (e.g., obtaining spirometry results).",
        "label": 1
    },
    "997": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, requiring home oxygen for the past 24 hours. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n2. The clinical trial (COAT) is evaluating the use of high frequency chest wall oscillation (HFCWO) for adults hospitalized for acute asthma or COPD exacerbations.\n\n3. The inclusion criteria are:\n   - Age 18 years and older (the patient is 63, so meets this criteria)\n   - Admission to the inpatient medical service (unclear if the patient is admitted or not from the note)\n   - Physician-diagnosed asthma, asthma/COPD or COPD exacerbation (the patient does not have an explicit diagnosis of asthma or COPD mentioned, but his symptoms and smoking history suggest a high likelihood of COPD exacerbation)\n   - Evidence of airflow obstruction on spirometry (no spirometry results provided)\n\n4. Based on the information provided, I would consider referring this patient to the COAT clinical trial upon further investigation (e.g., confirming admission status, getting spirometry done to check for airflow obstruction, and getting an official diagnosis of COPD exacerbation from the physician).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "998": {
        "output": "To determine the patient's eligibility for the clinical trial \"ANTEAB: a Study of Early Antibiotherapy in the ICU Management of Acute Exacerbations of COPD\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Patients included are those with documented or suspected COPD (chronic obstructive lung disease), exclusive of other bronchial or lung disease\n2. Admitted for acute exacerbation\n3. In the absence of overt sepsis or broncho-pneumonia\n4. Having no other organ failure\n\nFrom the patient note, we can see that the 63-year-old man has a history of heavy smoking, which could lead to COPD. He is presenting with cough, shortness of breath, and purulent sputum, which suggests an acute exacerbation of COPD. The chest x-ray shows hyperinflation but no consolidation, indicating the absence of broncho-pneumonia.\n\nHowever, the patient note does not explicitly mention the absence of sepsis or other organ failures. Additionally, the patient has comorbidities like spinal stenosis, diabetes, hypothyroidism, and mild psoriasis, which could potentially exclude him from the trial.\n\nBased on the available information, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "999": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 63-year-old man with a history of heavy smoking, which matches the inclusion criteria of \"smoking\" and \"age > 40 years\" for the clinical trial on COPD.\n\nAdditionally, the patient presents with cough, shortness of breath, and findings on chest x-ray consistent with COPD, which matches the inclusion criteria of \"clinical COPD\".\n\nTherefore, based on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1000": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, requiring home oxygen for the past 24 hours. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n2. The clinical trial is studying the use of nebulized budesonide as an alternative to systemic corticosteroids in the treatment of acute exacerbations of COPD (AECOPD).\n\n3. The key inclusion criteria is \"COPD patients who were admitted to our pulmonary department for an acute exacerbation were prospectively enrolled in the study.\"\n\n4. Based on the patient's presentation of an acute COPD exacerbation requiring oxygen, and the trial's inclusion criteria of enrolling COPD patients admitted for an acute exacerbation, this patient appears to meet the key eligibility criteria.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1001": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and a history of heavy smoking. This meets the first inclusion criteria of being a smoker or ex-smoker of at least 10 pack years.\n\nHis age of 63 meets the second inclusion criteria of being 40 or above.\n\nThere is no mention of prior or current use of inhaled corticosteroids for at least 6 months, so this inclusion criteria is not clearly met.\n\nThe patient has a barrel-shaped chest and diffuse rales, suggesting COPD, but there are no spirometry results provided to confirm FEV1 <80% of predicted and FEV1/FVC ratio <70%.\n\nThere is also no information provided about a bronchodilator reversibility test to assess the change in FEV1 after bronchodilator administration.\n\nFinally, there is no mention of whether the patient has had a previous COPD exacerbation in the last year.\n\nBased on the information provided, some of the key inclusion criteria are not clearly met or are missing.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their spirometry results, bronchodilator reversibility, prior inhaled corticosteroid use, and history of COPD exacerbations.",
        "label": 1
    },
    "1002": {
        "output": "Based on the patient note provided, the 63-year-old man does not have a diagnosis of ADHD or Tourette syndrome. The note describes his presentation with respiratory symptoms and a history of smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\nThe clinical trial titled \"Methylphenidate for Treating Children With ADHD and Tourette Syndrome\" has an inclusion criterion of a diagnosis of ADHD or ADHD plus Tourette syndrome.\n\nSince the patient does not meet this inclusion criterion, he would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1003": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man, which meets the age criteria of 2-59 months for the clinical trial.\n2. The patient's symptoms of cough, shortness of breath, and difficulty breathing align with the criteria of severe pneumonia according to WHO.\n3. However, the trial specifically mentions enrolling children, while this patient is an adult.\n4. Additionally, the trial requires attendance at specific clinics in Bangladesh, which is not mentioned for this patient.\n\nBased on the information provided, this patient would not be eligible for the clinical trial due to not meeting the age criteria and likely not attending the required clinics.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1004": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man, which falls outside the age range of 45-70 specified in the inclusion criteria.\n\n2. The patient has a diagnosis of COPD, which matches the inclusion criteria of \"Moderate COPD (GOLD classification)\".\n\n3. The patient's treatment is not specified, so it's unclear if he meets the criteria of being \"Treated with inhaled steroids and long acting beta agonists\".\n\nBased on the available information, the patient partially meets the inclusion criteria. His age is outside the specified range, but he has a diagnosis of moderate COPD. However, there is not enough information about his current treatment to fully assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into his current treatment regimen.",
        "label": 1
    },
    "1005": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting an exacerbation of an underlying lung disease.\n\n2. His past medical history includes heavy smoking (a risk factor for COPD), spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n3. The clinical trial is studying infective exacerbations in patients with asthma or COPD.\n\n4. The inclusion criteria state:\n   - Age 18-80 years (the patient is 63, so meets this criteria)\n   - Any severity of exacerbation of obstructive airway disease (the patient seems to be having an exacerbation)\n   - History of at least 2 exacerbations in the past 12 months requiring treatment (no information provided about this)\n   - Able to provide informed consent and return for follow-up visits (no information provided about this)\n\nBased on the available information, the patient meets some but not all of the inclusion criteria. More information would be needed about his exacerbation history and ability to participate in the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1006": {
        "output": "To determine the trial-level eligibility for this patient, I will need to review the inclusion criteria for the clinical trial titled \"Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease.\"\n\nThe inclusion criteria provided states: \"No change from the MIA and LEUKO trials.\"\n\nUnfortunately, without knowing the specific inclusion criteria from the MIA and LEUKO trials, it is difficult to make a definitive assessment of the patient's eligibility for this trial.\n\nHowever, based on the patient note provided, a few key points stand out:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive sputum, which could be indicative of a respiratory condition like COPD or asthma.\n2. The patient has a history of heavy smoking, which is a risk factor for COPD.\n3. The patient's symptoms and chest x-ray findings suggest a potential exacerbation or respiratory infection.\n\nGiven that the trial is investigating airway infection and inflammation in people with asthma and COPD, this patient could potentially be eligible, but further investigation would be needed to confirm if they meet the specific inclusion criteria from the MIA and LEUKO trials.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1007": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, requiring home oxygen for the past 24 hours. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n2. The clinical trial is studying the impact of corticosteroid-induced hyperglycemia on clinical outcomes in patients with COPD exacerbation.\n\n3. The inclusion criteria for the trial is: \"Patients admitted with COPD exacerbation\"\n\n4. Based on the patient note, this 63-year-old man is presenting with symptoms consistent with a COPD exacerbation (cough, shortness of breath, purulent sputum) and has a history of heavy smoking, which is a major risk factor for COPD.\n\n5. Therefore, this patient meets the inclusion criteria of being admitted with a COPD exacerbation.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1008": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and a history of heavy smoking. This aligns with the inclusion criteria of being a current smoker and having COPD.\n\n2. The inclusion criteria state that patients must be aged over 35 years, which this patient meets at 63 years old.\n\n3. The inclusion criteria require the GP to confirm the diagnosis of COPD, which is not explicitly stated in the patient note. However, the note mentions a history of heavy smoking and symptoms consistent with COPD (cough, shortness of breath, diffuse rales).\n\n4. The inclusion criteria also require patients to be in command of the Dutch language, but the patient note does not mention the patient's language proficiency.\n\nBased on the information provided, there are some uncertainties around whether the GP has confirmed the COPD diagnosis and whether the patient is proficient in Dutch. However, the patient's age, smoking history, and presenting symptoms are consistent with the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1009": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, requiring home oxygen for the past 24 hours. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis.\n\n2. The clinical trial is the Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE), which aims to determine why black and rural residents of Pennsylvania might be at higher risk for COPD exacerbations requiring hospitalization, and to test if access to a 1-800 call center can reduce these exacerbations.\n\n3. The inclusion criteria for the trial are:\n   - Current hospitalization for COPD exacerbation (Phase 1 & Gene Expression)\n   - COPD and one of the following: history of hospitalization for COPD exacerbation, currently on supplemental oxygen, history of evaluation for lung transplant or LVRS, or \u2265 6 months post-LVRS (Phase 1 & 2)\n   - Current or former smoker, \u2265 20 pack-year smoking history\n   - FEV1 \u2264 70%; FEV1/FVC \u2264 70%\n   - Life expectancy of > 6 months\n\n4. Based on the patient note, the patient meets several of the inclusion criteria:\n   - He is a current or former heavy smoker\n   - He is currently requiring supplemental oxygen, suggesting COPD\n   - His symptoms (cough, shortness of breath, purulent sputum) suggest a COPD exacerbation, though it's not clear if he's currently hospitalized for this\n\n5. However, there is no information provided about his FEV1 or FEV1/FVC values, which are required for inclusion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his lung function tests to determine if he meets the FEV1 and FEV1/FVC criteria.",
        "label": 1
    },
    "1010": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 63-year-old man with a history of heavy smoking, which is a major risk factor for COPD. He is presenting with symptoms of cough, shortness of breath, and purulent sputum production, which are consistent with an acute exacerbation of COPD.\n\nThe clinical trial is looking at using a forecasting system to predict COPD exacerbations and whether providing advice during predicted high-risk periods can reduce exacerbations or their impact.\n\nThe inclusion criteria are:\n1) Current or former smokers with a diagnosis of COPD\n2) Having impaired lung function as measured by spirometry\n\nBased on the patient's history of heavy smoking and his current presentation with an acute COPD exacerbation, he likely meets the first inclusion criterion of having a diagnosis of COPD.\n\nHowever, the note does not mention whether the patient has had spirometry testing to confirm impaired lung function, which is the second inclusion criterion.\n\nTherefore, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his lung function status via spirometry.",
        "label": 1
    },
    "1011": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, which matches the definition of an acute exacerbation of COPD in the inclusion criteria.\n\nHe has a history of heavy smoking, which likely contributed to the development of COPD, although his COPD diagnosis is not explicitly stated.\n\nHis symptoms required the use of home oxygen for the past 24 hours, suggesting significant respiratory distress.\n\nOn examination, he is cyanotic, tachypneic with a respiratory rate >30 breaths/min, and has diffuse rales, indicating acute respiratory failure.\n\nThe inclusion criteria specify that patients must have an acute exacerbation of COPD leading to acute respiratory failure requiring ICU admission and mechanical ventilation.\n\nWhile mechanical ventilation is not mentioned in the patient note, the severity of his symptoms and respiratory failure suggest he may require it.\n\nBased on the information provided, this patient appears to meet most of the key inclusion criteria for the clinical trial on antibiotics for acute exacerbations of COPD requiring mechanical ventilation.\n\nHowever, there are a few potential gaps, such as the lack of explicit COPD diagnosis and arterial blood gas values.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1012": {
        "output": "To determine the patient's eligibility for the clinical trial \"Responses Induced by Smoking in Individuals Being Susceptible and Non-Susceptible for Development of COPD\", let's go through the inclusion criteria:\n\nAge 18-75 years: The patient is 63 years old, which falls within this range.\n\nAge, pack years, FEV1/FVC and FEV1% predicted must fit in one of the 5 groups described above: The patient's smoking history is noted as \"heavy smoking\", but there are no specific details provided about pack years or lung function values to determine if they fit into one of the groups.\n\nAble to stop smoking for 10 days and start smoking 3-4 cigarettes within 1 hour: There is no information provided about the patient's ability or willingness to follow this protocol.\n\nPhysically and mentally able to undergo the total study protocol: The patient's physical and mental status is not described in detail, but the note mentions cough, shortness of breath, and the need for home oxygen, which may impact their ability to undergo the study protocol.\n\nWritten informed consent: There is no information provided about whether the patient would provide written informed consent.\n\nBased on the limited information provided in the patient note, it is difficult to make a definitive assessment of eligibility. However, given the patient's age, smoking history, and potential respiratory limitations, it would be reasonable to consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1013": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Specific allergy to at least one of the following allergen preparations: (House Dust Mite f, House dust mite p, Cockroach, Tree mix, Grass Mix, Weed Mix, Mold Mix 1, Mold Mix 2, Rat, Mouse, Guinea Pig, Rabbit, Cat or Dog) confirmed by positive immediate skin test response.\"\n- The patient note does not mention any allergies or positive skin tests, so this criterion is not met.\n\n2. \"FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .75 (without use of bronchodilating medications for 12 hours), consistent with lung function of persons with no more than mild episodic or mild persistent asthma.\"\n- There is no information provided about the patient's FEV1 or FEV1/FVC ratio, so this criterion cannot be evaluated.\n\n3. \"History of nasal allergy, including episodic, perennial, or seasonal sneezing, nasal congestion or cough, or such symptoms associated with specific exposures (such as cat or dog)\"\n- The patient note does not mention any nasal allergies or associated symptoms, so this criterion is not met.\n\n4. \"Criteria for classification as having asthma with allergic rhinitis vs. allergic rhinitis alone:\nHistory of episodic wheezing, chest tightness, or shortness of breath consistent with asthma, or physician diagnosed asthma.\nProvocative concentration of methacholine producing a 20% fall in FEV1 (PC20 methacholine) of less than 10 mg/ml by the method used (see below).\"\n- There is no information provided about the patient's history of wheezing, chest tightness, or shortness of breath consistent with asthma, nor any mention of a physician diagnosis of asthma or methacholine challenge test results.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1014": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\n1. FEV1/FVC < 70%: This criterion is not explicitly mentioned in the patient note, but the patient has a history of heavy smoking and symptoms suggestive of COPD (cough, shortness of breath, barrel-shaped chest, diffuse rales). It is likely that the patient's FEV1/FVC ratio is less than 70%, which meets this criterion.\n\n2. FEV1 % predicted > 60%: This criterion is also not explicitly stated in the patient note. However, the lack of consolidation on the chest X-ray and the absence of fever suggest that the patient's condition is not due to a severe acute exacerbation of COPD, which would typically result in a more significant decrease in lung function.\n\nBased on the available information, it is reasonable to consider referring this patient to the clinical trial upon further investigation to confirm the FEV1/FVC ratio and FEV1 % predicted values.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1015": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum for the past week. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n2. The clinical trial is studying granzymes and perforin levels in COPD exacerbations compared to stable disease and acute bronchitis in non-COPD patients.\n\n3. The inclusion criteria for COPD patients are:\n   - COPD diagnosis according to GOLD consensus\n   - Initiation of COPD exacerbation symptoms in the past 72 hours\n   - No new therapeutic interventions\n   - No signs of severe exacerbation requiring hospitalization\n\n4. Based on the patient's history of heavy smoking and presenting symptoms of cough, shortness of breath, and purulent sputum, it is highly likely that this patient has COPD and is experiencing an exacerbation.\n\n5. The patient meets the inclusion criteria of COPD diagnosis, initiation of exacerbation symptoms within 72 hours, and no signs of severe exacerbation requiring hospitalization (based on the information provided).\n\n6. There is no mention of the patient starting any new therapeutic interventions.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1016": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, likely due to an acute exacerbation of COPD given his history of heavy smoking.\n\n2. The clinical trial is studying the effect of adding theophylline to inhaled corticosteroids and long-acting beta agonists in patients with moderate to severe stable COPD.\n\n3. The key inclusion criteria are:\n   - Stable stage II or III COPD (moderate to severe)\n   - Diagnosed at least 2 years ago\n\n4. Based on the patient note, it does not explicitly state the stage or severity of the patient's COPD, only that he has a history of heavy smoking. However, his acute exacerbation symptoms suggest he likely has at least moderate COPD.\n\n5. The note also does not mention how long ago the COPD was diagnosed, so it's unclear if he meets the 2 year criteria.\n\nGiven the limited information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his COPD severity staging and time since diagnosis.",
        "label": 1
    },
    "1017": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man who is a current smoker with symptoms of cough, shortness of breath, and purulent sputum, suggesting chronic obstructive pulmonary disease (COPD).\n\n2. The clinical trial is studying gene expression changes in lung cells of non-smokers, smokers, and ex-smokers, both healthy and with COPD.\n\n3. The inclusion criteria for the trial include:\n   - Group B: Healthy current smokers\n   - Group D: Current smokers with COPD of any stage\n   - Group E: Current smokers with COPD who are willing to quit smoking\n\n4. Based on the patient note, this patient appears to meet the criteria for Group D (current smoker with COPD) or potentially Group E if he is willing to quit smoking.\n\nTherefore, Trial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1018": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man with a history of heavy smoking, which is a major risk factor for COPD.\n2. He presents with symptoms of cough, shortness of breath, and purulent sputum, which are common symptoms of COPD exacerbation.\n3. His chest x-ray findings of hyperinflation without consolidation are consistent with COPD.\n\n4. The clinical trial is studying the interaction between bronchodilators and cigarette smoking in COPD patients.\n5. One of the inclusion criteria is \"COPD Gold stage II-III (FEV1/FVC<0,70 and FEV1 30-80% of predicted value).\"\n   - While the patient's spirometry values are not provided, his symptoms and imaging findings strongly suggest he has COPD that would likely meet this criteria.\n6. Another inclusion criteria is \"Current cigarette smoking (at the time of performing the study).\"\n   - The patient has a history of heavy smoking, so he likely meets this criteria as well.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the COPD clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1019": {
        "output": "To determine the patient's eligibility for the clinical trial \"Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease\", let's go through the inclusion criteria one by one:\n\n1. Diagnosis of COPD according to GOLD criteria (FEV1/FVC<70%), classification into GOLD I (FEV1 70-100% predicted), GOLD II (FEV1 50-70% predicted), GOLD III (FEV1 30- 50% predicted) or GOLD IV (FEV1 \u2264 30% predicted)\n   - The patient note does not provide information about the patient's FEV1 or FEV1/FVC ratio, so it's unclear if they meet this criterion.\n\n2. Age \u2265 18 years\n   - The patient is 63 years old, so they meet this criterion.\n\n3. Three or more exacerbations of COPD in one year for which a course of prednisone and/or antibiotic therapy was started\n   - The patient note does not mention any previous exacerbations or treatments, so it's unclear if they meet this criterion.\n\n4. Clinically stable during 1 month. Patients have to be free of COPD exacerbation or respiratory tract infection within a month prior to involvement in the study and they should not have received a high dose of systemic glucocorticoids or antibiotics in this period\n   - The patient note indicates that the patient's symptoms began about a week prior to admission, which suggests they may not have been clinically stable for the past month.\n\n5. Informed consent\n   - The patient note does not mention whether the patient has provided informed consent.\n\nBased on the information provided in the patient note, there are some key criteria that cannot be determined, such as the patient's lung function and exacerbation history. Additionally, the patient may not meet the criterion of being clinically stable for the past month.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1020": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, which suggests a respiratory infection or exacerbation of COPD.\n\n2. The clinical trial is studying the use of antibiotics in non-purulent exacerbations of COPD.\n\n3. One of the inclusion criteria is \"COPD diagnosis according to GOLD guidelines\". The patient note mentions he has a history of heavy smoking, which is a risk factor for COPD, but does not explicitly state a COPD diagnosis.\n\n4. Another inclusion criteria is \"Hospitalization for any acute exacerbation of chronic obstructive pulmonary disease\". The patient is presenting with symptoms suggestive of an acute COPD exacerbation requiring hospitalization.\n\n5. The other inclusion criteria like failure of outpatient treatment, increasing dyspnea, and comorbidities causing respiratory detriment are not clearly mentioned in the patient note.\n\nBased on the available information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient seems to meet some of the key inclusion criteria like acute COPD exacerbation and hospitalization, but further details on explicit COPD diagnosis, failure of outpatient treatment, and comorbidities would be needed to fully assess eligibility. Additional testing like spirometry may also help confirm the COPD diagnosis.",
        "label": 1
    },
    "1021": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting a respiratory infection or exacerbation of underlying lung disease.\n\n2. His past medical history includes heavy smoking (a risk factor for COPD), spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n3. The clinical trial is studying the effects of inhaled corticosteroids on sputum bacterial load in COPD patients.\n\n4. The inclusion criteria specify enrolling stable moderate COPD patients (GOLD stage 2) requiring regular bronchodilator treatment, who have been steroid-free for the last 4 months.\n\n5. Based on the patient's presentation with an acute respiratory illness and the lack of information about his COPD severity/GOLD stage, it is unclear if he meets the inclusion criteria of being a stable, moderate COPD patient.\n\n6. Additionally, there is no mention of his current medication regimen, so it is unknown if he has been steroid-free for 4 months.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his COPD severity, medication history, and whether his current illness represents an acute exacerbation or a separate respiratory infection.",
        "label": 1
    },
    "1022": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 63-year-old man, which meets the age criteria of 40 or over with no upper age limit.\n\nHe presents with cough, shortness of breath, and productive purulent sputum, which are symptoms of an acute exacerbation of COPD according to the GOLD guideline definition provided.\n\nHis past medical history notes heavy smoking, which meets the criteria of being a former or current smoker with at least 10 pack-years of smoking history.\n\nThere is no mention of him being unable to ingest oral medication or being mentally incapable of participating in the study.\n\nHis life expectancy is not explicitly stated, but his presentation does not suggest a life expectancy of less than 30 days.\n\nBased on the information provided, this patient appears to meet all the inclusion criteria for the clinical trial on CRP-guided antibiotic treatment in COPD exacerbations admitted to the hospital.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1023": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting an acute exacerbation of COPD.\n\n2. The clinical trial is looking to evaluate predictive questionnaires and cardiovascular comorbidities as risk factors for acute COPD exacerbations.\n\n3. The inclusion criteria state:\n   - Age \u2265 40 years (the patient is 63, so meets this criteria)\n   - Fulfilling COPD criteria per GOLD guidelines stage I or higher (the patient's symptoms and history suggest COPD)\n   - Smoker or ex-smoker of \u2265 10 pack-years (the patient has a heavy smoking history, likely meeting this)\n   - Suffering an acute COPD exacerbation, either admitted to hospital or confirmed by GP (the patient's presentation suggests an acute exacerbation)\n\n4. Based on the information provided, this patient appears to meet all the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1024": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and productive sputum for about a week. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. His examination shows cyanosis, tachypnea, barrel-shaped chest, and diffuse rales over the lungs. The chest x-ray shows hyperinflation with no consolidation.\n\nThe clinical trial is studying the effect of lidocaine throat spray on chronic cough, defined as a cough lasting more than 8 weeks.\n\nThe inclusion criteria for the trial are:\n1. Male and female subjects, age 18 years and over (The patient meets this criterion as he is 63 years old)\n2. History of cough for more than 8 weeks (The patient's cough has been present for about a week, so he does not meet this criterion)\n3. Normal chest x-ray (The patient's chest x-ray shows hyperinflation, so he does not meet this criterion)\n4. Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers (It is unclear if the patient's cough is idiopathic or resistant to treatment, so this criterion cannot be definitively assessed)\n\nBased on the information provided, the patient does not meet at least two of the inclusion criteria (cough duration and normal chest x-ray). Therefore, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1025": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive sputum, which could be symptoms of COPD exacerbation. This aligns with the clinical trial's focus on COPD exacerbations.\n\n2. The patient has a history of heavy smoking, which is a risk factor for COPD and meets the inclusion criteria of \"Smokers or ex-smokers with a smoking history of more than 10 pack years.\"\n\n3. The patient's age (63 years) meets the inclusion criteria of \"40 years of age or older at Visit 1.\"\n\n4. While the patient's COPD diagnosis is not explicitly stated, the symptoms and smoking history strongly suggest the presence of COPD.\n\n5. There is no information provided about the patient's history of COPD exacerbations in the past 12 months, which is an inclusion criterion.\n\nBased on the available information, the patient appears to meet some of the key inclusion criteria, such as age and smoking history. However, the lack of information about the patient's COPD diagnosis and history of exacerbations makes it difficult to determine eligibility with certainty.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1026": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting a respiratory infection or exacerbation of an underlying lung condition.\n\n2. His past medical history includes heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis - none of which are exclusion criteria for the asthma trial.\n\n3. The clinical trial is looking at using a web-based tool (Asthma IQ) to improve asthma care and outcomes in primary care settings.\n\n4. The inclusion criteria are:\n   - Age 12-65 years (the patient is 63, so meets this)\n   - Documented clinical history of chronic persistent asthma requiring controller therapy (no clear mention of asthma diagnosis in the note)\n   - Able to complete 2-year study period\n   - Willing to forego other experimental treatments during the study\n\n5. While the patient meets the age criteria, there is no clear documentation of a chronic persistent asthma diagnosis requiring controller therapy in the note. The symptoms described could be due to an acute respiratory infection or exacerbation of COPD from heavy smoking.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether he has a documented diagnosis of chronic persistent asthma requiring controller therapy.",
        "label": 0
    },
    "1027": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive sputum. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n2. The clinical trial is studying cough responses to tussive agents (substances that induce coughing) in healthy individuals and those with respiratory diseases.\n\n3. The inclusion criteria for the trial are:\n   - Adults aged 18 years and over\n   - Meeting criteria for one of the subject groups:\n     - Healthy non-smokers\n     - Healthy smokers with \u226510 pack-year smoking history and normal spirometry\n     - Asthma patients with airway hyperresponsiveness, non-smokers or \u226410 pack-year smoking history\n     - COPD patients with \u226520 pack-year smoking history and airflow obstruction on spirometry\n     - Chronic cough patients with a dry cough for >8 weeks, normal chest X-ray, non-smokers or \u226410 pack-year smoking history\n\n4. Based on the patient's history of heavy smoking and presentation with cough and shortness of breath, he may potentially meet the criteria for the COPD group in the trial.\n\n5. However, the patient note does not provide information on spirometry results or the specific smoking history in pack-years, which are required to confirm eligibility for the COPD group.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of spirometry results and smoking history in pack-years to determine if he meets the COPD group criteria.",
        "label": 1
    },
    "1028": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum. He has a history of heavy smoking, which is a major risk factor for COPD.\n\n2. The clinical trial is studying systemic consequences and comorbidities in mild/moderate COPD patients.\n\n3. The inclusion criteria for the trial are:\n   - Age 40-80 years old (the patient is 63, so he meets this criteria)\n   - Cases: COPD diagnosis based on spirometry, smoking history of at least 10 pack-years, and active smoking until at least 10 years prior to enrollment\n   - Smoking controls: No COPD, smoking history of at least 10 pack-years, active smoking until at least 10 years prior\n   - Non-smoking controls: No COPD, less than 1 pack-year smoking history\n\n4. Based on the patient's presentation of respiratory symptoms, heavy smoking history, and lack of a confirmed COPD diagnosis, he would likely fall into the \"smoking controls\" group for this trial upon further investigation of spirometry results.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1029": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, likely due to an acute exacerbation of chronic obstructive pulmonary disease (COPD) given his history of heavy smoking.\n\n2. The clinical trial is studying COPD-related outcomes and costs for patients on combination fluticasone propionate-salmeterol xinafoate versus anticholinergics in a COPD population with comorbid depression/anxiety.\n\n3. The inclusion criteria require a diagnosis of COPD, a diagnosis of depression/anxiety with medication treatment, continuous eligibility for 1 year pre- and post-index date, and age \u2265 40 years.\n\n4. Based on the patient note, the patient meets the criteria for a COPD diagnosis and is over 40 years old.\n\n5. However, there is no mention of a diagnosis or treatment for depression/anxiety in the patient note.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether the patient has a diagnosis and treatment for depression/anxiety.",
        "label": 1
    },
    "1030": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, which matches the inclusion criteria of \"Currently smokes 10 or more pack years, meeting at least one of the following criteria: New or altered cough of any duration reported to primary care, Increased breathlessness or wheezing (with or without purulent sputum)\".\n\n2. He has no history of hemoptysis or unexplained/persistent signs or symptoms lasting more than 3 weeks, which would qualify him for an urgent referral under the NICE guidelines and exclude him from this trial.\n\n3. He has not had a chest x-ray within the past 3 months, meeting the inclusion criteria of \"No chest x-ray within in past 3 months\".\n\n4. There is no indication that he needs a chest x-ray in the next 3 weeks for reasons other than the symptoms listed, meeting the inclusion criteria of \"No need for a chest x-ray within the next 3 weeks for reasons other than those listed under Disease Characteristics\".\n\nBased on the information provided, this patient appears to meet all the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1031": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and a history of heavy smoking - consistent with chronic obstructive pulmonary disease (COPD). \n\nThe trial is studying the efficacy of the PPSV23 pneumococcal vaccine in severe COPD patients using high daily doses of inhaled corticosteroids.\n\nThe inclusion criteria are:\n1) No previous PPSV23 vaccination (unknown from note)\n2) Severe COPD defined by FEV1/FVC < 70%, FEV1 reversibility < 200ml, FEV1 < 50% predicted (spirometry results not provided)\n3) Current or past smoking exposure (patient has heavy smoking history)\n4) No exacerbation in prior month (unclear from note)\n5) Age < 65 years (patient is 63, meets criteria)\n6) Using high daily inhaled corticosteroid dose (not mentioned in note)\n7) Provide informed consent (assumed if enrolled)\n\nBased on the available information, the patient meets some of the key criteria like age and smoking history, but there are uncertainties around COPD severity, recent exacerbations, and inhaled steroid use.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1032": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, which are symptoms of a COPD exacerbation. His past medical history includes heavy smoking, which is a major risk factor for COPD.\n\nThe inclusion criteria for the clinical trial are:\n1) Minimum age 40 years (the patient is 63, so he meets this criteria)\n2) Diagnosis of COPD (based on symptoms and smoking history, he likely has COPD)\n3) At least one moderate exacerbation event (his current presentation seems to be a moderate exacerbation)\n\nThe exclusion criteria are:\n1) Comorbidities like respiratory cancers, cystic fibrosis, etc. (none mentioned, so assume he doesn't have these)\n2) Not receiving COPD treatment during the assessment period (unclear if he is already on treatment)\n3) Already on maintenance COPD medications prior to the exacerbation (unknown)\n4) Treatment switch, discontinuation or another exacerbation during assessment period (unknown)\n\nBased on the information provided, the patient seems to potentially meet the key inclusion criteria of being over 40 with a COPD diagnosis and a moderate exacerbation. However, there are some uncertainties around his current/prior COPD treatment that would need clarification.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1033": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man, so he does not meet the age criteria of 1 month to 16 years for this pediatric clinical trial.\n\n2. The trial is focused on diagnosing serious infections like meningitis, sepsis, pneumonia, etc. in children. While the patient does have respiratory symptoms like cough, shortness of breath, and rales on exam, the note does not mention any specific infectious diagnosis.\n\n3. The trial requires an acute illness episode of maximum 5 days duration. The note states the patient's symptoms began about a week prior to admission, so this would likely exceed the 5 day cutoff.\n\n4. Overall, based on the patient's age, lack of confirmed serious infection diagnosis, and duration of illness, he does not appear to meet the key inclusion criteria for this pediatric infectious disease trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1034": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, requiring home oxygen for the past 24 hours. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n2. The clinical trial is studying the timing of initiating maintenance treatment with controller medications after a COPD exacerbation and its impact on future exacerbations and costs.\n\n3. The inclusion criteria for the trial are:\n   - At least 40 years of age (the patient is 63, so meets this criteria)\n   - Continuously enrolled for medical and pharmacy benefits during pre- and post-period (no information given)\n   - Diagnosis of COPD (the patient has symptoms suggestive of COPD exacerbation and a history of heavy smoking, so likely meets this criteria)\n\nBased on the available information, the patient seems to meet the key inclusion criteria of age and COPD diagnosis. However, there is no information provided about his enrollment status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into his enrollment status.",
        "label": 1
    },
    "1035": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting an acute exacerbation of chronic obstructive pulmonary disease (COPD).\n\n2. The clinical trial is studying endothelial dysfunction in acute exacerbations of COPD.\n\n3. The inclusion criteria for the trial are:\n   - Presence of COPD according to standard criteria\n   - Acute exacerbation of COPD according to recommended international criteria\n   - Over 40 years of age\n   - History of at least 10 pack-years of smoking\n\n4. Based on the patient note, the patient meets the following inclusion criteria:\n   - He likely has COPD given his history of heavy smoking and symptoms\n   - He is presenting with an acute exacerbation of COPD\n   - He is 63 years old, which meets the age criteria\n   - Although his smoking history is not explicitly stated, his history of heavy smoking suggests he likely meets the 10 pack-year criteria\n\n5. Therefore, this patient appears to meet all the stated inclusion criteria for the clinical trial studying endothelial dysfunction in acute COPD exacerbations.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1036": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive cough with purulent sputum. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n2. The clinical trial is for acute chest syndrome in patients with sickle cell disease. The inclusion criteria specifically mention patients with hemoglobin SS, SC, SB0thal, or SBthal sickle cell disease.\n\n3. There is no mention of the patient having sickle cell disease in the note. The symptoms seem more consistent with an acute exacerbation of chronic obstructive pulmonary disease (COPD) given his heavy smoking history.\n\n4. Based on the information provided, this patient would not be eligible for the acute chest syndrome clinical trial as he does not have sickle cell disease.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1037": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man, which falls outside the age range specified in the inclusion criteria (18-30 years or 55-92 years).\n\n2. The patient has a history of heavy smoking, which is not allowed per the inclusion criteria (\"Must not currently be a cigarette smoker. If an ex-smoker then has not smoked for at least 10 years and consumption were no more than 10 pack years\").\n\n3. The patient has several comorbidities (spinal stenosis, diabetes, hypothyroidism, mild psoriasis), which may exclude him from the trial based on the requirement of \"Responses to the questionnaire deny current and prior respiratory diseases... and no current respiratory complaints\".\n\n4. The patient's presenting symptoms (cough, shortness of breath, purulent sputum) and physical examination findings (cyanosis, tachypnea, rales) suggest an active respiratory condition, which would likely exclude him based on the criteria mentioned in point 3.\n\n5. There is no information provided about the patient's spirometry, impedance oscillometry, exhaled nitric oxide levels, or other screening tests required by the inclusion criteria.\n\nBased on the information provided, it is highly unlikely that this patient would be eligible for the specified clinical trial due to his age, smoking history, comorbidities, and active respiratory symptoms/condition.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1038": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man, so he meets the age criteria of being 8 years or older.\n\n2. There is no mention of the patient having cystic fibrosis in the note, which is one of the key inclusion criteria. \n\n3. The note mentions the patient having a cough, shortness of breath, and productive sputum, which could potentially indicate a pulmonary exacerbation. However, without a diagnosis of cystic fibrosis, it's unclear if this would meet the criteria of a \"pulmonary exacerbation as defined by Fuchs et al.\"\n\n4. There is no mention of the patient having a Pseudomonas aeruginosa infection, which is another key inclusion criteria.\n\nBased on the information provided in the patient note, it does not appear that this patient would meet the inclusion criteria for this specific clinical trial on continuous infusion piperacillin-tazobactam for cystic fibrosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1039": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and a history of heavy smoking, which aligns with the inclusion criteria of being between 40-85 years old and having a confirmed diagnosis of COPD with a smoking history of at least 10 pack-years.\n\n2. The patient's symptoms and chest x-ray findings suggest an exacerbation of COPD, but the inclusion criteria state that patients with recent exacerbations can be enrolled one month post-exacerbation if they are in stable condition.\n\n3. The patient's lung function is not explicitly stated, but the inclusion criteria require an FEV1 of >80% (mild COPD) or >50% but \u226480% (moderate COPD) of predicted normal and FEV1/FVC<0.7.\n\n4. Based on the information provided, it is unclear if the patient meets all the inclusion criteria, particularly regarding lung function and stability after the recent exacerbation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their lung function and stability after the recent exacerbation.",
        "label": 1
    },
    "1040": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, which matches the inclusion criteria of \"presence of purulent sputum documented by colorimetric assay, plus at least two of the following signs-symptoms: increased cough, increased dyspnea, increase in sputum volume appeared at least 3 days\".\n\nHe is over 60 years old, which meets the age criteria of \u226560 years.\n\nHis chest x-ray is notable for hyperinflation with no consolidation, which likely means it is negative for inflammatory infiltrates, meeting that inclusion criteria.\n\nHowever, there is no information provided about his FEV1 or FEV1/FVC ratio to determine if he meets the criteria of \"FEV1 <80% and \u226530% and ratio FEV1/FVC <70%\".\n\nBased on the information given, he potentially meets most of the key inclusion criteria, but the lack of pulmonary function test results makes his eligibility uncertain.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his pulmonary function tests.",
        "label": 1
    },
    "1041": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\n1. The patient is a 63-year-old man, meeting the age criteria of \u2265 40 years old.\n\n2. He has a history of heavy smoking, meeting the smoking history criteria of \u2265 10 pack-years.\n\n3. He presented to the hospital with cough, shortness of breath, and requiring home oxygen, which aligns with the criteria of \"Presentation to the emergency room with increased dyspnea, increased sputum, or increased cough.\"\n\n4. The note mentions he was admitted to the hospital.\n\n5. While a COPD diagnosis is not explicitly stated, his symptoms of cough, shortness of breath, and smoking history strongly suggest COPD, meeting the criteria of \"Patients with a diagnosis of COPD, emphysema, or chronic bronchitis.\"\n\nBased on the patient meeting all the listed inclusion criteria for the \"Dose of Corticosteroids in COPD\" clinical trial, he appears highly eligible.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1042": {
        "output": "To determine the patient's eligibility for the clinical trial \"Corticosteroids and Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n- Diabetic patients with COPD exacerbation\n\nFrom the patient note, we know that the patient:\n- Is a 63-year-old man\n- Has a history of heavy smoking (likely contributing to COPD)\n- Has diabetes\n- Presents with cough, shortness of breath, and purulent sputum (suggesting a COPD exacerbation)\n\nSince the patient has both diabetes and is experiencing a COPD exacerbation, they meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1043": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 63-year-old man, which meets the age criteria of \u226518 years old for the clinical trial.\n\nThe patient has symptoms of cough, shortness of breath, and purulent sputum, which are consistent with an acute exacerbation of bronchiectasis, the condition being studied in the trial.\n\nThe patient's past medical history notes spinal stenosis, diabetes, hypothyroidism, and mild psoriasis, but does not explicitly mention a diagnosis of bronchiectasis confirmed by HRCT scan.\n\nThe inclusion criteria require an HRCT-diagnosed bronchiectasis, which is not clearly stated in the patient note.\n\nWhile the patient's symptoms are suggestive of bronchiectasis exacerbation, without a confirmed diagnosis by HRCT scan, it is uncertain if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to confirm the diagnosis of bronchiectasis by HRCT scan.",
        "label": 0
    },
    "1044": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n2. The clinical trial is looking for patients with cystic fibrosis who have chronic Pseudomonas aeruginosa infection, can produce daily sputum samples, and have had at least 2 pulmonary exacerbations in the past year.\n\n3. Based on the patient note, there is no mention of the patient having cystic fibrosis or a Pseudomonas aeruginosa infection. His symptoms seem more consistent with an acute exacerbation of COPD or pneumonia given his smoking history.\n\n4. Therefore, this patient would not meet the inclusion criteria for this particular cystic fibrosis clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1045": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, which could indicate an acute exacerbation of COPD.\n\n2. The clinical trial is studying whether antibiotics are needed for moderate acute exacerbations of COPD.\n\n3. The inclusion criteria include:\n   - Age \u2265 40 years (the patient is 63, so he meets this)\n   - Diagnosed with COPD stages I-IV\n   - Acute (onset < 7 days) moderate exacerbation of COPD\n   - Absence of community-acquired pneumonia or lower respiratory tract infection requiring antibiotics (based on procalcitonin level and chest X-ray)\n   - Smoking history of \u2265 10 pack-years\n   - Able to complete diaries and questionnaires\n\n4. Based on the information provided, the patient seems to meet most of the key inclusion criteria, including age, COPD diagnosis, acute moderate exacerbation, and smoking history.\n\n5. However, it is unclear if the patient meets the criteria for absence of community-acquired pneumonia or lower respiratory tract infection requiring antibiotics, as the procalcitonin level and chest X-ray findings are not provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the procalcitonin level and chest X-ray findings to rule out community-acquired pneumonia or lower respiratory tract infection requiring antibiotics.",
        "label": 1
    },
    "1046": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man, so he meets the age criteria of being an adult (>18 years old).\n\n2. He presents with cough, shortness of breath, and findings on chest x-ray consistent with an acute exacerbation of chronic obstructive pulmonary disease (COPD). This matches the inclusion criteria of having confirmed/suspected COPD and being hospitalized with a COPD exacerbation.\n\n3. There is no information provided about whether informed consent was obtained.\n\n4. The note does not specify if he was admitted on a weekday or weekend.\n\nOverall, based on the information provided, the patient appears to meet at least two of the key inclusion criteria (age, COPD exacerbation requiring hospitalization). However, there are two criteria that cannot be definitively assessed from the note - whether informed consent was obtained and if admission occurred on a weekday.\n\nGiven this uncertainty, I would rate this patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1047": {
        "output": "Based on the provided patient note and the clinical trial information, here is my assessment of the patient's eligibility for the trial:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and respiratory distress symptoms. The clinical trial is focused on diagnosing pneumonia in children under 5 years old in low-resource settings.\n\nSince the patient is an adult and does not meet the age criteria (under 5 years old) specified in the inclusion criteria, he would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1048": {
        "output": "To determine the patient's eligibility for the clinical trial \"Endothelial Dysfunction and Chronic Obstructive Pulmonary Disease\", let's go through the inclusion criteria one by one:\n\n1. COPD patients in stable condition (without exacerbation min 1 months ago)\n- The patient is presenting with an acute exacerbation of COPD symptoms, so this criterion is not met.\n\n2. Over 40 years\n- The patient is 63 years old, so this criterion is met.\n\n3. History of at least 10 pack-years of smoking\n- The patient has a history of heavy smoking, which likely meets the 10 pack-year criterion, but it's not explicitly stated.\n\nOverall, while the patient meets the age criterion and likely meets the smoking history criterion, the fact that they are currently experiencing an acute COPD exacerbation excludes them from this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1049": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, requiring home oxygen for the past 24 hours. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. His examination shows cyanosis, tachypnea, barrel-shaped chest, and diffuse rales over the lungs. Chest x-ray shows hyperinflation with no consolidation.\n\nThe clinical trial is for early treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) with a combination therapy of Salmeterol + Fluticasone Propionate (Advair) to reduce the use of prednisone.\n\nLooking at the inclusion criteria:\n1. Diagnosis of stable COPD - The patient likely has COPD based on his history of heavy smoking, symptoms, and exam findings, but it is not explicitly stated as a diagnosis.\n2. Age \u2265 40 years - The patient is 63 years old, meeting this criterion.\n3. Smoking history of \u2265 10 pack-years - The patient has a history of heavy smoking, likely meeting this criterion.\n4. FEV1 \u2264 70% predicted and FEV1/FVC < 0.70 - No spirometry results are provided.\n5. Dyspnea \u2265 2 on MRC scale - The patient has shortness of breath requiring home oxygen, suggesting at least moderate dyspnea.\n6. \u2265 2 exacerbations requiring prednisone in the past 3 years - No information is provided about prior exacerbations or prednisone use.\n7. Using a written action plan and demonstrated adequate use of self-administered antibiotic & prednisone - No information is provided about the patient's use of an action plan or self-administration of medications.\n8. Already on Advair BID or able to switch from another combination therapy - No information is provided about the patient's current medications.\n\nBased on the information provided, there are several inclusion criteria that cannot be definitively assessed, such as the spirometry results, prior exacerbation history, use of an action plan, and current medications.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1050": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, requiring home oxygen for the past 24 hours. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis.\n\n2. The clinical trial is studying the acute effect of aclidinium, an anticholinergic medication, on hyperinflation and ventilation inhomogeneity in severe COPD patients.\n\n3. The inclusion criteria for the trial are:\n   - Age 50-85 years old\n   - COPD diagnosis for at least 1 year\n   - Clinically stable in the last 3 months\n   - FEV1 < 50% predicted\n   - RV > 125% predicted\n   - FEV1/FVC < 88% (males) or 89% (females) of LLN\n   - Former or active smoker with \u2265 20 pack-year history\n\n4. Based on the information provided, this 63-year-old patient with a heavy smoking history and symptoms suggestive of an acute COPD exacerbation would likely meet several of the inclusion criteria, such as age, COPD diagnosis, smoking history, and potentially the spirometry criteria (though these values are not provided).\n\n5. However, the patient's clinical status is described as an acute exacerbation requiring home oxygen, which may exclude him from meeting the \"clinically stable in the last 3 months\" criterion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his spirometry values and clinical stability over the past 3 months.",
        "label": 1
    },
    "1051": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man with a history of heavy smoking, which is a risk factor for COPD.\n2. He presents with cough, shortness of breath, and purulent sputum, which are symptoms of COPD exacerbation.\n3. The chest x-ray findings of hyperinflation without consolidation are consistent with COPD.\n\n4. The clinical trial is studying the effects of inhaled corticosteroids on systemic inflammation in COPD patients.\n5. One of the inclusion criteria is \"ex-smokers (> 10 packets-year) with moderate-severe COPD patients\".\n6. Based on the patient's history of heavy smoking and current COPD exacerbation symptoms, he likely meets this inclusion criteria.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1052": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, which are symptoms of an acute exacerbation of chronic obstructive pulmonary disease (COPD). His past medical history includes heavy smoking, which is a major risk factor for COPD.\n\nThe inclusion criteria for the clinical trial are:\n1) Hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease\n2) Age \u2265 40 years old\n\nThis patient meets both of those criteria, as he is hospitalized with an acute COPD exacerbation and is 63 years old.\n\nTherefore, based on the information provided, this patient would be eligible for the clinical trial studying treatment for acute COPD exacerbations in hospitalized patients.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1053": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting a respiratory condition like COPD.\n\n2. The clinical trial is investigating molecular, cytological, and genetic features of occupational COPD in different environmental exposures (silica dust, polycyclic aromatic hydrocarbons, and smoking).\n\n3. One of the key inclusion criteria is a post-bronchodilator FEV1/FVC ratio less than 0.7, which is indicative of COPD. The patient's spirometry results are not provided, so we cannot confirm if he meets this criterion.\n\n4. Another inclusion criterion is a history of exposure to respirable silica dust, polycyclic aromatic hydrocarbons exhaust, or tobacco smoking for at least 12 months. The patient note mentions a history of heavy smoking, which would likely meet this criterion.\n\n5. The trial also requires male participants of Caucasian ethnicity between 40-75 years old. The patient is a 63-year-old man, so he meets the age and gender criteria, but his ethnicity is not specified.\n\n6. Based on the information provided, we cannot definitively determine if the patient meets all the inclusion criteria, as we lack details on his spirometry results and ethnicity.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his spirometry results and ethnicity.",
        "label": 1
    },
    "1054": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting a respiratory infection.\n\n2. He has a history of COPD (chronic obstructive pulmonary disease) risk factors like heavy smoking.\n\n3. The clinical trial is looking at using low-dose CT scans to diagnose pneumonia in COPD exacerbations and compare inflammatory profiles between patients with and without pneumonia.\n\n4. The inclusion criteria require a clinical and spirometric diagnosis of COPD, symptoms of an exacerbation and lower airway infection.\n\n5. This patient meets those key inclusion criteria - he has COPD based on his history, is experiencing an exacerbation with respiratory infection symptoms.\n\n6. None of the exclusion criteria seem to apply to him based on the provided note.\n\nSo in summary, this patient appears to be a good potential candidate for this clinical trial investigating pneumonia diagnosis in COPD exacerbations.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1055": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Adults aged 18 to 85, inclusive: The patient is 63 years old, so he meets this criterion.\n\n2. Has given written, informed consent: This is not mentioned in the patient note, so we cannot assess this criterion.\n\n3. Has acute illness with onset within previous 7 days: The patient's symptoms began about a week prior to admission, so he meets this criterion.\n\n4. Has at least 2 of the following symptoms: difficulty breathing or shortness of breath, cough, production of purulent sputum, pleuritic chest pain. The patient has cough, shortness of breath, and productive cough with purulent sputum, so he meets this criterion.\n\n5. Has at least 2 vital sign abnormalities: fever, hypotension, tachycardia, tachypnea. The patient is tachypneic, so he meets this criterion.\n\n6. Has at least one other clinical or laboratory abnormality: hypoxemia, clinical evidence of pulmonary consolidation, elevated WBC count or neutropenia, new lobar or multi-lobar infiltrates on chest radiograph. The patient has hypoxemia (requiring home oxygen) and hyperinflation on chest x-ray, so he meets this criterion.\n\n7. Has CURB-65 risk category 1 to 4: This is not mentioned in the patient note, so we cannot fully assess this criterion.\n\nOverall, the patient meets most of the key inclusion criteria based on the information provided. However, there are a couple of criteria (written informed consent and CURB-65 risk category) that cannot be assessed from the patient note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1056": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Male and female: The patient is a 63-year-old man, so he meets this criterion.\n\n2. COPD with an FEV1 of under 60% of predicted: The patient note does not mention the FEV1 value or explicitly state that the patient has COPD. However, it does mention that the patient has a history of heavy smoking, cough, shortness of breath, and findings on chest x-ray consistent with COPD (hyperinflation with no consolidation). So, while not definitively stated, it is highly suggestive that the patient has COPD.\n\n3. Non-smoker: The patient note states that the patient has a history of heavy smoking, so he does not meet this criterion.\n\n4. Between 50 and 75 years old: The patient is 63 years old, so he meets this criterion.\n\n5. Experiencing an acute exacerbation of COPD (24-48 hours, before treatment): The patient note mentions that the patient's symptoms (cough, shortness of breath, requiring home oxygen) began about a week prior to admission, suggesting an acute exacerbation of COPD. However, it is not clear if the patient has received any treatment yet.\n\nOverall, while the patient meets some of the inclusion criteria, there are a few uncertainties, such as the FEV1 value and whether the patient has received treatment for the acute exacerbation. Therefore, further investigation may be needed to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1057": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting a respiratory condition like COPD.\n\n2. The clinical trial is investigating molecular, cytological, and genetic features of occupational COPD in different environmental exposures like silica dust and polycyclic aromatic hydrocarbons.\n\n3. The inclusion criteria require:\n   - Post-bronchodilator FEV1/FVC ratio < 0.7 (indicating COPD)\n   - Stable phase of COPD\n   - History of exposure to silica dust, aromatic hydrocarbons, or tobacco smoke for \u2265 12 months\n   - Male\n   - Caucasian\n   - Age 40-75 years\n\n4. From the patient note, we know the patient is:\n   - A 63-year-old man (meets age and gender criteria)\n   - Has a history of heavy smoking (meets exposure criteria)\n   - Presenting with respiratory symptoms suggestive of COPD\n\n5. However, the patient note does not provide information on:\n   - Post-bronchodilator FEV1/FVC ratio\n   - Stable phase of COPD\n   - Ethnicity\n\nTherefore, based on the available information, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of his post-bronchodilator FEV1/FVC ratio, COPD stability, and ethnicity.",
        "label": 1
    },
    "1058": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one and assess the patient's eligibility:\n\n1. COPD diagnosis and severity: The patient note mentions that the patient has a history of heavy smoking, which is a risk factor for COPD. However, there is no explicit mention of a COPD diagnosis or lung function test results showing airflow obstruction. This criterion is unclear based on the information provided.\n\n2. Exacerbation History: There is no mention of the patient having a history of COPD exacerbations in the past 12 months requiring antibiotics, steroids, or hospitalization.\n\n3. Existing COPD maintenance treatment: The patient note does not mention if the patient is on any maintenance COPD medications.\n\n4. Tobacco use: The patient has a history of heavy smoking, which meets this inclusion criterion.\n\n5. Sex and age: The patient is a 63-year-old man, which meets this inclusion criterion.\n\n6. Capable of giving written informed consent: This is not mentioned in the patient note, but it is generally assumed that patients can provide informed consent unless stated otherwise.\n\n7. ECG QTc interval: There is no information provided about the patient's ECG or QTc interval.\n\nBased on the information provided in the patient note, there are several inclusion criteria that are unclear or not met. While the patient has a history of smoking, there is no clear COPD diagnosis, exacerbation history, or information about maintenance treatment or ECG findings.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information would be needed to fully assess the patient's eligibility, such as lung function test results, exacerbation history, current medications, and ECG findings. If these additional criteria were met, the patient could potentially be eligible for the trial.",
        "label": 1
    },
    "1059": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and a history of heavy smoking. This matches the inclusion criteria of having COPD or a smoking history.\n\n2. However, the inclusion criteria also mention including patients with lung diseases unrelated to smoking, such as bronchial asthma. The patient note does not mention if the patient has asthma or any other lung disease unrelated to smoking.\n\n3. The trial is looking at the prevalence of head and neck cancers in patients with COPD or other lung diseases. The patient note does not mention any head or neck cancers.\n\n4. Overall, while the patient fits some of the inclusion criteria with COPD/smoking history, there is not enough information to definitively determine eligibility without further investigation into potential asthma or other lung diseases unrelated to smoking.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1060": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting an acute exacerbation of COPD.\n\n2. The inclusion criteria for the clinical trial include:\n   - Age \u226540 years (the patient is 63, so meets this criteria)\n   - History of \u226510 pack-years of smoking (the patient has a history of heavy smoking, so likely meets this criteria)\n   - Airway obstruction with FEV1/FVC\u226470% (not mentioned in the note, so cannot confirm)\n   - Current acute exacerbation of COPD defined by at least two of: change in baseline dyspnea, change in cough, change in sputum quantity or purulence (the patient meets at least two of these criteria with cough and purulent sputum)\n\n3. Based on the information provided, the patient seems to meet most of the key inclusion criteria for the clinical trial on reducing corticosteroid use in outpatient treatment of exacerbated COPD.\n\n4. However, there is one crucial piece of information missing - the spirometry results to confirm airway obstruction with FEV1/FVC\u226470%.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of spirometry results to confirm airway obstruction.",
        "label": 1
    },
    "1061": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive sputum. He has a history of heavy smoking, which is relevant to the clinical trial.\n\n2. The clinical trial is looking for healthy smokers, COPD smokers, and COPD ex-smokers to analyze biomarkers of inflammation in sputum samples.\n\n3. Based on the inclusion criteria for COPD smokers:\n   - The patient is within the age range (40-75 years)\n   - He has a diagnosis of COPD based on the spirometry criteria (FEV1/FVC <0.7 and FEV1 40-80% predicted)\n   - He has a smoking history of at least 5 pack-years\n\n4. The patient meets the key inclusion criteria for COPD smokers in this trial.\n\n5. However, there are some potential exclusion criteria that need further investigation:\n   - It's unclear if he has had a recent respiratory tract infection (excluded within 4 weeks)\n   - His ability to produce at least 0.1g of sputum needs to be confirmed\n   - Any other reasons that may make him unsuitable (e.g., comorbidities, medications) need to be evaluated\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1062": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum. He has a history of heavy smoking, spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. His examination findings are consistent with COPD exacerbation.\n\nThe clinical trial titled \"MISSION COPD - Modern Innovative SolutionS in Improving Outcomes iN COPD\" is evaluating a new model of delivering specialized COPD care.\n\nThe inclusion criteria for patients are:\n1) Male or female, aged 18 years or above\n2) Attended the MISSION clinic as a patient\n3) Willing and able to give informed consent\n\nThis patient meets criteria 1 as he is a 63-year-old man. However, there is no information provided about whether he has attended the MISSION clinic previously. His ability to provide informed consent is also not mentioned.\n\nBased on the limited information provided, I would consider referring this patient to the clinical trial upon further investigation about his prior attendance at the MISSION clinic and ability to consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1063": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nHistory of and/or documented fever (rectal, ear, or oral temperature \u226538\u00b0C or axillary temperature \u226537.5\u00b0C) or hypothermia (rectal, ear, or oral temperature <35\u00b0C or axillary temperature <34.5\u00b0C)\n- The patient note does not mention fever or hypothermia, so this criterion is not met.\n\nChest radiograph infiltrates consistent with bacterial pneumonia (or pneumonia caused by atypical bacterial agents); if a subject is outpatient and starting on oral therapy, a radiograph is not required.\n- The chest x-ray shows hyperinflation but no consolidation, so this criterion is not clearly met.\n\nPresence of at least 2 of the following signs or symptoms:\nCough - Yes, the patient has cough\nDifficulty breathing - Yes, the patient has shortness of breath\nProduction of purulent sputum - Yes, the patient has purulent sputum\nChest pain - Not mentioned\nGrunting - Not mentioned \nHypotension - Not mentioned\nTachycardia - Not mentioned\nTachypnea - The patient is tachypneic\nPhysical exam consistent with pulmonary consolidation - No consolidation on chest x-ray\n\nSo the patient meets 3 of the symptom criteria.\n\nPresence of at least 1 of the following:\nLeukocytosis (\u226512,000 white blood cells [WBC]/mm3) - Not mentioned\nLeukopenia (<5000 WBC/mm3) - Not mentioned\n\u226510% immature neutrophils (bands) regardless of total peripheral WBC - Not mentioned\nElevated inflammatory markers (C-reactive protein or procalcitonin) - Not mentioned\nOxygen saturation <97% on room air - The patient is cyanotic, suggesting low oxygen saturation\nOrganism consistent with a typical respiratory pathogen identified - Not mentioned\n\nSo the patient likely meets the oxygen saturation criterion.\n\nOverall, while the patient has some symptoms consistent with community-acquired bacterial pneumonia, some key criteria like fever, chest x-ray findings, and lab abnormalities are not clearly met based on the information provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1064": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 63-year-old man presenting with cough, shortness of breath, and productive purulent sputum, suggesting a respiratory infection or exacerbation of underlying lung disease.\n\n2. His past medical history includes heavy smoking (a risk factor for COPD), spinal stenosis, diabetes, hypothyroidism, and mild psoriasis. No mention of a confirmed COPD diagnosis.\n\n3. The clinical trial is studying the effect of advanced dental cleaning on reducing exacerbations in COPD patients.\n\n4. The key inclusion criteria is \"COPD Gold standard 1-4\", meaning the patient must have a confirmed diagnosis of COPD at stages 1-4 based on spirometry.\n\n5. While the patient note mentions symptoms suggestive of a respiratory issue potentially related to COPD given his smoking history, there is no definitive statement that he has a confirmed COPD diagnosis meeting the GOLD criteria 1-4.\n\nBased on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther evaluation, such as spirometry testing to confirm a COPD diagnosis and staging, would be needed to determine if the patient meets the key inclusion criteria for this trial. Without a confirmed COPD diagnosis, the patient would not be eligible at this point, but further investigation is warranted given his symptoms and risk factors.",
        "label": 1
    },
    "1065": {
        "output": "Let's go through the inclusion criteria for this clinical trial:\n\n1. Male or Female \u2265 18 years of age: The patient is a 63-year-old man, so he meets this criterion.\n\n2. Patient has a clinically definite relapsing form of Multiple Sclerosis according to McDonald Criteria (2010 revision): The patient note does not mention multiple sclerosis or any relapsing form of the disease. This criterion is not met.\n\n3. Patient with an acute MS exacerbation as determined by their treating clinician: Since the patient does not have multiple sclerosis, this criterion is not applicable.\n\n4. Patient planning to initiate Acthar Gel for the treatment of an acute MS exacerbation: The patient note does not mention any plans to initiate Acthar Gel treatment.\n\n5. Patient capable of providing informed consent: There is no information provided about the patient's ability to provide informed consent.\n\nBased on the information provided in the patient note, the patient does not meet the key inclusion criteria of having a relapsing form of multiple sclerosis and an acute MS exacerbation. Therefore, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1066": {
        "output": "Analyzing the patient note and the clinical trial details:\n\nThe patient is a 33-year-old male athlete who suffered blunt trauma to the abdomen and has a ruptured spleen causing intraperitoneal hemorrhage.\n\nThe clinical trial is focused on evaluating the spleen during peripheral blood progenitor cell (PBPC) mobilization by filgrastim in normal donors.\n\nThe inclusion criteria require the participant to be eligible as a PBPC donor for allogeneic transplantation as determined by the local institution.\n\nThe exclusion criteria specifically exclude patients with a history of splenectomy, previous PBPC mobilization attempts, and previous treatment with GCSF or GMCSF.\n\nGiven that the patient has a ruptured spleen, which would likely require a splenectomy, they would not meet the inclusion criteria and would be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1067": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which falls within the age range of 18-85 specified in the inclusion criteria.\n\n2. The patient does not have a confirmed pulmonary embolism (PE). The clinical presentation is of abdominal pain and intraperitoneal hemorrhage due to a splenic rupture after blunt trauma, which is not relevant to the trial studying treatment for PE.\n\n3. There is no mention of the patient's blood pressure, but the low BP of 60/30 mmHg would exclude the patient as the criteria specifies normal blood pressure (SBP >100mmHg).\n\n4. There is no information provided about right ventricular dysfunction on echocardiography, which is an inclusion criteria.\n\nBased on the information provided, this patient does not meet the key inclusion criteria for the pulmonary embolism clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1068": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier. His vital signs show hypotension (BP 60/30 mmHg) and tachycardia (HR 140/min). Physical exam revealed abdominal muscle guarding and imaging showed intraperitoneal hemorrhage due to splenic rupture.\n\nThe clinical trial is evaluating the value of routine thoraco-abdominal CT in blunt trauma patients.\n\nLooking at the inclusion criteria:\n1) The patient does not have life-threatening vital problems based on the information given.\n2) The revised trauma score is not provided, so cannot assess this criteria.\n3) No signs of fractures from at least two long bones.\n4) No clinical signs of flail chest/multiple rib fractures.\n5) No clinically evident pelvic rim fracture.\n6) No signs of unstable vertebral fractures or neural cord compression.\n7) The mechanism of injury (fall off bike) could potentially be considered a high-energy injury.\n8) The fall height is not specified, so cannot definitively assess this criteria.\n\nOverall, while the patient suffered blunt abdominal trauma resulting in splenic rupture, the only definitive inclusion criteria met is potentially a high-energy mechanism. More information may be needed to fully assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1069": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which meets the age criteria (>18 years) for the clinical trial.\n\n2. The patient's condition is acute abdominal pain and spleen rupture due to blunt trauma, which is not related to immune thrombocytopenic purpura (ITP), the target disease of the clinical trial.\n\n3. The patient does not have a history of ITP or thrombocytopenia mentioned in the note.\n\n4. The inclusion criteria specifically require patients with ITP and a platelet count <30 x 109/l after 2 weeks of treatment with prednisolone or during prednisolone tapering period.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient does not appear to be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1070": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which does not meet the age criteria of 0-15 years old for this pediatric trauma trial.\n\n2. The patient is not asymptomatic, as they presented to the ER with acute abdominal pain and signs of internal bleeding from a spleen rupture after blunt trauma a week prior.\n\n3. The trial is specifically looking at the role of total body imaging in asymptomatic pediatric trauma patients, which this patient does not qualify for.\n\nTherefore, based on the patient note and inclusion criteria provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1071": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which fits the \"Adult\" criteria from the inclusion criteria.\n2. However, the inclusion criteria also specifies \"ASA 1-2\". ASA stands for American Society of Anesthesiologists physical status classification system. Based on the patient's presentation of acute abdominal pain, hypotension (BP 60/30 mmHg), tachycardia (HR 140/min), pallor, and splenic rupture with intraperitoneal hemorrhage, this patient would likely be classified as ASA 3 or higher, indicating severe systemic disease.\n3. Since the patient does not meet the ASA 1-2 criteria, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1072": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which does not meet the age criteria of 50 years or older for recently diagnosed diabetes, or 35 years or older for familial pancreatic cancer, Peutz-Jeghers syndrome, or suspicious clinical symptoms.\n\n2. The patient's presentation is related to abdominal trauma and splenic rupture, which is not relevant to the clinical trial's focus on pancreatic adenocarcinoma screening.\n\n3. There is no mention of the patient having diabetes, a family history of pancreatic cancer, Peutz-Jeghers syndrome, or suspicious symptoms of pancreatic cancer.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial titled \"Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1073": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a bike fall a week earlier. Imaging revealed intraperitoneal hemorrhage due to spleen rupture.\n\nThe clinical trial is titled \"Functional Outcome After Incisional Hernia Repair: Open Versus Laparoscopic Repair\" and is studying outcomes after open vs laparoscopic repair of incisional hernias.\n\nThe key inclusion criteria are:\n1) Male patient aged over 18 years (the patient is 33 years old, so meets this)\n2) Diagnosis of reducible incisional hernias up to 200 cm\u00b2 (the patient does not have an incisional hernia, he has a spleen rupture)\n\nSince the patient does not meet the key inclusion criteria of having an incisional hernia, he would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1074": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which meets the age criteria of being at least 18 years old.\n\n2. The patient has suffered a spleen rupture due to blunt trauma, which has led to intraperitoneal hemorrhage. This meets the inclusion criteria of having peritoneal metastases (although it is not from a malignancy).\n\n3. The patient has not received any previous chemotherapy or radiation therapy, which meets the inclusion criteria.\n\n4. The patient's performance status is not mentioned, but given that he is an athlete, it is likely that his Karnofsky performance score is \u2265 80%.\n\n5. The patient's hematologic, renal, and hepatic function are not mentioned, but given his age and athletic status, it is reasonable to assume that they are within the acceptable ranges.\n\n6. The patient does not have any metastatic disease outside the peritoneal cavity, which meets the exclusion criteria.\n\n7. The patient does not have a diagnosis of mesothelioma, which meets the exclusion criteria.\n\n8. The patient's neuropathy status is not mentioned, but given his age and athletic status, it is reasonable to assume that he does not have grade 2 or higher sensory neuropathy.\n\n9. The patient does not have a history of allergic reaction to platinum compounds, which meets the exclusion criteria.\n\n10. The patient's pregnancy and lactation status are not mentioned, but given his gender, these exclusion criteria are not applicable.\n\n11. The patient has not received previous peritoneal chemotherapy, which meets the exclusion criteria.\n\n12. The patient's concurrent medical problems and cardiovascular disease history are not mentioned, but given his age and athletic status, it is reasonable to assume that he does not have uncontrolled concurrent medical problems or a recent history of uncontrolled cardiovascular disease.\n\n13. The patient's psychiatric or addictive disorders are not mentioned, but given his age and athletic status, it is reasonable to assume that he does not have psychiatric or addictive disorders that would preclude obtaining informed consent.\n\nBased on the information provided, the patient appears to meet most of the inclusion criteria and does not seem to violate any of the exclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1075": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier. Imaging revealed intraperitoneal hemorrhage due to spleen rupture.\n\nThe clinical trial is studying the efficacy and safety of two antibiotic regimens (ertapenem vs ampicillin-sulbactam) for the treatment of community-acquired intra-abdominal infections (IAIs) of mild to moderate severity.\n\nThe key inclusion criteria are:\n1) Adult patients (>18 years)\n2) Requiring surgical intervention within 24 hours for localized IAI of mild to moderate severity, including conditions like perforated appendicitis, diverticulitis, cholecystitis, gastric/duodenal perforation, traumatic intestinal perforation, secondary peritonitis, and intra-abdominal abscess.\n\nThis patient meets the age criteria and has an IAI (splenic rupture with intraperitoneal hemorrhage) that would likely require surgical intervention within 24 hours. However, the IAI appears to be due to trauma rather than a community-acquired infection, which may exclude the patient from this particular trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether traumatic splenic rupture would meet the \"community-acquired IAI\" criteria for the study.",
        "label": 0
    },
    "1076": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male, which meets the age criteria of \u226518 to \u226475 years.\n\n2. The patient does not have a diagnosis of thrombotic microangiopathy (TMA). The presenting condition is acute abdominal pain due to a spleen rupture from blunt trauma.\n\n3. The inclusion criteria specifically require a diagnosis of TMA with thrombocytopenia, microangiopathic hemolytic anemia, and absence of an alternative explanation for these conditions.\n\n4. The patient's condition (spleen rupture) has a clear alternative explanation and does not involve thrombocytopenia or microangiopathic hemolytic anemia.\n\nBased on the information provided, this patient would not be eligible for the clinical trial studying ARC1779 Injection in patients with thrombotic microangiopathy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1077": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. Imaging revealed extended intraperitoneal hemorrhage due to spleen rupture.\n\n3. The clinical trial is a prospective randomized comparison of hand-assisted laparoscopic splenectomies and open splenectomies.\n\n4. The inclusion criteria for the trial are:\n   - Splenomegaly with spleens 15 cm or longer\n   - Patient confirmation to join the study\n\n5. Based on the patient's presentation of spleen rupture and intraperitoneal hemorrhage, it is highly likely that splenectomy would be indicated.\n\n6. The patient's age and gender are not exclusion criteria.\n\n7. While the patient's spleen size is not explicitly stated, a ruptured spleen would likely meet the 15 cm or longer criteria for splenomegaly.\n\n8. Assuming the patient consents to participate in the study, this patient would be eligible for this clinical trial comparing hand-assisted laparoscopic splenectomy and open splenectomy.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1078": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. The clinical trial is titled \"Anticoagulation Post Laparoscopic Splenectomy\" and is studying the use of low molecular weight heparin (Lovenox) after laparoscopic splenectomy to prevent splenic/portal vein thrombosis.\n\n3. One of the key inclusion criteria for the trial is \"Scheduled to undergo laparoscopic splenectomy at The University of Alberta or Grey Nun's Community Hospitals\".\n\n4. Based on the patient note, the CT scan revealed extended intraperitoneal hemorrhage due to spleen rupture. This would likely necessitate an emergency splenectomy.\n\n5. Therefore, this patient meets the key inclusion criteria of being scheduled for a laparoscopic splenectomy.\n\n6. The other inclusion criteria of being capable of understanding the study, willing to sign informed consent, and willing to undergo daily injections would need to be confirmed, but could potentially be met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1079": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not seem to be eligible for this trial. Here's my analysis:\n\nThe patient note describes a 33-year-old male athlete who presented with acute abdominal pain due to a spleen rupture caused by blunt trauma from a bicycle accident. The clinical trial is studying a delayed-release pancrelipase in patients with pancreatic exocrine insufficiency due to cystic fibrosis.\n\nThe inclusion criteria for the trial specifically mention:\n1. Confirmed cystic fibrosis diagnosis\n2. Pancreatic exocrine insufficiency (fecal elastase < 50\u00b5g/g stool)\n3. Age between 1 month and 6 years\n4. Currently receiving pancreatic enzyme treatment for at least 3 months\n5. Clinically stable condition without acute respiratory disease or other acute conditions\n\nThe patient note does not mention any diagnosis of cystic fibrosis or pancreatic exocrine insufficiency. Additionally, the patient is 33 years old, which is outside the age range specified in the inclusion criteria.\n\nTherefore, based on the information provided, this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1080": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a bike fall a week earlier.\n\n2. The clinical trial is titled \"Splenic Function After Spleen-Preserving Distal Pancreatectomy With Excision of Splenic Artery and Vein\".\n\n3. The summary indicates that the trial aims to establish data on the incidence of overwhelming post-splenectomy infection (OPSI) in Taiwan, as well as to determine the splenic function after spleen-preserving distal pancreatectomy with excision of splenic artery and vein.\n\n4. The inclusion criteria state: \"all patients received splenectomy (patient list will be applied from Dept. of Pathology) at National Taiwan University Hospital in the last 20 years.\"\n\n5. Based on the patient note, this patient has suffered a splenic rupture due to blunt trauma and will likely require a splenectomy.\n\n6. However, the inclusion criteria specifically state that only patients who have already received a splenectomy at the National Taiwan University Hospital in the last 20 years will be included.\n\nTherefore, based on the information provided, this patient would not be eligible for this particular clinical trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1081": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Age > 18: The patient is 33 years old, so this criterion is met.\n\n2. Abdominal pain > 2h and < 7 days: The patient presented with acute abdominal pain, and it is mentioned that the pain started a week earlier after a fall, which is within the 7-day window.\n\nBased on the provided information, the patient meets both inclusion criteria for the \"Computer Tomography (CT) Trial of Acute Abdomen\" clinical trial.\n\nThe patient's condition of spleen rupture and intraperitoneal hemorrhage due to blunt trauma is relevant to the study's purpose of evaluating the impact of early CT scanning in patients with acute abdomen.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1082": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Intraperitoneal Analgesia After Laparoscopic Cholecystectomy\", the patient does not seem eligible for this trial. The key reasons are:\n\n1. The patient did not undergo a laparoscopic cholecystectomy (gallbladder removal surgery). Instead, the patient suffered a spleen rupture due to blunt trauma from a bicycle accident.\n\n2. The trial is specifically studying the efficacy of intraperitoneal analgesia (pain relief) after laparoscopic cholecystectomy, which is not relevant to the patient's condition.\n\n3. The inclusion criteria explicitly state that the patient should have a diagnosis of symptomatic gallstones requiring laparoscopic cholecystectomy, which is not the case here.\n\nTherefore, based on the information provided, this patient would not be eligible for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1083": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients with liver cirrhosis accompanied by portal hypertension and secondary hypersplenism due to hepatitis, alcoholic cirrhosis or schistosomiasis: The patient note does not mention liver cirrhosis or portal hypertension. It states that the patient suffered a spleen rupture due to blunt trauma, which is not the same as secondary hypersplenism due to the listed conditions.\n\n2. Undergoing elective azygoportal disconnection and splenectomy: The patient note does not mention any planned surgical procedures. The spleen rupture appears to be an acute condition requiring emergency treatment.\n\nBased on the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial. The spleen rupture is due to trauma, not portal hypertension or liver cirrhosis, and there is no mention of planned surgical procedures.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1084": {
        "output": "Analyzing the patient note and the clinical trial details:\n\nThe patient is a 33-year-old male athlete who presented with acute abdominal pain and intraperitoneal hemorrhage due to a spleen rupture caused by blunt trauma from a bicycle accident.\n\nThe clinical trial is focused on comparing laparoscopic and open mesh repair techniques for incisional and umbilical hernias.\n\nThe inclusion criteria for the trial are:\n1. Age > 18 (the patient is 33 years old, so he meets this criterion)\n2. Incisional or umbilical hernia over 2 cm and less than 6 cm in diameter\n\nBased on the information provided, the patient does not have an incisional or umbilical hernia. Instead, he has a spleen rupture and intraperitoneal hemorrhage due to blunt trauma.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1085": {
        "output": "Let's go through the inclusion criteria for this clinical trial:\n\n1. Cytoreductive surgery and intraperitoneal chemotherapy\nThe patient note does not mention the patient undergoing any surgery or chemotherapy, so this criterion is not met.\n\n2. Single-Photon Emission Computed Tomography (SPECT) before the second course of treatment\nThe patient note does not mention the patient undergoing any SPECT scan or receiving any treatment courses, so this criterion is also not met.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria for this clinical trial, which is focused on evaluating the use of SPECT scans to predict the feasibility of sequential postoperative intraperitoneal chemotherapy courses after cytoreductive surgery and initial intraperitoneal chemotherapy.\n\nThe patient note describes a 33-year-old male athlete who presented to the ER with acute abdominal pain and was found to have a ruptured spleen due to blunt trauma from a bicycle accident. There is no mention of the patient having undergone any cancer treatment or being eligible for intraperitoneal chemotherapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1086": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"FLEX-Trial: Prospective Sonographic Assessment Of Healing Process Following Suture of Profound Flexor Tendon Due to Traumatic Rupture of FDP-Tendon in Zone II,\" this patient would not be eligible for the trial.\n\nThe patient note describes a 33-year-old male athlete who presented with acute abdominal pain and intraperitoneal hemorrhage due to a spleen rupture after blunt trauma from a bicycle accident. The clinical trial, however, is focused on assessing the healing process following suture of a ruptured flexor digitorum profundus (FDP) tendon in Zone II of the hand.\n\nThe patient's condition does not involve a traumatic rupture of the FDP tendon in Zone II, which is the primary inclusion criterion for the trial. Therefore, this patient would not meet the eligibility requirements for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1087": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which meets the age criteria of being over 18 years old.\n\n2. The patient presented with acute abdominal pain, which is one of the inclusion criteria for this clinical trial on assessing acute abdomen using MR imaging.\n\n3. The patient's abdominal pain is due to blunt trauma from a bicycle accident, which would be considered a traumatic cause. The inclusion criteria specify \"nontraumatic acute abdomen\".\n\n4. There is no information provided about the patient's weight, so it's unclear if they meet the <120kg weight criteria.\n\n5. There is no information about whether the patient can hold their breath for 15 seconds, which is another inclusion criteria.\n\n6. It's unclear if the surgeon considers the patient fit for participation in the study, which is the final inclusion criteria.\n\nBased on the information provided, while the patient meets some of the criteria, the traumatic cause of their acute abdomen and lack of information about weight, ability to hold breath, and surgeon approval makes their full eligibility uncertain.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1088": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. The clinical trial is titled \"Keller Prehospital Ultrasound Study\" and aims to evaluate the use of ultrasound by paramedics in the field.\n\n3. The inclusion criteria for the trial are:\n   - Activation of the Keller Fire Rescue Emergency Medical Service\n   - Meets disease process criteria described earlier\n\n4. Based on the information provided, this patient meets the inclusion criteria of being a case handled by the Keller Fire Rescue Emergency Medical Service.\n\n5. Additionally, the patient's presentation of acute abdominal pain and intraperitoneal hemorrhage due to spleen rupture after blunt trauma would likely fall under the \"disease process criteria\" mentioned in the inclusion criteria.\n\nTherefore, based on the available information, this patient would likely be eligible for the \"Keller Prehospital Ultrasound Study\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1089": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. The clinical trial is titled \"Prospective Evaluation of Spleen Injury Treatments in Languedoc Roussillon\" and is evaluating spleen injury treatments based on trauma severity, morbi-mortality, and length of hospitalization.\n\n3. The inclusion criteria for the trial are:\n   - Hospitalized for abdominal trauma\n   - Diagnosis of splenic contusion confirmed by scanner or during surgery for hemodynamically unstable cases\n   - Patient has signed a consent form\n   - Patient is a beneficiary of or affiliated with a social security program\n\n4. Based on the patient note, the patient meets the following inclusion criteria:\n   - Hospitalized for abdominal trauma (presented to the ER with acute abdominal pain)\n   - Diagnosis of splenic contusion confirmed by scanner (CT scan revealed spleen rupture)\n\n5. However, there is no information provided about whether the patient has signed a consent form or is a beneficiary of/affiliated with a social security program.\n\nGiven the information available, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1090": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients over 18 years of age up to 65 years\nThe patient note states that the patient is a 33-year-old male, which falls within this age range.\n\n2. Patients receiving a decompressive craniectomy for: severe head injuries, Subarachnoid hemorrhage, intra-cerebral hemorrhage, cerebral dural sinus thrombosis, malignant middle cerebral artery stroke and undergoing to reconstructive cranioplasty\nThe patient note does not mention any of these conditions or procedures. The patient seems to have suffered a spleen rupture due to blunt trauma from a bicycle accident.\n\n3. Patients informed about the study and giving consent\nThere is no information provided about whether the patient has been informed about the study or has given consent.\n\nBased on the information provided in the patient note, this patient does not appear to meet the inclusion criteria for this clinical trial, as the trial is focused on patients receiving specific neurosurgical procedures, which is not the case for this patient.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1091": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which meets the age criteria of \"Males and females aged over 18 years\" in the inclusion criteria.\n\n2. The patient's condition is related to a spleen rupture due to blunt trauma, which is not a myelodysplastic syndrome (MDS) or any of the specific MDS types listed in the inclusion criteria.\n\n3. The patient's hemoglobin level is not mentioned, so it is unclear if they meet the criteria of \"A haemoglobin concentration of less than 10g/dl and/or red cell transfusion dependence.\"\n\n4. The other inclusion criteria, such as ECOG performance status, life expectancy, and ability to provide informed consent, are not addressed in the patient note.\n\nBased on the information provided, the patient does not appear to have a confirmed diagnosis of MDS or any of the specific MDS types listed in the inclusion criteria. Therefore, the patient would likely not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1092": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not appear to be eligible for this particular trial. Here's my reasoning:\n\nThe patient note describes a 33-year-old male athlete who presented with acute abdominal pain and was diagnosed with a ruptured spleen due to blunt trauma from a bicycle accident.\n\nThe clinical trial, titled \"Identification of Microcirculation After Surgical Treatment of Rupture of the Achilles Tendon,\" is focused on studying microcirculation in patients undergoing surgical treatment for an Achilles tendon rupture.\n\nThe inclusion criteria for this trial specifically mention:\n1. Acute rupture of the Achilles tendon (on one or both sides)\n2. Age over 18 years\n3. Signed letter of approval\n4. Patient speaks/understands German\n5. Planned surgical treatment for Achilles tendon rupture\n6. No more than 48 hours after rupture\n\nThe patient in the given note does not have an Achilles tendon rupture but rather a ruptured spleen due to blunt abdominal trauma. Therefore, the patient does not meet the primary inclusion criterion for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1093": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier. Imaging revealed extended intraperitoneal hemorrhage due to spleen rupture.\n\nThe clinical trial is titled \"Single Incision Versus Standard Laparoscopic Splenectomy\" and is studying the differences between single incision and standard laparoscopic splenectomy procedures.\n\nThe only inclusion criterion listed is \"Need for splenectomy\".\n\nGiven that this patient has a ruptured spleen and likely needs a splenectomy procedure, he would meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1094": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient is a 33-year-old male, while the trial is focused on pregnant patients.\n2. The patient's condition is related to a spleen rupture due to blunt trauma, which is not relevant to the trial's focus on predicting preterm delivery due to abruptio placenta.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1095": {
        "output": "Analyzing the patient note and the clinical trial details:\n\nThe patient is a 33-year-old male athlete who suffered blunt trauma to the abdomen from a bike accident, leading to a ruptured spleen and intraperitoneal hemorrhage.\n\nThe clinical trial is focused on comparing sharp versus blunt fascial incision techniques during cesarean section in women undergoing their first cesarean delivery.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial, which specifically requires:\n\n1. Women undergoing their first cesarean section\n2. No previous lower abdominal surgery\n3. Ability to speak and understand Danish\n4. Ability to provide informed consent\n\nAs the patient is a male who suffered abdominal trauma and does not meet any of the inclusion criteria, he would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1096": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which meets the age criteria of 18 years or older for the clinical trial.\n\n2. However, the patient's condition is a spleen rupture due to blunt trauma from a bicycle accident, not a distal bicep tendon rupture.\n\n3. The inclusion criteria specifically state \"Complete rupture of the Distal Bicep tendon\" and \"Acute bicep tendon rupture (< 10 days since rupture)\".\n\n4. Since the patient does not have a distal bicep tendon rupture, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1097": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen a week earlier from a bike fall.\n\n2. The clinical trial is titled \"Impact of CT on Diagnosis of Acute Appendicitis\" and aims to determine whether computed tomography is a reliable investigation for diagnosing acute appendicitis.\n\n3. The inclusion criteria for the trial is: \"Patients who have been admitted and diagnosed as having acute appendicitis\"\n\n4. Based on the patient note, the patient was diagnosed with a spleen rupture and intraperitoneal hemorrhage after undergoing an ultrasound and CT scan of the abdomen. There is no mention of acute appendicitis.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the clinical trial on acute appendicitis diagnosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1098": {
        "output": "To determine the patient's eligibility for the clinical trial \"Comparison Between Open and Laparoscopic Splenic Aneurysms Repair\", let's go through the inclusion criteria:\n\n1. Splenic artery aneurysm with diameter greater than 2 cm\n   - The patient note mentions that the patient has a splenic rupture, which implies the presence of a splenic artery aneurysm. However, the size of the aneurysm is not specified.\n\n2. Splenic artery aneurysm with diameter smaller than 2 cm if risk factors for rupture are associated (child bearing age, pregnancy, blister or saccular shape, increasing diameter)\n   - While the size of the aneurysm is not given, the patient has experienced a splenic rupture, which is a risk factor for rupture.\n\nGiven the information provided in the patient note, it is highly likely that this patient would be eligible for the clinical trial, as they have experienced a splenic rupture, which implies the presence of a splenic artery aneurysm. However, further investigation may be needed to confirm the size of the aneurysm or the presence of other risk factors for rupture.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1099": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. Imaging revealed extended intraperitoneal hemorrhage due to spleen rupture.\n\n3. The clinical trial is for a surgical procedure called \"Distal Pancreatectomy With Partial Splenectomy\" for treating pancreatic tumors.\n\n4. The key inclusion criteria are:\n   - Patients with solid or cystic neoplasms of the pancreas being considered for distal pancreatectomy/splenectomy\n   - No evidence of metastatic disease\n   - No evidence of local invasion into surrounding organs\n   - ECOG performance status <3\n   - Age 18 years or greater\n\n5. Based on the patient note, there is no mention of a pancreatic tumor or neoplasm. The patient's condition appears to be related to a traumatic spleen rupture.\n\n6. Therefore, this patient would not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1100": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a bike fall a week earlier.\n\n2. The clinical trial is titled \"Pancreas Resection With and Without Drains\" and is studying the use of intraperitoneal drains after pancreatectomy surgery.\n\n3. The inclusion criteria for the trial are:\n   - Surgical indication for distal pancreatectomy\n   - No medical contraindications to pancreatectomy\n   - At least 18 years of age\n   - Willing to consent to randomization to drain or no drain group\n   - Willing to comply with 90-day follow-up and answer quality-of-life questionnaires\n\n4. Based on the patient note, this patient does not have a surgical indication for a pancreatectomy. Instead, the patient has a ruptured spleen due to blunt trauma, which would likely require a splenectomy.\n\n5. Therefore, this patient does not meet the inclusion criteria for the \"Pancreas Resection With and Without Drains\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1101": {
        "output": "To determine the patient's eligibility for the clinical trial \"Study of Tomography of Nephrolithiasis Evaluation\", let's go through the inclusion criteria:\n\n1. Age: The patient is 33 years old, which falls within the age range of \u226518 but <76 years.\n\n2. Presentation: The patient presented to the ER with acute abdominal pain, which could be indicative of renal colic.\n\n3. Suspicion of kidney stones: The emergency physician did not explicitly suspect kidney stones, but the patient's symptoms and imaging findings (intraperitoneal hemorrhage due to spleen rupture) suggest that kidney stones are not the primary diagnosis.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial, as the primary diagnosis is not suspected to be kidney stones (renal colic).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1102": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Role of Serum Total Antioxidant Level in Preterm Labor\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient is a 33-year-old male, while the trial requires pregnant women between 28th and 37th week of gestation.\n2. The patient's condition is related to a spleen rupture due to blunt trauma, which is not relevant to the study's focus on preterm labor and antioxidant levels.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1103": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. The clinical trial is studying the effects of Seprafilm adhesion barrier on patients undergoing open abdomen damage control management for traumatic injuries.\n\n3. The inclusion criteria for the trial are:\n   - Trauma patients undergoing damage control/open abdomen management for traumatic injury\n   - Age 18 or older\n   - Life expectancy longer than 48 hours\n\n4. Based on the patient note, this 33-year-old male patient suffered a traumatic injury (spleen rupture) due to blunt abdominal trauma and is undergoing emergency treatment, which likely includes open abdomen management.\n\n5. The patient meets the age criteria (33 years old) and, given that he is being treated in the ER, his life expectancy is likely longer than 48 hours.\n\nTherefore, based on the information provided, this patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1104": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. The clinical trial is titled \"Analysis of Risk Factors for Death After Blunt Traumatic Rupture of the Thoracic Aorta\".\n\n3. The inclusion criteria for the trial state that it includes \"all consecutive cases with traumatic rupture of the thoracic aorta being reported in the greater area of Zurich with about one million inhabitants\" during the study period of 1990 to 2003.\n\n4. The patient's CT scan revealed intraperitoneal hemorrhage due to spleen rupture, not a thoracic aortic rupture.\n\n5. Therefore, based on the inclusion criteria, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1105": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subject is \u226518 years old.\nThe patient is 33 years old, so this criterion is met.\n\n2. Diagnosed with ITP for at least 12 months prior to screening, and have a platelet count of <30 X109/L on Day 1 (or within 48 hours prior to dosing on Day 1).\nThe patient note does not mention a diagnosis of ITP or provide platelet count information, so this criterion cannot be evaluated.\n\n3. Patients who have no response or relapsed after splenectomy. Or patients who have not been splenectomised and have either not responded to one or more prior therapies (except splenectomy), or who have relapsed prior therapy.\nThe patient note does not mention any prior therapies or splenectomy, so this criterion cannot be evaluated.\n\n4. Previous therapy for ITP including rescue must have been completed at least 2 weeks prior to randomization.\nThe patient note does not mention any prior therapies, so this criterion cannot be evaluated.\n\n5. Subjects treated with maintenance immunosuppressive therapy must be receiving a dose that has been stable for at least 1 month.\nThe patient note does not mention any immunosuppressive therapy, so this criterion is not applicable.\n\n6. No pre-existing cardiac disease within the last 3 months. No arrhythmia known to increase the risk of thrombolic events (e.g. atrial fibrillation), or patients with a Corrected QT interval (QTc) >450msec or QTc >480 for patients with a Bundle Branch Block.\nThe patient note does not mention any cardiac disease or arrhythmia, so this criterion cannot be evaluated.\n\n7. No history of clotting disorder, other than ITP.\nThe patient note does not mention any clotting disorder, so this criterion cannot be evaluated.\n\n8. A complete blood count (CBC), within the reference range, with the following exceptions:\n   - Platelets <30\u00d7109/L on Day 1 (or within 48hours of Day 1) is required for inclusion,\n   - Hemoglobin: females and males 10.0 g/dl are eligible for inclusion,\n   - Absolute neutrophil count (ANC) \u22651500/\u00b5L (1.5\u00d7109/L) is required for inclusion\nThe patient note does not provide any CBC information, so this criterion cannot be evaluated.\n\n9. Blood chemistry test result no exceed normal by more than 20%. Total albumin must not be below the lower limit of normal (LLN) by more than 10%.\nThe patient note does not provide any blood chemistry test results, so this criterion cannot be evaluated.\n\n10. Subject is non-childbearing potential of childbearing potential and use acceptable methods of contraception from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study.\nThe patient note does not provide information about the patient's childbearing potential or contraceptive use, so this criterion cannot be evaluated.\n\nIn summary, based on the information provided in the patient note, it is not possible to determine the patient's eligibility for this clinical trial because several key inclusion criteria related to the diagnosis of ITP, platelet count, prior therapies, and laboratory values are not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1106": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. The clinical trial is titled \"Evaluation of Trauma Team Activation Criteria\" and aims to establish the predictive properties of the trauma team activation protocol and its individual criteria.\n\n3. The inclusion criteria for the clinical trial are:\n   - All patients admitted with the trauma team\n   - All patients admitted with Injury Severity Score >15\n\n4. Based on the patient note, the patient suffered blunt trauma to the abdomen, which led to a spleen rupture and intraperitoneal hemorrhage. This would likely warrant trauma team activation and admission.\n\n5. While the Injury Severity Score is not explicitly mentioned, the patient's vital signs (BP: 60/30 mmHg, HR: 140/min) and the presence of intraperitoneal hemorrhage suggest a potentially severe injury.\n\nGiven the information provided, it is highly likely that this patient would meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1107": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which does not violate the age criteria of being 18 years or older.\n\n2. The patient does not have any of the Philadelphia negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, or myelofibrosis) mentioned in the inclusion criteria.\n\n3. There is no mention of a palpable spleen length greater than 5 cm below the costal margin or any palpable spleen size.\n\n4. The patient's condition is related to a spleen rupture due to blunt trauma, which falls under the exclusion criteria of \"Known history of active bleeding.\"\n\nBased on the information provided, this patient would not be eligible for the clinical trial titled \"Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms\" because they do not meet the inclusion criteria of having one of the specified myeloproliferative neoplasms, and they have an active bleeding condition, which is an exclusion criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1108": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 33-year-old male athlete, which falls within the age range of 3-60 years specified in the inclusion criteria.\n\nHe presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier. This indicates he was evaluated for blunt trauma, satisfying another inclusion criterion.\n\nHis Glasgow Coma Scale (GCS) score is not explicitly stated, but he is described as alert, suggesting a GCS score of >14, meeting that inclusion criterion.\n\nFinally, the patient underwent CT imaging of the abdomen and pelvis, as the note mentions \"Emergency ultrasound and CT scan of the abdomen reveal extended intraperitoneal hemorrhage due to spleen rupture.\" This satisfies the final inclusion criterion of having an order for CT abdomen and pelvis imaging.\n\nBased on the information provided, this patient meets all the stated inclusion criteria for the clinical trial titled \"Pelvic CT Imaging in Blunt Abdominal Trauma.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1109": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. The clinical trial is titled \"Thoracic Endovascular Repair Versus Open Surgery for Blunt Injury\" and is studying the outcomes of different treatments for blunt aortic injury (BAI).\n\n3. The inclusion criteria for the trial is: \"Clinical diagnosis of blunt aortic injury (BAI)\".\n\n4. Based on the patient note, the patient has a ruptured spleen due to blunt trauma, but there is no mention of a blunt aortic injury.\n\n5. Therefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1110": {
        "output": "Let's analyze the patient note and inclusion criteria step-by-step:\n\nThe patient note describes a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen a week earlier. Imaging revealed intraperitoneal hemorrhage due to spleen rupture.\n\nThe clinical trial is focused on studying the alteration of macrophage function in the spleen tissues of patients with primary immune thrombocytopenia (ITP).\n\nThe inclusion criteria for the trial are:\n1. Adult ITP patients whose platelet counts remain less than 10 x 10^9/L\n2. Patients whose platelet counts remain less than 30 x 10^9/L and who continue to experience excessive bleeding after 4 to 6 weeks of appropriate medical treatment\n3. Patients who have experienced a transient response to primary treatment and have platelet counts less than 30 x 10^9/L after 3 months\n4. Require continuous glucocorticoid therapy to maintain safe platelet counts\n5. Willing and able to sign written informed consent\n\nBased on the information provided in the patient note, there is no mention of the patient having ITP or any platelet count values. The patient's condition appears to be related to a traumatic spleen rupture, which is different from the focus of the clinical trial.\n\nTherefore, based on the available information, this patient would not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1111": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\nAge 45-75 years old: The patient is 33 years old, which does not meet this criterion.\n\nPatients undergoing laparoscopic hysterectomy with promontofixation for uterine prolapse: The patient note does not mention any uterine prolapse or planned hysterectomy. This criterion is not met.\n\nMenopaused: There is no information about the patient's menopausal status in the note.\n\nASA class I or II: There is no information about the patient's ASA classification in the note.\n\nBased on the information provided in the patient note, the patient does not meet at least two of the inclusion criteria (age and planned surgery). There is also not enough information to determine if the other criteria are met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1112": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which fits the age criteria of 18-75 years old for the clinical trial.\n\n2. The patient is not a renal transplant recipient, which is a key inclusion criterion for this trial. The patient's condition is related to a spleen rupture due to blunt trauma, not antibody-mediated rejection following a renal transplant.\n\n3. There is no information provided about the patient having circulating anti-HLA antibodies, histological findings compatible with Banff Class II or III AMR, or peritubular capillary c4d positivity, which are the other inclusion criteria.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of being a renal transplant recipient with antibody-mediated rejection.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1113": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier. Imaging revealed extended intraperitoneal hemorrhage due to spleen rupture.\n\nThe clinical trial titled \"Different Fluidic Strategy in Patients With Acute Abdomen : The Sure Volume\" is studying fluid resuscitation strategies in patients with acute abdomen undergoing emergency abdominal surgery.\n\nThe key inclusion criteria are:\n1) Patients with acute abdomen undergoing abdominal surgery under emergency\n2) Presenting on arrival in ICU at least a sign of bad perfusion\n\nThis patient meets both of those criteria, as he has an acute abdomen condition (spleen rupture) requiring emergency surgery, and his vitals (BP 60/30 mmHg, HR 140/min) indicate poor perfusion.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1114": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not appear to have atrial fibrillation, which is a key requirement for inclusion in this trial. The patient note describes a 33-year-old male athlete who presented with acute abdominal pain and intraperitoneal hemorrhage due to a spleen rupture after a bike accident.\n\nThe inclusion criteria for the clinical trial specifically state that participants must have a coded diagnosis for atrial fibrillation in their primary or secondary care record. Since the patient note does not mention atrial fibrillation or any related condition, it is highly unlikely that this patient would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1115": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. Imaging revealed extended intraperitoneal hemorrhage due to spleen rupture.\n\n3. The clinical trial is studying the use of a continuous triple-tube instillation and suction system for the management of open abdomen in patients with complicated intra-abdominal infections.\n\n4. The inclusion criteria for the trial are:\n   - Age \u2265 18 years\n   - Patients with complicated intra-abdominal infections who need open abdomen and vacuum-assisted wound closure and mesh-mediated fascial traction (VAWCM)\n   - Patients with grade 1b or 2b open abdomen as classified by Bjorck\n\n5. Based on the information provided, the patient meets the age criteria (33 years old) and has a condition (spleen rupture with intraperitoneal hemorrhage) that would likely require an open abdomen procedure.\n\n6. However, it is not explicitly stated that the patient has a complicated intra-abdominal infection, which is a key inclusion criterion for this trial.\n\n7. Additionally, the Bjorck grade of the patient's open abdomen is not specified.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information would be needed to determine if the patient has a complicated intra-abdominal infection and the Bjorck grade of the open abdomen to fully assess eligibility for this specific trial.",
        "label": 0
    },
    "1116": {
        "output": "To determine the patient's eligibility for the clinical trial \"Neurological Outcome in Patients of Traumatic Subarachnoid Haemorrhage\", let's go through the inclusion criteria:\n\nInclusion criteria: All patients of traumatic subarachnoid haemorrhage\n\nBased on the patient note, the 33-year-old male athlete suffered blunt trauma to the abdomen after falling off his bike, which led to a spleen rupture and intraperitoneal hemorrhage. The note does not explicitly mention a traumatic subarachnoid hemorrhage (tSAH) or any head injury.\n\nWhile the patient experienced blunt trauma, there is no indication that it resulted in a tSAH, which is the primary inclusion criterion for this clinical trial.\n\nTherefore, based on the information provided in the patient note, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1117": {
        "output": "Based on the provided patient note and the clinical trial information, the patient does not meet the inclusion criteria for the trial titled \"Impact of Visceral Osteopathic Treatment on Meconium Evacuation in Preterm Infants.\"\n\nThe key reasons are:\n\n1. The patient is a 33-year-old male athlete, while the inclusion criteria specify premature infants with a birthweight of 1500 grams or less.\n\n2. The patient's condition is related to abdominal trauma and splenic rupture, which is not relevant to the trial's focus on meconium evacuation in preterm infants.\n\nTherefore, based on the provided information, this patient would not be eligible for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1118": {
        "output": "Based on the patient note provided, the patient is a 33-year-old male athlete who suffered blunt trauma to the abdomen and subsequently developed a ruptured spleen with intraperitoneal hemorrhage. The clinical trial you provided is focused on identifying better prognostic and diagnostic strategies for hemostatic changes during major obstetric hemorrhage in pregnant women.\n\nGiven that the patient is not pregnant and does not meet the inclusion criteria of being a pregnant woman with a gestational age greater than 24 weeks, I would assess the trial-level eligibility as follows:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1119": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. The clinical trial is comparing the use of a prehospital ultrasound system and standard prehospital care in thoracoabdominal trauma.\n\n3. The inclusion criteria for the FAST (Focused Assessment with Sonography for Trauma) cohort are:\n   - Patient is 18 years of age or older (the patient is 33, so meets this criteria)\n   - Patient presenting with blunt or penetrating trauma to the thorax or abdomen (the patient had blunt trauma to the left hemi-abdomen, so meets this criteria)\n   - Patient transported by MD Ambulance to Royal University Hospital (no information provided about this)\n   - Patient being transported by a paramedic who has received training in the ultrasound system and has the equipment (no information provided about this)\n   - Patient will take longer than 10 minutes to transport to hospital (no information provided about this)\n   - Patient's care will not be compromised in completing a FAST exam - opinion of paramedic (no information provided about this)\n   - Patient's care will not be compromised in completing a FAST exam - opinion of ER physician (no information provided about this)\n\n4. Based on the information provided, the patient meets some of the inclusion criteria (age and presenting with blunt abdominal trauma), but there is not enough information to determine if they meet all the criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1120": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 33-year-old male, which meets the age criteria of 18-65 years old for this trial.\n\nHowever, the trial is specifically for patients with stage IIIC unresectable ovarian, tube or peritoneal primary adenocarcinoma. This patient does not have ovarian cancer, but rather suffered a splenic rupture from blunt trauma.\n\nAdditionally, the trial requires patients to have received 6 cycles of carboplatin-cisplatin neoadjuvant chemotherapy prior to surgery and HIPEC, which this patient has not received.\n\nBased on the information provided, this patient does not meet the key inclusion criteria for this ovarian cancer trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1121": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a bike fall a week earlier.\n\n2. The clinical trial is titled \"The Effect of Different Types of Temporary Abdominal Closure on Intra Abdominal Hypertension\" and is studying patients undergoing emergency laparotomy who require temporary abdominal closure.\n\n3. One of the key inclusion criteria is \"Adults male or female over 18 year old undergoing emergency laparotomy. Patients that have their abdominal wall closed at the end of surgery by a temporary closure technique.\"\n\n4. Based on the patient note, the patient had a spleen rupture due to the blunt trauma and required emergency surgery (laparotomy) where the abdomen would likely need to be temporarily closed.\n\n5. The patient meets the age criteria (33 years old) and appears to meet the surgical criteria of undergoing an emergency laparotomy with temporary abdominal closure.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1122": {
        "output": "To determine the patient's eligibility for the clinical trial \"Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients,\" let's go through the inclusion criteria:\n\nInclusion Criteria: Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury.\n\nThe patient note mentions that the patient is a 33-year-old male athlete who presented with a spleen rupture due to blunt trauma from a bike fall a week earlier. This meets the inclusion criteria of being an adult trauma patient aged 18 to 65 years old who sustained a splenic injury.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1123": {
        "output": "Analyzing the patient note and the clinical trial inclusion criteria:\n\nThe patient note describes a 33-year-old male athlete who presented with acute abdominal pain and was diagnosed with a spleen rupture due to blunt trauma from a bicycle accident. The clinical trial is focused on comparing two mesh/fixation concepts for laparoscopic ventral and incisional hernia repair.\n\nBased on the inclusion criteria provided, this patient does not seem to be eligible for this clinical trial because:\n\n1. The patient's condition is related to a spleen rupture, not a ventral or incisional hernia.\n2. The inclusion criteria specifically mention primary or secondary ventral hernia, recurrence after former abdominal hernia repair with mesh, or recurrence after suture abdominal hernia repair.\n\nThere is no mention of the patient having any type of hernia or undergoing previous hernia repair in the provided note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1124": {
        "output": "To determine the patient's eligibility for the given clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Patients with histologically confirmed Malignant Pleural Mesothelioma\"\nThe patient note does not mention malignant pleural mesothelioma. Instead, it states that the patient suffered a spleen rupture due to blunt trauma from a bicycle accident.\n\n2. \"Age of 18 years or more.\"\nThe patient is 33 years old, which meets this criterion.\n\n3. \"first-line chemotherapy with platinum-Based agents\"\nThere is no mention of the patient receiving any chemotherapy in the provided note.\n\nSince the patient does not have malignant pleural mesothelioma and is not receiving platinum-based chemotherapy, which are two of the key inclusion criteria, it is highly unlikely that this patient would be eligible for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1125": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which meets the age criteria of being 18 years or older.\n\n2. The patient presented with acute abdominal pain due to a spleen rupture from blunt trauma a week earlier, which is not related to an Achilles tendon rupture.\n\n3. There is no mention of the patient having an Achilles tendon rupture or being diagnosed with one.\n\n4. The inclusion criteria specifically state that the patient must have an acute, complete Achilles tendon rupture and present within 12 days of the injury.\n\nBased on the information provided in the patient note, this patient does not meet the inclusion criteria for the PATH-2 clinical trial on Platelet Rich Plasma in Achilles Tendon Healing.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1126": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which fits the age criteria of 18-30 years old for this clinical trial on acute anterior cruciate ligament (ACL) rupture.\n\n2. The patient presented with acute abdominal pain after a fall from his bike a week earlier, which caused blunt trauma to the left hemi-abdomen. There is no mention of a knee injury or ACL rupture in the patient note.\n\n3. The imaging findings of intraperitoneal hemorrhage due to spleen rupture are not relevant to the inclusion criteria for this ACL rupture trial.\n\n4. There is no information provided about the patient's activity level (Tegner score) or willingness to comply with the rehabilitation protocol.\n\nBased on the lack of information about an ACL rupture and the details provided about an unrelated abdominal injury, this patient would not be eligible for the clinical trial on acute ACL rupture reconstruction or repair.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1127": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 33-year-old male athlete, which meets the age criteria of \u2265 21 years old.\n\nHowever, the patient does not have a diagnosis of melanoma or head and neck squamous cell cancer (HNSCC). The patient presented with acute abdominal pain and spleen rupture due to blunt trauma from a bicycle accident.\n\nThe inclusion criteria specifically state \"Biopsy proven incurable melanoma or incurable HNSCC amenable to have biopsy and/or surgical resection of either the primary and/or locoregional metastatic site, at the University of Colorado Hospital.\"\n\nSince the patient does not have melanoma or HNSCC, they would not meet this key inclusion criterion.\n\nThe other criteria related to performance status, lab values, measurable disease, etc. are not relevant since the patient does not have the target diseases.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1128": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Maternal Microcirculation & SDF Imaging\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient is a 33-year-old male, while the inclusion criteria specify pregnant women undergoing cesarean delivery.\n2. The patient's condition is related to a spleen rupture due to blunt trauma, which is not relevant to the study's focus on maternal microcirculation during cesarean delivery.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1129": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after falling off his bike a week earlier and suffering blunt trauma to the left hemi-abdomen.\n\n2. The clinical trial is titled \"Handlebar Grip Related Injury Prevention (GRIP) Study: Are Exposed Metal Handlebar Ends a Risk Factor for Injury?\". It is studying the association between bicycle/kick scooter injuries and the condition of the handlebar grips.\n\n3. The inclusion criteria for the trial are:\n   - Children 0-15 years inclusive\n   - Presenting to either of the study hospitals for assessment or treatment\n   - Sustained an injury or suspected to have sustained an injury (i.e. AIS >=0)\n   - Due to an incident involving any non-motorized bicycle, tricycle or kick scooter\n\n4. The patient is 33 years old, which does not meet the age criteria of 0-15 years inclusive.\n\n5. While the patient did sustain an injury due to a bicycle incident, the injury was related to blunt trauma from the fall rather than specifically involving the handlebar grips.\n\nBased on the information provided, this patient would not be eligible for the clinical trial due to not meeting the age criteria and the injury not being directly related to the handlebar grips.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1130": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier. His vitals show hypotension (BP 60/30 mmHg) and tachycardia (HR 140/min). Physical exam revealed abdominal muscle guarding and imaging showed intraperitoneal hemorrhage due to splenic rupture.\n\nThe clinical trial is looking at biomarkers for acute abdominal pain to help identify surgical emergencies. The inclusion criteria are:\n1) Presentation at ED with acute abdominal pain\n2) Aged at least 18 years\n\nThis patient meets both of those criteria. His acute abdominal pain presentation after trauma and hypotensive vitals strongly suggest he has a surgical emergency (splenic rupture).\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1131": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which fits the inclusion criteria of being an adult (age \u2265 18 years).\n\n2. The patient presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier. This suggests a minor blunt thoracic trauma, which is the focus of the clinical trial.\n\n3. The patient's vital signs are unstable, with low blood pressure (60/30 mmHg) and high heart rate (140/min). This may not meet the inclusion criteria of \"stable vital signs\".\n\n4. The CT scan revealed intraperitoneal hemorrhage due to spleen rupture, which is a major injury and may exclude the patient from a trial focused on \"minor blunt thoracic trauma\".\n\nBased on the information provided, while the patient initially presented with a minor blunt thoracic trauma, the unstable vital signs and major injury (spleen rupture) would likely exclude them from this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1132": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male, which fits the age criteria of 18-65 years old for the clinical trial.\n\n2. The clinical trial is for distal biceps tendon repair, but the patient's injury is a spleen rupture due to blunt trauma from a bicycle accident. This does not match the inclusion criteria for the trial.\n\n3. The inclusion criteria specifically state that participants must have had a distal biceps tendon rupture amenable to surgical repair. The patient's injury is not related to the biceps tendon.\n\n4. Another inclusion criterion is that participants must have been working prior to the injury and expected to return to work post-injury. While the patient's employment status is not mentioned, the nature of the injury (spleen rupture) would likely prevent a return to work in the near future.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the \"Early Functional Return to Work Following Distal Biceps Repair\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1133": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete who presented to the ER with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen from a fall off his bike a week earlier.\n\n2. The clinical trial is titled \"Clinical Relevance of Microbleeds In Stroke\" and is studying patients with non-valvular atrial fibrillation (AF) who have had an ischemic stroke or TIA and are starting oral anticoagulants.\n\n3. The inclusion criteria for the clinical trial state that patients must be adults (\u226518 years old) with a clinical diagnosis of non-valvular AF verified by ECG, have had a previous ischemic stroke or TIA diagnosed by a clinician, and be able to have a GRE MRI before or within 1 week of starting oral anticoagulants.\n\n4. Based on the patient note, there is no mention of the patient having atrial fibrillation, a stroke, or a TIA. The patient's presentation is related to abdominal trauma and a ruptured spleen.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1134": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) Adults over 18 years of age and under 65 years of age\nThe patient is 33 years old, so this criterion is met.\n\n2) Refractory cardiac arrest (defined by the failure of professionals to resuscitate at the 20th minute of cardiac arrest with a minimum of 3 Automatic External Defibrillator (AED) or equivalent analyze\nThe patient note does not mention cardiac arrest or failed resuscitation attempts, so this criterion is not met.\n\n3) Beginning of external cardiac massage within the first 5 minutes after cardiac arrest (no flow < 5 min.) with shockable rhythm or the presence of signs of life during resuscitation (any rhythm): spontaneous movement, absence of mydriasis and/or pupillary response, spontaneous breathing movements\nAgain, there is no mention of cardiac arrest or resuscitation attempts in the patient note.\n\n4) Medical cause of the cardiac arrest\nSince there is no mention of cardiac arrest, this criterion cannot be evaluated.\n\n5) End-Tidal CO2 (ETCO2) above 10 mm Hg at the time of inclusion\nNo ETCO2 value is provided in the patient note.\n\n6) Absence of major co-morbidity\nThe patient note does not mention any comorbidities.\n\n7) Extra-corporeal Membrane Oxygenation (ECMO) team available and on-site before the 40th minute\nThere is no information about the availability of an ECMO team in the patient note.\n\nBased on the information provided in the patient note, several key inclusion criteria for this clinical trial cannot be evaluated or are not met. The patient appears to be suffering from a ruptured spleen due to blunt trauma, rather than a cardiac arrest.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1135": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Intermediate-1, intermediate-2, or high-risk PMF, PPV-MF or PET-MF as based on The Dynamic International Prognostic Scoring System (DIPSS) criteria\n- The patient note does not mention the patient having myelofibrosis or any related conditions, so this criterion is not met.\n\n2. Palpable splenomegaly \u22655 cm below the LCM in midclavicular line by physical examination\n- The patient note mentions spleen rupture, but does not specify the size of the splenomegaly, so it's unclear if this criterion is met.\n\n3. TSS \u226513 on the MPN-SAF TSS 2.0, not including the inactivity question, based on a single assessment during screening visit\n- The patient note does not provide any information about the TSS score, so this criterion cannot be evaluated.\n\n4. Age \u226518 years old at the time of screening\n- The patient is 33 years old, so this criterion is met.\n\n5. ECOG performance status 0 to 3\n- The patient note does not provide information about the ECOG performance status, so this criterion cannot be evaluated.\n\n6. Peripheral blast count <10%\n- The patient note does not provide information about the peripheral blast count, so this criterion cannot be evaluated.\n\n7. Absolute neutrophil count >500/\u03bcL\n- The patient note does not provide information about the absolute neutrophil count, so this criterion cannot be evaluated.\n\n8. Participants who are platelet or RBC transfusion dependent are eligible\n- The patient note does not mention any transfusion dependence, so this criterion is likely not applicable.\n\n9. Adequate liver and renal function, defined by specific criteria\n- The patient note does not provide information about liver and renal function, so this criterion cannot be evaluated.\n\n10-13. Criteria related to prior treatments and procedures\n- The patient note does not provide information about prior treatments or procedures, so these criteria cannot be evaluated.\n\n14. If fertile, both males and females must agree to use effective birth control.\n- The patient note does not provide information about fertility or birth control, so this criterion cannot be evaluated.\n\n15-17. Criteria related to understanding the study, completing assessments, and providing informed consent\n- The patient note does not provide information about the patient's ability to understand the study, complete assessments, or provide informed consent, so these criteria cannot be evaluated.\n\nBased on the information provided in the patient note, it is difficult to determine the patient's eligibility for this clinical trial, as many of the key inclusion criteria cannot be evaluated. The only criterion that is clearly met is the age requirement.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1136": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 33-year-old male athlete, which meets the age criteria of 7-18 years old for the clinical trial.\n\n2. The patient presented with acute abdominal pain after suffering blunt trauma to the left hemi-abdomen a week earlier. CT scan revealed intraperitoneal hemorrhage due to spleen rupture.\n\n3. The inclusion criteria for the clinical trial specify patients scheduled for laparoscopic appendectomy surgery with uncomplicated appendicitis and no evidence of appendiceal perforation.\n\n4. Based on the information provided, this patient does not have appendicitis but rather a spleen rupture, which would exclude them from this particular clinical trial.\n\n5. Additionally, the patient is hemodynamically unstable with a blood pressure of 60/30 mmHg and a heart rate of 140/min, which is another exclusion criterion for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1137": {
        "output": "To determine the patient's eligibility for the clinical trial \"Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery\", I will go through the inclusion criteria provided and assess if the patient meets them based on the information given in the patient note.\n\nThe inclusion criteria states: \"Moderate to severe traumatic brain injury\"\n\nFrom the patient note, we can see that the 8-year-old boy suffered a traumatic brain injury after falling from his bike and striking his head. The note mentions that upon arrival at the emergency department, the Glasgow Coma Scale (GCS) score was 6/15, which indicates a severe brain injury. Additionally, the patient exhibited symptoms such as drowsiness, vomiting, asymmetrical pupils, and impaired movement in the right upper and lower extremities, further suggesting a moderate to severe traumatic brain injury.\n\nGiven that the patient meets the inclusion criteria of having a moderate to severe traumatic brain injury, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1138": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. GCS 3-8 on initial evaluation or deteriorates during transport\nThe patient's GCS was 6/15, which falls within this range, so this criterion is met.\n\n2. Mechanism of injury consistent with blunt, non-penetrating trauma to head\nThe patient fell from a bike and struck his left temple, which is consistent with blunt, non-penetrating head trauma, so this criterion is met.\n\n3. Systolic blood pressure > 110 mm Hg\nThe patient's systolic blood pressure was 155 mm Hg, which meets this criterion.\n\n4. Diastolic blood pressure > 60 mm Hg\nThe patient's diastolic blood pressure was 98 mm Hg, which meets this criterion.\n\n5. Heart rate (pulse) < 120 beats per minute\nThe patient's heart rate was 52 beats per minute, which meets this criterion.\n\n6. Estimated or known age 16-45\nThe patient is an 8-year-old boy, which does not meet this age criterion.\n\n7. No suspicion of pregnancy\nThis criterion is not applicable since the patient is a male child.\n\n8. Esophageal/rectal probe temperature > 35.5\u00b0C (Pre-hospital cooling only)\nThere is no information provided about the patient's temperature, so it is unclear if this criterion is met or not.\n\n9. Injured < 2 hours prior to arrival of pre-hospital providers\nThere is no specific information provided about the timing of the injury and arrival of pre-hospital providers, so it is unclear if this criterion is met or not.\n\n10. No evidence of severe chest trauma (unilaterally absent breath sounds with tracheal deviation or distended neck veins or requiring thoracentesis).\nThere is no mention of any chest trauma or related symptoms, so this criterion is likely met.\n\nBased on the information provided, the patient meets some of the inclusion criteria but does not meet the age criterion and there is not enough information to determine if the temperature and timing criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1139": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a traumatic brain injury (TBI) from a bike accident.\n2. The clinical trial is studying prospective memory in children with TBI.\n3. The inclusion criteria for the TBI group are:\n   - English speaker\n   - Minimum birth weight of 2500 grams and 37 weeks' gestation\n   - Head injury resulting in a post-resuscitation Glasgow Coma Scale score of either 13-15 or 3-8\n   - No evidence of hypoxic injury\n\n4. Based on the patient note, the boy suffered a head injury and had a Glasgow Coma Scale score of 6/15, which falls within the inclusion criteria range of 3-8.\n5. There is no information provided about his birth weight/gestation, English proficiency, or evidence of hypoxic injury.\n\nGiven the available information, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the key inclusion criterion of having a TBI with a qualifying Glasgow Coma Scale score. However, additional information would be needed to confirm eligibility, such as birth weight/gestation, English proficiency, and ruling out hypoxic injury or other exclusion criteria.",
        "label": 0
    },
    "1140": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is an 8-year-old boy who suffered a traumatic brain injury after falling from his bike. His Glasgow Coma Scale score upon arrival at the emergency department was 6/15, indicating a severe head injury.\n\nThe inclusion criteria for the clinical trial are:\n1. Traumatic Brain Injury with a Glasgow Coma Score < 9 (severe head injury) - This criterion is met as the patient's GCS was 6/15.\n2. Traumatic Brain Injury with a GCS > 8 with evidence of cerebral edema, midline shift, cerebral contusion, or evacuated subdural hematoma on CT scan - While the patient's GCS was <8, this is an \"or\" criterion, so it's not strictly required.\n3. Enrolled within the first 48 hours after trauma - The note doesn't specify the exact time elapsed, but it seems to imply the patient was brought in shortly after the injury.\n4. Aged 17-70 years - The patient is 8 years old, which falls outside of this age range.\n\nBased on the information provided, the patient meets criteria 1 and 3, but does not meet criterion 4 regarding age.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding the timing of enrollment and any potential exceptions for pediatric patients.",
        "label": 0
    },
    "1141": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of 18-70 years old for this clinical trial.\n\n2. The patient has suffered a severe closed head injury, with a Glasgow Coma Scale (GCS) score of 6/15, which meets the inclusion criteria of GCS 3-9.\n\n3. The patient has asymmetrical pupils, which meets the inclusion criteria of at least one reactive pupil.\n\n4. There is no mention of any known life-threatening disease prior to the trauma, so this inclusion criteria is likely met.\n\n5. There is no mention of brain oxygen monitoring, ventriculostomy/ICP monitor, or microdialysis being performed, so it is unclear if these inclusion criteria are met.\n\n6. There is no mention of a legal family representative being present to give informed consent for perfluorocarbon administration.\n\nOverall, while the patient meets some of the key inclusion criteria, such as severe closed head injury and GCS score, there are several criteria that are unclear or not met, such as age and the presence of a legal family representative.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1142": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effects of Hypothermia Upon Outcomes After Acute Traumatic Brain Injury\", let's go through the inclusion criteria one by one:\n\n1. Non-penetrating brain injury with post-resuscitation Glasgow Coma Score (GCS) < 8 (motor 1-5)\nThe patient has a GCS of 6/15, which meets this criterion.\n\n2. Estimated or known age > 16 and < 45 years old\nThe patient is an 8-year-old boy, which does not meet this criterion.\n\n3. Time of Injury within 2.5hrs of arrival at hospital\nThe patient arrived at the emergency department within half an hour of the injury, which meets this criterion.\n\nSince the patient meets two out of the three inclusion criteria, but fails to meet the age criterion, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the patient does not meet the age criterion, the trial may still consider enrolling the patient if there are no other suitable trials available for pediatric patients with traumatic brain injury. However, further investigation would be needed to determine if an exception can be made for the age criterion or if there are any other relevant factors to consider.",
        "label": 0
    },
    "1143": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a traumatic brain injury after falling from his bike and hitting his head.\n2. The inclusion criteria for the clinical trial include:\n   - Patients with a GCS <= 8\n   - Glasgow Motor Score < 6\n   - Closed head injury\n   - Age 0 < 18 years\n\n3. From the patient note, we can see that the patient's GCS was 6/15, which meets the inclusion criteria of GCS <= 8.\n4. The patient also suffered a closed head injury, which meets another inclusion criterion.\n5. The patient's age of 8 years old falls within the age range of 0 < 18 years, meeting another inclusion criterion.\n6. There is no information provided about the patient's Glasgow Motor Score, so we cannot confirm if they meet that specific criterion.\n\nBased on the information provided, the patient meets several of the key inclusion criteria for the clinical trial, but we cannot definitively confirm eligibility without knowing the Glasgow Motor Score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the Glasgow Motor Score.",
        "label": 2
    },
    "1144": {
        "output": "To determine the patient's eligibility for the \"Hypothermia in Traumatic Brain Injury in Children (HiTBIC)\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Have a severe traumatic brain injury as defined by either a GCS \u2264 8 and an abnormal CT scan (intracranial hemorrhage, cerebral edema or diffuse axonal injury) or a motor score \u2264 3 and normal CT scan\"\n   - The patient has a GCS of 6/15, which satisfies the GCS \u2264 8 criterion.\n   - No information is provided about the CT scan results.\n   - The patient has impaired movement of the right upper and lower extremities, suggesting a motor score \u2264 3.\n\n2. \"Are aged between 1 and 16 years\"\n   - The patient is an 8-year-old boy, which falls within the age range.\n\n3. \"Are mechanically ventilated\"\n   - No information is provided about mechanical ventilation.\n\nBased on the available information, the patient meets the age criterion and has a severe traumatic brain injury as defined by the trial's inclusion criteria. However, there is no information about mechanical ventilation or CT scan results.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1145": {
        "output": "To determine the patient's eligibility for the clinical trial \"Risk Factors of Minor Head Injury\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n- Minor head injury: The patient is an 8-year-old boy who fell from his bike and struck his left temple, which qualifies as a minor head injury.\n- Dizziness: The patient did not report any dizziness.\n- Nausea: The patient did not report any nausea.\n- Vomiting: The patient vomited half an hour after the fall.\n\nBased on the information provided, the patient meets the inclusion criteria of having a minor head injury and experiencing vomiting after the injury.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1146": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who fell from his bike and sustained a head injury.\n2. The inclusion criteria for the clinical trial are: \"Healthy pediatric emergency patients with isolated extremity injury requiring reduction\"\n3. This patient does not have an isolated extremity injury, but rather a head injury with concerning neurological symptoms like drowsiness, vomiting, asymmetric pupils, and impaired limb movement.\n4. Therefore, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1147": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which falls within the age range of \u226538 weeks gestation up to and including 17 years as per the inclusion criteria.\n\n2. The patient suffered a cardiac arrest, as evidenced by the need for compressions for \u22653 minutes, which meets the inclusion criteria.\n\n3. The patient remains comatose with a Glasgow Coma Score of 6/15, which is less than or equal to 10, as required by the inclusion criteria.\n\n4. The patient is on invasive mechanical ventilation, which meets the inclusion criteria.\n\n5. While the patient's consent is not explicitly mentioned, it is reasonable to assume that the parent or legal guardian would provide informed consent for a clinical trial in this situation.\n\nBased on the information provided, this patient meets all the listed inclusion criteria for the \"Hypothermia for Cardiac Arrest in Paediatrics\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1148": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Diagnosis TBI (Traumatic Brain Injury)\nThe patient is an 8-year-old boy who fell from his bike and struck his left temple on the pavement. He later became drowsy, pale, and vomited, suggesting a traumatic brain injury. This criterion is met.\n\n2. GCS 4-8\nThe patient's Glasgow Coma Scale (GCS) score was 6/15, which falls within the range of 4-8. This criterion is met.\n\n3. Age 16-70\nThe patient is an 8-year-old boy, which is outside the age range specified in the inclusion criteria.\n\nBased on the information provided, the patient meets two out of the three inclusion criteria. However, the age criterion is not met, which would likely exclude the patient from participating in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1149": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of 18-70 years old for this clinical trial.\n\n2. The patient suffered a traumatic brain injury (TBI) from a fall, which meets the requirement of having a severe non-penetrating TBI.\n\n3. The patient's Glasgow Coma Scale (GCS) score was 6/15, which falls within the required range of 4-8 for this trial.\n\n4. The patient showed signs of injury on arrival, such as asymmetrical pupils and impaired movement, which aligns with the requirement of definite anatomic signs of injury on a head CT scan.\n\n5. The patient had at least one reactive pupil upon arrival, meeting that inclusion criteria.\n\n6. Since the patient is a minor, informed consent would need to be obtained from a surrogate decision maker, which is allowed per the trial criteria.\n\nWhile the patient meets several key inclusion criteria related to the TBI and clinical presentation, the age requirement is not met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding the age criteria and any potential exceptions or amendments.",
        "label": 0
    },
    "1150": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of \"> 18 year\" for this clinical trial on chronic subdural hematoma.\n\n2. However, the patient did suffer a head injury and was diagnosed with a chronic subdural hematoma that required surgical evacuation, which meets the other inclusion criteria \"Patients with chronic subdural hematoma that needs surgical evacuation\".\n\nSince the patient meets one of the two inclusion criteria but not the other, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe age criteria is strict, but it may be worth discussing with the trial investigators if an exception could be made for a pediatric patient with a chronic subdural hematoma requiring surgery, as this condition is less common in children. More information would be needed to make a final determination.",
        "label": 0
    },
    "1151": {
        "output": "To determine the patient's eligibility for the clinical trial \"Interacting Together Everyday: Recovery After Childhood Traumatic Brain Injury (TBI) I-InTERACT\", let's go through the inclusion criteria one by one:\n\n1. Moderate to severe TBI that occurred within the last 24 months\nThe patient note mentions that the 8-year-old boy suffered a head injury after falling from his bike, and his Glasgow Coma Scale (GCS) score was 6/15, which indicates a severe traumatic brain injury. The note does not specify when the injury occurred, but it is reasonable to assume that it happened within the last 24 months.\n\n2. Overnight hospital stay\nThe patient note does not explicitly mention an overnight hospital stay, but it is implied that the child was transferred to the emergency department and received treatment, which likely involved an overnight stay.\n\n3. English-speaking\nThe patient note does not provide information about the patient's or family's language, but it is reasonable to assume that they are English-speaking since the note is written in English.\n\n4. Parent must be willing to provide informed consent\nThe patient note does not mention whether the parent is willing to provide informed consent, but it is a reasonable assumption that the parent would be willing to participate in an intervention aimed at improving their child's recovery after a traumatic brain injury.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, it is highly likely that this patient would be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1152": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Detection of Vascular Injury in Diabetes Through Eye and Nailfold Data (DIVIDEND) - A Pilot Study\", the patient does not meet the eligibility criteria for this trial.\n\nThe patient note describes an 8-year-old boy who suffered a head injury after falling from his bike, with symptoms suggesting a potential traumatic brain injury. The clinical trial, however, is focused on investigating small blood vessel disease in a pediatric population with type 1 diabetes mellitus.\n\nThe inclusion criteria for the trial specifically state that participants should be between 8-18 years old and have a diagnosis of type 1 diabetes mellitus. The patient note does not mention any diagnosis of diabetes, and the presenting condition is related to a traumatic head injury.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1153": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Children age 6 to 18: The patient is an 8-year-old boy, so he meets this criterion.\n\n2. Language spoken: Hebrew, Arabic: The patient note does not mention the language spoken, so we cannot determine if this criterion is met.\n\n3. DSM-IV R diagnosis: PTSD: The patient note does not mention a PTSD diagnosis, so this criterion is not met.\n\n4. Car accident event within past 3 years: The patient note mentions a fall from a bike, not a car accident, so this criterion is not met.\n\n5. For the m-TBI group:\n   - Any of the following symptoms or experiences occurring during or shortly after the accident: loss of consciousness, dazed, confused, saw stars, headache, dizziness, irritability, memory gap (not remembering injury or injury period), visual loss, abdominal pain]: The patient note mentions no immediate loss of consciousness, but the child became drowsy and vomited half an hour after the fall, which could indicate a mild traumatic brain injury.\n   - Diagnosis of MTBI within 3 years as confirmed by CT/MRI/fMRI: The patient note does not mention a confirmed diagnosis of MTBI.\n   - Glasgow coma scale; GCS<15: The patient note mentions a GCS of 6/15, which meets this criterion.\n\nBased on the information provided, the patient meets some of the inclusion criteria but not all of them. Specifically, the patient does not have a PTSD diagnosis or a car accident event within the past 3 years, which are required for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1154": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of 18-89 years old for this clinical trial.\n\n2. The patient has suffered a head injury and is in a critical condition, which could potentially meet the inclusion criteria of \"critical illness including ischemic or hemorrhagic stroke, epidural/subdural bleeds and subarachnoid hemorrhage\".\n\n3. However, there is no information provided about the expected length of stay in the ICU, which is required to be at least 5 days according to the inclusion criteria.\n\n4. There is also no information provided about the patient's blood glucose levels or hyperglycemia status, which is not an inclusion criterion but may be relevant for a study involving a diabetes-specific enteral formula.\n\nBased on the information provided, there are some criteria that are potentially met and some that are unclear or not met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the expected length of stay in the ICU and the patient's blood glucose levels/hyperglycemia status.",
        "label": 0
    },
    "1155": {
        "output": "Based on the given patient note and the clinical trial information, this patient would not be eligible for the \"Clinical Trial of Bilhvax, a Vaccine Candidate Against Schistosomiasis\" trial. The key reasons are:\n\n1. The patient is an 8-year-old boy, while the inclusion criteria specify \"adult healthy volunteers\".\n2. The patient has suffered a head injury and is in a critical condition, which does not align with the requirement of \"healthy volunteers\".\n3. There is no information provided about the patient's ethnicity, but the inclusion criteria specifically mention \"Caucasian volunteers\".\n\nTherefore, considering the patient's age, current medical condition, and the lack of information about ethnicity, it is highly unlikely that this patient would be referred for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1156": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes an 8-year-old boy who suffered a head injury after falling from his bike. He developed concerning neurological symptoms such as drowsiness, vomiting, and impaired consciousness and motor function, suggesting a potential traumatic brain injury.\n\nThe clinical trial titled \"The Affect of a Ventilated Helmet on Physiological Load\" is studying the effects of a ventilated helmet on cognitive and physiological strain during exertional heat stress conditions. The inclusion criteria specify healthy civilian volunteers aged 21-28 without known medical illnesses or medication use.\n\nGiven that the patient is an 8-year-old boy with a potential traumatic brain injury, he would not meet the inclusion criteria for this clinical trial, which requires healthy adult volunteers within a specific age range.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1157": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a head injury after falling from his bike. He initially had no loss of consciousness but later became drowsy, pale, and vomited.\n\n2. Upon arrival at the emergency department, his vital signs showed tachycardia and hypertension. His GCS was 6/15, with asymmetrical pupils and right-sided neurological deficits.\n\n3. The clinical trial is investigating induced hypertension for the treatment of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.\n\n4. The inclusion criteria for the trial specify that participants must be 18 years or older, have an aneurysmal subarachnoid hemorrhage, and provide informed consent.\n\n5. The exclusion criteria include evidence of delayed cerebral ischemia within 3 hours of the hemorrhage, severe head injury, perimesencephalic hemorrhage, cardiac rhythm disorders, heart failure, and pregnancy.\n\n6. Based on the patient note, this 8-year-old boy does not meet the inclusion criteria for age (he is not 18 years or older) and does not have an aneurysmal subarachnoid hemorrhage. Instead, he has a head injury from a fall.\n\n7. Additionally, he meets the exclusion criterion of having a severe head injury.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1158": {
        "output": "To determine the patient's eligibility for the clinical trial \"The Value of the Canadian CT Head Rule and the New Orleans Criteria in Minor Head Trauma\", let's go through the inclusion criteria:\n\nInclusion Criteria:\nPatient with acute MHI was defined as a patient having a blunt trauma to the head within 24 hours with a Glasgow Coma Scale (GCS) of 13 to 15 and at least 1 of the following risk factors: history of loss of consciousness, short-term memory deficit, amnesia for the traumatic event, post-traumatic seizure, vomiting, headache, external evidence of injury above the clavicles, confusion, and neurologic deficit.\n\nFrom the patient note, we can see that:\n1. The patient is an 8-year-old boy who fell from his bike and struck his left temple, which qualifies as a blunt trauma to the head within 24 hours.\n2. The patient's initial GCS was not provided, but later it was 6/15, which is lower than the required range of 13 to 15.\n3. The patient experienced vomiting, which is one of the risk factors listed.\n4. The patient had neurologic deficit, with impaired movement of the right upper and lower extremities, which is another risk factor listed.\n\nBased on the information provided, the patient meets some of the inclusion criteria, such as having a blunt trauma to the head within 24 hours, vomiting, and neurologic deficit. However, the patient's GCS of 6/15 is lower than the required range of 13 to 15, which is a crucial criterion for inclusion in this trial.\n\nTherefore, considering the low GCS score, which indicates a more severe head injury, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1159": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a head injury after falling from his bike. He initially seemed fine but then became drowsy, pale, and vomited about 30 minutes later. His vital signs and neurological exam findings upon arrival to the ED are concerning for an intracranial injury.\n\n2. The clinical trial is the \"Leuven Growing Into Deficit Follow-up Study\" which is studying neurocognitive impairment in 7-year-old children with congenital heart disease compared to healthy controls. \n\n3. The key inclusion criteria are:\n- 7-year-old children \n- With congenital heart disease who underwent cardiac surgery as infants\n- Or healthy control children\n- Who participated in a previous study at age 4\n\n4. This 8-year-old patient does not have a congenital heart disease or history of infant cardiac surgery. He is also not a previous participant from the age 4 study.\n\n5. Therefore, he does not meet the inclusion criteria for this neurocognitive follow-up study of children with congenital heart disease.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1160": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a traumatic head injury after falling from his bike. He initially had no loss of consciousness but later became drowsy, pale, and vomited.\n\n2. Upon arrival at the emergency department, his vital signs showed tachycardia and hypertension. His GCS was 6/15, pupils were asymmetrical, and he had right-sided weakness.\n\n3. The clinical trial is studying the use of Normal Saline (NS) versus Ringer's Lactate (RL) in pediatric trauma patients with an Injury Severity Score greater than 12, aged 1-17 years, and presenting within 8 hours of trauma.\n\n4. Based on the information provided, this patient meets the inclusion criteria for the clinical trial:\n   - He is a pediatric trauma patient\n   - His head injury suggests an Injury Severity Score greater than 12\n   - He is 8 years old, which falls within the 1-17 year age range\n   - He presented to the emergency department within 8 hours of the trauma\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1161": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of 18 years or older for this clinical trial.\n\n2. The patient has a traumatic brain injury (TBI) from a fall, which meets the inclusion criteria of having a primary diagnosis of TBI.\n\n3. There is no information provided about whether the patient requires mechanical ventilation or continuous IV sedation.\n\nBased on the available information, the patient does not clearly meet all the inclusion criteria. However, given the TBI diagnosis, I would consider referring this patient to this clinical trial upon further investigation of whether mechanical ventilation and continuous IV sedation are required.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1162": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which falls outside the age range of 10 to less than 17 years specified in the inclusion criteria.\n\n2. There is no mention of the patient having diabetes or diabetic ketoacidosis, which are required conditions according to the inclusion criteria.\n\n3. The study is focused on evaluating a non-invasive brain compliance measurement device in relation to diabetic ketoacidosis and its effects on the brain, learning, and development.\n\n4. The patient's condition appears to be related to a head injury from a fall, which is not relevant to the study's focus on diabetic ketoacidosis.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1163": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a traumatic brain injury (TBI) after falling from his bike and hitting his head.\n2. The clinical trial is studying physiologic mechanisms in pediatric TBI patients.\n3. The inclusion criteria for the trial are:\n   - TBI patients admitted to the pediatric intensive care service (PICU) or pediatric progressive care unit\n   - Age range from birth to 15 years\n   - TBI with a Glasgow Coma Scale of 3-15\n   - Acoustic window for adequate transcranial doppler (TCD) ultrasound\n   - English or Spanish speaking or understanding parent/legal guardian to consent\n   - Access for a buccal swab for genotyping\n\n4. Based on the patient note, the 8-year-old boy meets the following inclusion criteria:\n   - TBI patient admitted to the emergency department (likely to be admitted to PICU)\n   - Age of 8 years (within the range of birth to 15 years)\n   - Glasgow Coma Scale of 6/15 (within the range of 3-15)\n   - No information provided about acoustic window or language/consent, but these can likely be determined upon further investigation\n\n5. While not all criteria are explicitly met based on the information provided, the patient appears to be a potential candidate for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1164": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of being 60 years or older.\n\n2. The patient has suffered a head injury and likely has an acute subdural hematoma, not a chronic subdural hematoma which is required for inclusion.\n\n3. The trial is specifically looking at the effect of subdural drain placement after burr hole evacuation of chronic subdural hematomas on recurrence rates. This patient's acute condition requires immediate treatment, not the intervention being studied.\n\n4. There is no information provided about the patient's ethnicity, but the inclusion criteria specifies ethnic Chinese patients only.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1165": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of \"18 or more years old\".\n\n2. The patient has suffered a head injury from a fall, which could potentially qualify as an \"acute intellectual Aggression bound to a cranial trauma\".\n\n3. The patient was admitted to the emergency department, which may or may not count as being \"Admission in resuscitation within first 48 hours of the aggression\".\n\n4. The patient's Glasgow Coma Scale score of 6/15 meets the inclusion criteria of \"Score of Glasgow < 9\".\n\nOverall, while the patient meets some of the inclusion criteria, the age criteria is a clear exclusion factor. There are also some ambiguities around whether the emergency department counts as a resuscitation admission within 48 hours.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1166": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis\" and assess the eligibility of the patient based on the provided note.\n\nThe patient is an 8-year-old boy, so he does not meet the age criteria of being between 30 and 80 years old.\n\nThe patient had a traumatic brain injury after falling from a bike, which does not seem to be related to intracranial arterial stenosis or stroke, as required by the inclusion criteria.\n\nThe patient's Glasgow Coma Scale score of 6/15 suggests a severe neurological deficit, which may or may not be compatible with the required Modified Rankin Scale score of \u22643, depending on the specific deficits.\n\nThere is no mention of the patient having a confirmed 70-99% stenosis of a major intracranial artery, which is a key inclusion criterion.\n\nBased on the provided information, it does not appear that this patient would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1167": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the inclusion criteria of being at least 18 years of age.\n\n2. The patient has suffered a head injury and likely has a subdural hematoma, based on the symptoms described (drowsiness, vomiting, asymmetrical pupils, impaired limb movement).\n\n3. The clinical trial is specifically studying chronic subdural hematomas, and it is not clear from the patient note whether this is a chronic or acute subdural hematoma.\n\n4. Overall, while the patient may have a subdural hematoma, they do not meet the age criteria, and it is unclear if the hematoma is chronic or acute.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to determine if the subdural hematoma is chronic or acute.",
        "label": 0
    },
    "1168": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a traumatic brain injury (TBI) after falling from his bike and striking his head.\n2. The clinical trial is studying the use of methylphenidate for attention problems after pediatric TBI.\n3. The inclusion criteria for the trial are:\n   - Between ages of 6-17 (the patient is 8 years old, so he meets this criterion)\n   - Sustained Moderate to Severe TBI (the patient's Glasgow Coma Scale score of 6/15 and other symptoms suggest a moderate to severe TBI, so he meets this criterion)\n   - TBI occurred at least 6 months prior to beginning the study (the note does not specify when the TBI occurred, so we cannot confirm this criterion)\n   - TBI occurred no earlier than 5 years of age (the patient is 8 years old, so this criterion is likely met)\n   - Positive endorsement of 6 out of 9 items on the Vanderbilt ADHD inattention or hyperactivity scale (the note does not provide this information, so we cannot confirm this criterion)\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there are also some criteria that cannot be confirmed from the note. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1169": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, so he does not meet the age criteria of being 18 years or older for this clinical trial.\n\n2. The patient has suffered a recent head injury, not one that occurred at least 6 months ago as required by the inclusion criteria.\n\n3. There is no information provided about the patient's score on the OSU-TBI ID Survey, visual acuity, or visual field reliability.\n\n4. Given the acute nature of the head injury and the patient's young age, it is highly unlikely that he would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1170": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which meets the age/weight criteria of \"Estimated Age \u2265 15 (or estimated weight > 50 kg if age is unknown)\".\n2. The patient suffered a traumatic brain injury from a fall, which is consistent with the inclusion criteria of \"Blunt or penetrating traumatic mechanism consistent with traumatic brain injury\".\n3. The patient had a Glasgow Coma Scale (GCS) score of 6/15 upon arrival at the emergency department, which meets the criteria of \"Prehospital Glasgow Coma Score (GCS) score \u2264 12 at any time prior to randomization and administration of sedative and/or paralytic agents\".\n4. The patient had a blood pressure of 155/98 upon arrival, which meets the criteria of \"Prehospital systolic blood pressure (SBP) \u2265 90 mmHg prior to randomization\".\n5. The patient was being transported to the emergency department, which implies that the transport destination would be a participating trauma center, meeting the criteria of \"Emergency Medicine System (EMS) transport to a participating trauma center\".\n\nBased on the information provided, this patient meets all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1171": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of \u226518 and <90 years old for this clinical trial.\n\n2. The patient has a head injury with subdural hematoma, which aligns with the inclusion criteria of having a chronic subdural hematoma confirmed by CT scan.\n\n3. The patient's Glasgow Coma Scale score is 6/15, which meets the inclusion criteria of Markwalder's Grading Scale and Glasgow Coma Scale (MGS-GCS)<Grade 3.\n\n4. The patient has not undergone surgery on the hematoma, which meets the inclusion criteria.\n\n5. However, there is no information provided about whether the patient or their legal guardian understood the nature of the study and provided informed consent.\n\nOverall, while the patient meets some of the key inclusion criteria, the age criterion is not met, and there is no information about informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding informed consent and discussion with the clinical team about the age criterion.",
        "label": 0
    },
    "1172": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age criteria of 18-85 years for the clinical trial.\n\n2. The patient suffered a head injury from a fall, but it is not clear if there was an intracerebral or intraparenchymal hemorrhage, which is required for inclusion in the trial.\n\n3. The location of the potential hemorrhage is not specified, but the trial requires a supratentorial (above the tentorium in the brain) location.\n\nBased on the information provided in the patient note, there are not enough details to definitively determine eligibility for this specific clinical trial. More information would be needed regarding the presence, type, and location of any hemorrhage.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1173": {
        "output": "To determine the patient's eligibility for the clinical trial \"To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients\", let's go through the inclusion criteria one by one:\n\n1. Non-penetrating traumatic brain injury: The patient suffered a traumatic brain injury from falling off a bike and striking his head, which is a non-penetrating injury. This criterion is met.\n\n2. Glasgow Coma Scale (GCS) motor score \u22645 (not following commands): The patient's GCS score is reported as 6/15, which indicates a motor score of less than or equal to 5 (not following commands). This criterion is met.\n\n3. Estimated or known age 22-65 years: The patient is an 8-year-old boy, which does not meet the age criterion of 22-65 years.\n\n4. Acute subdural hematoma requiring emergent craniotomy within 6 hours of initial injury: The patient has an acute subdural hematoma, and the neurosurgical team advised immediate treatment, suggesting an emergent craniotomy is required within 6 hours of the initial injury. This criterion is met.\n\n5. Estimated time of injury to time to reach temp of 35\u00b0C<6 hrs: There is no information provided about the estimated time to reach a temperature of 35\u00b0C, so it is unclear if this criterion is met.\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria. The age criterion is not met, and there is insufficient information to determine if the time to reach the target temperature criterion is met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1174": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a head injury after falling from his bike and striking his left temple.\n2. Initially, he did not lose consciousness and was moving all four limbs.\n3. However, half an hour later, he became drowsy, pale, and vomited, which are concerning signs of a potential brain injury.\n4. Upon arrival at the emergency department, his Glasgow Coma Scale (GCS) was 6/15, indicating an altered level of consciousness.\n5. He also had asymmetrical pupils and impaired movement of the right upper and lower extremities, suggesting a focal neurological deficit.\n6. The neurosurgical team advised deferring the CT scan and initiating immediate treatment, implying a suspected brain injury.\n\nNow, let's look at the inclusion criteria for the clinical trial:\n\n1. The trial is recruiting patients with traumatic brain injury (TBI), including both structural (evident on CT scan) and non-structural (concussion) cases.\n2. For non-structural TBI (concussion), the criteria include loss of consciousness, memory loss, altered mental state, and focal neurological deficits, with specific limits on the duration of loss of consciousness, initial GCS score, and post-traumatic amnesia.\n\nBased on the information provided, this patient appears to meet the criteria for a non-structural TBI (concussion) due to the following:\n\n- Altered mental state (drowsiness, vomiting)\n- Focal neurological deficit (asymmetrical pupils, impaired movement of the right side)\n- Initial GCS score of 6/15, which falls within the specified range of 13-15\n\nTherefore, considering the patient's age, presenting symptoms, and the inclusion criteria for the clinical trial, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1175": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of \u226518 and <90 years old for this clinical trial.\n\n2. There is no mention of the patient having coagulation disorders or being on antiplatelet/anticoagulant drugs, which is a key inclusion criteria.\n\n3. The patient has an acute subdural hematoma from a traumatic head injury, not a chronic subdural hematoma which is the condition being studied in this trial.\n\n4. The patient's Glasgow Coma Scale score of 6/15 suggests a severe brain injury requiring urgent treatment, not conservative management which is another inclusion criteria.\n\nBased on the provided patient note and inclusion criteria, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1176": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a head injury after falling from his bike. He initially seemed okay but then became drowsy, pale, and vomited about 30 minutes later.\n\n2. Upon arrival at the hospital, his vital signs showed tachycardia and hypertension. His GCS was 6/15, pupils were asymmetric, and he had right-sided weakness.\n\n3. The neurosurgical team recommended immediate treatment instead of getting a CT scan first.\n\n4. The clinical trial is studying the use of fibrinogen concentrate vs placebo in trauma patients at risk of significant bleeding to prevent excessive bleeding.\n\n5. The key inclusion criteria are: injured trauma patient with systolic BP \u2264 100mmHg at any time from injury until 30 mins after hospital admission, and red blood cell transfusion ordered by the trauma team leader.\n\n6. This 8-year-old patient meets the inclusion criteria of being a trauma patient and likely needing a blood transfusion based on his presenting symptoms of head injury and neurological deficits.\n\nTherefore:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1177": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age criteria of being 18 years or older for this clinical trial.\n\n2. The patient has suffered a head injury and has a Glasgow Coma Scale (GCS) score of 6/15, which does not meet the inclusion criteria of being able to have a normal conversation and understand the information about the study (corresponding to a GCS Verbal Response of 5).\n\n3. While the patient has likely suffered a subdural hematoma based on the symptoms described, it is not explicitly stated that this is a chronic subdural hematoma, which is required for inclusion in this trial.\n\n4. There is no mention of whether a CT scan has been performed within the last 96 hours, which is another inclusion criteria.\n\nBased on the information provided in the patient note, this patient does not meet several of the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1178": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of \u226518 years for this clinical trial on subarachnoid hemorrhage.\n\n2. The patient had a traumatic head injury from a fall, not a spontaneous subarachnoid hemorrhage which is required for inclusion.\n\n3. The Glasgow Coma Scale (GCS) score of 6/15 meets the inclusion criteria of GCS \u226412. \n\n4. However, the cause of the patient's symptoms (head trauma) excludes them based on the exclusion criteria \"SAH due to any other cause or structural abnormality of the brain (trauma, dissection, arterio-venous malformation, dural arterio-venous fistula)\".\n\nOverall, while the patient meets some of the inclusion criteria like GCS score, they do not have the target condition of spontaneous subarachnoid hemorrhage and have an explicit exclusion of head trauma causing their symptoms.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1179": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a head injury after falling from his bike. He initially seemed fine but then became drowsy, pale, and vomited about 30 minutes later.\n\n2. Upon arrival at the emergency department, his vital signs showed tachycardia and hypertension. His GCS was 6/15, pupils were asymmetrical, and he had right-sided weakness.\n\n3. The clinical trial is studying the long-term neurotoxic effects of chemotherapy in survivors of pediatric bone and soft tissue sarcomas.\n\n4. The inclusion criteria specify that participants must be survivors of pediatric bone or soft tissue sarcomas treated with certain chemotherapy protocols at UZ Leuven hospital from 1992 onwards.\n\n5. This patient does not appear to have a bone or soft tissue sarcoma. He has suffered an acute head injury, likely a traumatic brain injury.\n\n6. Therefore, based on the information provided, this patient would not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1180": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes an 8-year-old boy who suffered a head injury after a fall from a bike. He initially appeared stable but later developed concerning neurological symptoms, including decreased consciousness, pupillary asymmetry, and impaired limb movement. The neurosurgical team recommended immediate treatment without a CT scan.\n\nThe clinical trial titled \"Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study\" aims to study the incidence and screening methods for opioid withdrawal syndrome in critically ill adult patients who have received prolonged opioid administration.\n\nThe key inclusion criterion for this trial is \"intermittent use or continuous infusion opioids for at least 96 hours.\"\n\nGiven that the patient is an 8-year-old child and the trial is focused on adult patients, it is highly unlikely that this patient would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1181": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, so he does not meet the age criteria of 18 years and older for this clinical trial.\n\n2. The patient has suffered a head injury and likely has an acute subdural hematoma, not a chronic subdural hematoma which is the focus of this trial.\n\n3. The patient's Glasgow Coma Scale score is 6/15, which would likely be classified as higher than a 2 on the Markwalder grading scale, making him ineligible.\n\n4. There is no mention of the patient having a supratentorial (above the tentorium cerebelli) subdural hematoma, which is an inclusion criteria.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1182": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who sustained an injury from falling off his bike and hitting his head.\n2. The clinical trial is studying injuries related to exposed metal handlebar ends in bicycles and kick scooters for children aged 0-15 years.\n3. The patient meets the age criteria (0-15 years) for the clinical trial.\n4. The patient sustained an injury involving a non-motorized bicycle, which meets the inclusion criteria.\n5. The patient is presenting to the hospital for assessment and treatment of the injury, which also meets the inclusion criteria.\n\nBased on the information provided, this patient appears to meet all the stated inclusion criteria for the \"Handlebar Grip Related Injury Prevention (GRIP) Study\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1183": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is an 8-year-old boy who suffered a traumatic brain injury (TBI) after falling from his bike and hitting his head. He initially seemed fine but then became drowsy, pale, and vomited about 30 minutes later. At the emergency department, his Glasgow Coma Scale score was 6/15, indicating an altered mental status. He also had asymmetric pupils and right-sided weakness.\n\nThe clinical trial is studying the use of fast MR imaging (instead of CT scans which expose children to radiation) in young children under 6 years old with suspected traumatic brain injury.\n\nThe key inclusion criteria are:\n1) Children under 72 months (6 years) old\n2) Head CT ordered/obtained with concerns for TBI\n3) Presenting to the emergency department or inpatient wards\n\nThis patient meets all of those criteria:\n1) He is 8 years old, which is under 72 months\n2) He suffered a TBI and likely had a head CT ordered based on his symptoms\n3) He presented to the emergency department\n\nTherefore, based on the information provided, this patient would be highly eligible for this clinical trial studying fast MR imaging in young children with TBI.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1184": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a head injury after falling from his bike. He initially seemed fine but then became drowsy, pale, and vomited about 30 minutes later.\n\n2. Upon arrival at the emergency department, his vital signs showed tachycardia and hypertension. His GCS was 6/15, indicating a severe brain injury. He had asymmetric pupils and right-sided weakness.\n\n3. The neurosurgical team recommended deferring the CT scan and initiating immediate treatment, suggesting a likely intracranial hemorrhage or mass effect.\n\n4. The clinical trial is studying whether ablating vestibular function prior to schwannoma surgery improves postoperative vestibular and postural compensation.\n\n5. The inclusion criteria are: 1) Vestibular schwannoma advised for surgical treatment, and 2) No measurable remaining vestibular function.\n\n6. Based on the patient note, there is no mention of a schwannoma or any vestibular dysfunction. The patient's symptoms and presentation are consistent with an acute traumatic brain injury, likely an intracranial hemorrhage.\n\nTherefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1185": {
        "output": "Let's go through the inclusion criteria for this clinical trial:\n\n1. Patients with ASA I to II: The patient note does not mention the ASA physical status, so we cannot determine if this criterion is met.\n\n2. Scheduled for elective head and neck surgery with minimum expected duration of 2 hours, requiring general anesthesia: The patient note mentions that the patient is an 8-year-old boy who suffered a head injury after falling from his bike. There is no indication that he is scheduled for an elective head and neck surgery.\n\nBased on the information provided in the patient note, it is unlikely that this patient meets the inclusion criteria for this clinical trial, as it appears to be focused on evaluating the effects of remifentanil during elective head and neck surgeries.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1186": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Patients treated in the ICU with the diagnosis of traumatic or nontraumatic brain damage\n2. More than 24-hour stay\n\nBased on the patient note, this 8-year-old boy suffered a traumatic brain injury after falling from his bike and striking his head. He was then transferred to the emergency department, where his Glasgow Coma Scale score was 6/15, indicating a severe brain injury. The note mentions that the neurosurgical team advised immediate treatment, implying that he would be admitted to the ICU.\n\nTherefore, this patient meets the inclusion criteria of being treated in the ICU for traumatic brain damage.\n\nAs for the 24-hour stay requirement, the note does not explicitly state the duration of the patient's stay. However, given the severity of the injury and the need for immediate treatment, it is highly likely that the patient would be admitted for more than 24 hours.\n\nStep-by-step reasoning:\n1. The patient suffered a traumatic brain injury after a fall.\n2. The patient's condition deteriorated, and he was transferred to the emergency department with signs of severe brain injury.\n3. The neurosurgical team advised immediate treatment, implying admission to the ICU.\n4. The patient meets the inclusion criteria of being treated in the ICU for traumatic brain damage.\n5. While the duration of stay is not specified, the severity of the injury suggests a stay longer than 24 hours.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1187": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which falls within the age range of 2-17 years specified in the inclusion criteria.\n\n2. The patient has suffered a suspected long-bone fracture (left temple injury after falling from a bike), which meets the inclusion criteria of \"suspected fracture of a long bone\".\n\n3. The patient's condition requires morphine analgesia, as evidenced by the Glasgow Coma Scale score of 6/15 and impaired movement of the right upper and lower extremities, which suggests a severe injury and likely significant pain.\n\n4. The patient presented within the first 12 hours after the injury, as specified in the inclusion criteria.\n\n5. While parental informed consent is not explicitly mentioned in the patient note, it is a reasonable assumption that this would be obtained for an 8-year-old patient in an emergency setting.\n\n6. There is no information provided about the patient's health insurance status, but this is a common requirement for most clinical trials.\n\nBased on the information provided, this patient appears to meet most of the key inclusion criteria for the clinical trial. However, there are a few potential concerns:\n\n1. The injury is to the left temple, which may not be considered a \"long-bone fracture\" as specified in the inclusion criteria.\n\n2. The patient's condition appears to be quite severe, with a low GCS score and impaired movement, which may exclude them from participating in a clinical trial due to the potential risks involved.\n\nOverall, I would consider referring this patient to this clinical trial upon further investigation, as they appear to meet most of the key criteria, but there are some potential concerns that would need to be addressed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1188": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy, which does not meet the age inclusion criteria of \u226518 years for this clinical trial on stroke prevention in non-valvular atrial fibrillation (NVAF).\n\n2. There is no mention of the patient having a diagnosis of NVAF, which is a key inclusion criteria.\n\n3. The patient appears to have suffered a head injury from a fall, rather than having a stroke or atrial fibrillation.\n\n4. Based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1189": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is an 8-year-old boy who suffered a head injury after falling from his bike. He initially seemed fine but then became drowsy, pale, and vomited about 30 minutes later.\n\n2. Upon arrival at the emergency department, his vital signs showed tachycardia and hypertension. His GCS was 6/15, pupils were asymmetric, and he had right-sided weakness.\n\n3. The neurosurgical team recommended immediate treatment instead of getting a CT scan first.\n\n4. The clinical trial is studying the use of tranexamic acid for the treatment of chronic subdural hematomas.\n\n5. The key inclusion criteria are: CT scan demonstrating a subdural hematoma with a chronic component, and diagnosis within the last 14 days.\n\n6. Based on the patient note, this 8-year-old boy likely has an acute subdural hematoma from his head injury, not a chronic one. The clinical presentation also suggests this is an acute event.\n\n7. Therefore, this patient would not meet the inclusion criteria for the tranexamic acid clinical trial, which is specifically for chronic subdural hematomas.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1190": {
        "output": "To determine the trial-level eligibility for this patient group, let's go through the inclusion criteria one by one:\n\n1. Healthy adult: male or female\nThe patient note mentions that the group consists of 14 humanitarian service workers, so they are likely adults. However, it does not specify if they are all healthy.\n\n2. Asymptomatic mono-infection with P. falciparum parasitemia with a parasite density of 1000 - 30,000 parasites/\u03bcL\nThe patient note does not mention any information about the group members having malaria or P. falciparum infection.\n\n3. Age 18 years to 60 years\nThe patient note does not provide specific ages, but it is reasonable to assume that humanitarian service workers are within this age range.\n\n4. Willingness to sign and ability to understand consent form\nThe patient note does not provide information about the group's willingness or ability to sign a consent form.\n\n5. Willingness and ability to return for scheduled follow up visits\nThe patient note does not mention anything about the group's ability or willingness to return for follow-up visits.\n\nBased on the limited information provided in the patient note, it is difficult to determine with certainty whether the group members would be eligible for this clinical trial. The key missing information is whether they have asymptomatic P. falciparum infection and their willingness to participate in the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1191": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note mentions a group of 14 humanitarian service workers preparing for a trip to the Amazon Rainforest region in Brazil. It states that all members have up-to-date vaccine certificates, and malaria chemoprophylaxis is indicated. However, three of the women in the group are in different stages of pregnancy.\n\nThe clinical trial titled \"Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda\" has the following inclusion criteria:\n\n1. Pregnant women\n2. 14-24 weeks gestation\n3. Consent\n4. Presenting for ANC at study hospitals/centers\n5. Agree to have an HIV test and to be examined for viral load\n\nWhile the patient note mentions that three women in the group are pregnant, it does not provide any information about their gestational age, whether they are receiving antenatal care at the study hospitals/centers, or if they have consented and agreed to HIV testing and viral load examination.\n\nTherefore, based on the limited information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional details regarding the specific gestational age, antenatal care status, and willingness to undergo HIV testing and viral load examination for the three pregnant women would be needed to determine their eligibility for this clinical trial more definitively.",
        "label": 0
    },
    "1192": {
        "output": "To determine the trial-level eligibility for this patient group, let's go through the inclusion criteria one by one:\n\n1. Ages 6 weeks to 59 months\nThe patient note does not mention the ages of the individuals in the group. However, it states that they are \"humanitarian service workers,\" which implies that they are adults and not within the age range specified in the inclusion criteria.\n\n2. Residence in the study area\nThe patient note mentions that the group is preparing a trip to the Amazon Rainforest region in Brazil, while the clinical trial is being conducted in Senegal. Therefore, they do not meet this inclusion criterion.\n\n3. Informed consent\nThe patient note does not provide any information about whether the individuals in the group have provided informed consent to participate in the clinical trial.\n\nBased on the information provided, this group of humanitarian service workers does not meet at least two of the inclusion criteria for the clinical trial. Therefore, they would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1193": {
        "output": "To determine the trial-level eligibility for this group of humanitarian service workers, let's go through the inclusion criteria one by one:\n\n1. Written informed consent: This is not mentioned in the patient note, but it can be obtained if the group agrees to participate.\n\n2. Available for 4 x monthly follow ups: The patient note does not provide information about the duration of their stay in the Amazon Rainforest region. However, as humanitarian service workers, they may be able to accommodate the monthly follow-ups during their trip.\n\n3. 5 or more individuals in household: The patient note mentions that the group consists of 14 members, which satisfies this criterion.\n\nWhile the patient note does not explicitly state that the group will be staying in households in the Bolivian Amazon, it is reasonable to assume that they will be residing in some form of accommodation during their trip to the Amazon Rainforest region in Brazil.\n\nHowever, it is important to note that three of the women in the group are in different stages of pregnancy. Depending on the specific insect repellent being used in the trial, there may be potential risks or contraindications for pregnant women.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to assess the potential risks or safety concerns for the pregnant women in the group, as well as to confirm their willingness to provide written informed consent and their availability for the monthly follow-ups during their stay in the Amazon Rainforest region.",
        "label": 1
    },
    "1194": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil.\n2. It states that all members of the group have up-to-date vaccine certificates, indicating they are likely healthy individuals.\n3. Malaria chemoprophylaxis is indicated, suggesting they are at risk of contracting malaria during their trip.\n4. Three of the women in the group are in different stages of pregnancy.\n\n5. The clinical trial is studying the efficacy and effectiveness of a combination therapy for uncomplicated malaria due to P. falciparum in Peru.\n6. The inclusion criteria specify that participants must be at least 1 year old, have a fever or history of fever in the past 48 hours, have an unmixed P. falciparum infection within a certain parasite count range, provide informed consent, and be willing to come for follow-up visits over 28 days.\n\n7. Based on the information provided, the group of humanitarian service workers appears to meet most of the inclusion criteria, except for the three pregnant women.\n8. Pregnancy is often an exclusion criterion in clinical trials due to potential risks to the fetus.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe non-pregnant members of the group could potentially be eligible for the trial, but further investigation would be needed to confirm their specific malaria infection status and willingness to participate in the study. The pregnant women would likely be ineligible due to their pregnancy status.",
        "label": 0
    },
    "1195": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Male or female aged 18 or older\" - The patient note does not specify ages, but it mentions a group of humanitarian service workers, so we can assume they are adults aged 18 or older. This criterion is likely met.\n\n2. \"Non-immune patients suffering from acute uncomplicated P. falciparum malaria, or mixed infection including P. falciparum, with parasitemia of less than or equal to 2% asexual P.falciparum parasites, confirmed by microscopy using Giemsa-stained thick film.\" - The patient note does not mention any of the group members having malaria, so this criterion is not met.\n\n3. \"Non-immune patients were regarded as those who had not spent the first five years of their life, nor the last five years in a malaria endemic area, and did not have acute P. falciparum malaria diagnosed during those past five years.\" - Again, there is no information about the group members' malaria history or exposure, so we cannot determine if this criterion is met or not.\n\n4. \"Non-immune patients who had received prophylaxis with anti-malarials (excluding halofantrine) were included only if clear progression of acute P. falciparum infection was documented.\" - The note mentions that malaria chemoprophylaxis is indicated, but it does not specify if any of the group members are taking it or have progressed to acute malaria infection.\n\n5. \"Female patients were eligible to participate in the study if they were of non-childbearing potential or had a negative pregnancy test (urine or serum) at screening, and using an acceptable contraceptive method\" - The note states that three of the women in the group are pregnant, so they would not meet this criterion.\n\n6. \"Patients, who had been informed of the study procedures and medication, and had given written informed consent and were willing to comply with the study protocol.\" - There is no information about whether the group members have been informed about the study or given consent.\n\nBased on the information provided in the patient note, it is unlikely that any of the group members would be eligible for this clinical trial, as there is no indication that they have acute uncomplicated P. falciparum malaria, and the pregnant women would be excluded.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1196": {
        "output": "To determine the trial-level eligibility for this clinical trial, let's go through the inclusion criteria one by one:\n\n1. Primigravida or Secundigravida: The patient note mentions that there are three pregnant women in the group, but it does not specify their gravida status. So, we cannot confirm if they meet this criterion.\n\n2. Permanent resident: The patient note states that this is a group of humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. This implies that they are not permanent residents of the study area in Ghana.\n\n3. Hemoglobin (Hb) > 7 g/dl: There is no information provided about the hemoglobin levels of the pregnant women.\n\nSince the patient note lacks crucial details about the gravida status, residency, and hemoglobin levels of the pregnant women, it is difficult to determine their eligibility for this clinical trial with certainty.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1197": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. It mentions that all members have up-to-date vaccine certificates and that malaria chemoprophylaxis is indicated, but three of the women are in different stages of pregnancy.\n\n2. The clinical trial is titled \"Early Childhood Malaria Prevention With Maloprim in The Gambia\" and is focused on assessing the impact of malaria chemoprophylaxis with Maloprim on mortality, morbidity, cognitive abilities, and educational outcomes in young children aged 3-59 months.\n\n3. The inclusion criteria for the original trial were children aged 3-59 months present in participating villages, and for the follow-up, children who were in the original trial for at least 1 year.\n\n4. Based on the information provided, the group of humanitarian service workers does not meet the inclusion criteria for this clinical trial, as the trial is focused on young children and not adults.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1198": {
        "output": "To determine the trial-level eligibility for this patient group, let's go through the inclusion criteria one by one:\n\n1. Permanent residents of the Luanshya district: The patient note does not mention where the group resides, so this criterion cannot be evaluated.\n\n2. Males and non-pregnant adults between 18 and 50 years old: The patient note mentions that the group consists of 14 humanitarian service workers, but it does not specify their ages or genders. However, it does state that three of the women are in different stages of pregnancy, which would exclude them from this criterion.\n\n3. Having a CD4 cell count of at least 350 per \u00b5L at enrollment: The patient note does not provide any information about the CD4 cell counts of the group members.\n\n4. HIV sero-status determined at the VCT of the health center: Again, the patient note does not mention the HIV status of the group members.\n\n5. No obvious underlying disease at the time of enrollment: The patient note does not indicate the presence of any underlying diseases in the group members.\n\n6. Signed informed consent: The patient note does not mention whether the group members have provided informed consent.\n\nBased on the information provided in the patient note, the main exclusion criterion is that three of the women in the group are pregnant, which is not allowed according to the inclusion criteria. Additionally, there is not enough information to determine if the other criteria are met or not.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1199": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. All members have up-to-date vaccine certificates.\n\n2. The clinical trial is testing the efficacy and safety of Dihydroartemisinin/Piperaquine (Artekin\u00ae) for the treatment of uncomplicated malaria in Peru.\n\n3. One of the key inclusion criteria is \"Monoinfection with P. falciparum, with parasitic density between 1,000 and 200,000 par/\u00b5l\". The patient note does not mention any of the group members having malaria infection.\n\n4. Another inclusion criteria is \"Age: 5 - 60 years old\". The patient note does not provide age details for the group members.\n\n5. One of the exclusion criteria is \"Pregnancy or breastfeeding to child \u2264 6 months of age\". The patient note mentions that three of the women in the group are in different stages of pregnancy, which would exclude them from the trial.\n\nBased on the information provided, it is unlikely that any of the group members would be eligible for this clinical trial, primarily due to the lack of confirmed malaria infection and the pregnancy exclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1200": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil.\n2. All members of the group have up-to-date vaccine certificates, which is a positive factor.\n3. Malaria chemoprophylaxis is indicated, which aligns with the clinical trial's objective of inducing a protective immune response against malaria.\n4. However, three of the women in the group are in different stages of pregnancy.\n5. The inclusion criteria for the clinical trial specifically state \"Negative pregnancy test\" and \"Use of adequate contraception for females\".\n\nBased on the information provided, the three pregnant women in the group would not be eligible for this clinical trial due to their pregnancy status. However, the remaining 11 members of the group who are not pregnant could potentially be eligible, assuming they meet the other inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1201": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. All members have up-to-date vaccine certificates.\n\n2. The clinical trial is titled \"Different Approaches for Delivery of IPT in Pregnancy in Burkina Faso\" and is studying different approaches to deliver intermittent preventive treatment (IPT) for malaria in pregnant women in Burkina Faso.\n\n3. The inclusion criteria for the trial are:\n   - Pregnant women of all parities\n   - Second trimester\n\n4. From the patient note, we know that 3 of the women in the group are pregnant, but we don't know their trimester or parity.\n\n5. Since the patient note lacks key details about the pregnant women's trimester and parity, it would be premature to definitively include or exclude them from this trial.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1202": {
        "output": "Based on the provided patient note and the clinical trial information, this group of humanitarian service workers would not be eligible for the clinical trial titled \"RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants\". The key reasons are:\n\n1. The inclusion criteria specifically state that participants must be infants born in the San Francis Designated District Hospital of Ifakara, Tanzania. The patient note describes a group of adult humanitarian service workers, not infants born in a specific hospital in Tanzania.\n\n2. The trial aims to evaluate the efficacy of iron supplementation and malaria chemoprophylaxis in infants aged 2 to 12 months living in an area of intense and perennial malaria transmission. The patient note does not provide any information about infants or their living conditions.\n\n3. The trial is focused on preventing severe anemia and malaria in infants, which is not relevant to the group of adult humanitarian service workers described in the patient note.\n\nTherefore, based on the provided information, this group of humanitarian service workers would not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1203": {
        "output": "To determine the trial-level eligibility for this patient group, let's go through the inclusion criteria one by one:\n\n1. \"All patients admitted with the diagnosis of preterm labor between 24 0/7 and 33 6/7 weeks gestation. Preterm labor will be defined by regular contractions and/or cervical change from last documented exam.\"\n\nThe patient note does not mention any information about preterm labor or gestational age, so this criterion cannot be evaluated.\n\n2. \"Cervical exam 4 cm or greater\"\n\nThe patient note does not provide any information about cervical exams or dilation.\n\n3. \"Intact membranes\"\n\nAgain, there is no information provided about the status of the membranes.\n\nSince the patient note does not provide enough information to determine if the inclusion criteria are met, it would be difficult to make a definitive assessment of eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1204": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, it does not appear that the group of humanitarian service workers would be eligible for this orthopedic surgery trial. The inclusion criteria states \"Unwillingness to sign informed consent\", which is an unusual and likely unintended criterion.\n\nWithout any specific information about orthopedic conditions or mobility problems in the patient note, and with the provided inclusion criteria being essentially a contradiction, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1205": {
        "output": "Based on the provided patient note and the clinical trial information, here is my assessment of the trial-level eligibility:\n\nThe patient note mentions a group of 14 humanitarian service workers preparing for a trip to the Amazon Rainforest region in Brazil. It states that all members have up-to-date vaccine certificates, and malaria chemoprophylaxis is indicated. However, three of the women in the group are in different stages of pregnancy.\n\nThe clinical trial titled \"New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa\" focuses on evaluating strategies to improve the coverage and uptake of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) for pregnant women in areas with moderate to high malaria transmission.\n\nThe inclusion criteria for the clinical trial are:\n1. Female\n2. First or second trimester of pregnancy\n3. First or second pregnancy\n4. Resident in the study area\n\nWhile the patient note mentions that three women in the group are pregnant, it does not provide specific details about their trimester or pregnancy number. Additionally, the study area for the clinical trial is in rural Africa, whereas the group is preparing for a trip to the Amazon Rainforest region in Brazil.\n\nGiven the limited information available and the mismatch between the study location and the group's travel destination, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo make a more definitive assessment, additional details would be needed, such as the specific trimester and pregnancy number for the three pregnant women, as well as their residency status in the study area mentioned in the clinical trial.",
        "label": 0
    },
    "1206": {
        "output": "To determine the trial-level eligibility for this patient group, let's go through the inclusion criteria one by one:\n\n1. Confirmed HIV seropositivity: The patient note does not mention the HIV status of the group members, so this criterion cannot be evaluated.\n\n2. Permanent residency in the study catchment's area: The patient note states that the group is preparing a trip to the Amazon Rainforest region in Brazil, but it does not specify if they are permanent residents of that area.\n\n3. Confirmed pregnancy, gestational age < 28 weeks: The patient note mentions that three of the women in the group are in different stages of pregnancy, but it does not provide information about their gestational age.\n\n4. More than 18 years of age: The patient note does not provide information about the ages of the group members.\n\n5. Karnofsky index \u226580: The patient note does not mention the Karnofsky index or any other measure of functional status for the group members.\n\n6. Willingness to deliver at the hospital: The patient note does not mention any plans for delivery or willingness to deliver at a hospital.\n\n7. Written informed consent: The patient note does not indicate whether the group members have provided written informed consent.\n\nBased on the limited information provided in the patient note, it is difficult to determine with certainty whether the group members would be eligible for this clinical trial. However, since the trial is specifically focused on pregnant women who are HIV-positive and require malaria prophylaxis, and the patient note mentions that three women in the group are pregnant and malaria chemoprophylaxis is indicated, it is possible that these three women could be considered for further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1207": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil.\n2. All members of the group have up-to-date vaccine certificates, which is a good sign.\n3. Malaria chemoprophylaxis is indicated, meaning they need to take medication to prevent malaria.\n4. However, three of the women in the group are pregnant, which is relevant for the inclusion criteria of the clinical trial.\n\n5. The clinical trial is studying the effectiveness of taking Malarone weekly instead of daily for malaria prevention.\n6. One of the inclusion criteria is \"If the participant is female, not pregnant or lactating and willing to use contraception to prevent pregnancy.\"\n7. Since three of the women in the group are pregnant, they would not meet this inclusion criterion.\n\n8. The other inclusion criteria, such as age range (18-50), being free of significant health problems, and BMI range (19-30), are not mentioned in the patient note, so we cannot make a definitive assessment for the entire group.\n\nBased on the information provided, it is unlikely that the entire group would be eligible for this clinical trial due to the pregnancy exclusion criterion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1208": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. They all have up-to-date vaccine certificates.\n\n2. The clinical trial is a study to assess the safety, immunogenicity, and parasite growth inhibition of an asexual blood stage vaccine for P. falciparum malaria.\n\n3. One of the key inclusion criteria for the clinical trial is that participants should be healthy, non-pregnant adults aged 18-50 years.\n\n4. The patient note mentions that three of the women in the group are in different stages of pregnancy.\n\n5. Since the inclusion criteria specifically exclude pregnant women, these three women would not be eligible for the clinical trial.\n\n6. However, the remaining 11 members of the group who are not pregnant may potentially be eligible, provided they meet the other inclusion criteria such as being aged 18-50 years, residing near Oxford for the duration of the study, and being willing to comply with all study requirements.\n\nBased on the information provided, it is difficult to make a definitive assessment of eligibility for the entire group. However, we can say that at least some members of the group may be eligible, while others are clearly ineligible due to pregnancy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1209": {
        "output": "To determine the trial-level eligibility for this group of humanitarian service workers, let's go through the inclusion criteria one by one:\n\n1. Age 18-65: The patient note does not specify the ages of the group members, but it is reasonable to assume that they are adults within this age range.\n\n2. Have the ability to provide informed consent: Since they are preparing for a trip, it is implied that they have the capacity to provide informed consent.\n\n3. If a woman of child-bearing potential, willing to use contraception for the period of the trial: The patient note mentions that three of the women are in different stages of pregnancy. This would make them ineligible for the trial, as they would not be willing or able to use contraception during the trial period.\n\nSince some members of the group (the pregnant women) do not meet the inclusion criteria, it would not be appropriate to refer the entire group for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1210": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. They all have up-to-date vaccine certificates.\n\n2. The clinical trial is about immunization with different doses of Plasmodium falciparum sporozoites under chloroquine prophylaxis for malaria.\n\n3. One of the key inclusion criteria is \"Negative pregnancy test\". The patient note mentions that three of the women in the group are in different stages of pregnancy.\n\n4. Since these three women are pregnant, they would not meet the inclusion criteria of a negative pregnancy test.\n\n5. The other members of the group who are not pregnant may potentially be eligible, but we don't have enough information about their individual ages, health status, willingness to undergo procedures, etc.\n\nTrial-level eligibility: 0) Would not refer this patient group for this clinical trial, as at least three members (the pregnant women) do not meet the inclusion criteria. The eligibility of the other members cannot be determined from the given information.",
        "label": 0
    },
    "1211": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. They all have up-to-date vaccine certificates.\n\n2. The clinical trial is about experimental human malaria infection after immunization with Plasmodium falciparum sporozoites under chloroquine prophylaxis.\n\n3. One of the key inclusion criteria is \"Negative pregnancy test\". The patient note mentions that three of the women in the group are in different stages of pregnancy.\n\n4. Since these three women are pregnant and would not meet the \"Negative pregnancy test\" inclusion criteria, they would not be eligible for this clinical trial.\n\n5. For the remaining 11 members of the group who are not pregnant, we don't have enough information to determine if they meet all the other inclusion criteria like age range, willingness to undergo malaria challenge, availability for study visits, etc.\n\nBased on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThis is because while the 3 pregnant women are ineligible, the remaining 11 members may potentially be eligible pending further evaluation against the full inclusion/exclusion criteria. More information would be needed to make a definitive assessment for those 11 individuals.",
        "label": 0
    },
    "1212": {
        "output": "To determine the trial-level eligibility for this patient group, let's go through the inclusion criteria one by one:\n\nAge > 18 and < 35 years healthy volunteers (males or females)\n- The patient note does not specify ages, but it mentions they are humanitarian service workers, so we can assume they are adults.\n\nGood health based on history and clinical examination\n- No health issues are mentioned for most of the group members.\n\nNegative pregnancy test\n- This is not met, as the note states that three of the women are pregnant.\n\nUse of adequate contraception for females\n- Not mentioned in the patient note.\n\nSigning of the informed consent form, thereby demonstrating understanding of the meaning and procedures of the study\n- Not mentioned, but can potentially be obtained.\n\nAgreement to inform the general practitioner and to sign a request to release medical information concerning contra-indications for participation in the study\n- Not mentioned, but can potentially be obtained.\n\nWillingness to undergo a Pf controlled infection through mosquito bites\n- Not mentioned, but their purpose is to travel to the Amazon rainforest, which has a risk of malaria infection.\n\nAgreement to stay in a hotel room close to the trial center during a part of the study (Day 5 after challenge till treatment is finished)\n- Not mentioned, but they are preparing for travel, so they may be able to accommodate this.\n\nReachable (24/7) by mobile phone during the whole study period\n- Not mentioned, but they are likely to have mobile phones for communication during their travel.\n\nAvailable to attend all study visits\n- Not mentioned, but their travel plans may allow for this.\n\nAgreement to refrain from blood donation to Sanquin or for other purposes, during the whole study period\n- Not mentioned, but they can potentially agree to this.\n\nWillingness to undergo HIV, hepatitis B and hepatitis C tests\n- Not mentioned, but they likely have up-to-date vaccinations and health checks for travel.\n\nNegative urine toxicology screening test at screening visit and the day before challenge\n- Not mentioned, but they can potentially undergo this screening.\n\nWillingness to take a prophylactic regime of chloroquine or mefloquine and curative regimen of Malarone\u00ae\n- The patient note mentions that malaria chemoprophylaxis is indicated, but three women are pregnant, which may preclude them from taking certain medications.\n\nBased on the information provided, the main concern is the pregnancy status of three women, which would likely exclude them from participating in this trial due to the requirement for a negative pregnancy test and the need to take antimalarial medications.\n\nFor the remaining non-pregnant members of the group, there is not enough information to definitively determine eligibility, but they may potentially meet the criteria upon further investigation and consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1213": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. All members have up-to-date vaccine certificates.\n\n2. The clinical trial is titled \"Chloroquine Population Pharmacokinetics in Pre and Post-partum Women\" and is studying the pharmacokinetics of chloroquine when used to treat P. vivax malaria in pregnant women.\n\n3. The inclusion criteria for the trial state that participants must be aged 18-50 years, have a gestational age greater than 13 weeks, have a viable fetus confirmed by ultrasound, have microscopically confirmed uncomplicated P. vivax malaria, be willing and able to comply with the study protocol, provide written informed consent, and have no signs of labor.\n\n4. The patient note mentions that three of the women in the group are in different stages of pregnancy, but does not provide any other details about their gestational age, malaria status, or willingness to participate in the trial.\n\n5. Without more specific information about the three pregnant women, it is difficult to determine their eligibility for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1214": {
        "output": "Based on the provided patient note and the clinical trial information, this group of humanitarian service workers would not be eligible for the \"Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome\" clinical trial. The key reasons are:\n\n1. The trial is specifically studying HIV-infected patients who are starting antiretroviral therapy (ART) for the first time. The patient note does not mention that the service workers have HIV or are initiating ART.\n\n2. The inclusion criteria explicitly state that participants must be ART-naive, meaning they have not received antiretroviral therapy before. The patient note does not provide any information about the service workers' ART status.\n\nTherefore, based on the available information, this group of humanitarian service workers does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1215": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. This is relevant background information.\n\n2. All members of the group have up-to-date vaccine certificates, which is a positive factor for potential inclusion in the clinical trial.\n\n3. Malaria chemoprophylaxis is indicated for the trip, which aligns with the purpose of the clinical trial.\n\n4. However, three of the women in the group are in different stages of pregnancy, which is a potential exclusion factor based on the inclusion criteria \"Negative pregnancy test\".\n\n5. The inclusion criteria also specify an age range of 18-35 years old. The patient note does not provide the ages of the group members, so we cannot determine if they all meet this criterion.\n\n6. Other inclusion criteria, such as being in good health, willingness to undergo specific procedures, and availability for study visits, cannot be fully assessed based on the provided patient note.\n\nGiven the information that three members of the group are pregnant, which is an exclusion criterion, and the lack of information on the ages of the group members, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to determine if any of the non-pregnant group members meet all the inclusion criteria, particularly the age range requirement.",
        "label": 0
    },
    "1216": {
        "output": "Based on the provided patient note and the clinical trial information, this group of humanitarian service workers would not be eligible for the clinical trial titled \"Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin.\"\n\nThe key reasons are:\n\n1. The patient note does not mention any trauma or injuries that would require venous thromboembolism prophylaxis, which is the focus of the clinical trial.\n\n2. The inclusion criteria specifically state that participants must be admitted to the Scripps Mercy Trauma Service, be 18 years or older, and be stratified as having a significant or highest risk of venous thromboembolism according to the ACCP guidelines.\n\nSince the patient note does not provide any information about trauma, admission to a specific trauma service, or risk stratification for venous thromboembolism, it is highly unlikely that this group of humanitarian service workers would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1217": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. They all have up-to-date vaccine certificates and malaria chemoprophylaxis is indicated. However, three of the women are in different stages of pregnancy.\n\n2. The clinical trial is studying the efficacy of antifolates against malaria in HIV-infected pregnant women.\n\n3. The inclusion criteria for the trial are:\n   - Age \u2265 18 years\n   - HIV positivity\n   - Gestational age between 16 and 28 weeks\n   - CD4+ count > 350 cells/mm3 and no sign of WHO stage 2, 3 or 4\n   - Agreement to attend all antenatal consultations for the study\n   - Willingness to adhere to study requirements including HIV-1 counseling and testing\n   - Signed informed consent\n\n4. Based on the information provided in the patient note, we cannot determine if any of the pregnant women meet the inclusion criteria for HIV positivity, CD4+ count, or WHO stage. We also don't know if they would agree to the study requirements.\n\n5. Therefore, without further investigation into their specific medical conditions and willingness to participate, we cannot definitively determine their eligibility for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1218": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil.\n2. All members of the group have up-to-date vaccine certificates and have traveled multiple times before.\n3. Malaria chemoprophylaxis is indicated, but three of the women in the group are pregnant.\n4. The clinical trial is about inducing protection against malaria through immunization under chemoprophylaxis.\n5. One of the inclusion criteria is that female subjects should agree to use adequate contraception and not breastfeed for the duration of the study.\n6. Since three of the women in the group are pregnant, they would not meet this inclusion criterion.\n\nBased on the information provided, it seems unlikely that all members of the group would be eligible for this clinical trial due to the pregnancy status of three women.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1219": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil.\n2. All members of the group have up-to-date vaccine certificates.\n3. Malaria chemoprophylaxis is indicated, but 3 of the women are in different stages of pregnancy.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. Age between 5 and 65 years old inclusive\n   - Assuming the group members are adults, this criterion is likely met.\n2. Monoinfection of P. falciparum confirmed by microscopy\n   - The patient note does not mention any current malaria infection, so this criterion is not met.\n3. Documented fever or history of fever during the previous 48 hours\n   - No mention of fever in the patient note, so this criterion is not met.\n4. Infection with P. falciparum within a certain parasitemia range\n   - Again, no mention of a current malaria infection, so this criterion is not met.\n5. Informed consent and willingness to return for follow-ups\n   - Unclear from the patient note if this would be possible.\n\nBased on the information provided, it seems unlikely that any of the group members would be eligible for this clinical trial, as there is no indication of a current malaria infection.\n\nHowever, given that they are traveling to a malaria-endemic region and chemoprophylaxis is indicated, it may be worth considering referring them to this trial upon further investigation, in case any of them contract malaria during their trip.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1220": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. All members have up-to-date vaccine certificates.\n\n2. The clinical trial is studying chemoprophylaxis and immunization against malaria using Plasmodium falciparum sporozoites.\n\n3. One of the inclusion criteria is that subjects must be aged between 18 and 35 years. The patient note does not specify the ages of the service workers, so we cannot determine if they meet this criterion.\n\n4. Another inclusion criterion is that female subjects must agree to use adequate contraception and not breastfeed during the study. The patient note mentions that three of the women are in different stages of pregnancy, which would likely exclude them from participating.\n\n5. Other inclusion criteria, such as being in good health, able to communicate well, and willing to follow study procedures, are not addressed in the patient note.\n\nBased on the information provided, it is unlikely that all 14 service workers would be eligible for this clinical trial due to the pregnancy exclusion and lack of age information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1221": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note mentions a group of 14 humanitarian service workers preparing a trip to the Amazon Rainforest region in Brazil. All members have up-to-date vaccine certificates.\n\n2. The clinical trial is evaluating chemoprophylaxis (preventive medication) against travelers' diarrhea using the drug rifaximin.\n\n3. One of the inclusion criteria is that women cannot be pregnant or nursing while taking the study drug.\n\n4. The patient note mentions that three of the women in the group are in different stages of pregnancy.\n\n5. Since these three women are pregnant, they would not be eligible to participate in the clinical trial due to the inclusion criteria regarding pregnancy.\n\n6. For the remaining 11 members of the group who are not pregnant, they may potentially be eligible if they meet the other inclusion criteria.\n\nBased on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThis is because while 3 members are ineligible due to pregnancy, the remaining 11 members may potentially be eligible if they meet the other criteria, but further investigation would be needed to confirm their eligibility.",
        "label": 0
    },
    "1222": {
        "output": "Based on the provided patient note and the inclusion/exclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note mentions that the group consists of 14 humanitarian service workers preparing for a trip to the Amazon Rainforest region in Brazil. All members have up-to-date vaccine certificates, and malaria chemoprophylaxis is indicated. However, three of the women in the group are in different stages of pregnancy.\n\nThe clinical trial's inclusion criteria specifically state that females who are pregnant are excluded from participating. Additionally, the trial involves administering live, infectious malaria parasites (Sanaria PfSPZ Challenge) and antimalarial drugs, which could potentially pose risks to pregnant women and their unborn babies.\n\nGiven that three members of the group are pregnant and would not meet the eligibility criteria, I would not recommend referring this entire group for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1223": {
        "output": "Based on the provided patient note and the clinical trial information, here is my assessment of the trial-level eligibility:\n\nThe patient note describes a group of 14 humanitarian service workers preparing for a trip to the Amazon Rainforest region in Brazil. All members have up-to-date vaccine certificates, and malaria chemoprophylaxis is indicated. However, three of the women in the group are in different stages of pregnancy.\n\nThe clinical trial titled \"Prophylaxis Against Malaria to Enhance Child Development (PROTECT Study)\" is focused on studying the effects of malaria in pregnancy on childhood neurodevelopmental outcomes. The inclusion criteria specifically mention enrolling participants in the Makerere University-UCSF PROMOTE II study, being HIV-uninfected, and having a child aged 12 months at the time of enrollment, within 30 km of the clinic.\n\nGiven that the patient note describes a group of humanitarian service workers preparing for travel and does not mention any children or enrollment in the PROMOTE II study, it is unlikely that these individuals would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1224": {
        "output": "To determine the trial-level eligibility for this patient group, let's go through the inclusion criteria one by one:\n\n1. Provide signed and dated informed consent form.\n   - This is not mentioned in the patient note, but it can be assumed that the group is willing to provide consent if they meet the other criteria.\n\n2. Willing to comply with all study procedures and be available for the duration of the study.\n   - This is also not explicitly stated, but it can be assumed that the group is willing to comply if they meet the other criteria.\n\n3. Male or female, aged \u2265 18 to \u2264 60 years on day of inclusion.\n   - The patient note does not provide any information about the ages of the group members, so we cannot determine if they meet this criterion.\n\n4. In good general health based on medical history and physical exam.\n   - The patient note states that all members of the group have up-to-date vaccine certificates, which suggests they are in good general health. However, it also mentions that three of the women are in different stages of pregnancy, which may exclude them from being considered in good general health for this trial.\n\nBased on the information provided, we cannot definitively determine if the group meets all the inclusion criteria. The main concern is the age criterion, which is not specified, and the pregnancy status of three women, which may exclude them from being considered in good general health.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1225": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has a diagnosis of familial adenomatous polyposis, which meets this criterion.\n\nPATIENT CHARACTERISTICS:\nAge: \n- The patient is 21 years old, which falls within the 18-80 age range.\n\nHematopoietic, Hepatic, and Renal:\n- There is no information provided about the patient's hemoglobin, platelet count, liver enzymes, or creatinine levels. We would need further investigation to determine if they meet these criteria.\n\nOther:\n- The patient is not pregnant or nursing (based on being a 21-year-old male).\n- There is no information about any underlying medical or psychiatric illnesses, alcohol/drug abuse, or allergies to sulindac or related compounds.\n\nPRIOR CONCURRENT THERAPY:\n- There is no information provided about any prior therapies or current use of NSAIDs/aspirin.\n\nBased on the available information, the patient meets the disease characteristics criterion and the age criterion. However, there are several criteria where we would need further investigation to determine eligibility, such as hematologic, hepatic, and renal function, as well as any underlying medical conditions, allergies, or current/prior therapies.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1226": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\nDiagnosis of colon cancer or polyps at age 70 or under\n- The patient is 21 years old and was found to have dozens of colonic polyps, so this criterion is met.\n\nHas a living full sibling with diagnosis of colon cancer or polyps at age 70 or under\n- The patient has a brother who underwent total proctocolectomy at age 22 and a sister who underwent the same at age 28, both due to having hundreds of colonic adenomas. This criterion is met.\n\nNo history of familial adenomatous polyposis syndrome\n- There is no mention of familial adenomatous polyposis syndrome, so this criterion is likely met.\n\nNo hereditary nonpolyposis colon cancer, according to Amsterdam criteria\n- There is no mention of hereditary nonpolyposis colon cancer, so this criterion is likely met.\n\nNo known I1370K adenomatous polyposis of the colon susceptibility variant\n- There is no mention of this variant, so this criterion is likely met.\n\nEnrolled on 1 of the following clinical trials: CLB-9581, CLB-89803, CLB-80001\n- There is no mention of the patient being enrolled in any of these trials, so this criterion is not met. However, the summary states that patients do not need to be receiving protocol therapy, so this may not be a strict requirement.\n\nPATIENT CHARACTERISTICS:\nAge 70 and under at diagnosis\n- The patient is 21 years old, so this criterion is met.\n\nNo significant psychiatric illness that would preclude giving informed consent\n- There is no mention of any psychiatric illness, so this criterion is likely met.\n\nNo inflammatory bowel disease (in patient or sibling)\n- There is no mention of inflammatory bowel disease, so this criterion is likely met.\n\nBased on the information provided, the patient meets most of the key inclusion criteria for this genetic study of familial factors in colon cancer/polyps. The only potential issue is the requirement to be enrolled in one of the listed clinical trials, but the summary suggests this may not be a strict requirement.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1227": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Males or females at least 18 years of age with familial adenomatous polyposis.\n\nBased on the patient note, the patient is a 21-year-old college student, which meets the age requirement of being at least 18 years old. Additionally, the note mentions that the patient has a family history of multiple polyps in their older siblings, and the patient was found to have dozens of small colonic polyps during a sigmoidoscopy, which were benign adenomas.\n\nGiven that the patient meets the age requirement and has a diagnosis of familial adenomatous polyposis (FAP) based on the presence of multiple adenomatous polyps and a strong family history, this patient is highly likely to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1228": {
        "output": "To determine the patient's eligibility for the APACC clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients are aged between 18 and 75 years\nThe patient is 21 years old, which falls within the age range.\n\n2. At least 3 adenomas irrespective size or at least one measuring 6mm or more\nThe patient is noted to have \"dozens of small colonic polyps within rectosigmoid\" and \"several of these are biopsied and are all benign adenomas.\" This meets the criteria of having at least 3 adenomas.\n\n3. All subjects had a clean colon at the study entry\nThe patient underwent a colonoscopy, which would have cleared the colon of any polyps or adenomas before the study entry.\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria for the APACC clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1229": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: Patients with Familial adenomatous polyposis who have had ileo-rectal anastomosis and had 20 or less adenomas at previous surveillance examination\n\nFrom the patient note, we can see that:\n1. The patient is a 21-year-old college student, so age is not an issue.\n2. The patient has a family history of multiple polyps in older siblings, and both siblings underwent total proctocolectomy due to hundreds of colonic adenomas.\n3. The patient's own colonoscopy revealed dozens of small colonic polyps within the rectosigmoid, which were benign adenomas.\n\nHowever, the inclusion criteria specifically mentions patients with Familial adenomatous polyposis who have had ileo-rectal anastomosis and had 20 or less adenomas at previous surveillance examination.\n\nThere is no mention of the patient having Familial adenomatous polyposis or having undergone ileo-rectal anastomosis. Additionally, the patient had dozens of adenomas, which is more than the 20 or less adenomas specified in the inclusion criteria.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1230": {
        "output": "To determine the patient's eligibility for the clinical trial \"Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis\", let's go through the inclusion criteria:\n\n1. Clinically or genetically proven familial adenomatous polyposis\nThe patient note mentions that the patient's brother and sister both underwent total proctocolectomy due to hundreds of colonic adenomas, which is a characteristic of familial adenomatous polyposis (FAP). The patient is also found to have dozens of small colonic polyps, which are likely adenomas given the family history. Therefore, this criterion is likely met.\n\n2. Restorative proctocolectomy with ileal pouch anal anastomosis\nThe patient note does not mention if the patient has undergone this procedure or not.\n\nSince one of the inclusion criteria is not clearly met based on the information provided, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1231": {
        "output": "Based on the patient note provided, this 21-year-old college student does not have Parkinson's disease, which is the target condition for the REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study clinical trial. The patient underwent a colonoscopy due to a family history of multiple polyps and was found to have benign adenomas in the colon.\n\nSince the patient does not have Parkinson's disease, they would not meet the key inclusion criteria for this clinical trial, which requires participants to have a diagnosis of Parkinson's disease.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1232": {
        "output": "To determine the patient's eligibility for the clinical trial \"Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)\", let's go through the inclusion criteria one by one:\n\n1) Having a confirmed genetic or clinical diagnosis of FAP between the age of 13-24 at the time of recruitment to this study.\nThe patient note mentions that the patient is a 21-year-old college student who was found to have dozens of small colonic polyps during a colonoscopy. While a genetic diagnosis is not explicitly stated, the presence of multiple polyps and the family history of FAP in siblings who underwent total proctocolectomy strongly suggests that the patient has FAP. The patient's age of 21 also falls within the specified range. This criterion is likely met.\n\n2) 18-21 year old with a previous cancer diagnosis.\nThere is no mention of a previous cancer diagnosis in the patient note. This criterion is not met.\n\n3) Able to read and speak English.\nThere is no information provided about the patient's language abilities, but it is reasonable to assume that a college student in the United States would be able to read and speak English. This criterion is likely met.\n\nBased on the information provided, the patient meets one of the three inclusion criteria (having a confirmed or likely diagnosis of FAP between the ages of 13-24) and potentially meets another criterion (ability to read and speak English). However, the patient does not meet the criterion of having a previous cancer diagnosis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1233": {
        "output": "To determine the patient's eligibility for the clinical trial \"Unprepped CT Colonography\", let's go through the inclusion criteria:\n\n1. Average risk or higher for colorectal cancer and scheduled for colonoscopy with any of the following indications: Prior colorectal cancer, prior colorectal adenoma, strong family history of colorectal neoplasia, iron deficiency.\n\nThe patient is a 21-year-old college student who underwent colonoscopy due to a strong family history of multiple polyps in his older siblings. Both siblings had hundreds of colonic adenomas and underwent total proctocolectomy at a young age. This indicates that the patient has a strong family history of colorectal neoplasia, meeting this inclusion criterion.\n\n2. Age \u2265 40 -100 years\n\nThe patient is 21 years old, which does not meet this age criterion.\n\n3. Known or highly suspected primary colorectal neoplasms > 10 mm (n = 160)\n\nThe patient was found to have dozens of small colonic polyps within the rectosigmoid during the sigmoidoscopy. However, the size of the polyps is not specified, so it is unclear if any of them are larger than 10 mm.\n\n4. Higher than average risk for colorectal cancer and scheduled for colonoscopy with any of the following indications: prior colorectal cancer, prior colorectal adenoma, strong family history of colorectal neoplasia, iron deficiency.\n\nAs mentioned earlier, the patient has a strong family history of colorectal neoplasia, meeting this criterion.\n\nOverall, the patient meets some of the inclusion criteria, such as having a strong family history of colorectal neoplasia and being scheduled for colonoscopy. However, the patient's age does not meet the age criterion, and it is unclear if any of the polyps found are larger than 10 mm.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1234": {
        "output": "To determine the patient's eligibility for the clinical trial \"Curcumin in Treating Patients With Familial Adenomatous Polyposis\", let's go through the inclusion criteria:\n\n1. \"Patients with familial adenomatous polyposis who have undergone subtotal colectomy with ileorectal anastomosis, total colectomy with ileo-anal pull through (reservoir), and patients with intact colons with 5 or more adenomas in the rectum-sigmoid or reservoir\"\n\nThe patient note mentions that the patient is a 21-year-old college student who underwent a sigmoidoscopy and was found to have dozens of small colonic polyps within the rectosigmoid, with several benign adenomas confirmed by biopsy. This matches the inclusion criteria of having an intact colon with 5 or more adenomas in the rectum-sigmoid.\n\n2. \"Patients with familial adenomatous polyposis (FAP) and duodenal adenomatous polyposis without current lower tract adenomatous polyposis i.e. status/post (s/p) ileostomy\"\n\nThe patient note does not mention any information about duodenal adenomatous polyposis or ileostomy, so this criterion is not applicable.\n\nBased on the information provided, the patient meets the first inclusion criterion for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1235": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old college student undergoing a colonoscopy due to a family history of multiple polyps in older siblings.\n2. The patient's brother and sister both underwent total proctocolectomies in their early 20s due to hundreds of colonic adenomas found on colonoscopy.\n3. The patient was found to have dozens of small colonic polyps within the rectosigmoid during their sigmoidoscopy, with biopsies confirming benign adenomas.\n4. The clinical trial is evaluating the use of bioabsorbable staple line reinforcement in colorectal, coloanal, and ileoanal anastomoses.\n5. The inclusion criteria include undergoing restorative proctectomy or proctocolectomy (<10 cm from anal verge) with a low circular stapled colorectal, coloanal or ileoanal anastomosis, including treatment for familial adenomatous polyposis.\n\nGiven the patient's young age, family history of multiple polyps leading to proctocolectomies in siblings, and the finding of dozens of adenomatous polyps on their own colonoscopy, it seems highly likely that this patient has familial adenomatous polyposis (FAP).\n\nSince the clinical trial includes patients undergoing proctectomy/proctocolectomy for FAP, and the patient meets the age and anatomic criteria, I would assess this patient as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1236": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Diagnosis of familial adenomatous polyposis (FAP) based on genetic predisposition testing - Satisfied (The patient has a family history of FAP and was found to have dozens of colonic polyps on colonoscopy)\n- Genotype-positive FAP (pathologic Adenomatous polyposis coli (APC) mutation) - Likely satisfied based on family history, but not explicitly stated\n- No attenuated FAP genotype - Likely satisfied based on family history, but not explicitly stated\n- Has an intact colon - Satisfied\n- No requirement for colectomy - Satisfied\n- Colorectal adenoma burden meets criteria (No severe dysplasia, \u226410 adenomas \u22651cm, \u2264100 adenomas of any size, no anemia, no carcinoma) - Satisfied based on information provided\n\nPATIENT CHARACTERISTICS:\n- Meets blood count and liver/kidney function criteria - Not explicitly stated, but likely satisfied for a 21-year-old\n- Not pregnant/nursing and using contraception if fertile - Not stated\n- No hypersensitivity, peptic ulcer disease, or other significant medical/psychiatric issues - Not stated but likely for a 21-year-old\n- No invasive carcinoma in past 5 years - Satisfied\n\nPRIOR CONCURRENT THERAPY:\n- No recent investigational agents, chemotherapy, pelvic radiation - Satisfied\n- Meets criteria for NSAID/steroid use - Not stated\n\nBased on the information provided, the patient seems to meet the key inclusion criteria related to diagnosis and disease characteristics. However, some details about patient characteristics and prior/concurrent therapy are not provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1237": {
        "output": "To determine the patient's eligibility for the given clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria:\n- Outpatient services\n\nThe patient note does not mention whether the patient is an outpatient or inpatient. However, the note describes a routine colonoscopy procedure, which is typically done on an outpatient basis. Therefore, the patient likely meets this inclusion criterion.\n\nHowever, the clinical trial appears to be focused on specific conditions such as cyclic vomiting syndrome, irritable bowel syndrome, postural orthostatic tachycardia syndrome, functional abdominal pain, and chronic nausea. The patient note does not indicate that the patient has any of these conditions. Instead, it mentions that the patient underwent a colonoscopy due to a family history of multiple polyps and was found to have benign adenomas.\n\nBased on the information provided, the patient does not seem to meet the primary inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1238": {
        "output": "To determine the patient's eligibility for the clinical trial \"Colonography Versus Colonoscopy in High Risk Patient\", let's go through the inclusion criteria one by one:\n\n1. Informed consent obtained: This is not mentioned in the patient note, so we cannot assess this criterion.\n\n2. Age \u2265 18 and \u2264 80 years old: The patient is 21 years old, which falls within this age range.\n\n3. History of advanced adenomatous polyps: The patient is noted to have \"dozens of small colonic polyps within rectosigmoid\" and \"several of these are biopsied and are all benign adenomas\". This meets the criterion of having a history of adenomatous polyps, although it is not specified if they are \"advanced\" adenomas.\n\n4. History of non-metastatic CRC with curative surgery and without other treatment more than 2 years before enrollment: This criterion is not applicable to the patient, as there is no mention of a history of colorectal cancer.\n\n5. First-degree family history of colorectal cancer diagnosed <60yrs during the five previous years: The patient note mentions that the patient's brother underwent a total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. This suggests a strong family history of colorectal cancer or precancerous conditions at a young age, which likely meets this criterion.\n\n6. Previous medical examination: This is not explicitly mentioned in the patient note, but it is implied that the patient has undergone a colonoscopy and sigmoidoscopy, which would qualify as previous medical examinations.\n\nBased on the information provided, the patient appears to meet several of the inclusion criteria, particularly the age range, history of adenomatous polyps, and strong family history of colorectal cancer or precancerous conditions at a young age.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1239": {
        "output": "To determine the patient's eligibility for the clinical trial \"Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)\", let's go through the inclusion criteria one by one:\n\n1. Diagnosis of familial adenomatous polyposis with at least 5 rectal polyps which are greater than or equal to 2 mm on baseline colonoscopy\n- The patient note mentions that the patient has dozens of small colonic polyps within the rectosigmoid, and several were biopsied and found to be benign adenomas. This suggests that the patient likely meets this criterion.\n\n2. Have an endoscopically assessable rectal segment\n- The patient underwent a sigmoidoscopy, which examines the rectum and sigmoid colon, so this criterion is likely met.\n\n3. Have not taken NSAIDs or selective COX-2 inhibitors for two months prior to the study and willing to remain off NSAIDs for the study duration.\n- There is no information provided about the patient's medication history, so it is unclear if this criterion is met.\n\nOverall, based on the information provided in the patient note, the patient appears to meet at least two of the three inclusion criteria for the clinical trial. However, there is not enough information to definitively determine if the patient meets the third criterion regarding NSAID use.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1240": {
        "output": "To determine the patient's eligibility for the clinical trial \"Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis\", let's go through the inclusion criteria:\n\n1. Patients with Familial adenomatous Polyposis: APC-mutation identified or more than 100 colorectal polyps on diagnosis\n   - The patient note mentions that the patient's brother and sister both underwent total proctocolectomy due to hundreds of colonic adenomas, which strongly suggests a diagnosis of Familial Adenomatous Polyposis (FAP) in the patient as well.\n\n2. Spigelman score of duodenal adenoma equal to II or III\n   - The patient note does not mention any information about duodenal adenomas or the Spigelman score.\n\nBased on the available information, the patient meets the first inclusion criterion for having FAP, but there is no information provided about the second criterion regarding the Spigelman score of duodenal adenomas.\n\nTherefore, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the presence and extent of duodenal adenomas and the corresponding Spigelman score.",
        "label": 1
    },
    "1241": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 21-year-old college student who underwent a colonoscopy due to a family history of multiple polyps in his siblings. The colonoscopy found dozens of small colonic polyps, which were benign adenomas.\n\n2. The clinical trial is evaluating the efficacy and safety of ropinirole PR/XR tablets as an adjunctive therapy to L-dopa in subjects with advanced Parkinson's disease.\n\n3. The key inclusion criteria for this trial are:\n   - Diagnosed with advanced Parkinson's disease (Hoehn & Yahr Stages II-IV)\n   - Receiving a stable dose of L-dopa for at least 4 weeks prior to screening\n   - Demonstrating lack of control with L-dopa therapy (wearing-off phenomena, on-off fluctuations, delayed-on/no on phenomena)\n   - QTc interval within specified limits\n   - Age 20 years or older\n   - Able to provide informed consent\n   - Meets specific criteria for female participants of child-bearing potential\n\n4. Based on the patient note, this 21-year-old college student does not have Parkinson's disease or any mention of being on L-dopa therapy. Therefore, this patient would not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1242": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old college student, which meets the age criteria of being at least 18 years old.\n\n2. The patient underwent a colonoscopy and was found to have dozens of small colonic polyps within the rectosigmoid region. Several of these polyps were biopsied and found to be benign adenomas.\n\n3. The inclusion criteria state that subjects with pathologically confirmed adenomas present in the colon at the time of stool collection can be included in the \"Adenoma Bin\".\n\n4. Additionally, subjects with a family history of colorectal cancer (CRC) in a first-degree relative can be included in the \"Higher Risk Non-neoplastic Bin\".\n\n5. The patient's brother and sister both underwent total proctocolectomies at a young age due to hundreds of colonic adenomas, indicating a strong family history of colorectal neoplasia.\n\nBased on the information provided, this patient meets the inclusion criteria for both the \"Adenoma Bin\" and the \"Higher Risk Non-neoplastic Bin\" due to the presence of confirmed adenomas and a strong family history of colorectal neoplasia.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1243": {
        "output": "To determine the patient's eligibility for the clinical trial \"Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery\", let's go through the inclusion criteria:\n\n1. DISEASE CHARACTERISTICS:\n   - Biopsy-proven adenocarcinoma of the pancreas or pancreatic mass suspicious for pancreatic cancer\n     - The patient note does not mention pancreatic cancer or any pancreatic mass. This criterion is not met.\n   - Localized disease\n     - The patient note does not provide information about the disease stage or localization. This criterion cannot be evaluated.\n   - Scheduled to undergo a resection or exploration of their pancreatic tumor\n     - The patient note does not mention any planned surgery or exploration related to the pancreas. This criterion is not met.\n\n2. PATIENT CHARACTERISTICS:\n   - Not specified in the inclusion criteria.\n\n3. PRIOR CONCURRENT THERAPY:\n   - See Disease Characteristics\n     - Since the disease characteristics are not met, this criterion is not applicable.\n\nBased on the information provided in the patient note, the patient does not meet the disease characteristics and planned procedure criteria for this clinical trial on localized pancreatic cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1244": {
        "output": "To determine the patient's eligibility for the clinical trial \"Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome\", let's go through the inclusion criteria one by one:\n\n1. \"proven carrier of a MLH1, MSH2 or MSH6 mutation\"\n   - The patient note does not mention whether the patient is a carrier of any of these mutations. This criterion cannot be evaluated based on the given information.\n\n2. \"age between 20 and 70 years\"\n   - The patient is a 21-year-old college student, which falls within the age range specified in the inclusion criteria.\n\n3. \"written informed consent\"\n   - The patient note does not mention whether the patient has provided written informed consent. This criterion cannot be evaluated based on the given information.\n\nSince one of the inclusion criteria cannot be evaluated, and another is not explicitly mentioned as being met, it would be premature to give a definitive assessment of eligibility. However, based on the information provided, the patient meets the age criterion and has a family history of multiple polyps and colorectal neoplasia, which aligns with the purpose of the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1245": {
        "output": "To determine the patient's eligibility for the clinical trial \"Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?\", let's go through the inclusion criteria:\n\nInclusion Criteria: patients having total proctocolectomy with ileal pouch anal anastomosis.\n\nBased on the patient note, the 21-year-old college student underwent a colonoscopy and was found to have dozens of small colonic polyps within the rectosigmoid. While the note does not explicitly mention a total proctocolectomy with ileal pouch anal anastomosis, the patient's family history of multiple polyps and the need for total proctocolectomy in their older siblings suggests that the patient may be a candidate for this procedure in the future.\n\nGiven the patient's young age, family history, and the presence of colonic polyps, it is highly likely that they will require a total proctocolectomy with ileal pouch anal anastomosis in the future, which would make them eligible for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1246": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients\", let's go through the inclusion criteria one by one:\n\n1. Patients who are 18 years or older with a clinical or genetic diagnosis of FAP or attenuated FAP.\nThe patient is 21 years old and has a family history of multiple polyps in siblings, suggesting a possible diagnosis of FAP or attenuated FAP. This criterion is likely met.\n\n2. Presence of duodenal polyps with a sum of diameters \u2265 5mm.\nThe patient note does not mention duodenal polyps, only colonic polyps. This criterion is unclear based on the information provided.\n\n3. Minimum of two weeks since any major surgery\nThe patient note does not mention any recent major surgery. This criterion is likely met.\n\n4. WHO performance status \u22641\nThe patient's performance status is not provided in the note. This criterion is unclear.\n\n5. Adequate bone marrow function as shown by normal leukocyte count, platelet count \u2265 120 x 109/L, Hgb > 12 g/dL\nThe patient's bone marrow function is not provided in the note. This criterion is unclear.\n\n6. Adequate liver function as shown by normal serum bilirubin (\u2264 1.5 Upper Limit Normal {ULN}) and serum transaminases (\u2264 2.0 ULN)\nThe patient's liver function is not provided in the note. This criterion is unclear.\n\n7. Patient must discontinue taking any Nonsteroidal anti-inflammatory drugs (NSAIDS) within one month of treatment initiation.\nThe patient note does not mention the patient taking any NSAIDs. This criterion is likely met.\n\n8. Patients must be able to provide written informed consent.\nThe patient's ability to provide informed consent is not mentioned in the note. This criterion is unclear.\n\nBased on the information provided in the patient note, some of the inclusion criteria are likely met, while others are unclear. Further investigation would be needed to determine if the patient meets all the criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1247": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Diagnosis of phenotypic Familial Adenomatous Polyposis (FAP) of the colorectum based on meeting the criteria in one of two groups:\n   - Group 1: Greater than 100 adenomatous colorectal polyps prior to age 40.\n   - Group 2: Greater than 10 adenomatous polyps and age <40 or greater than 25 polyps and age >40; combined with a dominant family history or genotype.\n\nThe patient note mentions that the 21-year-old patient has dozens of small colonic polyps within the rectosigmoid, and several of these were biopsied and found to be benign adenomas. Additionally, the patient has a family history of FAP, with both siblings undergoing total proctocolectomy due to hundreds of colonic adenomas. Therefore, this criterion is likely met.\n\n2. No colorectal surgery or prior colon surgery for polyposis at least 1 year prior.\nThe patient note does not mention any prior colorectal surgery, so this criterion is likely met.\n\n3. Baseline endoscopy criteria:\n   - If no prior colorectal surgery, at least 3 polyps in a cluster each \u2265 2 mm in diameter; or\n   - If rectum is in situ and to be assessed, baseline rectal segment endoscopy documenting 3 or more rectal polyps each at least 2 mm in diameter in a defined cluster and/or at least 6 polyps, \u2265 2 mm in diameter, in the distal 10 cm of rectum.\n\nThe patient note mentions that the patient has dozens of small colonic polyps within the rectosigmoid, so this criterion is likely met.\n\nThe remaining criteria related to hematologic, hepatic, renal, hearing, pregnancy, stool occult blood, hypersensitivity, ulcers, malignancy, medical/psychiatric problems, medications, and willingness to sign informed consent are not addressed in the patient note. However, based on the information provided, the patient appears to meet the key inclusion criteria related to the diagnosis of FAP and the presence of colonic polyps.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1248": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 21-year-old college student undergoing a colonoscopy due to a family history of multiple polyps in older siblings. The patient was found to have dozens of small colonic polyps within the rectosigmoid, which were biopsied and found to be benign adenomas.\n\nThe clinical trial is looking to evaluate the effectiveness of a new imaging technology called \"bright-NBI\" in detecting colorectal adenomas during screening colonoscopies, compared to standard white light endoscopy.\n\nThe key inclusion criteria for this trial are:\n1) Asymptomatic subjects undergoing screening colonoscopy\n2) Age > 40 years\n3) Average risk subjects without personal history of inflammatory bowel disease, colon adenoma/cancer, or family history of FAP/HNPCC\n4) No colonoscopy in the past 5 years\n5) Ability to provide written consent\n\nLooking at the patient details, while the patient does have colonic adenomas detected on colonoscopy, there are a few issues with eligibility:\n1) The patient is only 21 years old, while the trial requires age > 40\n2) The patient has a strong family history of adenomatous polyps, which may exclude them from being \"average risk\"\n3) It's unclear if this was a true screening colonoscopy or done for evaluation of the family history\n\nBased on the provided information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional details about the patient's clinical presentation, exact indication for the colonoscopy, and family history would be needed to make a final determination of eligibility. But the presence of adenomas at a young age with a strong family history raises concerns about the patient being truly \"average risk.\"",
        "label": 0
    },
    "1249": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old college student, which meets the age criteria (\u226518 years) for the clinical trial.\n\n2. The patient has a family history of familial adenomatous polyposis (FAP), with both siblings having undergone total proctocolectomy due to hundreds of colonic adenomas.\n\n3. The patient underwent a sigmoidoscopy and was found to have dozens of small colonic polyps within the rectosigmoid, which were biopsied and confirmed to be benign adenomas.\n\n4. The inclusion criteria for the clinical trial specifically mention a diagnosis of phenotypic classical FAP with disease involvement of the duodenum and/or colon/rectum/pouch, and the presence of an APC mutation (with or without family history).\n\n5. The patient meets the criteria for classical FAP phenotype with hundreds of colorectal adenomatous polyps appearing at a young age (21 years).\n\n6. The inclusion criteria also require an upper gastrointestinal (UGI) endoscopy/lower gastrointestinal (LGI) endoscopy within 30 days of randomization, which the patient has undergone (sigmoidoscopy).\n\n7. The patient has an intact colon/rectum with polyposis, which is one of the stratification sites mentioned in the inclusion criteria.\n\n8. Based on the information provided, the patient appears to meet the inclusion criteria for this clinical trial on eflornithine plus sulindac in patients with familial adenomatous polyposis (FAP).\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1250": {
        "output": "To determine the patient's eligibility for the clinical trial \"Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\n- Abdominal pain related disorder (functional dyspepsia, irritable bowel syndrome or functional abdominal pain (FAPS) diagnosed according to Rome III criteria.\n\nBased on the patient note, the 21-year-old college student underwent a colonoscopy due to a family history of multiple polyps in his older siblings. The patient was found to have dozens of small colonic polyps within the rectosigmoid, which were biopsied and found to be benign adenomas.\n\nThe patient note does not mention any abdominal pain-related functional gastrointestinal disorders or a diagnosis based on the Rome III criteria. The patient's condition appears to be related to the presence of colonic polyps, which is not covered by the inclusion criteria for this clinical trial.\n\nTherefore, based on the information provided, I would not refer this patient for the clinical trial \"Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1251": {
        "output": "To determine the patient's eligibility for the clinical trial \"Screening and Risk Factors of Colon Neoplasia\", let's go through the inclusion criteria:\n\nInclusion Criteria: patients undergoing routine colonoscopy at University Hospitals, Cleveland Ohio\n\nBased on the patient note, the key points are:\n\n1. The patient is a 21-year-old college student, so their age is not mentioned.\n2. The patient underwent a colonoscopy due to a family history of multiple polyps in their older siblings.\n3. The patient was found to have dozens of small colonic polyps within the rectosigmoid during the colonoscopy.\n\nSince the inclusion criteria only specify that patients undergoing routine colonoscopy at University Hospitals, Cleveland Ohio are eligible, and the patient note mentions that the patient underwent a colonoscopy (although the location is not specified), it is reasonable to consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1252": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Any adenoma found on screening/surveillance colonoscopy (ICD9-211.3, Procedure code 45385 or 45380)\"\nThe patient note mentions that the patient underwent a colonoscopy and was found to have \"dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.\" This meets the inclusion criterion of having adenomas found on colonoscopy.\n\n2. \"Greater than 18 years old\"\nThe patient note states that the patient is a 21-year-old college student, which meets the age requirement.\n\nSince the patient meets both inclusion criteria, they would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1253": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 21-year-old college student who underwent a colonoscopy due to a family history of multiple polyps in older siblings. The colonoscopy found dozens of small colonic polyps within the rectosigmoid region, which were biopsied and found to be benign adenomas.\n\nThe clinical trial is for the treatment of malignant pleural mesothelioma with pleural effusion using re-directed T cells targeting FAP (fibroblast activation protein).\n\nLooking at the inclusion criteria for the clinical trial:\n1. The patient does not have a histologically or cytologically confirmed diagnosis of malignant pleural mesothelioma with pleural effusion.\n2. The patient does not meet any of the other inclusion criteria related to bone marrow function, liver function, renal function, etc., as these details are not provided in the patient note.\n\nBased on the information given, this patient would not be eligible for this particular clinical trial as they do not have the target disease (malignant pleural mesothelioma).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1254": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old college student, which falls within the age range of 20-65 years specified in the inclusion criteria.\n\n2. The patient has a family history of familial adenomatous polyposis (FAP), with both siblings having undergone total proctocolectomy due to hundreds of colonic adenomas.\n\n3. The patient was found to have dozens of small colonic polyps within the rectosigmoid region during a colonoscopy, and several of these polyps were biopsied and confirmed to be benign adenomas.\n\n4. The inclusion criteria specifically state that patients with FAP who have colonic or duodenal polyps, and have five or more polyps 2mm or more in diameter, are eligible for the clinical trial.\n\nBased on the information provided, this patient meets all the inclusion criteria for the clinical trial titled \"The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1255": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\nAge \u226550 years: The patient is 21 years old, which does not meet this criterion.\n\nIndividuals able to provide informed consent: There is no information provided about the patient's ability to provide informed consent, but we can assume that as a college student, they are likely able to do so.\n\nIndividuals presenting for average-risk colorectal cancer screening by colonoscopy: The patient is undergoing a colonoscopy due to a family history of multiple polyps in their siblings, which suggests an increased risk for colorectal cancer. Therefore, this criterion is not met.\n\nIndividuals presenting for surveillance of adenomatous/sessile serrated colon polyps as per the US multi-society taskforce on colorectal cancer: The patient was found to have dozens of small colonic polyps, which were benign adenomas. This criterion is likely met.\n\nOverall, while the patient meets some of the inclusion criteria, they do not meet the age requirement and are not presenting for average-risk colorectal cancer screening. However, they may be eligible for the trial based on the surveillance of adenomatous polyps criterion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1256": {
        "output": "To determine the patient's eligibility for the clinical trial \"Comparison Between White Light Endoscopy and Bright Narrow Band Imaging in Diagnosis Colonic Adenomas\", let's go through the inclusion criteria:\n\n1. Asymptomatic subjects undergoing screening colonoscopy\n- The patient note does not explicitly state if the colonoscopy was for screening purposes or due to the family history of polyps. However, it is reasonable to assume it was for screening given the patient's young age (21 years old) and the presence of polyps in older siblings.\n\n2. Age > 50\n- The patient is 21 years old, which does not meet this criterion.\n\n3. Average risk subjects\n- Given the strong family history of multiple polyps and proctocolectomies in siblings at a young age, this patient would likely be considered high risk rather than average risk.\n\n4. Ability to provide a written consent to trial participation\n- There is no information provided about the patient's ability to provide consent.\n\nWhile the patient meets some of the criteria, such as undergoing a colonoscopy and having polyps detected, the age criterion is not met, and the patient would likely be considered high risk rather than average risk due to the significant family history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient's young age and strong family history of polyps/proctocolectomies are concerning for an inherited polyposis syndrome. Further investigation into the specific syndrome and the patient's ability to provide consent would be needed to determine full eligibility. However, the presence of multiple adenomatous polyps at a young age makes this an interesting case that could potentially be considered for the trial, pending additional evaluation.",
        "label": 0
    },
    "1257": {
        "output": "To determine the patient's eligibility for the clinical trial \"High Definition Endoscopy With i-Scan for Small Colonic Polyp Evaluation: The HiScope Study\", let's go through the key points:\n\n1. The patient is a 21-year-old college student, so their age meets the inclusion criteria (which does not specify an age range).\n\n2. The patient underwent a colonoscopy and was found to have dozens of small colonic polyps within the rectosigmoid region. Several of these polyps were biopsied and found to be benign adenomas.\n\n3. The inclusion criteria for the clinical trial specifically states: \"Patients found to have colonic polyps up to 10mm in size\".\n\nSince the patient has multiple small colonic polyps that were found during a colonoscopy, and the polyps were confirmed to be adenomas (which are the type of polyps the trial is interested in evaluating), this patient meets the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1258": {
        "output": "To determine the patient's eligibility for the clinical trial \"Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia\", let's go through the inclusion criteria:\n\n1. Asymptomatic subjects aged 45 - 75 years\nThe patient is a 21-year-old college student, which does not meet the age criteria of 45-75 years.\n\n2. Subjects who will give the written consent\nThere is no information provided about whether the patient will give written consent or not.\n\nBased on the available information, the patient does not meet the age criteria for inclusion in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1259": {
        "output": "Let's go through the inclusion criteria for the clinical trial \"APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis\" and assess the eligibility of the patient based on the provided patient note.\n\nThe inclusion criteria are:\n1. Male or female of 18 to 85 years of age (inclusive)\n   - The patient is 21 years old, which falls within this age range.\n2. Have a diagnosis of FAP (Familial Amyloid Polyneuropathy)\n   - There is no mention of the patient having FAP in the note. The note mentions a family history of multiple polyps and adenomas, but not FAP specifically.\n3. Neuropathy Impairment Score requirement of 5-130\n   - The patient's Neuropathy Impairment Score is not provided.\n4. Meet Karnofsky performance status requirements\n   - The patient's Karnofsky performance status is not provided.\n5. Have adequate complete blood counts and liver function tests\n   - No information is provided about the patient's blood counts or liver function tests.\n6. Have adequate cardiac function\n   - No information is provided about the patient's cardiac function.\n7. Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)\n   - No information is provided about the patient's HBV and HCV status.\n\nBased on the provided information, the patient does not meet the inclusion criterion of having a diagnosis of FAP, which is a key requirement for this clinical trial. Additionally, there is insufficient information to determine if the patient meets several other inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1260": {
        "output": "To determine the patient's eligibility for the clinical trial \"I-Scan Vs High Definition White Light (Main Study)\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n\"All increased risk patients (Patients with family history or personal history of colon polyps or colon cancer and FOBT positive) referred for a screening colonoscopy at the Forzani and MacPhail Colon Cancer Screening Centre will be considered for enrollment.\"\n\nBased on the patient note, the 21-year-old college student has a family history of multiple polyps in his older siblings, with both siblings having undergone total proctocolectomy due to hundreds of colonic adenomas. The patient's colonoscopy also revealed dozens of small colonic polyps within the rectosigmoid, with biopsies confirming benign adenomas.\n\nGiven the patient's young age and significant family history of colonic polyps, along with the finding of multiple adenomas during the colonoscopy, this patient would be considered at increased risk for colon cancer.\n\nTherefore, this patient meets the inclusion criteria for the clinical trial, which aims to assess the effectiveness of I-Scan technology in detecting adenomas in high-risk populations.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1261": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old college student, which does not meet the age criteria of 50-69 years old for this clinical trial.\n\n2. However, the patient has a strong family history of multiple polyps and colon cancer, with both siblings requiring total proctocolectomy at a young age due to hundreds of colonic adenomas.\n\n3. The patient was found to have dozens of small colonic polyps on sigmoidoscopy, with biopsies confirming benign adenomas.\n\n4. Given the significant family history and presence of adenomatous polyps at a young age, this patient likely has an inherited polyposis syndrome and would be at very high risk for developing colon cancer.\n\n5. While the patient does not meet the strict age criteria, they would be an excellent candidate for this colon cancer screening trial comparing colon capsule and virtual colonoscopy, given their extremely high risk.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1262": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 21-year-old college student who underwent a colonoscopy due to a family history of multiple polyps in his older siblings. The colonoscopy revealed dozens of small colonic polyps within the rectosigmoid region, and several of these were biopsied and found to be benign adenomas.\n\nThe clinical trial is titled \"Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW.\" The inclusion criteria state that patients must have genetically or clinically proven Familial Adenomatous Polyposis (FAP), defined as having an identified Adenomatous Polyposis Coli (APC) mutation or more than 100 colorectal polyps at diagnosis.\n\nGiven the patient's young age (21 years old) and the presence of dozens of colonic polyps, it is highly likely that the patient has FAP, even though the genetic mutation is not explicitly mentioned. Therefore, the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1263": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old college student who underwent a colonoscopy due to a family history of multiple polyps in older siblings.\n\n2. The patient was found to have dozens of small colonic polyps within the rectosigmoid region, and biopsies confirmed they were benign adenomas.\n\n3. The clinical trial is titled \"Prevalence of Small Bowel Polyps in Patients With Sporadic Duodenal Adenomas\".\n\n4. The inclusion criteria for the trial are:\n   - Cases: Patients diagnosed with or underwent resection of a duodenal adenoma/ampulloma at Westmead hospital between 2005-2014.\n   - Controls: Patients undergoing capsule endoscopy for obscure gastrointestinal bleeding or iron deficiency anemia.\n\n5. Based on the patient note, this patient does not have duodenal adenomas or ampullomas. The polyps found were in the colon, not the duodenum or ampulla.\n\n6. Additionally, the patient is not undergoing capsule endoscopy for obscure GI bleeding or iron deficiency anemia, which are the criteria for the control group.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1264": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old college student, which falls within the age range (40-70 years) specified in the inclusion criteria for first-degree relatives.\n\n2. The patient's brother and sister both had hundreds of colonic adenomas and underwent total proctocolectomy at a young age (22 and 28 years old, respectively). This suggests that they likely had advanced adenomas or colorectal cancer, which is not the focus of this trial.\n\n3. The trial is specifically looking at first-degree relatives of individuals diagnosed with non-advanced adenomas on screening colonoscopy.\n\n4. The patient themselves underwent a sigmoidoscopy and was found to have dozens of small colonic polyps, which were biopsied and found to be benign adenomas.\n\n5. Based on the information provided, the patient does not appear to be a first-degree relative of an individual diagnosed with non-advanced adenomas. Instead, the patient's siblings seem to have had advanced neoplasms.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1265": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 21-year-old college student undergoing a colonoscopy due to a family history of multiple polyps in older siblings.\n2. The patient's brother and sister both underwent total proctocolectomies in their early 20s after being found to have hundreds of colonic adenomas.\n3. During the patient's sigmoidoscopy, dozens of small colonic polyps were found in the rectosigmoid region, and biopsies confirmed they were benign adenomas.\n4. The clinical trial is studying the utility of dedicating half of the withdrawal time during a screening colonoscopy to examining the right side of the colon, with the aim of increasing adenoma detection rate.\n5. The inclusion criteria for the trial are adult patients aged 18-80 years undergoing colonoscopy for screening or surveillance purposes.\n\nGiven the patient's young age (21 years old), family history of multiple colonic adenomas, and the finding of dozens of small colonic polyps on their own sigmoidoscopy, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1266": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman, so she does not meet the age criteria of being a young girl in pubertal stage II.\n\nThere is no information provided about her calcium intake level, so we cannot determine if she meets that inclusion criteria.\n\nShe is not specified as being Caucasian.\n\nShe has a history of hypertension and diabetes, so she may not meet the \"normal health\" criteria depending on how strictly that is defined.\n\nOverall, based on the information given, it does not seem highly likely that this patient would be eligible for the calcium and bone mass study focused on young Caucasian girls going through puberty.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1267": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman who is postmenopausal within the last year. This meets the inclusion criteria of being a postmenopausal woman.\n\nHer medical history includes hypertension and diet-controlled diabetes mellitus, which are not explicitly listed as exclusion criteria. However, the criteria state \"Good general health\", so her medical conditions may need further evaluation.\n\nShe currently smokes 1 pack of cigarettes per day, which could potentially impact her \"good general health\" status and may need further investigation.\n\nThe inclusion criteria specify a spine bone mineral density (BMD) T-score between -1.0 and -2.5, or a hip T-score between -1.0 and -2.5. The patient note does not provide this information, so further testing may be required.\n\nThe other inclusion criteria, such as willingness to participate, ability to give informed consent, ability to travel to the research center, and age \u226560 years, cannot be fully assessed from the provided patient note.\n\nOverall, based on the available information, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1268": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman, which meets the age criteria of 6.0 - 17.0 years for this clinical trial on childhood osteoporosis.\n\n2. The patient is concerned about osteoporosis prevention, but there is no mention of her being diagnosed with osteoporosis or having a low bone mineral density score.\n\n3. The inclusion criteria specifically state that patients must have \"AP Lumbar spine bone mineral density less than or equal to -2 standard deviations for age matched controls (z-score)\" and have idiopathic juvenile osteoporosis.\n\n4. There is no information provided about the patient's bone mineral density or if she has been diagnosed with idiopathic juvenile osteoporosis.\n\n5. The other inclusion/exclusion criteria cannot be fully assessed based on the limited information provided about the patient.\n\nBased on the available information, this patient does not seem to meet the key inclusion criteria for this clinical trial on childhood osteoporosis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1269": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman who is in menopause within the last year. This matches the inclusion criteria of being between 18-42 years old and having premature ovarian failure diagnosed before age 40.\n\n2. However, she currently smokes 1 pack of cigarettes per day, which is an exclusion criterion (smokers of more than 2 cigarettes per day are excluded).\n\n3. She also has a history of hypertension and diabetes mellitus, which could potentially exclude her depending on how well-controlled these conditions are (the exclusion criteria mention insulin-dependent diabetes and other major illnesses).\n\n4. There is no information provided about her body mass index, history of fractures/hip pathology, skin sensitivity, hirsutism/acne scores, hormone levels, or other medical conditions that are listed as exclusion criteria.\n\nBased on the limited information provided, I would consider referring this patient to the clinical trial upon further investigation into her medical history and current status of conditions like hypertension and diabetes.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1270": {
        "output": "To determine the patient's eligibility for the clinical trial \"Dietary Phytoestrogens and Bone Metabolism\", let's go through the inclusion criteria one by one:\n\n1. Postmenopausal: The patient note states that the 51-year-old woman was documented to be in menopause within the last year, so she meets this criterion.\n\n2. Weight within 90% to 120% of ideal body weight: The patient note does not provide information about the patient's weight or height, so it is unclear if she meets this criterion.\n\n3. 12 or more months since last menstrual period: The patient note states that she was documented to be in menopause within the last year, which implies it has been at least 12 months since her last menstrual period. Therefore, she meets this criterion.\n\n4. New York Metro Area resident: The patient note does not provide information about the patient's location or residence, so it is unclear if she meets this criterion.\n\nSince the patient meets at least two of the inclusion criteria (postmenopausal and 12 or more months since last menstrual period), but there is not enough information to determine if she meets the other two criteria (weight and location), I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1271": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effects of Black Cohosh on Menopausal Hot Flashes\", let's go through the inclusion criteria one by one:\n\n1. Resident of the New York Metro Area: The patient's location is not mentioned, so we cannot determine if they meet this criterion.\n\n2. Postmenopausal: The patient note states that \"She was documented by previous LH and FSH levels to be in menopause within the last year.\" This meets the postmenopausal criterion.\n\n3. Weight within 90% to 120% of ideal body weight: The patient's weight or body mass index (BMI) is not provided, so we cannot determine if they meet this criterion.\n\nSince one of the inclusion criteria is met (postmenopausal), and we lack information to determine if the other two criteria are met, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1272": {
        "output": "To determine the trial-level eligibility for this patient, let's go through the inclusion criteria for the clinical trial:\n\nVeterans aged 50 and older drawn from two existing VA cohorts, the Normative Aging Study (NAS) and the Veterans Health Study (VHS).\n\nThe patient note mentions that the patient is a 51-year-old woman, so she does not meet the criteria of being a male veteran aged 50 and older from the NAS or VHS cohorts.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1273": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman, which falls within the age range of 50-75 years specified in the inclusion criteria.\n\nThe patient is noted to be postmenopausal within the last year, satisfying the \"postmenopausal\" criterion.\n\nHowever, there is no information provided about the patient's bone mineral density or whether she has osteoporosis, which is a key inclusion criterion.\n\nAdditionally, the inclusion criteria specifies that participants must be on estrogen replacement therapy for at least 3 years, but there is no mention of the patient's estrogen replacement status.\n\nThe inclusion criteria also specifies \"healthy caucasian\" participants, but the patient's race/ethnicity is not provided.\n\nBased on the information given, there are some key missing details that would be needed to fully assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her bone mineral density, estrogen replacement therapy status, and race/ethnicity.",
        "label": 1
    },
    "1274": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman who is postmenopausal within the last year. This meets the inclusion criteria of being a woman at high risk for osteoporosis.\n\n2. She has a history of hypertension and diet-controlled diabetes, which are not exclusion criteria for this trial.\n\n3. She is a current smoker, which increases her risk for osteoporosis and fractures. This would likely make her eligible for the trial.\n\n4. She is seeking advice on osteoporosis prevention, which aligns with the goal of the trial to educate patients about osteoporosis diagnosis and treatment.\n\n5. The inclusion criteria for patients specify PACE beneficiaries who filled a prescription in the prior year and had an outpatient visit with a participating doctor. This information is not provided in the patient note.\n\nBased on the available information, this patient appears to meet several key inclusion criteria for being at high risk for osteoporosis and seeking education on prevention. However, without knowing if she meets the PACE beneficiary and participating doctor criteria, I cannot definitively determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1275": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old postmenopausal woman with osteoporosis, which matches the inclusion criteria of being a postmenopausal woman with osteoporosis.\n\n2. However, the inclusion criteria also state that the patient must be postmenopausal for at least 3 years, and the note does not specify how long she has been postmenopausal.\n\n3. The patient has hypertension and diabetes, which are not explicitly listed as exclusion criteria, but the exclusion criteria mention \"moderate or severe hypertension which is uncontrolled\" and \"other significant end organ diseases (genitourinary, cardiovascular, endocrine, hepatic, psychiatric, renal, hematologic, or pulmonary).\" Her hypertension and diabetes could potentially fall under these exclusions, but more information would be needed.\n\n4. The patient is a current smoker, which is not listed as an exclusion criterion.\n\n5. Overall, based on the information provided, the patient appears to potentially meet the inclusion criteria, but there are some uncertainties around the duration of her menopause and the severity of her comorbidities that would require further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1276": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Members of the Harvard Pilgrim Health Plan\n   - The patient note does not mention which health plan the patient is a member of, so we cannot confirm or deny this criterion.\n\nSince the patient note lacks information about the patient's health plan membership, which is a key inclusion criterion, I would not be able to definitively determine eligibility. However, based on the available information, the patient seems to fit the target population of women at high risk for osteoporosis due to her age (51 years old) and being post-menopausal.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1277": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman, so she does not meet the inclusion criteria of being male.\n\n2. The trial is specifically looking at bone density and testosterone levels in men receiving methadone maintenance therapy. This patient is not receiving methadone maintenance therapy.\n\n3. The inclusion criteria specify an age range of 18-50 years old. This patient is 51 years old, which is outside of the specified age range.\n\nBased on the information provided in the patient note and the inclusion criteria for this clinical trial, this patient would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1278": {
        "output": "To determine the patient's eligibility for the \"Osteoporosis School\" clinical trial, let's go through the inclusion and exclusion criteria:\n\nInclusion Criteria:\n1. Fracture caused by osteoporosis: The patient note does not mention any fractures, so this criterion is not met.\n2. Fifty years or more of age: The patient is 51 years old, so this criterion is met.\n3. Informed consent: The patient note does not mention whether the patient has provided informed consent or not, so we cannot determine if this criterion is met.\n\nExclusion Criteria:\n- Physically or mental state that does not allow participation: The patient note does not provide any information about the patient's physical or mental state that would prevent participation.\n\nBased on the available information, the patient meets one of the inclusion criteria (age) but does not meet the other inclusion criterion (fracture caused by osteoporosis). There is not enough information to determine if the patient meets the informed consent criterion or the exclusion criterion related to physical or mental state.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1279": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old postmenopausal woman, which matches the inclusion criteria of \"Postmenopausal women\".\n\n2. She has a wrist fracture, which is not explicitly mentioned in the patient note. However, the trial is looking for \"low trauma distal radius fracture\", so a wrist fracture would likely qualify.\n\n3. The patient is not currently taking any of the medications listed (Didrocal, Miacalcin, or hormone replacement therapy), but the criteria state that patients can be taking these medications, not that they must be taking them.\n\nBased on the information provided, this patient seems to meet the key inclusion criteria of being a postmenopausal woman with a likely wrist/distal radius fracture.\n\nWhile there are some missing details like the exact type of fracture and whether it was low trauma, I would consider referring this patient to the clinical trial upon further investigation to confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1280": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman, which does not meet the age criteria of 25-44 years for this clinical trial on osteoporosis education in premenopausal women.\n\n2. The patient note mentions that she was documented to be in menopause within the last year, which further excludes her from a trial focused on premenopausal women.\n\n3. While the patient is concerned about osteoporosis prevention, which aligns with the goal of the trial, her age and menopausal status make her ineligible based on the stated inclusion criteria.\n\nTherefore, based on the given patient note and inclusion criteria for this clinical trial, my assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1281": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman who is concerned about osteoporosis prevention and the risk of hip fractures as she gets older.\n\n2. The clinical trial is titled \"Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities\" and aims to test an intervention to improve the prescription of FDA-approved osteoporosis medications in long-term care facilities.\n\n3. The inclusion criteria for the trial are: \"Any North Carolina long-term care facility with ten residents who had had a hip fracture or osteoporosis diagnosis.\"\n\n4. Based on the information provided, this patient does not meet the inclusion criteria for this clinical trial, as she is not a resident of a long-term care facility and has not had a hip fracture or osteoporosis diagnosis.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1282": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women\", let's go through the inclusion criteria one by one:\n\n1. Healthy as assessed by the health and lifestyle questionnaire, physical examination, and pre-study laboratory tests: The patient note does not provide information about these assessments, so we cannot determine if this criterion is met.\n\n2. Caucasian women: The patient note does not mention the patient's race or ethnicity, so we cannot determine if this criterion is met.\n\n3. Postmenopausal (\u226512 - \u226460 months since last menses), determined by interview and FSH level \u2265 20 IU/l: The patient note states that the patient was documented by previous LH and FSH levels to be in menopause within the last year, which suggests she meets this criterion.\n\n4. Body Mass Index (BMI) \u226522 - \u226429 kg/m2: The patient note does not provide information about the patient's height and weight, so we cannot calculate her BMI to determine if this criterion is met.\n\n5. Voluntary participation: The patient note does not indicate whether the patient is willing to participate in the study or not.\n\n6. Having given their written informed consent: The patient note does not mention if the patient has provided written informed consent.\n\n7. Willing to comply with the study procedures: The patient note does not provide information about the patient's willingness to comply with the study procedures.\n\n8. Willing to accept use of all nameless data, including publication and the confidential use and storage of all data: The patient note does not mention the patient's willingness to accept the use and storage of her data.\n\n9. Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned: The patient note does not mention the patient's willingness to accept the disclosure of financial benefits.\n\nBased on the information provided in the patient note, we can determine that the patient meets the criterion for being postmenopausal within the specified time frame. However, there is not enough information to determine if the patient meets the other inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1283": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman who has recently entered menopause within the last year. This matches the inclusion criteria of being a post-menopausal woman.\n\nShe has been newly diagnosed with osteoporosis and is seeking advice on prevention/treatment. This matches the inclusion criteria of being newly diagnosed with post-menopausal osteoporosis requiring treatment.\n\nThere is no mention of her having received any prior bisphosphonate treatment, so she can be considered treatment naive or having not received bisphosphonates for at least 5 years prior.\n\nBased on the information provided, this patient appears to meet all the key inclusion criteria for the clinical trial studying the effects of monthly ibandronate (Boniva) on bone turnover markers in post-menopausal women with osteoporosis.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1284": {
        "output": "To determine the patient's eligibility for the clinical trial \"Optimizing Vitamin D Nutrition in Healthy Adults\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Healthy African-American and Caucasian adults aged 18-65 years.\n\nThe patient note mentions that the patient is a 51-year-old woman, which falls within the age range of 18-65 years. However, the note does not specify her race or ethnicity.\n\nAdditionally, the patient has a past medical history of significant hypertension and diet-controlled diabetes mellitus, which may not be considered \"healthy\" for the purposes of this trial.\n\nBased on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to determine the patient's race/ethnicity and whether her medical conditions of hypertension and diabetes mellitus would exclude her from being considered \"healthy\" for this trial.",
        "label": 1
    },
    "1285": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Postmenopausal women and men over the age of 40: The patient is a 51-year-old woman who has been documented to be in menopause within the last year, so she meets this criterion.\n\n2. Starting therapy with teriparatide: The patient note does not mention if she is starting therapy with teriparatide or not.\n\nSince the patient meets one of the inclusion criteria but it is unclear if she meets the other, I would consider referring her to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1286": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old postmenopausal woman, which meets the \"Postmenopausal\" inclusion criteria.\n\nHowever, the note does not mention if the patient has asthma or is receiving glucocorticoid treatment, which are required by the inclusion criteria \"asthmatic outpatients under 60 years of age on long-term oral or inhaled glucocorticoid treatment for at least one year.\"\n\nWithout information about the patient's asthma status and glucocorticoid treatment, it is difficult to definitively determine eligibility for this particular trial.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her asthma status and glucocorticoid treatment history.",
        "label": 0
    },
    "1287": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nAge: The patient is 51 years old, which falls within the 45-55 year old range specified in the inclusion criteria.\n\nHistory of natural menopause: The patient was documented to be in menopause within the last year, satisfying this criterion.\n\nHormonal medication/supplements: There is no mention of the patient taking any hormonal medications or supplements, so we can assume she meets this criterion.\n\nNormal thyroid, prolactin, factor V Leiden, and CBC: These lab values are not provided, so we cannot definitively say if she meets these criteria.\n\nNormal BUN/creatinine: These lab values are also not provided.\n\nBMI \u2264 30: The patient's BMI is not given.\n\nNon-smoker or smokes <10 cigarettes/day: The patient currently smokes 1 pack per day, which is more than the allowed 10 cigarettes per day.\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria. The major issue is her heavy smoking status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her lab values and potentially getting her to cut down on smoking.",
        "label": 0
    },
    "1288": {
        "output": "To determine the patient's eligibility for the \"Falls Prevention in Osteoporosis\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. Osteoporosis (DXA T-score < -2.5 in hip and/or vertebrae): The patient note does not mention any DXA scan results or osteoporosis diagnosis. This criterion cannot be confirmed.\n\n2. Able to walk at least 15 minutes without an assisting device: The patient note does not provide any information about the patient's mobility or ability to walk. This criterion cannot be confirmed.\n\n3. 65 years or older: The patient is 51 years old, which does not meet this criterion.\n\n4. Community dwelling: The patient note does not specify whether the patient is community-dwelling or not. This criterion cannot be confirmed.\n\n5. At least one fall in the prior year: The patient note does not mention any falls in the past year. This criterion cannot be confirmed.\n\nSince the patient's age does not meet the inclusion criteria, and several other criteria cannot be confirmed based on the provided information, I would not refer this patient for this clinical trial without further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1289": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman with hypertension, diet-controlled diabetes mellitus, and current smoking history of 1 pack per day. She is in menopause within the last year.\n\n2. The clinical trial is titled \"Bone Density in Patients With Schizophrenia\" and aims to evaluate the prevalence of bone mineral density in men with schizophrenia with and without alcohol abuse.\n\n3. The inclusion criteria for the trial are:\n   - DSM-IV diagnosis of schizophrenia\n   - Onset of illness more than 5 years\n\n4. Based on the patient note, there is no mention of the patient having schizophrenia or any other mental disorder. The note only mentions her concerns about osteoporosis prevention.\n\n5. Therefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1290": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old post-menopausal woman, which matches the first inclusion criteria of \"post-menopausal women\".\n\nShe has a history of hypertension and diabetes, but these are not exclusion criteria for the trial.\n\nShe is a current smoker of 1 pack per day. This is not listed as an exclusion criteria.\n\nThe key piece of information is that she is concerned about osteoporosis prevention and has not yet started any bisphosphonate therapy like alendronate or risedronate. The trial requires participants to have been on daily or weekly alendronate or risedronate for at least 3 months prior.\n\nSince she has not been on prior bisphosphonate therapy, she would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1291": {
        "output": "To determine the patient's eligibility for the clinical trial \"Education for Osteoporosis in Persons With Existing Fractures\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n- Presented to Modbury Hospital's Accident and Emergency Department with a new bone fracture\n\nBased on the patient note provided, there is no mention of the patient presenting to the emergency department or having a new bone fracture. The note states that the 51-year-old woman is seen in the clinic for advice on osteoporosis prevention, but does not indicate that she has had a recent fracture.\n\nSince the patient does not meet the inclusion criteria of having a new bone fracture, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1292": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female, post-menopausal women aged 50 to 90.\nThe patient note states that the patient is a 51-year-old woman who was documented to be in menopause within the last year. This meets the age and menopausal status criteria.\n\n2. Have a bone mineral density (BMD) evaluation resulting in a T-Score of <-1.0.\nThe patient note does not mention the patient's bone mineral density or T-Score, so we cannot confirm if this criterion is met.\n\n3. Have a follow-up appointment with a provider in the areas of Family Medicine (FM), Primary Care Internal Medicine (PCIM), or POM.\nThe patient note does not specify the type of provider the patient is seeing, so we cannot confirm if this criterion is met.\n\n4. Have no major barriers (i.e., severe hearing impairment, dementia, require interpreter, etc.) to participation in shared decision-making (per provider's assessment)\nThe patient note does not mention any barriers to shared decision-making, so we can assume this criterion is met.\n\n5. Enrollment is open to females of diverse racial backgrounds.\nThis criterion is met as the patient is a female.\n\nBased on the information provided in the patient note, we can say that the patient meets some of the inclusion criteria, but there is not enough information to confirm eligibility for all criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1293": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman, which meets the age criteria of 18 or older for the clinical trial.\n\n2. However, the patient does not have rheumatoid arthritis, which is one of the inclusion criteria for this trial. The note mentions hypertension, diabetes mellitus, and concerns about osteoporosis prevention, but does not indicate a diagnosis of rheumatoid arthritis.\n\n3. The patient is also not taking any glucocorticoids (e.g., prednisone), which is another inclusion criterion for this trial.\n\nBased on the information provided in the patient note, this patient does not meet the key inclusion criteria of having rheumatoid arthritis and being on glucocorticoid therapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1294": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nPatient note:\n- 51-year-old woman\n- Past medical history of hypertension and diet-controlled diabetes mellitus\n- Currently smokes 1 pack of cigarettes per day\n- Documented to be in menopause within the last year\n- Seeking advice on osteoporosis prevention\n\nInclusion criteria:\n- Female\n- Age 45 (inclusive) to 55 years (inclusive) - The patient is 51, so meets this criteria\n- Race: Caucasian - Not mentioned for the patient\n- Non-smokers / Smokers up to 10 cigarettes/day - The patient smokes 1 pack per day, which is more than the allowed 10 cigarettes\n- Postmenopausal hormone status: 1-3 years since last menstrual bleeding and FSH >75 IU/ml and E2 < 20 ng/L - The patient is documented to be in menopause within the last year, so likely meets this\n- Years since menopause between 1-3 years - Meets this criteria\n- Natural menopause or total hysterectomy with bilateral salpingo-oophorectomy - Assuming natural menopause for the patient\n- Willingness and ability to give written informed consent and comply with study requirements - Not mentioned but can likely be obtained\n- Ability to understand, speak, read and write English language - Not mentioned but can likely be met\n\nThe major exclusion factor is that the patient smokes more than the allowed 10 cigarettes per day for the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her ability to understand English, willingness to participate, and exact hormone levels to confirm postmenopausal status within the allowed range. However, her current smoking of 1 pack per day is a significant exclusion criteria that would need to be addressed.",
        "label": 0
    },
    "1295": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old postmenopausal woman, which meets the age and gender criteria for the trial.\n\n2. She has a history of diet-controlled diabetes mellitus, which meets the inclusion criteria of having Type II diabetes for more than 5 years.\n\n3. Her smoking status and hypertension are not exclusion criteria for this trial.\n\n4. There is no mention of her having any fractures, so she would likely fall into the group of diabetic patients with no fracture history.\n\n5. Her BMI is not provided, but this could potentially be calculated or obtained during screening.\n\nBased on the information provided, this patient appears to meet most of the key inclusion criteria for the trial. However, her BMI and ability to move without assistance would need to be confirmed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1296": {
        "output": "To determine the patient's eligibility for the clinical trial \"The Interaction Between Calcium and Vitamin D Intake\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Healthy women aged 45 and above who have been menopausal at least 1 year (absence of menstrual period for a period of 12 months or more)\n\nBased on the patient note, the patient is a 51-year-old woman who was documented to be in menopause within the last year. This meets the inclusion criteria for age and menopausal status.\n\nHowever, the patient note mentions that she has a past medical history of significant hypertension and diet-controlled diabetes mellitus, which may exclude her from being considered \"healthy\".\n\nAdditionally, the patient currently smokes 1 pack of cigarettes per day, which is another potential factor that could exclude her from being considered \"healthy\".\n\nGiven these additional medical conditions and smoking status, the patient may not be considered entirely \"healthy\" as required by the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1297": {
        "output": "To determine the patient's eligibility for the clinical trial \"Role of T-cells in Post-Menopausal Osteoporosis\", let's go through the inclusion criteria one by one:\n\n1. Women between the age of 18-55: The patient is 51 years old, which falls within this range.\n\n2. Pre-menopausal by history (regular spontaneous menstrual bleeding every 21-35 days) or documented FSH <10: The patient is documented to be in menopause within the last year, which implies that she was pre-menopausal before that.\n\n3. No current estrogen therapy: There is no mention of the patient being on estrogen therapy.\n\n4. Undergoing hysterectomy with (ovx) or without ovariectomy (control group) for benign gynecologic disease (fibroid uterus, endometriosis, dysfunctional uterine bleeding, chronic pelvic pain) or for prophylaxis against ovarian cancer (BRCA positive): There is no information provided about the patient undergoing any surgical procedure.\n\nBased on the information given, the patient meets some of the inclusion criteria (age and pre-menopausal status), but there is no mention of her undergoing a hysterectomy or ovariectomy, which is a key requirement for this study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1298": {
        "output": "Okay, let's go through the inclusion criteria for the \"Women's Health Habits Study\" clinical trial step-by-step:\n\n1. Has diabetes, hypertension, osteoporosis, or infertility: The patient note mentions that the 51-year-old woman has hypertension and diet-controlled diabetes mellitus, so she meets this criterion.\n\n2. Not currently receiving treatment for alcohol or drug problems or substance-related medical illness: There is no mention of the patient receiving such treatment, so we can assume she meets this criterion.\n\n3. Not currently experiencing physical dependence on alcohol, requiring medically supervised detoxification: There is no indication of alcohol dependence in the patient note.\n\n4. Not currently abusing or physically dependent on opiates, cocaine, or other illicit drugs: There is no mention of drug abuse or dependence.\n\n5. Not currently pregnant. Subjects with infertility may become pregnant during the course of the study: The patient note does not mention pregnancy, and infertility is not listed as one of her conditions.\n\n6. Not currently nursing: There is no mention of the patient nursing.\n\n7. Able to complete study measures: We can assume the patient is able to complete study measures unless stated otherwise.\n\nBased on the information provided in the patient note, this 51-year-old woman with hypertension, diet-controlled diabetes mellitus, and concerns about osteoporosis appears to meet the inclusion criteria for the \"Women's Health Habits Study\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1299": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman who is postmenopausal within the last year. This meets the age criteria of 45-60 years old for early postmenopause.\n\nShe has hypertension and diet-controlled diabetes, but the inclusion criteria do not explicitly exclude these conditions.\n\nShe is a current smoker of 1 pack per day. The inclusion criteria do not mention smoking status.\n\nHer chief concern is osteoporosis prevention and advice, which aligns with the purpose of studying prevention and treatment of postmenopausal osteoporosis.\n\nThe only potential issue is that her bone mineral density is not mentioned, which is required to be between -1 and -2.5 standard deviations compared to normal young women for early postmenopause.\n\nOverall, assuming her bone mineral density meets the criteria, this patient seems eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her bone mineral density.",
        "label": 0
    },
    "1300": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman, which meets the \"female\" inclusion criteria.\n\nHowever, the inclusion criteria specifies \">= 65 years old\", and the patient is only 51 years old, so she does not meet the age criteria.\n\nThe patient is also noted to be in menopause within the last year, which does not meet the \"> 5 years\" postmenopausal criteria.\n\nBased on not meeting the age and postmenopausal duration criteria, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1301": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 51-year-old woman, which meets the age criteria of being 60 years or older for cases and controls in the trial.\n\nShe has a history of hypertension and diabetes, but these conditions are not explicitly listed as exclusion criteria.\n\nShe is a current smoker, which is not mentioned in the inclusion/exclusion criteria.\n\nThe key point is that she is concerned about osteoporosis prevention and risk of hip fracture as she gets older. However, she has not actually had a hip fracture yet.\n\nThe trial is specifically looking at women aged 60 and over who have already had an osteoporotic hip fracture (cases) or women without hip fracture matched to cases by age (controls).\n\nSince this patient has not had a hip fracture, she would not qualify as a case. And since she is under 60, she also would not qualify as a control matched to the cases.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1302": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Adult patients, >/= 55 years of age\nThe patient is 51 years old, which meets this criterion.\n\n2. Postmenopausal osteoporosis\nThe patient is a 51-year-old woman who has been in menopause for the past year and is concerned about osteoporosis prevention. This suggests that she likely has or is at risk for postmenopausal osteoporosis, meeting this criterion.\n\n3. Patients who are in the opinion of the physician eligible to participate in this study\nThere is no information provided about the physician's opinion on the patient's eligibility. However, based on the available information, the patient seems to meet the other inclusion criteria.\n\nOverall, based on the provided patient note and the inclusion criteria for the clinical trial, the patient appears to be eligible for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1303": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman, which falls within the age range of 40-55 specified in the inclusion criteria.\n\nHer BMI is not provided, but it is stated that she is concerned about osteoporosis prevention, suggesting she may be overweight or obese (BMI > 25 kg/m^2) as required.\n\nIt is mentioned that she was documented to be in menopause within the last year, satisfying the criteria of being in late menopausal transition or early menopause.\n\nHowever, there is no information provided about whether she suffers from menopausal symptoms, which is one of the inclusion criteria.\n\nBased on the information given, I would consider referring this patient to the clinical trial upon further investigation into whether she experiences menopausal symptoms and her exact BMI.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1304": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman who is in menopause within the last year. This matches the inclusion criteria of being a perimenopausal woman.\n\n2. There is no information provided about her willingness to participate in the 6-month study, undergo testing of bone turnover markers, or provide self-assessments on quality of life and sleep. We would need to investigate further to determine if she meets these criteria.\n\n3. There is no information provided about her willingness to take the medication before bed or to avoid consuming alcohol with the medication. Again, we would need to investigate further.\n\n4. Based on the information given, I would consider referring this patient to the clinical trial upon further investigation to determine if she meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1305": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 51-year-old woman who is postmenopausal within the last year. She has risk factors for osteoporosis including smoking and being postmenopausal. She is concerned about preventing osteoporosis and hip fractures.\n\nThe clinical trial is focused on developing an intervention model for osteoporosis and fall prevention in Taiwan. \n\nThe inclusion criteria are:\n1) The risk of osteoporosis\n2) The risk of falls\n\nThis patient meets the inclusion criteria of being at risk for osteoporosis due to her postmenopausal status, age, and smoking history. Her concern about preventing hip fractures also suggests she may be at risk for falls.\n\nTherefore, based on the information provided, this patient would be a good candidate for this clinical trial on osteoporosis and fall prevention interventions.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1306": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Who have been diagnosed with postmenopausal osteoporosis by physician\"\n   - The patient note mentions that the 51-year-old woman is concerned about osteoporosis prevention, but it does not explicitly state that she has been diagnosed with postmenopausal osteoporosis by a physician.\n\n2. \"Who have received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide answer of OPSAT-QTM questionnaire\"\n   - There is no information provided about whether the patient has received any oral bisphosphonates.\n\n3. \"Who provide informed consent for study participation\"\n   - This criterion cannot be assessed based on the given information.\n\nSince the patient note does not confirm that the patient has been diagnosed with postmenopausal osteoporosis or has received oral bisphosphonates for at least 2 months, it is unclear if she meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1307": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old postmenopausal woman with osteoporosis concerns, which matches the target population of \"ambulatory post-menopausal women aged between 55-85 years\" and \"Post-menopausal osteoporosis\".\n\nShe does not have a history of previous fragility fractures mentioned, but she is concerned about breaking her hip as she gets older, which could qualify as having \"at least one clinical risk factor\" for osteoporosis.\n\nThere is no mention of her being on bisphosphonate and calcium/vitamin D supplements for at least 12 months, which is an inclusion criteria.\n\nHer smoking status (1 pack per day) and comorbidities like hypertension and diabetes are not explicitly listed as exclusion criteria.\n\nOverall, she seems to potentially meet some of the key inclusion criteria like being a postmenopausal woman with osteoporosis risk factors. However, the lack of information on her current osteoporosis treatment makes it difficult to definitively assess full eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her current osteoporosis treatment and willingness to potentially discontinue smoking.",
        "label": 0
    },
    "1308": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age 40-80 years old\n   - The patient is 51 years old, which falls within this range. This criterion is met.\n\n2. Cases: Spirometry-based diagnosis of COPD, smoking history of at least 10 pack-years, and active smoking behavior till at least 10 years from the moment of enrollment.\n   - The patient note does not mention a COPD diagnosis or spirometry results, so we cannot determine if this criterion is met.\n   - However, it does state that the patient currently smokes 1 pack of cigarettes per day, which would likely meet the smoking history requirement.\n\n3. Smoking controls: No COPD, smoking history of at least 10 pack-years, and active smoking behavior till at least 10 years from the moment of enrollment.\n   - Since there is no mention of a COPD diagnosis, the patient could potentially meet the criteria for a smoking control.\n   - The current smoking behavior of 1 pack per day would likely meet the smoking history requirement.\n\n4. Non-smoking controls: No COPD and less than 1 pack-year smoking history.\n   - This criterion is not met, as the patient is an active smoker.\n\nBased on the information provided, it is unclear if the patient would meet the criteria for a COPD case or a smoking control. More information is needed regarding the patient's spirometry results and COPD diagnosis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1309": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Have been diagnosed with type 2 diabetes mellitus - The patient note does not mention if the patient has type 2 diabetes, so this is unclear.\n2. Have an HgbA1c value \u2265 7% and \u226417% - No HgbA1c value is provided in the note.\n3. Are on basal insulin, with or without oral agents - The note does not mention the patient's diabetes treatment.\n4. Are not on basal bolus insulin therapy - Unknown from the note.\n5. Have had no severe hypoglycemic episodes in the 6 months prior to enrollment - Unknown from the note.\n6. Have no known allergy to medical tape or sensors - Unknown from the note.\n7. Are capable of and willing to test their blood glucose (BG) on an average of 4 times per day - Unknown from the note.\n8. Are willing to not use Acetaminophen while enrolled in the study - Unknown from the note.\n9. Are willing not to undergo a MRI procedure while wearing the CGM sensor - Unknown from the note. \n10. Are willing and capable of performing self insertions of the device sensor - Unknown from the note.\n11. Women of child bearing potential must be willing to use an approved form of birth control while enrolled - The patient is a 51-year-old woman, so likely postmenopausal but unclear if still of child-bearing potential.\n12. Women of child bearing potential must be willing to perform pregnancy tests monthly - See above.\n13. Can understand and speak English fluently - Unknown from the note.\n\nExclusion Criteria:\n1. Have been on pump therapy in the 6 months prior to enrollment - Unknown from the note.\n2. Are receiving basal-bolus insulin therapy - Unknown from the note.\n3. Are taking any medication that is not approved with insulin - The note mentions hypertension and diabetes medications, but does not provide details.\n4. Are pregnant or have intentions of becoming pregnant - Likely not pregnant given age, but intentions unknown.\n5. Have any skin condition that would inhibit wearing the CGM sensor - Unknown from the note.\n6. Have a hematocrit \u226430% or \u226555% - No hematocrit value provided.\n7. Are currently enrolled in another clinical study - Unknown from the note.\n8. Are employed by a company manufacturing/developing a CGM device - Unknown from the note.\n9. Are deemed incapable by the Primary Investigator for any reason - Unable to assess from the note.\n\nIn summary, there is not enough information provided in the patient note to definitively determine eligibility for this clinical trial. More details about the patient's diabetes type, treatment, blood glucose control, willingness to follow study procedures, etc. would be needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1310": {
        "output": "To determine the patient's eligibility for the clinical trial \"Teriparatide Treatment in Patients With Inherited Osteoporosis\", let's go through the inclusion criteria one by one:\n\n1. Inherited low-turnover osteoporosis: The patient note does not mention if the patient has an inherited form of osteoporosis or not. More information is needed to determine if this criterion is met.\n\n2. Lumbar spine or hip BMD T-score \u2264 -2.5: The patient note does not provide any information about the patient's bone mineral density (BMD) or T-score. Without this information, it is unclear if this criterion is met.\n\n3. A written informed consent: This criterion is typically met after the patient is deemed eligible and agrees to participate in the trial.\n\nBased on the information provided in the patient note, it is unclear if the patient meets the inclusion criteria for this clinical trial. More information is needed regarding the type of osteoporosis the patient has (inherited or not) and the patient's BMD or T-score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1311": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman who is post-menopausal within the last year. This matches the inclusion criteria of premenopausal women aged 20-45 years.\n\n2. She has a history of hypertension and diet-controlled diabetes mellitus, which are not listed as exclusion criteria.\n\n3. She is a current smoker of 1 pack per day. Smoking status is not mentioned in the inclusion/exclusion criteria.\n\n4. She is concerned about breaking her hip as she gets older, indicating she may have low bone mineral density (BMD) or osteoporosis, which matches the inclusion criteria.\n\n5. However, there is no mention of her having any documented adult fractures, which is an inclusion criteria for this trial.\n\nBased on the information provided, while she meets some of the criteria, the lack of documented adult fractures makes her ineligible for this particular trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether she has had any low-trauma fractures.",
        "label": 0
    },
    "1312": {
        "output": "To determine the patient's eligibility for the clinical trial \"Prevention of Falls and Fractures in Old People by Administration of Calcium and Vitamin D. Randomized Clinical Trial\", let's go through the inclusion criteria one by one:\n\n1. Aged over 65 years: The patient is 51 years old, which does not meet this criterion.\n\n2. Normal renal function: There is no information provided about the patient's renal function.\n\n3. Normal transaminase levels: There is no information provided about the patient's transaminase levels.\n\n4. Normal calcium blood levels: There is no information provided about the patient's calcium blood levels.\n\n5. Not homebound (not immobilized) nor in socio-healthcare institutions: There is no information provided about the patient's mobility or living situation.\n\nBased on the information given in the patient note, the only inclusion criterion that is clearly not met is the age requirement (over 65 years). However, there is not enough information provided to determine if the patient meets the other inclusion criteria related to renal function, transaminase levels, calcium blood levels, and mobility/living situation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1313": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Postmenopausal women or men > 60 years\nThe patient note states that the patient is a 51-year-old woman who was documented to be in menopause within the last year. This meets the criteria of being a postmenopausal woman.\n\n2. DXA T-Score at lumbar spine, total hip or femur neck <-2.0 before the start of the bisphosphonate therapy or at baseline or at least one low trauma vertebral fracture grade 2-3 or multiple low trauma vertebral fractures independent of bone mineral density\nThe patient note does not mention any DXA T-Score or history of vertebral fractures, so we cannot determine if this criterion is met.\n\n3. Pretreatment with bisphosphonates for at least four years\nThe patient note does not mention any prior treatment with bisphosphonates, so this criterion is likely not met.\n\n4. Risk for hip and vertebral fractures min. 30% according to DVO-guideline for osteoporosis 2009\nThe patient note does not provide enough information to determine the patient's risk for hip and vertebral fractures according to the specified guideline.\n\n5. Signed informed consent\nThis is a procedural requirement that cannot be determined from the patient note.\n\nBased on the information provided in the patient note, we cannot definitively determine if the patient meets all the inclusion criteria for this clinical trial. Some key information is missing, such as DXA T-Score, history of vertebral fractures, and prior bisphosphonate treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1314": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Virgin spines: The patient note does not mention any previous spinal surgeries or conditions, so this criterion is likely met.\n\n2. No emergency operation: The patient note does not indicate an emergency situation, so this criterion is likely met.\n\n3. Age above 18: The patient is 51 years old, which meets this criterion.\n\n4. Sufficient knowledge of the German language: The patient note does not provide information about the patient's language proficiency, so it is unclear if this criterion is met.\n\n5. Indication for anterior cervical discectomy and fusion: The patient note does not mention any indication for this specific procedure, so this criterion is likely not met.\n\n6. Absence of concomitant spinal disease: The patient note does not mention any spinal diseases, so this criterion is likely met.\n\nBased on the available information, the patient does not seem to meet all the inclusion criteria, particularly the indication for anterior cervical discectomy and fusion. Additionally, there is no information about the patient's language proficiency.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1315": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 51-year-old postmenopausal woman who is concerned about osteoporosis prevention. \n\nThe clinical trial is titled \"Osteoporosis Screening Trial\" and aims to screen for osteoporosis.\n\nThe inclusion criteria are:\n- Females\n- Postmenopausal women\n- Outpatients screened for osteoporosis \n- Women > 45 years\n- Women < 45 years under menopause\n- Women who have provided consent to be measured\n\nThis patient meets several of the key inclusion criteria:\n- She is female\n- She is postmenopausal (documented within the last year)\n- She is over 45 years old\n- She is seeking screening/advice for osteoporosis prevention\n\nBased on the information provided, she appears to be a good potential candidate for this osteoporosis screening trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1316": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 51-year-old woman with hypertension, diet-controlled diabetes mellitus, and current smoking history. She is in menopause within the last year and is concerned about osteoporosis prevention.\n\nThe clinical trial is looking at prescribing exercise for prevention of falls and fractures in individuals aged 65 and over who are at high risk of falls or fractures.\n\nThe inclusion criteria for the trial are:\n- Age 65 or older\n- Patient of the Centre for Family Medicine Family Health Team (CFFM FHT)\n- Have at least one of the following:\n    - 2 or more falls in the past 12 months\n    - Age 75 or older\n    - High risk of fracture based on CAROC\n    - Difficulty with walking or balance as determined by attending physician\n    - Acute fall\n    - History of a fragility fracture after age 50\n\nBased on the information provided, this patient does not meet the age criteria (she is 51 years old) and there is no mention of her having any falls or fractures in the past. Therefore, I would assess her eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1317": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Active smokers over 40 years: The patient is 51 years old and currently smokes 1 pack of cigarettes per day, so this criterion is met.\n\n2. More than 10 pack-years: The patient's smoking history is not explicitly stated in pack-years, but since she is a current smoker of 1 pack per day, it is reasonable to assume that she has smoked for more than 10 pack-years (1 pack-year = smoking 1 pack per day for 1 year). Therefore, this criterion is likely met.\n\n3. Without a chronic obstructive pulmonary disease (COPD) diagnosis: The patient's medical history does not mention COPD, so we can assume this criterion is met.\n\nSince the patient meets all the stated inclusion criteria, she would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1318": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 51-year-old woman who is postmenopausal and has concerns about osteoporosis prevention. She has a history of hypertension, diet-controlled diabetes mellitus, and currently smokes 1 pack of cigarettes per day.\n\nThe clinical trial is studying osteoporosis in patients with type 2 diabetes mellitus.\n\nThe inclusion criteria for the trial are:\n- Age 40-99 years old\n- Type 2 diabetes mellitus\n\nThis patient meets the age criteria as she is 51 years old. She also has diet-controlled diabetes mellitus, which based on the information provided, seems to be type 2 diabetes.\n\nThere are no explicit exclusion criteria listed other than \"organization people\", which I assume means people affiliated with the organization running the trial cannot participate.\n\nGiven that the patient meets the key inclusion criteria of age and having type 2 diabetes, I would assess her eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1319": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Postmenopausal women: The patient note states that the 51-year-old woman was documented to be in menopause within the last year, so she meets this criterion.\n\n2. Diagnosis of osteoporosis in the medical record: The patient note does not explicitly mention a diagnosis of osteoporosis, but it states that the patient is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention. This suggests that she may be at risk for osteoporosis or has been diagnosed with it, but it is not clearly stated.\n\n3. At least one prescription drug to treat osteoporosis in the last 5 years: The patient note does not mention any prescription drugs for osteoporosis treatment.\n\n4. Insured by Clalit Health Services: There is no information provided about the patient's insurance provider.\n\n5. Hebrew-speaking capability and readiness to answer a questionnaire: There is no information provided about the patient's language or willingness to answer a questionnaire.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for the clinical trial. While she is postmenopausal, there is no clear mention of an osteoporosis diagnosis or treatment history. Additionally, there is no information about her insurance provider or language proficiency.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1320": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman, which meets the age criteria of \u226550 years old.\n\nShe has diet-controlled diabetes mellitus, which meets the criteria of having either type 1 or type 2 diabetes.\n\nHer diabetes treatment has been stable for at least 6 months with no changes, which meets that criteria.\n\nHer HbA1c level is not mentioned, so we cannot confirm if she meets the criteria of HbA1c \u22657% for the past 6 months.\n\nHer BMI is not mentioned, so we cannot confirm if she meets the BMI criteria of 19-35.\n\nFor the type 2 diabetes specific criteria, it is not mentioned what medications she is taking, if any.\n\nOverall, based on the information provided, she potentially meets some of the key inclusion criteria like age, diabetes diagnosis, and stable treatment. However, there are some missing details like HbA1c level, BMI, and medication that would need further investigation to fully assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1321": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman, which falls within the age range of 20-75 years specified in the inclusion criteria.\n\n2. The patient is not pregnant or breastfeeding, which satisfies the second inclusion criterion.\n\n3. Assuming the patient is able to comply with the study requirements and has provided informed consent (which is not explicitly stated in the patient note), the third and fourth inclusion criteria would be met.\n\n4. The study is focused on evaluating the effects of vitamin K2 on osteoporosis, blood vessel calcification, and sclerosis. The patient's primary concern is osteoporosis prevention, which aligns with one of the study objectives.\n\nBased on the information provided, this patient appears to meet the inclusion criteria for the clinical trial on vitamin K2 and osteoporosis.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1322": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman, which falls within the age range of 40-90 specified in the inclusion criteria.\n\nIt is not mentioned if she has had any prior fractures, so we cannot confirm if she meets that inclusion criteria.\n\nShe seems to be of sound mind and able to complete questionnaires, meeting that inclusion criteria.\n\nOverall, based on the information provided, I would assess her eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWe would need to clarify if she has had any prior fractures to fully determine her eligibility. But her age and ability to complete questionnaires makes her a potential candidate that warrants further investigation.",
        "label": 0
    },
    "1323": {
        "output": "Okay, let's go through the patient note and inclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 51-year-old postmenopausal woman concerned about osteoporosis prevention. The clinical trial is studying a novel ultrasound device (Bindex) for osteoporosis diagnostics in postmenopausal women and men.\n\nThe key inclusion criteria are:\n1. Postmenopausal women\n2. Men referred for bone density examination\n\nThis patient meets the first inclusion criteria of being a postmenopausal woman. She was also referred to the clinic for advice on osteoporosis, which suggests she may be a candidate for bone density examination.\n\nHowever, there are a few potential concerns:\n1. Her smoking history (1 pack per day) may exclude her from the trial due to potential confounding effects on bone health.\n2. Her medical history of hypertension and diabetes may also complicate her eligibility, depending on the trial's exclusion criteria (which are not provided).\n\nOverall, while she meets the key inclusion criteria of being a postmenopausal woman, her smoking history and medical conditions raise some potential concerns. Further investigation into the trial's exclusion criteria would be needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1324": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman, which falls within the age range of 50-89 years specified in the inclusion criteria.\n\n2. The trial is specifically looking at osteoporosis diagnosis and prevention in women.\n\n3. The patient is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention, which aligns with the goals of the clinical trial.\n\n4. The inclusion criteria only specify female sex and age range, with no exclusion criteria mentioned.\n\nBased on the information provided, this patient meets the inclusion criteria for the clinical trial on osteoporosis diagnosis using the Bindex Ultrasonometer.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1325": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old postmenopausal woman, which meets the age criteria of 50-79 years old for the trial.\n\nShe has a history of hypertension and diet-controlled diabetes mellitus. Hypertension and diabetes are potential causes of secondary osteoporosis listed in the inclusion criteria.\n\nShe is a current smoker, which is also listed as a clinical risk factor for fracture in the inclusion criteria.\n\nThe patient is concerned about breaking her hip as she gets older, indicating suspicion of osteoporosis.\n\nBased on the information provided, this patient meets multiple inclusion criteria for the osteoporosis clinical trial, including being postmenopausal, having risk factors for secondary osteoporosis (hypertension, diabetes), being a current smoker which increases fracture risk, and having suspicion of osteoporosis.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1326": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 51-year-old woman, which fits the age range of 50-80 years in the inclusion criteria.\n\nShe is being seen in a clinic, so she is likely able to respond to a questionnaire and provide consent to participate, as required by the inclusion criteria.\n\nThe trial is looking to screen for osteoporosis risk in hospitalized women across various departments like medical, gynecology, surgery, and orthopedics. The patient note doesn't specify if she is hospitalized or not.\n\nThere is no mention of her being previously treated for osteoporosis or having a recent bone density scan, which would exclude her based on the criteria.\n\nOverall, her age and ability to participate fit the criteria. The main uncertainty is whether she is currently hospitalized in one of the specified departments.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether she is currently hospitalized.",
        "label": 0
    },
    "1327": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman, which falls within the age range of 35-70 years specified in the inclusion criteria.\n\n2. The patient has a history of hypertension and diabetes mellitus, which are two of the cardiovascular risk factors mentioned in the inclusion criteria.\n\n3. The patient currently smokes 1 pack of cigarettes per day, which qualifies as being a current daily smoker, another risk factor listed in the inclusion criteria.\n\n4. The inclusion criteria state that individuals with at least one cardiovascular risk factor (hypertension, diabetes, or current daily smoking) will be enrolled in the study.\n\nSince the patient meets the age criteria and has multiple cardiovascular risk factors (hypertension, diabetes, and smoking), she would likely be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1328": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Vitamin D Status in Relation to Insulin Sensitivity Among Saudi Women With Polycystic Ovary Syndrome\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient is a 51-year-old woman, and the trial requires participants to have a diagnosis of polycystic ovary syndrome (PCOS), which is not mentioned in the patient note.\n\n2. The inclusion criteria specifically state that participants must meet three of the Rotterdam criteria for PCOS diagnosis, but there is no information provided about whether this patient meets any of those criteria.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1329": {
        "output": "To determine the patient's eligibility for the clinical trial \"Periodontal Disease and Post-menopausal Osteoporosis\", let's go through the inclusion criteria:\n\n1. Women between 45-70 years: The patient is a 51-year-old woman, which meets this criterion.\n\n2. Absorptiometry Dual Energy X-ray (DEXA): There is no information provided about whether the patient has undergone a DEXA scan or not.\n\n3. Control group: post-menopausal women with periodontal disease and normal osseous condition: The patient is post-menopausal, but there is no information about her periodontal or osseous condition.\n\n4. Study group: post-menopausal women with periodontal disease and osteoporosis/osteopenia with and without bisphosphonate treatment (risedronate or ibandronate 150 mg) for longer than 3 months before the study and another: The patient is post-menopausal, but there is no information about her periodontal condition, osteoporosis/osteopenia status, or bisphosphonate treatment.\n\nBased on the information provided in the patient note, there are several missing details that would be required to determine eligibility for this clinical trial. While the patient meets the age and menopausal status criteria, there is no information about her periodontal condition, bone density status, or bisphosphonate treatment history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1330": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Male and Female: The patient is a female, so this criterion is met.\n2. Patients aged between 35.00 Year(s) to 60.00 Year(s): The patient is 51 years old, which falls within the specified age range, so this criterion is met.\n3. Diagnosed with Osteoporosis: The patient is seeking advice on osteoporosis prevention, but it is not explicitly stated that she has been diagnosed with osteoporosis. This criterion is unclear based on the provided information.\n4. Diagnosed with Chronic Periodontitis: There is no mention of the patient being diagnosed with chronic periodontitis or any gum disease. This criterion is not met based on the provided information.\n5. Willing to participate in the study: There is no information provided about the patient's willingness to participate in the study.\n\nBased on the available information, the patient meets some of the inclusion criteria (gender and age range), but it is unclear if she meets the criteria for being diagnosed with osteoporosis. Additionally, the criterion for being diagnosed with chronic periodontitis is not met, and there is no information about the patient's willingness to participate in the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1331": {
        "output": "To determine the patient's eligibility for the clinical trial \"Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia\u00ae in France\", let's go through the inclusion criteria:\n\n1. Post-menopausal osteoporosis women: The patient note mentions that the 51-year-old woman was documented to be in menopause within the last year, and she is seeking advice on osteoporosis prevention. This criterion is met.\n\n2. In whom a decision has been made to treat with Prolia in the last 4 weeks: The patient note does not explicitly state that a decision has been made to treat with Prolia. It only mentions that the patient is seeking advice on osteoporosis prevention.\n\n3. Received their first prescription of Prolia in the last 4 weeks: There is no information provided about the patient receiving a prescription for Prolia.\n\n4. Patient has provided informed consent before enrolling in the study: The patient note does not mention whether the patient has provided informed consent.\n\nBased on the information provided in the patient note, the patient meets one of the inclusion criteria (being a post-menopausal woman with osteoporosis), but it is unclear if the other criteria are met. Further investigation would be needed to determine if a decision has been made to treat with Prolia, if the patient has received a prescription for Prolia, and if the patient has provided informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1332": {
        "output": "To determine the patient's eligibility for the clinical trial \"Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan\", let's go through the inclusion criteria:\n\n1. Postmenopausal women: The patient note mentions that the 51-year-old woman was documented to be in menopause within the last year, so she meets this criterion.\n\n2. Age 50 years or greater: The patient is 51 years old, so she meets this criterion as well.\n\nSince the patient meets both inclusion criteria, she would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1333": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 51-year-old woman who is postmenopausal within the last year. She has a history of hypertension and diet-controlled diabetes mellitus. She is a current smoker of 1 pack per day.\n\nThe clinical trial inclusion criteria are:\n1. Female patients with postmenopausal osteoporosis (T-score \u2264-2.5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of \u2265 low-energy fracture during the last 10 years prior the study.\n2. Male patients \u2265 50 years old with idiopathic osteoporosis (T-score \u2264-2.5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of \u2265 low-energy fracture during the last 10 years prior the study.\n3. Male and female patients with steroid-induced osteoporosis (T-score \u2264-2.5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of \u2265 low-energy fracture during the last 10 years prior the study.\n\nThe patient meets the first criteria of being a postmenopausal female. However, there is no information provided about her T-score, osteoporosis treatment history, or history of low-energy fractures.\n\nBased on the available information, I would assess:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1334": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman, which meets the age criteria of being 50 years or older for the retrospective part of the study.\n\n2. The study is looking at patients who underwent spinal fusion surgery performed by a specific neurosurgeon at a particular institute between certain dates. The patient note does not mention if this patient had spinal fusion surgery or not.\n\nSince there is not enough information to determine if the patient meets the inclusion criteria of having undergone a spinal fusion surgery by the specified surgeon during the given date range, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1335": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 51-year-old woman, which meets no specific inclusion criteria for this trial.\n\n2. The patient has a history of hypertension and diet-controlled diabetes mellitus. The trial specifically requires patients to have type 2 diabetes for at least 3 years.\n\n3. The patient's smoking status and menopausal status are not relevant to the inclusion criteria provided.\n\n4. The main inclusion criterion is the presence of type 2 diabetes for at least 3 years. The patient note does not specify the duration of her diabetes, only that it is diet-controlled.\n\nBased on the information provided, there is not enough evidence to definitively determine if the patient meets the inclusion criteria of having type 2 diabetes for at least 3 years. More information would be needed regarding the duration of her diabetes diagnosis and treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into the duration of her type 2 diabetes diagnosis and treatment.",
        "label": 2
    },
    "1336": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Age of at least 20 years: The patient is 51 years old, so this criterion is met.\n\n2. Able to read and fill out the questionnaire: This information is not provided in the patient note, but we can assume that the patient is able to read and fill out the questionnaire unless stated otherwise.\n\n3. Willingness to participate: This information is also not provided in the patient note. However, since the patient is seeking advice on osteoporosis prevention, we can assume that she would be willing to participate in a study related to osteoporosis risk assessment.\n\nBased on the information provided, the patient meets the age criterion, and there is no information suggesting that she would not meet the other two criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1337": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is titled \"Effects of Brain Stimulation on Learning and Reasoning\" and aims to use repetitive transcranial magnetic stimulation (rTMS) to study the roles of different brain regions in learning and reasoning processes.\n\n3. The inclusion criteria for the trial are:\n   - Right-handed normal volunteers (18-65 years old)\n   - Patients with Parkinson's disease off medication\n   - Patients with cerebellar deficits\n   - Patients with frontal lobe lesions\n   - Patients with frontal lobe dementia\n\n4. The patient has a solitary mass in the right frontal lobe, which could potentially qualify them as having a frontal lobe lesion.\n\n5. However, there is no mention of the patient having any specific deficits related to learning or reasoning processes, which is the focus of the trial.\n\n6. Additionally, the patient's age (58 years old) falls outside the specified age range of 18-65 years old for normal volunteers.\n\nBased on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the patient has a frontal lobe mass that could potentially qualify them for the trial, further investigation would be needed to determine if they exhibit any specific deficits in learning or reasoning processes that align with the trial's objectives. Additionally, their age falls outside the specified range for normal volunteers, but they may still be eligible if they meet the criteria for one of the other patient groups (e.g., frontal lobe lesion).",
        "label": 1
    },
    "1338": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD)\" and assess the eligibility of the patient based on the provided note.\n\nThe patient note states:\n\"A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.\"\n\nInclusion criteria:\n1. \"Characterized as having behavioral manifestations using a standardized neuropsychiatric scale and interview.\"\n   - The patient note does not mention any behavioral manifestations or neuropsychiatric evaluation, so this criterion is unclear.\n\n2. \"FLD patients' frontal cognitive sysfunctions characterized using a short neurobehavioral test battery.\"\n   - The patient note does not mention any cognitive testing or characterization of frontal lobe dysfunction, so this criterion is unclear.\n\n3. \"Patients must be able to be tested and cooperative with the procedures required in this protocol.\"\n   - The patient note does not provide information about the patient's ability to cooperate with testing procedures, so this criterion is unclear.\n\n4. \"No contraindications to the use of Sertraline.\"\n   - The patient note does not mention any contraindications to Sertraline, so this criterion is potentially met.\n\n5. \"No medical conditions that can reasonably be expected to subject the patient to unwarranted risk (e.g., cancer) or require frequent changes in medication. Well-controlled medical conditions such as hypertension and diabetes will not be excluded.\"\n   - The patient note mentions a left lung mass, which could potentially be cancer, so this criterion may not be met.\n\n6. \"Patients must not be pregnant or nursing and must be using effective contraception, if still at child-bearing age.\"\n   - The patient note does not provide information about pregnancy, nursing, or contraceptive use, so this criterion is unclear.\n\n7. \"No history of prior severe traumatic brain injury or other severe neurologic or psychiatric condition, such as psychosis, stroke, multiple sclerosis, or spinal cord injury.\"\n   - The patient note does not mention any history of severe neurologic or psychiatric conditions, so this criterion is potentially met.\n\n8. \"Not using any psychotropic medication which cannot be stopped 4 weeks before the study.\"\n   - The patient note does not provide information about the patient's medication use, so this criterion is unclear.\n\nBased on the provided information, there are several inclusion criteria that cannot be clearly assessed, and the presence of a potential lung mass raises concerns about meeting the criterion related to medical conditions that could subject the patient to unwarranted risk.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1339": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed stage IIIB with metastatic pleural effusion or metastatic stage IV non-small cell lung cancer - The patient has a left lung mass, which could potentially be non-small cell lung cancer, but the stage is not specified.\n- Large cell, adenocarcinoma, squamous cell, bronchioalveolar carcinoma, or undifferentiated histologies allowed - No histology mentioned for the patient yet.\n- At least 1 bidimensionally measurable or evaluable indicator lesion - The patient has a left lung mass which could potentially be measurable.\n- No current CNS metastases at study entry - The patient has a solitary brain mass in the right frontal lobe, which would exclude them.\n- No meningeal carcinomatosis - Not mentioned for the patient.\n\nPATIENT CHARACTERISTICS:\n- Age 18 and over - The patient is 58 years old, meeting this criteria.\n- Performance status: Zubrod 0-2 - Not mentioned for the patient.\n- Life expectancy greater than 12 weeks - Not mentioned, but potentially met given limited information provided.\n- Adequate hematologic, hepatic, and renal function - Not mentioned for the patient.\n- No concurrent illness that would affect assessment - Unclear based on the limited information provided.\n- Not pregnant/nursing, use effective contraception if fertile - Not mentioned, but the patient is 58 so likely postmenopausal.\n\nPRIOR/CONCURRENT THERAPY:\n- No prior systemic chemotherapy allowed - Not mentioned if the patient received any prior treatment.\n- No other concurrent chemotherapy allowed - Unclear if the patient is receiving any other treatment.\n- Prior radiotherapy for NSCLC allowed - Not mentioned if the patient received any prior radiotherapy.\n- Concurrent radiotherapy to other sites allowed if no objective disease progression - Unclear disease status/progression for the patient.\n\nBased on the information provided, the main exclusion criteria appears to be the brain metastasis in the right frontal lobe. There are also several criteria that are unclear or not mentioned about the patient's status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1340": {
        "output": "To determine the patient's eligibility for the clinical trial \"Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS\", let's go through the inclusion criteria:\n\n1. DISEASE CHARACTERISTICS: \n   - Histologically proven primitive neuroectodermal tumors of the central nervous system\n     - The patient has a solitary mass in the right frontal lobe, which could potentially be a primitive neuroectodermal tumor, but it is not confirmed histologically.\n   - No metastatic disease within or outside the central nervous system\n     - This criterion is met as the patient only has a solitary mass.\n\n2. PATIENT CHARACTERISTICS:\n   - Age: 3 to 16\n     - The patient is 58 years old, which does not meet this criterion.\n   - Performance status: Not specified\n   - Life expectancy: Not specified\n   - Hematopoietic: No concurrent hematological disorder\n     - This criterion is likely met as there is no information suggesting a hematological disorder.\n   - Hepatic: Not specified\n   - Renal: Renal dysfunction allowed\n   - Other: No prior history of malignant disease\n     - This criterion is likely met as there is no information suggesting a prior malignant disease.\n\n3. PRIOR CONCURRENT THERAPY:\n   - Biologic therapy: Not specified\n   - Chemotherapy: Not specified\n   - Endocrine therapy: Not specified\n   - Radiotherapy: Not specified\n   - Surgery: See Disease Characteristics\n     - The patient has not undergone surgery for the mass yet.\n\nBased on the information provided, the patient does not meet the age criterion for this clinical trial. Additionally, the histology of the mass is not confirmed to be a primitive neuroectodermal tumor, which is a requirement.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1341": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray, and a solitary mass in the right frontal lobe found on CT scan of the head.\n\n2. The clinical trial is for patients with inoperable non-small cell lung cancer (NSCLC) to explore the utility of PET imaging in addition to CT imaging for radiation treatment planning.\n\n3. The inclusion criteria for the trial are:\n   - Histologically confirmed locally advanced NSCLC\n   - Disease limited to the thorax, adjacent mediastinum and neurovascular structures, and supraclavicular or scalene lymph node area (Stage IIIA and IIIB)\n   - Performance status of 0-2 by Southwest Oncology Group criteria\n   - Medically inoperable patients (Stage I or II)\n   - Locoregional recurrent tumor following surgery\n\n4. Based on the information provided, the patient has a left lung mass, which could potentially be NSCLC, but there is no confirmation of the histology or staging. Additionally, the patient has a brain mass, which is not mentioned in the inclusion criteria.\n\n5. Given the limited information and the presence of the brain mass, which may complicate radiation treatment planning, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1342": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Patients at high risk for the development of lung cancer as defined by the following:\n    - At least 40 pack years smoking (may have stopped smoking within past 10 years) at time of study entry\n        - The patient note does not mention smoking history, so this criterion cannot be evaluated.\n    - FEV-1/FVC ratio less than 70% predicted OR FEV-1 less than 80% predicted obtained from 3 serial performances with less than 5% difference\n        - No information is provided about FEV-1/FVC ratio or FEV-1 values.\n    - Normal or stable current chest x-ray\n        - The patient has a left lung mass on chest x-ray, so this criterion is not met.\n\nPATIENT CHARACTERISTICS:\n- Age: 40 to 70\n    - The patient is 58 years old, so this criterion is met.\n- Performance status: Not specified\n- Life expectancy: At least 5 years\n    - No information is provided about life expectancy.\n- Hematopoietic, Hepatic, Renal: Not specified\n- Pulmonary: See Disease Characteristics\n- Other: No other comorbidity that limits life span to less than 5 years, No prior cancer except nonmelanomatous skin cancer or carcinoma in situ of the cervix, Not pregnant, Negative pregnancy test, Fertile patients must use effective contraception\n    - The patient has a solitary mass in the right frontal lobe, which may be a prior cancer, so this criterion may not be met. No information is provided about pregnancy status or use of contraception.\n\nPRIOR CONCURRENT THERAPY: Not specified\n\nBased on the information provided in the patient note, some of the key inclusion criteria are not met (e.g., normal/stable chest x-ray, no prior cancer) or cannot be evaluated due to lack of information (e.g., smoking history, pulmonary function tests, life expectancy).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1343": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is titled \"Test of A Model of Representational Knowledge Stored in the Human Prefrontal Cortex\" and is studying cognitive processes related to social behavior, memory, and thinking in healthy individuals and those with brain lesions or psychiatric disorders.\n\n3. The inclusion criteria state that healthy controls must not have any neurological, psychiatric, or medical conditions that would compromise the interpretation of the test results.\n\n4. Patients must have a diagnosed central nervous system (CNS) disorder with lesions verified by CT or MRI scans. The bulk of the patients will have focal or degenerative lesions of the human prefrontal cortex (HPFC).\n\n5. The patient in this case has a solitary mass in the right frontal lobe, which could potentially be a lesion of the HPFC, making her eligible for the study.\n\n6. However, the patient also has a left lung mass, which could be a medical condition that compromises the interpretation of the test results, potentially excluding her from the control group.\n\nBased on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to determine the nature and extent of the patient's brain and lung masses, and whether they would significantly impact the interpretation of the cognitive testing in this trial.",
        "label": 1
    },
    "1344": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria of at least 18 years old.\n\n2. The patient has a left lung mass, which could potentially be non-small cell lung cancer (NSCLC). However, the histological confirmation of NSCLC is not provided in the patient note.\n\n3. The stage of the lung cancer is not mentioned, so it's unclear if the patient meets the criteria of Stage IV or Stage IIIB.\n\n4. There is no information provided about prior therapies or treatments the patient has received, so it's unknown if the patient has progressed during or after first-line therapies with platinum-containing regimens.\n\n5. The patient's performance status is not mentioned, so it's unclear if the patient meets the criteria of good performance status (ECOG 0 to 1).\n\n6. There is no information provided about the patient's liver, renal, and bone marrow function, so it's unknown if the patient meets the criteria of adequate function in these areas.\n\n7. The patient note does not mention any exclusion criteria, such as pregnancy, lactation, prior radiation to the whole pelvis, or unstable medical conditions.\n\nBased on the information provided in the patient note, there are several key pieces of information missing to determine eligibility for this clinical trial. More investigation would be needed to confirm the histological type of lung cancer, the stage, prior treatments, performance status, and organ function.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1345": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient has histological proof of a primary non-small cell lung cancer (a left lung mass was found on chest x-ray).\n2. The patient has not been staged yet, so it's unclear if they meet the stage IB, II, or IIIA criteria.\n3. It's unknown if a complete mediastinal lymph node resection or sampling was done during surgery.\n4. No information is provided about the surgery type (lobectomy, etc.) or if all gross disease was removed with negative surgical margins.\n5. No information is provided about the time elapsed between surgery and potential randomization.\n6. No information is provided about the patient consenting to provide a tumor tissue sample.\n7. The patient's ECOG performance status is not stated.\n8. No laboratory values (blood counts, liver tests, etc.) are provided to assess eligibility criteria.\n9. No information about recent imaging (chest x-ray, CT/MRI, etc.) is provided.\n10. No information about the patient's ability to use contraception is stated.\n11. No information about prior radiation therapy is provided.\n12. No information about the patient's ability to understand and sign an informed consent is stated.\n13. No information about the patient's accessibility for treatment and follow-up is provided.\n14. No information about whether the patient received prior adjuvant chemotherapy is stated.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1346": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which falls within the age range of 20-70 years old specified in the inclusion criteria.\n\n2. The patient is described as having a left lung mass and a solitary mass in the right frontal lobe of the brain. This suggests a potential central nervous system disorder, which is an exclusion criterion for the trial.\n\n3. There is no information provided about the patient's handedness, medical history, use of medications, or presence of metal implants/devices.\n\n4. The trial is specifically studying the effect of direct current polarization on brain function in healthy individuals without central nervous system disorders.\n\nBased on the information provided, the patient's eligibility for this clinical trial is unclear due to the presence of brain and lung masses, which could indicate an underlying central nervous system disorder or other medical condition.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1347": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Single presumed brain metastasis on contrast magnetic resonance imaging (MRI) scan within two weeks before commencement of treatment.\n   - The patient note mentions a solitary mass in the right frontal lobe on CT scan, which likely meets this criterion.\n\n2. Systemic cancer diagnosed histologically or cytologically synchronous with, or within 5 years of treatment of the presumed brain metastasis (other than non-melanoma skin cancer and cancer in-situ of the cervix, neither of which would be reasonably attributable as the primary site). Exception - melanoma diagnosed > 5 years previously is allowable in view of the extremely variable natural history of melanoma.\n   - The patient note does not mention the primary cancer diagnosis or when it was diagnosed, so it's unclear if this criterion is met.\n\n3. Age >= 18 (no upper age limit).\n   - The patient is 58 years old, so this criterion is met.\n\n4. Considered suitable for both surgery and radiosurgery by the neurosurgeon and radiation oncologist (see exclusions).\n   - The patient note does not provide information about the assessment by the neurosurgeon and radiation oncologist, so it's unclear if this criterion is met.\n\n5. Patient must agree to adjuvant whole brain radiation therapy (WBRT).\n   - The patient note does not mention the patient's agreement to WBRT, so it's unclear if this criterion is met.\n\n6. RTOG RPA Class 1 or 2 (Karnofsky Performance Status [KPS] >= 70 after adequate trial of corticosteroids).\n   - The patient note does not provide information about the patient's performance status or use of corticosteroids, so it's unclear if this criterion is met.\n\n7. RPA Class 3 patients (KPS < 70) eligible if it is considered that the poor performance status is due primarily to the solitary metastasis, aggressive local treatment of which may be expected to restore good performance status. This would ordinarily be associated with minimal systemic disease burden.\n   - The patient note does not provide information about the patient's performance status or systemic disease burden, so it's unclear if this criterion is met.\n\n8. Accessible for treatment and follow-up.\n   - The patient note does not provide information about the patient's accessibility for treatment and follow-up, so it's unclear if this criterion is met.\n\n9. Patient is infertile or is aware of the risk of becoming pregnant or fathering children and will use adequate contraception.\n   - The patient note does not provide information about the patient's fertility status or use of contraception, so it's unclear if this criterion is met.\n\n10. Written informed consent\n    - The patient note does not mention whether the patient has provided written informed consent, so it's unclear if this criterion is met.\n\nBased on the information provided in the patient note, there are several inclusion criteria that cannot be determined as met or not met. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1348": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria for most clinical trials.\n\n2. The patient has a left lung mass and a solitary mass in the right frontal lobe of the brain. The clinical trial is specifically for benign brain tumors.\n\n3. The inclusion criteria state that the tumor must be \"histopathologically confirmed newly diagnosed base of skull benign tumour.\"\n\n4. The patient note does not specify if the brain tumor is benign or malignant, nor does it state the location as being at the base of the skull.\n\n5. The patient note also does not mention the patient's Karnofsky Performance Status, which is required to be \u226570 per the inclusion criteria.\n\nGiven the lack of information about the tumor type, location, and the patient's performance status, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1349": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: patients who have solitary pulmonary nodules in CT\n\nBased on the patient note, the key points are:\n- The patient is a 58-year-old female\n- She has a left lung mass found on chest x-ray\n- A CT scan of the head shows a solitary mass in the right frontal lobe\n\nThe inclusion criteria specifically mentions patients with solitary pulmonary nodules in CT. While the patient has a left lung mass found on chest x-ray, there is no mention of a solitary pulmonary nodule being confirmed on CT scan. Additionally, the patient has a solitary mass in the brain, which is not part of the inclusion criteria.\n\nGiven this information, the patient does not clearly meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1350": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with mild exertional dyspnea (shortness of breath with exertion) and occasional cough. She has a left lung mass on chest x-ray but is otherwise asymptomatic.\n\n2. The clinical trial is studying the use of macrolide antibiotics to prevent exacerbations (worsening of symptoms) in patients with asthma or chronic obstructive pulmonary disease (COPD).\n\n3. The inclusion criteria for the trial are:\n   - Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation\n   - Admitted to the inpatient medical service at Johns Hopkins Hospital or Johns Hopkins Bayview Medical Center\n   - Evidence of airflow obstruction on spirometry (FEV1/FVC<70%)\n   - Age 18 years or older\n\n4. Based on the patient note, there is no clear diagnosis of asthma or COPD mentioned. The patient has a lung mass and mild exertional dyspnea, but no other respiratory symptoms or evidence of airflow obstruction is provided.\n\n5. Additionally, the patient is not mentioned to be admitted to the specified hospitals for this trial.\n\nGiven the lack of a clear asthma/COPD diagnosis and the fact that the patient is not an inpatient at the trial sites, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1351": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female who was found to have a left lung mass on chest x-ray. This matches the inclusion criteria of being a lung cancer patient.\n\n2. However, the inclusion criteria specifically states \"lung cancer patients undergoing resection with intent to cure\". The patient note does not mention if the patient has undergone or is planned to undergo resection surgery for the lung mass.\n\n3. There is also an incidental finding of a solitary mass in the right frontal lobe of the brain, which could potentially complicate the patient's eligibility depending on the nature and severity of this finding.\n\n4. Given the lack of information about whether the patient will undergo resection surgery, and the presence of the brain mass which may impact eligibility, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1352": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray and a solitary mass in the right frontal lobe of the brain found on CT scan.\n\n2. The clinical trial is comparing chest x-ray (CXR) and minimum dose CT (MnDCT) in detecting acute findings in acutely ill patients.\n\n3. The inclusion criteria for the trial is \"All patients admitted for investigation of acute pulmonary embolus\".\n\n4. Based on the patient note, there is no mention of the patient being admitted for investigation of acute pulmonary embolus. The lung mass and brain mass appear to be incidental findings.\n\n5. Therefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1353": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria (>18 and <75 years) for the clinical trial.\n\n2. The patient has a left lung mass and a solitary mass in the right frontal lobe of the brain. However, the clinical trial is specifically for early-stage (T1 or T2) squamous cell carcinoma of the oral cavity (buccal mucosa, lower alveolus, oral tongue, and floor of mouth).\n\n3. The patient's condition does not seem to match the inclusion criteria for the type and location of cancer required for this clinical trial.\n\n4. There is no information provided about the patient's treatment history or comorbidities, which are also part of the inclusion criteria.\n\nBased on the information given, this patient does not appear to meet the key inclusion criteria for this specific clinical trial on early-stage oral cavity cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1354": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with mild exertional dyspnea (shortness of breath with exertion) and occasional cough. This could potentially fit the inclusion criteria of having a diagnosis of mild COPD.\n\n2. However, the note also mentions she is a non-smoker, which goes against the inclusion criteria of having a smoking history > 10 pack years for mild COPD patients.\n\n3. The note mentions she has a left lung mass and a solitary mass in the right frontal lobe of the brain. These findings suggest she may have lung cancer with brain metastasis, rather than just mild COPD.\n\n4. The trial is specifically looking at the effects of bronchodilators in mild COPD patients, not patients with suspected lung cancer.\n\nGiven this information, my assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.\n\nThe main reasons being her non-smoking history does not fit the inclusion criteria, and her lung and brain masses suggest a more serious underlying condition like lung cancer rather than just mild COPD alone. This clinical trial does not appear to be suitable for her current medical status.",
        "label": 0
    },
    "1355": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically or cytologically confirmed malignant pulmonary neoplasm - The patient has a left lung mass, which could potentially meet this criteria pending further testing.\n- New lung lesion(s) with definitive clinical and imaging features of primary or metastatic disease allowed - The patient has a left lung mass, which meets this criteria.\n- No other criteria specified for disease characteristics.\n\nPATIENT CHARACTERISTICS:\n- Karnofsky performance status (PS) > 60-100% OR WHO/ECOG/Zubrod PS 0-2 - No information provided about the patient's performance status.\n- FEV_1 > 30% of predicted - No information provided about the patient's FEV_1.\n- DLCO > 40% of predicted - No information provided about the patient's DLCO.\n- Platelet count \u2265 70,000/mm^3 - No information provided about the patient's platelet count.\n- INR < 1.5 - No information provided about the patient's INR.\n- No uncontrolled coagulopathy or bleeding diathesis - No information provided, but unlikely given limited details in patient note.\n- Not pregnant or nursing - The patient is a 58-year-old female, so likely not pregnant or nursing.\n- Negative pregnancy test - No information provided, but could be obtained if needed.\n- No serious medical illness listed as exclusions - No information provided about conditions like uncontrolled congestive heart failure, angina, recent MI or stroke.\n\nPRIOR CONCURRENT THERAPY:\n- At least 7 days since prior aspirin and aspirin-like medications - No information provided.\n- At least 3 days since prior warfarin, clopidogrel bisulfate, or similar compounds - No information provided.\n- No concurrent drugs causing bleeding tendencies - No information provided.\n- No concurrent participation in other experimental studies - No information provided.\n\nBased on the limited information in the patient note, the main eligibility criteria that could potentially be met are the disease characteristics of a lung mass that could be primary lung cancer or a lung metastasis. However, there is insufficient information about the patient's performance status, pulmonary function tests, blood tests, medications, and other medical conditions to fully assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1356": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria for late-life depression studies.\n\n2. The patient has a solitary mass in the right frontal lobe, which could be relevant to the study's focus on brain lesions and frontal lobe function.\n\n3. However, there is no explicit mention of the patient being diagnosed with major depressive disorder (MDD) or having a MADRS score greater than 20 or a MMSE score greater than 20.\n\n4. Without confirmation of an MDD diagnosis and meeting the MADRS and MMSE score criteria, it is difficult to definitively determine eligibility.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of MDD diagnosis and MADRS/MMSE scores.",
        "label": 0
    },
    "1357": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is studying the effects of transcranial magnetic stimulation (TMS) on frontal lobe epilepsy and evaluating cortical excitability and inhibition before and after TMS sessions.\n\n3. The inclusion criteria for the trial are:\n   - Cryptogenic frontal lobe epilepsy\n   - Normal cerebral MRI\n\n4. Based on the patient note, the patient has a solitary mass in the right frontal lobe, which could potentially be related to epilepsy. However, the note does not explicitly mention that the patient has been diagnosed with frontal lobe epilepsy.\n\n5. Additionally, the patient note does not provide information about the patient's MRI results, which is a requirement for inclusion in the trial.\n\nGiven the limited information provided in the patient note and the specific inclusion criteria of the clinical trial, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to determine if the patient has been diagnosed with frontal lobe epilepsy and to obtain the results of the patient's cerebral MRI. If these criteria are met, the patient may be eligible for the clinical trial.",
        "label": 0
    },
    "1358": {
        "output": "Based on the patient note provided, the 58-year-old female patient has a left lung mass and a solitary mass in the right frontal lobe of the brain. However, the clinical trial is specifically for metastatic or recurrent renal cell carcinoma (kidney cancer).\n\nThe patient note does not mention any kidney cancer or renal cell carcinoma. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1359": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which does not meet the age inclusion criteria of 6-16 weeks for this clinical trial studying pneumococcal vaccine efficacy in preventing pneumonia and acute otitis media in young children.\n\n2. The patient has a lung mass and brain mass, indicating potential health problems that would likely exclude her from a vaccine trial in healthy children.\n\n3. There is no indication that the patient is a child or that the parent/guardian has provided consent, which are required for this pediatric vaccine trial.\n\nTherefore, based on the provided patient note and the inclusion criteria for the COMPAS pneumococcal vaccine trial, this patient would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1360": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is for children and young adults (age 3-25 years) with low-grade and benign brain tumors such as low-grade glioma, meningioma, craniopharyngiomas, ependymomas, and other benign tumors.\n\n3. The patient does not meet the age criteria for this trial, as she is 58 years old.\n\n4. While the patient has a brain mass, it is not specified whether it is a low-grade or benign tumor, which is a requirement for this trial.\n\n5. The trial also requires that the tumor size be up to 7 cm in maximum dimension, but the size of the patient's brain mass is not provided.\n\nBased on the information given, the patient does not meet the age criteria and may or may not meet the tumor type and size criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1361": {
        "output": "To determine the patient's eligibility for the clinical trial \"Lung Cancer Location: a Repository\", let's go through the inclusion criteria:\n\n1. \"Subjects undergoing EUS evaluation of a mediastinal mass, or suspected/known lung cancer\"\n   - The patient note mentions a left lung mass found on chest x-ray, which suggests suspected lung cancer. This criterion is met.\n\n2. \"Subjects with a prior history of lung cancer\"\n   - There is no mention of a prior history of lung cancer in the patient note.\n\n3. \"Subjects referred to thoracic surgery for evaluation of a suspected/known lung cancer\"\n   - The patient note does not mention a referral to thoracic surgery, but it does state that the patient has a suspected lung cancer based on the lung mass found on chest x-ray.\n\nSince the patient meets the first inclusion criterion of having suspected lung cancer based on the lung mass found on imaging, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1362": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray, which is concerning for lung cancer.\n\n2. The clinical trial is assessing the variability of CT scan measurements for non-small cell lung cancer tumors.\n\n3. The inclusion criteria for the trial are:\n   - Have pathologically confirmed non-small cell lung cancer\n   - Have measurable primary pulmonary tumors \u2265 1cm\n   - Have plans for a clinically indicated non-contrast CT scan of the chest\n   - Age \u2265 18 years old\n\n4. Based on the patient note, the patient has not yet had a pathological confirmation of non-small cell lung cancer, but she does have a lung mass concerning for lung cancer.\n\n5. The patient also has a brain mass noted on CT scan, which is not mentioned in the inclusion criteria for this particular trial.\n\nGiven this information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets some of the key criteria like having a suspected lung cancer and being an adult, but further workup and confirmation of non-small cell lung cancer is needed before definitively referring her to this trial. The brain mass is also a potential confounding factor that may need to be evaluated.",
        "label": 1
    },
    "1363": {
        "output": "Okay, let's go through the patient note and inclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 58-year-old female with a left lung mass and a solitary brain mass in the right frontal lobe. The clinical trial is for stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer.\n\nSome key points from the inclusion criteria:\n- Histologically confirmed non-small cell lung cancer\n- Stage I or II (T1N0M0, T2<=7cm N0M0, T3<=7cm N0M0)\n- Primary tumor must be in certain central chest locations \n- Tumor must be technically resectable but patient is inoperable due to medical reasons\n- No evidence of metastases\n- No previous lung/mediastinal radiation\n- No other concomitant cancer therapy planned\n\nThe patient meets some of the criteria like being an adult and having a lung mass suspicious for non-small cell lung cancer. However, there are a few potential issues:\n\n1) The stage is not clearly stated, and the presence of a brain mass raises concern for metastatic disease which would exclude the patient.\n\n2) The location of the lung mass is not specified, so it's unclear if it meets the central chest location requirement.\n\n3) It's not stated if the patient is inoperable due to medical reasons or refusing surgery.\n\nGiven this uncertainty around key eligibility criteria, I would rate this patient as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional work-up like biopsy, staging, and assessment of operability status would be needed to definitively determine eligibility. But based on the information provided, the patient cannot be definitively included or excluded yet.",
        "label": 0
    },
    "1364": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria of >18 years old.\n\n2. The patient has a left lung mass, which could potentially be an undiagnosed pulmonary nodule that meets the inclusion criteria of \"Referral to the pulmonary or thoracic surgery service for undiagnosed pulmonary nodules.\"\n\n3. However, there is no information provided about the patient's smoking history or pack-year history, which is a key inclusion criteria of \"History of smoking exceeding 10 pack-years.\"\n\n4. The size of the lung mass/nodule is also not specified, so it's unclear if it meets the criteria of \"Nodule size 5 to 15 mm in diameter.\"\n\nSince there are some key pieces of information missing regarding the patient's smoking history and nodule size, I would consider referring this patient to the clinical trial upon further investigation to determine if they fully meet the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1365": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is titled \"A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors\".\n\n3. The inclusion criteria for the trial are:\n   - Participant has a known or clinically suspected solid malignancy (excluding brain tumor)\n   - Nodule must be discovered at the time of diagnosis of the primary malignancy or after the completion of therapy\n\n4. Based on the patient note, the patient has a lung mass and a brain mass. The inclusion criteria exclude brain tumors.\n\n5. The patient meets the first inclusion criteria of having a known or clinically suspected solid malignancy (the lung mass).\n\n6. However, it is unclear from the patient note if the lung nodule was discovered at the time of diagnosis or after completion of therapy.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1366": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 58-year-old female who was found to have a left lung mass on chest x-ray and a solitary mass in the right frontal lobe on CT scan of the head. She is otherwise asymptomatic.\n\nThe clinical trial is comparing esomeprazole and famotidine for stress ulcer prophylaxis in neurosurgical intensive care unit patients.\n\nThe key inclusion criteria for this trial is:\n\"Within 24 hours of admission to Neurosurgical ICU after neurosurgery with ventilator support\"\n\nBased on the patient note provided, there is no mention of the patient being admitted to the neurosurgical ICU after neurosurgery or requiring ventilator support.\n\nTherefore, this patient would not meet the eligibility criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1367": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient must be over the age of 18 years\n   - The patient is 58 years old, so this criterion is met.\n\n2. Pulmonary nodule with maximum diameter \u2264 5 cm\n   - The patient has a left lung mass, which could potentially meet this criterion. However, the size of the mass is not specified.\n\n3. Histological confirmation of primary NSCLC\n   - The note does not mention whether a biopsy was done to confirm non-small cell lung cancer (NSCLC).\n\n4. Eligible stages: Stage I (T1N0M0 or T2N0M0 with tumor size \u2264 5cm), Stage II (T3N0M0 with chest wall invasion only and tumor size \u2264 5cm)\n   - The stage of the lung mass is not provided in the note.\n\n5. ECOG/Zubrod status of 0, 1 or 2\n   - The patient's performance status is not mentioned.\n\n6. Determined to be medically inoperable based on specific criteria\n   - There is no information provided about the patient's operability status or whether they meet any of the listed major/minor criteria for inoperability.\n\n7. Other criteria like PET-CT scan, informed consent, etc.\n   - These are not addressed in the patient note.\n\nBased on the information provided in the patient note, there are several key eligibility criteria that cannot be assessed, such as confirmation of NSCLC, tumor stage and size, performance status, and operability status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1368": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria for the trial (no specific age range given in the inclusion criteria).\n\n2. The patient is a nonsmoker, which does not meet the inclusion criteria of having at least a 30 pack-year smoking history.\n\n3. The patient has a left lung mass and a solitary mass in the right frontal lobe of the brain, but the trial is specifically looking at emphysema and chronic obstructive pulmonary disease (COPD).\n\n4. There is no mention of the patient having emphysema or COPD in the patient note.\n\nBased on the information provided, this patient would not be eligible for the \"Biomarkers and Genetic Factors Related to Emphysema\" clinical trial due to not meeting the smoking history and disease criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1369": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is titled \"Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis\" and is studying the effectiveness of these two drugs in preventing stress ulcers in patients admitted to the surgical ICU after major abdominal surgery.\n\n3. The inclusion criteria state that patients must have received major abdominal surgery with an expected surgical ICU stay of more than 7 days, and they must provide written consent and be randomized within 24 hours of admission.\n\n4. Based on the patient note, there is no mention of the patient undergoing major abdominal surgery or being admitted to the surgical ICU.\n\n5. Therefore, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1370": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the inclusion criteria of being an adult patient.\n\n2. The patient has a left lung mass, which is consistent with the inclusion criteria of having histologically confirmed non-small cell lung cancer.\n\n3. The patient is described as having a solitary mass in the right frontal lobe, which suggests the lung cancer may be stage I or II (T1-3, N0, M0) as per the inclusion criteria.\n\n4. There is no information provided about the size of the lung tumor, but the inclusion criteria allows for T2 or T3 tumors up to 5 cm.\n\n5. There is no information provided about the patient's performance status or ability to use effective contraception if fertile.\n\nBased on the available information, it seems likely that this patient could potentially meet the inclusion criteria for this clinical trial, but further investigation would be needed to confirm details like tumor size, stage, performance status, and fertility status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1371": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologic or cytologic proven, non-resectable carcinoma of unknown primary (adenocarcinoma or non-differentiated carcinoma)\n- The patient note mentions a left lung mass and a solitary mass in the right frontal lobe, which could potentially be carcinoma of unknown primary. This criterion is possibly met.\n\n2. Measurable tumor lesion(s) according to RECIST criteria\n- The patient has a left lung mass and a brain mass, which are likely measurable lesions. This criterion is likely met.\n\n3. WHO PS 0 to 1\n- The patient's performance status is not mentioned, so it's unclear if this criterion is met.\n\n4. Signed written informed consent\n- This cannot be determined from the patient note.\n\n5. \u2265 18 years of age\n- The patient is 58 years old, so this criterion is met.\n\n6. Effective contraception for both male and female subjects if the risk of conception exists\n- The patient's gender is mentioned as female, but her childbearing potential is not stated. This criterion cannot be fully assessed.\n\n7. Adequate bone marrow function, liver function, and renal function\n- The patient's lab values are not provided, so these criteria cannot be assessed.\n\nBased on the available information, some of the key inclusion criteria are potentially met, but there are several unknowns as well. Further investigation would be needed to fully determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1372": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion and exclusion criteria:\n\nInclusion criteria:\n1. Diagnosis of suspected lung cancer or lung cancer\n\nThe patient note mentions that the patient has a left lung mass found on chest x-ray, which suggests suspected lung cancer. This meets the inclusion criterion.\n\nExclusion criteria:\n1. Inability to undergo therapy\n\nThere is no information in the patient note suggesting that the patient would be unable to undergo therapy. Therefore, this exclusion criterion is not violated.\n\nBased on the available information, the patient appears to meet the eligibility criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1373": {
        "output": "Let's go through the inclusion criteria for the clinical trial \"Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial\" and assess the eligibility of the given patient.\n\nThe patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain. The clinical trial is focused on esophageal cancer treatment.\n\nInclusion criteria:\n1. \"Histologically documented squamous cell carcinoma or adenocarcinoma of the thoracic esophagus (> 20 cm from the incisors) or gastroesophageal junction are included.\" - The patient note does not mention esophageal cancer, so this criterion is not met.\n\n2. \"No distant metastases (M0).\" - The patient has a mass in the brain, which could indicate metastasis, but it is not explicitly stated. This criterion is unclear based on the information provided.\n\n3. \"Patients will be stratified by stage (clinical N0 versus clinical N1), and surgeon.\" - No information is provided about the staging or the surgeon.\n\n4. \"Patients with tumours within 3 cm distal spread into gastric cardia as detected by esophagogastroscopy.\" - No information is provided about the tumor location or esophagogastroscopy findings.\n\n5. \"Resectable mediastinal nodes are eligible.\" - No information is provided about mediastinal nodes.\n\n6. \"No prior chemotherapy for this malignancy.\" - No information is provided about prior chemotherapy.\n\n7. \"No prior radiotherapy that would overlap the field(s) treated in this study.\" - No information is provided about prior radiotherapy.\n\n8. \"Patients with other malignancies are eligible only if > 5 years without evidence of disease or completely resected or treated non-melanoma skin cancer.\" - The patient has a lung mass and a brain mass, which could be malignancies, but there is no information about their history or treatment.\n\n9. \"Age > 18 years and able to tolerate tri-modality therapy at the discretion of the treating thoracic surgeon, medical and radiation oncologists. Tumours must be resectable after assessment by the thoracic surgeon.\" - The patient is 58 years old, which meets the age criterion, but there is no information about her ability to tolerate tri-modality therapy or the resectability of the tumors.\n\nBased on the limited information provided in the patient note and the specific inclusion criteria for this esophageal cancer clinical trial, it is difficult to make a definitive assessment of eligibility. More information would be needed to determine if the patient meets the criteria or not.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1374": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically or cytologically confirmed neuroblastoma, brain tumor or other solid tumor (at diagnosis)\n- The patient has a lung mass and a brain mass, so this criterion is potentially met.\n\n2. Relapsed or refractory tumors in which correct standard treatment approaches have failed\n- It's not clear if the patient has received any prior treatment yet, so this criterion cannot be evaluated.\n\n3. No more than 2 lines of prior chemotherapy\n- Again, unclear if the patient has received any prior chemotherapy.\n\n4. Measurable primary and/or metastatic disease on CT/MRI at least one bi-dimensionally measurable lesion.\n- The patient has a lung mass and brain mass visible on imaging, so this is met.\n\n5. Age at inclusion: 6 months to \u2264 20 years\n- The patient is 58 years old, so this criterion is not met.\n\n6. Other criteria related to performance status, life expectancy, organ function, washout periods, birth control, etc.\n- Unable to evaluate these as more clinical details are needed.\n\nSince the patient's age of 58 clearly falls outside the eligible range of 6 months to 20 years for this pediatric trial, they would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1375": {
        "output": "To determine the patient's eligibility for the clinical trial \"GE Healthcare VolumeRAD Lung Nodule Detection Study\", let's go through the inclusion criteria one by one:\n\n1. \"Scheduled for chest CT as part of their needed medical care\": The patient note mentions that a chest x-ray revealed a left lung mass, which would likely lead to a chest CT being scheduled as part of the needed medical care. This criterion is likely met.\n\n2. \"If available, individuals who have had previous imaging to suggest they fulfill the needs of the study\": No previous imaging is mentioned in the patient note, but this criterion is not strictly required.\n\n3. \"18 years of age, or older\": The patient is described as a 58-year-old female, so this criterion is met.\n\n4. \"In good enough physical condition to stand motionless and hold their breath during the image acquisition procedures\": There is no information provided about the patient's physical condition, but the note does not mention any significant impairments that would prevent them from standing motionless and holding their breath.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, it seems that the patient would likely be eligible for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1376": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female who was found to have a left lung mass on chest x-ray after presenting with mild exertional dyspnea and occasional cough.\n\n2. The clinical trial is titled \"Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms\" and aims to evaluate the use of VRI as a complementary diagnostic tool for lung examination in children with acute respiratory symptoms.\n\n3. The inclusion criteria for the trial are:\n   - Subject's parent or legal guardian provides informed consent (not applicable for this adult patient)\n   - Age range of 3-18 years (the patient is 58 years old, outside the age range)\n   - Presented with acute respiratory complaints, acute cough, onset of shortness of breath, or fever (the patient had mild exertional dyspnea and occasional cough, which may or may not qualify as acute respiratory complaints)\n   - Referred by an ED physician and presented for a chest x-ray (the patient had a chest x-ray, but it's unclear if they were referred by an ED physician)\n\n4. Based on the information provided, the patient does not meet at least two of the inclusion criteria (age range and potentially the acute respiratory complaints requirement).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1377": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is studying the use of microcoil insertion to reduce the rate of open thoracotomy for removal of lung nodules.\n\n3. The inclusion criteria state that patients must have newly diagnosed small lung nodules < 1cm that require excision, with no history of prior ipsilateral thoracotomy. The nodules must be located in parts of the lung amenable to thoracoscopic wedge excision, at least 2 cm from major pulmonary arteries/veins/bronchi.\n\n4. The patient note mentions a left lung mass, but does not specify the size. It also mentions a brain mass, which is not relevant to this lung nodule trial.\n\n5. Based on the limited information provided, it is unclear if the patient's lung mass meets the size criteria of < 1cm and location criteria specified in the inclusion criteria.\n\nTherefore, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the lung mass size and location to determine if it meets the inclusion criteria.",
        "label": 0
    },
    "1378": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria of 18-85 years old for the clinical trial.\n\n2. The patient has a left lung mass found on chest x-ray and a solitary mass in the right frontal lobe found on CT scan of the head. This meets the inclusion criteria of \"Patients referred to pulmonologists, oncologists, or thoracic surgeons for the evaluation of peripheral lung nodules found on CT scan.\"\n\n3. The lung mass is described as a \"left lung mass\", which implies it is a peripheral lung nodule, meeting the criteria of \"One or more lung nodules must be between 8 mm and 30 mm in the greatest diameter.\"\n\n4. There is no information provided about whether repeat CT scans, biopsy, or surgical excision are clinically indicated for this patient, but it is reasonable to assume that further evaluation would be recommended given the findings of a lung mass and brain mass.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial on biomarkers for the diagnosis of lung nodules.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1379": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which falls outside the age range of 18-45 years specified in the inclusion criteria for both patients and controls.\n\n2. There is no mention of the patient being diagnosed with schizophrenia or receiving antipsychotic medication like aripiprazole or risperidone, which are requirements for the patient group.\n\n3. The patient does not seem to fit the criteria for the control group either, as there is no information provided about handedness, socio-educational level, psychiatric history, or musical practice.\n\n4. The main findings for this patient are a left lung mass and a solitary mass in the right frontal lobe of the brain, which do not appear to be relevant to the study's focus on schizophrenia and antipsychotic medication effects.\n\nBased on the information provided, this patient does not meet the inclusion criteria for either the patient or control groups in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1380": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which falls within the age range of 18-80 specified in the inclusion criteria.\n\n2. The patient is described as having a left lung mass on chest x-ray, and a CT scan of the head shows a solitary mass in the right frontal lobe. This suggests the presence of lung cancer, which is one of the inclusion criteria.\n\n3. There is no information provided about the patient's competency level, which is another inclusion criterion.\n\nBased on the available information, the patient meets some but not all of the inclusion criteria. Specifically, the patient's age and suspected lung cancer diagnosis make them potentially eligible, but their competency level is unknown.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their competency level.",
        "label": 1
    },
    "1381": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray, and a solitary mass in the right frontal lobe of the brain found on CT scan.\n\n2. The clinical trial is titled \"Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules\" and is studying the use of interferon-gamma release assay in addition to percutaneous needle biopsy for diagnosing pulmonary nodules.\n\n3. The inclusion criteria for the trial are:\n   - Age > 18 years\n   - Patients with solitary pulmonary nodule\n   - Who had percutaneous needle biopsy for diagnosis of lung nodule\n\n4. Based on the patient note, the patient meets the age criteria (58 years old) and has a solitary pulmonary nodule. However, there is no mention of the patient having undergone a percutaneous needle biopsy for diagnosis of the lung nodule.\n\n5. Without the information about the percutaneous needle biopsy, it is unclear if the patient fully meets the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding whether a percutaneous needle biopsy has been performed for the diagnosis of the lung nodule.",
        "label": 1
    },
    "1382": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray and a solitary mass in the right frontal lobe of the brain found on CT scan.\n\n2. The clinical trial is titled \"Sonography After Thoracic Surgery (SATS)\" and is studying the use of thoracic ultrasound in the post-operative setting following thoracic surgery.\n\n3. The inclusion criteria for the trial is: \"Patients undergoing elective, open and thoracoscopic thoracic surgery for any indication\"\n\n4. Based on the patient note, it is unclear if the patient is undergoing or planning to undergo thoracic surgery. The note mentions a lung mass and brain mass, but does not specify if surgery is planned.\n\n5. Without confirmation that the patient will be undergoing thoracic surgery, it is difficult to definitively determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether thoracic surgery is planned for the lung mass.",
        "label": 1
    },
    "1383": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain, suggesting metastatic cancer.\n\n2. The clinical trial is for patients with metastatic or recurrent melanoma (skin cancer).\n\n3. Checking the inclusion criteria:\n   - The patient does not have a histologically documented diagnosis of melanoma, which is required.\n   - The patient's cancer type (lung and brain masses) does not match the required melanoma diagnosis.\n   - There is no mention of the patient having prior tissue samples available, which is also required.\n\n4. Based on the information provided, this patient would not be eligible for this particular clinical trial on metastatic melanoma.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1384": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray, and a solitary mass in the right frontal lobe of the brain found on CT scan.\n\n2. The clinical trial is about using intracavitary thoracoscopic ultrasound to localize pulmonary nodules during video-assisted thoracoscopic surgery (VATS) for resection.\n\n3. The key inclusion criteria are:\n   - Patients with CT-identified pulmonary nodules\n   - Nodules not deemed to be visualizable during VATS\n   - Candidates for VATS resection\n\n4. This patient meets the criteria of having a CT-identified pulmonary nodule (the left lung mass).\n\n5. However, there is no information provided about whether the nodule is expected to be visualizable during VATS or not.\n\n6. Additionally, the presence of the brain mass may complicate or preclude the patient from being a candidate for VATS resection of the lung nodule.\n\nBased on the available information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther information is needed about the visualizability of the lung nodule during VATS, and whether the brain mass would preclude the patient from undergoing VATS resection of the lung nodule.",
        "label": 1
    },
    "1385": {
        "output": "To determine the patient's eligibility for the clinical trial \"EBUS Guided Cryo Biopsy of Solitary Pulmonary Nodules\", let's go through the inclusion criteria one by one:\n\n1. \"solitary pulmonary nodule < 4 cm\"\nThe patient note mentions that the patient has a left lung mass, which can be considered a solitary pulmonary nodule. The size is not specified, but it meets this criterion.\n\n2. \"no endobronchial lesion\"\nThe patient note does not mention any endobronchial lesion, so this criterion is likely met.\n\n3. \"indication for bronchoscopy\"\nThe patient note does not explicitly state an indication for bronchoscopy, but the presence of a lung mass and the need for further investigation could potentially warrant a bronchoscopy.\n\nBased on the information provided in the patient note, the patient appears to meet the inclusion criteria for this clinical trial. However, there are some missing details, such as the size of the lung mass and the specific indication for bronchoscopy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1386": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which does not meet the age criteria of 18 years or less for this clinical trial on craniopharyngioma in children and adolescents.\n\n2. The patient has a lung mass and a brain mass, but there is no mention of a confirmed diagnosis of craniopharyngioma, which is required for inclusion.\n\n3. There are no details provided about whether the patient has undergone surgery or the extent of resection, which is a key criteria for the randomization part of the trial.\n\nBased on the information given in the patient note, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1387": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with mild exertional dyspnea, occasional cough, and a left lung mass on chest x-ray. She also has a solitary mass in the right frontal lobe of the brain based on a CT scan.\n\n2. The clinical trial is titled \"Watchful Waiting Versus Repair of Oligosymptomatic Incisional Hernias\" and is studying whether watchful waiting is non-inferior to surgical repair for asymptomatic or oligosymptomatic (minimally symptomatic) incisional hernias.\n\n3. The inclusion criteria for the trial are:\n   - Age \u2265 18 years\n   - Asymptomatic or oligosymptomatic incisional hernia\n\n4. Based on the patient note, there is no mention of the patient having an incisional hernia. The note describes a lung mass and a brain mass, which are not relevant to the inclusion criteria of this trial.\n\nTherefore, based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1388": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age at diagnosis at least 4 years or 5 years and less than 22 years.\n   - The patient is 58 years old, which does not meet this criteria.\n\n2. Histologically proven medulloblastoma.\n   - The patient has a lung mass and a brain mass, but there is no mention of medulloblastoma specifically.\n\n3. No CNS metastasis on MRI - supratentorial, arachnoid of the posterior fossa or spine.\n   - It is not mentioned if the brain mass has metastasized or not.\n\n4. No clinical evidence of extra-CNS metastasis\n   - There is no mention of extra-CNS metastasis.\n\n5. No tumour cells on the cytospin of lumbar CSF.\n   - There is no information provided about CSF cytology.\n\n6. Radiotherapy to start no more than 40 days after surgery.\n   - There is no mention of any prior surgery.\n\n7. Ability to receive twice daily radiotherapy.\n   - This is not addressed in the patient note.\n\n8. Vital functions within normal range for their age group.\n   - Vital signs are not provided.\n\n9. CTC grades < 2 for liver, renal, haematological and audiological function.\n   - No lab values or audiology testing results are given.\n\n10. No medical contraindication to radiotherapy or chemotherapy.\n    - Potential contraindications are not discussed.\n\n11. Written informed consent obtained.\n    - This is not mentioned.\n\nBased on the limited information provided in the patient note, this 58-year-old patient does not meet the age criteria for inclusion in this pediatric medulloblastoma clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1389": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is studying the incidence of nontuberculous mycobacterial pulmonary infection in patients with bilateral bronchiectasis and bronchiolitis.\n\n3. The inclusion criteria for the trial is \"All patients with bronchiectasis or bronchiolitis\".\n\n4. Based on the patient note, there is no mention of the patient having bronchiectasis or bronchiolitis. The note only mentions a lung mass and a brain mass.\n\n5. Therefore, this patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1390": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer\", let's go through the inclusion criteria:\n\nInclusion Criteria: Participant is a lung cancer patient.\n\nBased on the patient note, it states that the patient is found to have a left lung mass on chest x-ray and a solitary mass in the right frontal lobe on CT scan of the head. While the lung mass suggests the possibility of lung cancer, it is not explicitly stated that the patient has been diagnosed with lung cancer.\n\nGiven this information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient appears to have potential lung cancer based on the imaging findings, but further diagnostic confirmation would be needed to determine if they meet the inclusion criteria of being a lung cancer patient. Additional tests or biopsy results may provide clarity on the patient's eligibility for this specific clinical trial.",
        "label": 2
    },
    "1391": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain found on imaging.\n\n2. The clinical trial is titled \"Extracolonic Findings on Computed Tomography (CT) Colonography\" and aims to study the incidence, predictors, and clinical diagnoses associated with extracolonic findings (findings outside the colon) detected on CT colonography scans.\n\n3. The inclusion criteria state that no participant sub-populations will be excluded prior to selection. The study aims to enroll participants from the ACRIN 6664 trial who had extracolonic findings reported on their CT colonography scans.\n\n4. Given that the patient in this case has extracolonic findings (lung mass and brain mass) detected on imaging, she would likely be eligible for inclusion in this trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1392": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients 18 years and older: The patient is 58 years old, so this criterion is met.\n\n2. Patient or proxy willing to provide informed consent: There is no information provided about the patient's willingness to provide informed consent, so we cannot determine if this criterion is met or not.\n\n3. Patients who require placement of a nasogastric/orogastric tube, in the ED or ICU, as standard of care, AND a member of the study staff is available and present for NG/OG tube placement: The patient note does not mention the need for a nasogastric/orogastric tube placement, so this criterion is not met.\n\n4. It is anticipated that the patient will remain in the ED/ICU in order to obtain RightSpot pH Indicator reading and verifying CXR: There is no information provided about the patient's anticipated stay in the ED/ICU, so we cannot determine if this criterion is met or not.\n\nBased on the information provided in the patient note and the inclusion criteria, the patient does not meet at least one of the criteria (the need for nasogastric/orogastric tube placement). Additionally, there is not enough information to determine if the patient meets the other criteria related to informed consent and anticipated stay in the ED/ICU.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1393": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria of 18 or older for the clinical trial.\n\n2. The patient has a left lung mass found on chest x-ray and a solitary mass in the right frontal lobe of the brain found on CT scan of the head. This meets the inclusion criteria of having undergone a CT scan of the lung(s) that indicates one or more nodules or lesions suspicious for lung cancer.\n\n3. The lung mass is described as being in the left lung, which implies it is greater than 4mm in size, meeting that inclusion criteria.\n\n4. While the patient is not specifically indicated for a tissue biopsy or surgical resection yet, the lung mass and brain mass findings would likely lead to further investigation and potential biopsy/resection, potentially meeting that inclusion criteria.\n\n5. There is no information provided that would exclude the patient based on the listed exclusion criteria.\n\nBased on the information provided, this patient appears to potentially meet the key inclusion criteria for the clinical trial, pending further investigation of the lung and brain masses.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1394": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with mild exertional dyspnea, occasional cough, and a left lung mass on chest x-ray. She also has a solitary mass in the right frontal lobe on CT scan of the head.\n\n2. The clinical trial is titled \"Ultrasound in Undifferentiated Hypotension\" and is studying the use of focused ultrasound to evaluate hypotensive patients presenting to the emergency department with signs of inadequate tissue perfusion.\n\n3. The inclusion criteria for the trial are:\n   - Arterial pressure <100 mmHg at presentation\n   - At least one of the following symptoms: unresponsive, syncope, impaired mental status, respiratory distress, severe malaise and fatigue\n\n4. Based on the patient note, there is no mention of the patient's blood pressure or any of the listed symptoms required for inclusion. The note describes findings of lung and brain masses, but does not indicate that the patient meets the criteria for undifferentiated hypotension.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1395": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray and a solitary mass in the right frontal lobe of the brain found on CT scan.\n\n2. The clinical trial is about using lung ultrasound to evaluate the size of pneumothorax (collapsed lung) and compare it to CT scan measurements.\n\n3. The inclusion criteria for the trial are:\n   - Radiologic diagnosis of pneumothorax\n   - Clinical need to perform a CT scan\n   - Ability to perform lung ultrasound within 20 minutes of the CT scan\n\n4. Based on the patient note, there is no mention of the patient having a pneumothorax. The note describes a lung mass and a brain mass.\n\n5. Since the patient does not have a radiologic diagnosis of pneumothorax, which is one of the key inclusion criteria, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1396": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain. This suggests the possibility of metastatic cancer, though the primary site is not definitively stated.\n\n2. The clinical trial is for metastatic pancreatic adenocarcinoma that has not been previously treated with palliative systemic therapy.\n\n3. The inclusion criteria require:\n   - Histologically documented metastatic pancreatic adenocarcinoma\n   - Measurable disease\n   - Available tissue for hENT1 testing (core biopsy, not fine needle aspiration)\n   - ECOG performance status 0-1\n   - Age \u2265 18 years\n   - Adequate hematologic, hepatic, and renal function\n   - No prior palliative chemotherapy or radiation (some exceptions allowed)\n   - Ability to provide informed consent\n\n4. Based on the provided patient note, there is no definitive evidence that the patient has metastatic pancreatic adenocarcinoma, which is a key inclusion criterion for this trial.\n\n5. The patient's performance status and ability to provide consent are not mentioned, but these could potentially be met upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient's cancer type and stage need to be confirmed to determine eligibility for this specific trial targeting metastatic pancreatic adenocarcinoma. Additional information about the patient's performance status, ability to provide consent, and meeting the other inclusion criteria would also be needed for a more definitive assessment.",
        "label": 0
    },
    "1397": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is studying the use of extravascular lung water index (ELWI) and pulmonary permeability index (PPI) to detect and predict primary graft dysfunction (PGD) following lung transplantation.\n\n3. The inclusion criteria for the trial is \"All consecutive bilateral lung transplant recipients\".\n\nSince the patient has not undergone a lung transplant, she would not meet the inclusion criteria for this particular trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1398": {
        "output": "Based on the patient note provided, the 58-year-old female patient has a left lung mass and a solitary mass in the right frontal lobe of the brain. The clinical trial you provided is focused on improving implantation rates in ICSI (intracytoplasmic sperm injection) patients using stem cell therapy.\n\nGiven that the patient's condition does not seem to be related to fertility or implantation issues, it is unlikely that she would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1399": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female presenting with mild exertional dyspnea and occasional cough, found to have a left lung mass on chest x-ray.\n\n2. The clinical trial is studying the use of lung ultrasound compared to chest x-ray for diagnosing pneumonia in the emergency department.\n\n3. The inclusion criteria for the trial are:\n   - Patients who present to the ED with respiratory symptoms suspicious for pneumonia\n   - In whom the treating physician believes would benefit from diagnostic imaging\n\n4. This patient meets the inclusion criteria as she is presenting with respiratory symptoms (exertional dyspnea and cough) and has already had a chest x-ray done which showed a lung mass, indicating the physician believed diagnostic imaging would be beneficial.\n\n5. However, the patient note also mentions she has a solitary mass in the right frontal lobe on CT scan of the head. This additional neurological finding is not directly relevant to the pneumonia diagnosis trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the patient meets the stated inclusion criteria based on her respiratory symptoms and chest x-ray findings, the additional neurological finding of a brain mass may complicate her overall clinical picture and eligibility. Further investigation into her overall health status and the nature of the brain mass would be prudent before definitively referring her to this particular pneumonia diagnosis trial.",
        "label": 0
    },
    "1400": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old nonsmoker white female, so she does not meet the smoking history criteria for inclusion in this lung cancer screening trial.\n\n2. The trial is looking for current or former smokers with a certain pack-year history, with or without additional risk factors like family history of lung cancer or COPD.\n\n3. While the patient does have a lung mass found incidentally, she does not have the specific smoking exposure that is required for this particular trial.\n\n4. There are no other details provided that would suggest she meets the inclusion criteria.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1401": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a lung mass and a brain mass, likely cancerous.\n2. The clinical trial is for patients with transitional cell carcinoma (bladder or upper urinary tract cancer) that has progressed after platinum-based chemotherapy.\n\nBased on the information provided, this patient does not seem to have transitional cell carcinoma of the bladder or upper urinary tract. The masses described are in the lung and brain.\n\nTherefore, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1402": {
        "output": "Based on the provided patient note and the clinical trial information, this patient would not be eligible for the clinical trial titled \"Spinal Anesthesia for Cesarean Delivery is Associated With Decreases in Regional Cerebral Oxygen Saturation as Assessed by Near- Infrared Spectroscopy\".\n\nThe key reasons are:\n\n1. The patient is a 58-year-old female, while the inclusion criteria specify \"Term healthy parturients\", which refers to pregnant women at or near their due date for delivery.\n\n2. The patient note does not mention pregnancy or an upcoming cesarean delivery, which is the focus of the clinical trial.\n\n3. The patient note describes findings related to a lung mass and a brain mass, which are not relevant to the clinical trial's objective of assessing cerebral oxygen saturation during spinal anesthesia for cesarean delivery.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1403": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, so her age does not match the inclusion criteria of \"adolescents\" for this clinical trial.\n\n2. The patient has a solitary mass in the right frontal lobe, which could potentially indicate frontal lobe damage. However, the inclusion criteria specifically mentions \"at least one year after injury\", and there is no information provided about when the frontal lobe mass was discovered or if it caused any brain injury.\n\n3. There is no information provided about whether the patient is a native Hebrew speaker or not.\n\nBased on the information given, this patient does not clearly meet all of the inclusion criteria for the clinical trial. Her age and language are not specified as meeting the criteria, and there is no clear indication that she has had a frontal lobe injury for at least one year.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1404": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which falls within the age range of 55-75 years old specified in the inclusion criteria.\n\n2. The patient has a lung mass and a brain mass, which could potentially be cancers. The trial is looking for patients with lung, colon, rectal, prostate, or ovarian cancers.\n\n3. There is no mention of the patient currently undergoing cancer treatment or having had previous cancers that would exclude her.\n\n4. There is no mention of the patient having had surgical removal of a lung, colon, prostate, or ovaries that would exclude her.\n\n5. There is no mention of the patient participating in another cancer screening or prevention trial that would exclude her.\n\n6. There is no mention of the patient taking any medications that would exclude her.\n\nBased on the information provided, this patient seems to potentially meet the inclusion criteria for the lung cancer screening portion of the trial. However, further investigation would be needed to confirm the nature of the lung and brain masses before definitively referring her.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1405": {
        "output": "To determine the patient's eligibility for the \"Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker\" clinical trial, let's go through the inclusion criteria:\n\n1. Smokers or former smokers: The patient note does not mention the patient's smoking status, so we cannot confirm this criterion.\n\n2. At least 20 pack year history of smoking: Again, the patient note does not provide information about the patient's smoking history or pack-year history.\n\n3. Ages 50 - 75: The patient note states that the patient is a 58-year-old female, which meets this age criterion.\n\nSince the patient's smoking status and pack-year history are not provided, it is difficult to make a definitive assessment of eligibility based on the given information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their smoking history and pack-year history.",
        "label": 0
    },
    "1406": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluating the Pulmonary Nodule With Imaging and Biomarkers,\" let's go through the inclusion criteria:\n\n1. \"All patients aged above 21 years\": The patient is 58 years old, which meets this criterion.\n\n2. \"Capable of giving consent\": There is no information provided about the patient's ability to give consent, but we can assume they are capable unless stated otherwise.\n\n3. \"Suspected of lung cancer with radiological lung nodules and masses\": The patient has a left lung mass found on chest x-ray, which meets this criterion.\n\nBased on the information provided in the patient note, the patient appears to meet all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1407": {
        "output": "To determine the patient's eligibility for the clinical trial \"Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas\", I will compare the patient note with the inclusion criteria provided.\n\nThe patient note states:\n\"A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.\"\n\nThe inclusion criteria for the clinical trial is:\n\"49 cases of undifferentiated sarcomas from ARST0332 (additional cases may be ascertained as eligible for this current project that also fall under ARST0332 to be requested later if necessary)\"\n\nBased on the information provided in the patient note, there is no mention of the patient having an undifferentiated sarcoma or being part of the ARST0332 study. The patient appears to have a lung mass and a solitary mass in the right frontal lobe of the brain, but the type of cancer is not specified.\n\nTherefore, based on the available information, I would not refer this patient for the clinical trial \"Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1408": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Stereotactic Radiotherapy (SBRT) of Lung Metastasis\" and assess the eligibility of the patient based on the provided note.\n\nThe patient is a 58-year-old nonsmoker white female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n1. Histological confirmation of malignancy: The note does not mention if a biopsy was done to confirm the malignancy of the lung mass or brain mass. This criterion is unclear based on the information provided.\n\n2. Eligible patients must have staging studies identifying them as:\n   a) Patients with stage I or II, non-metastatic NSCLC: The note does not provide information about the stage of the lung mass.\n   b) Patients with a non-lung primary that is controlled and has metastasized to the lungs alone: The presence of a brain mass suggests that the patient may have metastatic disease, which would make them ineligible for this criterion.\n   c) Patients with limited volume metastatic NSCLC or other primary site tumors where it is felt they may derive benefit from high-dose SBRT treatment: The patient has a brain mass, which may make them eligible for this criterion, but more information is needed about the primary site and extent of metastatic disease.\n\n3. Patients who have potentially resectable disease should be considered medically inoperable: The note does not provide information about the patient's operability status.\n\n4. Early stage lung cancer: \u22643 parenchymal lung lesions, Metastatic disease to lungs: \u22645 parenchymal lung lesions: The note mentions only one lung mass, but the presence of a brain mass suggests metastatic disease, which may make the patient ineligible for this criterion.\n\n5. Patients with early stage primary NSCLC should have hilar or mediastinal lymph nodes that are considered N0 on clinico-radiological grounds: The note does not provide information about lymph node involvement.\n\n6. In patients with early stage primary NSCLC and a co-existing malignancy, the co-existing malignancy must have an expected prognosis better than the primary lung lesion: The note does not provide information about the prognosis of the lung mass or brain mass.\n\n7. Adequate lung function to tolerate the planned stereotactic radiation: The note does not provide information about the patient's lung function.\n\n8. Previous conventional RT to mediastinum/lung allowed as long as SBRT is not expected to have a high probability of impairing lung function: The note does not mention any previous radiation therapy.\n\n9. Must be \u2265 18 years of age: The patient is 58 years old, so they meet this criterion.\n\n10. Zubrod performance status must be between 0 and 3: The note does not provide information about the patient's performance status.\n\n11. Women of child-bearing potential and male participants must use an effective contraceptive method: The note does not provide information about the patient's child-bearing potential or use of contraceptives.\n\n12. Willing and able to give informed consent: The note does not mention whether the patient is willing and able to give informed consent.\n\nBased on the information provided in the patient note, there are several inclusion criteria that are unclear or potentially not met, such as the confirmation of malignancy, the staging and extent of disease, the patient's operability status, lung function, performance status, and willingness to provide informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1409": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray. She is otherwise asymptomatic.\n\n2. The clinical trial is for percutaneous image guided video-assisted thoracic surgery (VATS) resection of lung lesions.\n\n3. The inclusion criteria are:\n   - Peripheral lung nodules < 3cm in size\n   - Surgical candidate\n\n4. Based on the patient note, the lung mass found on chest x-ray seems to meet the criteria of a peripheral lung nodule. The size is not explicitly stated, but it does not seem to contradict the <3cm requirement.\n\n5. The patient is described as otherwise asymptomatic, which suggests she may be a suitable surgical candidate.\n\n6. There is no information provided that would exclude the patient from meeting the inclusion criteria.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1410": {
        "output": "To determine the patient's eligibility for the clinical trial \"Avonex\u00ae: Safety, Blood Levels and Effects\", let's go through the inclusion criteria one by one:\n\n1. \"Must be between the ages of 18 and 45 years, inclusive.\"\nThe patient is 58 years old, which does not meet this criterion.\n\n2. \"Must have a body mass index (BMI) of 19 to 28 kilograms/height (m)2, inclusive, and have a minimum body weight of 50 kilograms (at screening and baseline).\"\nThere is no information provided about the patient's BMI or weight.\n\n3. \"Must give written informed consent.\"\nThere is no information about whether the patient has provided informed consent or not.\n\nBased on the available information, the patient does not meet the age criterion for inclusion in this clinical trial. Additionally, there is not enough information provided about the patient's BMI, weight, and consent status.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1411": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old female, which meets the age criteria of \"At least 18 years of age\".\n\nShe has a left lung mass and a solitary mass in the right frontal lobe of the brain. The trial is specifically for advanced melanoma, which is not mentioned in the patient note. However, the brain mass could potentially be a metastatic melanoma lesion.\n\nThe inclusion criteria state \"Histologically documented cutaneous or mucosal malignant melanoma, which is recurrent or metastatic and is not curable by surgical or other means.\" While we don't have a histological confirmation of melanoma yet, the brain lesion raises that possibility of metastatic disease.\n\nThe criteria also require \"Adequate tumour tissue (greater than 0.5cm3 preferred, 3 X core biopsy acceptable) available and agreement from subjects that this tissue from their primary and/or metastatic tumour be made available for assessment of potential biomarkers.\" We don't have information about availability of tumor tissue.\n\nOther criteria like ECOG performance status, prior treatments, organ function, etc. are not mentioned in the patient note.\n\nOverall, based on the limited information provided, I would consider this patient for the clinical trial upon further investigation to confirm the diagnosis and stage of disease, availability of tumor tissue, and meeting the other inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1412": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age > or = 40 years at the time of screening\n   - The patient is 58 years old, so this criterion is met.\n\n2. Advanced lower or lower and upper lobe predominant heterogeneous emphysema by CT scan\n   - The patient note does not mention emphysema or specify the location of the lung mass. This criterion cannot be evaluated based on the information provided.\n\n3. Minimum of 2 subsegments appropriate for treatment\n   - There is no information about subsegments or potential treatment areas in the patient note.\n\n4. MRCD questionnaire score of 2 or greater at screening\n   - The patient note does not provide an MRCD questionnaire score.\n\n5. Failure of medical therapy to provide relief of symptoms\n   - The patient note does not mention any medical therapy or lack of symptom relief.\n\n6. Spirometry criteria (FEV1 < 50% predicted and FEV1/FVC ratio <70%)\n   - The patient note does not provide any spirometry values.\n\n7. Lung volume criteria (TLC > 100% predicted and RV > 150% predicted)\n   - The patient note does not provide any lung volume measurements.\n\n8. Diffusing Capacity of Carbon Monoxide (DLco) > = 20 and < = 60 percent predicted\n   - The patient note does not provide a DLco value.\n\n9. Oxygen saturation (SpO2) > 90% on < or = 4 L/min supplemental O2, at rest\n   - The patient note does not mention oxygen saturation or supplemental oxygen use.\n\n10. Six-Minute Walk Test distance > or = 150 m\n    - The patient note does not provide a Six-Minute Walk Test result.\n\n11. Abstinence from smoking for at least 16 weeks prior to screening\n    - The patient note states that the patient is a nonsmoker, so this criterion is likely met.\n\nBased on the limited information provided in the patient note, several key inclusion criteria cannot be evaluated. Additional diagnostic tests and clinical information would be needed to determine eligibility for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1413": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain. This matches the inclusion criteria of having advanced, non-resectable and/or metastatic solid tumors.\n\nThe patient's age of 58 years meets the inclusion criteria of being 18 years or older.\n\nThere is no information provided about the patient's life expectancy, so it is unclear if she meets the criteria of having a life expectancy of at least three months.\n\nThere is no information provided about whether the patient has given written informed consent.\n\nThere is no information provided about the patient's Eastern Cooperative Oncology Group (ECOG) performance score, so it is unclear if she meets the criteria of having a score less than 2.\n\nThere is no information provided about whether the patient has recovered from all therapy-related toxicities from previous treatments.\n\nBased on the available information, some of the key inclusion criteria are met, but there are also some unclear points.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1414": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old female, which meets the age criteria of 18 years or over.\n\nShe has a left lung mass found on chest x-ray, and a CT scan shows a solitary mass in the right frontal lobe. The lung mass likely meets the criteria of \"A soft tissue solitary dominant pulmonary nodule of \u2265 8mm and \u226430mm on axial plane Measured on lung window using conventional CT scan.\"\n\nThere is no mention of other evidence strongly indicative of malignancy like distant metastases or local invasion.\n\nThe patient is described as otherwise asymptomatic, able to provide consent, and there are no details provided that would suggest an inability to consent to the study.\n\nBased on the information provided, this patient appears to meet all the key inclusion criteria for the \"Single Pulmonary Nodule Investigation\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1415": {
        "output": "Based on the patient note provided, this is a 58-year-old female patient with a lung mass and a brain mass. The clinical trial titled \"Prostate Cancer Genomic Heterogeneity\" is specifically focused on studying prostate cancer in men.\n\nSince this patient is a female and does not have prostate cancer, she would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1416": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray and a solitary mass in the right frontal lobe of the brain found on CT scan.\n\n2. The clinical trial is titled \"ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT\" and is studying the feasibility of thoracoscopic surgery guided by radioactive marking and SPECT imaging for removing lung nodules.\n\n3. The inclusion criteria for the trial are:\n   - Age over 18 years\n   - Planned thoracoscopic surgery of a pulmonary nodule\n   - Informed consent\n\n4. The patient meets the age criteria (58 years old) and has a lung mass/nodule that would potentially require thoracoscopic surgery.\n\n5. However, the patient also has a brain mass noted, which is not mentioned in the inclusion/exclusion criteria. This additional condition may complicate or preclude their participation in the trial.\n\nBased on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe lung nodule meets the basic criteria, but the presence of the brain mass would need to be evaluated further to determine if it is an exclusion factor or potential complicating condition for participating in this surgical trial.",
        "label": 1
    },
    "1417": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is for advanced anal cancer, specifically inoperable, locally recurrent or metastatic squamous cell carcinoma of the anus.\n\n3. The inclusion criteria require histologically or cytologically verified squamous cell carcinoma of the anus, age \u226518 years, ECOG Performance status \u22642, measurable disease, and adequate organ function.\n\n4. The exclusion criteria rule out tumors of non-squamous cell histology, previous treatment for advanced anal cancer, brain metastases, and certain comorbidities.\n\n5. Based on the patient note, this patient does not have anal cancer, but rather a lung mass and a brain mass. Therefore, she would not meet the inclusion criteria for this specific clinical trial on advanced anal cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1418": {
        "output": "Okay, let's go through the patient note and inclusion criteria for the clinical trial step-by-step:\n\nPatient Note:\n- 58-year-old female\n- Nonsmoker\n- Mild exertional dyspnea and occasional cough\n- Left lung mass found on chest x-ray\n- Otherwise asymptomatic\n- Neurological exam unremarkable\n- CT scan shows solitary mass in right frontal lobe\n\nClinical Trial Inclusion Criteria:\n- Intubation and mechanical ventilation in the ICU\n- Ramsay score 6 under sedation and analgesia  \n- ICU respirator implemented with pressure-volume curve device\n- Age \u2265 18 years\n- ARDS defined from the Berlin criteria\n- Absence of pneumothorax on CXR before the study\n- Absence of pleural effusion >500 ml estimated from ultrasonography\n- No child-bearing woman\n- Written informed consent signed by next of kin\n\nBased on the patient note, there is no indication that the patient meets several of the key inclusion criteria, such as being intubated and mechanically ventilated in the ICU, having ARDS, or being under sedation. The patient appears to be an outpatient with a lung mass and brain mass found incidentally.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1419": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria of being over 18 years old.\n2. The patient has a left lung mass, which is described as a solitary pulmonary nodule 5cm or less in size. This meets the inclusion criteria of having a \"suspicious or known to be malignant solitary pulmonary nodule, 5cm or less in size.\"\n3. There is no information provided that would exclude the patient from the trial based on the given inclusion criteria.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the \"Feasibility Study Using Imaging Biomarkers in Lung Cancer\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1420": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria of 18-90 years old for the clinical trial.\n\n2. The patient does not have a history of stroke mentioned in the note. The trial is specifically for patients who have had a stroke within the last 6 weeks.\n\n3. The note mentions a left lung mass and a right frontal lobe mass in the brain, but does not provide any information about paralysis or weakness of the upper extremity, which is a key inclusion criteria.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets the inclusion criteria of having a \"hemisyndrome (central paralysis of the upper extremity, and all degrees of weakness: M0 - M5 on the paresis scale) as a result of a first stroke\" within the last 6 weeks.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether the patient has had a recent stroke resulting in upper extremity paralysis or weakness.",
        "label": 0
    },
    "1421": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a right frontal lobe brain mass found incidentally on imaging.\n\n2. The clinical trial is studying different techniques for achieving lung isolation during left video-assisted thoracoscopic surgery (VATS). \n\n3. The key inclusion criteria are:\n    - Signed informed consent\n    - Elective left video-assisted thoracoscopy\n    - Requiring one lung ventilation\n\n4. Based on the patient note, it states that the patient has a left lung mass and is asymptomatic otherwise. It does not explicitly mention that the patient is scheduled for a left VATS procedure.\n\n5. Given the lack of information about an upcoming left VATS for this patient, I would consider referring them to this clinical trial upon further investigation to determine if they meet all inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1422": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with mild exertional dyspnea (shortness of breath with exertion) and occasional cough. She has a left lung mass on chest x-ray but is otherwise asymptomatic.\n\n2. The clinical trial is studying bronchial thermoplasty, a treatment for severe asthma, in patients aged 18-65 with confirmed asthma diagnosis and specific criteria related to asthma severity and medication use.\n\n3. The inclusion criteria specifically state that patients must have:\n   - Asthma confirmed by certain tests\n   - Be taking regular asthma maintenance medication at specified doses\n   - Have bronchial hyperresponsiveness (PC20 < 4 mg/ml)\n   - FEV1 (lung function) in a specified range\n   - Asthma Control Questionnaire score > 1.5\n   - Non-smoker or former light smoker\n   - Ability to undergo bronchoscopy/bronchial thermoplasty\n\n4. Based on the limited information provided about this patient, she does not appear to meet several of the key inclusion criteria:\n   - Her asthma diagnosis and severity are not confirmed\n   - Her medication use is not specified \n   - Her lung function and bronchial hyperresponsiveness are not provided\n   - Her asthma control score is not given\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1423": {
        "output": "Okay, let's go through the patient note and inclusion criteria for the clinical trial step-by-step:\n\nPatient Note:\n- 58-year-old female\n- Nonsmoker\n- Mild exertional dyspnea and occasional cough\n- Left lung mass on chest x-ray\n- Otherwise asymptomatic\n- Neurological exam unremarkable\n- CT scan shows solitary mass in right frontal lobe\n\nClinical Trial:\nTitle: Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer\n\nSummary: Evaluating ceritinib (ALK inhibitor) in anaplastic/undifferentiated thyroid cancer with ALK mutations/rearrangements.\n\nInclusion Criteria:\n- Histologically/cytologically confirmed anaplastic or undifferentiated thyroid cancer with ALK mutation/rearrangement\n- No other curative options like radiation or surgery\n- WHO performance status 0-2\n- Age \u2265 18 years\n- Adequate organ function based on lab values\n- Written informed consent\n\nBased on the patient note, there is no mention of the patient having anaplastic/undifferentiated thyroid cancer or any information about ALK mutation status, which are key inclusion criteria for this trial. The lung and brain masses suggest a different cancer type.\n\nAdditionally, the patient's age of 58 years meets the age criteria, but there is no information provided about performance status or organ function to assess other eligibility requirements.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1424": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 58-year-old female, which meets the age criteria of \u226518 years.\n\nShe has been diagnosed with a left lung mass and a solitary mass in the right frontal lobe of the brain. This suggests she likely has melanoma with brain metastases, which meets the criteria of \"AJCC Stage IV (any T, any N, M1c) histologically confirmed melanoma or unknown primary melanoma. Patients must have at least 1 radiological definitive brain metastasis that is \u2265 5mm and \u226440mm measurable per RECIST version 1.1 guidelines.\"\n\nThere is no mention of her receiving any prior treatment, so she meets the criteria of \"No prior localised treatment for brain metastases (eg. surgery or radiotherapy).\"\n\nShe is described as asymptomatic, which meets the criteria of \"Neurologically asymptomatic from brain metastases.\"\n\nHer ECOG performance status is not mentioned, but she is described as having only mild exertional dyspnea, suggesting her performance status is likely 0-2.\n\nThere is no information provided about her ability to undergo MRI or her organ function, but these could potentially be evaluated further.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation of her ability to undergo MRI and evaluation of her organ function.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1425": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is for patients with malignant melanoma (a type of skin cancer) with a tumor thickness of at least 1.0mm and evidence of metastases (spread) in the sentinel lymph node.\n\n3. The inclusion criteria specifically state:\n\"Cutaneous melanoma with a tumour thickness of at least 1,00mm\nPositive sentinel node with micro metastases of max. 2mm in diameter\"\n\n4. Based on the patient note, there is no mention of the patient having melanoma or any lymph node involvement. The masses described are in the lung and brain.\n\n5. Therefore, this patient does not meet the inclusion criteria for this particular clinical trial on malignant melanoma.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1426": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is for patients with rectal cancer who are undergoing neoadjuvant chemoradiotherapy.\n\n3. The key inclusion criteria are:\n   - Patients with biopsy-proven confirmed rectal cancer\n   - MRI stage: T3/T4 and/or N1/N0\n   - No contraindication to MRI and PET-CT\n\n4. Based on the patient note, this patient does not have rectal cancer. Instead, she has a lung mass and a brain mass.\n\n5. Therefore, she does not meet the inclusion criteria for this clinical trial on rectal cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1427": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which falls within the age range (18-50 years) specified in the inclusion criteria for both patients and controls.\n\n2. The patient has a solitary mass in the right frontal lobe, which could potentially indicate frontal lobe epilepsy, one of the key inclusion criteria for patients.\n\n3. However, the patient note does not explicitly mention a diagnosis of frontal lobe epilepsy or any history of seizures/epilepsy.\n\n4. The patient note also does not provide information about the patient's handedness, language skills, social insurance status, or scores on the Hospital Anxiety and Depression Scale and Obsessive Compulsive Inventory, which are required for inclusion.\n\n5. There is no information provided about exclusion criteria such as other neurological diseases, mental retardation, pregnancy, or non-MRI suitability.\n\nBased on the limited information provided in the patient note, it is difficult to make a definitive assessment of eligibility. More information would be needed to determine if the patient meets all the inclusion criteria and does not meet any of the exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1428": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old nonsmoker white female, which does not match the inclusion criteria of having COPD or a history of smoking.\n\n2. The patient has a left lung mass and a solitary mass in the right frontal lobe of the brain, which could potentially be lung cancer or brain cancer. However, the trial is specifically looking for patients with non-small cell lung cancer (NSCLC) or small-cell lung cancer (SCLC).\n\n3. There is no mention of the patient being enrolled in the COPDGene Phase 1 or Phase 2 studies, which is an inclusion criterion.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of having COPD or a history of smoking, being enrolled in the COPDGene studies, and having a confirmed diagnosis of NSCLC or SCLC.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1429": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass found on chest x-ray and a solitary mass in the right frontal lobe of the brain found on CT scan.\n\n2. The clinical trial is studying the use of 18F-FSPG PET/CT imaging in patients with newly diagnosed lung cancer or indeterminate pulmonary nodules.\n\n3. The inclusion criteria for the trial are:\n   - Have an indeterminate untreated pulmonary nodule (7-30 mm diameter) on CT, or an indeterminate lung mass (> 30 mm diameter), without prior examinations that establish that the lesion has been stable for two or more years, untreated.\n   - OR have a newly diagnosed, untreated primary lung cancer diameter 7 mm or more.\n   - Be able to give informed consent.\n   - Must agree to undergo clinically indicated biopsy(ies) or a 24-month period of follow-up.\n\n4. Based on the patient note, the patient has a left lung mass, which meets the inclusion criteria of having an indeterminate lung mass > 30 mm diameter.\n\n5. The patient note does not mention any prior examinations establishing the stability of the lung mass, so it can be assumed to be untreated.\n\n6. The patient note does not mention any treatment for the lung mass or brain mass, so they can be considered untreated.\n\n7. The patient note does not provide information about the patient's ability to give informed consent or agree to follow-up procedures.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding the patient's ability to give informed consent and agree to follow-up procedures.",
        "label": 0
    },
    "1430": {
        "output": "To determine the patient's eligibility for the clinical trial \"Ultrathin Bronchoscopy for Solitary Pulmonary Nodules\", let's go through the inclusion criteria:\n\n1. Pulmonary nodule on a recent CT: The patient note mentions that a CT scan showed a left lung mass, which satisfies this criterion.\n\n2. Non-visible on standard-size bronchoscopy: The patient note does not mention whether a standard bronchoscopy was performed or if the lung mass was visible during such a procedure. Without this information, it is difficult to determine if the patient meets this criterion.\n\nSince one of the inclusion criteria cannot be definitively confirmed based on the provided patient note, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1431": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which meets the age criteria of being 40 years or older.\n\n2. However, the clinical trial is specifically looking at patients with interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). The patient note does not mention the patient having either of these conditions.\n\n3. The patient note mentions a left lung mass and a solitary mass in the right frontal lobe of the brain, but these do not necessarily indicate ILD or IPF.\n\n4. There is no mention of the patient having a connective tissue disorder (CTD) or COPD, which are also part of the inclusion criteria.\n\nBased on the information provided in the patient note, this patient does not seem to meet the inclusion criteria for this particular clinical trial on the prevalence of lung cancer in patients with ILD.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "1432": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female with a left lung mass and a solitary mass in the right frontal lobe of the brain.\n\n2. The clinical trial is for early rectal adenocarcinoma and involves neoadjuvant chemoradiotherapy followed by a radiotherapy boost.\n\n3. The inclusion criteria specifically mention:\n   - Adenocarcinoma of the rectum\n   - Classified clinically as T2, T3a, T3b\n   - Tumor size < 5 cm\n   - < half rectal circumference\n   - N0-N1 (lymph node involvement)\n   - M0 (no distant metastasis)\n   - Operable patient\n   - Tumor accessible for endocavitary contact X-ray brachytherapy\n   - Distance from lower tumor border to anal verge \u2264 10cm\n   - Age \u2265 18 years\n\n4. Based on the patient note, this patient does not have rectal cancer. Instead, they have a lung mass and a brain mass.\n\n5. Therefore, this patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1433": {
        "output": "To determine the patient's eligibility for the clinical trial \"Low-dose Computed Tomography Screening for Lung Cancer in Relatives With Family History of Lung Cancer\", let's go through the inclusion criteria:\n\n1. Relatives of lung cancer patients: The patient note does not mention if the patient has any relatives with lung cancer, so this criterion cannot be evaluated.\n\n2. Age older than 55 years old or age older than the age of onset of lung cancer proband if the family members were less than 55 years old: The patient is 58 years old, which meets this age criterion.\n\n3. Compulsory signing of the consent agreement after understanding the purpose of the study and the exposure to radiation: This criterion cannot be evaluated based on the provided information.\n\nSince one of the inclusion criteria cannot be evaluated (having relatives with lung cancer), and another criterion is not mentioned (signing the consent agreement), it is difficult to make a definitive assessment of the patient's eligibility.\n\nHowever, based on the available information, the patient meets the age criterion and has a lung mass, which could potentially be lung cancer. Therefore, it would be reasonable to consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1434": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 58-year-old female, which does not match the inclusion criteria for prostate cancer.\n2. The patient has a lung mass and a brain mass, but the trial is specifically for metastatic prostate cancer.\n3. There is no mention of the patient having prostate cancer or being diagnosed with prostate adenocarcinoma.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the \"Stereotactic Radiotherapy for Oligometastatic Prostate Cancer\" trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1435": {
        "output": "To determine the patient's eligibility for the \"Watch the Spot Trial\" clinical trial, let's go through the inclusion criteria:\n\n1. Aged \u226535 years: The patient is 58 years old, so they meet this criterion.\n\n2. At least one nodule measuring \u226415 mm in average diameter on chest CT: The patient note mentions a left lung mass found on chest x-ray, but it does not specify the size of the nodule. Additional information would be needed to confirm if the nodule meets the size criterion.\n\nSince the patient meets the age criterion but the nodule size is not specified, I would consider referring this patient to the clinical trial upon further investigation to determine the nodule size.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1436": {
        "output": "To determine the patient's eligibility for the \"Strong Heart Study\" clinical trial, let's go through the details step-by-step:\n\nThe patient is a 72-year-old man presenting with the following:\n- Increasing calf pain when walking uphill, gradually worsening over the past 3 months\n- History of uncomplicated myocardial infarction 2 years ago\n- Transient ischemic attack 6 months ago\n- Worsening blood pressure despite medication (diltiazem, hydrochlorothiazide, propranolol)\n- Currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin\n- Physical exam findings: Blood pressure 151/91 mmHg, right carotid bruit, diminished lower extremity pulses\n\nThe clinical trial \"Strong Heart Study\" aims to determine morbidity and mortality from cardiovascular disease among American Indians and compare cardiovascular disease risk factors among different Indian groups.\n\nThe inclusion criteria for this trial are: \"No eligibility criteria\"\n\nSince there are no specific eligibility criteria mentioned, and the patient appears to have cardiovascular disease risk factors and history, it is highly likely that this patient would be eligible for the \"Strong Heart Study\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1437": {
        "output": "To determine the patient's eligibility for the clinical trial \"Natural History of Peripheral Arterial Disease\", let's go through the details:\n\nThe patient note describes a 72-year-old man with the following relevant information:\n- Increasing calf pain when walking uphill (symptom of peripheral arterial disease)\n- History of myocardial infarction and transient ischemic attack\n- Uncontrolled hypertension\n- Diminished pulses in the lower extremities\n\nThe clinical trial is studying the natural history and progression of peripheral arterial disease (PAD) in patients with large vessel PAD or isolated small vessel PAD.\n\nThe inclusion criteria for the trial are: \"No eligibility criteria\"\n\nBased on the patient's symptoms and history, which suggest the presence of PAD, and the fact that there are no specific eligibility criteria for the trial, this patient would be a good candidate for enrollment.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1438": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man with symptoms of peripheral vascular disease (PVD), including calf pain when walking uphill, worsening blood pressure, and diminished pulses in the lower extremities.\n\n2. The clinical trial is studying the relationship between homocysteine levels and the progression of atherosclerosis, specifically peripheral vascular disease.\n\n3. The inclusion criteria for the trial are not specified, so in theory, any patient could be eligible.\n\n4. Given the patient's symptoms and medical history suggestive of PVD, and the trial's focus on PVD progression, this patient seems like a good potential candidate for the study.\n\n5. However, since the inclusion criteria are not provided, it's difficult to definitively assess eligibility without further information.\n\nTherefore, based on the information given, I would consider the following assessment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1439": {
        "output": "To determine the patient's eligibility for the clinical trial \"Exercise Training for Patients With Poor Leg Circulation\", let's go through the inclusion criteria:\n\n1. Group I (PAD patients):\n   - Diagnosis of PAD (acute or chronic occlusive arterial disease), with or without diabetes mellitus\n     - The patient note does not explicitly mention a diagnosis of PAD, but it describes symptoms suggestive of poor leg circulation (calf pain when walking uphill, cool lower extremities, diminished pulses).\n   - Positive Edinburgh Claudication Questionnaire\n     - The patient note does not provide information about this questionnaire.\n   - Fontaine stage IIa only (mild claudication, walking distance > 200 feet)\n     - The patient note does not specify the walking distance, but it mentions increasing calf pain when walking uphill, which could be indicative of mild claudication.\n   - Ambulatory, without assistive devices\n     - The patient note does not mention the use of assistive devices, so this criterion is likely met.\n   - Calf muscle claudication within 10 minutes of treadmill walking and calf muscle exercise\n     - The patient note does not provide information about treadmill walking or calf muscle exercise.\n\n2. Group II (normal control/reference subjects):\n   - Healthy adults, matched by age and sex to PAD subjects\n     - The patient note describes a 72-year-old man with a history of myocardial infarction and transient ischemic attack, which would likely exclude him from the control group.\n\nBased on the available information, it is difficult to determine with certainty if the patient meets all the inclusion criteria for Group I (PAD patients). While some criteria are potentially met, there is not enough information to confirm others, such as the Edinburgh Claudication Questionnaire and the specific walking distance.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1440": {
        "output": "To determine the patient's eligibility for the clinical trial \"Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension\", let's go through the inclusion criteria one by one:\n\n1. Postmenopausal women: The patient note does not mention the gender or menopausal status of the patient. However, it does state that the patient is a 72-year-old man, which would not meet this inclusion criterion.\n\n2. Mild to moderate hypertension: The patient note mentions that the patient's blood pressure has worsened over the past month despite being on multiple antihypertensive medications, and the current blood pressure reading is 151/91 mm Hg, which would be considered hypertension.\n\n3. Statin therapy or LDL\u2264 4.1 mmol/L: The patient note does not provide any information about the patient's lipid profile or statin therapy.\n\nBased on the available information, the patient does not meet the first inclusion criterion of being a postmenopausal woman. Additionally, there is not enough information provided to determine if the patient meets the third inclusion criterion regarding statin therapy or LDL levels.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1441": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"The Burden of Peripheral Artery Occlusion Disease and Associated Factors in Peritoneal Dialysis Patients,\" the patient does not appear to be eligible for this trial.\n\nThe key points are:\n\n1. The patient is not mentioned to be receiving peritoneal dialysis, which is a requirement for inclusion in this trial.\n2. The patient's symptoms and medical history suggest peripheral artery disease, but the trial is specifically focused on evaluating the burden of peripheral artery occlusion disease in peritoneal dialysis patients.\n\nTherefore, based on the available information, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1442": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. 18 years of age: The patient is 72 years old, so this criterion is met.\n\n2. Patients with stage II systolic hypertension: The patient's blood pressure is 151/91 mm Hg, which falls under stage II hypertension (systolic BP \u2265 160 mm Hg or diastolic BP \u2265 100 mm Hg). However, the criterion specifically mentions \"stage II systolic hypertension,\" which means a systolic BP \u2265 160 mm Hg. The patient's systolic BP is 151 mm Hg, so this criterion is not fully met.\n\n3. If female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study: The patient is a 72-year-old man, so this criterion is not applicable.\n\nBased on the information provided, the patient does not fully meet the inclusion criteria for this clinical trial due to not having stage II systolic hypertension (systolic BP \u2265 160 mm Hg).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1443": {
        "output": "To determine the patient's eligibility for the clinical trial \"Treatment of Orthostatic Intolerance\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n- Chronic symptoms (> 6 months) with standing upright\n\nFrom the patient note, we can see that the patient complains of \"increasing calf pain when walking uphill\" and that \"The symptoms have gradually increased over the past 3 months.\" This suggests that the patient may be experiencing symptoms related to standing upright, but the duration of 3 months does not meet the criteria of chronic symptoms for more than 6 months.\n\nAdditionally, the patient note does not explicitly mention orthostatic intolerance or symptoms related to standing upright, such as dizziness, lightheadedness, or increased heart rate upon standing.\n\nBased on the information provided, there is not enough evidence to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1444": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man, which falls within the age range of 18-80 years specified in the inclusion criteria.\n\n2. The patient does not appear to have a diabetic ulcer or venous insufficiency ulcer, which are required for inclusion in this trial.\n\n3. No information is provided about the size, grade, stage, or location of any wounds the patient may have.\n\n4. The patient has diminished pulses at the dorsalis pedis, which may or may not meet the inclusion criteria of \"Palpable pulses in the Posterior Tibial and the Dorsalis Pedis arteries\".\n\n5. No information is provided about the patient's Ankle-Brachial Index or the duration of any wounds.\n\nBased on the limited information provided in the patient note, there is not enough evidence to determine if the patient meets all of the inclusion criteria for this clinical trial on chronic wound management.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1445": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man, which meets the age criteria of \u2265 21 years old.\n\nHe complains of increasing calf pain when walking uphill, which has gradually increased over the past 3 months. This suggests he has symptoms of intermittent claudication (leg pain when walking due to poor blood flow) for at least 6 months, meeting that criteria.\n\nHe had a previous myocardial infarction and transient ischemic attack, indicating he likely has peripheral arterial disease (PAD) secondary to atherosclerosis for at least 6 months.\n\nThe physical exam findings of diminished pulses in the legs also point towards PAD with blocked leg arteries causing his claudication symptoms.\n\nWhile the specific arteries involved are not mentioned, the calf claudication symptoms suggest involvement of the popliteal or infrapopliteal arteries.\n\nBased on the information provided, this patient seems to meet all the key inclusion criteria for the stem cell trial for severe intermittent claudication.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1446": {
        "output": "To determine the patient's eligibility for the clinical trial \"Rajavithi Health Promotion Project (Population Base Cohort),\" let's go through the inclusion criteria one by one:\n\n1. Age 16 years or more: The patient is 72 years old, which meets this criterion.\n\n2. Informed consent: There is no information provided about whether the patient has given informed consent or not. We would need to obtain informed consent from the patient to enroll them in the trial.\n\n3. Living in selected community (Health Promotion area of Rajavithi Hospital): There is no information provided about where the patient resides. We would need to confirm if the patient lives in the selected community for the trial.\n\nBased on the information provided in the patient note, we cannot definitively determine if the patient meets all the inclusion criteria. While the patient's age meets the age requirement, we do not have information about informed consent or the patient's residence.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1447": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man, so he meets the age criteria of being > 18 years old.\n\nHe is complaining of increasing calf pain when walking uphill, which could be a symptom of critical limb ischemia. However, the note does not explicitly state that he has been diagnosed with critical limb ischemia or provide details on the Fontaine stage or Rutherford category.\n\nThe note mentions he had a previous myocardial infarction and transient ischemic attack, but does not provide information on the patency of his iliac, femoral, popliteal or crural arteries as required by the inclusion criteria.\n\nThere are no details provided about the presence of stenotic or occluded infrapopliteal arteries with lesion length \u2264 60 mm and diameter 2-4 mm.\n\nBased on the limited information provided in the patient note, I cannot definitively determine if this patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1448": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patient \u2265 18 years old: The patient is 72 years old, so this criterion is met.\n\n2. Coronary or peripheral vascular intervention: The patient note does not explicitly mention if the patient underwent a coronary or peripheral vascular intervention. However, the mention of \"increasing calf pain when walking uphill\" and \"diminished pulses at the dorsalis pedis\" suggests the possibility of peripheral vascular disease.\n\n3. 6 French arterial sheath used: There is no information provided about the use of an arterial sheath.\n\n4. Overnight hospitalization following procedure: There is no information provided about an overnight hospitalization following a procedure.\n\nBased on the available information, it is unclear if the patient meets all the inclusion criteria. While the patient's age meets the criterion, there is no definitive information about whether the patient underwent a coronary or peripheral vascular intervention, the use of an arterial sheath, or an overnight hospitalization following a procedure.\n\nTherefore, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1449": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient must have a venous leg ulcer: The patient note does not mention a venous leg ulcer, so this criterion is not met.\n\n2. Participants, either men or women are between 18 and 85 years of age: The patient is 72 years old, so this criterion is met.\n\n3. Clinical presentation of venous insufficiency demonstrated by Doppler: There is no mention of venous insufficiency or Doppler findings in the patient note.\n\n4. Ankle-Brachial Index > 0.7 by Doppler: No Ankle-Brachial Index or Doppler findings are provided.\n\n5. Good palpable pulses in the Posterior Tibial and the Dorsalis Pedis arteries: The note mentions \"diminished pulses at the dorsalis pedis,\" which suggests this criterion may not be met.\n\n6. Wound present for at least 6 weeks prior to enrolment: There is no mention of a wound or its duration.\n\n7. Wound length is in the range of: 1.5 - 7 centimeters: No wound details are provided.\n\n8. The necrotic tissue area is at least 20% of wound area: No wound details are provided.\n\n9. Wound San Antonio classification: Grade 1 or 2, Stage A or B: No wound classification is provided.\n\n10. Wound location: foot or calf, at a location where the device can be attached properly: No wound location is specified.\n\n11. Participant understands the nature of the procedure and provides written informed consent prior to any study procedure: This cannot be determined from the patient note.\n\n12. Women of child bearing potential must use adequate birth-control precautions: The patient is a 72-year-old man, so this criterion is not applicable.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets the inclusion criteria for this clinical trial. Several key criteria related to the presence, characteristics, and location of a venous leg ulcer are not addressed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1450": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 72-year-old man, which falls within the age range specified in the inclusion criteria (men aged 50-80).\n\nHe has a history of myocardial infarction 2 years ago, which would exclude him from the trial based on the exclusion criteria \"Existing cardiovascular disease (stroke, transient ischaemic attack, myocardial infarction or angina)\".\n\nHe also had a transient ischemic attack 6 months ago, which further excludes him based on the same criteria.\n\nWhile his blood pressure of 151/91 mm Hg is not explicitly stated as an exclusion criteria, it is quite high and may be considered as having \"clinical indications for treatment with antihypertensive drugs\", which is an exclusion criteria.\n\nHe is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin, which would exclude him based on the criteria \"Already taking antihypertensive drugs, aspirin or statins\".\n\nBased on the information provided, this patient would not be eligible for the clinical trial due to multiple exclusion criteria being met.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1451": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man presenting with increasing calf pain when walking uphill, gradually worsening over the past 3 months. This matches the inclusion criteria of \"Limb ischemia with claudication\".\n\n2. He has a history of myocardial infarction and transient ischemic attack, which could potentially complicate treatment, but does not explicitly exclude him from the trial.\n\n3. His blood pressure is elevated at 151/91 mmHg despite medication, which could be a concern but is not an explicit exclusion criterion.\n\n4. Physical exam findings of diminished pulses and cool extremities are consistent with limb ischemia.\n\n5. The trial is specifically looking for patients with severe leg ischemia who are not candidates for surgical revascularization.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria of having severe limb ischemia with claudication and being a poor candidate for surgical revascularization. While his medical history and elevated blood pressure are potential concerns, they do not explicitly exclude him.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1452": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) Aged 40 or older, male or female\nThe patient is a 72-year-old man, so he meets this criterion.\n\n2) 6-mo. history of walking limitation or symptoms of intermittent claudication (IC) in at least 1 lower limb, severity of which has not changed in the past 3 mo. and diagnosed by principal investigator as clinically stable Fontaine Stage II peripheral artery disease (PAD)\nThe patient complains of increasing calf pain when walking uphill, which has gradually increased over the past 3 months. This suggests symptoms of intermittent claudication, which meets this criterion.\n\n3) Diagnosis of PAD secondary to atherosclerosis\nThe patient note does not explicitly state the diagnosis, but the symptoms and history suggest peripheral artery disease secondary to atherosclerosis.\n\n4) If ankle-brachial index (ABI) is > 1.3 or cannot be measured in either leg, vascular etiology documented by toe-brachial index (TBI) \u2264 0.7 in at least 1 leg\nThere is no information provided about ABI or TBI measurements.\n\n5) Claudication severity, meds. for the treatment of coronary artery disease (CAD), PAD and IC, and exercise habits should be clinically stable for 3 mo. prior to Screening (SCRN) and during study. Pt. is not likely to change smoking and/or exercise habits during study\nThe patient's symptoms have gradually increased over the past 3 months, so the claudication severity may not be stable. There is no information about exercise habits or smoking.\n\n6) On an exercise treadmill test (ETT), peak walking time (PWT) of at least 1 min., but no more than 12 min. at Baseline\nThere is no information provided about an exercise treadmill test or peak walking time.\n\n7) Willing and able to discontinue Pletal or Trental for 21 days before SCRN and during study\nThere is no mention of the patient taking Pletal or Trental.\n\n8) Antihypertensive therapy, cholesterol-lowering therapy, chronic oral nitrates, and diabetic therapy have been stable for 30 days prior to SCRN\nThe patient is taking isosorbide dinitrate (a nitrate), hydrochlorothiazide (an antihypertensive), and aspirin, but there is no information about whether these have been stable for 30 days.\n\n9) Willing and able to provide written, signed, informed consent after the nature of the study has been explained and prior to any research-related procedures\nThere is no information provided about the patient's willingness or ability to provide informed consent.\n\n10) Willing and able to comply with all study-related procedures\nThere is no information provided about the patient's willingness or ability to comply with study procedures.\n\n11) Sexually active patients must use an acceptable method of contraception while participating in the study\nThere is no information provided about the patient's sexual activity or use of contraception.\n\n12) Females of childbearing potential must have a negative pregnancy test at SCRN and have additional pregnancy tests during the study\nThis criterion is not applicable since the patient is a male.\n\nBased on the information provided in the patient note, there are several inclusion criteria that cannot be definitively determined, such as ABI/TBI measurements, exercise treadmill test results, stability of medications, willingness to provide informed consent and comply with study procedures, and sexual activity/contraception use.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1453": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man, so he meets the age criteria of being 18 years or older.\n\nThe patient is described as having worsening hypertension, with a blood pressure reading of 151/91 mmHg. This meets the inclusion criteria of having stage 2 hypertension, defined as a systolic blood pressure \u2265160 mmHg.\n\nHowever, there is no mention of the patient's ethnicity or race in the note. The trial specifically requires participants to be of African American background.\n\nBased on the information provided, while the patient meets some of the inclusion criteria, the lack of information about ethnicity/race makes it uncertain if they would be eligible for this particular trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their ethnicity/race.",
        "label": 0
    },
    "1454": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man complaining of increasing calf pain when walking uphill, which has gradually increased over the past 3 months. This aligns with the inclusion criteria of \"an obliterating lower extremity atherosclerosis IIB a stage (on Fontaine classification)\".\n\nThe note mentions he has diminished pulses at the dorsalis pedis, which matches the criteria of \"pulse absence on \u0430\u0430. dorsalis pedis, tibialis posterior, poplitea\".\n\nThere is no mention of ischemia at rest or necrotic changes, fitting the criteria of \"absence of a ischemia in a rest and necrotic changes\".\n\nThe note does not specify the exact location of the arterial lesion, but it seems to be affecting the lower extremities, potentially matching the criteria of \"mainly distal form of disease (a lesion of a superficial femoral artery, a popliteal artery, anticnemion arteries)\".\n\nThere is no information provided about previous procedures like lumbar sympathectomy or tibial bone osteoperforations.\n\nThe patient's smoking status is not mentioned.\n\nBased on the available information, this patient appears to meet several of the key inclusion criteria for the clinical trial, particularly the lower extremity ischemia and diminished pulses. However, there are some criteria that cannot be definitively assessed from the provided note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1455": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Male or female subject 18 to 90 years, of any race.\nThe patient is a 72-year-old man, so he meets this criterion.\n\n2. Patients with proven Peripheral Arterial Disease (PAD) in Doppler Ultrasound and Ankle-Brachial Pressure Index (ABPI \u2264 0.9 in one leg)\nThe patient note does not mention any Doppler Ultrasound or ABPI results, so we cannot confirm if he meets this criterion.\n\n3. Subject with stable (>3 month) PAD Fontaine Stage II.\nThe patient note mentions that the patient complains of increasing calf pain when walking uphill, which has gradually increased over the past 3 months. This could be indicative of PAD Stage II, but it is not explicitly stated.\n\n4. Aortoiliac vessels with no significant hemodynamic disturbances, as confirmed by recent (<30 days) clinical examination\nThere is no information provided about the patient's aortoiliac vessels or any recent clinical examination.\n\n5. Subject has intermittent claudication and claudication pain of the calf\nThe patient note states that the patient complains of increasing calf pain when walking uphill, which could be indicative of intermittent claudication.\n\n6. Subject has stable intermittent claudication (>3 month and not more than one year) with initial claudication distance not more than 250 meters, as determined by treadmill test (3.2 km/h, 10% grade)\nThe patient note does not provide any information about the patient's initial claudication distance or a treadmill test.\n\n7. Subject willing to participate as evidenced by signing the written informed consent.\nThere is no information provided about the patient's willingness to participate or signing an informed consent.\n\n8. Treatment with Aspirin or Clopidogrel for at least 7 days\nThe patient note mentions that the patient is currently taking aspirin, so he meets this criterion.\n\n9. Willingness to undergo standardized walking exercise\nThere is no information provided about the patient's willingness to undergo standardized walking exercise.\n\nBased on the information provided in the patient note, there are several inclusion criteria that cannot be confirmed or ruled out. Therefore, further investigation would be needed to determine the patient's eligibility for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1456": {
        "output": "To determine the patient's eligibility for the clinical trial \"Hyperspectral Imaging Pre and Post Endovascular Intervention\", let's go through the inclusion criteria one by one:\n\n1. \"Patients with established diagnosis of lower limb ischemic based on their symptoms of claudication, rest pain, non-healing ulcers or gangrene and other vascular laboratory tests that are currently used to make this diagnosis and have been scheduled for endovascular revascularization.\"\n\nThe patient note mentions that the 72-year-old man complains of increasing calf pain when walking uphill, which could be a symptom of claudication (leg pain due to poor blood circulation). The note also mentions diminished pulses at the dorsalis pedis, which is a sign of lower limb ischemia. However, it is not explicitly stated that the patient has been scheduled for endovascular revascularization.\n\n2. \"Age group between 50-85\"\nThe patient is 72 years old, which falls within the age range specified in the inclusion criteria.\n\n3. \"Gender - Male or Female\"\nThe patient is a male, which meets this criterion.\n\n4. \"Race - all race and ethnicities\"\nThis criterion is met as the patient's race or ethnicity is not specified.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria, but it is unclear if they have been scheduled for endovascular revascularization, which is a key requirement. Therefore, I would consider the following assessment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1457": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man, which meets the age criteria of being over 40 years old.\n\nHe complains of increasing calf pain when walking uphill, which is likely due to claudication (leg pain from peripheral arterial disease). This matches the inclusion criteria of having claudication secondary to lower extremity atherosclerotic arterial disease.\n\nThe note mentions he had a myocardial infarction 2 years ago and a transient ischemic attack 6 months ago, indicating he has cardiovascular disease.\n\nHis medications diltiazem, hydrochlorothiazide, propranolol, isosorbide dinitrate, and aspirin are not explicitly listed as exclusion criteria.\n\nThe only potential issue is that it does not explicitly state he has had peripheral arterial disease for more than 6 months, which is an inclusion criteria.\n\nOverall, this patient seems to largely meet the main inclusion criteria of having peripheral arterial disease with claudication symptoms. The duration criteria is unclear but could potentially be met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into duration of peripheral arterial disease.",
        "label": 0
    },
    "1458": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Has a Rutherford Clinical Category Score of 1 - 6. (The patient's Rutherford score is not provided, so this cannot be assessed)\n2. Has evidence of \u2265 50% stenosis or occlusion in the superficial femoral, popliteal, anterior tibial, posterior tibial and/or peroneal arteries, confirmed by angiography. (The patient note mentions \"calf pain when walking uphill\" which could indicate peripheral artery disease, but no specifics on location or severity are provided)\n3. Has identifiable distal target vessel which upon completion of the intervention, is anticipated to provide re-constitution of blood flow to the foot. (Not enough information is provided to assess this)\n4. Exchangeable guidewire must cross lesion(s), with ability of catheter to cross lesion. (Not applicable at this stage)\n5. Each discrete target lesion's length is \u2264 20 cm. (Lesion length not provided)\n6. Reference vessel diameter is \u2265 1.5 mm and \u2264 7 mm. (Vessel diameter not provided)\n\nExclusion Criteria:\n1. Has surgical or endovascular procedure of the target vessel within 14 days prior to the index procedure. (No information provided)\n2. Has any planned surgical intervention or endovascular procedure within 30 days after the index procedure. (No information provided)\n3. Has had a previous peripheral bypass affecting the target limb. (No information provided)\n4. Has end-stage renal disease defined as undergoing hemodialysis for kidney failure. (No indication of this)\n5. Has presence of severe calcification in target lesion(s). (No information provided on calcification)\n6. Has in-stent restenosis of the target lesion. (No information provided on prior stenting)\n7. Has an aneurysmal target vessel. (No indication of aneurysm)\n8. Has significant stenosis or occlusion of inflow tract that has not been revascularized prior to treatment of the target vessel. (No information provided on inflow disease)\n9. Has perforation, dissection or other injury of the access or target vessel requiring additional stenting or surgical intervention prior to enrollment. (No indication of this)\n10. Has disease that precludes safe advancement of the SilverHawk/TurboHawk device to the target lesion(s). (Cannot assess at this stage)\n11. Has had a previous amputation above the metatarsal line on the target limb. (No indication of prior amputation)\n\nIn summary, while the patient has symptoms potentially suggestive of peripheral artery disease, there is insufficient information provided in the note to definitively assess eligibility for this specific trial based on the inclusion/exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1459": {
        "output": "Based on the given patient note and the clinical trial information, this patient would not be eligible for the clinical trial titled \"Cerebral Near Infrared Spectroscopy During Blood Sampling From a Peripheral Artery Catheter in Preterm Infants\".\n\nThe key reasons are:\n\n1. The patient is a 72-year-old man, while the inclusion criteria specify that the participants should be preterm infants (Gestational Age <37+0 weeks).\n\n2. The patient note does not mention the patient having a peripheral arterial catheter, which is another inclusion criterion for the trial.\n\nThe patient note describes a 72-year-old man with cardiovascular issues, such as a previous myocardial infarction, transient ischemic attack, and worsening blood pressure. However, these conditions are not relevant to the inclusion criteria of the given clinical trial, which focuses on preterm infants and cerebral oxygenation during blood sampling from a peripheral artery catheter.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1460": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effects of Individualized Exercise Training in Patients With Peripheral Arterial Disease\", let's go through the inclusion criteria:\n\n1. Peripheral arterial disease post surgery > 1 month\nThe patient note does not explicitly mention if the patient had surgery for peripheral arterial disease, but it does state that the patient is experiencing increasing calf pain when walking uphill, which is a symptom of peripheral arterial disease. However, without confirmation of surgery, this criterion cannot be definitively met.\n\n2. No discharge of surgical incision\nThere is no information provided about any surgical incisions or discharge.\n\n3. Intermittent claudication post invasive treatment\nThe patient is experiencing calf pain when walking uphill, which could be indicative of intermittent claudication, a symptom of peripheral arterial disease. However, there is no mention of any invasive treatment.\n\nBased on the information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for this clinical trial. While the patient appears to have symptoms of peripheral arterial disease, there is no confirmation of surgery or invasive treatment, which are required by the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1461": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man with hypertension that is not well-controlled on his current medications (diltiazem, hydrochlorothiazide, propranolol, isosorbide dinitrate). His blood pressure reading of 151/91 mmHg meets the inclusion criteria of having a systolic BP \u2265160 and \u2264190 mmHg.\n\nThe trial requires participants to be willing to discontinue current antihypertensive medications up to 3 weeks before enrollment. This is not explicitly stated for this patient.\n\nThere are no details provided about the patient's clinical laboratory test results or whether they are within the reference range as required.\n\nThe patient is not stated to be female, so the criteria about contraception do not apply.\n\nBased on the available information, I would assess this patient as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore details would be needed about his willingness to discontinue medications temporarily and his laboratory test results to fully assess eligibility. But his uncontrolled hypertension meets one of the key inclusion criteria.",
        "label": 0
    },
    "1462": {
        "output": "Okay, let's go through the inclusion criteria for the \"Gene Therapy for Painful Diabetic Neuropathy\" clinical trial and assess the eligibility of the patient based on the provided note.\n\nAge \u2265 18 years to 75 years: The patient is 72 years old, which meets this criterion.\n\nDocumented history of Type I or II diabetes with current treatment control (glycosylated hemoglobin A1c of \u2264 10.0%): The patient note does not mention diabetes or glycosylated hemoglobin A1c levels, so this criterion cannot be evaluated.\n\nDiagnosis of painful diabetic peripheral neuropathy in both lower extremities: The patient note mentions increasing calf pain when walking uphill, but it does not specify if this is due to diabetic neuropathy or any other condition.\n\nThe physical examination component of the Michigan Neuropathy Screening Instrument Score (MNSI) is \u2265 3 at Screening: The patient note does not provide information about the MNSI score.\n\nVisual analog scale (VAS) score of \u2265 4 cm at Screening (0 cm = no pain - 10 cm worst imaginable pain): The patient note does not provide information about the VAS score for pain.\n\nStable treatment of diabetes for at least 3 months with no anticipated changes in medication regimen, and no new symptoms associated with diabetes: The patient note does not mention diabetes or any treatment for it.\n\nLower extremity pain for at least 6 months: The patient note mentions increasing calf pain when walking uphill over the past 3 months, which does not meet this criterion.\n\nIf female of childbearing potential, negative pregnancy test at screening and using acceptable method of birth control during the study: The patient is a 72-year-old man, so this criterion is not applicable.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets the inclusion criteria for this clinical trial. Some key information, such as the presence of diabetes, diabetic neuropathy, and pain severity, is missing.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1463": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man with peripheral vascular disease and critical limb ischemia, which matches the first inclusion criteria \"Atherosclerotic ischemic peripheral vascular disease or Thromboangiitis Obliterans with Critical Limb Ischemia (Fontaine stages III and IV)\".\n\nThe note mentions he has \"diminished pulses at the dorsalis pedis\", which suggests his ankle brachial index (ABI) is likely \u2264 0.7, satisfying the second part of the first inclusion criteria.\n\nHe is over 18 years old, satisfying the fourth criteria.\n\nThe note does not explicitly state if he is a non-surgical candidate for revascularization, but it mentions he had a previous myocardial infarction and transient ischemic attack, suggesting he may not be an ideal surgical candidate.\n\nThe note states he is on aspirin therapy, satisfying part of the maximal medical therapy requirement in the sixth criteria. However, it does not mention if he has stopped smoking, has controlled diabetes/HbA1c, hyperlipidemia, or hypertension.\n\nOverall, while the patient seems to meet some of the key inclusion criteria like peripheral vascular disease, critical limb ischemia, and age, there are some unclear areas like surgical candidacy and maximal medical therapy optimization.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1464": {
        "output": "To determine the patient's eligibility for the clinical trial \"Long-term Pleiotropic Effect of Statins in Patients With Peripheral Arterial Disease,\" let's go through the inclusion criteria:\n\n1. Patients at the time of diagnosis of Fontaine grade II peripheral arterial disease (PAD), confirmed by hemodynamic evaluation (Doppler ultrasound):\nThe patient note mentions that the patient complains of increasing calf pain when walking uphill, which is a symptom of peripheral arterial disease (PAD). However, there is no explicit mention of the Fontaine grade or confirmation by Doppler ultrasound.\n\n2. Over 18 years old:\nThe patient is 72 years old, which meets this criterion.\n\nBased on the information provided in the patient note, it is unclear if the patient meets the first inclusion criterion regarding the diagnosis and confirmation of Fontaine grade II PAD. Therefore, further investigation would be needed to determine the patient's eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1465": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man with a history of myocardial infarction 2 years ago and transient ischemic attack 6 months ago. This meets the inclusion criteria of \"Documented acute coronary syndrome (Unstable angina, non-Q-wave myocardial infarction, Q-wave myocardial infarction) or/and documented ischemic stroke/transient ischemic attack (IS/TIA)\".\n\n2. The patient is complaining of increasing calf pain when walking uphill, which could be a symptom of peripheral arterial disease (PAD). However, the trial is looking to screen for PAD in patients not known to have it at the time of enrollment.\n\n3. Based on the information provided, there are no clear indications that the patient has been diagnosed with PAD yet. The symptoms and diminished pulses suggest PAD may be present, but a formal diagnosis is not mentioned.\n\n4. Given that the patient meets the inclusion criteria of documented ACS/IS/TIA and is not explicitly stated to have a PAD diagnosis at enrollment, I would consider referring this patient to the clinical trial upon further investigation to confirm PAD status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1466": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man, which does not meet the age inclusion criteria of 20-30 years old for this clinical trial.\n\n2. The patient has a history of myocardial infarction and transient ischemic attack, which excludes him from being a healthy volunteer with no cardiac or peripheral vascular diseases as required by the inclusion criteria.\n\n3. There is no information provided about whether the patient is willing to enter the study and sign an informed consent.\n\nBased on the available information, this patient does not meet the key inclusion criteria of age and health status for this clinical trial on limb ischemic preconditioning in healthy volunteers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1467": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man, which meets the age criteria (> 40 years) for both healthy participants and peripheral arterial disease participants in the clinical trial.\n\n2. The patient has a history of myocardial infarction and transient ischemic attack, which suggests he has peripheral arterial disease. This meets the inclusion criteria for peripheral arterial disease participants.\n\n3. The patient is currently taking medications (isosorbide dinitrate, hydrochlorothiazide, and aspirin), and his medication profile has been stable for at least 3 months, which meets the inclusion criteria for peripheral arterial disease participants.\n\n4. The patient's physical examination findings (diminished pulses, cool extremities) are consistent with peripheral arterial disease, further supporting his eligibility.\n\n5. There is no information provided that would exclude the patient based on the exclusion criteria listed.\n\nBased on the information provided, this patient appears to meet the inclusion criteria for peripheral arterial disease participants in the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1468": {
        "output": "Let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note describes a 72-year-old man with calf pain when walking uphill, a history of myocardial infarction and transient ischemic attack, and uncontrolled hypertension. There is no mention of end-stage kidney disease or the need for a kidney transplant.\n\nThe clinical trial is studying the effect of remote ischemic preconditioning on renal function in patients undergoing living donor kidney transplantation.\n\nThe inclusion criteria specifically state:\n1. Subject capable of giving written informed consent, with end-stage kidney disease, who is a suitable candidate for primary kidney transplantation\n2. Living donors\n3. Compatible ABO blood type\n4. PRA < 20%\n\nBased on the information provided in the patient note, there is no indication that this patient has end-stage kidney disease or is a candidate for a kidney transplant. Therefore, he would not meet the primary inclusion criterion for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1469": {
        "output": "To determine the patient's eligibility for the clinical trial \"African American Community Health Project on Cardiovascular Disease\", let's go through the inclusion criteria:\n\nInclusion Criteria:\nAfrican American adults > 18 years old\n\nFrom the patient note, we can see that the patient is a 72-year-old man, so he meets the age criteria of being an adult over 18 years old. However, there is no information provided about the patient's race or ethnicity.\n\nSince the inclusion criteria specifically state \"African American adults\", and we do not have information about the patient's race or ethnicity, we cannot definitively determine if the patient meets this criterion.\n\nTherefore, based on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the patient's race/ethnicity.",
        "label": 0
    },
    "1470": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\n1. Essential hypertensive patient no less than 18 years old\nThe patient is 72 years old and has hypertension, so this criterion is met.\n\n2. Patient who gave informed consent form\nThere is no information provided about whether the patient gave informed consent, so we cannot determine if this criterion is met.\n\nBased on the information provided, the patient meets at least one of the inclusion criteria for the clinical trial. However, since we do not know if the patient provided informed consent, we cannot definitively say if they are eligible or not.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1471": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man, which meets the age criteria of 18-75 years old.\n\nHe has a history of myocardial infarction 2 years ago, which meets the criteria of being diagnosed with coronary heart disease (CHD) and having a history of myocardial infarction.\n\nHis current symptoms of calf pain when walking uphill could be indicative of peripheral artery disease, which is often associated with coronary artery disease.\n\nThe note mentions he has worsening blood pressure despite medication, and hyperlipidemia is one of the inclusion criteria.\n\nHowever, there is no specific mention of his LDL-C levels or whether he meets the hyperlipidemia criteria based on LDL-C values.\n\nThere is also no information provided about CT scan findings of coronary artery stenosis, plaque characteristics, etc. which are required based on the inclusion criteria.\n\nOverall, while the patient meets some of the key criteria like age, history of myocardial infarction and likely has hyperlipidemia, there is not enough information provided to definitively determine if he meets all the inclusion criteria, especially the CT scan requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of LDL-C levels and CT scan findings.",
        "label": 1
    },
    "1472": {
        "output": "To determine the patient's eligibility for the \"Peripheral Perfusion Targeted Fluid Management\" clinical trial, let's go through the inclusion criteria one by one:\n\n1) All adult patients (>18 years)\nThe patient is 72 years old, so this criterion is met.\n\n2) admitted to the intensive care with hemodynamic instability due to severe sepsis\nThere is no mention of the patient being admitted to the intensive care or having severe sepsis, so this criterion is not met.\n\n3) a mean arterial pressure < 65 mmHg\nThe patient's blood pressure is 151/91 mmHg, which corresponds to a mean arterial pressure of around 111 mmHg (calculated as (2 \u00d7 diastolic) + systolic / 3). This is higher than the required 65 mmHg, so this criterion is not met.\n\n4) an arterial lactate concentration > 3.0 mmol/L\nThere is no information provided about the patient's arterial lactate concentration.\n\nBased on the information given, the patient does not meet at least two of the inclusion criteria (hemodynamic instability due to severe sepsis and mean arterial pressure < 65 mmHg). Therefore, it is unlikely that this patient would be eligible for the \"Peripheral Perfusion Targeted Fluid Management\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1473": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n- Male or female: The patient is a 72-year-old man, so he meets this criterion.\n- 60-85 years: The patient is 72 years old, which falls within this age range.\n- Femoro-popliteal stenosis: The patient is complaining of calf pain when walking uphill, which could be a symptom of peripheral arterial disease (PAD) affecting the femoro-popliteal artery. However, the note does not explicitly state that he has femoro-popliteal stenosis.\n- TASC B or C category: The note does not provide information about the TASC category of the patient's stenosis.\n- HBA1c <9%, if diabetic: The note does not mention whether the patient has diabetes or provide an HBA1c value.\n- Creatinine <130\u00b5g/ml: The note does not provide the patient's creatinine level.\n- Blood pressure <160/95mmHg: The patient's blood pressure is 151/91 mm Hg, which meets this criterion.\n- Thrombocyte aggregation inhibitors or coumarine derivatives: The patient is taking aspirin, which is a thrombocyte aggregation inhibitor.\n\nExclusion Criteria:\n- <60 or >85 years: The patient is 72 years old, so he does not meet this exclusion criterion.\n- Stenosis not in femoro-popliteal axis: The note does not specify the location of the stenosis.\n- TASC A or D category: The note does not provide information about the TASC category of the patient's stenosis.\n- HBA1c >9%, if diabetic: The note does not mention whether the patient has diabetes or provide an HBA1c value.\n- Creatinine >130\u00b5g/ml: The note does not provide the patient's creatinine level.\n- Blood pressure >160/95mmHg: The patient's blood pressure is 151/91 mm Hg, so he does not meet this exclusion criterion.\n- Major trauma, malignancy, anti-phospholipid syndrome, relevant hepatic disease, major operation within 1 month of enrolment: The note does not mention any of these conditions for the patient.\n\nBased on the information provided in the patient note, there are some criteria that are not clearly met or excluded, such as the presence of femoro-popliteal stenosis, the TASC category of the stenosis, the patient's HBA1c level (if diabetic), and the patient's creatinine level.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1474": {
        "output": "To determine the patient's eligibility for the clinical trial \"Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography\", let's go through the inclusion criteria:\n\n1. The subject is over 18 years old.\nThe patient is 72 years old, so this criterion is met.\n\n2. Subjects are referred to undergo a peripheral arteriography as part of their routine clinical care.\nThe patient note mentions that the patient is complaining of increasing calf pain when walking uphill, which could indicate peripheral artery disease. However, it does not explicitly state that the patient is referred for a peripheral arteriography.\n\nBased on the information provided, it is unclear if the patient meets the second inclusion criterion. Additional investigation may be needed to determine if the patient is indeed referred for a peripheral arteriography.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1475": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy\" and assess the eligibility of the given patient note.\n\nAge \u2265 18 years to \u2264 75 years: The patient is 72 years old, which meets this criterion.\n\nDocumented history of Type I or II diabetes with current treatment control (glycosylated hemoglobin A1c of \u2264 10.0% at Screening) and currently on oral medication and/or insulin: The patient note does not mention whether the patient has diabetes or is on any diabetes medication. This criterion cannot be evaluated based on the given information.\n\nDiagnosis of painful diabetic peripheral neuropathy in both lower extremities: The patient complains of increasing calf pain when walking uphill, which could be indicative of peripheral neuropathy. However, the note does not explicitly state that the patient has been diagnosed with painful diabetic peripheral neuropathy in both lower extremities.\n\nLower extremity pain for at least 6 months: The note mentions that the patient's symptoms have gradually increased over the past 3 months, which does not meet the 6-month duration criterion.\n\nVisual analog scale (VAS) score of \u2265 40 mm at Initial Screening (0 mm = no pain - 100 mm very severe pain): The patient note does not provide any information about the patient's pain score on a visual analog scale.\n\nSymptoms from the Brief Pain Neuropathy Screening (BPNS) is \u2264 5 point difference between legs at Initial Screening: The patient note does not mention any information about the Brief Pain Neuropathy Screening or the difference in symptoms between legs.\n\nThe average daily pain intensity score of the Daily Pain and Sleep Interference Diary completed after medication wash-out is \u2265 4 with a standard deviation \u2264 2: The patient note does not provide any information about a Daily Pain and Sleep Interference Diary or the patient's pain intensity score.\n\nThe physical examination component of the Michigan Neuropathy Screening Instrument Score (MNSI) is \u2265 3 at Screening: The patient note does not mention the Michigan Neuropathy Screening Instrument Score or any related physical examination findings.\n\nStable treatment of diabetes for at least 3 months with no anticipated changes in medication regimen, and no new symptoms associated with diabetes: As mentioned earlier, the patient note does not indicate whether the patient has diabetes or is on any diabetes treatment.\n\nIf female of childbearing potential, negative urine pregnancy test at screening and using acceptable method of birth control during the study: The patient is a 72-year-old man, so this criterion is not applicable.\n\nBased on the information provided in the patient note, several inclusion criteria for the clinical trial cannot be evaluated due to lack of relevant details. While the patient's age meets the criterion, there is insufficient information about the patient's diabetes status, neuropathy diagnosis, pain duration, pain severity scores, and other specific assessments required for eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1476": {
        "output": "Let's go through the inclusion criteria one by one:\n\n1. Men and non-pregnant, non-lactating women 45 years of age or older\nThe patient is a 72-year-old man, so he meets this criterion.\n\n2. Able to give informed consent and complete scheduled visits\nThere is no information provided about the patient's ability to give consent or complete visits, so I cannot determine if he meets this criterion.\n\n3. Mild-moderate bilateral lower extremity peripheral arterial disease as defined by an ankle-brachial index (ABI measurement of 0.6-0.9. If a subject has baseline claudication symptoms, the symptoms must be stable for the 3 months preceding enrollment.\nThe patient complains of increasing calf pain when walking uphill, which suggests claudication symptoms. However, there is no information provided about the ankle-brachial index or the duration of symptoms, so I cannot determine if he meets this criterion.\n\n4. History of hypertension. Blood pressure at the screening visit must be \u2264160/100 mmHg and \u2265100/60 mmHg for all subjects. If a subject is currently prescribed beta-blocker therapy, BP at the screening visit must be \u2264140/90 mmHg. In addition, heart rate must be \u226555 beats per minute if currently prescribed a beta-blocker and \u226460 beats per minute if not currently prescribed a beta-blocker.\nThe patient has a history of hypertension, and his current blood pressure is 151/91 mm Hg, which falls within the required range. There is no information provided about his heart rate or whether he is currently prescribed a beta-blocker, so I cannot fully determine if he meets this criterion.\n\n5. At least moderate risk for CAD.\nThe patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago, which suggests a moderate risk for coronary artery disease (CAD). Therefore, he likely meets this criterion.\n\nBased on the information provided, the patient appears to meet some of the inclusion criteria, but there are several criteria for which there is not enough information to make a definitive determination. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1477": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Bacterial Growth in Vascular Surgery Wounds\", here is my assessment:\n\nThe patient is a 72-year-old man with symptoms suggestive of peripheral artery disease, including calf pain when walking uphill and diminished pulses in the lower extremities. He has a history of myocardial infarction and transient ischemic attack, which may increase his risk for vascular complications.\n\nThe inclusion criteria for the clinical trial is \"need for lower limb vascular by-pass surgery\". Given the patient's symptoms and risk factors, it is highly likely that he would require lower limb vascular bypass surgery.\n\nTherefore, this patient meets the inclusion criteria for the clinical trial \"Bacterial Growth in Vascular Surgery Wounds\".\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1478": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Adult patients 18 years or older: The patient is 72 years old, so this criterion is met.\n\n2. Admitted to the Intensive Care Unit (ICU): There is no information provided about the patient being admitted to the ICU, so this criterion cannot be confirmed.\n\n3. Determined by their treating clinicians to require both a central venous line and arterial line: There is no information provided about the patient requiring central venous or arterial lines, so this criterion cannot be confirmed.\n\nBased on the limited information provided in the patient note, it is unclear if the patient meets all the inclusion criteria for the clinical trial. The note primarily focuses on the patient's symptoms and medical history related to cardiovascular issues, but does not provide details about their current admission status or the need for central venous or arterial lines.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1479": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 72-year-old man, so he meets the age criteria of being > 17 years old.\n\nHe has symptoms of calf pain when walking uphill, which could be indicative of stable angina pectoris. The note mentions he had an uncomplicated myocardial infarction 2 years ago, but no Q-wave MI in the area undergoing CFI measurement is specified.\n\nHe does not seem to have congestive heart failure NYHA III-IV based on the note. No severe valvular heart disease, hepatic or renal failure is mentioned.\n\nThe only potential exclusion criteria is that he had a previous transient ischemic attack 6 months ago, which may or may not exclude him depending on if that is considered an \"unstable cardio-pulmonary condition\".\n\nOverall, based on the information provided, I would consider referring this patient to the clinical trial upon further investigation into whether his previous TIA would exclude him.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1480": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man, which meets the age criteria of being over 18 years old.\n\n2. The patient is complaining of increasing calf pain when walking uphill, which could be a symptom of peripheral artery disease (PAD). This suggests he may be a candidate for lower limb revascularization surgery, one of the included procedures.\n\n3. The patient has a history of myocardial infarction and transient ischemic attack, indicating existing vascular disease that puts him at higher risk for complications during vascular surgery.\n\n4. No information is provided about whether the patient is scheduled for an elective vascular surgery procedure included in the trial criteria.\n\nBased on the available information, the patient appears to potentially meet some of the inclusion criteria, but it is unclear if he is actually scheduled for one of the specific vascular surgery procedures required for enrollment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether he is scheduled for an eligible vascular surgery procedure.",
        "label": 0
    },
    "1481": {
        "output": "To determine the patient's eligibility for the given clinical trial, let's go through the inclusion criteria:\n\nInclusion criteria:\n1. age > 18 years old\nThe patient is 72 years old, so this criterion is met.\n\n2. undergoing totally thoracoscopic cardiac surgery with cardiopulmonary bypass\nThere is no mention of the patient undergoing or planning to undergo thoracoscopic cardiac surgery in the provided note.\n\nSince one of the key inclusion criteria is not met based on the information given, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1482": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note describes a 72-year-old man with the following relevant details:\n- Complaints of increasing calf pain when walking uphill over the past 3 months\n- History of myocardial infarction 2 years ago and transient ischemic attack 6 months ago\n- Uncontrolled hypertension despite medications\n- Physical exam findings suggestive of peripheral artery disease\n\nThe clinical trial is studying the use of remote ischemic preconditioning to reduce contrast-induced nephropathy in patients receiving contrast for abdominal/pelvic CT scans.\n\nThe key inclusion criterion is: \"Hospital inpatients undergoing contrast enhanced abdomino-pelvic CT scanning.\"\n\nBased on the patient note, it does not explicitly state that this patient is scheduled for an abdominal/pelvic CT scan with contrast. The note describes symptoms suggestive of peripheral artery disease, but does not mention an upcoming CT scan.\n\nTherefore, without additional information confirming the patient will undergo a contrast-enhanced abdominal/pelvic CT scan, I would assess this patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1483": {
        "output": "To determine the patient's eligibility for the clinical trial \"Obstructive Sleep Apnoea in Patients With Intermittent Claudication\", let's go through the inclusion criteria one by one:\n\n1. Register to the social health insurance: The patient note does not mention whether the patient is registered for social health insurance or not, so we cannot confirm this criterion.\n\n2. Referred for a walk test because of claudication: The patient note mentions that the patient complains of increasing calf pain when walking uphill, which is a symptom of claudication. However, it does not explicitly state that the patient was referred for a walk test.\n\n3. Maximal walking distance < 750m: The patient note does not provide information about the patient's maximal walking distance.\n\n4. Older than 18 years old: The patient is mentioned as a 72-year-old man, so he meets this criterion.\n\n5. Able to understand the protocol of the study: There is no information provided about the patient's ability to understand the study protocol.\n\nBased on the information provided in the patient note, we cannot definitively confirm or rule out the patient's eligibility for this clinical trial. Some key information is missing, such as whether the patient was referred for a walk test, their maximal walking distance, and their ability to understand the study protocol.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1484": {
        "output": "To determine the patient's eligibility for the clinical trial \"Osteoarthritis Cardiovascular Risk Factors\", let's go through the inclusion criteria:\n\n1. Patients referred for symptomatic hand or knee osteoarthritis\nThe patient note does not mention any symptoms related to hand or knee osteoarthritis. This criterion is not met.\n\n2. All patients referred in the same period for soft tissue disease\nThe patient note does not indicate that the patient was referred for soft tissue disease. This criterion is not met.\n\n3. > 50 years old\nThe patient is 72 years old, so this criterion is met.\n\nSince the patient does not meet the first two inclusion criteria, which are specific to the target conditions of the study, it is unlikely that this patient would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1485": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man complaining of increasing calf pain when walking uphill, which has gradually increased over the past 3 months. This could potentially be a symptom of intermittent claudication.\n\n2. The patient has a history of myocardial infarction and transient ischemic attack, which suggests underlying vascular disease.\n\n3. The patient's blood pressure is elevated despite being on multiple antihypertensive medications, which could be a risk factor for vascular disease.\n\n4. On physical examination, the patient has a carotid bruit and diminished peripheral pulses, which are signs of peripheral artery disease.\n\n5. The clinical trial is studying the mechanisms and potential treatments for intermittent claudication.\n\n6. The inclusion criteria for the trial are:\n   a) A positive history of chronic claudication\n   b) Exercise-limiting claudication established by a screening walking test\n   c) An ankle-brachial index < 0.9 at rest\n\nBased on the information provided, this patient meets the inclusion criteria for the trial:\na) The patient has a history of increasing calf pain when walking uphill, which could be claudication.\nb) While a screening walking test is not mentioned, the symptoms are exercise-limiting.\nc) The diminished peripheral pulses suggest the possibility of an ankle-brachial index < 0.9.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1486": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man presenting with calf pain when walking uphill, which has gradually increased over the past 3 months.\n2. He has a history of myocardial infarction 2 years ago and a transient ischemic attack 6 months ago.\n3. His blood pressure is currently uncontrolled despite being on multiple medications.\n4. Physical examination reveals diminished pulses in the lower extremities, suggesting possible peripheral artery disease.\n\nNow, let's look at the inclusion criteria for the clinical trial:\n\n1. The trial is looking for high-risk hypertension patients with evidence of target organ damage or reduced kidney function.\n2. It is also including patients with diabetes mellitus and microalbuminuria.\n3. Patients with end-stage renal disease on dialysis are eligible.\n4. Relatives of young patients with myocardial infarction are eligible.\n5. Patients with atherosclerotic cardiovascular disease, such as carotid artery stenosis or coronary artery disease, are eligible.\n6. Rheumatoid arthritis patients on specific medications are eligible.\n7. Atrial fibrillation patients with a certain risk score are eligible.\n8. Kidney transplant recipients are eligible.\n\nBased on the information provided, this patient does not seem to meet any of the specific inclusion criteria for this clinical trial. While he has a history of myocardial infarction and possible peripheral artery disease, he does not fit into any of the listed eligible categories.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1487": {
        "output": "To determine the patient's eligibility for the \"Swedish Drug-elution Trial in Peripheral Arterial Disease\" clinical trial, let's go through the inclusion criteria:\n\n1. All adults > 18 years old willing to be randomized\nThe patient is 72 years old, so this criterion is met.\n\n2. Symptomatic PAD (critical limb ischemia or intermittent claudication) caused by >50% stenosis or occlusion of infrainguinal arteries and eligible for endovascular treatment according to established indications\nThe patient complains of increasing calf pain when walking uphill, which suggests intermittent claudication, a symptom of PAD. The note also mentions diminished pulses in the lower extremities, indicating possible stenosis or occlusion in the infrainguinal arteries.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial. However, further investigation may be needed to confirm the presence of significant stenosis or occlusion in the infrainguinal arteries and the patient's eligibility for endovascular treatment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1488": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man with hypertension and symptoms of peripheral artery disease (calf pain when walking uphill, diminished pulses in lower extremities).\n\n2. The clinical trial is studying the effects of two antihypertensive medications (telmisartan and nebivolol) on 24-hour ambulatory blood pressure and arterial stiffness in patients with stage I hypertension.\n\n3. The inclusion criteria specifically state that patients must have stage I hypertension, defined as 24-hour systolic BP \u2265130 mmHg or diastolic BP \u226580 mmHg on ambulatory blood pressure monitoring (ABPM).\n\n4. The patient's blood pressure in the note is 151/91 mmHg, which meets the criteria for stage I hypertension.\n\n5. While the patient has some comorbidities (prior MI, TIA, peripheral artery disease), these are not explicitly listed as exclusion criteria.\n\nBased on the available information, this patient appears to meet the key inclusion criteria of having stage I hypertension documented by elevated office blood pressure readings.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1489": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man, which meets the age criteria of being over 18 years old.\n\n2. The patient is complaining of increasing calf pain when walking uphill, which could be a symptom of peripheral artery disease (PAD). This suggests he may be a candidate for lower limb revascularization surgery, one of the included procedures.\n\n3. The patient has a history of myocardial infarction and transient ischemic attack, indicating existing vascular disease that puts him at higher risk for complications during vascular surgery.\n\n4. No information is provided about whether the patient is scheduled for an elective vascular surgery procedure included in the trial criteria.\n\nBased on the available information, the patient appears to potentially meet some of the inclusion criteria, but it is unclear if he is actually scheduled for one of the specific vascular surgery procedures required for enrollment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether he is scheduled for an eligible vascular surgery procedure.",
        "label": 0
    },
    "1490": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 72-year-old man with peripheral arterial disease (PAD) symptoms of calf pain when walking uphill, which have gradually increased over the past 3 months.\n\n2. He has a history of myocardial infarction 2 years ago and a transient ischemic attack 6 months ago.\n\n3. His blood pressure is currently uncontrolled despite being on multiple medications.\n\n4. On physical exam, he has diminished pulses in the lower extremities, suggesting PAD.\n\n5. The clinical trial is studying the effects of exercise therapy, risk factor management, and lifestyle coaching in addition to standard treatment (revascularization) for patients with critical limb ischemia due to PAD.\n\n6. The inclusion criteria are:\n   - Patients with PAD Rutherford stage 4 and 5 (critical limb ischemia)\n   - Able to undergo revascularization procedure\n   - Both legs affected, but most severe leg not exceeding stage 5\n\n7. This patient seems to have PAD with symptoms suggestive of claudication (stage 3), but not yet critical limb ischemia (stage 4-5).\n\n8. However, his symptoms are gradually worsening, and he has other risk factors like uncontrolled hypertension and history of cardiovascular events.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1491": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man, which meets the age criteria of \u226518 years old and <80 years old.\n\nThe patient had a myocardial infarction 2 years ago, which could potentially qualify as ST-segment elevation myocardial infarction (STEMI) receiving percutaneous coronary intervention (PCI), as required by the inclusion criteria.\n\nHowever, there is no specific mention of the patient receiving PCI or having ST-segment elevation during the myocardial infarction event.\n\nAdditionally, the current symptoms described (calf pain when walking uphill) do not seem directly related to a STEMI event.\n\nBased on the limited information provided, it is unclear if this patient would definitively meet all the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1492": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Established diagnosis of non-ischemic dilated cardiomyopathy: The patient note does not mention dilated cardiomyopathy, so this criterion is not met.\n\n2. EF < 35%: The patient's ejection fraction is not provided in the note.\n\n3. NYHA f.c. II - IV: The patient's NYHA functional class is not provided.\n\n4. Optimal medical management > 6 months: It's unclear if the patient has been on optimal medical management for at least 6 months.\n\n5. Age < 75 years and > 18 years: The patient is 72 years old, so this criterion is met.\n\nSince the patient note does not provide enough information to determine if several key inclusion criteria are met, I would not be able to definitively refer this patient to the clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1493": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man, which meets the age criteria of at least 18 years old.\n\nHe complains of increasing calf pain when walking uphill, which suggests symptomatic peripheral arterial disease (PAD) in the lower extremities (Rutherford/Becker category 2 or 3).\n\nHe had a previous myocardial infarction and transient ischemic attack, but the trial does not exclude patients with these conditions.\n\nHis current medications include aspirin, which is allowed per the pre-index procedure use of aspirin or clopidogrel.\n\nThe trial requires undergoing a clinically indicated endovascular intervention for iliac, femoropopliteal, or below-the-knee arterial disease. While the patient note does not explicitly state that he underwent such a procedure, his symptoms and diminished pulses suggest he may be a candidate for revascularization.\n\nBased on the available information, I would consider referring this patient to the clinical trial upon further investigation to determine if he meets all the angiographic criteria and has undergone or is planned for an endovascular intervention.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1494": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: Symptomatic peripheral arterial disease (PAD) involving the above-the-knee femoropopliteal arteries\n\nFrom the patient note, we can see that the 72-year-old man is experiencing calf pain when walking uphill, which has gradually increased over the past 3 months. This could be a symptom of peripheral arterial disease (PAD). Additionally, the note mentions that the patient's lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis, which are also potential signs of PAD.\n\nWhile the note does not explicitly state that the PAD involves the above-the-knee femoropopliteal arteries, it is a reasonable assumption based on the symptoms described.\n\nGiven the information provided, it seems likely that this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1495": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 72-year-old man\n- Complains of increasing calf pain when walking uphill (claudication symptoms)\n- Had a myocardial infarction 2 years ago\n- Had a transient ischemic attack 6 months ago\n- Uncontrolled hypertension\n- Diminished pulses in lower extremities\n\nThe inclusion criteria for the clinical trial are:\n1. Known moderate peripheral vascular disease (PVD)\n2. New claudication patient with Rutherford stage 2 and Fontaine stage 2a symptoms\n\nBased on the patient note, this 72-year-old man seems to have symptoms consistent with moderate PVD, including new onset of claudication (calf pain with walking uphill). His medical history of myocardial infarction and TIA also suggest underlying vascular disease.\n\nWhile the note doesn't explicitly state the Rutherford or Fontaine staging, the described symptoms appear to align with the inclusion criteria of Rutherford stage 2 (mild claudication) and Fontaine stage 2a (claudication after walking a limited distance).\n\nTherefore, this patient appears to meet the key inclusion criteria for the clinical trial on remote ischemic preconditioning for moderate PVD.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1496": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effects of Remote Ischemic Preconditioning on Restenosis Post Lower Limb Revascularization Angioplasty\", let's go through the inclusion and exclusion criteria:\n\nInclusion criteria:\n1. Patients planned for lower limb Angioplasty\n\nThe patient note mentions that the 72-year-old man is complaining of increasing calf pain when walking uphill, which could be indicative of peripheral artery disease and may require a lower limb revascularization procedure like angioplasty. However, the note does not explicitly state that the patient is planned for angioplasty.\n\nExclusion criteria:\n1. Known upper limb PVD\n2. Previous history of upper limb deep vein thrombosis\n3. Patients on glibenclamide or nicorandil - May affect RIPC\n4. Raynaud's Disease\n5. Intra operative decision to use graft - will be documented\n\nThe patient note does not mention any information related to the exclusion criteria.\n\nBased on the available information, it is unclear if the patient meets the inclusion criteria for the clinical trial. More information is needed to determine if the patient is planned for a lower limb angioplasty procedure.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1497": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\nAge \u2265 18 years to \u2264 75 years: The patient is 72 years old, which meets this criterion.\n\nDocumented history of type I or II diabetes with current treatment control (HbA1c of \u2264 10.0% at Screening) and currently on medication for diabetes (oral, injectable, and/or insulin): The patient note does not mention if the patient has diabetes or is on any diabetes medication. This criterion cannot be evaluated based on the information provided.\n\nNo significant changes anticipated in diabetes medication regimen: Again, there is no information about the patient's diabetes status or medication.\n\nNo new symptoms associated with diabetes within the last 3 months prior to study entry: No information provided about diabetes or related symptoms.\n\nDiagnosis of painful diabetic peripheral neuropathy in both lower extremities: The patient complains of increasing calf pain when walking uphill, which could potentially be related to peripheral neuropathy. However, there is no clear diagnosis of painful diabetic peripheral neuropathy mentioned.\n\nLower extremity pain for at least 6 months: The patient note states that the symptoms have gradually increased over the past 3 months, which does not meet this criterion.\n\nVisual analog scale (VAS) score of \u2265 40 mm at Initial Screening (0 mm = no pain - 100 mm very severe pain): No VAS score is provided in the patient note.\n\nSymptoms from the Brief Pain Neuropathy Screening (BPNS) is \u2264 5 point difference between legs at Initial Screening: No information about BPNS score or difference between legs is provided.\n\nThe average daily pain intensity score of the Daily Pain and Sleep Interference Diary completed after medication wash-out is \u2265 4 with a standard deviation \u2264 2: No information about pain intensity score or sleep interference diary is provided.\n\nThe physical examination component of the Michigan Neuropathy Screening Instrument Score (MNSI) is \u2265 3 at Screening: No information about MNSI score is provided.\n\nSubjects on gabapentin (Neurontin), pregabalin (Lyrica), duloxetine (Cymbalta) for painful DPN at study entry must be on stable regimen of these treatments for at least 3 months prior to study entry: The patient note does not mention if the patient is on any of these medications.\n\nIf female of childbearing potential, negative urine pregnancy test at screening and using acceptable method of birth control during the study: The patient is a 72-year-old man, so this criterion is not applicable.\n\nBased on the information provided in the patient note, several key inclusion criteria cannot be evaluated, such as the patient's diabetes status, neuropathy diagnosis, pain scores, and medication history. Additionally, the duration of lower extremity pain does not meet the required 6 months.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1498": {
        "output": "Okay, let's go through the patient note and inclusion criteria for the clinical trial step-by-step:\n\nPatient Note:\n- 72-year-old man\n- Complains of increasing calf pain when walking uphill over the past 3 months\n- History of myocardial infarction 2 years ago and transient ischemic attack 6 months ago\n- Uncontrolled blood pressure despite medications\n- Physical exam shows high blood pressure, carotid bruit, diminished peripheral pulses\n\nClinical Trial:\nTitle: Ischaemic PReconditioning In Non Cardiac surgEry\nSummary: Testing if remote ischemic preconditioning (brief episodes of ischemia/reperfusion) can reduce cardiac damage in high-risk non-cardiac surgery patients\n\nInclusion Criteria:\n- Written informed consent\n- Intermediate and high risk non-cardiac surgery\n- General anesthesia \n- Ongoing or recently suspended antiplatelet therapy\n\nAnalysis:\nThe patient meets some of the key inclusion criteria - he is undergoing a high-risk non-cardiac surgery (based on his vascular disease symptoms/history) and is likely on antiplatelet therapy (aspirin). However, it's unclear if he has provided written informed consent or will be under general anesthesia for the procedure.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of whether he will consent and undergo general anesthesia.",
        "label": 0
    },
    "1499": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluation of the Safety of Compressive Socks to Treat Venous Insufficiency in Patients With Peripheral Arterial Disease,\" let's go through the inclusion criteria:\n\n1. Patient suffering from PAD (systolic pressure index \u2265 0.60 and \u2264 0.75): The patient note does not explicitly mention the systolic pressure index, but it does state that the patient has peripheral arterial disease (PAD), as evidenced by the calf pain when walking uphill and diminished pulses in the lower extremities.\n\n2. Having moderate venous insufficiency or classified as C1s to C4 using the CEAP classification: The patient note does not provide information about the severity of venous insufficiency or the CEAP classification.\n\n3. Age over 18 years: The patient is 72 years old, which meets this criterion.\n\n4. French health insurance: The patient note does not mention the patient's health insurance or location.\n\n5. Signed informed consent: This criterion cannot be assessed based on the provided information.\n\nGiven the available information, it is unclear if the patient meets all the inclusion criteria for the clinical trial. While the patient appears to have PAD and is over 18 years old, there is no information about the severity of venous insufficiency, the CEAP classification, the patient's health insurance, or whether the patient has provided informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1500": {
        "output": "To determine the patient's eligibility for the clinical trial \"Risk Factors for Acquired Cardiovascular Disease in Adults With Congenital Heart Disease\", let's go through the inclusion criteria:\n\n1. Male or Female over 18 years of age: The patient is a 72-year-old man, so he meets this criterion.\n\n2. Moderate or Complex Congenital Heart Disease: The patient note does not mention any congenital heart disease. Instead, it states that the patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. These are acquired cardiovascular conditions, not congenital heart diseases.\n\n3. Willingness to Consent: There is no information provided about the patient's willingness to consent.\n\nBased on the available information, the patient does not meet the inclusion criterion of having a moderate or complex congenital heart disease. Therefore, he would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1501": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man, which meets the age criteria of being above 18 years old.\n\nHe complains of increasing calf pain when walking uphill, which is a symptom of intermittent claudication, meeting the diagnosis criteria.\n\nHis blood pressure is 151/91 mm Hg, which is under moderate control (< 160/100 mmHg) as per the criteria.\n\nThere is no mention of foot ulceration, so we can assume he does not have any current foot ulceration.\n\nThe only potential issue is that the patient had a transient ischemic attack 6 months ago, which is not explicitly mentioned in the inclusion/exclusion criteria. However, since he meets all the other criteria, we can consider referring him for further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1502": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 72-year-old man, which meets the age criteria of >21 years old.\n\nHe is undergoing evaluation for peripheral arterial disease and will likely need an angiogram/angioplasty, which meets the criteria of \"Elective intra-arterial peripheral angiography/angioplasty\".\n\nHis renal function is not explicitly stated, but he has risk factors like hypertension and previous myocardial infarction that could impair kidney function and put him at risk for contrast-induced nephropathy.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation of his kidney function (eGFR level).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1503": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy, which meets the age criteria of 4-12 years for the OCD participants group.\n\n2. However, the patient does not have a diagnosis of OCD, which is a key inclusion criteria for the OCD participants group. The symptoms described (fever, conjunctivitis, strawberry tongue, inflammation of hands/feet, desquamation, lymphadenopathy, hepatomegaly, elevated inflammatory markers) are more consistent with Kawasaki disease rather than OCD.\n\n3. The patient does not meet the criteria to be included in the healthy controls group either, as he has a significant medical illness (suspected Kawasaki disease).\n\n4. There are no exclusion criteria listed that would explicitly exclude this patient, but the lack of OCD diagnosis and presence of another significant medical condition make him ineligible.\n\nTherefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1504": {
        "output": "Based on the patient note provided, this is a 2-year-old boy presenting with symptoms consistent with Kawasaki disease, including fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, elevated inflammatory markers, and coronary artery aneurysm on echocardiogram.\n\nThe clinical trial you provided is studying the effect of exercise on stem cell mobilization and heart function in patients undergoing cardiac rehabilitation for coronary artery disease.\n\nGiven that the patient is a 2-year-old child with Kawasaki disease and not an adult with coronary artery disease, this patient would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1505": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy, which meets the age criteria of \">= 6 months -12 years\" for the clinical trial.\n\n2. The patient has symptoms of fever, irritability, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy. These symptoms are consistent with a clinical diagnosis of acute tonsillitis and/or pharyngitis, as required by the inclusion criteria.\n\n3. The patient has an elevated white blood cell count (17,580/mm3), which meets the inclusion criteria of \"WBC >12,000/mm3 or 10% bands.\"\n\n4. The patient has a strawberry tongue, which is specifically mentioned in the inclusion criteria.\n\n5. However, the inclusion criteria require a positive rapid screening test for Streptococcus pyogenes (Group A Streptococcus), which is not mentioned in the patient note.\n\n6. Additionally, the patient note mentions symptoms that are not typical of strep throat, such as conjunctivitis, inflammation of the hands and feet, desquamation of the skin, and an enlarged liver. These symptoms suggest a possible diagnosis of Kawasaki disease rather than strep throat.\n\nBased on the information provided, while the patient meets some of the inclusion criteria for the clinical trial, the lack of a positive rapid strep test and the presence of atypical symptoms make it unlikely that this patient would be eligible for this particular clinical trial on strep throat.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1506": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy, which meets the age criteria of 4-16 years old. However, the inclusion criteria specifically state \"be able to exercise adequately to achieve 85% age predicted maximum heart rate\". A 2-year-old would likely not be able to exercise adequately for the stress test portion of the trial.\n\n2. The patient does appear to meet the diagnostic criteria for Kawasaki disease based on the symptoms described (fever, conjunctivitis, mucosal changes, rash, lymphadenopathy, elevated inflammatory markers, coronary artery aneurysm on echocardiogram).\n\n3. Given that the patient meets the diagnostic criteria but likely cannot exercise for the stress test, I would assess this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nSpecifically, I would want to clarify if there are any accommodations or alternatives for very young patients who cannot exercise, since the patient otherwise meets the main inclusion criteria of having Kawasaki disease with coronary artery involvement. With some additional investigation into how they handle such cases, the patient could potentially still participate.",
        "label": 0
    },
    "1507": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, this patient would not be eligible for the trial. Here's my reasoning:\n\nThe patient note describes a 2-year-old boy with symptoms suggestive of Kawasaki disease, an acute febrile illness that can cause inflammation of the blood vessels, including coronary artery aneurysms. The clinical trial, however, is focused on treating behavioral disorders in children with learning disabilities using the antipsychotic medication risperidone.\n\nThe inclusion criteria for the trial specifically require:\n\n1. A DSM-IV Axis II diagnosis of mental retardation (intellectual disability)\n2. Failed behavioral and family therapy for 6 months\n3. The child must be in school, at least part-time\n4. A score of >=8 on the hostility scale\n5. The subject must be otherwise healthy\n\nThe patient note does not mention any intellectual disability or behavioral disorder. Instead, it describes a medical condition (Kawasaki disease) with physical symptoms and laboratory abnormalities.\n\nTherefore, based on the information provided, this patient would not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1508": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. All eligible subjects, or legal representative, must provide written informed consent/assent, prior to initiation of any study procedure. \n   - This is likely met as the patient is a 2-year-old child with parents/legal representatives.\n2. Eligible subjects will be infants and children, under 18 years old, with acute KD who remain or become febrile (>/= 38.3\u02da C or 101.0\u02da F) after the end of the 48 h-period after completing their IVIG infusion (2gm/kg).\n   - The patient is a 2-year-old boy, so meets the age criteria. It is not mentioned if he has received IVIG yet.\n3. Patients must have persistent or reoccurrence of fever > 48 hours of observation to be eligible for the trial.\n   - The patient has had a fever for 5 days, so meets this criteria.\n4. Prior to the initial IVIG treatment, patients must have been febrile for >/= 3 days and have met 4/5 standard clinical criteria (Table 1) - OR - patients with fever and 3/5 clinical criteria will be eligible if echocardiogram demonstrates at least one coronary artery segment with a Z score of > 2.\n   - The patient meets at least 4 of the 5 clinical criteria (conjunctivitis, strawberry tongue, inflammation of extremities, cervical lymphadenopathy). The echocardiogram also shows coronary artery dilation/aneurysm.\n5. Patients must present for their initial diagnosis and IVIG treatment within the first 14 days after fever onset (Illness Day 14).\n   - This is not explicitly stated, but can be assumed to be met.\n6. Females of childbearing potential and males must be using adequate contraception throughout the trial.\n   - Not applicable for a 2-year-old boy.\n7. All eligible subjects must have a chest radiograph within one week prior to first infusion of study drug with no evidence of malignancy, infection or fibrosis.\n   - This is not mentioned, but can potentially be done.\n\nExclusion Criteria:\n1. Have been receiving corticosteroids at doses > 1 mg/kg prednisone equivalent daily.\n   - Not mentioned, so assumed to not apply.\n2. Have history of TB or TB exposure.\n   - Not mentioned, so assumed to not apply.\n3. Have history of histoplasmosis or coccidiomycosis.\n   - Not mentioned, so assumed to not apply.\n4. Have received certain biologics within 1 month prior.\n   - Not mentioned, so assumed to not apply.\n5. Have any chronic disease, except asthma, atopic dermatitis or controlled seizure disorder.\n   - Not mentioned, so assumed to not apply.\n6. Have documented history of current active hepatitis B, hepatitis C, or HIV infection.\n   - Not mentioned, so assumed to not apply.\n7. Have received a transplanted organ.\n   - Not mentioned, so assumed to not apply.\n8. Have a known malignancy or history of malignancy within the 5-year period.\n   - Not mentioned, so assumed to not apply.\n9. Have a history of prior lymphoproliferative disease including lymphoma. \n   - Not mentioned, so assumed to not apply.\n10. Have multiple sclerosis or other central demyelinating disorder.\n    - Not mentioned, so assumed to not apply.\n11. Have received any previous treatment with infliximab or other monoclonal antibodies.\n    - Not mentioned, so assumed to not apply.\n12. Have used any investigational drug within 1 month prior.\n    - Not mentioned, so assumed to not apply.\n13. Are participating in another investigative trial.\n    - Not mentioned, so assumed to not apply.\n14. Have a history of substance abuse within the previous 3 years.\n    - Not applicable for a 2-year-old child.\n15. Are pregnant, nursing, or planning pregnancy during the trial or within the 6-month period thereafter.\n    - Not applicable for a 2-year-old boy.\n16. Have a known allergy to murine proteins or other chimeric proteins.\n    - Not mentioned, so assumed to not apply.",
        "label": 2
    },
    "1509": {
        "output": "To determine the trial-level eligibility for this patient, let's go through the inclusion criteria one by one:\n\n1. History of Kawasaki disease more than 12 months before enrollment:\nThe patient note mentions that this is a 2-year-old boy presenting with symptoms consistent with Kawasaki disease, so he likely has a history of Kawasaki disease more than 12 months ago. This criterion is met.\n\n2. Present age of 8 years or older:\nThe patient is only 2 years old, which does not meet this age criterion.\n\nSince one of the inclusion criteria is not met, this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1510": {
        "output": "To determine the patient's eligibility for the clinical trial \"New Treatment for Donor Sites\", I will go through the inclusion criteria one by one:\n\nAges 0-90 years: The patient is a 2-year-old boy, which falls within this age range.\n\nAny patient admitted to the hospital with burn injury requiring grafting and a donor site: The patient note does not mention any burn injury or need for grafting. The symptoms described (fever, conjunctivitis, strawberry tongue, inflammation of hands/feet, desquamation, lymphadenopathy, abdominal tenderness, elevated liver enzymes, leukocytosis, anemia, proteinuria, and coronary artery aneurysm) are more consistent with Kawasaki disease, an acute vasculitis, rather than a burn injury.\n\nSince the patient does not appear to have a burn injury requiring grafting and a donor site, they would not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1511": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"The Effect of Omalizumab on Responses to Cat Allergen Challenge\", this patient would not be eligible for the trial. The key reasons are:\n\n1. The patient is a 2-year-old boy, while the inclusion criteria specify an age range of 18-50 years.\n2. The patient's condition appears to be Kawasaki disease, which is a systemic vasculitis, and not related to cat allergies or allergic rhinitis as required by the trial.\n3. The inclusion criteria specifically mention the ability to provide informed consent, which a 2-year-old child cannot do.\n\nTherefore, based on the information provided, this patient does not meet the eligibility criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1512": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy presenting with high fever, irritability, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, cervical lymphadenopathy, abdominal tenderness, enlarged liver, and elevated inflammatory markers.\n\n2. The clinical trial is studying the efficacy of azithromycin vs amoxicillin for the treatment of strep throat in children.\n\n3. The inclusion criteria require evidence of acute pharyngitis/tonsillitis with erythematous pharyngeal mucosa or thick exudate, plus at least one of: sore/scratchy throat, pain on swallowing, chills/fever, cervical adenopathy, scarlet fever rash, or strawberry tongue. Patients must also have a positive rapid strep test or culture.\n\n4. While the patient does have a strawberry tongue and cervical lymphadenopathy, which are included in the criteria, the overall clinical picture with desquamation, conjunctivitis, abdominal findings, and coronary artery changes is more consistent with Kawasaki disease rather than strep pharyngitis.\n\n5. Therefore, this patient would likely not meet inclusion criteria for a trial specifically studying strep throat treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1513": {
        "output": "Based on the patient note provided, this 2-year-old boy does not appear to meet the inclusion criteria for the clinical trial titled \"Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study.\"\n\nThe key reasons are:\n\n1. The patient is a 2-year-old boy, while the inclusion criteria specify patients must be 18 years of age or older.\n\n2. The patient does not have a diagnosis of rheumatoid arthritis (RA) based on the 1987 American College of Rheumatology (ACR) criteria, which is a requirement for inclusion in this trial.\n\n3. The patient's symptoms and clinical presentation (high fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, abdominal tenderness, enlarged liver, elevated inflammatory markers, and possible coronary artery aneurysm) are more consistent with Kawasaki disease, an acute vasculitis of childhood, rather than rheumatoid arthritis.\n\nTherefore, based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1514": {
        "output": "To determine the patient's eligibility for this clinical trial, let's go through the inclusion criteria one by one:\n\n1. Age: The patient is a 2-year-old boy, which falls within the age range of 2 months to 20 years for males.\n\n2. Parental consent: The patient note does not mention whether parental consent has been obtained, but this is typically a requirement for enrolling minors in clinical trials.\n\n3. Kawasaki Disease Presentation: The patient's symptoms and laboratory findings are consistent with Kawasaki Disease, including fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, elevated inflammatory markers, and coronary artery aneurysm on echocardiogram.\n\nBased on the information provided in the patient note, this patient meets the inclusion criteria for the clinical trial on Etanercept in children with Kawasaki Disease.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1515": {
        "output": "Based on the given patient note and the clinical trial information, this patient would not be eligible for the clinical trial titled \"Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use\".\n\nThe key reasons are:\n\n1. The patient is a 2-year-old boy, while the clinical trial is focused on hypertensive patients.\n2. The patient's condition appears to be related to Kawasaki disease, an acute febrile illness affecting young children, and not hypertension.\n3. The clinical trial is specifically studying the long-term use of Micombi Tablets, which are likely antihypertensive medications, in hypertensive patients.\n\nTherefore, this patient does not meet the inclusion criteria of being a hypertensive patient who has never taken Micombi Tablets.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1516": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 2-year-old boy presenting with fever, irritability, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, cervical lymphadenopathy, abdominal tenderness, enlarged liver, elevated liver enzymes, leukocytosis, hypoalbuminemia, elevated inflammatory markers, anemia, and leukocyturia. The echocardiogram shows moderate coronary artery dilation/aneurysm.\n\nThese clinical features are consistent with Kawasaki disease, an acute vasculitis that predominantly affects children.\n\nThe clinical trial is studying the effects of standard vs intensive statin therapy on preventing major adverse cardiac events in patients with diabetes, hypercholesterolemia, and hypertension.\n\nThe key inclusion criteria are:\n- Age \u2265 50 years\n- Hypercholesterolemia \n- Type 2 diabetes\n- Hypertension\n- Certain cardiovascular risk factors\n\nThis 2-year-old patient with Kawasaki disease does not meet any of the inclusion criteria for this statin therapy trial in diabetic/hypercholesterolemic adults.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1517": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy, while the inclusion criteria specify age \u226518 years. This alone would make the patient ineligible for this clinical trial on psoriatic arthritis.\n\n2. The patient does not have a diagnosis of psoriatic arthritis, which is a key inclusion criterion. The symptoms described (fever, conjunctivitis, strawberry tongue, etc.) are more consistent with Kawasaki disease, an acute vasculitis of childhood.\n\n3. There is no mention of the patient having psoriasis lesions \u22652 cm, which is another inclusion criterion.\n\n4. The other inclusion criteria regarding joint counts, prior DMARD treatment, etc. are not applicable since the patient does not have psoriatic arthritis.\n\nIn summary, this 2-year-old patient with suspected Kawasaki disease would not meet the key inclusion criteria for this clinical trial on psoriatic arthritis in adults.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1518": {
        "output": "Based on the patient note provided, the 2-year-old boy does not appear to have perennial allergic rhinitis, which is the condition being studied in the given clinical trial. The patient's symptoms and findings suggest Kawasaki disease, an acute febrile illness of childhood characterized by fever, conjunctivitis, mucosal changes, rash, and cervical lymphadenopathy, among other features.\n\nSince the patient does not meet the inclusion criteria of having perennial allergic rhinitis and instead has a different condition, I would not refer this patient for the clinical trial on Allegra for perennial allergic rhinitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1519": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Intravenous Immunoglobulin for PANDAS\", here is my assessment:\n\nThe patient is a 2-year-old boy presenting with symptoms that suggest Kawasaki disease, including fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, abdominal tenderness, elevated liver enzymes, leukocytosis, anemia, and possible coronary artery aneurysm.\n\nThe inclusion criteria for the PANDAS trial specify children aged 4-13 years with obsessive-compulsive disorder (OCD) and/or tic disorder with sudden onset following a Group A streptococcal infection. The patient's symptoms do not appear to be consistent with PANDAS or OCD, but rather suggest Kawasaki disease, which is a different condition.\n\nTherefore, based on the information provided, this patient would not be eligible for the \"Intravenous Immunoglobulin for PANDAS\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1520": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy, while the inclusion criteria specify the age as \u226518 years. So the patient does not meet the age criteria.\n\n2. There is no mention of the patient having psoriatic arthritis or meeting the CASPAR criteria for psoriatic arthritis, which are required by the inclusion criteria.\n\n3. The inclusion criteria require \u22653 swollen and \u22653 tender joints, but there is no information provided about the patient's joint involvement.\n\n4. The inclusion criteria exclude patients previously treated with DMARDs, but there is no information about the patient's treatment history.\n\n5. The inclusion criteria have specific laboratory requirements, but the patient's laboratory values do not fully match those (e.g., elevated white blood cell count, low albumin).\n\n6. The inclusion criteria have requirements for contraception use, which would not apply to a 2-year-old child.\n\nBased on the information provided, this patient does not meet several key inclusion criteria for this clinical trial of apremilast for psoriatic arthritis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1521": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Laparoscopy-assisted Proximal Gastrectomy Versus and Laparoscopy-assisted Total Gastrectomy\", this patient would not be eligible for the trial.\n\nThe patient note describes a 2-year-old boy with symptoms consistent with Kawasaki disease, such as fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, and possible coronary artery aneurysm. The patient does not have proximal gastric cancer, which is a requirement for inclusion in the clinical trial.\n\nThe inclusion criteria specifically state that eligible patients must have proximal gastric cancer (cancer located in the upper one-third of the stomach) that meets certain conditions, such as lesion size, depth, and absence of metastatic lymph node involvement or distant metastasis.\n\nSince the patient in the provided note does not have proximal gastric cancer and instead appears to have Kawasaki disease, they would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1522": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy, which meets the inclusion criteria of \"18 years old or older at the time of the study\" for the Kawasaki disease history group, since he is under 18 years old.\n\n2. The clinical presentation strongly suggests a diagnosis of Kawasaki disease, with fever, conjunctivitis, mucocutaneous inflammation, lymphadenopathy, and coronary artery aneurysm seen on echocardiogram.\n\n3. There is no mention of cardiovascular risk factors, which meets the inclusion criteria of \"Absence of cardiovascular risk factors\".\n\n4. The other inclusion criteria of agreeing to participate in study procedures and genotyping are not mentioned, but could potentially be met upon further discussion with the family.\n\nGiven that this is a classic case of acute Kawasaki disease in a young child without cardiovascular risk factors, he would be an excellent candidate for enrollment in this study looking at long-term vascular outcomes in adults with a history of Kawasaki disease.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1523": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy, which does not meet the inclusion criteria of being 3 years of age or older for this strep throat clinical trial.\n\n2. The patient is exhibiting symptoms like high fever, irritability, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, abdominal tenderness, and enlarged liver. These symptoms are more consistent with Kawasaki disease rather than strep throat.\n\n3. While the patient does have an elevated white blood cell count and leukocytes in the urine, there is no mention of symptoms like sore throat, swollen lymph nodes in the neck, redness of the throat and tonsils, or white/yellow patches on the tonsils that are required for inclusion in this strep throat study.\n\n4. Based on the information provided, this patient would not be eligible for this particular strep throat clinical trial evaluating a rapid strep test.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1524": {
        "output": "Based on the patient note provided, this 2-year-old boy does not appear to have symptoms of a streptococcal throat infection, which is the focus of the Sofia Strep A FIA clinical trial. Instead, the note describes symptoms consistent with Kawasaki disease, such as fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, abdominal tenderness, elevated inflammatory markers, and coronary artery aneurysm.\n\nSince the inclusion criteria for the Sofia Strep A FIA trial specifically require the presence of symptoms like sore throat, redness of the posterior pharyngeal wall, tonsillar exudate or swelling, and fever, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1525": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy, which meets the inclusion criteria of being an \"incipient case\" of Kawasaki disease.\n\n2. The patient exhibits 5 of the 6 major symptoms of Kawasaki disease: fever, conjunctivitis, mucosal changes (strawberry tongue), changes in extremities (inflammation and desquamation of fingers/toes), and cervical lymphadenopathy.\n\n3. The patient has received initial IVIG therapy, as evidenced by the statement \"refractory to initial IVIG therapy.\"\n\n4. The patient has a fever of 37.5\u00b0C or higher at the time of potential enrollment, as stated in the note.\n\n5. The note does not specify the exact day of illness, but it is reasonable to assume the patient is within day 8 of disease onset given the acute presentation.\n\n6. The echocardiogram shows coronary artery dilation/aneurysm, which is a serious complication of Kawasaki disease and would make the patient a good candidate for additional therapy.\n\nBased on the information provided, this patient meets all of the stated inclusion criteria for the clinical trial of TA-650 in refractory Kawasaki disease.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1526": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 2-year-old boy, which falls within the age range of 1 month to 21 years specified in the inclusion criteria.\n\n2. The patient has a confirmed diagnosis of Kawasaki disease, as evidenced by the clinical presentation (fever, conjunctivitis, strawberry tongue, inflammation of hands and feet, desquamation of skin, cervical lymphadenopathy, elevated inflammatory markers).\n\n3. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm, which meets the inclusion criteria of \"dilation of the right or left anterior descending coronary artery beyond a z-score of +2.5 during the acute febrile phase of KD\" or \"aneurysms of the right or left main coronary arteries during the acute febrile phase of KD.\"\n\nBased on the information provided, this patient meets the key inclusion criteria for the treatment arm of the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1527": {
        "output": "To determine the patient's eligibility for the clinical trial \"Management of Drug Hypersensitivity in Children\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n\"Participation will be proposed to any children (0 to 16 years) receiving one or several drug(s) and developing one of the following clinical manifestations: urticaria, maculopapular rash, bullous eruption, flush, anaphylaxis, serum sickness-like disease, SJS, TEN, DRESS or fever linked to drug intake.\"\n\nThe patient note mentions a 2-year-old boy, which falls within the age range of 0 to 16 years. The note also mentions that the patient has a high fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, cervical lymphadenopathy, enlarged liver, and possible coronary artery aneurysm.\n\nWhile the note does not explicitly state that the symptoms are linked to drug intake, the constellation of symptoms is consistent with Kawasaki disease, which is a systemic vasculitis that can be triggered by an infectious agent or potentially a drug hypersensitivity reaction.\n\nGiven the patient's age and the presence of fever and other systemic manifestations that could potentially be related to a drug hypersensitivity reaction, it would be reasonable to consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1528": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 2-year-old boy presenting with:\n- High fever and irritability for 5 days\n- Conjunctivitis\n- Strawberry tongue\n- Inflammation of hands and feet\n- Desquamation (peeling) of skin on fingers and toes\n- Cervical lymphadenopathy with smallest node 1.5 cm\n- Abdominal tenderness and enlarged liver\n- Elevated liver enzymes (ALT)\n- High white blood cell count\n- Low albumin\n- Elevated inflammatory markers (CRP, ESR)\n- Mild anemia\n- Leukocytes in urine\n- Moderate coronary artery dilation/possible aneurysm on echocardiogram\n\nThe clinical trial is for an intravenous immunoglobulin product to treat immune thrombocytopenia (ITP).\n\nThe key inclusion criteria are:\n- Age \u2265 19 years \n- Primary ITP\n- Platelet count < 20 x 10^9/L\n\nThis 2-year-old patient does not have ITP, but rather appears to have Kawasaki disease based on the clinical presentation. Kawasaki disease is an acute vasculitis that can cause coronary artery aneurysms in children.\n\nTherefore, this patient would not be eligible for the ITP clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1529": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes a 2-year-old boy with symptoms suggestive of Kawasaki disease, including fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, abdominal tenderness, elevated liver enzymes, leukocytosis, anemia, and possible coronary artery aneurysm.\n\nThe inclusion criteria for the clinical trial are:\n1. Male or female of any race\n2. 18-50 years old, inclusive\n3. Females: negative urine pregnancy test on the day of study participation (prior to exposure to hypoxia)\n4. Completed within the last year: physical exam by a licensed physician, physician assistant (PA), or advanced practice nurse; including a 12 lead ECG, a medical history, and blood test (complete blood count and sickle cell trait/disease screening)\n5. Meets specific demographic requirements for the monitoring device under study\n6. Willing and able to provide written informed consent\n7. Able to participate for the duration of the evaluation\n\nBased on the age criterion (18-50 years old), this 2-year-old patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1530": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial on Kawasaki Disease in Shanghai:\n\n1. The patient meets the 5th revised diagnostic criteria for Kawasaki Disease, having at least 5 of the 6 clinical manifestations:\n   - Fever persisting 5 days or longer (yes, 5 days of high fever)\n   - Bilateral conjunctival congestion (yes, conjunctivitis noted)\n   - Changes of lips and oral cavity like reddening of lips, strawberry tongue (yes, strawberry tongue present)\n   - Polymorphous exanthema (yes, desquamation of skin on fingers/toes)\n   - Changes of peripheral extremities like reddening, edema, desquamation (yes, inflammation and desquamation of hands/feet)\n   - Acute non-purulent cervical lymphadenopathy (yes, cervical lymphadenopathy present)\n\n2. The patient also has coronary artery abnormalities documented on echocardiogram (moderate coronary artery dilation/possible aneurysm).\n\nThis 2-year-old patient meets all the diagnostic criteria for Kawasaki Disease laid out in the inclusion criteria, including having coronary artery involvement.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1531": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 2-year-old boy, which meets the age criteria of \u2265 3 months.\n\nHe has the following symptoms consistent with Kawasaki disease:\n- Fever for 5 days\n- Conjunctivitis\n- Strawberry tongue\n- Inflammation of hands and feet\n- Desquamation of skin on fingers and toes\n- Cervical lymphadenopathy with node > 1.5 cm\n- Elevated inflammatory markers (CRP, ESR, WBC count)\n- Coronary artery aneurysm on echocardiogram\n\nThe inclusion criteria state he must have fever \u2265 5 days and \u2265 4 of the 5 main clinical signs, which he meets.\n\nIt also mentions that for incomplete cases, supportive criteria like elevated inflammatory markers can help confirm the diagnosis, which he has.\n\nMost importantly, the criteria require that the patient failed to respond to standard IVIG therapy, which this patient did based on the persistent fever after IVIG.\n\nThe only potential issue is the weight criteria of \u22655 kg, which is not provided but may be met given his age of 2 years.\n\nOverall, this patient appears to meet all the major inclusion criteria for this trial of anakinra for Kawasaki disease refractory to IVIG.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1532": {
        "output": "To determine the patient's eligibility for the clinical trial \"Different Doses of IVIG for Kawasaki Disease\", let's go through the inclusion criteria one by one:\n\n1. \"Individual patient's medical file data confirmed the diagnosis of KD using the 5th revised edition of diagnostic criteria for KD, issued by the Japan Kawasaki Disease Research Committee at the 7th International Kawasaki Disease Symposium in 2002.\"\n\nThe patient note mentions symptoms consistent with Kawasaki disease, such as fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, and possible coronary artery aneurysm. Therefore, this criterion is likely met.\n\n2. \"The patients aged from 1 months to 12 years old.\"\n\nThe patient note states that the patient is a 2-year-old boy, which falls within the age range specified in the inclusion criteria.\n\n3. \"All included patients required to sign an informed consent form.\"\n\nThis criterion is not addressed in the patient note, but it is a standard requirement for clinical trials and can be fulfilled if the patient's parents or legal guardians provide informed consent.\n\n4. \"The patients didn't receive treatment before.\"\n\nThe patient note does not mention any prior treatment for Kawasaki disease, so this criterion is likely met.\n\nBased on the information provided in the patient note and the inclusion criteria, this patient appears to be eligible for the clinical trial \"Different Doses of IVIG for Kawasaki Disease\".\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1533": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes a 2-year-old boy with symptoms suggestive of Kawasaki disease, including fever, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin, cervical lymphadenopathy, abdominal tenderness, elevated liver enzymes, and possible coronary artery aneurysm.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients 18 and older\n2. Patients who have clinically documented cirrhosis\n3. Patients who are coagulopathic (INR > 1.5 and/or platelets < 50,000)\n4. Patients undergoing an endoscopic procedure or neurosurgical procedure\n\nThe patient in the note is a 2-year-old child and does not appear to have cirrhosis or coagulopathy based on the information provided. Additionally, the patient is not undergoing an endoscopic or neurosurgical procedure.\n\nTherefore, this patient does not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1534": {
        "output": "Based on the patient note provided, the 2-year-old boy appears to be suffering from Kawasaki disease, a rare childhood illness that causes inflammation in the walls of small- and medium-sized arteries throughout the body, including the coronary arteries. The symptoms described, such as fever, conjunctivitis, rash, swollen lymph nodes, and potential coronary artery aneurysm, are characteristic of Kawasaki disease.\n\nThe clinical trial you provided is titled \"Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk.\" The inclusion criteria for this trial are:\n\n1. Men and women aged 35-65 years\n2. BMI \u2265 25 and \u2264 39 kg/m^2\n3. LDL-C > 116 mg/dL\n4. Total Cholesterol below 273 mg/dL for men and below 284 mg/dL for women\n5. Triglycerides below 350 mg/dL\n6. Non-smokers\n7. Blood pressure < 160/100 mmHg\n\nThe patient in this case is a 2-year-old boy, which does not meet the age criteria for the clinical trial. Additionally, the patient's condition is Kawasaki disease, which is not related to the study's focus on vascular function and cardiovascular risk markers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1535": {
        "output": "To determine the patient's eligibility for the clinical trial \"Impact of Antibiotic Treatment of Group A Streptococcal Blistering Distal Dactylitis in Children\", let's go through the inclusion criteria one by one:\n\n1. Children 0-18 years: The patient is a 2-year-old boy, so he meets this criterion.\n\n2. Distal blistering dactylitis collected or not collected: The patient has desquamation of the skin of the fingers and toes, which suggests distal blistering dactylitis, so he meets this criterion.\n\n3. Positive rapid Group A Streptococcus test: The patient note does not mention a rapid Group A Streptococcus test result, so we cannot confirm if he meets this criterion.\n\n4. Informed consent signed by the parents: The patient note does not mention whether the parents have provided informed consent, so we cannot confirm if he meets this criterion.\n\nBased on the information provided in the patient note, the patient meets at least two of the inclusion criteria (age and distal blistering dactylitis). However, there is not enough information to confirm if he meets the other two criteria (positive rapid Group A Streptococcus test and informed consent).\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1536": {
        "output": "To determine the patient's eligibility for the \"Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED)\" clinical trial, let's go through the key points:\n\n1. The patient is a 56-year-old female, which meets the inclusion criteria of \"Men and women\".\n2. The patient presents with shortness of breath, malaise, and decreased breath sounds, especially at the right base, which could be indicative of a suspected pulmonary embolism.\n3. The patient has an elevated D-dimer, which is a marker for potential pulmonary embolism.\n\nBased on the information provided, this patient meets the inclusion criteria of being suspected of having a pulmonary embolism and being eligible to undergo angiography for further evaluation.\n\nTherefore, considering the clinical presentation and the inclusion criteria of the trial, I would assess the eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1537": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 56-year-old female, which meets the age criteria of 18 and over.\n\nShe has advanced breast cancer that has failed prior treatment, as evidenced by her recent mastectomy and the statement that she has remained in bed for the last two weeks, suggesting her cancer has progressed.\n\nThere is no mention of active CNS metastases or history of heparin-associated thrombocytopenia.\n\nHer lab values are not provided, but she has an elevated D-dimer, which could indicate a clotting issue and potential eligibility for the dalteparin arm of the trial.\n\nThe only potential exclusion criteria is that she presented to the emergency department, which could indicate an acute issue that may make her ineligible.\n\nOverall, assuming her lab values meet the criteria and she does not have any acute issues requiring hospitalization, she seems like a potential candidate for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1538": {
        "output": "To determine the patient's eligibility for the clinical trial \"Incidence and Outcomes of Venous Thromboembolism\", let's analyze the patient note and the inclusion criteria:\n\nThe patient note states:\n- 56-year-old female\n- Post-mastectomy\n- Complaining of shortness of breath and malaise\n- Tenderness on the left upper thoracic wall and right calf\n- Bilateral decreased breath sounds, especially at the right base\n- Elevated D-dimer\n\nThe inclusion criteria for the clinical trial are:\n\"No eligibility criteria\"\n\nSince the trial does not have any specific inclusion criteria, and the patient's symptoms and findings (shortness of breath, tenderness in the calf, decreased breath sounds, and elevated D-dimer) are suggestive of a possible venous thromboembolism (DVT or PE), which is the focus of the trial, this patient would be highly eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1539": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy (breast cancer surgery).\n2. She is presenting with shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, and decreased breath sounds bilaterally, especially at the right base.\n3. Laboratory tests reveal an elevated D-dimer, which is a marker for blood clots.\n\n4. The clinical trial (TEMPEST) is studying the efficacy and safety of a drug in preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) after total hip replacement surgery.\n\n5. The key inclusion criteria are: patients scheduled for primary elective unilateral total hip arthroplasty and patients who have given written informed consent.\n\n6. While this patient did not undergo a hip replacement surgery, she is showing signs and symptoms suggestive of a DVT and/or PE after her recent mastectomy surgery.\n\n7. Evaluating her eligibility for this trial could provide important safety data on the study drug's efficacy in preventing DVT/PE in post-operative patients beyond just hip replacements.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1540": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the inclusion criteria of being an adult.\n2. The patient has not received any chemotherapy yet, which meets the inclusion criteria of being chemotherapy-naive.\n3. The patient is presenting with shortness of breath and malaise, which could be symptoms of extensive small cell lung cancer, though a confirmed diagnosis is not mentioned.\n4. There is no information provided about measurable or non-measurable disease, surgery within the last 3 weeks, or recent radiotherapy.\n5. There is no information provided about the patient's bone marrow reserve, kidney function, or liver function.\n\nBased on the limited information provided, there are some potential eligibility concerns, but further investigation would be needed to determine if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1541": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age inclusion criteria of 18-85 years old.\n\n2. The patient has shortness of breath and decreased breath sounds on auscultation, suggesting underlying lung disease. This meets the inclusion criteria of \"Evidence of underlying lung disease by history and physical and/or chest x-ray and/or pulmonary function testing (PFT's).\"\n\n3. The patient has an elevated D-dimer, which can be a marker of pulmonary embolism and pulmonary hypertension. However, the note does not explicitly state that the patient has pulmonary hypertension documented by Doppler echocardiography within the last 30 days, as required by the inclusion criteria.\n\n4. There is no information provided about the patient's ability to give informed consent.\n\nBased on the available information, the patient meets some but not all of the inclusion criteria. Further investigation would be needed to determine if the patient has documented pulmonary hypertension and can provide informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1542": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of 18-85 years old for the clinical trial.\n\n2. The patient presents with shortness of breath and malaise, which could be symptoms of acute heart failure as per the inclusion criteria.\n\n3. However, there is no information provided about the patient's left ventricular ejection fraction (LVEF), which is a key inclusion criteria (LVEF \u2265 40%).\n\n4. There is also no information about the patient's New York Heart Association (NYHA) class, baseline systolic blood pressure, or B-type natriuretic peptide (BNP) level, which are other inclusion criteria.\n\n5. The patient's presentation seems more consistent with a potential pulmonary embolism or deep vein thrombosis, given the elevated D-dimer and right calf tenderness.\n\nBased on the limited information provided, I would consider referring this patient to this clinical trial upon further investigation of their LVEF, NYHA class, blood pressure, and BNP level.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1543": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of \u226518 years old.\n\n2. The patient presents with shortness of breath and malaise, along with tenderness on the left upper thoracic wall and right calf. These symptoms could potentially indicate a deep vein thrombosis (DVT), which is the target condition for this trial.\n\n3. The patient is on the 20th day post-left mastectomy, which could increase the risk of DVT due to immobility and the surgical procedure itself.\n\n4. Laboratory tests reveal an elevated D-dimer, which is a marker for the presence of a blood clot or DVT.\n\n5. The inclusion criteria specifically state that the patient should have a moderate or high pre-test probability (PTP) for DVT, but this information is not provided in the patient note.\n\nBased on the available information, it seems that this patient could potentially be eligible for the clinical trial, as she meets some of the key criteria (age, symptoms suggestive of DVT, elevated D-dimer). However, without knowing the pre-test probability for DVT, it is difficult to make a definitive assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the pre-test probability for DVT.",
        "label": 2
    },
    "1544": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently had a mastectomy and is now presenting with shortness of breath, malaise, and signs of potential deep vein thrombosis (DVT) like tenderness in the right calf and elevated D-dimer.\n\n2. The clinical trial is studying the safety and pharmacokinetics of the low molecular weight heparin dalteparin as prophylaxis in ICU patients with severe renal insufficiency (creatinine clearance < 30 mL/min/1.73m2).\n\n3. One of the key inclusion criteria is \"Adult patient aged > 18 years Admitted to an ICU with an expected ICU length of stay > 72 hours Severe renal insufficiency, defined by a calculated CrCl < 30 mL/min/1.73m2\"\n\n4. Based on the patient note, there is no mention of the patient being admitted to the ICU or having severe renal insufficiency. The note indicates she is 20 days post-mastectomy and presenting to the emergency department.\n\n5. Therefore, based on the information provided, I would assess:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her renal function and potential need for ICU admission.",
        "label": 0
    },
    "1545": {
        "output": "To determine the patient's eligibility for the clinical trial \"BNP Testing in Patients With SOB on Presentation to ED\", let's go through the inclusion criteria:\n\n1. Inclusion Criteria: We plan to include all patients presenting to the ED with shortness of breath that are over 40 years old and present with an emergency department triage category of 3 or higher.\n\nThe patient note mentions that the 56-year-old female patient presented to the emergency department complaining of shortness of breath, which meets the first part of the inclusion criteria. However, there is no information provided about the emergency department triage category.\n\nBased on the available information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo make a more definitive assessment, we would need additional information about the patient's emergency department triage category. If the triage category was 3 or higher, the patient would likely be eligible for the clinical trial.",
        "label": 1
    },
    "1546": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female presenting with shortness of breath, malaise, and tenderness on the left upper thoracic wall and right calf after a recent mastectomy. She has decreased breath sounds bilaterally and an elevated D-dimer.\n\n2. The clinical trial is studying the accuracy of emergency physician diagnosis of proximal deep vein thrombosis (DVT) using ultrasound.\n\n3. The inclusion criteria are:\n   - Presenting signs and symptoms sufficiently suspicious for lower extremity DVT to warrant a formal radiology study\n   - AND EITHER:\n      a) Moderate or high pre-test clinical probability of DVT (Wells Criteria)\n      b) Low pre-test clinical probability of DVT with a positive D-dimer\n\n4. This patient has signs/symptoms suspicious for DVT (right calf tenderness, recent surgery, immobility) and a positive D-dimer, meeting inclusion criteria 3b.\n\n5. Therefore, this patient would likely be eligible for the clinical trial studying emergency physician ultrasound diagnosis of DVT.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1547": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of being over 18 years old.\n\n2. The patient is admitted to the emergency department, but the trial requires admission to the ICU. It's unclear if the patient will be admitted to the ICU or not.\n\n3. The trial requires an expected ICU stay of greater than 72 hours, but there is no information provided about the expected length of stay for this patient.\n\n4. The patient has shortness of breath, malaise, and an elevated D-dimer, which could indicate a thromboembolic event, making them potentially eligible for a trial studying thromboembolism prophylaxis.\n\nBased on the information provided, there are some uncertainties around whether the patient will meet the ICU admission and length of stay criteria. However, their presenting symptoms and risk factors suggest they could potentially be eligible.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1548": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy and is now presenting with shortness of breath, malaise, and tenderness on the left upper thoracic wall and right calf.\n\n2. The clinical trial is a randomized, double-blind trial comparing unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in heparin-induced thrombocytopenia (HIT) for trauma-surgical patients.\n\n3. The inclusion criteria for the trial are:\n   - Trauma-surgical patient\n   - Consent given\n   - Minimum age 18\n   - Expected inpatient period at least 7 days\n   - Need for thrombosis prophylaxis with heparin\n\n4. Based on the information provided, the patient meets the following inclusion criteria:\n   - She is a trauma-surgical patient (post-mastectomy)\n   - She is 56 years old, which meets the minimum age requirement of 18\n   - She is likely to have an inpatient period of at least 7 days given her current condition\n   - She may need thrombosis prophylaxis with heparin, given the elevated D-dimer and tenderness in the right calf (potential deep vein thrombosis)\n\n5. However, it is unclear if the patient has provided consent to participate in the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation (to confirm consent and assess the need for thrombosis prophylaxis).",
        "label": 0
    },
    "1549": {
        "output": "To determine the patient's eligibility for the clinical trial \"Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services\", let's go through the inclusion criteria:\n\nInclusion criteria: Patients admitted to General Medicine Services with a primary or secondary diagnosis related to venous thromboembolism\n\nBased on the patient note, the 56-year-old female patient presents with shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, and an elevated D-dimer. These symptoms and findings are suggestive of a possible venous thromboembolism, such as deep vein thrombosis (DVT) or pulmonary embolism (PE).\n\nWhile the patient's primary diagnosis is not explicitly stated, the elevated D-dimer and clinical presentation are consistent with a potential diagnosis of venous thromboembolism as a secondary condition.\n\nGiven that the patient meets the inclusion criteria of being admitted to the General Medicine Services with a suspected diagnosis related to venous thromboembolism, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1550": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes\", it appears that the patient does not meet the inclusion criteria for this trial.\n\nThe patient note mentions that the patient is a 56-year-old female who recently underwent a mastectomy and is presenting with shortness of breath, malaise, and potential deep vein thrombosis (DVT) or pulmonary embolism (PE). There is no mention of the patient having type 2 diabetes or any information related to their glycemic control or insulin therapy.\n\nThe inclusion criteria for the clinical trial specifically require participants to have a diagnosis of type 2 diabetes, an HbA1c level of 12.0% or lower within the past 12 months, a BMI of 45.0 kg/m^2 or lower, and the initiation, addition, change, or continuation of basal insulin therapy with insulin detemir.\n\nSince the patient note does not indicate that the patient has type 2 diabetes or meets any of the other inclusion criteria, it is unlikely that this patient would be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1551": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of being 70 years or older for patients with creatinine clearance \u226430 mL/min, or 75 years or older for patients with creatinine clearance \u226460 mL/min.\n\n2. The patient presents with shortness of breath, malaise, and tenderness on the left upper thoracic wall and right calf, which could be indicative of a deep vein thrombosis (DVT) or pulmonary embolism (PE).\n\n3. The patient has an elevated D-dimer, which is a marker for thrombosis and supports the possibility of DVT or PE.\n\n4. The inclusion criteria specifically mention patients with symptomatic and objectively confirmed DVT or PE, with a mandatory presence of objectively confirmed and treatment-requiring DVT.\n\n5. While the patient note does not explicitly mention an objective confirmation of DVT, the clinical presentation and elevated D-dimer suggest a high likelihood of DVT or PE.\n\nBased on the available information, it seems reasonable to consider referring this patient to the clinical trial upon further investigation to objectively confirm the presence of DVT or PE.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1552": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently had a left mastectomy and is now presenting with shortness of breath, malaise, and signs of possible pulmonary embolism (elevated D-dimer, decreased breath sounds).\n\n2. The clinical trial is studying the use of inhaled prostacyclin for adult respiratory distress syndrome (ARDS) and pulmonary hypertension.\n\n3. The inclusion criteria for the trial are:\n   - Patients admitted to the ICU with pulmonary hypertension (mean PA > 35 mmHg)\n   - Patients in the ICU with post-operative pulmonary hypertension (mean PA > 35 mmHg)\n   - Patients with ARDS (defined as PaO2/FiO2 < 200, arterial hypoxemia, bilateral infiltrates on chest X-ray, and wedge pressure < 20 mmHg)\n\n4. Based on the information provided, this patient does not currently meet the inclusion criteria for pulmonary hypertension or ARDS, as those specific criteria are not mentioned. However, the shortness of breath and decreased breath sounds could potentially indicate an underlying respiratory issue.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient's respiratory symptoms and recent surgery warrant further evaluation to determine if she meets the criteria for ARDS or pulmonary hypertension. Additional testing, such as arterial blood gas analysis, chest imaging, and hemodynamic measurements, would be needed to make a definitive assessment of eligibility for this trial.",
        "label": 0
    },
    "1553": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient must be 18 and older\n   - The patient is 56 years old, so this criterion is met.\n\n2. Patients must have histologically confirmed (by routine H&E staining) invasive adenocarcinoma or Ductal Carcinoma In Situ of the left breast.\n   - The patient has undergone a left mastectomy, which implies they had breast cancer, likely invasive adenocarcinoma or DCIS of the left breast. This criterion is likely met.\n\n3. Patients must have undergone a segmental mastectomy (SM) or Mastectomy\n   - The patient has undergone a left mastectomy, so this criterion is met.\n\n4. Patients must not have received prior radiation therapy to the breast at any time for any reason.\n   - There is no mention of prior radiation therapy, so this criterion is likely met.\n\n5. Any patient with active local-regional disease prior to registration is not eligible.\n   - There is no mention of active local-regional disease, so this criterion is likely met.\n\n6. Patients must not be pregnant due to the potential for fetal harm as a result of this treatment regimen. Women of child-bearing age will be given a serum pregnancy test prior to study entry to ensure they are not pregnant. Women of child-bearing potential must use effective non-hormonal contraception while undergoing radiation therapy.\n   - The patient is a 56-year-old female, so pregnancy is unlikely, but a pregnancy test may still be required.\n\n7. Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment.\n   - There is no mention of any serious medical or psychiatric illness, so this criterion is likely met.\n\n8. All patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines.\n   - This is a requirement for enrollment, not an inclusion criterion.\n\nBased on the information provided, it seems that the patient meets most of the key inclusion criteria for this clinical trial. However, further investigation may be needed to confirm pregnancy status and rule out any serious medical conditions.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1554": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy (breast cancer surgery).\n2. She is presenting with shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, decreased breath sounds bilaterally (especially on the right base), and an elevated D-dimer level.\n3. The clinical trial is studying the use of desirudin vs heparin to prevent venous thromboembolism (VTE) after cardiac or thoracic surgery.\n4. The inclusion criteria are: patients scheduled for elective cardiac or thoracic surgery, and age > 18 years.\n\nGiven this information, this patient meets the inclusion criteria of being over 18 years old and having recently undergone thoracic surgery (mastectomy). Her symptoms of shortness of breath, decreased breath sounds, and elevated D-dimer also suggest she may have developed a postoperative VTE, which is the condition the trial is trying to prevent/treat.\n\nTherefore, I would consider this patient as potentially eligible for the clinical trial upon further investigation of her condition and risk factors.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1555": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which does not violate any inclusion/exclusion criteria for age or gender.\n\n2. The patient has no clear diagnosis of COPD mentioned in the note. The shortness of breath and malaise could be related to other conditions like a post-operative complication.\n\n3. There is no mention of the patient's smoking history, FEV1 values, or FEV1/FVC ratio to determine if they meet the COPD severity criteria.\n\n4. The patient is post-operative from a mastectomy, which could potentially be an \"uncontrolled disease likely to interfere with the study.\"\n\n5. There is no mention of the patient's medication history to check for exclusions like beta-blockers.\n\nBased on the limited information provided in the patient note, it is difficult to definitively determine eligibility for this COPD clinical trial. More investigation would be needed into the patient's pulmonary function tests, COPD diagnosis and severity, smoking history, and comorbidities.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1556": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of 18 years or older.\n\n2. The patient is presenting with shortness of breath, malaise, and an elevated D-dimer, which could indicate a deep vein thrombosis (DVT) or pulmonary embolism (PE).\n\n3. The inclusion criteria state \"Patients aged 18 years or more with suspected or proven DVT/PE whom the clinician intended to anticoagulate.\"\n\nBased on the information provided, this patient meets the inclusion criteria of being 18 years or older and having suspected DVT/PE, for which anticoagulation would likely be considered.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1557": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy for breast cancer. She is presenting with shortness of breath, malaise, and an elevated D-dimer, which could indicate a pulmonary embolism (PE).\n\n2. The clinical trial is evaluating a new diagnostic device called the Carboximeter for detecting PEs by measuring carbon dioxide and oxygen output.\n\n3. The inclusion criteria for Phase I of the trial include patients who have undergone certain surgeries or have certain types of cancer, which would put them at risk for developing a PE.\n\n4. The inclusion criteria for Phase II include patients with clinical suspicion of a PE within 24 hours, at least one risk factor for PE, and a CT angiogram ordered by their clinical care providers.\n\n5. Based on the information provided, this patient meets the inclusion criteria for Phase II of the trial, as she has recently undergone surgery (mastectomy), is presenting with symptoms suggestive of a PE (shortness of breath, elevated D-dimer), and likely had a CT angiogram ordered to investigate the possibility of a PE.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1558": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of 2-59 months for the clinical trial.\n2. However, the clinical trial is specifically for children with severe pneumonia, while the patient note mentions shortness of breath and malaise after a mastectomy, with no clear indication of pneumonia.\n3. The physical examination reveals tenderness on the left upper thoracic wall and right calf, as well as decreased breath sounds bilaterally, especially at the right base. This could potentially be consistent with pneumonia, but it is not definitively stated.\n4. The elevated D-dimer suggests a potential blood clot or thrombosis, which is not directly related to the inclusion criteria for severe pneumonia.\n\nBased on the information provided, there is not enough evidence to conclusively determine if this patient meets the inclusion criteria for severe pneumonia. Additional investigation or clarification would be needed regarding the presence and severity of pneumonia.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1559": {
        "output": "To determine the patient's eligibility for the clinical trial \"Epidemiology of Venous Thromboembolism\", let's go through the key points:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy.\n2. She is presenting with shortness of breath, malaise, and has been bedridden for the last two weeks.\n3. Physical examination reveals tenderness on the left upper thoracic wall and right calf.\n4. Laboratory tests show an elevated D-dimer level.\n\nThe inclusion criteria for the clinical trial is \"Ultrasound-confirmed DVT patients from 183 institutions.\"\n\nBased on the patient's symptoms, physical examination findings, and elevated D-dimer level, there is a high suspicion of deep vein thrombosis (DVT) or venous thromboembolism (VTE). However, the patient note does not explicitly mention an ultrasound confirmation of DVT.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation (ultrasound confirmation of DVT).",
        "label": 1
    },
    "1560": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which does not meet the inclusion criteria of \"Males 18 to 45 years of age\" for this clinical trial.\n\n2. The patient has recently undergone a left mastectomy and is presenting with shortness of breath, malaise, and potential signs of deep vein thrombosis (tenderness in right calf and elevated D-dimer). This suggests the patient is not \"healthy\" as required by the inclusion criteria.\n\n3. There is no information provided about the patient's history of cardiovascular, pulmonary, coagulation, or bleeding disorders, which are part of the exclusion criteria.\n\n4. There is no information about any medications the patient may be taking.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of being a healthy male aged 18-45 years old. Additionally, the patient's recent surgery and potential complications suggest they would not be considered \"healthy.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1561": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the inclusion criteria of being an adult patient.\n\n2. The patient is hospitalized for an acute medical condition (post-mastectomy) and has been on bed rest for the last two weeks, which meets the inclusion criteria of being an acute medical patient requiring bed rest for at least 3 days.\n\n3. The patient has shortness of breath and malaise, which could potentially indicate acute respiratory failure (not requiring mechanical ventilation), one of the listed acute medical conditions in the inclusion criteria.\n\n4. The patient has tenderness on the right calf, which could be a sign of deep vein thrombosis (DVT), a type of venous thromboembolism (VTE). The elevated D-dimer also suggests a potential VTE.\n\n5. The patient has recently undergone surgery (mastectomy), which could be considered an additional risk factor for VTE.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial, which is evaluating the prevention of VTE in acutely ill medical patients with restricted mobility.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1562": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of being an adult (\u2265 21 years old).\n\n2. The patient is presenting with shortness of breath and malaise, along with decreased breath sounds on auscultation, which could indicate pulmonary pathology.\n\n3. The trial is looking to study the use of Vibration Response Imaging (VRI) in diagnosing pulmonary diseases, and the patient's symptoms and findings suggest the presence of a pulmonary condition.\n\n4. The inclusion criteria state that all adult patients under the care of the Department of Respiratory and Critical Care Medicine between specific dates will be considered eligible. While the patient's department is not explicitly stated, her symptoms and findings suggest she would likely be under the care of this department.\n\n5. The ability to provide informed consent is also an inclusion criterion, which is not mentioned for this patient.\n\nBased on the information provided, there is a strong possibility that this patient could be eligible for the clinical trial, as she meets the age criteria and appears to have a pulmonary condition that the trial aims to study. However, her ability to provide informed consent is unclear.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding her ability to provide informed consent.",
        "label": 2
    },
    "1563": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy for breast cancer. She is presenting with shortness of breath, malaise, and signs of potential blood clots (elevated D-dimer, tenderness in right calf).\n\n2. The clinical trial is studying the effects of sequential compression devices (SCDs) on blood clotting in patients undergoing major abdominal surgery.\n\n3. The key inclusion criteria are:\n   - Elective major abdominal surgery for neoplasm (cancer)\n   - Planned admission to ICU after surgery due to certain risk factors\n\n4. This patient does not meet the inclusion criteria because:\n   - She did not undergo major abdominal surgery, but rather a mastectomy\n   - There is no indication that she was admitted to the ICU after her surgery\n\n5. While the patient may be at risk for blood clots based on her symptoms, she does not fit the specific criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1564": {
        "output": "To determine the patient's eligibility for the clinical trial \"Ultrasound Elasticity Imaging of Venous Thrombi\", let's go through the inclusion criteria:\n\n1. \"Male or female subjects who have a diagnosis of chronic DVT that is at least 2 weeks old and are free from an acute DVT on top of your chronic DVT.\"\n   - The patient note does not mention a chronic DVT, so this criterion is not met.\n\n2. \"Male and female patients who have been diagnosed with an acute blood clot by the Diagnostic Vascular Lab and w/symptoms occurring within the previous 2 weeks.\"\n   - The patient note mentions that the patient has an elevated D-dimer, which is a marker for acute blood clots. Additionally, the patient has tenderness in the right calf, which could indicate a deep vein thrombosis (DVT). The note does not specify if the patient has been diagnosed by the Diagnostic Vascular Lab, but the symptoms seem to have occurred within the previous 2 weeks.\n\n3. \"Patients under the age of 18 who give assent (permission) and whose parents give consent.\"\n   - The patient is 56 years old, so this criterion does not apply.\n\n4. \"Adult patients who give consent.\"\n   - Assuming the patient is willing to provide consent, this criterion would be met.\n\nBased on the information provided in the patient note, the patient seems to meet the second inclusion criterion for an acute blood clot with symptoms occurring within the previous 2 weeks. However, it is not explicitly stated that the patient has been diagnosed by the Diagnostic Vascular Lab.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1565": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently had a left mastectomy for breast cancer. The clinical trial is studying the effects of fenoldopam on renal function in patients undergoing partial nephrectomy (removal of part of the kidney) for renal cell carcinoma.\n\n2. The inclusion criteria for the trial are:\n- Patients who have a solitary kidney and present for a partial nephrectomy\n- Patients who have one atrophic minimally functioning kidney and present for partial nephrectomy on the other kidney\n\n3. Based on the patient note, there is no mention of the patient having renal cell carcinoma or needing a partial nephrectomy. The patient's presenting complaints are related to her recent mastectomy.\n\n4. Therefore, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1566": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of being over 18 years old for the clinical trial.\n\n2. However, the clinical trial is specifically for patients with chronic kidney disease stage V treated with hemodiafiltration. There is no mention of the patient having chronic kidney disease or being on hemodiafiltration in the patient note.\n\n3. The patient note mentions that the patient recently had a left mastectomy and is experiencing shortness of breath, malaise, and potential blood clots (elevated D-dimer). These conditions are not relevant to the inclusion criteria for the clinical trial, which is focused on chronic kidney disease and hemodiafiltration.\n\n4. Based on the information provided, the patient does not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1567": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently had a left mastectomy for breast cancer. She is presenting with shortness of breath, malaise, and signs of a potential blood clot (elevated D-dimer, tenderness in right calf).\n\n2. The clinical trial is studying the use of the low molecular weight heparin enoxaparin in advanced non-small cell lung cancer patients undergoing first-line chemotherapy.\n\n3. The key inclusion criteria are:\n- Locally advanced or metastatic non-small cell lung cancer (stage IIIB or IV)\n- At least one measurable lesion per RECIST criteria\n- Good performance status \n- Adequate hematologic, renal and liver function\n\n4. Based on the patient note, there is no mention of the patient having lung cancer. The symptoms seem more related to her recent mastectomy and potential blood clot.\n\n5. Therefore, this patient would not meet the key inclusion criteria for this lung cancer clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1568": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of being 18 years or older for the clinical trial.\n\n2. The patient has undergone a left mastectomy, which is not an exclusion criterion for the trial. The trial is focused on patients undergoing coronary artery bypass graft (CABG) surgery.\n\n3. The patient is presenting with shortness of breath, malaise, and an elevated D-dimer, which could indicate a potential venous thromboembolism (VTE). However, the trial is specifically for the prevention of VTE in patients undergoing CABG surgery.\n\n4. There is no mention of the patient undergoing or being scheduled for CABG surgery in the patient note.\n\nBased on the information provided, this patient does not meet the inclusion criteria of undergoing isolated or redo isolated CABG surgery for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1569": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 56-year-old female presenting with shortness of breath, malaise, and tenderness in the left upper thoracic wall and right calf on the 20th day post-left mastectomy. She has remained in bed for the last two weeks. Physical exam shows decreased breath sounds bilaterally, especially at the right base. Lab tests reveal an elevated D-dimer.\n\nThe clinical trial is studying the natural history of isolated deep vein thrombosis (DVT) of the calf in outpatients with suspected leg DVT who have intermediate/high pre-test clinical probability or high D-dimer levels.\n\nGiven the patient's recent surgery, immobility, and elevated D-dimer, there is a high suspicion for DVT, potentially involving the calf veins.\n\nBased on the inclusion criteria of the clinical trial and the patient's presentation, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation with compression ultrasonography of the leg veins would be needed to confirm the presence and extent of DVT before definitively enrolling the patient in this trial studying the natural history of isolated calf DVT.",
        "label": 0
    },
    "1570": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which does not meet the age criteria of 18-40 years old for this clinical trial.\n\n2. There is no information provided about the patient's body mass index, smoking status, or history of respiratory diseases.\n\n3. The patient is post-mastectomy and has been in bed for the last two weeks, suggesting potential complications or underlying conditions that may exclude them from a trial studying healthy breathing techniques.\n\n4. The trial is specifically looking for healthy subjects to evaluate diaphragm activity during different breathing exercises.\n\nGiven the information provided, this patient does not seem to meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1571": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of \"from full-term newborns to < 18 years\" for the clinical trial.\n\n2. The patient has a functioning central venous catheter (CVC) in place, as evidenced by the mention of a recent mastectomy and the presence of the surgical incision.\n\n3. The patient is experiencing symptoms that could be related to a catheter-related deep vein thrombosis (DVT), such as shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, and an elevated D-dimer level.\n\n4. The clinical trial is specifically looking for patients with suspected catheter-related DVTs, either asymptomatic (Cohort A) or symptomatic (Cohort B).\n\nBased on the information provided, this patient appears to meet the inclusion criteria for Cohort B of the clinical trial, as she is symptomatic and has a CVC in place, with symptoms that could be indicative of a catheter-related DVT.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1572": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy for cancer.\n2. She is presenting with shortness of breath, malaise, and signs of a possible deep vein thrombosis (DVT) or pulmonary embolism (PE).\n3. The clinical trial is studying the long-term treatment of cancer patients with DVT or PE who have already completed 6-12 months of anticoagulant treatment.\n\nAssessing against the inclusion criteria:\n- The patient has cancer and a suspected DVT or PE, meeting the first inclusion criteria.\n- It's not explicitly stated if she has completed 6-12 months of prior anticoagulant treatment, which is required.\n- However, given her recent cancer surgery and current symptoms, it seems highly likely she would meet this criteria upon further investigation.\n\nTherefore, based on the information provided:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1573": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female presenting with shortness of breath and malaise after a recent mastectomy surgery. She has been bedridden for the past 2 weeks.\n\n2. Physical exam findings include tenderness on the left upper thoracic wall and right calf. Pulmonary auscultation reveals decreased breath sounds bilaterally, especially at the right base. \n\n3. Laboratory tests show an elevated D-dimer level.\n\n4. The clinical trial is studying the diagnostic performance of V/Q SPECT for pulmonary embolism.\n\n5. The inclusion criteria for the trial is \"Pulmonary embolism suspicion\".\n\nGiven the patient's recent surgery, immobility, shortness of breath, decreased breath sounds, and elevated D-dimer, there is a high suspicion for pulmonary embolism.\n\nTherefore, this patient meets the inclusion criteria for the clinical trial studying V/Q SPECT for pulmonary embolism diagnosis.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1574": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of \u226518 years.\n\n2. There is no mention of the patient having psoriatic arthritis or meeting the CASPAR criteria for psoriatic arthritis.\n\n3. The patient is post-mastectomy and presenting with shortness of breath, malaise, and potential deep vein thrombosis (elevated D-dimer), which are not relevant to the inclusion criteria for this psoriatic arthritis trial.\n\n4. There is no information provided about the patient's treatment history with DMARDs or other medications relevant to psoriatic arthritis.\n\n5. There is no information about the patient having swollen or tender joints, which is a key inclusion criterion.\n\nBased on the information provided in the patient note, this patient would not be eligible for the PALACE 2 clinical trial on apremilast for psoriatic arthritis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1575": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of being above 18 years old for the clinical trial.\n\n2. However, the clinical trial is focused on studying uteroplacental and fetal pulmonary circulation in pregnant women with oligohydramnios (low amniotic fluid). This patient has just undergone a mastectomy and there is no mention of her being pregnant.\n\n3. The inclusion criteria specifically state that it is for \"Singleton pregnancy\" and requires \"Normal structural examination between 16 and 20 weeks of gestation\".\n\n4. Since this patient is not pregnant, she would not meet the key inclusion criteria for this particular clinical trial.\n\nTherefore, based on the given patient note and the inclusion criteria of the clinical trial, my assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1576": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the inclusion criteria of being an adult patient.\n\n2. However, the patient note does not mention anything about atrial fibrillation, paroxysmal or persistent. The patient is presenting with shortness of breath and malaise after a recent mastectomy, with findings suggestive of a pulmonary embolism.\n\n3. The clinical trial is specifically for patients with paroxysmal or persistent atrial fibrillation undergoing ablation procedures.\n\n4. Since there is no mention of the patient having atrial fibrillation, they would not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1577": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy surgery.\n2. She is presenting with shortness of breath, malaise, and tenderness on the left upper thoracic wall and right calf.\n3. Lab tests reveal an elevated D-dimer, which could indicate the presence of a blood clot.\n\nThe clinical trial is looking at the incidence of deep vein thrombosis (DVT) in the lower extremities, both before and after surgery.\n\nThe inclusion criteria for the trial are:\n1. Age 18 or older\n2. Able to provide consent\n\nThis patient meets both of those criteria. Additionally, her symptoms and elevated D-dimer suggest she may have a DVT, which is exactly what the trial is studying.\n\nTherefore, based on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1578": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of \u226518 years for the clinical trial.\n\n2. The patient note does not mention a diagnosis of psoriatic arthritis or meeting the CASPAR criteria for psoriatic arthritis, which are required for inclusion in this trial.\n\n3. There is no information provided about the patient having swollen or tender joints, which is another inclusion criterion.\n\n4. The patient note indicates the patient recently had a mastectomy, but there is no mention of her being treated with disease-modifying antirheumatic drugs (DMARDs) previously, which is an inclusion criterion.\n\n5. The patient note does not provide any information about the laboratory values required for inclusion, such as white blood cell count, platelet count, creatinine, liver enzymes, bilirubin, hemoglobin, or HbA1c.\n\n6. There is no information about the patient's contraceptive use or pregnancy status.\n\nBased on the lack of information confirming the patient meets several key inclusion criteria, particularly the diagnosis of psoriatic arthritis and joint involvement, as well as missing laboratory values:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1579": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently had a left mastectomy and is now presenting with shortness of breath, malaise, and tenderness in the left upper thoracic wall and right calf.\n\n2. The clinical trial is studying the effects of intermittent pneumatic compression (IPC) on complications and healing of Achilles tendon ruptures.\n\n3. The key inclusion criterion for this trial is having an Achilles tendon rupture that was operated on within 96 hours of diagnosis.\n\n4. Based on the patient note, there is no mention of an Achilles tendon rupture or any surgery related to that. The patient's symptoms seem to be related to her recent mastectomy and potential complications like deep vein thrombosis (DVT).\n\nTherefore, based on the information provided, this patient would not be eligible for the clinical trial studying Achilles tendon ruptures.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1580": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, so age is not an exclusion criteria for this trial.\n\n2. The trial is looking at patients with known or suspected COPD who are experiencing an exacerbation. The patient note does not explicitly mention COPD, but it does state that the patient is experiencing shortness of breath and malaise, which could potentially be symptoms of a COPD exacerbation.\n\n3. The patient has decreased breath sounds bilaterally, especially at the right base, which is consistent with a potential pulmonary issue like COPD exacerbation or pulmonary embolism.\n\n4. The patient has an elevated D-dimer, which is a risk factor for pulmonary embolism.\n\nWhile the patient note does not definitively state that the patient has COPD, the symptoms of shortness of breath, malaise, and decreased breath sounds, along with the elevated D-dimer, suggest that this patient could potentially be a candidate for this clinical trial investigating pulmonary embolism in COPD exacerbations.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1581": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy (breast cancer surgery). This matches the inclusion criteria of being 18 years or older.\n\n2. However, the trial is specifically for patients undergoing total hip replacement surgery, which this patient did not have. The patient's surgery was a mastectomy.\n\n3. The trial is also evaluating a drug (TB-402) for prevention of venous thromboembolism (VTE) after hip surgery. While the patient does have an elevated D-dimer suggesting a possible VTE, she did not have hip surgery.\n\n4. Based on the mismatch between the patient's condition (post-mastectomy) and the trial's focus on hip replacement surgery and VTE prophylaxis after that procedure, this patient would likely not be eligible for this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1582": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which does not meet the age criteria of 18-40 years for the clinical trial.\n\n2. The patient is not pregnant, as she is described as being on the 20th day post-left mastectomy.\n\n3. The patient is not undergoing a planned caesarean section.\n\nBased on the inclusion criteria provided for the clinical trial \"Evaluation of the LMWH Thromboprophylaxis in Pregnancy\", this patient would not be eligible as she does not meet any of the criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1583": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 56-year-old female, which meets the age criteria of 18 and older.\n\nShe has recently undergone a left mastectomy, indicating a primary inpatient discharge diagnosis of cancer.\n\nThe note mentions she is on the 20th day post-left mastectomy, so she had a cancer-related surgery during the index hospitalization.\n\nThere is no explicit mention of being prescribed an anticoagulant treatment as thromboprophylaxis therapy around the time of the cancer surgery.\n\nHowever, the note does state that she presents to the emergency department with shortness of breath, malaise, tenderness on the left thoracic wall and right calf, decreased breath sounds especially at the right base, and an elevated D-dimer. These symptoms and findings are suggestive of a venous thromboembolism like deep vein thrombosis or pulmonary embolism.\n\nGiven her recent cancer surgery and clinical presentation concerning for VTE, it is quite likely that she would be a candidate for anticoagulant thromboprophylaxis if she has not already received it.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether she has already received anticoagulant thromboprophylaxis after her cancer surgery.",
        "label": 0
    },
    "1584": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently had a left mastectomy and is presenting with shortness of breath, malaise, and signs of potential deep vein thrombosis (tenderness in right calf and elevated D-dimer).\n\n2. The clinical trial is about detecting air embolism during an ERCP procedure using echocardiography.\n\n3. The inclusion criteria for the trial are:\n   - Subject is undergoing ERCP as part of their medical care\n   - Subject will be of age 19 or older\n\n4. Based on the patient note, there is no mention of the patient undergoing or scheduled for an ERCP procedure. The patient's presentation seems to be related to post-surgical complications rather than issues with the biliary or pancreatic systems.\n\n5. Therefore, this patient does not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1585": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient is a 56-year-old female who has undergone a left mastectomy, which is not one of the inclusion criteria procedures (meniscectomy, diagnostic arthroscopy, or removal of corpora libera).\n\n2. The patient's symptoms (shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, elevated D-dimer) suggest a possible post-operative complication like deep vein thrombosis or pulmonary embolism, rather than a condition related to knee arthroscopy.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the \"Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1586": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 56-year-old female who recently had a left mastectomy and is now presenting with shortness of breath, malaise, and signs of potential deep vein thrombosis (DVT) like tenderness in the right calf and elevated D-dimer.\n\nThe clinical trial is studying the effectiveness of thrombosis prophylaxis with low molecular weight heparin (LMWH) during lower leg immobilization with a plaster cast following trauma, surgery, or other non-traumatic indications.\n\nThe key inclusion criteria are:\n1) Patients requiring immobilization of the lower leg with a plaster cast (or equivalent) for at least 1 week due to trauma, surgery on the lower leg, or non-traumatic indications.\n\nWhile the patient does not have a plaster cast on the lower leg currently, she is at high risk for DVT given her recent surgery and immobilization. Providing thromboprophylaxis could potentially prevent complications like pulmonary embolism.\n\nTherefore, based on the information provided, I would assess:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1587": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy (breast cancer surgery).\n2. She is presenting with shortness of breath, malaise, and has been bedridden for the past 2 weeks.\n3. Physical exam shows tenderness in the left upper thoracic wall and right calf, with decreased breath sounds bilaterally.\n4. Lab tests reveal an elevated D-dimer, which can indicate a blood clot.\n\nThe clinical trial is studying the frequency of vascular events (like blood clots) with short-term thromboprophylaxis (blood thinners to prevent clots) after hip or knee arthroplasty (joint replacement surgery).\n\nThe key inclusion criteria are:\n- Primary uni/bilateral hip or knee replacement surgery\n- Revision hip or knee replacement surgery \n- Discharged within 3 +/- 2 days after fast-track setup\n\nThis patient does not meet the inclusion criteria, as she had a mastectomy and not a hip or knee replacement surgery.\n\nAdditionally, her symptoms and elevated D-dimer suggest she may have a blood clot already, which could exclude her from a trial studying clot prevention.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1588": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy (breast cancer surgery).\n2. She is presenting with shortness of breath, malaise, and tenderness in the left upper thoracic wall and right calf.\n3. Lab tests show an elevated D-dimer, which can indicate the presence of a blood clot.\n\nThe clinical trial is studying the influence of tourniquet use and surgery duration on the incidence of deep vein thrombosis (DVT) in patients undergoing total knee arthroplasty (knee replacement surgery).\n\nThe key inclusion criteria is: \"patients that underwent cemented total knee arthroplasty\"\n\nSince this patient did not undergo a knee replacement surgery, but rather a mastectomy, she would not meet the inclusion criteria for this particular clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1589": {
        "output": "To determine the patient's eligibility for the \"Italian Pulmonary Embolism Registry - IPER\" clinical trial, let's go through the details:\n\nThe patient is a 56-year-old female who presented to the emergency department with shortness of breath and malaise, 20 days after a left mastectomy. Physical examination revealed tenderness on the left upper thoracic wall and right calf, decreased breath sounds bilaterally (especially at the right base), and an elevated D-dimer level.\n\nThe inclusion criteria for the clinical trial are \"consecutive patients with acute pulmonary embolism.\"\n\nGiven the patient's symptoms (shortness of breath, malaise), physical examination findings (decreased breath sounds, tenderness in the calf), and elevated D-dimer level, it is highly likely that this patient has an acute pulmonary embolism.\n\nTherefore, based on the information provided, this patient meets the inclusion criteria for the \"Italian Pulmonary Embolism Registry - IPER\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1590": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\n1. Age: The patient is 56 years old, which falls within the age range of 18-89 years.\n\n2. Chief complaint: The patient presents to the emergency department complaining of shortness of breath, which matches the chief complaint requirement.\n\nBased on the information provided, the patient meets the inclusion criteria for the clinical trial titled \"BRIPPED Scan for Evaluation of Emergency Department (ED) Patients With Shortness of Breath.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1591": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, so she meets the inclusion criteria of being a pregnant woman.\n\n2. However, the note does not explicitly state that she is pregnant or has a suspected deep vein thrombosis (DVT). The note mentions that she recently had a mastectomy and is experiencing shortness of breath, malaise, and tenderness in her left thoracic wall and right calf.\n\n3. While the elevated D-dimer could be indicative of a potential DVT, there is no clear mention of a clinical suspicion of DVT in the patient note.\n\n4. Based on the information provided in the patient note, it is unclear if this patient would be eligible for the clinical trial, as the inclusion criteria specifically state \"Pregnant women with clinically suspected DVT\".\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information regarding the patient's pregnancy status and whether there is a clinical suspicion of DVT would be needed to make a more definitive determination of eligibility for this particular trial.",
        "label": 0
    },
    "1592": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female presenting with shortness of breath and malaise after a recent mastectomy. She has tenderness on the left upper thoracic wall and right calf.\n\n2. The clinical trial is looking at the usefulness of chest wall tenderness in excluding acute coronary syndrome in patients presenting with acute chest pain.\n\n3. The inclusion criteria for the trial are:\n   - Patients over 18 years old\n   - Presenting with first time or recurrent acute chest pain\n   - At the emergency department of the University Hospital of Zurich\n\n4. The exclusion criteria are:\n   - Missing informed consent\n   - Cardiopulmonary unstable patients\n   - No self-reported chest pain\n   - Recent thoracic surgery within 1 year\n   - Inflammatory joint disease\n   - Fibromyalgia\n   - Cardiogenic shock\n\n5. Based on the information provided, this patient does not seem to meet the inclusion criteria as she is not presenting with acute chest pain, which is a key requirement for this trial. Her primary complaints are shortness of breath and malaise.\n\n6. Additionally, she has recently undergone thoracic surgery (mastectomy), which is an exclusion criterion for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1593": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy and is now presenting with shortness of breath, malaise, and tenderness on the left upper thoracic wall and right calf.\n\n2. Laboratory tests reveal an elevated D-dimer, which can indicate the presence of a blood clot or deep vein thrombosis (DVT).\n\n3. The clinical trial is studying the effectiveness of different dosing regimens of unfractionated heparin and enoxaparin (a low molecular weight heparin) for venous thromboembolism (VTE) prophylaxis in trauma patients at high risk for DVT and pulmonary embolism (PE).\n\n4. The inclusion criteria for the trial are:\n   - Admitted to Scripps Mercy Trauma Service\n   - Age \u2265 18 years\n   - Stratified to either Significant or Highest risk of VTE by ACCP guidelines\n\n5. Based on the patient's recent surgery, immobility, and elevated D-dimer, she is likely at high risk for VTE and meets the age criteria.\n\n6. However, it is unclear from the patient note if she was admitted to the Scripps Mercy Trauma Service or if her risk of VTE has been stratified according to the ACCP guidelines.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1594": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently had a left mastectomy and is now presenting with shortness of breath, malaise, and tenderness on the left upper thoracic wall and right calf.\n\n2. The clinical trial is about visualizing uncertainty in the diagnostic reasoning process for pulmonary embolism.\n\n3. The inclusion criteria for the trial are:\n   - Medical students at the University of Calgary in clerkship who finished at least 4 weeks of a medicine rotation\n   - First-year subspecialty or Internal Medicine residents\n   - Practicing physicians in Internal Medicine or Emergency Medicine\n\n4. This patient does not meet the inclusion criteria, as she is not a medical student, resident, or practicing physician in the specified fields.\n\n5. Additionally, the trial seems to be focused on the diagnostic reasoning process rather than treating patients with suspected pulmonary embolism.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1595": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age and gender criteria for the clinical trial.\n\n2. However, the patient note does not mention any temporomandibular joint (TMJ) issues, arthralgia, myalgia, or TMJ sounds. The note is about a post-mastectomy patient with shortness of breath, malaise, and potential deep vein thrombosis (elevated D-dimer).\n\n3. The note also does not mention any history of using an occlusal appliance therapy for at least 6 weeks, which is one of the inclusion criteria.\n\n4. Based on the information provided in the patient note, there is no indication that this patient meets the inclusion criteria for the clinical trial titled \"Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management.\"\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1596": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which falls within the age range of 18-45 years specified in the inclusion criteria. This is a potential exclusion factor.\n\n2. The patient is post-mastectomy, which is not mentioned in the inclusion criteria. This could potentially exclude her, depending on whether her condition is considered stable enough for participation.\n\n3. There is no mention of the patient being pregnant or seeking care for a pregnancy at one of the study locations, which are required by the inclusion criteria.\n\n4. The patient's ability to provide informed consent and comply with the protocol is not mentioned, which is another inclusion criterion.\n\nBased on the information provided, there are multiple potential exclusion factors and no clear indication that the patient meets the key inclusion criteria of being pregnant and seeking prenatal care at one of the specified locations.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1597": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently had a left mastectomy and is presenting with shortness of breath, malaise, and signs of potential deep vein thrombosis (tenderness in right calf and elevated D-dimer).\n\n2. The clinical trial is studying the effect of nasal steroids on snoring intensity. \n\n3. The key inclusion criteria are:\n- Every night snoring\n- No medications affecting nasal resistance\n- No smoking for last 6 months\n- No upper/lower respiratory tract disease or nasal allergy\n- Provide written informed consent\n\n4. Based on the patient note, there is no mention of the patient snoring or having any nasal/respiratory issues that would make them eligible for this snoring study.\n\n5. The patient seems to be dealing with potential post-operative complications like deep vein thrombosis rather than issues related to snoring.\n\nTherefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1598": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of \u226518 years for the clinical trial.\n\n2. The clinical trial is specifically for patients with pulmonary arteriovenous malformations (AVMs) requiring embolization treatment. The patient note does not mention any diagnosis of pulmonary AVMs or hereditary hemorrhagic telangiectasia (HHT), which is a requirement for the trial.\n\n3. The patient's presenting symptoms of shortness of breath, malaise, and elevated D-dimer could potentially be related to a pulmonary issue, but there is no definitive diagnosis of pulmonary AVMs mentioned.\n\n4. The patient has recently undergone a left mastectomy, which could be a confounding factor for her current symptoms.\n\nBased on the information provided in the patient note, there is not enough evidence to confirm that the patient meets the inclusion criteria of having documented pulmonary AVMs and a definite diagnosis of HHT or genetic diagnosis of HHT.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nIf additional diagnostic tests were performed and confirmed the presence of pulmonary AVMs and a diagnosis of HHT, then the patient could potentially be eligible for the clinical trial. However, with the current information available, further investigation would be needed to determine eligibility.",
        "label": 0
    },
    "1599": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently had a left mastectomy and is now presenting with shortness of breath, malaise, and tenderness on the left upper thoracic wall and right calf.\n\n2. The clinical trial is for treating submassive pulmonary embolism with ultrasound-accelerated thrombolysis.\n\n3. The inclusion criteria for the trial are:\n   - Patients with acute (\u2264 14 days) symptomatic pulmonary embolism by CT angiogram of the thorax\n   - Embolus involving at least one main or lower lobe pulmonary artery\n   - RV:LV ratio > 0.9\n\n4. Based on the patient note, the patient has an elevated D-dimer, which is a marker for pulmonary embolism. However, there is no mention of a CT angiogram confirming the presence of a pulmonary embolism or the RV:LV ratio.\n\n5. Without these specific details, it is difficult to determine if the patient meets the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1600": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 56-year-old female who recently had a mastectomy and is now presenting with shortness of breath, malaise, and an elevated D-dimer level. She is being evaluated for a possible pulmonary embolism.\n\nThe clinical trial is studying the efficacy of low-dose (30ml) versus full-dose (100ml) contrast CT pulmonary angiography in detecting pulmonary emboli.\n\nThe key inclusion criterion for this trial is \"Patients referred for CT pulmonary angiogram to exclude pulmonary embolus\".\n\nGiven the patient's presenting symptoms of shortness of breath, malaise, and elevated D-dimer after recent surgery, along with the clinical suspicion of pulmonary embolism, she meets the key inclusion criterion of being referred for a CT pulmonary angiogram to rule out a pulmonary embolus.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1601": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of over 18 years old for the clinical trial.\n\n2. The clinical trial is looking at patients with congestive heart failure (CHF) and comparing them to non-CHF controls. \n\n3. The patient note does not explicitly state that the patient has CHF. However, it mentions shortness of breath, malaise, decreased breath sounds on auscultation, and an elevated D-dimer level. These could potentially be signs of pulmonary congestion or pulmonary edema, which are inclusion criteria for the \"acute decompensated left HF\" group.\n\n4. However, the note does not provide enough information to definitively diagnose acute decompensated left HF, such as BNP levels, chest X-ray findings, or the presence of rales on auscultation.\n\nBased on the available information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional tests and information, such as BNP levels, chest X-ray, and auscultation findings, would be needed to determine if the patient meets the criteria for acute decompensated left HF or if they would be better classified as a non-CHF control.",
        "label": 0
    },
    "1602": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of \u226518 years old for the clinical trial.\n\n2. The patient presents with shortness of breath, malaise, and decreased breath sounds on auscultation, especially at the right base. These symptoms, along with an elevated D-dimer, suggest the possibility of a pulmonary embolism (PE).\n\n3. The clinical trial is specifically studying the treatment of acute massive pulmonary embolism with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) in combination with thrombolytic treatment.\n\n4. One of the inclusion criteria is \"Acute massive PE patients who require thrombolytic treatment.\"\n\nBased on the information provided, this patient appears to have an acute pulmonary embolism and may require thrombolytic treatment, which would make them eligible for this clinical trial.\n\nHowever, further investigation would be needed to confirm the diagnosis of acute massive PE and determine if thrombolytic treatment is indeed required for this patient.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1603": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of being \u226550 years old for the clinical trial.\n\n2. The patient note does not mention if she has type 2 diabetes, which is an inclusion criteria for the trial. \n\n3. There is no information provided about her HbA1c levels, cardiovascular disease history, renal disease, or current diabetes medications, which are also part of the inclusion criteria.\n\n4. The note mentions she recently had a mastectomy for presumably breast cancer, which would exclude her from the trial based on the exclusion criteria of \"Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma)\".\n\nBased on the limited information provided in the patient note and the inclusion/exclusion criteria, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1604": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy for breast cancer. She is presenting with shortness of breath, malaise, and signs of possible deep vein thrombosis (DVT) like tenderness in the right calf and elevated D-dimer.\n\n2. The clinical trial is studying different dosing regimens of the anticoagulant enoxaparin for venous thromboembolism (VTE) prophylaxis after sleeve gastrectomy surgery for morbid obesity.\n\n3. While the patient did have recent surgery (mastectomy), it was not the specific sleeve gastrectomy surgery that is the focus of this trial.\n\n4. The inclusion criteria specifically state the patient must be undergoing laparoscopic sleeve gastrectomy surgery at that particular medical center.\n\n5. Since this patient had a different type of surgery (mastectomy) at a different center, she would not meet the key inclusion criteria for this VTE prophylaxis trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1605": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy for breast cancer. She is not currently enrolled in a bariatric surgery program.\n\n2. The clinical trial is looking for patients who are enrolled in a pre- or post-operative bariatric surgery program at a specific center.\n\n3. The patient does not meet this key inclusion criteria of being enrolled in a bariatric surgery program.\n\n4. There is no information provided about the patient's ability to perform a 6-minute walk test, age, or willingness to receive dietary recall phone calls.\n\nBased on the information given, this patient would not be eligible for the clinical trial titled \"Physical Fitness and Nutrition Intake in Bariatric Surgery Population\" as she does not meet the key inclusion criteria of being enrolled in a bariatric surgery program.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1606": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy (breast cancer surgery).\n2. She is presenting with shortness of breath, malaise, and tenderness in the left upper thoracic wall and right calf.\n3. Lab tests show an elevated D-dimer, which can indicate a blood clot or deep vein thrombosis (DVT).\n\nThe clinical trial is studying the use of a mechanical compression device (MCD) for preventing DVT after total knee arthroplasty (TKA) surgery.\n\nWhile the patient did not have a TKA, she is at risk for DVT due to her recent surgery and immobility. The inclusion criteria state that patients must be candidates for TKA and able to understand the study intent.\n\nGiven the patient's risk factors for DVT and the relevance of the trial intervention, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient does not meet the strict inclusion criteria for TKA candidacy, but her DVT risk factors make her potentially eligible if the trial allows for some flexibility in enrollment criteria. Further investigation into her specific condition and the trial's allowances would be needed to determine full eligibility.",
        "label": 0
    },
    "1607": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which does not meet the age inclusion criteria of >3 months and <16 years for this dengue fever clinical trial.\n\n2. There is no mention of clinical suspicion of dengue hemorrhagic fever in the patient note. The symptoms described (shortness of breath, malaise, tenderness, decreased breath sounds, elevated D-dimer) seem more indicative of a potential pulmonary issue or deep vein thrombosis rather than dengue fever.\n\n3. The inclusion criteria specifically mentions the study is being conducted in Siem Reap, Cambodia, while the patient note does not provide any location details.\n\nBased on the information provided in the patient note and inclusion criteria, this patient does not appear eligible for the dengue fever clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1608": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: Concern for PE by attending physician and CTPA ordered\n\nBased on the patient note, the 56-year-old female patient presents with shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, decreased breath sounds, and an elevated D-dimer. These symptoms and findings raise concern for a possible pulmonary embolism (PE). Additionally, the note mentions that a computed tomography of the pulmonary arteries (CTPA) is likely ordered to evaluate for PE.\n\nSince the patient meets the inclusion criteria of having a concern for PE by the attending physician and a CTPA ordered, she would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1609": {
        "output": "To determine the patient's eligibility for the clinical trial \"DVT Ultrasound in the Emergency Department\", let's go through the inclusion criteria:\n\n1. Age 18 or older: The patient is 56 years old, so they meet this criterion.\n\n2. Suspect of having DVT: The patient presents with shortness of breath, malaise, tenderness on the left upper thoracic wall and right calf, and an elevated D-dimer. These symptoms and findings raise suspicion for a deep vein thrombosis (DVT), especially in the right calf.\n\nSince the patient meets both inclusion criteria, they would likely be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1610": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy for breast cancer. The clinical trial is focused on reducing blood transfusions in patients undergoing total hip or knee arthroplasty for osteoarthritis.\n\n2. The inclusion criteria for the clinical trial are:\n- Patients with osteoarthritis\n- Scheduled for elective primary unilateral total hip or knee replacement\n- Provided informed consent\n- Can read, write and speak English\n\n3. Based on the patient note, this patient does not have osteoarthritis and is not scheduled for a total hip or knee replacement surgery. She recently had a mastectomy for breast cancer.\n\n4. Therefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1611": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria of 18-65 years old.\n\n2. The patient has a BMI of at least 35 kg/m^2, as she recently underwent a left mastectomy, suggesting she was obese prior to the surgery.\n\n3. The patient is not currently undergoing bariatric surgery, but the trial is looking at pre- and post-operative patients, so she could potentially be enrolled for the pre-operative phase.\n\n4. There is no information provided about whether the patient is pregnant or breastfeeding.\n\n5. There is no information provided about whether the patient has signed an informed consent form.\n\nBased on the available information, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional information would be needed regarding pregnancy/breastfeeding status and willingness to provide informed consent before definitively enrolling the patient. However, her age, obesity status, and potential for pre-operative enrollment make her a reasonable candidate for further screening.",
        "label": 0
    },
    "1612": {
        "output": "Based on the patient note provided, the 56-year-old female patient does not appear to meet the inclusion criteria for the clinical trial titled \"The Effects of Sound Energy on Pulmonary Gas Exchange.\" The key points are:\n\n1. The patient is not described as a healthy volunteer, but rather is presenting with shortness of breath, malaise, and potential complications from a recent mastectomy surgery.\n\n2. The inclusion criteria specifically state \"Healthy male or female volunteers in the age group.\"\n\nSince the patient is not a healthy volunteer and is experiencing medical issues, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1613": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, so she meets the inclusion criteria of being a pregnant woman (as pregnancy is self-reported).\n\n2. She presents with shortness of breath and malaise, which are not specific symptoms of deep vein thrombosis (DVT) mentioned in the inclusion criteria.\n\n3. However, the physical examination reveals tenderness on the right calf, which could be a sign of DVT as per the inclusion criteria of \"New leg pain (buttock, groin, thigh or calf) with onset in the last month.\"\n\n4. Additionally, the elevated D-dimer level is a risk factor for DVT, although not explicitly mentioned in the inclusion criteria.\n\n5. Based on the calf tenderness and elevated D-dimer, there is a possibility of DVT, which meets the inclusion criteria of \"Suspected acute symptomatic deep vein thrombosis.\"\n\nConsidering all the factors, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1614": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 56-year-old female, which meets the age criteria for the trial (no specific age range given in the inclusion criteria).\n\n2. The patient is intubated, which is one of the inclusion criteria for the trial.\n\n3. The patient is complaining of shortness of breath and has decreased breath sounds on auscultation, which could indicate secretion accumulation in the bronchial airways, meeting another inclusion criterion.\n\n4. The patient has been in bed for the last two weeks, suggesting a stable condition for at least 2 days before the study, as required by the inclusion criteria.\n\n5. There is no mention of the patient receiving vasopressors or having unstable cardiopulmonary function or hydration status, so we can assume these criteria are met.\n\n6. The patient's conscious level and ability to cooperate are not mentioned, but we can assume she is conscious and cooperative since she is able to communicate her complaints.\n\nBased on the information provided, this patient appears to meet most of the inclusion criteria for the clinical trial. However, some additional information would be needed to confirm eligibility, such as the patient's respiratory status, oxygen requirements, and ability to tolerate spontaneous breathing trials.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1615": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Tranexamic Acid Dosing for Total Joint Arthroplasty\", this patient would not be eligible for the trial.\n\nThe key reasons are:\n\n1. The patient is a 56-year-old female who recently underwent a left mastectomy (breast cancer surgery), not a total knee or total hip arthroplasty (joint replacement surgery).\n\n2. The trial specifically includes patients undergoing primary unilateral total knee arthroplasty or primary unilateral total hip arthroplasty at a specific hospital (Columbia University Medical Center/New York Presbyterian Hospital).\n\nSince the patient does not meet the inclusion criteria of undergoing a total joint replacement surgery, which is the focus of this clinical trial, I would not refer this patient for enrollment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1616": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This aligns with the clinical trial's focus on type 2 diabetes in Hispanic patients.\n\n2. However, the patient note does not specify the patient's ethnicity, which is a key inclusion criterion for this trial (Hispanic patients).\n\n3. The patient's age (64 years old) is outside the specified age range of 10-18 years old for this pediatric trial.\n\n4. There are no details provided about the duration of the patient's diabetes diagnosis, which needs to be at least 1 year according to the inclusion criteria.\n\n5. While the patient's obesity and poor compliance with medication/lifestyle changes are relevant to type 2 diabetes, these factors alone do not outweigh the age and ethnicity exclusions.\n\nBased on the information provided, this patient would likely not meet the eligibility criteria for this specific clinical trial on type 2 diabetes in Hispanic youth.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1617": {
        "output": "To determine the patient's eligibility for the clinical trial \"Achilles Tendon Lengthening in Patients With Diabetes to Prevent Foot Ulcers\", let's go through the inclusion criteria one by one:\n\n1. History of Diabetes Mellitus: The patient note mentions that the patient has a diagnosis of diabetes mellitus, so this criterion is met.\n\n2. Limitation of dorsiflexion ankle range of motion to zero degrees or less: There is no information provided about the patient's ankle range of motion in the note.\n\n3. Recurrent or nonhealing ulcer (Grade II, Wagner scale): The patient note mentions that the patient has a painful skin lesion on the left lower leg that has increased in size and is now oozing. This could potentially be a nonhealing ulcer, but more information would be needed to confirm if it meets the Grade II criteria of the Wagner scale.\n\nBased on the information provided in the patient note, the patient meets one of the inclusion criteria for sure (history of diabetes mellitus), but there is not enough information to determine if the other two criteria are met.\n\nTherefore, I would consider the following assessment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1618": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk\", let's go through the inclusion criteria:\n\nInclusion criteria: Diabetic patients with foot ulcers\n\nFrom the patient note, we know that the 64-year-old female patient has diabetes mellitus and a painful skin lesion on the left lower leg that is oozing. While the note does not explicitly state that the lesion is a diabetic foot ulcer, it is highly suggestive of one, given the patient's diabetes and the description of the lesion.\n\nTherefore, based on the information provided, this patient appears to meet the inclusion criteria of being a diabetic patient with a foot ulcer (or a lesion that is likely a diabetic foot ulcer).\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1619": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of being an obese patient (wt > 95th percentile for age, for adults increased BMI > 27) and having complications of insulin resistance (diabetes mellitus).\n\nHowever, the patient note does not mention if she has any of the other listed complications of insulin resistance such as acanthosis nigricans, dyslipidemia, elevated blood pressure, or hyperandrogenism. It also does not mention if she has a family history of type 2 diabetes or if any of her siblings/parents have documented insulin resistance.\n\nGiven the limited information provided, I would consider referring this patient to the clinical trial upon further investigation to determine if she meets any of the other inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1620": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c, which meets the inclusion criteria of having a diagnosis of Type I or Type II diabetes mellitus and a glycohemoglobin A1c<12%.\n\n2. The patient complains of a painful skin lesion on the left lower leg that has increased in size and is oozing. This could potentially meet the inclusion criteria of having a neuropathic, diabetic ulcer that is stage III or IV, located on the distal lower extremity, between 1 and 15 square centimeters.\n\n3. There is no mention of exposed bone at the ulcer site or osteomyelitis affecting the area of the ulcer, which meets those inclusion criteria.\n\n4. There is no information provided about the patient's arterial circulation to the foot, so it is unclear if she meets that inclusion criteria.\n\n5. The patient's gender (female) meets the inclusion criteria for females.\n\nBased on the information provided, it seems highly likely that this patient could be eligible for the clinical trial, assuming she has adequate arterial circulation to the foot.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her arterial circulation status.",
        "label": 2
    },
    "1621": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having Type 1 or Type 2 diabetes.\n\n2. The patient's age (64 years old) meets the inclusion criteria of being 18 years or older.\n\n3. The patient's skin lesion on the left lower leg is not directly relevant to the inclusion criteria for this diabetes trial.\n\n4. There is no information provided that would exclude the patient from this trial based on the given inclusion criteria.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1622": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication and exercise regimen. The key issue here is that she has a painful skin lesion on her left lower leg that has increased in size and is now oozing, despite trying topical lotions and creams.\n\nThe clinical trial is studying the effect of a gel called SACCHACHITIN on healing chronic wounds, specifically looking at its impact on matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), and wound healing in humans.\n\nThe inclusion criteria state that patients with a poorly healed wound, in which skin graft is clinically indicated, are eligible for this trial.\n\nGiven that the patient has a chronic, non-healing wound on her lower leg that has worsened despite treatment attempts, she would likely meet the inclusion criteria for this wound healing trial.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1623": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of being diagnosed with type 1 or type 2 diabetes mellitus.\n\nShe has a painful skin lesion on her left lower leg that has increased in size and is oozing. This could potentially be a diabetic foot ulcer, which is the target condition for this clinical trial.\n\nThe inclusion criteria state that patients must have a foot ulcer with a duration of 12 months or less. The patient note does not specify the duration of the lesion/ulcer, so we cannot confirm if she meets this criterion.\n\nThe other inclusion criteria are:\n- Provision of written informed consent (unknown from the note)\n- Age above 30 years (she is 64, so meets this)\n- Fertile women need contraception or be sterilized (her fertility status is unknown)\n\nBased on the information provided, this patient could potentially be eligible for the trial if her skin lesion is confirmed as a diabetic foot ulcer of 12 months duration or less, she provides informed consent, and meets the criteria regarding fertility/contraception if applicable.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1624": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. 18 years of age or older: The patient is 64 years old, so this criterion is met.\n\n2. Ambulatory (i.e. walking is the primary method of mobilization. Crutches, walker, walking frame or other ambulation aids are permitted): There is no information provided about the patient's ambulatory status, so I cannot definitively say whether this criterion is met or not.\n\n3. Diagnosed Type 2 diabetic (i.e. not juvenile onset): The patient is diagnosed with diabetes mellitus, which is typically Type 2 in adults. This criterion is likely met.\n\n4. Have a DFU (diabetic foot ulcer) on the plantar surface of either foot: The patient has a painful skin lesion on the left lower leg, which may or may not qualify as a diabetic foot ulcer on the plantar surface. More information is needed to determine if this criterion is met.\n\n5. Have a DFU of >4 weeks but <6 months duration: There is no information provided about the duration of the patient's skin lesion, so I cannot determine if this criterion is met.\n\n6. Willing and capable of cooperating to the extent and degree required by the study protocol: Based on the information provided, the patient seems reluctant to follow medical advice and is non-compliant with her diabetes medication and exercise regimen. This may indicate that she is not willing or capable of cooperating with the study protocol, but more information is needed to make a definitive assessment.\n\nOverall, based on the limited information provided in the patient note, I would consider referring this patient to this clinical trial upon further investigation to clarify some of the ambiguous criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1625": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not directly match the inclusion criteria for the clinical trial, which is focused on patients with pressure ulcers in a complex nursing department.\n\n2. The patient does mention having a painful skin lesion on her left lower leg that is oozing. This could potentially be a pressure ulcer, but it is not explicitly stated as such.\n\n3. The inclusion criteria specifically mention patients with \"contaminated pressure ulcers\" who are \"going to have a debridement procedure\". There is no mention of the patient having a pressure ulcer or plans for debridement in the patient note.\n\nBased on the information provided, it does not seem that this patient meets the clear inclusion criteria for the clinical trial on prevention of bacteremia induced by debridement of pressure ulcers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1626": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the first inclusion criteria of having a diagnosis of diabetes by WHO criteria.\n\nThe patient's age of 64 falls within the 18-80 years age range specified in the inclusion criteria.\n\nThere is no information provided about the patient's ability to provide informed consent, but we can assume this is likely unless stated otherwise.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial on infrared temperature monitoring for diabetic foot ulcer prevention.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1627": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of \"confirmed diabetes\".\n\n2. The patient has a painful skin lesion on the left lower leg that is oozing. This could potentially be a neuropathic foot ulcer, which is part of the inclusion criteria. However, the note does not specify if it is a neuropathic ulcer or provide the Wagner grade.\n\n3. The note does not mention if the patient has confirmed sensory neuropathy, which is another inclusion criteria.\n\nBased on the information provided, there are some key details missing to definitively determine eligibility. However, given the patient's diabetes and potential foot ulcer, it would be reasonable to consider referring them for further evaluation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1628": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having a clinical diagnosis of Type 1 or 2 Diabetes and a most recent A1C greater than or equal to 7.0%.\n\n2. The patient is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. This suggests that she may benefit from an educational intervention to improve her self-management skills.\n\n3. The patient's age (64 years old) falls within the age range of 18-80 specified in the inclusion criteria.\n\n4. There is no information provided about the patient's language, but we can assume that she is English-speaking since the note is written in English.\n\n5. The only potential issue is that the patient is not explicitly referred to the Diabetes Improvement Program for diabetes care, as stated in the inclusion criteria.\n\nBased on the information provided, I would consider referring this patient to this clinical trial upon further investigation to confirm her referral to the Diabetes Improvement Program.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1629": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having Type I or Type II diabetes.\n\n2. The patient has a painful skin lesion on the left lower leg that has increased in size and is oozing. This could potentially be a diabetic foot ulcer, which is required for the trial. However, more details are needed to confirm if it meets the specific criteria of being a plantar forefoot ulcer beneath the metatarsal head or toe ulcer.\n\n3. There is no information provided about arterial perfusion, infection/osteomyelitis status, platelet count, orthopedic assessment, or skeletal deformities. These would need to be investigated further.\n\n4. The patient's medication compliance and reluctance to see a nutritionist are not directly relevant to the inclusion criteria.\n\nBased on the information provided, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore details are needed to confirm if the skin lesion meets the criteria for a diabetic foot ulcer eligible for the trial, as well as assessing the other inclusion criteria related to arterial perfusion, infection status, platelet count, orthopedic evaluation, and skeletal deformities. However, the patient's age, diabetes status, and potential foot ulcer make her a potential candidate worth further evaluation.",
        "label": 0
    },
    "1630": {
        "output": "Based on the given patient note and the clinical trial information, here is my assessment of the patient's eligibility for the trial:\n\nThe patient note describes a 64-year-old obese female with diabetes mellitus and a skin lesion on her left lower leg. The clinical trial is titled \"Antibiotics for the Treatment of Ulcerative Colitis\" and is studying the use of antibiotics for treating ulcerative colitis.\n\nThe key inclusion criterion mentioned is \"Active ulcerative colitis, CAI greater than or equal to 4\". However, the patient note does not indicate that the patient has ulcerative colitis or any other bowel disease. The note only mentions diabetes mellitus and a skin lesion.\n\nTherefore, based on the information provided, this patient would not meet the inclusion criteria for this particular clinical trial on ulcerative colitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1631": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not directly match the inclusion criteria for the clinical trial, which is looking for adolescents aged 12-<17 years with type 1 diabetes.\n\n2. The patient is described as being reluctant to see a nutritionist and not compliant with diabetes medication or exercise. This suggests potential issues with treatment adherence, which the trial is aiming to address through family communication and problem-solving interventions.\n\n3. However, the trial specifically mentions type 1 diabetes, whereas the patient note does not specify the type of diabetes. Type 2 diabetes is more common in older adults and is often associated with obesity.\n\n4. The patient note does not mention any information about the patient's living situation or family dynamics, which are relevant to the trial's focus on family communication and problem-solving.\n\nBased on the information provided, it is unlikely that this patient would be eligible for the clinical trial, as she does not meet the age and diabetes type criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1632": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having type I or II diabetes mellitus diagnosed for more than 3 years.\n\nShe also has a painful skin lesion on her left lower leg that has increased in size and is oozing. This likely qualifies as a chronic foot ulcer distal to the knee, which is another inclusion criteria.\n\nThe patient's age is not explicitly stated but being 64 years old meets the criteria of being over 18 years of age.\n\nThe only potential issue is that the stage of the foot ulcer is not specified, but it is mentioned as a skin lesion that is oozing, which suggests it may not involve deep tissues (stages I and II of Wagner's classification).\n\nOverall, based on the information provided, this patient appears to meet most of the key inclusion criteria for the clinical trial on the efficacy of bemiparin for treating chronic foot ulcers in diabetic patients.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of the stage/severity of the foot ulcer.",
        "label": 2
    },
    "1633": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. The clinical trial is focused on oxidative stress and hemodialysis access failure in patients with end-stage renal disease (ESRD) treated by hemodialysis.\n\n2. One of the inclusion criteria for the clinical trial is \"Adults, end stage renal disease treated by hemodialysis, patent hemodialysis vascular access (graft or fistula)\".\n\n3. Based on the information provided in the patient note, there is no mention of the patient having ESRD or being treated with hemodialysis.\n\n4. Therefore, this patient does not meet the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1634": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients of any race and are between 18 and 90 years of age.\nThe patient is 64 years old, so this criterion is met.\n\n2. Patients that are able to understand and are willing to give written informed consent.\nThere is no information provided about the patient's ability to understand or provide consent, so I cannot determine if this criterion is met.\n\n3. Patients that have a non-healing open venous ulcer for at least one month. \nThe patient has a painful skin lesion on the left lower leg, but it is not specified if this is a venous ulcer or how long it has been present. More information is needed to determine if this criterion is met.\n\n4. Patients that have greater than 50% of the ulcers surface area covered with non-viable tissue such as fibrin slough, dry crust or a combination of both.\nThere is no information provided about the characteristics of the skin lesion, so I cannot determine if this criterion is met.\n\n5. Patients that have the clinical signs and symptoms of venous ulceration such as varicosities, hyper pigmentation, stasis dermatitis, lipodermatosclerosis, and edema.\nNo such signs or symptoms are mentioned in the patient note.\n\n6. Patients that have a venous ulcer with a surface area of greater than or equal to 1.5 cm2.\nThere is no information about the size of the skin lesion.\n\n7. Patients that have an ankle to brachial index (ABI) > 0.70.\nThere is no information provided about the patient's ABI.\n\nBased on the limited information in the patient note, I cannot definitively determine if the patient meets all the inclusion criteria. More details would be needed, especially regarding the nature and characteristics of the skin lesion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1635": {
        "output": "To determine the patient's eligibility for the clinical trial \"Improving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills\", let's go through the inclusion criteria one by one:\n\n1. Clinical diagnosis of Type 2 Diabetes\n   - The patient note mentions a diagnosis of diabetes mellitus, which likely refers to type 2 diabetes given the patient's age and obesity. This criterion is met.\n\n2. Most recent A1C >= 7.5%\n   - The patient note states that the patient has a persistently elevated HbA1c, which suggests that the most recent value is likely above 7.5%. This criterion is likely met.\n\n3. Referred to the Diabetes Care Program for diabetes care\n   - There is no information provided about whether the patient has been referred to a Diabetes Care Program.\n\n4. Age 18-85\n   - The patient's age is given as 64 years old, which falls within the eligible range.\n\n5. English Speaking\n   - There is no information provided about the patient's language proficiency.\n\nBased on the available information, the patient meets at least two of the inclusion criteria (diagnosis of type 2 diabetes and age range), with one criterion (HbA1c level) likely met but not explicitly stated. However, there is no information about whether the patient has been referred to a Diabetes Care Program or is English-speaking.\n\nGiven the partial information, I would consider referring this patient to the clinical trial upon further investigation to confirm the remaining criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1636": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the target population of diabetic patients for the clinical trial.\n\n2. The patient has a painful skin lesion on the left lower leg that is oozing, which could potentially be a diabetic foot ulcer. However, the inclusion criteria specifically mentions \"A diabetic foot ulcer corresponding to grade 2\".\n\n3. There is no information provided about the grade or severity of the patient's foot ulcer. More investigation would be needed to determine if it meets the \"grade 2\" criteria specified in the inclusion criteria.\n\n4. There is also no mention of whether the patient has a history of deep venous thrombosis or hemorrhage in the ulcer, which are exclusion criteria.\n\nGiven the limited information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo definitively determine eligibility, more details would be needed about the grade/severity of the foot ulcer and whether the patient meets the other inclusion/exclusion criteria related to deep vein thrombosis and hemorrhage.",
        "label": 0
    },
    "1637": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"diabetic ulcer of primarily neuropathic origin on the plantar region of the forefoot\"\n- The patient note mentions a \"painful skin lesion on the left lower leg\", but does not specify if it is a diabetic ulcer or its location. This criterion is unclear from the note.\n\n2. \"ulcer extending through the dermis but without sinus tract, tendon, capsule or bone exposure\"\n- There are no details provided about the depth or characteristics of the skin lesion.\n\n3. \"ulcer present for at least 2 weeks and measuring 1- 16 cm2\" \n- No information is given about the duration or size of the skin lesion.\n\n4. \"diminished sensation on target extremity/foot\"\n- The patient has diabetes, which can cause neuropathy and diminished sensation, but this is not explicitly stated.\n\n5. \"ulcer is not infected\"\n- No mention of infection status.\n\n6. \"Type 1 or 2 diabetes with adequate glycemic control\"\n- The patient has diabetes mellitus with \"persistently elevated HbA1c\", indicating poor glycemic control.\n\n7. \"Adequate vascular supply to the target extremity\"\n- No information about vascular supply is provided.\n\nBased on the limited information in the patient note, several key inclusion criteria cannot be definitively assessed. The glycemic control criterion is not met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1638": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not seem directly relevant to the inclusion criteria for the keloid clinical trial.\n\n2. The patient is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. Again, this information is not relevant to the keloid trial inclusion criteria.\n\n3. The patient complains of a painful skin lesion on the left lower leg that has increased in size and is now oozing despite trying topical lotions and creams. This could potentially be a keloid lesion.\n\n4. The inclusion criteria state that participants must be male or female, at least 12 years of age, have 2 or more keloids between 0.5 and 2 cm in length on the trunk, arm, leg or neck, be willing to participate in the study requirements, and in the investigator's opinion, the keloids can be excised and closed properly with the two techniques being studied.\n\n5. Based on the information provided, it is possible that the patient's skin lesion on the left lower leg could be a keloid that meets the size criteria. However, we do not know if she has at least one other keloid lesion as required.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation to determine if she has at least one other qualifying keloid lesion and meets the other inclusion criteria.",
        "label": 0
    },
    "1639": {
        "output": "To determine the patient's eligibility for the clinical trial \"Testing MST to Improve Adherence Among Youth With Chronic Poor Metabolic Control\", let's go through the inclusion criteria one by one:\n\n1. \"a current hemoglobin A1c(HbA1c) of >8.0%\"\nThe patient note mentions that the patient has \"persistently elevated HbA1c\", which implies that her current HbA1c is likely above 8.0%. This criterion is likely met.\n\n2. \"an average HbA1c of >8.0% during the past year\"\nThe patient note does not provide information about the patient's average HbA1c over the past year. However, given that her current HbA1c is elevated, it is reasonable to assume that her average HbA1c over the past year was also elevated and likely above 8.0%.\n\n3. \"diagnosed with Type 1 diabetes for at least one year\"\nThe patient note mentions that the patient has a diagnosis of diabetes mellitus, but it does not specify whether it is Type 1 or Type 2 diabetes. Without this information, it is unclear if this criterion is met.\n\n4. \"reside in the metro Detroit tri-county area\"\nThe patient note does not provide information about the patient's location or residence.\n\nBased on the available information, the patient meets at least one of the inclusion criteria (current elevated HbA1c) and potentially meets another criterion (average elevated HbA1c over the past year). However, there is not enough information to determine if the patient has Type 1 diabetes specifically or if she resides in the required geographic area.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1640": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This meets the age criteria of being at least 18 years old.\n\n2. The patient has a painful skin lesion on the left lower leg that has increased in size and is oozing. This could potentially be classified as a diabetic foot ulcer, which is one of the inclusion criteria for the trial.\n\n3. The trial is specifically looking at patients undergoing surgical debridement of their lower limb ulcers in the operating room. There is no mention of the patient undergoing or planning to undergo surgical debridement in the patient note.\n\n4. The other inclusion criteria, such as being able to understand the evaluation and provide written consent, are not addressed in the patient note.\n\nBased on the information provided, there is not enough evidence to definitively determine if the patient meets all the inclusion criteria for the trial. However, the presence of a potentially diabetic foot ulcer and the patient's age make them a potential candidate for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1641": {
        "output": "To determine the patient's eligibility for the clinical trial \"Hyperbaric Oxygen Therapy (HBOT) for Chronic Diabetic Lower Limb Ulcers\", let's go through the inclusion criteria one by one:\n\n1. Age > 18 years\nThe patient is 64 years old, so this criterion is met.\n\n2. Type 1 or 2 Diabetes Mellitus\nThe patient has a diagnosis of diabetes mellitus, so this criterion is met.\n\n3. Wagner grading of foot lesions 3 or 4 on lower limb not healing for 4 weeks.\nThe patient has a painful skin lesion on the left lower leg that has increased in size and is oozing, despite trying topical lotions and creams. This suggests a chronic non-healing wound, potentially meeting this criterion.\n\nBased on the information provided, the patient appears to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1642": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having either type 1 or type 2 diabetes.\n\n2. The clinical trial is evaluating the use of Levemir, which is a basal insulin. The patient is a candidate for using a basal insulin as part of their diabetes regimen, given their uncontrolled diabetes.\n\n3. There are no exclusion criteria mentioned that would disqualify this patient.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial evaluating Levemir for the treatment of type 1 and type 2 diabetes.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1643": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. At least 2 dispensings for oral medications used to treat diabetes and dyslipidemia in the last 18 months.\nThe patient note does not mention if the patient has been dispensed oral medications for diabetes or dyslipidemia, so this criterion cannot be evaluated.\n\n2. At least one laboratory result for both glycated hemoglobin and LDL-cholesterol in the last 6 months. \nThe patient note mentions the patient has a \"persistently elevated HbA1c\", which suggests they have had a glycated hemoglobin test recently. However, there is no mention of an LDL-cholesterol test.\n\n3. Average HbA1c \u2265 7% OR an average LDL \u2265 100 mg/dL\nThe patient note states the patient has a \"persistently elevated HbA1c\", so this part of the criterion is likely met. There is no information on LDL levels.\n\n4. Continuous health plan enrollment currently and in the previous calendar year with no more than a 1 month lapse of coverage, and benefits that include both medical and pharmacy coverage.\nThere is no information provided about the patient's health plan enrollment or coverage.\n\nBased on the limited information in the patient note, I would assess this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient seems to meet at least one of the key inclusion criteria (elevated HbA1c), but more information would be needed to fully evaluate eligibility, such as medication history, lab results, and health plan details.",
        "label": 1
    },
    "1644": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 64-year-old obese female with diabetes mellitus and a skin lesion on her left lower leg that is oozing.\n\n2. The clinical trial is titled \"Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients\" and is studying the efficacy of a local anesthetic in reducing pain from subconjunctival injections for corneal ulcers.\n\n3. The inclusion criteria state that patients must have a diagnosed corneal ulcer with specific features, and must be receiving subconjunctival antibiotic injections at least twice.\n\n4. Based on the patient note, there is no mention of the patient having a corneal ulcer or receiving any subconjunctival injections.\n\n5. Therefore, this patient does not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1645": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients over 18 who have given written informed consent\n- The patient note does not mention whether the patient has given written informed consent, but we can assume this would be obtained if the patient is referred.\n\n2. Patients with a venous or predominantly venous leg ulcer (ankle-brachial index > 0.8) that is between 2 cm and 13 cm in all directions\n- The patient note mentions a \"painful skin lesion on the left lower leg\" that is oozing, which could potentially be a venous leg ulcer within the size range specified.\n\n3. Patients with a moderately or severely exudating leg ulcer in the phase of debridement or formation of granulation tissue\n- The oozing skin lesion suggests it is exudating, but the note does not provide details on the phase of debridement or granulation tissue formation.\n\n4. Patients with a leg ulcer that is not healing properly despite suitable and well-conducted local treatment in the four weeks prior to inclusion\n- The note mentions the patient has tried topical lotions and creams, but the lesion has increased in size, suggesting it is not healing properly with the current treatment.\n\n5. Patients with a leg ulcer that has been treated with appropriate compression in the four weeks prior to inclusion\n- There is no mention of compression treatment in the patient note.\n\n6. Patients who are available for monitoring for at least 10 weeks\n- The note does not provide information about the patient's availability for monitoring.\n\nBased on the information provided, some of the inclusion criteria are potentially met (e.g., age, leg lesion/ulcer, not healing with current treatment), but there are also some criteria that cannot be definitively determined from the note (e.g., venous etiology, ulcer size, treatment with compression, availability for monitoring).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1646": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not seem directly relevant to the inclusion criteria for the clinical trial on hyperbaric oxygen therapy for chronic brain injury.\n\n2. The patient is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise regimen. Again, this information does not seem directly relevant to the brain injury trial's inclusion criteria.\n\n3. The patient complains of a painful skin lesion on her left lower leg that has increased in size and is oozing despite using topical treatments. This information is also not relevant to the brain injury trial's inclusion criteria.\n\n4. Looking at the inclusion criteria for the clinical trial:\n   - Subject has had a brain injury at least 12 months prior to study enrollment.\n   - Subject is at least 18 years old.\n   - Etiology of brain injury: Stroke, anoxia, and trauma\n   - Must be able to equalize ears, or have tympanostomy tubes\n   - Willingness to complete outcome measures and complies with the research protocols.\n   - Commitment to pay the hospital for hyperbaric oxygen.\n\nThe patient note does not mention any history of brain injury, stroke, anoxia, or trauma. Therefore, based on the information provided, the patient does not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1647": {
        "output": "To determine the patient's eligibility for the clinical trial \"Trial of Herb Yuyang Ointment to Diabetic Foot Ulcer\", let's go through the inclusion criteria one by one:\n\n1. \"In-patient or out-patient patients diagnosed with diabetic foot ulcers\"\n   - The patient note mentions that the patient has a \"painful skin lesion on the left lower leg\" which is \"oozing\". This could potentially be a diabetic foot ulcer, but it is not explicitly stated.\n\n2. \"Gangrene or ulceration occurred more than 3 weeks\"\n   - There is no information provided about the duration of the skin lesion.\n\n3. \"Over 18 years of age\"\n   - The patient is 64 years old, so this criterion is met.\n\n4. \"Gender-open\"\n   - The patient is a female, so this criterion is met.\n\n5. \"The type of diabetes (type 1 or type 2) open\"\n   - The patient has a diagnosis of diabetes mellitus, but the type is not specified.\n\n6. \"Patients receive a written informed consent to participate in the trial\"\n   - There is no information provided about whether the patient has given informed consent.\n\nBased on the information provided in the patient note, there are some uncertainties regarding whether the skin lesion qualifies as a diabetic foot ulcer and its duration. Additionally, the type of diabetes and informed consent are not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1648": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\nAge 18-70: The patient's age is 64 years old, which falls within the specified range.\n\nPrimary TN patient (MRI examination support diagnosis): The patient note does not mention trigeminal neuralgia or any MRI examination related to it. This criterion is not met.\n\nSuffering from this pain for at least 3 months: The patient note does not mention any pain related to trigeminal neuralgia. This criterion is not met.\n\nVAS\ufe6540mm: The patient note does not provide any information about the patient's pain intensity or VAS score. This criterion cannot be evaluated.\n\nPatient can assess pain intensity correctly: There is no information provided about the patient's ability to assess pain intensity. This criterion cannot be evaluated.\n\nBased on the information provided in the patient note, the patient does not meet at least two of the inclusion criteria (primary TN patient and suffering from this pain for at least 3 months). Additionally, there is not enough information to evaluate two other criteria (VAS score and ability to assess pain intensity).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1649": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not directly conflict with the inclusion criteria for the cervical cancer clinical trial.\n\nHowever, one of the exclusion criteria is \"Uncontrolled diabetes\". Since the patient's diabetes is described as uncontrolled with persistently elevated HbA1c levels, this would likely exclude her from participating.\n\nAdditionally, the trial is specifically for cervical cancer patients in stages 2b to 4a. The patient note does not mention cervical cancer, only a skin lesion on her leg.\n\nGiven the uncontrolled diabetes and lack of cervical cancer diagnosis, I would assess:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1650": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having Type 2 diabetes.\n\n2. However, there is no mention of the patient having at-risk drinking in the past month, which is one of the key inclusion criteria for this clinical trial.\n\n3. There is also no mention of the patient having poor diabetes treatment adherence, which is another inclusion criterion.\n\n4. The note focuses more on the patient's skin lesion and reluctance to see a nutritionist or comply with medication/exercise, which are not relevant to the inclusion criteria of this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "1651": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication and exercise regimen. She also has a painful, oozing skin lesion on her left lower leg that has not improved with topical treatments.\n\nThe clinical trial is comparing the effects of autologous mesenchymal stem cells (MSCs) and mononuclear cells (MNCs) transplantation on diabetic patients with critical limb ischemia and foot ulcers.\n\nThe key inclusion criteria are:\n1) Age 40-70 years (the patient is 64, so meets this criteria)\n2) Type 2 diabetes (the patient has diabetes mellitus, likely type 2 given her age)\n3) Bilateral critical limb ischemia with ABI 0.3-0.6 (no information given about ABI)\n4) At least one foot ulcer (the patient has a skin lesion/ulcer on her left lower leg)\n\nBased on the information provided, the patient meets some but not all of the key inclusion criteria. Her age and diabetes status make her eligible, and she has a lower extremity ulcer. However, there is no information about whether she has critical limb ischemia or what her ABI values are.\n\nGiven this, I would assess her eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her ABI values and presence of critical limb ischemia.",
        "label": 0
    },
    "1652": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) \"patients 18 years of age or older, able to give informed consent and to follow the treatment procedure\"\n- The patient note states the patient is 64 years old, so this criterion is met.\n\n2) \"target ulcer area between 1 and 30 cm2\"\n- There is no information about the size of the ulcer, so I cannot determine if this criterion is met or not.\n\n3) \"consecutive patients presenting with one or more leg ulcers diagnosed as hypertensive MARTORELL's ulcers\"\n- The patient note does not specify if the leg ulcer is a hypertensive MARTORELL's ulcer, so this criterion cannot be evaluated.\n\n4) \"presence of an arterial hypertension, according to the WHO criteria, treated or not; and/or presence of a diabetes treated by oral agent, insulin or diet\"\n- The patient has diabetes mellitus, so this criterion is met.\n\n5) \"absence of clinical signs of chronic venous insufficiency: skin hyperpigmentation, lipodermatosclerosis\"\n- There is no mention of these signs, so I will assume this criterion is met for now.\n\n6) \"absence of significant peripheral arterial occlusive disease: presence of peripheral pulses or ankle brachial index \u22650.8\"\n- There is no information provided about peripheral pulses or ankle brachial index.\n\n7) \"absence of clinical sign of arterial insufficiency: intermittent claudication, resting pain\"\n- There is no mention of these signs.\n\n8) \"superficial spreading necrotic ulcer\"\n- The ulcer is described as oozing, but not specifically as necrotic.\n\n9) \"presence of spontaneous pain\"\n- The ulcer is described as painful.\n\n10) \"presence of a red purpuric margin\"\n- There is no mention of the appearance of the ulcer margin.\n\nIn summary, some criteria are clearly met (age, diabetes), some cannot be evaluated due to lack of information (ulcer size, type, vascular status), and others may or may not be met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1653": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subject must have evidence of a full-thickness cutaneous wound of at least 30 days duration.\nThe patient note mentions a painful skin lesion on the left lower leg that has increased in size and is oozing, so this criterion is likely met.\n\n2. Subject must be at least 18 years of age. \nThe patient is 64 years old, so this criterion is met.\n\n3. Subject must have a minimum life expectancy of at least 1 year to be determined by the Investigator.\nThere is no information about the patient's life expectancy, so this criterion needs further investigation.\n\n4. The study ulcer must be from 1 cm2 to 20 cm2 in size.\nThere is no information about the size of the skin lesion, so this criterion needs further investigation.\n\n5. The study ulcer must have been present for at least 30 days at study Day -7.\nThe patient note mentions that the skin lesion has increased in size, implying that it has been present for some time, but the exact duration is not specified. This criterion needs further investigation.\n\n6. The subject's Glycosylated hemoglobin (HbA1C) must be equal to or less than 10.0% for subjects with diagnosed diabetes at study Day 0.\nThe patient has a diagnosis of diabetes mellitus with persistently elevated HbA1c, but the exact value is not provided. This criterion needs further investigation.\n\n7. The subject, legal guardian or authorized representative must have understood, signed and dated the IRB approved informed consent form.\nThere is no information about informed consent, so this criterion needs further investigation.\n\n8. The subject must be available for evaluation on a weekly basis for the twelve (12) weeks of the study. Visits at Week 13 and Week 14 are required for initial wound healing, which is achieved in study Week 11 or 12. The Investigator will evaluate both groups at Week 16. Subjects must be available for evaluation at Week 16.\nThere is no information about the patient's availability for the study visits, so this criterion needs further investigation.\n\n9. The subject's TCpO2 must be equal to or greater than 25 mm of mercury in the periwound area and ABI greater than 0.7.\nThere is no information about the patient's TCpO2 or ABI values, so this criterion needs further investigation.\n\nBased on the available information, some of the inclusion criteria are potentially met, but several criteria need further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1654": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having Type 1 or Type 2 diabetes mellitus.\n\nShe is described as having a painful skin lesion on the left lower leg that is oozing. This could potentially be a neuropathic foot ulcer, which the trial is aiming to prevent. However, the inclusion criteria specifically state that participants must be \"intact from lower limb vascular or neuropathic ulceration, scoring Grade 0 on the Wagner classification for foot ulcer.\"\n\nSince the patient already has an oozing skin lesion on her lower leg, she may not meet this inclusion criterion. More information would be needed to determine if this lesion qualifies as a neuropathic foot ulcer or not.\n\nThe other inclusion criteria of being able to walk 10 meters unaided and being willing to comply with the study requirements are not addressed in the patient note.\n\nBased on the available information, I would assess this patient as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore details are needed about the nature and severity of the skin lesion to determine if it disqualifies the patient from participating in the trial aimed at preventing neuropathic foot ulcers in diabetic patients.",
        "label": 1
    },
    "1655": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the diabetic population targeted by the clinical trial.\n\n2. The patient has a painful skin lesion on the left lower leg that is oozing. This could potentially be a neuropathic plantar foot ulcer, which is one of the inclusion criteria for the trial.\n\n3. However, the inclusion criteria specifically mention the presence of a neuropathic plantar ulcer graded IA according to the Texas University classification. The patient note does not provide enough information to determine if the skin lesion meets this criteria.\n\n4. The inclusion criteria also require the presence of peripheral neuropathy, diagnosed based on insensitivity to a 10-g Semmes-Weinstein monofilament and a vibration perception threshold measured by a biothesiometer. The patient note does not provide this information.\n\nBased on the information provided in the patient note, there is not enough evidence to definitively determine if the patient meets all the inclusion criteria for the clinical trial. More investigation would be needed to assess the nature and severity of the skin lesion and to evaluate for peripheral neuropathy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1656": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Is the subject 18 years of age or older?\n   - The patient is 64 years old, so this criterion is met.\n\n2. Does the subject have a chronic full thickness diabetic foot ulcer (DFU) inferior to the malleolus that has been present for a minimum of four (4) weeks?\n   - The patient has a painful skin lesion on the left lower leg, which could potentially be a diabetic foot ulcer, but it is not explicitly stated. This criterion needs further investigation.\n\n3. Does the diabetic foot ulcer measure greater than 1.0 cm2 and less than 25.0 cm2 after the wound is debrided?\n   - The size of the lesion is not provided, so this criterion needs further investigation.\n\n4. Does the subject show evidence of neuropathy?\n   - The patient's neuropathy status is not mentioned, so this criterion needs further investigation.\n\n5. Is the subject's wound free of tunneling and showing no exposed periosteum or bone and free of clinical infection defined as the presence of local signs and symptoms including purulence, warmth, tenderness, pain, induration, cellulitis, bullae, crepitus, abscess, fasciitis and osteomyelitis?\n   - The lesion is described as oozing, which could indicate infection, but more details are needed to determine if it meets this criterion.\n\n6. Is the study wound able to be off loaded or achieve pressure relief and permit daily dressing changes?\n   - There is no information provided about offloading or pressure relief for the lesion, so this criterion needs further investigation.\n\n7. Is the subject willing to have three (3) wound biopsies taken (Visit 0, 4 and 8)?\n   - The patient's willingness to undergo biopsies is not mentioned, so this criterion needs further investigation.\n\n8. Is the subject willing to have photos taken of their wound and permit use of the photos in publications?\n   - The patient's willingness to have photos taken is not mentioned, so this criterion needs further investigation.\n\n9. Has the subject or their legally authorized representative signed an Institutional Review Board approved informed consent document and authorized the use and disclosure of protected health information?\n   - There is no information provided about informed consent, so this criterion needs further investigation.\n\n10. Does the subject have adequate circulation to the foot as evidenced by an Ankle Brachial Index (ABI) of 0.8 - 1.2; or if the ABI is greater than 1.2, does the subject show toe pressures >40 mmHg, or transcutaneous oximetry (TcPO2) > 40 mm Hg, or does the subject show adequate circulation on an arterial Doppler study? (ABI or Doppler results must be < 45 days old.)\n    - There is no information provided about the patient's circulation or ABI, so this criterion needs further investigation.\n\n11. Is the subject able to comply with the protocol requirements?\n    - The patient's ability to comply with the protocol requirements is not mentioned, so this criterion needs further investigation.\n\n12. If the subject is a woman of child bearing potential is she practicing an acceptable form of birth control as determined by the Investigator, and is she willing to have a pregnancy test?\n    - The patient is a 64-year-old female, so this criterion is likely not applicable.\n\nBased on the information provided in the patient note, several of the inclusion criteria need further investigation to determine the patient's eligibility for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1657": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria for Part 2 of the trial, which includes patients with type 1 or type 2 diabetes.\n\n2. The patient's age (64 years) falls within the inclusion criteria range of 18-65 years for Part 2.\n\n3. The patient's gender (female) is also allowed in Part 2, which includes both males and females of no childbearing potential.\n\n4. The patient's BMI is not provided, but she is described as obese. The BMI range for type 2 diabetes patients in Part 2 is 22-35 kg/m^2, so her obesity likely falls within this range.\n\n5. The patient has had diabetes for an unspecified duration, but the inclusion criteria require at least 12 months for both type 1 and type 2 diabetes patients.\n\n6. The patient's treatment history is not provided, but the inclusion criteria require at least 12 months of insulin treatment for type 1 diabetes patients and at least 3 months of insulin treatment for type 2 diabetes patients.\n\nBased on the information provided, there are some uncertainties regarding the patient's diabetes type (type 1 or type 2), duration of diabetes, and treatment history. However, given her age, gender, and obesity, she could potentially be eligible for Part 2 of the trial upon further investigation of her diabetes type and treatment history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1658": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of \"Adults with diabetes\".\n\n2. There is no mention of the patient's LDL cholesterol levels in the note, which is a key inclusion criteria for this trial (\"LDL greater than or equal to 100\").\n\n3. It is mentioned that the patient is not compliant with her diabetes medication, but the inclusion criteria requires \"Cholesterol-lowering drug therapy for > 6 months\".\n\n4. There is no information provided about whether the patient has had at least 2 primary care visits in the past 1.5 years or has a working telephone, which are also inclusion criteria.\n\nBased on the information provided in the patient note, there are some key inclusion criteria that cannot be definitively confirmed or ruled out.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her LDL levels, medication compliance for cholesterol-lowering drugs, primary care visit history, and access to a working telephone.",
        "label": 1
    },
    "1659": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Abnormal Structure and Bone Density in Diabetes\", here is my assessment:\n\nThe patient is a 64-year-old obese female with a diagnosis of diabetes mellitus and persistently elevated HbA1c levels. This matches one of the key inclusion criteria for the trial, which is \"Adult with type 1 or 2 diabetes\".\n\nHowever, the note does not mention if the patient has neuropathy or not, which is another part of the inclusion criteria (\"with or without neuropathy\"). More information would be needed to determine if the patient meets that criteria.\n\nAdditionally, the main focus of the patient note seems to be on a painful skin lesion on the left lower leg, rather than bone abnormalities or density issues which are the primary focus of this clinical trial.\n\nGiven the limited information provided, I would rate this patient's eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore details about the presence of neuropathy, as well as the patient's specific bone health status, would be needed to make a more definitive assessment of eligibility for this particular trial.",
        "label": 1
    },
    "1660": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) Patient is 18 years of age or older - The patient is 64 years old, so this criterion is met.\n\n2) Patient has type I or II diabetes - The patient is diagnosed with diabetes mellitus, so this criterion is met. \n\n3) Foot ulcer has been present for a minimum of 2 weeks under the current investigator's care - It's not explicitly stated how long the foot ulcer has been present, but it mentions she has tried topical lotions and creams without success, implying it has been there for some time. Let's assume this criterion is potentially met upon further investigation.\n\n4) Foot ulcer is on the plantar surface of the forefoot or heel - The ulcer is described as being on the left lower leg, not specifically the forefoot or heel. This criterion may not be met.\n\n5) Ulcer size is >/=1.0 cm2 at Day 0 - No information is given about the size of the ulcer.\n\n6) Ulcer extends through the dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone, or joint capsule - No details are provided about the depth of the ulcer.\n\n7) Ulcer is free of necrotic debris, exhibits no signs of clinical infection, and appears to be made up of healthy vascularized tissue - It states the ulcer is oozing, which could indicate infection, but no other details are given.\n\n8) Patient's Ankle-Arm Index by Doppler is >/=0.7 - No information provided.\n\n9) Patient has adequate circulation to the foot as evidenced by a palpable pulse - No information provided.\n\n10) Female patients of child bearing potential must not be pregnant and must use accepted means of birth control - Not applicable as the patient is 64 years old.\n\n11) Patient and caregiver are willing to participate in the clinical study and can comply with the follow-up regimen - No information provided, but could potentially be met.\n\n12) Patient or his/her legal representative has read and signed the IRB approved Informed Consent form before treatment - No information provided, but could potentially be met.\n\n13) Patient's study ulcer has been present (open) for at least 6 weeks at the time of the Screening visit - Potentially met based on the ulcer description, but needs further investigation.\n\nOverall, based on the limited information provided, some of the key inclusion criteria like ulcer location, size, depth, circulation status are unclear. More details would be needed to make a definitive assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1661": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication and exercise regimen. The main issue relevant to this trial is the painful skin lesion on her left lower leg that has increased in size and is oozing despite trying topical treatments.\n\nThe clinical trial is studying the efficacy of maggot therapy for wound debridement compared to classical treatments in non-healing fibrinous wounds.\n\nLooking at the inclusion criteria:\n- Patient is between 18-90 years old (meets criteria)\n- Has a non-healing fibrinous wound <= 40cm2 (meets criteria based on the oozing skin lesion)\n- For limb wounds, the ankle-brachial pressure index must be >= 0.8 (no information provided)\n- Able to provide informed consent (assumed yes)\n\nThe main potential issue is the ankle-brachial pressure index requirement, as no information is provided about this. However, based on the other criteria being met and the relevant wound issue, I would consider referring this patient upon further investigation of the ankle-brachial pressure index.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1662": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n- Age 18 years or older: The patient is 64 years old, so meets this criteria.\n- Type 1 or 2 diabetes: The patient has diabetes mellitus, so meets this criteria. \n- A single full-thickness diabetic foot ulcer present for at least 2 weeks: The patient has a painful skin lesion on the left lower leg that has increased in size and is oozing, suggesting it could be a diabetic foot ulcer. More investigation would be needed to confirm if it meets the full criteria.\n- Ulcer wound surface area \u2264 34 cm2: No information given about wound size, so unable to assess this criteria.\n- No exposure of bone in the target ulcer: No information given about bone exposure.\n- Neuropathy confirmed by monofilament test: No information given about neuropathy testing.\n- No predominant ischemia based on ABPI/TBPI values: No information given about vascular testing.\n\nExclusion Criteria:\n- Active Charcot foot: No information provided.\n- Non-neuropathic ulcers: Potentially meets this as it is a diabetic foot ulcer, but more investigation needed.\n- Ulcer requiring antibiotic treatment: No information provided about infection status.\n- Evidence of skin cancer: No information provided.\n- Infected ulcers requiring antibiotics: No information provided about infection status.\n- Another wound on same foot: No information provided about other wounds.\n- Active malignancy: No information provided.\n- Morbid obesity (BMI \u2265 45): The patient is noted to be obese, but no BMI value given to assess morbid obesity.\n- Significant medical conditions impairing wound healing: No specific conditions mentioned.\n- Severe renal failure requiring dialysis: No information provided.\n- Pregnant/breastfeeding: The patient is a 64-year-old female, so likely does not meet this exclusion.\n- High-dose corticosteroid use: No information provided about medication use.\n- Participation in another clinical trial: No information provided.\n- Drug/alcohol abuse within past year: No information provided.\n- Severe psychiatric disease: No information provided.\n- Intolerance to study drug/excipients: No information provided about prior intolerances.\n- Uncooperative or noncompliant: The patient is noted to be reluctant to see a nutritionist and non-compliant with diabetes medications/exercise, suggesting potential non-compliance.\n- Unable to apply study drug daily at home: Likely able to apply topical spray at home if visiting nurse assistance available.\n\nIn summary, based on the limited information provided in the patient note, I would assess this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore details would be needed about the wound characteristics, neuropathy/vascular testing, infection status, BMI, medication use, and ability to be compliant with the study procedures to fully determine eligibility. But the patient meets some of the key inclusion criteria related to having a diabetic foot ulcer.",
        "label": 0
    },
    "1663": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is not compliant with her diabetes medication or exercise regimen.\n\n2. The clinical trial is titled \"Subcuticular Suture Versus Staples for Closure of the Skin After Caesarean Section.\"\n\n3. The inclusion criteria for the trial are:\n- Woman having elective or level III caesarean section\n- Woman who speak and understand Danish\n- Woman who can give informed consent\n\n4. Based on the patient information provided, this 64-year-old female patient does not meet the inclusion criteria for this clinical trial, as the trial is specifically looking for women undergoing caesarean section.\n\n5. Her medical conditions (diabetes, obesity) and the skin lesion on her leg are not relevant to the inclusion criteria of this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1664": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having a diabetic wound.\n\n2. She has a painful skin lesion on her left lower leg that has increased in size and is oozing. This likely qualifies as a chronic wound needing debridement >3 cm2 based on the description.\n\n3. The ulcer history is not explicitly stated, but it is implied that the lesion has been present for some time since she has tried topical lotions and creams without success. This suggests it may meet the criteria of ulcer history >4 months.\n\n4. There is no information provided about arterial blood flow or ankle-brachial index (ABI), so we cannot definitively assess that inclusion criteria.\n\nOverall, based on the information provided, this patient appears to meet at least some of the key inclusion criteria for the ultrasonic wound debridement vs standard sharp debridement clinical trial. However, the lack of information about arterial blood flow introduces some uncertainty.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of arterial blood flow and exact ulcer duration.",
        "label": 0
    },
    "1665": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female, which matches the inclusion criteria of being obese.\n2. The patient has a diagnosis of diabetes mellitus, which matches the inclusion criteria of having a clinical diagnosis of diabetes mellitus.\n\nBased on the patient note and the inclusion criteria provided, this patient appears to meet the eligibility requirements for the \"Plantar Faciitis and Diabetes Mellitus\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1666": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female, which does not meet the age criteria of 18-50 years old for this clinical trial.\n\n2. There is no information provided about the patient's background or ethnicity, so we cannot determine if she meets the inclusion criteria of being an immigrant from the Middle East, Africa, or South Asia.\n\n3. The patient's primary medical issues seem to be diabetes mellitus, obesity, and a skin lesion on her leg. The clinical trial is focused on the effects of vitamin D supplementation on muscular strength, musculoskeletal pain, and headaches.\n\n4. Based on the information provided, this patient does not appear to be a good fit for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1667": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication and exercise regimen. She also has a painful, oozing skin lesion on her left lower leg that has not responded to topical treatments.\n\nThe clinical trial is evaluating the use of Integra\u00ae Artificial Dermis for the treatment of leg ulcers. The key inclusion criteria are:\n\n1. Patient with a lower limb ulcer present for more than 6 months or larger than 10 cm\u00b2\n2. Patient recommended for Integra\u00ae matrix implantation before a dermo-epidermal graft\n3. Patient not eligible for skin flap surgery\n4. Patient or representative agrees to sign informed consent\n\nBased on the information provided, this patient appears to meet the inclusion criteria for the trial:\n\n1. She has a lower leg skin lesion/ulcer that has persisted despite treatment attempts\n2. The trial is evaluating Integra\u00ae as a treatment option prior to grafting\n3. No mention of eligibility for skin flap surgery\n4. Presuming she would provide informed consent\n\nWhile her diabetes and obesity may be relevant comorbidities, they do not explicitly exclude her from this trial based on the stated criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1668": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication and exercise regimen. She also has a painful, oozing skin lesion on her left lower leg that has not responded to topical treatments.\n\nThe clinical trial is evaluating the impact of a wound dressing called Drawtex on moderately to highly exuding venous leg ulcers.\n\nLooking at the inclusion criteria:\n1. Subject > 18 years - The patient is 64 years old, so she meets this criterion.\n2. Subject is attending weekly office visits at SW Wound Care Center as an out-patient - This is not mentioned in the patient note, so we cannot confirm if she meets this criterion.\n3. Subject has a moderately to highly exudative venous leg ulcer that would be indicated for treatment with Drawtex - The patient has a painful, oozing skin lesion on her left lower leg, which could potentially be a moderately to highly exudative venous leg ulcer, but this is not explicitly stated.\n4. Subject or is informed about the trial, understands its nature of the study and provides written informed consent prior to study enrollment - This is not mentioned in the patient note.\n5. Subject is willing and able to comply with all specified care and visit requirements - The patient's non-compliance with her diabetes medication and exercise regimen suggests she may not be willing or able to comply with the trial requirements, but this is not definitive.\n\nBased on the information provided, there are some uncertainties regarding the patient's eligibility for this clinical trial. While her age and leg lesion potentially meet some of the criteria, there are other criteria that cannot be confirmed or denied based on the patient note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1669": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female, which meets the age criteria of \u226545 years for the clinical trial.\n\n2. The patient has a diagnosis of diabetes mellitus, which is relevant to the trial's objective of evaluating a diabetes risk score.\n\n3. The patient's skin tone is not explicitly mentioned, but the trial requires a dark skin tone (Von Luschan chromatic skin color > 35). We don't have enough information to determine if the patient meets this criterion.\n\n4. The patient is obese, which is a risk factor for diabetes mentioned in the inclusion criteria.\n\n5. The patient complains of a skin lesion, which is not directly relevant to the inclusion criteria for this trial.\n\nBased on the information provided, we cannot definitively determine if the patient meets all the inclusion criteria, as the skin tone is not specified.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of their skin tone.",
        "label": 0
    },
    "1670": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is not compliant with her diabetes medication or exercise regimen. The clinical trial is focused on pressure ulcer prevention in intensive care unit (ICU) patients.\n\nTo be eligible for this trial, the inclusion criteria state that the patient must:\n1) Be admitted to the emergency department (ED) and subsequently transferred to the ICU for critical illness and/or major trauma\n2) Be over 18 years old\n\nFrom the patient note, there is no mention of the patient being admitted to the ED or ICU, or having any critical illness or major trauma. The note only mentions a skin lesion on her leg.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the pressure ulcer prevention trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1671": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of \"Patients with type 2 diabetes\".\n\n2. However, there is no mention of polyneuropathy or Charcot's disease in the patient note. The inclusion criteria specifically states \"Patients with type 2 diabetes with and without polyneuropathy\" and \"Patients with type 2 diabetes with a history of Charcot's disease\".\n\n3. Without information on whether the patient has polyneuropathy or a history of Charcot's disease, it is difficult to definitively determine eligibility.\n\n4. The patient does have a skin lesion on the lower leg, which could potentially be related to polyneuropathy or Charcot's disease, but more information would be needed to confirm this.\n\nBased on the available information, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1672": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) Is 18 years or older; male or female. \n   - The patient is 64 years old and female, so this criterion is met.\n\n2) Previous diagnosis of venous insufficiency proven by a positive venous duplex with reflux.\n   - There is no mention of a venous insufficiency diagnosis or venous duplex in the patient note.\n\n3) Has a venous ulcer with a wound area between 5 cm2 - 40 cm2. \n   - The patient has a skin lesion on the left lower leg, but it is not specified if this is a venous ulcer or what the size is.\n\n4) Has an ankle brachial index (ABI) >0.8.\n   - There is no information provided about the patient's ABI.\n\n5) Has a venous ulcer with duration less than 24 months.\n   - Again, it is not clear if the skin lesion is a venous ulcer or how long it has been present.\n\n6) Has a venous ulcer which is critically colonized (not infected) based on the Lazareth Study Model...\n   - No details are given about the level of colonization/infection of the skin lesion.\n\n7) Is currently using Profore as their standard of care.\n   - There is no mention of the patient using Profore.\n\n8) Has not received antibiotics for 6 weeks prior to enrollment.\n   - No information is provided about recent antibiotic use.\n\nExclusion Criteria:\n1) Has an allergy to one of the components of the dressings (calcium alginate, hydrocolloid, silver).\n   - No mentioned allergies.\n\n2) Is currently on antibiotics. \n   - No information about current antibiotic use.\n\n3) Has a negative venous duplex.\n   - No venous duplex results mentioned.\n\n4) Is unable to tolerate 4 layer compression.\n   - No information about ability to tolerate compression.\n\n5) Is unable to continue contact with the investigator for >=2 weeks. \n   - Likely able to continue contact, but not explicitly stated.\n\n6) Is unwilling or unable to comply with the study protocol.\n   - No information about willingness/ability to comply.\n\nBased on the limited information provided in the patient note, there are many inclusion/exclusion criteria that cannot be definitively assessed. More details would be needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1673": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subject is \u226518 years of age and has type 1 or 2 diabetes\n   - The patient is 64 years old and has diabetes mellitus, so this criterion is met.\n\n2. Texas grade 1a or 2a wound located distal to the malleolus (excluding ulcers between the toes but including those of the heel) and depth \u2264 5 mm with no exposed capsule, tendon or bone and no tunneling, undermining or sinus tracts\n   - The patient has a painful skin lesion on the left lower leg, but there are no details provided about the grade, depth, or characteristics of the lesion.\n\n3. Prior to inclusion of an ulcer in the study, each wound will be reviewed for eligibility by an independent assessor using a central online review process that includes images of the ulcer.\n   - No information is provided about this process.\n\n4. For patients with potentially multiple eligible DFUs, the biggest ulcer will be chosen as the study ulcer.\n   - Not applicable since only one lesion is mentioned.\n\n5. Ulcer size between 1 cm2 and 12 cm2 (post-debridement).\n   - No information is provided about the size of the lesion.\n\n6. Ulcer duration of \u2265 30 days.\n   - No information is provided about the duration of the lesion.\n\n7. Study ulcer separated from other ulcers by at least 2 cm.\n   - Only one lesion is mentioned, so this criterion is likely met.\n\n8. Ulcer or affected limb free of clinical signs of infection.\n   - No information is provided about signs of infection.\n\n9. Post-debridement, ulcer free of necrotic tissue.\n   - No information is provided about necrotic tissue.\n\n10. Subject has adequate vascular perfusion of the affected limb, as defined by specific criteria.\n    - No information is provided about vascular perfusion.\n\n11. HbA1c \u2264 12.0% (diabetic patients)\n    - The patient has persistently elevated HbA1c, but the exact value is not provided.\n\n12. Demonstrated adequate offloading regimen.\n    - No information is provided about offloading.\n\n13. Subject must be willing to comply with the protocol including having blood drawn to create the RD1.\n    - No information is provided about the patient's willingness to comply.\n\n14. Female subjects who are capable of conceiving and all males capable of insemination must use an acceptable form of contraception in order to participate in the study.\n    - Not applicable since the patient is a 64-year-old female.\n\nBased on the information provided, there are several inclusion criteria that cannot be evaluated due to lack of details about the patient's condition and willingness to participate. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1674": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patient has diabetic foot ulceration, venous ulcer, or mixed aetiology ulcer with a surface area <100 cm2 and <10 cm in widest diameter on lower extremity, but larger than 1 cm2\"\n- The patient note mentions a \"painful skin lesion on the left lower leg\" that is \"oozing\", which suggests it could potentially be a diabetic foot ulceration given the patient's diabetes diagnosis. However, the size is not specified.\n\n2. \"Wound present for >30 days.\"\n- There is no information provided about how long the skin lesion has been present.\n\n3. \"Patient has wound in location amenable to creation of airtight seal around wound using TNP dressings.\"\n- This criteria is likely met since the wound is on the lower leg.\n\n4. \"Patient is able to comply with study protocol requirements.\" \n- There is no information about the patient's ability to comply with protocol.\n\n5. \"Patient is able to understand and provide written consent.\"\n- There is no information about the patient's ability to provide consent.\n\nGiven the limited information provided, I would assess this case as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nAdditional details like the exact size and duration of the wound would be needed to make a more definitive assessment. The patient's ability to comply with the protocol and provide consent would also need to be evaluated.",
        "label": 1
    },
    "1675": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not seem directly relevant to the inclusion criteria for the Buruli ulcer clinical trial.\n\n2. The patient has a painful skin lesion on the left lower leg that has increased in size and is oozing. This could potentially be a Buruli ulcer lesion.\n\n3. The inclusion criteria state that patients must have a clinical picture of Buruli ulcer disease confirmed by diagnostic tests in the specified districts of Benin.\n\nSince the patient note does not mention the location or any diagnostic confirmation of Buruli ulcer, I would consider referring this patient to the clinical trial upon further investigation to determine if the skin lesion is indeed a Buruli ulcer.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1676": {
        "output": "To determine the patient's eligibility for the given clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patient over 18 years old who has provided his/her written informed consent\n   - The patient is 64 years old, so this criterion is met. However, we don't have information about whether the patient has provided written informed consent.\n\n2. Patient who can be monitored by the same investigation team throughout the duration of the study\n   - We don't have enough information to determine if this criterion is met or not.\n\n3. Patient who agrees to wear effective venous compression every day, associated with the trial dressing\n   - The patient note doesn't mention anything about venous compression or the patient's willingness to wear it.\n\n4. Leg ulcer with a distal Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3\n   - The patient note doesn't provide any information about the ABPI value.\n\n5. Ulcer with a minimum area of 3 cm2 and a maximum area of 30 cm2\n   - The patient note mentions a skin lesion on the left lower leg, but it doesn't specify the size.\n\n6. Ulcer duration between 3 and 36 months\n   - The patient note doesn't provide any information about the duration of the skin lesion.\n\n7. Ulcer where the surface area is 70% or more covered by fibrinous tissue\n   - The patient note doesn't provide any details about the surface area or the type of tissue covering the skin lesion.\n\n8. Ulcer at least 3 cm away from any other lesion\n   - The patient note doesn't mention any other lesions, so we can assume this criterion is met.\n\n9. Ulcer moderately or strongly exudative justifying the use of an absorbent dressing\n   - The patient note mentions that the skin lesion is oozing, which suggests it is exudative and may justify the use of an absorbent dressing.\n\nBased on the information provided in the patient note, there are several inclusion criteria that cannot be determined, such as the ABPI value, the size and duration of the skin lesion, and the type of tissue covering the lesion. Additionally, we don't have information about the patient's willingness to provide written informed consent or wear venous compression.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1677": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches some of the risk factors mentioned in the trial summary (obesity, diabetes).\n\n2. She has a painful skin lesion on her left lower leg that is oozing, which could potentially be related to wound healing issues after surgery.\n\n3. The inclusion criteria for the trial is simply that the patient is receiving a primary hip or knee arthroplasty at the specified hospital during the given date range.\n\n4. There is no information provided about whether this patient is scheduled for an arthroplasty procedure.\n\nGiven the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient exhibits some risk factors of interest (obesity, diabetes), but it is unclear if she meets the key inclusion criteria of being scheduled for a primary hip or knee arthroplasty at that hospital during the specified dates. More information would be needed to make a definitive assessment.",
        "label": 0
    },
    "1678": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not seem directly relevant to the inclusion criteria for the clinical trial, which is focused on ischemic lower limb.\n\n2. The patient has a painful skin lesion on the left lower leg that is oozing. This could potentially be related to ischemic lower limb, but more information would be needed to determine if it meets the specific inclusion criteria.\n\n3. The inclusion criteria for the clinical trial are:\n   - Ischemic lower limb based on TASK guideline\n   - Rutherford score: 2 or 3\n   - ABI < 0.6\n   - Absolute ankle pressure < 60 mmHg\n   - Age: 20-62 years\n\n4. Based on the information provided in the patient note, there is not enough detail to definitively determine if the patient meets all of the inclusion criteria. The note mentions a painful skin lesion on the lower leg, but it does not provide specifics on the Rutherford score, ABI, or ankle pressure measurements.\n\n5. Additionally, the patient's age of 64 years old falls outside of the specified age range of 20-62 years in the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile the patient's lower leg lesion could potentially be related to ischemic lower limb, more diagnostic information would be needed to confirm eligibility based on the specific inclusion criteria outlined for this trial. The patient's age also falls outside of the specified range, but it may be worth further discussion with the trial investigators.",
        "label": 0
    },
    "1679": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication and exercise regimen. She also has a painful, oozing skin lesion on her left lower leg that has not responded to topical treatments.\n\nThe clinical trial is studying the efficacy of a topical ointment (PedyPhar\u00ae) for treating diabetic foot ulcers. The key inclusion criteria are:\n\n1. Adult diabetic patients over 18 years of age\n2. Any stage of diabetic foot syndrome, including Wagner stage 5 (midfoot gangrene after surgical treatment)\n3. Type 1 or type 2 diabetes mellitus with diabetic foot syndrome\n4. Stable metabolic and pharmacological control at recruitment and during the trial\n5. Adequate lower limb perfusion confirmed by tests\n\nBased on the information provided, this patient meets several of the key inclusion criteria:\n\n- She is an adult over 18 years old\n- She has diabetes mellitus\n- She has a diabetic foot ulcer/skin lesion on her lower leg\n\nHowever, there are a couple of potential issues:\n\n1. Her diabetes does not appear to be well-controlled, as she has persistently elevated HbA1c levels and is non-compliant with medication and lifestyle modifications. The trial requires stable metabolic control.\n\n2. It is unclear if her lower limb perfusion has been adequately assessed and confirmed to be adequate, as required by the trial criteria.\n\nGiven these potential issues, I would rate her eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther evaluation would be needed to confirm her metabolic control and lower limb perfusion status to fully determine eligibility for this specific trial studying diabetic foot ulcers.",
        "label": 0
    },
    "1680": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having insufficiently controlled type 1 or type 2 diabetes mellitus.\n\n2. However, the patient note also mentions that she has a painful skin lesion on her left lower leg that is oozing. This condition is not directly related to the clinical trial, which is focused on evaluating the use of insulin detemir (Levemir\u00ae) in patients with insufficiently controlled diabetes.\n\n3. While the skin lesion is not an exclusion criterion, it may complicate the patient's participation in the trial or require additional monitoring and management.\n\nBased on the information provided, I would consider the following assessment:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets the primary inclusion criteria of having insufficiently controlled diabetes, but the skin lesion condition may require additional evaluation to determine if it would impact her participation in the trial. Further investigation and discussion with the study team would be recommended before making a final decision on referral.",
        "label": 2
    },
    "1681": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of being between ages 40 and 75 and having a history of diabetes.\n\n2. The patient has a painful skin lesion on the left lower leg that is oozing. This could potentially be related to a diabetic neuropathic plantar ulcer, which is one of the inclusion criteria for the test subjects.\n\n3. However, the inclusion criteria specifically mentions a history of diabetic neuropathic plantar ulcer, which is an ulcer on the bottom of the foot. The patient's lesion is on the lower leg, so it may not qualify as a plantar ulcer.\n\n4. There is no information provided about whether the patient has peripheral sensory neuropathy or not, which is an exclusion criterion for the control group.\n\nBased on the information given, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets some of the inclusion criteria for the test group, but more information is needed to confirm if the skin lesion qualifies as a diabetic neuropathic plantar ulcer and if the patient has peripheral sensory neuropathy. Further investigation into the patient's medical history and examination of the skin lesion would be required to make a definitive determination of eligibility.",
        "label": 1
    },
    "1682": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication, diet, and exercise regimen. She also has a painful, oozing skin lesion on her left lower leg that has not responded to topical treatments.\n\nThe clinical trial is studying the efficacy of a device called Aquamantys for reducing blood loss, transfusion requirements, and improving wound healing in patients undergoing total hip arthroplasty via the anterior supine intermuscular approach.\n\nThe inclusion criteria for the trial are:\n1) Undergoing primary unilateral total hip arthroplasty via the anterior supine intermuscular approach\n2) Patient is willing and able to complete follow-up visits at 6 weeks and 1 year\n\nBased on the information provided, this patient does not appear to be undergoing a total hip arthroplasty procedure. Her medical issues seem to be related to uncontrolled diabetes and a skin lesion, which are not relevant to the clinical trial.\n\nTherefore, my assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1683": {
        "output": "Based on the given patient note and the clinical trial information, this patient does not seem eligible for the trial titled \"A Repeated Instruction by Telephone on the Day Before Colonoscopy to Patients Undergoing Colonoscopy\".\n\nThe patient note describes a 64-year-old obese female with diabetes mellitus and a skin lesion on her left lower leg. There is no mention of the patient undergoing a colonoscopy or any bowel preparation.\n\nThe inclusion criteria for the clinical trial states that the participants should be \"patients undergoing colonoscopy\".\n\nSince the patient note does not indicate that the patient is scheduled for a colonoscopy, she would not meet the inclusion criteria for this particular trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1684": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication and exercise regimen. She also has a painful skin lesion on her left lower leg that has increased in size and is oozing despite trying topical treatments.\n\nThe clinical trial is studying the efficacy and safety of a new off-loading shoe (SANIDIAB) compared to an older model (BAROUK) for treating chronic diabetic foot ulcers that have a high risk of amputation.\n\nThe inclusion criteria for the trial are:\n- Age 18 or older\n- Type 1 or 2 diabetes mellitus\n- New plantar ulcer of the forefoot or toes\n- Grade 1A or 2A of the University of Texas Classification\n- Neuropathy assessed by absence of sensation with 10g monofilament test\n\nThis patient meets several of the key inclusion criteria:\n- She is over 18 years old\n- She has diabetes mellitus (type unspecified)\n- She has a skin lesion/ulcer on her lower leg, which could potentially qualify as a \"plantar ulcer of the forefoot or toes\"\n\nHowever, some additional information is needed to fully assess eligibility, such as:\n- The specific grade/classification of her ulcer\n- Confirmation of neuropathy via monofilament testing\n\nBased on the information provided, I would assess her trial eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1685": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient is 18 years old or older. \nThe patient is 64 years old, so this criterion is met.\n\n2. Patient has a diagnosis of arterial, diabetic foot, venous insufficiency, or pressure ulcer or surgical and traumatic wound.\nThe patient has diabetes mellitus, so a diabetic foot ulcer is possible. This criterion is potentially met.\n\n3. Patient's target study ulcer/wound is a lower extremity full thickness ulcer/wound not involving tendon, capsule, or bone.\nThe patient has a painful skin lesion on the left lower leg that is oozing, suggesting a full thickness wound. This criterion is likely met.\n\n4. Patient's target study ulcer/wound and is \u22651.0 cm2 and \u2264 10.0 cm2 in size at the day of initial consult.\nThe size of the wound is not specified, so this criterion cannot be evaluated definitively.\n\n5. Study ulcer/wound has been present for greater than 6 weeks prior to initial consult.\nThere is no information about how long the wound has been present, so this criterion cannot be evaluated.\n\n6. Patients with Charcot foot deformities can be entered so long as the Charcot disease is not active, and the ulcer can be offloaded by an orthotic device.\nThere is no mention of Charcot foot deformities, so this criterion is not applicable.\n\n7. The patient has adequate circulation to the lower extremity as evidenced by an ABI (measured by Doppler) of \u2265 0.7. If the patient has non-compressible leg arteries, as documented by an ABI >1.3, then the patient must have a Toe-Brachial Index be > 0.6, or a toe pressure >50 mm Hg.\nThere is no information about the patient's circulation or ABI, so this criterion cannot be evaluated.\n\n8. Patient must have adequate in-home support to comply with all protocol-mandated visits and procedures, offloading or pressure redistribution as required, and proper application of study products and wound care regimen.\nThere is no information about the patient's in-home support, so this criterion cannot be evaluated definitively.\n\n9. Patient or his/her legal representative has read and signed the Institutional Review Board-approved Informed Consent form before Screening.\nThis criterion cannot be evaluated based on the provided information.\n\nIn summary, while some criteria are potentially met or likely met, there is not enough information to definitively determine eligibility. Further investigation would be needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1686": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of being at least 18 years old.\n\n2. She has a non-healing skin lesion/ulcer on her left lower leg that has increased in size and is oozing despite trying topical treatments. This matches the inclusion criteria of having a non-healing lower limb ulcer for more than 3 months.\n\n3. There is no mention of her undergoing any angiological diagnostic work-up like ABI, toe pressure, tcPO2 measurements or non-invasive arterial imaging to determine if she has mild to moderate peripheral artery disease (PAD) without critical limb ischemia (CLI). This is a key inclusion criteria that is not clearly met based on the patient note provided.\n\n4. There is also no mention if she has received any skin grafting or conservative inpatient care for 2-4 weeks, which is part of the study protocol before endovascular revascularization.\n\nIn summary, while the patient meets some of the inclusion criteria like age and having a non-healing lower limb ulcer, there is not enough information provided to definitively determine if she meets all the key criteria around arterial assessment and previous treatments received.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her arterial status and previous treatments received for the ulcer as per the trial protocol.",
        "label": 1
    },
    "1687": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not seem relevant to the inclusion criteria for the clinical trial, which is focused on pediatric neurogenic bladder due to spina bifida.\n\n2. The patient is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. Again, this is not relevant to the inclusion criteria.\n\n3. The patient complains of a painful skin lesion on the left lower leg, which has increased in size and is oozing. This is also not relevant to the inclusion criteria.\n\n4. The clinical trial is specifically looking for children with a diagnosis of spina bifida and neurogenic bladder who are performing clean intermittent catheterization (CIC) and taking oxybutynin for a poorly compliant bladder.\n\n5. There is no information provided in the patient note that suggests the patient meets any of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1688": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not match the inclusion criteria for the clinical trial, which requires patients to be between 10-18 years old with type 1 diabetes.\n\n2. The patient is described as being reluctant to see a nutritionist and non-compliant with diabetes medication or exercise. This suggests poor diabetes management, which could potentially match the \"poor diabetes control\" criteria, but the trial specifies type 1 diabetes.\n\n3. The patient's complaint about a skin lesion on the leg is not relevant to the trial's focus on pet ownership and glucose control in type 1 diabetes.\n\n4. The trial requires English-speaking patients, but the patient note does not mention the patient's language proficiency.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of being between 10-18 years old and having type 1 diabetes with poor control (HbA1c > 8%).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1689": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not seem directly relevant to the inclusion criteria for the clinical trial, which is focused on neurogenic detrusor overactivity.\n\n2. The patient complains of a painful skin lesion on the left lower leg, which is also not relevant to the trial's inclusion criteria.\n\n3. The inclusion criteria for the trial are:\n   - Diagnosis of overactive bladder as a result of a neurogenic condition (e.g., spinal cord injury, multiple sclerosis, Parkinson's disease, or cerebrovascular accidents)\n   - Women must not be pregnant and be of either non-childbearing potential or using adequate birth control\n   - Overactive bladder symptoms and/or urge incontinence episodes\n   - Normal results on urine culture tests and urinalysis\n   - ECOG performance status score of \u2264 3\n\n4. Based on the information provided in the patient note, there is no mention of the patient having a neurogenic condition or overactive bladder symptoms/urge incontinence. Therefore, the patient does not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1690": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication, exercise, and nutritionist recommendations. She also has a painful, oozing skin lesion on her left lower leg.\n\n2. The clinical trial is studying the effect of hyperbaric oxygen therapy (HBOT) on patients with fibromyalgia, which is a chronic pain syndrome.\n\n3. The inclusion criteria for the trial specifically states that participants must have a diagnosis of fibromyalgia confirmed by physical examination of pain sensitivity, Dolorimeter, and finger pressure.\n\n4. Based on the information provided in the patient note, there is no mention of the patient having fibromyalgia or meeting the diagnostic criteria outlined in the inclusion criteria.\n\n5. Therefore, based on the available information, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1691": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This aligns with the trial's focus on type 1 and type 2 diabetes.\n\n2. However, the inclusion criteria specifically state that for type 1 diabetes, the BMI must be between 18.0 and 27.0 kg/m^2, and for type 2 diabetes, the BMI must be between 22.0 and 35.0 kg/m^2. Since the patient is described as obese, her BMI is likely outside of these ranges.\n\n3. Additionally, the trial requires that patients with type 1 diabetes have been treated with insulin for at least 12 months prior to screening, and patients with type 2 diabetes have been treated with insulin for the past 3 months prior to screening. The patient note does not provide information about her insulin treatment history.\n\n4. The inclusion criteria also specify an HbA1c level below or equal to 10%. The patient note does not provide her exact HbA1c level, but it states that it is persistently elevated, which may or may not meet this criterion.\n\nBased on the available information, there are some uncertainties regarding the patient's eligibility for this trial. Her obesity and lack of information about insulin treatment history and HbA1c level make it difficult to determine if she meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1692": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Korean patients aged \u2265 18 years: The patient note does not mention the patient's ethnicity, but it states that she is a 64-year-old female, which meets the age requirement.\n\n2. Who had biopsy-confirmed BD lesions on the lower extremities: The patient note mentions that the patient has a painful skin lesion on the left lower leg, which has increased in size and is oozing. However, it does not explicitly state that the lesion is biopsy-confirmed Bowen's disease (BD).\n\nSince the patient's ethnicity is not specified, and the lesion is not confirmed as BD through a biopsy, there is not enough information to determine if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1693": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Subject is able to understand the evaluation and willing to consent and comply with all post-debridement visits and procedures - Unable to assess from the patient note provided.\n2. Age 18 years and older - The patient is 64 years old, so meets this criteria.\n3. Subjects fulfilling any one or all of the following criteria:\n   a. chronic wound(s) below the level of the knee, defined by delayed healing or cellular senescence\n   b. acute wound(s) as a result of a surgical procedure, laceration, abrasion or trauma\n   c. diabetic foot ulcer(s)\n   d. subjects with venous leg ulcers below the knee on the leg or foot with one or more documented failure of maximal medical therapy for their study wound >30 days such as compression bandages\n   - The patient has a painful skin lesion on the left lower leg, which could potentially meet criteria a or b, but more details would be needed.\n4. Subjects with the following lab results within 30 days of treatment:\n   a. serum albumin level >20g/L\n   b. clinically non significant results of liver function test (LFTs), serum glucose and complete blood count (CBC) with differential\n   - No lab results provided in the patient note.\n5. Subjects with a Braden Score \u226513-14 (Moderate Risk) - No Braden Score provided.\n6. Subjects with adequate arterial blood flow [Ankle-Brachial Index (ABI) >0.75] - No ABI provided.\n\nExclusion Criteria:\n1. Subjects that have tunneling wounds - Unable to assess from the patient note.\n2. Subject presents with an active infection in the study wound, as defined by purulence and: Fever and leukocytosis OR any TWO of the following: Malodor, pain or tenderness, warmth, erythema, induration, swelling, lymphangitis - The patient note mentions the lesion is oozing, which could indicate infection, but no other details provided.\n3. Infected bone diagnosed by imaging modality (e.g., Magnetic Resonance Imaging (MRI) and/or radiographic images) - No imaging results provided.\n4. Subjects whose study wound does not require debridement - Unable to assess from the patient note.\n5. Cardiac pacemaker or other electronic implant(s) - No mention of this in the patient note.\n6. Subjects with irradiate, burn or ischaemic wounds or history of keloids - No mention of this in the patient note.\n7. Subjects with vasculitis, non-reconstructive peripheral vascular disease, pyoderma gangrenosum, renal failure or lymphoedema - No mention of these conditions in the patient note.\n8. Subjects with uncontrolled bleeding disorder (PT/PTT) and coagulopathy (including those with hemophilia) - No mention of this in the patient note.\n9. Subjects taking treatment with any of the following:\n   a. Systemic corticosteroids\n   b. Immunosuppressive agent(s)\n   c. Chemotherapy or Radiation therapy\n   - No mention of these treatments in the patient note.\n10. Subjects deemed to require biologic dressing/ skin substitute - Unable to assess from the patient note.\n11. Terminally ill subjects - No mention of this in the patient note.\n12. Subjects that have an immunodeficiency disorder that interferes with wound healing, including Acquired Immunodeficiency Syndrome (AIDS) or know to be infected with Human Immunodeficiency Virus (HIV) - No mention of this in the patient note.\n13. Subjects that have chronic skin conditions such as psoriasis, etc. - No mention of this in the patient note.\n14. Subjects that reside in a nursing home - No mention of this in the patient note.\n15. Subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant - No mention of this in the patient note.\n16. Subject is pregnant and/or intending to become pregnant during this clinical investigation period - Unable to assess from the patient note provided.\n17. Subject has documented evidence of a",
        "label": 0
    },
    "1694": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Is aged \u2265 18: The patient is 64 years old, so this criterion is met.\n\n2. Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria: The patient is diagnosed with diabetes mellitus, so this criterion is met.\n\n3. Has an open foot wound with visible inflammation, namely at least 1 skin ulcer located on or below the malleolus that presents with the following clinical manifestations of a moderate or severe infection based on the Infectious Disease Society of America (IDSA): The patient has a painful skin lesion on the left lower leg that is oozing, which suggests a moderate or severe infection. This criterion is likely met.\n\n4. Has received appropriate surgical intervention to remove all necrotic and infected bone if diagnosed with osteomyelitis: There is no mention of osteomyelitis or bone infection in the patient note, so this criterion may not apply.\n\n5. Meets certain minimal laboratory criteria: There is no information provided about the patient's laboratory results, so it is unclear if this criterion is met.\n\nBased on the information provided, the patient appears to meet at least the first three inclusion criteria. However, there is not enough information to determine if the last two criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1695": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of being 18 years or older.\n\n2. The patient has a chronic wound (painful skin lesion on the left lower leg that has increased in size and is oozing) that has been present for an unspecified duration. The inclusion criteria require a chronic wound history of more than 2 months, which is not clearly stated for this patient.\n\n3. The type of wound is not specified as a leg ulcer, pressure ulcer category III-IV, or diabetic foot ulcer, which are the wound types included in the trial criteria.\n\n4. There is no mention of the patient providing informed consent.\n\nBased on the information provided, there are some uncertainties regarding whether the patient fully meets the inclusion criteria for this trial. More details would be needed about the wound type and duration to make a definitive assessment.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1696": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not seem directly relevant to the inclusion criteria for the brain injury clinical trial.\n\n2. She has a painful skin lesion on her left lower leg that is oozing. Again, this does not appear to be relevant to the brain injury trial criteria.\n\n3. The key inclusion criteria for the brain injury trial are:\n   - Adults aged 18-70 years (the patient is 64, so meets this)\n   - Able to speak and read English as primary language (no information provided, so assume yes)\n   - Able to provide informed consent (no information provided, so assume yes)\n   - Able to complete assessments and provide samples (no information provided, so assume yes)\n   - Able to tolerate chamber environment (no information provided, so assume yes)\n   - History of brain injury 6 months to 10 years ago with persistent symptoms like headaches, dizziness, vision issues, fatigue, cognitive issues, etc. (no mention of brain injury in patient note)\n   - Normal thyroid and hematocrit levels (no information provided)\n\n4. Based on the information given in the patient note, there is no indication that this patient meets the key brain injury inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1697": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication and exercise regimen. The key issue here is the painful skin lesion on her left lower leg that has increased in size and is now oozing despite trying topical treatments.\n\nThe clinical trial is looking at chronic venous ulceration of the lower limb and trying to determine biomarkers that can predict healing.\n\nThe inclusion criteria are:\n1) Male or female over 18 years old (the patient meets this at 64 years old)\n2) Chronic venous ulceration between the foot and ankle with ABPI > 0.85 for at least 4 weeks (the patient appears to meet this with the oozing lesion on her lower leg)\n3) Color venous duplex evidence of chronic venous insufficiency (no information provided)\n\nBased on the information given, the patient potentially meets at least 2 of the 3 inclusion criteria. However, there is no mention of venous insufficiency testing being done.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of venous insufficiency status.",
        "label": 0
    },
    "1698": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of being over 20 years of age.\n\n2. The patient has a painful skin lesion on the left lower leg that has increased in size and is oozing. This could potentially be a chronic pressure ulcer or wound, which matches the inclusion criteria of having an untreated wound.\n\n3. While the size of the wound is not explicitly stated, the fact that it has increased in size and is oozing suggests it may be over 3cm x 3cm in size, which meets the inclusion criteria.\n\n4. The stage of the wound is not specified, but given that it is a skin lesion that has progressed to oozing, it is likely at least stage 2 or higher, meeting the inclusion criteria.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1699": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She has a painful skin lesion on her left lower leg that has increased in size and is oozing, despite trying topical treatments.\n\nThe clinical trial is looking at a novel brace (Toad Brace) for offloading and healing plantar ulcers in diabetic patients.\n\nThe key inclusion criteria are:\n1) Age > 18 years (the patient is 64, so meets this)\n2) Diagnosis of diabetes mellitus (the patient has this)\n3) One or more foot ulcers without osteomyelitis (the patient has a skin lesion/ulcer on her lower leg, no mention of osteomyelitis)\n4) Specific ulcer grades (1A, 1C, 2A, 2C) - no grade mentioned for the patient's ulcer\n5) ABI >0.7 and Toe pressure >30mmHg (no values provided for the patient)\n\nBased on the information provided, the patient meets some of the key criteria like age and diabetes diagnosis. However, there are a few unclear areas like the ulcer grade and ABI/toe pressure values that would need further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1700": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Type 1 diabetes: The patient note does not specify the type of diabetes, so this criterion cannot be confirmed or ruled out.\n\n2. Males and females: The patient is a 64-year-old female, so this criterion is met.\n\n3. Age between 14-24 years: The patient is 64 years old, which is outside the specified age range. This criterion is not met.\n\n4. Any diabetes duration: Since the patient has a diagnosis of diabetes mellitus, this criterion is likely met, but the duration is not specified.\n\n5. Cared for by the diabetes center for at least 1 year: There is no information about this in the patient note.\n\n6. HbA1c \u2265 8%: The patient note mentions that the patient has a \"persistently elevated HbA1c,\" which suggests this criterion is likely met, but the exact value is not provided.\n\n7. Basal bolus treatment (any insulin): There is no information about the patient's treatment regimen in the note.\n\n8. Poor compliance with Self-Monitoring of Blood Glucose: The patient note states that the patient is \"not compliant with her diabetes medication or exercise,\" which suggests poor compliance with self-monitoring of blood glucose as well.\n\n9. Written informed consent obtained from patient or legal representative: This is a procedural requirement that cannot be assessed from the patient note.\n\nBased on the information provided, some of the key inclusion criteria are potentially met (e.g., female gender, elevated HbA1c, poor compliance with self-monitoring), while others cannot be confirmed or are not met (e.g., age range, treatment regimen). However, the patient's age of 64 years old is a clear exclusion criterion for this trial, which is focused on young patients aged 14-24 years.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1701": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the diabetic condition required for the clinical trial.\n\n2. The patient has a painful skin lesion on the left lower leg that is oozing. This could potentially be a diabetic foot ulcer, which is the target condition for the trial. \n\n3. However, the inclusion criteria specifically states that the diabetic foot ulcer must be classified as grade 1 or 2 according to the International Working Group of the Diabetic Foot (IWGDF) criteria. The patient note does not provide enough details to determine if the skin lesion meets this grading criteria.\n\n4. Given the patient has diabetes and a concerning skin lesion that could be a diabetic foot ulcer, it would be reasonable to consider referring them to this clinical trial for further evaluation to determine if they meet the specific inclusion criteria regarding ulcer grading.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1702": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is non-compliant with her diabetes medication and exercise regimen.\n\nThe clinical trial is looking for patients with type 2 diabetes mellitus who are aged over 19 years, have an HbA1c \u22657% in the past year, are willing to attend diabetes education sessions, and self-identify as South Asian with the ability to speak English or Punjabi.\n\nThis patient meets several of the key inclusion criteria:\n- She is over 19 years old\n- She has type 2 diabetes mellitus requiring medication\n- Her HbA1c is persistently elevated, indicating poor control (\u22657%)\n- She self-identifies as South Asian (assuming she can speak English or Punjabi)\n\nHowever, there is a concern about her willingness/ability to attend the education sessions and follow-up assessments, given her stated reluctance to see a nutritionist and non-compliance with her current regimen.\n\nOverall, while she meets several core criteria, her non-compliance raises some doubts about her ability to fully participate in and adhere to the trial protocol.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her willingness/ability to adhere to the protocol requirements.",
        "label": 0
    },
    "1703": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not seem directly relevant to the inclusion criteria for the atopic dermatitis clinical trial.\n\n2. The patient is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. Again, this information is not relevant to the atopic dermatitis trial.\n\n3. The patient complains of a painful skin lesion on the left lower leg that has increased in size and is oozing despite using topical lotions and creams. This could potentially be relevant if the lesion is related to atopic dermatitis.\n\n4. Looking at the inclusion criteria:\n   - The patient's age (64 years old) falls within the 18-80 year range specified.\n   - The criteria state a diagnosis of atopic dermatitis for at least 6 months using the Hanifin and Rajka Diagnostic Criteria. We don't have information on whether the patient meets this specific criteria.\n   - The criteria require the presence of lesional atopic dermatitis skin in both antecubital fossae (inner elbow regions). The patient's lesion is on the lower leg, so this criteria is not met.\n   - The criteria require positive S. aureus colonization based on a skin culture from an affected antecubital fossa. We don't have this information for the patient.\n\nOverall, while the patient has a skin lesion, there is not enough information provided to determine if it is specifically related to atopic dermatitis and if the patient meets all of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1704": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"An adult patient (18-80 years)\"\n   - The patient note states the patient is 64 years old, which falls within this age range. This criterion is met.\n\n2. \"Suffering from infected neuropathic fore- or mid-foot ulceration originated from type I or II diabetes (PEDIS-classification \u2265 Grade II)\"\n   - The patient note mentions the patient has diabetes mellitus, but does not specify if it is type I or II.\n   - It also mentions a \"painful skin lesion on the left lower leg\" but does not clearly state if this is a neuropathic foot ulcer or its grade/classification.\n\nSince the patient note does not provide enough details to definitively confirm the patient meets this key inclusion criterion regarding the type and severity of the foot ulcer, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1705": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is not compliant with her diabetes medication or exercise regimen.\n\n2. The clinical trial is titled \"Use of the Ulcerative Colitis Diet for Induction of Remission\" and is studying the effects of a specific diet on ulcerative colitis in patients aged 5-18 years old.\n\n3. The inclusion criteria for the trial are:\n   - Informed consent\n   - Established diagnosis of ulcerative colitis\n   - Age: 5-18 years (inclusive)\n   - Mild to moderate active disease (PUCAI score 10-45)\n   - Stable medication use for the past 6 weeks\n   - For patients who received antibiotic treatment: age 10-18 (inclusive)\n\n4. Based on the patient note and the inclusion criteria, this patient would not be eligible for the clinical trial because:\n   - She does not have a diagnosis of ulcerative colitis\n   - She is 64 years old, which is outside the age range specified in the inclusion criteria\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1706": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having type 1 or type 2 diabetes.\n\nShe also has a painful skin lesion on her left lower leg that has increased in size and is oozing. This likely qualifies as a Wagner 1 or 2 diabetic foot ulcer, which is another inclusion criteria.\n\nThe patient is over 18 years old, satisfying that criteria as well.\n\nThere is no mention of how long the diabetic ulcer has persisted, but it states she has tried topical lotions/creams, implying it has been present for over 8 weeks at least.\n\nThe only potential issue is her willingness to participate and provide informed consent, which is not explicitly stated.\n\nOverall, based on the information provided, this patient appears to meet most of the key inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her willingness to participate and provide informed consent.",
        "label": 2
    },
    "1707": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of having diabetes type I or II.\n\n2. However, the patient note does not mention anything about diabetic retinopathy, which is a key inclusion criterion for this trial. \n\n3. The patient note mentions a skin lesion on the left lower leg, but this trial is specifically studying the effect of hyperbaric chamber treatment on diabetic retinopathy, not other diabetic complications.\n\n4. There is no information provided about whether the patient is scheduled for hyperbaric treatment for other indications, which is another inclusion criterion.\n\n5. Based on the information given, the patient does not clearly meet all the inclusion criteria for this clinical trial on diabetic retinopathy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into whether they have diabetic retinopathy and are scheduled for hyperbaric treatment for other indications.",
        "label": 1
    },
    "1708": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She has a painful skin lesion on her left lower leg that has increased in size and is oozing, despite trying topical treatments.\n\nThe clinical trial is studying the use of shockwave therapy for treating chronic diabetic foot ulcers. \n\nThe key inclusion criteria are:\n1) Patients receiving care at the specified wound clinic\n2) Having a diabetic foot ulcer classified as Wagner groups 1 or 2\n\nSince the patient has diabetes and a worsening skin lesion/ulcer on her lower leg, she potentially meets the inclusion criteria of having a diabetic foot ulcer. However, it's unclear if she is receiving care at the specified wound clinic or if her ulcer would be classified as Wagner groups 1 or 2.\n\nBased on the information provided, I would assess her eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nTo definitively determine eligibility, more details would be needed about where she is receiving care and the severity classification of her foot ulcer. But she seems potentially eligible based on having diabetes and a worsening foot ulcer.",
        "label": 1
    },
    "1709": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Veterans over 21 years of age: The patient's age is not mentioned, but it is reasonable to assume that a 64-year-old female would meet this criterion.\n\n2. With chronic lower extremity or diabetic foot ulcers (wound duration over 8 weeks): The patient has a painful skin lesion on the left lower leg, which has increased in size and is oozing. This could potentially be a chronic lower extremity ulcer, but the duration is not specified.\n\n3. Who at the clinician's judgment requires wound debridement (25% or more of wound bed covered with non-viable tissue): The note does not provide details about the wound bed or the need for debridement.\n\n4. Wound size 1.5 cm (roughly the size of a quarter) or larger in diameter: The size of the lesion is not mentioned.\n\nBased on the information provided, there are some uncertainties regarding the patient's eligibility for this clinical trial. While the patient has a lower extremity skin lesion, which could potentially be a chronic ulcer, the duration, size, and the need for debridement are not clearly specified.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1710": {
        "output": "To determine the patient's eligibility for this clinical trial, let's go through the inclusion criteria one by one:\n\n1. Male or female, age \u2265 18: The patient is a 64-year-old female, so this criterion is met.\n\n2. Type 2 Diabetes: The patient has a diagnosis of diabetes mellitus, which is likely type 2 diabetes given her age and obesity. This criterion is met.\n\n3. A break in the skin on the foot \u2265 0.5cm2 and is Grade 1 or 2 as defined by the Wagner grading system: The patient has a painful skin lesion on the left lower leg, which is oozing. While the note doesn't specify the size or grade of the lesion, it is reasonable to assume that it meets this criterion.\n\n4. Hemoglobin A1c \u2265 5.9%: The patient has a persistently elevated HbA1c, which suggests that it is likely above 5.9%.\n\n5. Ability to provide written informed consent: There is no information provided about the patient's ability to provide informed consent, but we can assume that she is capable unless stated otherwise.\n\nBased on the information provided in the patient note, it appears that the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1711": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Healthy male or female \u2265 18 and \u2264 70 years of age.\nThe patient is a 64-year-old female, so she meets this criterion.\n\n2. Body mass index (BMI) \u2265 20 and \u2264 35 kg/m2. \nThe patient is described as obese, which typically means a BMI over 30, so she may not meet this criterion without further investigation of her exact BMI.\n\n3. Subjects with mild to moderate eczema; determined at screening visit.\nThe patient has a painful skin lesion on the left lower leg that is oozing, which could potentially be eczema, so she may meet this criterion pending further evaluation.\n\n4. Judged by the Investigator to be in general good health on the basis of medical history.\nThe patient has diabetes mellitus with persistently elevated HbA1c, which suggests her diabetes is not well-controlled. This may disqualify her from being considered in general good health.\n\n5. Agree to use the Study-supplied cleanser and moisturizer as the only body cosmetic applied to irritated skin.\nThis is not mentioned in the patient note, so it's unclear if she would meet this criterion.\n\n6. Agree to stop all medications and supplements during the entire length of the study\nThe patient is currently taking diabetes medication, which she would likely need to continue. So she may not meet this criterion.\n\n7. Females of child bearing potential must agree to use appropriate birth control methods during the entire study period.\nThe patient's age and reproductive status are not mentioned, so it's unclear if this criterion applies or if she would meet it.\n\n8. Agree not to initiate any new exercise or diet programs during the entire study period.\nThis is not mentioned in the patient note, so it's unclear if she would meet this criterion.\n\n9. Agree not to change their current diet or exercise program during the entire study period.\nThe patient is described as reluctant to see a nutritionist and not compliant with exercise, so she may not meet this criterion.\n\n10. Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator.\nThis is not mentioned in the patient note, so it's unclear if she would meet this criterion.\n\nOverall, based on the information provided, there are several inclusion criteria that the patient may not meet, such as BMI, general good health, stopping medications, and maintaining her current diet and exercise routine. However, further investigation would be needed to determine if her skin lesion qualifies as mild to moderate eczema.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1712": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She is not compliant with her diabetes medication or exercise regimen.\n\n2. The clinical trial is titled \"Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients\" and is investigating the use of hyperbaric chamber treatment for patients with CRVO.\n\n3. The inclusion criteria for the trial are:\n   - Patients age 18-80 years with a documented CRVO who treated by Avastin for more than 12 months.\n   - Patients who signed an informed consent form.\n\n4. Based on the patient note provided, there is no mention of the patient having CRVO or being treated with Avastin. The note only mentions that the patient has diabetes mellitus and a skin lesion on her left lower leg.\n\nTherefore, based on the information given, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1713": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria.\nThe patient note states that the patient has a diagnosis of diabetes mellitus, so this criterion is met.\n\n2. Has at least 1 skin ulcer located on or below the malleolus that presents with the following clinical manifestations of a moderate or severe infection based on the Infectious Disease Society of America guidelines...\nThe patient note mentions a \"painful skin lesion on the left lower leg\" that is \"oozing\", which suggests a skin ulcer with signs of infection. However, it does not specify if the lesion is located on or below the malleolus (ankle).\n\n3. Has documented adequate arterial perfusion in the affected limb(s)...\nThere is no information provided about the patient's arterial perfusion or blood flow to the affected limb.\n\n4. Has received appropriate surgical intervention to remove all necrotic and infected bone if diagnosed with osteomyelitis.\nThere is no mention of osteomyelitis (bone infection) in the patient note.\n\n5. Has received appropriate surgical debridement to remove all gangrenous tissue.\nThere is no mention of gangrenous tissue or surgical debridement in the patient note.\n\nBased on the information provided, there are some uncertainties regarding whether the patient meets all the inclusion criteria, particularly the location and severity of the skin lesion/ulcer, and the status of arterial perfusion. Further investigation may be needed to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1714": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This matches the inclusion criteria of being an adult (18 years or older) diagnosed with type 2 diabetes mellitus and having a recent A1c of 7.0 or greater.\n\n2. The patient is being treated with diabetes medication, which is also one of the inclusion criteria.\n\n3. However, the patient note does not mention if she is enrolled as a patient in the Vanderbilt APPC or the Eskind Diabetes Clinic, or if she is a registered My Health at Vanderbilt user. These are important inclusion criteria that cannot be confirmed from the given information.\n\nBased on the available information, I would consider referring this patient to the clinical trial upon further investigation to confirm her enrollment status and access to the patient web portal.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1715": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. A signed and dated informed consent has been obtained from the subject.\n   - This is not mentioned in the patient note, so we cannot make a determination.\n\n2. Subject is able and willing to comply with study procedures.\n   - This is not explicitly stated, but could potentially be inferred from the note.\n\n3. Subject is able to comply with weekly visits.\n   - Again, this is not explicitly mentioned.\n\n4. Subject is 18 years of age or older.\n   - The patient is 64 years old, so this criterion is met.\n\n5. There is presence of at least 50% or greater necrotic tissue (including slough and eschar) in the wound bed and a total wound surface area of > 1cm2 to < 64cm2.\n   - The note mentions a \"painful skin lesion on the left lower leg\" that is \"oozing\", but does not provide details on the amount of necrotic tissue or wound surface area.\n\n6. Subject will not have currently used parenteral or oral antibiotics except for UTI.\n   - This is not mentioned in the note.\n\n7. Diabetic subjects: HbA1c < 12.0 % within 90 days preceding enrollment.\n   - The patient has diabetes mellitus with a \"persistently elevated HbA1c\", but the specific value is not provided.\n\n8. Pre-albumin greater than 16 mg/dl within 90 days preceding enrollment.\n   - This lab value is not mentioned.\n\n9. Subject with a pressure ulcer must be currently receiving adequate pressure redistribution to the affected area via group 2 or 3 specialty bed, a static wheel chair cushion while patient is out of bed.\n   - The note does not indicate that the lesion is a pressure ulcer.\n\n10. Subject with diabetic plantar surface ulcer will use an offloading boot if ambulatory.\n    - The location of the lesion is the left lower leg, not the plantar surface, so this does not apply.\n\n11. Subject with a venous ulcer must be currently receiving and using compression therapy that can be managed daily.\n    - There is no mention of the lesion being a venous ulcer.\n\n12. Subject and caregiver are trainable and able to perform dressing changes.\n    - This is not explicitly stated in the note.\n\n13. Subject has no allergies to collagenase or honey.\n    - Allergies are not mentioned.\n\n14. Subject has no allergies to semi-occlusive or absorptive secondary dressing.\n    - Allergies are not mentioned.\n\n15. If subject has multiple wounds only the wound that fits the inclusion criteria will be selected. If more than one wound meets criteria then the largest wound will be selected.\n    - Only one lesion is mentioned.\n\nBased on the information provided in the patient note, there are several inclusion criteria that cannot be definitively determined, such as the amount of necrotic tissue, wound surface area, HbA1c value, pre-albumin level, and the patient's ability to comply with study procedures and dressing changes.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1716": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female, which meets the inclusion criteria of being over 18 years old and of either sex.\n\n2. She has a diagnosis of diabetes mellitus, which is one of the conditions listed in the inclusion criteria for cutaneous leg ulcers.\n\n3. She has a painful skin lesion on her left lower leg that is oozing, which suggests she may have a cutaneous leg ulcer that requires treatment.\n\n4. The inclusion criteria do not specify any exclusions based on comorbidities, so her obesity and lack of compliance with diabetes treatment should not disqualify her.\n\n5. The trial is recruiting patients to evaluate a topical device for treating skin ulcers in patients with diabetes mellitus, which appears to match this patient's condition.\n\nBased on the information provided, this patient seems to meet the key inclusion criteria for the clinical trial on skin ulcer treatment.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1717": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. This does not seem directly relevant to the inclusion criteria for the clinical trial, which is focused on dry skin conditions.\n\n2. The patient is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. Again, this information is not directly relevant to the dry skin clinical trial.\n\n3. The patient complains of a painful skin lesion on the left lower leg that has increased in size and is oozing despite using topical lotions and creams. This could potentially be relevant to the dry skin clinical trial.\n\n4. The inclusion criteria for the clinical trial are:\n   - Signed informed consent (unknown for this patient)\n   - Subjects with a general good and stable health condition (unclear if the patient meets this due to diabetes)\n   - Subjects with clinically stable medical conditions (unclear if diabetes is clinically stable)\n   - Accept to abstain from sunbathing and solarium during the study (unknown for this patient)\n   - Overall Dry Skin score (ODS) of 1 to 2 at arms and lower legs (the patient has a skin lesion on the lower leg, but the ODS score is unknown)\n   - TEWL > 12 g/m2/h on the left mid volar forearm (unknown for this patient)\n\nBased on the information provided, there are several unknown factors that would need further investigation to determine the patient's eligibility for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1718": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 64-year-old obese female with diabetes mellitus and persistently elevated HbA1c levels. She has a painful skin lesion on her left lower leg that is oozing despite trying topical treatments.\n\nThe clinical trial is looking for diabetic patients with active, chronic infections who are undergoing hyperbaric oxygen therapy.\n\nThe inclusion criteria are:\n1. Adult patients aged 18-65 years old\n2. Diabetes mellitus\n3. Current antibiotic use for active infection\n4. Anticipated course of at least 4 hyperbaric oxygen sessions for chronic clinical indications like diabetic lower extremity wounds or osteomyelitis\n\nThe patient meets criteria 2 and 3, as she has diabetes mellitus and likely has an active infection based on the oozing skin lesion on her leg.\n\nHowever, she does not meet criteria 1 as she is 64 years old, which is outside the age range. It's also unclear if she meets criteria 4, as the note does not specify if she will be undergoing hyperbaric oxygen therapy for her leg wound.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation into whether she will be receiving hyperbaric oxygen therapy and if an exception can be made for her age.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1719": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient over 18 years old who has provided his/her written informed consent\n- The patient is 64 years old, so this criterion is met. However, we don't know if written informed consent has been provided.\n\n2. Patient who can be monitored by the same investigation team throughout the whole duration of the study\n- There is no information about this, so we cannot determine if this criterion is met or not.\n\n3. Patient who agrees to wear an effective venous compression system every day, associated with the trial dressing\n- There is no mention of the patient agreeing to wear a compression system, so this criterion is not met based on the information provided.\n\n4. Leg ulcer with an Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3\n- There is no information about the patient's ABPI, so we cannot determine if this criterion is met.\n\n5. Ulcer area > or equal to 5cm2\n- The patient has a skin lesion on the left lower leg, but the size is not specified. So we cannot determine if this criterion is met.\n\n6. Ulcer duration > or equal to 6 months\n- There is no information about the duration of the skin lesion, so we cannot determine if this criterion is met.\n\n7. Ulcer presenting a the surface wound bed covered with 50% or more by sloughy tissue\n- There is no description of the wound bed, so we cannot determine if this criterion is met.\n\n8. Moderately or heavily exudative ulcers\n- The skin lesion is described as oozing, which suggests it may be exudative, but the level of exudate is not specified.\n\nIn summary, based on the information provided, some of the key inclusion criteria cannot be determined as met or not met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1720": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Diabetes (according to AAFP diagnostic criteria): The patient note mentions that the patient has a diagnosis of diabetes mellitus, so this criterion is met.\n\n2. Presence of neuropathy with Loss of Protective Sensation (LOPS): The patient note does not mention anything about neuropathy or loss of protective sensation, so it is unclear if this criterion is met.\n\n3. Active plantar diabetic foot ulcer (Grade 1A, according to the University of Texas Wound Classification System): The patient note mentions a painful skin lesion on the left lower leg, but it is not clear if this qualifies as a plantar diabetic foot ulcer of Grade 1A.\n\n4. A minimum size ulcer \u22650.5cm2 and \u2264 12 cm2 post debridement at time of randomization: The size of the lesion is not provided in the patient note.\n\n5. If the subject has more than one ulcer, they should be identified and at least 2 cm apart: The patient note only mentions one lesion.\n\n6. Age >18: The patient is 64 years old, so this criterion is met.\n\n7. At least one palpable foot pulse: The patient note does not mention anything about foot pulses.\n\n8. Ability to understand all of the study requirements: There is no information provided about the patient's ability to understand study requirements.\n\n9. Life expectancy greater than the duration of the study: No information is provided about the patient's life expectancy.\n\n10. Subject or responsible caregiver is willing and able to maintain the required offloading (as applicable for the location of the ulcer) and applicable dressing changes: There is no information about the patient's willingness or ability to maintain offloading or dressing changes.\n\n11. Doppler Ultrasound positive for at least one pedal pulse in each foot: The patient note does not mention any Doppler ultrasound results.\n\nBased on the information provided in the patient note, it is unclear if several of the inclusion criteria are met. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1721": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient is 18 years of age or older. \nThe patient is 64 years old, so this criterion is met.\n\n2. Patient has one of the following difficult-to-treat chronic ulcers in the lower limb:\n   2.1. Neuropathic lower limb ulcer\n   2.2. Venous lower limb ulcer\n   2.3. Post traumatic lower limb ulcer\n   2.4. Post operative lower limb ulcer\nThe patient has a painful skin lesion on the left lower leg that is oozing, which could potentially qualify as a lower limb ulcer. However, more details would be needed to determine if it meets the specific ulcer types listed.\n\n3. In case of Neuropathic foot grade according to University of Texas Classification 1A\nThis criterion is not applicable since the ulcer type is not specified as neuropathic.\n\n4. Wound area measurement ranging between 1-20cm2.\nNo details are provided about the size of the lesion, so it's unclear if this criterion is met.\n\n5. Ulcer defined as grade \u2265E on the granulometer scale.\nNo details are provided about the grade of the lesion, so it's unclear if this criterion is met.\n\n6. Willing to adhere to the proper off-loading device (off loading cast, healing shoe) according to investigator recommendation.\nNo information is provided about the patient's willingness to use an off-loading device.\n\n7. Female patients must have a negative serum pregnancy test at screening and be willing and able to use a medically acceptable method of birth control or declare that they are abstaining from sexual intercourse, from the screening visit through the study termination visit or be surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal.\nThe patient is a 64-year-old female, so she is likely post-menopausal and would meet this criterion.\n\n8. Ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study.\nNo information is provided about the patient's ability or willingness to comply with study procedures or provide informed consent.\n\nBased on the information provided, there are several inclusion criteria that are unclear or potentially not met. More details would be needed about the specific type and characteristics of the lesion, as well as the patient's willingness to use an off-loading device and comply with study procedures.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1722": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subject is between 18 years and 80 years of age.\n   - The patient is 64 years old, which falls within this range. This criterion is met.\n\n2. Subject is diagnosed with Type I or Type II diabetes, and had defined as diabetic foot ulcers presence of wound for more than 4 weeks at the screening visit.\n   - The patient is diagnosed with diabetes mellitus and has a skin lesion/ulcer on the left lower leg. However, it is not explicitly stated that this lesion has been present for more than 4 weeks. More information is needed to determine if this criterion is met.\n\n3. Ulcer located the foot, and ulcer size is between 1 cm^2 and 25 cm^2.\n   - The lesion is located on the left lower leg, not the foot. This criterion is not met.\n\n4. Ulcer extends into the dermis, subcutaneous tissue, tendon or joint capsule (Wagner grade 1 or 2).\n   - No information is provided about the depth of the lesion. More information is needed to determine if this criterion is met.\n\n5. Ulcer is free of necrotic debris.\n   - No information is provided about the presence of necrotic debris in the lesion. More information is needed to determine if this criterion is met.\n\n6. Subjects had adequate circulation to ulcer as documented by one of the methods below:\n   - No information is provided about the patient's circulation or any of the listed methods. More information is needed to determine if this criterion is met.\n\n7. Subject is able to give written informed consent prior to study start and to comply with the study requirements.\n   - No information is provided about the patient's ability to give informed consent or comply with study requirements. More information is needed to determine if this criterion is met.\n\nBased on the information provided, the patient does not meet at least one of the inclusion criteria (ulcer location), and there is not enough information to determine if several other criteria are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1723": {
        "output": "To determine the patient's eligibility for the clinical trial \"Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities,\" let's go through the inclusion criteria one by one:\n\n1. Diabetes patients who are users of CVD risk factor medications (antihypertensive therapies, antihyperlipidemics therapies, and oral antihyperglycemic therapies):\nThe patient note mentions that the patient has a diagnosis of diabetes mellitus, but it does not specify whether she is taking any medications for cardiovascular disease risk factors.\n\n2. Diabetes patients considered to be poorly adherent to CVD risk factor medications within the prior 12 months:\nThe patient note states that the patient is \"not compliant with her diabetes medication,\" which suggests poor adherence to medications.\n\n3. Diabetes patients who have not used the mail order pharmacy to fill any prescribed medications at least once in the prior 12 months:\nThere is no information provided about whether the patient has used a mail order pharmacy service in the past 12 months.\n\nBased on the available information, it is unclear if the patient meets all the inclusion criteria. While she appears to have diabetes and poor medication adherence, it is not specified if she is taking any cardiovascular disease risk factor medications or if she has used a mail order pharmacy service in the past year.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1724": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 26-year-old obese woman with bipolar disorder, which matches the inclusion criteria of having bipolar I disorder and being at least 18 years old.\n\nShe is currently experiencing symptoms of depression, anxiety, agitation, suicidal thoughts, and irritability, which suggests she is experiencing a depressed episode at the time of study entry as required by the inclusion criteria.\n\nThe patient note also mentions that she is currently taking lithium carbonate, which is a required treatment for inclusion in this trial.\n\nBased on the information provided, this patient appears to meet all of the stated inclusion criteria for the \"Maintenance Therapies in Bipolar Disorders\" clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1725": {
        "output": "To determine the patient's eligibility for the clinical trial \"Treatment of Depression in Youth With Bipolar Disorders\", let's go through the inclusion criteria one by one:\n\n1. Free of manic symptoms for at least 4 weeks: The patient note does not mention any manic symptoms, so this criterion is likely met.\n\n2. Must be treated with valproate or lithium (mood stabilizers) for at least 4 weeks: The patient note states that the patient is currently taking lithium carbonate, which is a mood stabilizer, so this criterion is met.\n\n3. Meet criteria for major depression and bipolar disorder (BP-I, BP-II, or BP-NOS): The patient note mentions that the patient has a history of bipolar disorder and is currently experiencing symptoms of depression, such as difficulty sleeping, excessive anxiety, agitation, suicidal thoughts, irritability, and inability to sit still. These symptoms suggest that the patient is experiencing a major depressive episode in the context of bipolar disorder, so this criterion is likely met.\n\n4. Not pregnant: The patient note does not mention pregnancy, so this criterion is likely met.\n\nBased on the information provided in the patient note, it appears that the patient meets all the inclusion criteria for the clinical trial \"Treatment of Depression in Youth With Bipolar Disorders\".\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1726": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Smoke at least 10 cigarettes per day\"\nThe patient note does not mention smoking or cigarette use, so this criterion cannot be evaluated.\n\n2. \"Report concern about cessation-related weight gain\"\nThe patient is described as an obese woman who is struggling with her weight and eating, which suggests she may be concerned about weight gain if she were to quit smoking. However, this is not explicitly stated.\n\n3. \"Motivated to quit smoking\"\nAgain, the patient note does not mention smoking or a desire to quit, so this criterion cannot be evaluated.\n\nSince two out of the three inclusion criteria cannot be definitively evaluated based on the information provided in the patient note, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1727": {
        "output": "Okay, let's go through the inclusion criteria for the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) clinical trial step-by-step:\n\nGeneral Inclusion Criteria:\n1) Current age 15 or older (Best Practice Pathway) or 18 years or older (Randomized Care Pathways)\n- The patient is 26 years old, so they meet this criteria.\n\n2) Able to give informed consent for data to be harvested\n- No information is provided about the patient's ability to give informed consent, so I will assume they are able to do so unless stated otherwise.\n\n3) Meet DSM-IV criteria for Bipolar I Disorder, Bipolar II Disorder, Bipolar Disorder NOS, or Cyclothymic Disorder\n- The patient has a history of bipolar disorder, so they likely meet this criteria.\n\n4) Undergo a complete standard evaluation including clinical interview, self ratings, and laboratory studies\n- No information is provided about whether the patient has undergone these evaluations, so I cannot confirm if they meet this criteria.\n\n5) Meet with Clinical Specialist as scheduled\n- Again, no information about whether the patient would be able to meet this requirement.\n\n6) Able to complete all Study Registry Forms within 3 months of registration\n- Likely able to do so, but no definitive information provided.\n\nThe patient does not seem to meet any of the general exclusion criteria listed.\n\nOverall, based on the limited information provided, the patient appears to potentially meet the key inclusion criteria of age and bipolar disorder diagnosis. However, there are some criteria I cannot confirm they meet based on the note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1728": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. She is currently experiencing depressive symptoms, anxiety, agitation, suicidal thoughts, and irritability.\n\n2. The clinical trial is studying the effects of mifepristone (a glucocorticoid receptor antagonist) on bipolar depression.\n\n3. The inclusion criteria for bipolar patients in the trial are:\n   - Male or female inpatients in need of treatment for severe bipolar depression\n   - Age 18-75 years\n   - Using adequate contraception (for women of childbearing potential)\n   - DSM-IV diagnosis of bipolar depression I/II, severe, with or without psychotic features\n   - Current major depressive episode of at least 6 weeks' duration\n   - Specific scores on the HAM-D and CGI-BP scales\n   - In good physical health\n   - Able to understand procedures and provide informed consent\n   - On lithium and/or valproate for at least 4 weeks (or able to start)\n   - Able to come off prior drugs except zolpidem and lorazepam\n\n4. The patient meets several of the inclusion criteria, including:\n   - Bipolar disorder diagnosis\n   - Severe depressive episode\n   - Within the age range\n   - Currently on lithium\n\n5. However, there are some potential concerns:\n   - Her obesity and physical health status are not mentioned, so it's unclear if she meets the \"good physical health\" criterion\n   - Her current medications (lithium and zolpidem) may need to be adjusted or discontinued per the trial protocol\n\nOverall, based on the information provided, I would consider referring this patient to this clinical trial upon further investigation into her physical health status and ability to adjust her medications as required by the trial protocol.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1729": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder, which matches the inclusion criteria of being diagnosed with bipolar I disorder.\n\n2. She is currently taking lithium carbonate and zolpidem, but not olanzapine, which is a requirement for this trial.\n\n3. Her age of 26 falls within the 18-65 age range specified in the inclusion criteria.\n\n4. There is no mention of her ability to visit the doctor's office as scheduled for the next 4 months, which is another inclusion criteria.\n\nBased on the information provided, while she meets some of the criteria, the lack of being on olanzapine and the uncertainty around her ability to attend follow-up visits makes her eligibility unclear.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1730": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Bipolar I or II Disorder: The patient note mentions that the patient has a history of bipolar disorder, so this criterion is met.\n\n2. Meet criteria for rapid cycling, defined as four or more episodes over the past 12 months: The patient note does not provide information about the frequency of episodes, so it is unclear if this criterion is met.\n\n3. Meet criteria for a major depressive episode: The patient note states that the patient is feeling depressed due to struggles with weight and eating, but it does not explicitly mention a major depressive episode. More information would be needed to determine if this criterion is met.\n\nBased on the available information, it is unclear if the patient meets all the inclusion criteria for the clinical trial. While the patient has bipolar disorder, there is not enough information to determine if they meet the criteria for rapid cycling or a major depressive episode.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1731": {
        "output": "To determine the patient's eligibility for the clinical trial \"Reducing Symptoms of Depression in Low-Income Mothers\", let's go through the inclusion criteria one by one:\n\n1. Score of 16 or higher on the Center for Epidemiological Studies Depression (CES-D) Scale\n   - The patient note does not mention the patient's CES-D score, so we cannot confirm if this criterion is met.\n\n2. Child who is 6 weeks to 30 months old\n   - The patient note does not mention if the patient has a child in this age range.\n\n3. Child who is enrolled in an Early Head Start program\n   - The patient note does not mention if the patient has a child enrolled in an Early Head Start program.\n\nSince the patient note does not provide enough information to confirm if the patient meets all the inclusion criteria, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1732": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. The clinical trial is studying the effects of lithium and divalproex on tau proteins in Alzheimer's disease patients.\n\n2. The inclusion criteria state that patients must be between 40-90 years old and have a diagnosis of Alzheimer's disease. This patient does not meet these criteria as she is only 26 years old and has bipolar disorder, not Alzheimer's.\n\n3. There are also several exclusion criteria listed, such as having clinically significant laboratory abnormalities, taking certain prohibited medications, being pregnant or breastfeeding, and others. While we don't have full details on this patient's medical history and medications, her bipolar disorder diagnosis and lithium prescription would likely exclude her.\n\n4. Based on the information provided, this patient would not be eligible for this particular clinical trial studying lithium and divalproex in Alzheimer's patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1733": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with a history of bipolar disorder. This matches the inclusion criteria of being at least 18 years old.\n\n2. The patient is not explicitly stated to have a cannabis dependence diagnosis or seeking treatment for a primary cannabis problem. However, she is taking lithium carbonate, which is mentioned in the trial as a potential treatment.\n\n3. The patient is experiencing symptoms of depression, anxiety, agitation, suicidal thoughts, insomnia, and irritability. These could potentially be withdrawal symptoms from cannabis cessation, although it's not explicitly stated.\n\n4. The inclusion criteria state that withdrawal should be identified as a barrier to abstinence. While the patient is not explicitly seeking cannabis abstinence, her symptoms could be indicative of withdrawal acting as a barrier.\n\nBased on the information provided, I would consider the following:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient meets some of the criteria, such as age and current lithium treatment, and is experiencing symptoms that could potentially be related to cannabis withdrawal. However, more information would be needed to confirm a cannabis dependence diagnosis, the role of withdrawal as a barrier to abstinence, and the patient's willingness to participate in a trial focused on cannabis cessation.",
        "label": 0
    },
    "1734": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\nAge: 8-17\nThe patient is 26 years old, which does not meet the age criteria.\n\nBD type I or II comorbid with ADHD\nThe patient has a history of bipolar disorder, which meets this criterion. However, there is no mention of ADHD comorbidity.\n\nBaseline score in the YMRS > or = 20\nThere is no information provided about the patient's YMRS (Young Mania Rating Scale) score.\n\nBased on the available information, the patient does not fully meet the inclusion criteria for this clinical trial. The age criterion is not met, and there is no mention of comorbid ADHD or a YMRS score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be needed to determine if the patient has comorbid ADHD and to assess their YMRS score. If these criteria are met, the patient could potentially be eligible for the trial despite being outside the specified age range.",
        "label": 0
    },
    "1735": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 26-year-old obese woman with bipolar disorder. She is currently experiencing depressive symptoms like difficulty sleeping, excessive anxiety, agitation, suicidal thoughts, irritability, and inability to sit still. Her medications include lithium carbonate and zolpidem.\n\nThe clinical trial is investigating the efficacy of escitalopram (an SSRI antidepressant) as a mood stabilizer for Bipolar II Disorder.\n\nThe key inclusion criteria are:\n- Age 18-65 (the patient is 26, so meets this criteria)\n- Minimum 2-year history of depressive and hypomanic episodes (not explicitly stated, but can be inferred from her bipolar disorder diagnosis)\n- Mood episodes occurring monthly (not stated)\n- Meet DSM-IV criteria for Bipolar II Disorder, except minimum 4-day period for hypomanic episodes (her diagnosis suggests she likely meets this)\n\nBased on the information provided, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nWhile she meets some of the key criteria like age and bipolar diagnosis, there are some unclear aspects like frequency of mood episodes that would need further investigation to definitively determine eligibility. But she is a potential candidate worth considering for the trial.",
        "label": 0
    },
    "1736": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman, which falls within the age range of 25-55 specified in the inclusion criteria.\n\n2. The patient is currently taking zolpidem, which is one of the medications being studied in this trial.\n\n3. However, there is no information provided about whether the patient meets the criteria for Primary Insomnia or Psychophysiologic Insomnia according to the ICSD manual.\n\n4. There is also no information about the patient's sleep/wake schedule, preferred sleep phase, sleep onset latency, wake after sleep onset time, total sleep time, sleep efficiency, problem frequency, or problem duration.\n\nBased on the limited information provided, it is difficult to determine with certainty whether this patient would be eligible for the clinical trial. More details about the patient's sleep patterns and insomnia diagnosis would be needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1737": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) Subjects must be 18 years of age or older.\nThe patient is 26 years old, so this criterion is met.\n\n2) Subjects must have lifetime bipolar I, II, or NOS disorder as defined by DSM-IV criteria. \nThe patient has a history of bipolar disorder, so this criterion is met.\n\n3) Subjects must have lifetime panic disorder or generalized anxiety disorder (GAD) as defined by DSM-IV criteria.\nThe patient does not explicitly mention having panic disorder or GAD, but does complain of excessive anxiety and agitation, which could potentially qualify under further investigation.\n\n4) Subjects' bipolar symptoms must be no more than moderately severe, defined as a CGI-BP < 4.\nThere is no information provided about the severity of the patient's bipolar symptoms based on the CGI-BP scale.\n\n5) Subjects' anxiety symptoms must be at least moderately severe, defined as a CGI-S > 4.\nThere is no information provided about the severity of the patient's anxiety symptoms based on the CGI-S scale.\n\n6) Subjects must not be receiving mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication for > one week prior to baseline.\nThe patient is currently taking lithium carbonate, which is a mood stabilizer, so this criterion is not met unless the patient discontinues this medication.\n\n7) Subjects or their legally authorized representative must sign the Informed Consent Document after the nature of the trial has been fully explained.\nThere is no information about whether the patient would consent, but this is generally obtained if the patient is referred.\n\n8) If female, subjects must be: postmenopausal, surgically incapable of childbearing, or practicing medically acceptable effective method(s) of contraception.\nThe patient is female, but there is no information about her childbearing status or use of contraception.\n\nOverall, while some criteria are potentially met, there are key criteria that are not met or where there is not enough information to make a determination.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1738": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. This does not directly match or contradict the inclusion criteria for the clinical trial, which is focused on major depressive disorder.\n\n2. She is complaining of recent struggles with weight, eating issues, depression, difficulty sleeping, excessive anxiety, agitation, suicidal thoughts, fidgetiness, and irritability. These symptoms could potentially be indicative of a major depressive episode.\n\n3. Her current medications are lithium carbonate (a mood stabilizer) and zolpidem (for sleep). The trial is looking to add aripiprazole to an existing FDA-approved antidepressant, which she does not seem to be on currently.\n\n4. The inclusion criteria specifically mention:\n   - Ages 18-65 (she is 26, so meets this)\n   - DSM-IV diagnosis of major depressive disorder, non-psychotic (her bipolar disorder diagnosis doesn't necessarily rule this out)\n   - HRSD score \u2265 14 (no score provided)\n   - Adequate trial of two antidepressants (not clear if she has tried this)\n   - Ability to give informed consent\n   - Use of contraception if child-bearing potential\n\nBased on the limited information provided, I would assess her eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore details would be needed about her current depressive symptoms, previous antidepressant trials, and ability to provide informed consent and use contraception if applicable. Her bipolar disorder diagnosis complicates things slightly, but does not necessarily exclude her if she is experiencing a major depressive episode.",
        "label": 0
    },
    "1739": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Physically healthy: The patient note does not mention any physical health issues, so this criterion is likely met.\n\n2. Meets DSM-IV criteria for primary insomnia: The patient note does not explicitly state that the patient meets the criteria for primary insomnia. However, it mentions that the patient has difficulty sleeping, which could be a symptom of insomnia.\n\n3. For subjects interested in PET study only: right-handedness: The patient note does not mention the patient's handedness, so we cannot determine if this criterion is met or not.\n\nBased on the information provided, it is unclear if the patient meets all the inclusion criteria for the clinical trial. While the patient appears to have some sleep-related issues, it is not specified if they meet the diagnostic criteria for primary insomnia.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1740": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Must have Bipolar disorder as confirmed by the Mini Neuropsychiatric Interview (MINI)\n- The patient note states that the patient has a history of bipolar disorder, so this criterion is likely met.\n\n2. Must be age 50 or older\n- The patient note states the patient is 26 years old, so this criterion is not met.\n\n3. Must have sub-optimal response to current psychotropic management including at least one of the following:\n    a) Behaviors and symptoms of irritability, agitation, mood liability or diminished ability to interact with others in their place of residence\n    b) Diminished ability to take care of basic personal needs in their place of residence due to symptoms of bipolar disorder\n    c) Intolerance to current psychotropic medications\n- The patient note mentions the patient is increasingly irritable and agitated, so criteria (a) is likely met.\n\n4. Must live in the Northeast Ohio area.\n- There is no information about the patient's location, so this criterion cannot be evaluated.\n\nOverall, while the patient meets some of the key criteria like having bipolar disorder and exhibiting symptoms like irritability and agitation, the age criterion of 50 or older is not met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation regarding their location and confirmation of bipolar disorder diagnosis.",
        "label": 0
    },
    "1741": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. She is currently experiencing symptoms of depression, anxiety, agitation, suicidal thoughts, and irritability.\n\n2. The clinical trial is for comparing two treatment combinations (olanzapine+lithium or chlorpromazine+lithium) in patients experiencing their first manic episode with psychotic features.\n\n3. The inclusion criteria state that participants must:\n   - Be aged 15-29 years old\n   - Be experiencing a first episode of psychosis\n   - Meet DSM-IV criteria for bipolar manic/mixed episode or schizoaffective manic episode\n   - Have a minimum score of 20 on the Young Mania Rating Scale (YMRS)\n   - Provide written informed consent\n\n4. Based on the information provided, this patient does not seem to meet all the inclusion criteria:\n   - Her age (26 years old) falls within the eligible range.\n   - However, it is not clearly stated that she is experiencing her first manic episode with psychotic features. The note mentions symptoms of depression, anxiety, and irritability, but not mania or psychosis.\n   - Her diagnosis of bipolar disorder is mentioned, but it is unclear if she meets the specific DSM-IV criteria for a manic/mixed episode or schizoaffective manic episode required for this trial.\n   - Her YMRS score is not provided, so it is unknown if she meets the minimum score of 20.\n\n5. Given the ambiguity around whether she meets all the key inclusion criteria, particularly regarding the current manic episode with psychotic features, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1742": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Are men or women, between the ages of 19 and 65, inclusive\" - The patient is a 26-year-old woman, so she meets this criterion.\n\n2. \"Have a diagnosis of any type of bipolar disorder or any type of psychotic disorder based on structured diagnostic interview (MINI).\" - The patient has a history of bipolar disorder, so she meets this criterion. \n\n3. \"Are currently outpatients or inpatients and taking a neuroleptic or mood stabilizer medication (listed below) for the past 6 months, and on a stable dose for the past 2 months.\" - The patient is currently taking lithium carbonate, which is a mood stabilizer listed, so she likely meets this criterion.\n\n4. \"Have a body mass index > 25.\" - The patient is described as obese, so her BMI is likely over 25, meeting this criterion.\n\n5. \"No substance use disorder in the past 2 months (except for nicotine or caffeine).\" - There is no mention of substance use disorder, so she likely meets this criterion.\n\n6. Other criteria related to pregnancy, ability to swallow capsules, follow instructions, report adverse events, not actively suicidal/homicidal, no recent topiramate use, no medical contraindication to zonisamide - Based on the limited information provided, she seems to potentially meet these as well.\n\nOverall, based on the patient note, this patient appears to meet all the key inclusion criteria for this clinical trial on using zonisamide (Zonegran) for weight gain associated with psychotropic medication use.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1743": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients will meet DSM-IV criteria for BED for at least the last 6 months.\n   - The patient note does not explicitly mention binge eating disorder or its criteria, so this is unclear from the information provided.\n\n2. Obesity as defined by body mass index > 30 kg/m2.\n   - The patient is described as a 26-year-old obese woman, so she likely meets this criteria.\n\n3. Men or women, between the ages of 18 and 65.\n   - The patient is a 26-year-old woman, so she meets this age criteria.\n\nBased on the limited information in the patient note, it seems possible that the patient could meet the inclusion criteria for binge eating disorder and obesity, but more investigation would be needed to confirm the binge eating disorder diagnosis and criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1744": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nA. The patient meets the DSM-IV diagnosis of bipolar disorder.\n\nB. The patient is exhibiting symptoms of a mixed state, with depressive symptoms (feeling depressed, difficulty sleeping, suicidal thoughts) and manic/hypomanic symptoms (excessive anxiety, agitation, irritability, fidgety/unable to sit still).\n\nC. The patient likely has a MADRS score \u2265 14 given the depressive symptoms described.\n\nD. The patient likely has a YMRS score \u2265 14 given the manic/hypomanic symptoms described. \n\nE. The patient is 26 years old, which falls within the 13-75 year age range.\n\nF. The patient is female.\n\nG. It is not explicitly stated, but it can be assumed the patient is an outpatient since no inpatient status is mentioned.\n\nBased on the information provided in the patient note, this 26-year-old woman with bipolar disorder exhibiting a mixed state appears to meet all of the listed inclusion criteria for this clinical trial evaluating Lamictal as an add-on treatment for mixed states in bipolar disorder.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1745": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. This matches the inclusion criteria of being over 18 years old and having bipolar disorder.\n\n2. She is currently experiencing symptoms of depression, anxiety, agitation, suicidal thoughts, and irritability. This suggests she may be experiencing a current affective episode as required by the inclusion criteria.\n\n3. She is taking lithium carbonate, which is one of the drugs being studied in the trial.\n\n4. There is no mention of her having any contraindications to the study drugs, severe somatic diseases, pregnancy, substance abuse issues, or anticipated protocol violations that would exclude her based on the listed exclusion criteria.\n\n5. The only potential issue is that there is no information provided about whether she has had a previous manic/mixed episode within the last 5 years, which is an inclusion criterion.\n\nOverall, based on the information given, I would consider referring this patient to the clinical trial upon further investigation into her episode history to confirm she meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1746": {
        "output": "To determine the patient's eligibility for the clinical trial \"Zonisamide for Weight Reduction in Obese Adults\", let's go through the inclusion criteria:\n\n1. Age 18-65 years: The patient is 26 years old, which falls within this range.\n\n2. BMI 30-50: The patient is described as obese, which typically means a BMI of 30 or higher. However, the exact BMI value is not provided.\n\nBased on the information given, the patient meets the age criterion but their BMI is not explicitly stated as being within the required range of 30-50. Therefore, I would consider referring this patient to the clinical trial upon further investigation of their BMI.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1747": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients will meet DSM-IV-TR criteria for BED for at least the last 6 months, determined by the Structured Clinical Interview for DSM-IV-TR (SCID) and supported by the Eating Disorder Examination (EDE).\n   - The patient note does not explicitly mention if the patient meets the DSM criteria for binge eating disorder (BED) or for how long they have had it. More investigation would be needed.\n\n2. Recurrent episodes of binge eating characterized by eating a large amount of food in a short period of time with a sense of lack of control.\n   - The patient note does not mention any specifics about binge eating episodes.\n\n3. The binge eating episodes are associated with at least three of the listed criteria (eating rapidly, eating until uncomfortably full, etc.).\n   - Again, no details are provided about the patient's binge eating episodes.\n\n4. Marked distress regarding binge eating.\n   - The patient complains about struggles with weight and eating causing depression, which could indicate distress related to binge eating.\n\n5. The binge eating occurs, on average, at least two days a week for six months.\n   - No information is given about the frequency of binge eating episodes.\n\n6. Does not occur exclusively during the course of bulimia nervosa and anorexia nervosa.\n   - No mention of bulimia nervosa or anorexia nervosa.\n\n7. Obesity, defined by body mass index > 30 kg/m2.\n   - The patient is described as a 26-year-old obese woman, so she likely meets this criteria.\n\n8. Men or women, between the ages of 18 and 65.\n   - The patient is a 26-year-old woman, so she meets the age criteria.\n\nBased on the information provided in the patient note, there are some criteria that the patient seems to meet (obesity, age), but several key criteria related to binge eating disorder are unclear or not mentioned. More investigation would be needed to determine if the patient definitively meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1748": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) Subjects must be 18 years of age or older.\nThe patient is 26 years old, so this criterion is met.\n\n2) Subjects must have lifetime bipolar I, II, or NOS disorder as defined by DSM-IV criteria. \nThe patient has a history of bipolar disorder, so this criterion is met.\n\n3) Subjects must have lifetime panic disorder or generalized anxiety disorder (GAD) as defined by DSM-IV criteria.\nThe patient does not explicitly mention having panic disorder or GAD, but does complain of excessive anxiety and agitation, so this may need further investigation.\n\n4) Subjects' bipolar symptoms must be no more than moderately severe, defined as a CGI-BP < 4.\nThere is no information provided about the severity of the patient's bipolar symptoms, so this would need further assessment.\n\n5) Subjects' anxiety symptoms must be at least moderately severe, defined as a CGI-S > 4.\nThe patient reports excessive anxiety and agitation, which suggests at least moderately severe anxiety symptoms, so this criterion may be met.\n\n6) Subjects must not be receiving certain medications for specified times prior to baseline.\nThe patient's current medications are listed as lithium carbonate and zolpidem, so this would need to be checked against the medication exclusion criteria.\n\n7) Informed consent required.\nNo information provided, so this would need to be obtained.\n\n8) Acceptable contraception if female.\nThe patient is female, so contraceptive status would need to be confirmed.\n\nOverall, there are several criteria that may be met based on the information provided, but some key details are missing that would require further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1749": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. The trial excludes patients with a history of bipolar disease, so this is a potential exclusion criterion.\n\n2. The patient is complaining of depression, anxiety, agitation, and suicidal thoughts. The trial includes patients with major depressive disorder and a QIDS-SR16 score between 6 and 15. However, it excludes patients with severe depressive episodes or a history of suicide attempts/suicidal ideation.\n\n3. The patient is currently taking lithium carbonate and zolpidem. The trial excludes patients currently using benzodiazepines or SSRIs within 28 days prior to randomization.\n\n4. The trial requires patients to be either newly diagnosed with depression or showing symptoms of relapse/recurrence while not on medication. It's unclear from the note if this patient's depression is newly diagnosed or a relapse.\n\n5. The trial has age criteria of 21-64 years old, which the 26-year-old patient meets.\n\n6. The trial requires women to use contraception, which is not mentioned for this patient.\n\nConsidering these factors, there are some potential exclusion criteria (bipolar disorder, suicidal thoughts, current medications) as well as missing information (newly diagnosed depression, use of contraception). Therefore, I would assess this patient as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1750": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. The trial excludes patients with bipolar disorder, so this is a potential exclusion criterion.\n\n2. The patient is complaining of depression, anxiety, agitation, suicidal thoughts, and insomnia. These symptoms align with the trial's focus on insomnia associated with generalized anxiety disorder.\n\n3. The patient is currently taking lithium carbonate and zolpidem. The trial excludes patients currently taking benzodiazepines or SSRIs, but does not mention lithium or zolpidem specifically.\n\n4. The trial requires patients to be between 21-64 years old, which the patient meets at 26 years old.\n\n5. The trial requires a score of at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A), but the patient's HAM-A score is not provided.\n\n6. The trial excludes patients with major depressive disorder, but the patient's depression seems to be secondary to her bipolar disorder and anxiety/insomnia.\n\nOverall, while the patient meets some of the inclusion criteria, the presence of bipolar disorder is a clear exclusion criterion. Additionally, the lack of information on the patient's HAM-A score makes it difficult to fully assess eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation of her HAM-A score and the impact of her bipolar disorder on trial eligibility.",
        "label": 0
    },
    "1751": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder, which is not relevant to the inclusion criteria for this ADHD trial.\n\n2. The trial is specifically looking for children aged 6-17 years old with ADHD and associated insomnia. This patient is 26 years old, which does not meet the age criteria.\n\n3. There is no mention of the patient having ADHD or insomnia associated with ADHD in the patient note.\n\n4. The patient is taking lithium carbonate for bipolar disorder and zolpidem (Ambien) for sleep, but the trial is investigating zolpidem specifically for ADHD-associated insomnia in children.\n\nBased on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1752": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Between the ages of 13 years, 0 months and 17 years, 11 months\nThe patient is 26 years old, so they do not meet this criteria.\n\n2. Meets The Diagnostic and Statistical Manual of Mental Disorders - IV criteria for either of the following conditions: bipolar I or bipolar II disorder with a manic, mixed, or hypomanic episode within 3 months of study entry; or a depressed episode within 3 months of study entry with a prior history of a manic, hypomanic, or mixed episode (if the participant only meets criteria for a current hypomanic episode, there must also be a history of at least one prior depressive, manic, or mixed episode)\nThe patient has a history of bipolar disorder, so they likely meet this criteria.\n\n3. Has experienced severe depression, hypomania, or mania symptoms for a period of at least 1 week within the 3 months prior to study entry\nThe patient complains of recent struggles with weight, eating, and feeling depressed, so they may meet this criteria depending on the severity and duration of symptoms.\n\n4. Lives with at least one biological or step-parent who is available and willing to participate in treatment (parents not currently living with the adolescent participant may also participate)\nThere is no information provided about the patient's living situation or family members, so it is unclear if they meet this criteria.\n\nOverall, based on the information provided, the patient does not meet the age criteria but may potentially meet some of the other criteria related to bipolar disorder diagnosis and symptoms. However, there is not enough information to definitively determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1753": {
        "output": "To determine the patient's eligibility for the clinical trial \"Group Intervention for Interpersonal Trauma\", let's go through the inclusion criteria one by one:\n\n1. Exposure to an interpersonal traumatic event: The patient note does not mention any exposure to interpersonal trauma, so this criterion is not met.\n\n2. Diagnosis of depression or PTSD (threshold or subthreshold): The patient is described as feeling depressed, having difficulty sleeping, feeling excessively anxious and agitated, and having thoughts of suicide. While a formal diagnosis is not provided, these symptoms suggest the possibility of depression. However, there is no mention of PTSD or trauma-related symptoms.\n\n3. Functional literacy: There is no information provided about the patient's literacy level.\n\nBased on the available information, the patient does not clearly meet the inclusion criteria for exposure to interpersonal trauma and a diagnosis of PTSD. While there are indications of possible depression, the lack of information about trauma exposure and literacy level makes it difficult to determine eligibility with certainty.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1754": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male and female outpatients, aged 18 to 75 years.\nThe patient is a 26-year-old woman, so she meets this criterion.\n\n2. Diagnosis of Bipolar Disorder (Bipolar I or Bipolar II). \nThe patient has a history of bipolar disorder, so she meets this criterion.\n\n3. Current diagnosis of Generalized Anxiety Disorder (GAD).\nThe patient is described as feeling \"excessively anxious and agitated\", which could potentially indicate generalized anxiety disorder, but a formal diagnosis is not explicitly stated. This criterion needs further investigation.\n\n4. Participants must be on at least one of the following mood stabilizers at steady dose for at least 4 weeks prior to randomization: lithium with blood levels between 0.4-1.4 meq/L, valproic acid/divalproate sodium (with levels between 50-150 ugm/dl) carbamazepine (blood levels between 4-12 mcg/ml), or lamotrigine (dosed 50-400 mg/day).\nThe patient is currently taking lithium carbonate, which meets this criterion.\n\nOverall, the patient meets some of the key inclusion criteria, but there is not enough information to definitively determine if she has a current diagnosis of generalized anxiety disorder.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1755": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Insomnia as defined by DSM-IV criteria and supported by subject diary\n   - The patient note does not explicitly mention insomnia or sleep issues, so this criterion is unclear.\n\n2. Male or female between the ages of 18-64 years\n   - The patient is a 26-year-old woman, so she meets this criterion.\n\n3. Body mass index (BMI) between 18-34 kg/m^2\n   - The patient is described as obese, which typically means a BMI of 30 or higher. However, her exact BMI is not provided, so this criterion is unclear.\n\n4. Females of childbearing potential must use a medically acceptable method of contraception\n   - There is no information provided about the patient's use of contraception.\n\n5. Capable of understanding and willing to comply with study procedures and has provided informed consent\n   - There is no information provided about the patient's capability or willingness to comply with study procedures or provide informed consent.\n\nBased on the information provided in the patient note, it is difficult to make a definitive assessment of eligibility. Some key criteria, such as the presence of insomnia and the patient's BMI, are unclear or not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1756": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Written informed consent is obtained. (This is not mentioned in the patient note, so we cannot make a determination.)\n\n2. The patient is an outpatient, man or woman of any ethnic origin, 18-75 years of age (inclusive). (The patient is a 26-year-old woman, so she meets this criterion.)\n\n3. Patient reports insomnia for at least six months, and insomnia causes the patient distress. (The patient note does not mention insomnia or sleep disturbances, so we cannot determine if she meets this criterion.)\n\n4. The Investigator determines that the patient meets diagnostic criteria for Chronic Insomnia according to International Classification of Sleep Disorders (ICSD) criteria. (There is no information about whether the patient meets these diagnostic criteria.)\n\n5. Sleep diary based screening shows sleep onset latency >30 minutes, and /or wake after sleep onset >30 minutes per night at least 3 nights per week, with combined wake-time-in-bed _> 45 minutes. (No sleep diary information is provided.)\n\n6. The patient is in good health as determined by a medical and psychiatric history, and physical examination. (The patient has a history of bipolar disorder, which may exclude her from being considered in \"good health\".)\n\n7. Women must be surgically sterile, 2 years post-menopausal, or if of child-bearing potential, using a medically accepted method of birth control, and agree to continued use of this method for the duration of the study. (There is no information about the patient's fertility status or use of birth control.)\n\n8. The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol. (This is not mentioned in the patient note.)\n\nBased on the limited information provided in the patient note, it is difficult to determine with certainty whether the patient would be eligible for this clinical trial. Some key criteria, such as the presence of chronic insomnia and sleep diary data, are not mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1757": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. A principal diagnosis of bipolar 1 or II disorder - The patient note mentions a history of bipolar disorder, so this criterion is met.\n\n2. Ages 18-60 - The patient is 26 years old, which falls within this age range.\n\n3. Physically healthy - There is no mention of any physical health issues, so we can assume this criterion is met.\n\n4. Outpatient status - This is not explicitly stated, but since there are no details about hospitalization, we can assume the patient is an outpatient.\n\n5. Montgomery-Asberg Rating Scale (MADRS) Score greater than or equal to 15 - This score is not provided in the patient note.\n\n6. BMI 23-30 - The patient is described as obese, but the specific BMI is not given.\n\n7. Able and willing to give written informed consent - This is not mentioned in the patient note.\n\nBased on the information provided, some criteria are clearly met (diagnosis, age), while others are unclear or potentially not met (MADRS score, BMI range, ability to provide consent).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1758": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n- The patient is 26 years old, which falls within the age range of 12-21 years. \n- The patient has a diagnosis of bipolar disorder, which meets the criteria of having bipolar I disorder.\n- The patient is experiencing symptoms of mania (agitation, irritability, difficulty sleeping), which meets the criteria of being in a current manic or mixed episode with a YMRS score >16.\n- The patient's medication lithium carbonate suggests she is not currently on mood stabilizers other than what is allowed in the trial.\n\nExclusion Criteria:\n- The patient does not appear to have a history of mental retardation.\n- There is no indication that the patient is acutely intoxicated or has withdrawal symptoms.\n- There is no mention of unstable medical or neurological illness.\n- No laboratory abnormalities are mentioned.\n- There is no indication that the patient is pregnant or lactating.\n- No history of nephrolithiasis is mentioned.\n- No mention of requiring concurrent treatment with carbonic anhydrase inhibitors.\n- While the patient has thoughts of suicide, it is not specified as significant suicidal ideation.\n- There is no mention of a history of eating disorders.\n- No family history of glaucoma is mentioned.\n- No history of non-response or hypersensitivity to quetiapine or topiramate is mentioned.\n- No contraindications for MRI scanning are mentioned.\n- No history of significant head trauma is mentioned.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria and does not seem to have any clear exclusion criteria. However, further investigation may be needed to confirm details like the YMRS score and cannabis use frequency.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1759": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. This matches the inclusion criteria of being female and between the ages of 10-18 years old.\n\n2. There is no mention of the patient's contraceptive use, so we cannot determine if she meets that inclusion criteria.\n\n3. There is no mention of obtaining informed consent/assent, so we cannot determine if that criteria is met.\n\n4. The patient has a diagnosis of bipolar disorder, which matches the inclusion criteria.\n\n5. There is no mention of the patient's Young Mania Rating Scale score, so we cannot determine if she meets that criteria of a score \u2265 16.\n\n6. There is no mention of the patient's fluency in English.\n\nOverall, while the patient seems to potentially meet some of the key inclusion criteria like age range and bipolar diagnosis, there are several criteria that cannot be determined from the provided note.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1760": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with a history of bipolar disorder. This matches the inclusion criteria of having a diagnosis of Bipolar 1 Disorder.\n\n2. The patient is complaining of symptoms that could indicate a manic or mixed episode, such as difficulty sleeping, excessive anxiety and agitation, suicidal thoughts, irritability, and inability to sit still.\n\n3. The patient is currently taking lithium carbonate, which is one of the medications being studied in this clinical trial.\n\nBased on the information provided, this patient appears to meet the inclusion criteria for this clinical trial on the safety and efficacy of lithium in treating acute mania in Bipolar 1 Disorder.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1761": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. The clinical trial is looking at lithium levels in patients with spinal cord injury.\n\n2. The inclusion criteria for the trial state that participants must be 18-60 years old, have a chronic spinal cord injury confirmed by MRI, and have an ASIA impairment scale score of A, B or C.\n\n3. This patient does not appear to have a spinal cord injury based on the note provided. She has bipolar disorder and is already taking lithium.\n\n4. Therefore, she would not meet the key inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1762": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman, which does not meet the age criteria of 12-18 years old for this clinical trial on zolpidem in adolescent insomnia patients.\n\n2. The patient has a history of bipolar disorder, which is not mentioned as an inclusion criteria for this trial. Bipolar disorder could potentially complicate the assessment of insomnia and response to treatment.\n\n3. The patient is currently taking lithium carbonate for bipolar disorder, which could interact with zolpidem and is likely an exclusion criteria for this trial, although exclusion criteria are not provided.\n\n4. The patient is also taking zolpidem, which is the study drug being investigated in this trial. However, her use of zolpidem is likely for a different indication than insomnia alone.\n\n5. The patient complains of depression, anxiety, agitation, suicidal thoughts, and irritability, which are likely symptoms related to her bipolar disorder rather than insomnia alone.\n\nBased on the provided information, this patient does not meet the key inclusion criteria of being an adolescent aged 12-18 with insomnia, and has several complicating factors that would likely exclude her.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1763": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder, which matches the inclusion criteria of having bipolar disorder.\n\n2. She is currently experiencing depressive symptoms like feeling depressed, having difficulty sleeping, excessive anxiety and agitation, thoughts of suicide, irritability, and inability to sit still. This suggests she may be in a major depressive episode.\n\n3. Her current medications lithium carbonate and zolpidem suggest she is already on mood stabilizing medications, which is required per the inclusion criteria.\n\n4. Her age of 26 falls within the 18-70 years range specified in the inclusion criteria.\n\n5. There is no information provided about her MADRS score, which is required to be at least 20 at screening and baseline according to the inclusion criteria.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation of her MADRS score and confirmation that her mood stabilizer dose has been unchanged for at least 6 weeks prior.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1764": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: Adults with history of sleeplessness\n\nThe patient note mentions that the 26-year-old woman is taking zolpidem, which is a medication used to treat insomnia or sleeplessness. Therefore, she meets the inclusion criteria of being an adult with a history of sleeplessness.\n\nWhile the patient note also mentions other conditions like bipolar disorder, obesity, and depression, these are not explicitly listed as exclusion criteria for the trial. The trial seems to be focused on evaluating a medication for insomnia in adult patients with sleeplessness.\n\nBased on the information provided, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1765": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder, which is not relevant to the inclusion criteria for this clinical trial on brain metastases.\n\n2. There is no mention of the patient having any primary cancer outside the brain or brain metastases.\n\n3. The inclusion criteria specifically require \"Histopathologically confirmed extracranial primary malignancy\" and \"Multiple (i.e., > 3) brain metastases OR < 3 metastases with at least 1 metastasis > 4.0 cm in diameter\".\n\n4. Based on the information provided in the patient note, the patient does not meet these key inclusion criteria.\n\nTherefore, my assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1766": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with a history of bipolar disorder. This matches the inclusion criteria of being at least 18 years old and having a diagnosis of bipolar I disorder.\n\n2. The patient is currently displaying symptoms of depression, anxiety, agitation, suicidal thoughts, irritability, and difficulty sleeping. These could potentially be indicative of a manic or mixed episode, which is required by the inclusion criteria.\n\n3. The patient is currently taking lithium carbonate, which is one of the treatments being compared in this trial.\n\n4. There is no information provided about the patient's level of understanding or reliability, which are also part of the inclusion criteria.\n\n5. There is no information provided about the patient's Y-MRS total score, which is another inclusion criteria.\n\nBased on the information given, I would consider referring this patient to this clinical trial upon further investigation to assess her level of understanding, reliability, and Y-MRS total score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1767": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with a history of bipolar disorder. This meets the exclusion criteria of \"History of bipolar disorder\".\n\n2. She is currently taking lithium carbonate for bipolar disorder and zolpidem for sleep. The trial specifically includes patients taking zolpidem \u226510 mg at least 4 times per week for chronic insomnia, which she seems to meet.\n\n3. However, the exclusion criteria state \"History of bipolar disorder, schizophrenia, mental retardation, or cognitive disorder.\" Since the patient has a history of bipolar disorder, she would be excluded from this trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1768": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. The clinical trial is for evaluating the pharmacokinetics and pharmacodynamics of zolpidem (a sleep medication) in children aged 2-18 years.\n\n2. The inclusion criteria state that participants must be between 2-18 years old. The patient is 26 years old, so she does not meet this criteria.\n\n3. The inclusion criteria also require a diagnosis of insomnia, which is not explicitly stated for this patient. Her sleep difficulties seem to be related to her bipolar disorder and medications.\n\n4. There are no other inclusion criteria that the patient clearly meets based on the provided information.\n\nTherefore, based on the patient note and inclusion criteria provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1769": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. The clinical trial is for patients with low-grade neuroendocrine tumors, so her condition does not match the inclusion criteria.\n\n2. The inclusion criteria specifically exclude patients with small cell lung cancers, paragangliomas, and pheochromocytomas, but do not mention excluding patients with bipolar disorder or other mental health conditions.\n\n3. However, the inclusion criteria require patients to have histologically confirmed metastatic low-grade neuroendocrine neoplasms, measurable disease, and radiographic evidence of disease progression following prior treatment or observation. The patient note does not mention any of these criteria.\n\n4. The inclusion criteria also list several laboratory value requirements, which are not mentioned in the patient note.\n\n5. The patient is currently taking lithium carbonate and zolpidem, but the inclusion criteria specifically exclude patients already taking lithium for any reason.\n\nBased on the information provided, this patient does not meet the key inclusion criteria for this clinical trial on low-grade neuroendocrine tumors.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1770": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Adult patients, >=18 years of age\nThe patient note states the patient is 26 years old, so this criterion is met.\n\n2. Chronic hepatitis C, genotype 1  \nThere is no mention of the patient having hepatitis C in the note, so this criterion is not met.\n\n3. Insulin resistance\nThere is no mention of the patient having insulin resistance in the note, so this criterion is also not met.\n\nSince the patient does not appear to have chronic hepatitis C or insulin resistance based on the information provided, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1771": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Provision of written informed consent before initiation of any study-related procedures\n   - This is not mentioned in the patient note, so we cannot make a determination.\n\n2. Men and women aged 18 to 65 years.\n   - The patient is a 26-year-old woman, so she meets this criterion.\n\n3. A documented clinical diagnosis according to the DSM-IV meeting criteria 296.4x Bipolar I disorder, most recent episode manic, 296.6x Bipolar I disorder, most recent episode mixed, or 296.5x Bipolar I disorder, most recent episode depressed.\n   - The patient has a history of bipolar disorder, but her current episode is not specified.\n\n4. PSQI total score of >=5.\n   - The patient's PSQI score is not provided.\n\n5. MADRS total score of <=12.\n   - The patient's MADRS score is not provided.\n\n6. YMRS total score of <= 12\n   - The patient's YMRS score is not provided.\n\n7. Female patients of childbearing potential must have a negative urine pregnancy test at enrollment and be willing to use a reliable method of birth control, i.e., double-barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device or tubal ligation, during the study.\n   - This is not mentioned in the patient note.\n\n8. Be able to understand and comply with the requirements of the study, as judged by the investigator.\n   - This is not mentioned in the patient note.\n\n9. Outpatient status at enrollment.\n   - This is not mentioned in the patient note.\n\nBased on the information provided, the patient meets the age criterion, but there is not enough information to determine if she meets the other criteria, such as her current bipolar episode, sleep quality, mood scores, pregnancy status, and ability to comply with the study requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1772": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Current major depressive episode or mixed episode\nThe patient is described as feeling depressed, excessively anxious, agitated, and having thoughts of suicide, which suggests a current major depressive episode. This criterion is met.\n\n2. Bipolar disorder\nThe patient has a history of bipolar disorder, so this criterion is met.\n\n3. History of suicidal behavior\nThe patient is stated to have thoughts of suicide, which can be considered a form of suicidal behavior. This criterion is met.\n\nSince all the inclusion criteria are met, this patient is likely eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1773": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Persons with Bipolar Condition: The patient note mentions that the patient has a history of bipolar disorder, so this criterion is met.\n\n2. Depression: The patient note states that the patient's recent struggles with weight and eating have caused her to feel depressed, so this criterion is also met.\n\n3. Anxiety: The patient note mentions that the patient feels excessively anxious and agitated, indicating the presence of anxiety symptoms.\n\n4. Stress: While stress is not explicitly mentioned, the patient's symptoms of depression, anxiety, and irritability suggest that she is likely experiencing stress as well.\n\n5. Insomnia: The patient note states that the patient has had difficulty sleeping, which indicates the presence of insomnia.\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria for the clinical trial titled \"Far Infrared Radiation Treatment for Bipolar Condition.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1774": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) \"Subjects must be at least 18 years of age and not older than 65\"\n- The patient is 26 years old, so this criterion is met.\n\n2) \"Subjects must have lifetime bipolar I, II, or not otherwise specified (NOS) disorder as defined by DSM-IV TR criteria\"\n- The patient has a history of bipolar disorder, so this criterion is met.\n\n3) \"Subjects must have lifetime panic disorder or generalized anxiety disorder (GAD) as defined by DSM-IV, criteria\"\n- The patient does not explicitly mention having panic disorder or GAD, but does complain of excessive anxiety and agitation, which could potentially qualify under further investigation.\n\n4) \"Subjects' bipolar symptoms must be no more than moderate in severity, defined as a CGI-BP< 4\"\n- There is no mention of the severity of the bipolar symptoms based on the CGI-BP scale.\n\n5) \"Subjects' anxiety symptoms must be at least moderate in severity, defined as a CGI-S > 4\" \n- There is no explicit mention of the severity of anxiety symptoms based on the CGI-S scale, but the description of excessive anxiety could potentially qualify as at least moderate severity upon further investigation.\n\n6) Medication criteria is not clearly met based on the patient's current medications.\n\n7) Ability to provide informed consent.\n\n8) Acceptable contraceptive methods if female - not applicable for this patient.\n\nOverall, some key inclusion criteria are potentially met (bipolar disorder, anxiety symptoms), while others require further investigation (specific anxiety disorder diagnosis, severity scales). There are no clear exclusion criteria mentioned.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1775": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder, which is not relevant to the inclusion criteria for this clinical trial on medullary thyroid cancer.\n\n2. There is no mention of the patient having medullary thyroid cancer or any other type of thyroid cancer in the patient note.\n\n3. The inclusion criteria specifically state that patients must have histologically confirmed medullary thyroid cancer with signs of residual/persistent disease based on tumor marker levels and/or radiographic imaging.\n\n4. There is no information provided about the patient's tumor marker levels, radiographic imaging, or any prior treatment for thyroid cancer.\n\n5. The inclusion criteria also require specific laboratory values, performance status, tissue specimens, age, pregnancy status, and contraceptive use, none of which are addressed in the patient note.\n\nBased on the lack of information regarding the patient's thyroid cancer status and the specific inclusion criteria for this clinical trial, I would not be able to refer this patient for enrollment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1776": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients with diagnosis of Bipolar Disorder (DSM-IV TR)\nThe patient note mentions that the patient has a history of bipolar disorder, so this criterion is met.\n\n2. Patients or their legal representatives have provided informed consent\nThe patient note does not mention whether the patient has provided informed consent or not. We would need to investigate further to determine if this criterion is met.\n\nSince one of the inclusion criteria is met, and we need further investigation for the other criterion, the appropriate trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1777": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Age: The patient is 26 years old, which does not meet the age criteria of 12-19 years old.\n\n2. Major depression: The patient is described as feeling depressed, having difficulty sleeping, feeling excessively anxious and agitated, and having thoughts of suicide. These symptoms suggest the possibility of major depression, but a formal diagnosis is not provided.\n\n3. Smoke cigarettes: There is no mention of the patient smoking cigarettes in the provided information.\n\n4. Lives with parents: There is no information provided about the patient's living situation.\n\n5. No confidentiality issues related to smoking: Since there is no information about the patient smoking, this criterion cannot be evaluated.\n\nBased on the available information, the patient does not clearly meet the age and smoking criteria for the clinical trial. Additionally, there is not enough information to determine if the patient meets the criteria for major depression, living with parents, and confidentiality issues related to smoking.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1778": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder, which is not directly relevant to the inclusion criteria of this bioequivalence study of lithium carbonate formulations.\n\n2. The inclusion criteria state: \"No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.\"\n\n3. The patient note mentions a history of bipolar disorder, which could potentially be considered a clinically significant abnormal finding in the medical history. However, it does not provide information about physical examination or laboratory results.\n\n4. The patient is currently taking lithium carbonate, which is the drug being studied in this trial. This could potentially make her eligible, depending on the other criteria.\n\n5. There is no information provided about whether the patient has any other medical conditions or abnormal findings that could exclude her from the trial.\n\nBased on the limited information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nMore information would be needed about the patient's physical examination, laboratory results, and any other medical conditions to determine if she meets all the inclusion criteria and has no exclusion criteria. Her current use of lithium carbonate could potentially make her eligible, but her bipolar disorder history may need to be evaluated further.",
        "label": 1
    },
    "1779": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder, which is not directly relevant to the inclusion criteria of this bioequivalence study of lithium carbonate formulations.\n\n2. The inclusion criteria state: \"No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.\"\n\n3. The patient note mentions a history of bipolar disorder, which could potentially be considered a clinically significant abnormal finding in the medical history.\n\n4. However, the patient is currently taking lithium carbonate, which is the drug being studied in this trial.\n\n5. There is no mention of any other significant medical conditions or abnormal findings that would clearly exclude the patient from the trial.\n\nBased on the information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient's bipolar disorder history may or may not be considered a clinically significant abnormal finding that would exclude them from the trial. Further investigation into the specifics of the patient's condition and any other potential abnormal findings would be needed to make a more definitive determination of eligibility.",
        "label": 0
    },
    "1780": {
        "output": "To determine the trial-level eligibility for this patient, let's go through the inclusion criteria for the clinical trial:\n\n\"Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.\"\n\nThe patient note mentions that the 26-year-old woman has a history of bipolar disorder, obesity, depression, anxiety, agitation, suicidal thoughts, irritability, and difficulty sleeping. These conditions could be considered clinically significant abnormal findings in her medical history.\n\nAdditionally, the patient is currently taking lithium carbonate and zolpidem, which may affect the bioequivalency study of lithium carbonate.\n\nBased on the information provided, this patient does not seem to meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1781": {
        "output": "To determine the patient's eligibility for the clinical trial \"Antidepressant Therapy in Treating Bipolar Type II Major Depression\", let's go through the inclusion criteria one by one:\n\n1. \"Meets DSM-IV criteria for Axis I bipolar II disorder\"\n   - The patient note mentions that the patient has a history of bipolar disorder, which likely meets this criterion.\n\n2. \"Meets DSM-IV criteria for Axis I major depressive episode\"\n   - The patient note states that the patient is feeling depressed due to struggles with weight and eating, which could potentially meet this criterion.\n\n3. \"Score of 16 on 17-item HAM-D rating scale\"\n   - The patient note does not provide information about the patient's HAM-D score, so it's unclear if this criterion is met.\n\n4. \"Not taking monoamine oxidase inhibitors (MAOI) for more than 2 weeks prior to study entry\"\n   - The patient note does not mention the patient taking MAOIs, so this criterion is likely met.\n\n5. \"Willing to use an effective form of birth control throughout the study\"\n   - The patient note does not provide information about the patient's willingness to use birth control during the study.\n\nBased on the information provided in the patient note, it seems that some of the inclusion criteria are potentially met, while others are unclear or unknown. Therefore, I would consider referring this patient to this clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1782": {
        "output": "To determine the patient's eligibility for the \"Weight Gain Prevention\" clinical trial, let's go through the inclusion criteria one by one:\n\nAge 18-35: The patient is 26 years old, which falls within this range.\n\nBody mass index between 23 and 30: The patient is described as obese, which typically means a BMI of 30 or higher. However, without specific height and weight information, it's difficult to determine the exact BMI.\n\nInterested in preventing weight gain: The patient complains about her recent struggles with weight and eating, which suggests she may be interested in preventing further weight gain.\n\nBased on the available information, the patient meets the age criterion and appears to be interested in preventing weight gain. However, there is some uncertainty regarding her BMI, as she is described as obese, which could potentially exclude her from the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her specific BMI.",
        "label": 0
    },
    "1783": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) Patients will meet DSM-IV criteria for type I bipolar disorder, depressed: The patient note states that the patient has a history of bipolar disorder and is currently depressed, so this criterion is likely met.\n\n2) Patient has experienced a maximum of three documented affective episodes: The patient note does not provide information about the number of previous affective episodes, so it is unclear if this criterion is met.\n\n3) Patient has been off medications for one week prior to study enrollment: The patient note indicates that the patient is currently taking lithium carbonate and zolpidem, so this criterion is not met.\n\n4) Patient has a Hamilton Depression Rating Scale (HDRS) total score \u226520: The patient note does not provide the patient's HDRS score, so it is unclear if this criterion is met.\n\n5) Patient is between the ages of 12 and 35 years: The patient is 26 years old, so this criterion is met.\n\nExclusion Criteria:\n1) Any chemical use disorder within 3 months: The patient note does not mention any chemical use disorder, so this criterion is likely met.\n\n2) Any history of significant suicidality that would place the patient at risk to participate in this protocol: The patient note states that the patient has had thoughts of suicide, which may be considered significant suicidality, so this criterion may not be met.\n\n3) Current score \u22653 on item 3 of the HDRS-17 (Suicide Item): The patient note does not provide the patient's score on this item, so it is unclear if this criterion is met.\n\n4) Any medical or neurological disorder that could influence fMRI results: The patient note mentions that the patient is obese, but it is unclear if this would influence fMRI results, so it is uncertain if this criterion is met.\n\n5) A history of mental retardation or an estimated IQ total score <85: The patient note does not mention any history of mental retardation or IQ score, so it is unclear if this criterion is met.\n\n6) An MRI scan is contraindicated in the subject for any reason: The patient note does not mention any contraindications for MRI, so this criterion is likely met.\n\n7) The patient lives >100 miles from the University of Cincinnati or cannot attend follow-up visits: The patient note does not provide information about the patient's location or ability to attend follow-up visits, so it is unclear if this criterion is met.\n\n8) Meets DSM-IV criteria for a bipolar mixed episode: The patient note does not mention a mixed episode, so this criterion is likely met.\n\nBased on the information provided in the patient note, it is unclear if the patient would be eligible for this clinical trial. Some criteria are likely met, some are likely not met, and for others, there is not enough information to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1784": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\n1. Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria\n\nThe patient note does not explicitly mention a diagnosis of primary insomnia. However, it states that the patient has \"difficulty sleeping,\" which could potentially be related to primary insomnia. More information would be needed to confirm if the patient meets the DSM-IV criteria for primary insomnia.\n\nBased on the limited information provided, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe patient's difficulty sleeping and use of zolpidem (a medication for insomnia) suggest that she may be eligible for the trial, but additional details about her specific sleep issues and whether she meets the diagnostic criteria for primary insomnia would be needed to make a more definitive assessment.",
        "label": 1
    },
    "1785": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effects of Cognitive Behavioral Therapy on Brain Serotonin Activity in People With Depression\", let's go through the inclusion criteria one by one:\n\n1. DSM-IV diagnosis of major depressive disorder (MDD)\nThe patient note mentions that the patient is complaining of feeling depressed, having difficulty sleeping, feeling excessively anxious and agitated, and having thoughts of suicide. These symptoms could potentially indicate major depressive disorder, but a formal diagnosis is not explicitly stated.\n\n2. Drug naive from prior psychotropic medication for more than 6 months before study entry\nThe patient note states that the patient is currently taking lithium carbonate and zolpidem, which are psychotropic medications.\n\n3. Hamilton-Depression (HAM-D) 17 score greater than or equal to 16\nThe patient note does not provide information about the patient's HAM-D score.\n\n4. Woman of childbearing age with a negative pregnancy test within 48 hours of scanning\nThe patient note indicates that the patient is a 26-year-old woman, which suggests she is of childbearing age. However, there is no information about a pregnancy test.\n\nBased on the available information, the patient meets some of the inclusion criteria but not others. Additionally, there are some criteria for which information is lacking.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1786": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman, which meets the age criteria of \"At least 18 years\".\n\n2. The patient's weight is described as obese, which may or may not meet the criteria of \"must be 15% of ideal weight for height and frame\". More information would be needed to determine if she meets this criteria.\n\n3. The patient has a history of bipolar disorder, which may or may not meet the criteria of \"must be in good health and physical condition as determined by medical history\". More clarification would be needed.\n\n4. The patient is currently taking lithium carbonate and zolpidem, which are relevant medications for this trial studying zolpidem.\n\n5. There is no information provided about whether the patient can read and sign the consent form.\n\nOverall, based on the limited information provided, I would consider referring this patient to this clinical trial upon further investigation to clarify her weight, health condition, and ability to provide consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1787": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. The clinical trial is focused on insomnia treatment, not bipolar disorder or obesity.\n\n2. The patient complains of recent struggles with weight and eating that have caused her to feel depressed. Depression is not an inclusion criterion for this insomnia trial.\n\n3. The patient states she has difficulty sleeping, feels anxious/agitated, has thoughts of suicide, is fidgety, and is increasingly irritable. These could potentially be related to insomnia.\n\n4. The inclusion criteria specify patients must meet the criteria for psychophysiologic insomnia, which involves difficulty initiating or maintaining sleep, or non-restorative sleep despite adequate opportunity for sleep.\n\n5. The patient's current medications (lithium, zolpidem) are not exclusion criteria.\n\n6. The age criteria is not specified, so the patient's age of 26 is assumed to meet it.\n\nBased on the limited information provided, there are some potential signs the patient may have insomnia that could make her eligible. However, more details on her specific sleep issues/patterns would be needed to definitively determine if she meets the insomnia criteria outlined.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1788": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 26-year-old obese woman with bipolar disorder, which meets the first inclusion criteria of \"Clinical diagnosis of bipolar I disorder mania, manic or mixed episode, with or without psychotic features\".\n\nShe is currently taking lithium carbonate, which meets the second inclusion criteria of \"Current ongoing lithium or valproate treatment with the possibility of benefiting, based on the investigator's clinical judgment, from adjunctive treatment with aripiprazole\".\n\nThe note doesn't mention her Young Mania Rating Total Score, so I can't definitively say if she meets that inclusion criteria or not.\n\nShe doesn't seem to meet any of the key exclusion criteria listed.\n\nBased on the information provided, I would consider referring this patient to the clinical trial upon further investigation to determine her Young Mania Rating Total Score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "1789": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Provision of written informed consent before initiation of any study related procedures. \n   - This is not mentioned in the patient note, so we cannot make a determination.\n\n2. Documented clinical diagnosis meeting the DSM-IV criteria for 296.4X Bipolar I Disorder, Most Recent Episode Manic or 296.0X Bipolar I Disorder, Single Manic Episode.\n   - The patient note states that the patient has a history of bipolar disorder, so this criterion is likely met.\n\n3. Have a YMRS score of at least 20 and a score of at least 4 on 2 of the following 4 YMRS items both at enrolment and at randomisation: Irritability, Speech, Content, and Disruptive/Aggressive Behaviour.\n   - The patient note does not provide the YMRS score or specific details about the patient's symptoms related to these items, so we cannot make a definitive determination.\n\n4. Female patients of childbearing potential must have a negative urine pregnancy test at enrolment and be willing to use a reliable method of birth control during the study.\n   - The patient is a 26-year-old woman, so this criterion may apply, but there is no information provided about pregnancy status or willingness to use birth control.\n\n5. Be able to understand and comply with the requirements of the study, as judged by the investigator.\n   - There is no information provided about the patient's ability to understand and comply with the study requirements.\n\nBased on the information provided in the patient note, we cannot definitively determine if the patient meets all the inclusion criteria for this clinical trial. However, the patient does have a history of bipolar disorder, which is a key criterion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "1790": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Sex: Male or Female; similar proportions of each preferred\nThe patient is a 26-year-old woman, so this criterion is met.\n\n2. Age: At least 18 years\nThe patient is 26 years old, so this criterion is met.\n\n3. Weight: must be 15% of ideal weight for height and frame\nThe patient is described as obese, which suggests that her weight is likely more than 15% above the ideal weight for her height and frame. This criterion may not be met.\n\n4. Subjects must be in good health and physical condition as determined by medical history\nThe patient has a history of bipolar disorder and is currently experiencing symptoms of depression, anxiety, agitation, suicidal thoughts, and irritability. Additionally, she is taking lithium carbonate and zolpidem. Based on this information, she may not be considered in good health and physical condition.\n\n5. Subjects must read and sign the Consent Form\nThere is no information provided about whether the patient can read and sign the consent form.\n\nBased on the available information, the patient may not meet all the inclusion criteria, particularly the criteria related to weight and overall health and physical condition.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1791": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. She meets the age criteria of 12-59 years old for the clinical trial.\n\n2. She is currently taking lithium carbonate and zolpidem, which are not antipsychotic medications. However, the inclusion criteria state that patients must have a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform, bipolar I, bipolar II, bipolar NOS, psychotic disorder NOS, or autism spectrum disorder.\n\n3. Since the patient has a diagnosis of bipolar disorder, she meets this inclusion criterion.\n\n4. The patient complains of recent struggles with her weight and eating, which suggests she may have gained weight recently. However, the note does not provide specific details on her weight gain percentage or BMI to determine if she meets the weight gain criteria.\n\n5. Based on the information provided, the patient potentially meets some of the inclusion criteria, but there is not enough detail to definitively determine if she meets all the weight gain criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation into her specific weight gain history and BMI to see if she meets the weight-related inclusion criteria.",
        "label": 0
    },
    "1792": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\nAge 18-55: The patient is 26 years old, which falls within this range.\n\nBMI 18-30 kg/m2: The patient is described as obese, which typically means a BMI greater than 30 kg/m2. This criterion is not met.\n\nBody weight > 50 kg: This criterion is likely met, as obesity generally implies a weight above 50 kg, but it is not explicitly stated.\n\nOverall, the patient meets one of the three inclusion criteria definitively (age), potentially meets another (body weight), but does not meet the BMI criterion.\n\nGiven the incomplete information and the patient not meeting at least one of the criteria, I would consider referring this patient to the clinical trial upon further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1793": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Medically healthy: The patient note does not mention any significant medical conditions other than obesity and bipolar disorder, so this criterion is likely met.\n\n2. Meets DSM-IV criteria for bipolar disorder of any subtype: The patient note states that the patient has a history of bipolar disorder, so this criterion is met.\n\n3. No more than 32 weeks gestation, dated by last menstrual period: The patient note does not mention pregnancy, so this criterion is not applicable.\n\nSince the patient meets the first two inclusion criteria and the third criterion is not applicable, it is highly likely that this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "1794": {
        "output": "To determine the patient's eligibility for the clinical trial \"Staccato Loxapine in Agitated Patients With Bipolar Disorder\", let's go through the inclusion criteria:\n\n1. Male and female adult patients with bipolar 1 disorder and acute agitation\n\nThe patient note mentions that the 26-year-old woman has a history of bipolar disorder and is currently experiencing agitation, anxiety, irritability, and difficulty sleeping. These symptoms suggest acute agitation in a patient with bipolar disorder.\n\nBased on the information provided in the patient note and the inclusion criteria, this patient appears to meet the eligibility requirements for the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "1795": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old woman with bipolar disorder, which matches one of the inclusion criteria (DSM-IV criteria for bipolar I affective disorder).\n\n2. Her age (26) falls within the 18-65 age range specified in the inclusion criteria.\n\n3. There is no mention of her ability or willingness to provide informed consent, but we can assume she would be able to do so if referred to the trial.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial studying the association between tobacco smoking and bipolar affective disorder.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "1796": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. She is currently taking lithium carbonate and zolpidem.\n\n2. The clinical trial is studying the efficacy and safety of lithium carbonate in treating chronic spinal cord injuries.\n\n3. Looking at the inclusion criteria:\n- Age 18-60 years: The patient is 26, so she meets this criterion.\n- Chronic spinal cord injury for 12 months or longer: The patient note does not mention any spinal cord injury, so she does not meet this criterion.\n- ASIA classification A, B, or C for at least 6 months: No information about this in the patient note.\n- Spinal cord injury vertebral level between C4 and T10: No information about this in the patient note.\n- Able to read, understand and complete the VAS: No information about this in the patient note.\n- Signed informed consent: No information about this in the patient note.\n\nSince the patient does not have a chronic spinal cord injury, which is a key inclusion criterion, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1797": {
        "output": "Let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Healthy Males age 18 to 35 inclusive\n- The patient is a 26-year-old woman, so she does not meet this criterion.\n\n2. Body Mass Index 18 to 30\n- The patient is described as obese, so it's unlikely her BMI falls within this range. However, we don't have the exact BMI value.\n\n3. Willing to adhere to prohibitions and restrictions specified in protocol\n- There is no information provided about the patient's willingness to adhere to protocol restrictions.\n\n4. Must give informed consent.\n- There is no information provided about whether the patient would give informed consent.\n\nOverall, based on the information given, the patient does not meet at least one of the inclusion criteria (being a healthy male aged 18-35). There are also some criteria where we lack information to make a definitive assessment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1798": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman with bipolar disorder. This matches the inclusion criteria of having a DSM diagnosis that has an FDA indication for atypical antipsychotic use (bipolar disorder).\n\n2. She is currently taking lithium carbonate and zolpidem. The inclusion criteria state that the patient should be clinically stable on their current treatment regimen, including antipsychotic medication, for at least 30 days. It's not explicitly stated if she is taking an antipsychotic or how long she has been on her current medications.\n\n3. Her BMI is not provided, but it is stated that she is obese. The inclusion criteria require a BMI at least in the 85th percentile for age and gender, which obesity would likely meet.\n\n4. It is mentioned that her recent struggles with weight and eating have caused her to feel depressed, suggesting substantial weight gain over the previous 3 years while taking an antipsychotic medication.\n\n5. Other inclusion criteria, such as agreeing to use birth control, having a primary caretaker, and participating in study appointments, are not addressed in the patient note.\n\nBased on the information provided, I would consider referring this patient to this clinical trial upon further investigation to confirm if she meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "1799": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman, which does not meet the age inclusion criteria of 60-99 years for this clinical trial.\n\n2. The patient has a history of bipolar disorder, but the trial is specifically looking for patients with dementia of the Alzheimer's type or vascular dementia. Bipolar disorder is not mentioned in the inclusion criteria.\n\n3. There is no information provided about the patient's Mini Mental Status Examination score, which is required to be greater than or equal to 10 for inclusion.\n\nBased on the information provided in the patient note and the inclusion criteria for this clinical trial, this patient would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1800": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 26-year-old obese woman, which does not meet the age criteria of 21-55 years old for this clinical trial.\n\n2. The patient has a history of bipolar disorder and is currently taking lithium carbonate, which is relevant to this trial investigating the effects of a drug on lithium pharmacokinetics.\n\n3. However, the inclusion criteria specifically state \"Healthy males and/or females\", and this patient has a pre-existing mental health condition (bipolar disorder).\n\n4. The patient's BMI is not provided, but she is described as obese, which may fall outside the BMI range of 18-30 kg/m^2 required for inclusion.\n\nBased on the information provided, this patient would likely not be eligible for this particular clinical trial due to not meeting the age, health status, and potentially the BMI criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    }
}